Page last updated: 2024-10-15

nintedanib

Description

nintedanib : A member of the class of oxindoles that is a kinase inhibitor used (in the form of its ethylsulfonate salt) for the treatment of idiopathic pulmonary fibrosis and cancer. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135423438
CHEMBL ID2136735
CHEBI ID85164
CHEBI ID91413
SCHEMBL ID431007
SCHEMBL ID431006
SCHEMBL ID1535871
MeSH IDM0549010

Synonyms (103)

Synonym
HY-50904
cid 9809715
vargatef
nintedanib
intedanib
bibf-1120
bibf 1120 ,
chebi:85164 ,
bibf1120
AKOS005145820
928326-83-4
1160294-26-7
BCP9000405
(z)-methyl 3-((4-(n-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate
hsdb 8339
methyl (3z)-3-(((4-(n-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1h-indole-6-carboxylate
nintedanib [usan:inn]
unii-g6hrd2p839
g6hrd2p839 ,
656247-17-5
FT-0670358
HMS3244B14
HMS3244B10
HMS3244B06
bibf1120,vargatef
D10481
nintedanib (usan/inn)
NCGC00263156-02
NCGC00263156-01
AM84929
CS-0104
S1010
gtpl5936
BRD-K49075727-001-01-0
methyl (3z)-3-[({4-[n-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1h-indole-6-carboxylate
nintedanib [who-dd]
intedanib [mi]
nintedanib [vandf]
nintedanib [usan]
nintedanib component of ofev
nintedanib [inn]
ofev component nintedanib
SCHEMBL431007
SCHEMBL431006
smr004701273
MLS006010165
J-502642
XZXHXSATPCNXJR-ZIADKAODSA-N
3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone
SCHEMBL1535871
CHEMBL2136735
methyl (3z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1h-indole-6-carboxylate
KS-1434
AC-25071
nintedanib (bibf 1120)
mfcd11974012
AKOS025401745
DB09079
AKOS026750205
EX-A341
bdbm50026612
methyl (3z)-3-[[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1h-indole-6-carboxylate
CHEBI:91413
HMS3654A05
bdbm445209
us10669235, nintedanib
1h-indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3z)-; 1h-indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]a
NCGC00389321-03
SW218301-2
methyl 2-hydroxy-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-3h-indole-6-carboxylate
DTXSID20918936
FT-0772497
Q27163267
3-[[4-[methyl-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]amino]anilino]-phenylmethylidene]-2-oxo-1h-indole-6-carboxylic acid methyl ester
(z)-methyl 3-((4-(n-methyl-2-(4-methylpiperazin-1-yl)acetamido)-phenylamino)(phenyl)methylene)-2-oxoindoline-6-carboxylate
BCP01744
BCP09316
vargatef base
EX-A2818
Q15149723
SB11190
HMS3295K01
(z)-methyl 3-(((4-(n-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate
AMY9163
CCG-264775
NCGC00263156-14
methyl 2-hydroxy-3-[n-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-c-phenylcarbonimidoyl]-1h-indole-6-carboxylate
nsc757442
nsc756659
nsc800805
nsc-757442
nsc-756659
nsc-800805
NCGC00263156-13
nintedanib- bio-x
BN164249
DTXSID201025948
nintedanib (free base)
nintedanib, free base
EN300-188528
methyl 3-[({4-[n-methyl-2-(4-methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1h-indole-6-carboxylate
Z2756516920
1h-indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester

Research Excerpts

Overview

Nintedanib (N.T.B) is an orally administered tyrosine kinase inhibitor that has been approved recently by U.S.F.A for idiopathic pulmonary fibrosis (I.P.F) and systemic sclerosis-associated interstitial lung disease (S.Sc-I.L.D). NintedAnib is an antifibrotic drug that has an inhibitory effect on growth factor tyrosin kinases.

ExcerptReference
"Nintedanib is a tyrosine kinase inhibitor that has anti-inflammatory, anti-angiogenesis, and anti-fibrotic effects."( Nintedanib ameliorates imiquimod-induced psoriasis in mice by inhibiting NF-κB and VEGFR2 signaling.
Gao, J; Li, X; Ma, X; Miao, Y; Wei, W; Xi, B; Yang, C; Zhang, J; Zhou, H, 2021
)
"Nintedanib (N.T.B) is an orally administered tyrosine kinase inhibitor that has been approved recently by U.S.F.D.A for idiopathic pulmonary fibrosis (I.P.F) and systemic sclerosis-associated interstitial lung disease (S.Sc-I.L.D). "( Advances and challenges in nintedanib drug delivery.
Mehta, CH; Nayak, UY; Suresh, A; Velagacherla, V, 2021
)
"Nintedanib is an antifibrotic drug that has an inhibitory effect on growth factor tyrosine kinases. "( Nintedanib-mediated improvement in CT imaging in pulmonary fibrosis associated with systemic scleroderma.
Kagohashi, K; Nishino, K; Ohara, G; Sasatani, Y; Satoh, H, 2021
)
"Nintedanib is a tyrosine kinase inhibitor approved for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD), idiopathic pulmonary fibrosis, and other chronic fibrosing ILDs with a progressive phenotype. "( A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Avis, M; Gahlemann, M; Guillén-Del-Castillo, A; Kreuter, M; Mack, SR; Marzin, K; Vonk, MC; Wind, S, 2022
)
"Nintedanib is an oral antifibrotics with proven role in idiopathic pulmonary fibrosis, however its use in COVID-19 related pulmonary fibrosis has not been studied."( Early experience of nintedanib in COVID-19 ARDS-related pulmonary fibrosis: a case series.
Choudhary, R; Malik, V; Marwah, V; Pemmaraju, A; Peter, D, 2021
)
"Nintedanib is an oral triple kinase inhibitor with anti-fibrotic and anti-inflammatory properties."( The anti-fibrotic agent nintedanib protects chondrocytes against tumor necrosis factor-ɑ (TNF-ɑ)-induced extracellular matrix degradation.
Qu, L; Wang, C, 2022
)
"Nintedanib is a tyrosine kinase inhibitor used successfully in the treatment of idiopathic pulmonary fibrosis and there is no information about its use in BIP treatment."( Bleomycin-induced Pneumonitis in a Child Treated With Nintedanib: Report of the First Case in a Childhood.
Arikoglu, T; Balci, Y; Citak, EC; Gundogan, BD; Taskinlar, S, 2022
)
"Nintedanib is an effective inhibitor of multityrosine kinase receptors developed for the treatment of fibrosis, which was recently reported to exert inhibitory effects against inflammation and oxidative stress."( Nintedanib ameliorates oxidized low-density lipoprotein -induced inflammation and cellular senescence in vascular endothelial cells.
Chen, Y; Li, L; Shi, C, 2022
)
"Nintedanib esylate is a kinase inhibitor designated for the cure of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability (~ 4.7%). "( Bioavailability enhancement of vitamin E TPGS liposomes of nintedanib esylate: formulation optimization, cytotoxicity and pharmacokinetic studies.
Chinni, S; Kala, SG, 2022
)
"Nintedanib is an oral small-molecule kinase inhibitor and first-line treatment for idiopathic pulmonary fibrosis. "( The influence of green tea extract on nintedanib's bioavailability in patients with pulmonary fibrosis.
Chandoesing, PP; de Bruijn, P; Koolen, SLW; Mathijssen, RHJ; Miedema, JR; Oomen-de Hoop, E; van der Mark, SC; van der Werff, SC; Veerman, GDM; Wijsenbeek, MS, 2022
)
"Nintedanib is a multi-tyrosine kinase inhibitor widely used to treat progressive fibrosing interstitial lung diseases because it slows the reduction in forced vital capacity. "( Nintedanib induces gene expression changes in the lung of induced-rheumatoid arthritis-associated interstitial lung disease mice.
Kanazawa, S; Kondo, S; Koyama, N; Kyoyama, H; Mikami, S; Miura, Y; Moriyama, G; Nishimura, H; Noguchi, H; Ohkubo, H; Sakai, K; Uematsu, K, 2022
)
"Nintedanib is a licensed treatment for pulmonary fibrosis in adults."( Nintedanib in children and adolescents with fibrosing interstitial lung diseases.
Bertulis, J; Brown, KK; Cunningham, S; DeBoer, EM; Deterding, R; Dumistracel, M; Erhardt, E; Flaherty, KR; Gahlemann, M; Griese, M; Schwerk, N; Stowasser, S; Warburton, D; Young, LR, 2023
)
"Nintedanib is an inhibitor of tyrosine kinases that has been shown to slow the progression of interstitial lung disease (ILD), including ILD associated with SSc. "( Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study.
Atsumi, T; Fujieda, Y; Hisada, R; Ishizaka, S; Ito, YM; Kato, M; Kono, M; Ninagawa, K; Tsuneta, S; Ujiie, H, 2023
)
"Nintedanib is an effective treatment for pulmonary fibrosis (PF), but the exact mechanism by which this agent works to delay the progression of PF remains unclear. "( Nintedanib alleviates pulmonary fibrosis in vitro and in vivo by inhibiting the FAK/ERK/S100A4 signalling pathway.
Cheng, Y; Pan, L; Tang, B; Wu, X; Yang, W; Zhang, M; Zhang, Y; Zhu, H, 2022
)
"Nintedanib is a potent antifibrotic angio-kinase inhibitor, which has shown clinical efficacy in combination with chemotherapy in patients with locally advanced muscle-invasive bladder cancer."( Tumor and Stromal Cell Targeting with Nintedanib and Alpelisib Overcomes Intrinsic Bladder Cancer Resistance.
Corral, S; Del Pozo, N; Hilberg, F; Marqués, M; Martínez de Villarreal, J; Real, FX; Sánchez-Díaz, M; Schweifer, N; Zagorac, I, 2023
)
"Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases. "( A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Cottin, V; Podolanczuk, AJ, 2023
)
"Nintedanib (NDNB) is a novel triple-angiokinase inhibitor for the treatment of lung cancer. "( Simultaneously Inhibiting P-gp Efflux and Drug Recrystallization Enhanced the Oral Bioavailability of Nintedanib.
Tan, C; Wang, J; Wei, Q; Xiong, S; Zhang, S, 2023
)
"Nintedanib is an oral tyrosine kinase inhibitor targeting, among others, vascular endothelial growth factor receptor. "( Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer.
Braicu, EI; Casado, A; Debruyne, PR; Falcó, E; Ferrero, A; García-Martinez, E; Gennigens, C; Guerra-Alia, E; Kerger, J; Laenen, A; Lorusso, D; Muallem, MZ; Pignata, S; Rubio, MJ; Sehouli, J; Van Gorp, T; Van Nieuwenhuysen, E; Vergote, I; Wimberger, P; Zola, P, 2023
)
"Nintedanib is a tyrosine kinase inhibitor that was approved for the treatment of patients with idiopathic pulmonary fibrosis in 2014. "( Drug-Induced Thrombocytopenia Due to Nintedanib during Treatment of Idiopathic Pulmonary Fibrosis.
Charokopos, A; Cosiquien, RJS; Dagnon da Silva, M; Dumic, I; Grant, CR; Parmar, A; Petcu, E, 2023
)
"Nintedanib (NIN) is an antifibrotic drug approved to slow the progression of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-related interstitial lung disease (SSc-ILD). "( Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects.
Carrozzi, L; Da Rio, M; Della Rossa, A; Di Battista, M; Morganti, R; Mosca, M; Pistelli, F; Puccetti, L; Romei, C; Rossi, A; Tavanti, L; Tavoni, A, 2023
)
"Nintedanib is a competitive inhibitor of non-receptor tyrosine kinase (nRTKs) and receptor tyrosine kinase (RTKs). "( Nintedanib as the First Treatment for Group of Progressive Interstitial Lung Diseases: A Review of Patent Literature.
Dubal, G; Trivedi, MD; Vora, PA, 2023
)
"Nintedanib is a tyrosine kinase inhibitor that efficiently slows the progression of idiopathic pulmonary fibrosis (IPF) and has an acceptable tolerability profile. "( Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Akasaka, K; Amano, M; Kawabe, R; Kida, G; Kuwano, K; Matsushima, H; Nishizawa, T; Oba, T; Ohta, H; Sato, S; Tsukahara, Y; Tsumiyama, E; Yamakawa, H, 2019
)
"Nintedanib is an inhibitor of receptor tyrosine kinases, including vascular endothelial growth factor receptor, but its effects on pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) patients with chronic hypoxia were unclear."( Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy.
Kawaguchi, T; Kawanami, T; Mukae, H; Noguchi, S; Oda, K; Sakamoto, N; Sennari, K; Tahara, M; Yamasaki, K; Yatera, K, 2019
)
"Nintedanib (NDNB) is a triple receptor tyrosine kinase inhibitor with poor solubility in neutral conditions and low bioavailability. "( Improving The Oral Absorption Of Nintedanib By A Self-Microemulsion Drug Delivery System: Preparation And In Vitro/In Vivo Evaluation.
Chen, D; Ding, H; Huang, S; Liu, H; Mei, J; Tang, L; Webster, TJ; Xu, Y; Zhu, Y, 2019
)
"Nintedanib is a promising tyrosine kinase inhibitor for clinically treating idiopathic pulmonary fibrosis (IPF). "( Metabolic profiling of tyrosine kinase inhibitor nintedanib using metabolomics.
Cheng, Y; Fang, JH; Li, F; Wang, YK; Xiao, XR; Xu, KP; Yan, DM; Zhang, T; Zhou, ZM, 2020
)
"Nintedanib is an important drug for the treatment of idiopathic pulmonary fibrosis (IPF). "( Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis.
Abe, M; Hirasawa, Y; Kawasaki, T; Sakayori, M; Suzuki, K; Tatsumi, K; Terada, J; Tsushima, K; Yoshioka, K, 2020
)
"Nintedanib is a protein kinase inhibitor authorized in accelerated regulatory procedures for the treatment of idiopathic pulmonary fibrosis (IPF)."( Nintedanib and ischemic colitis: Signal assessment with the integrated use of two types of real-world evidence, spontaneous reports of suspected adverse drug reactions, and observational data from large health-care databases.
Chandler, RE, 2020
)
"Nintedanib is a small tyrosine kinase inhibitor that reduces IPF progression, significantly slowing the annual decline in Forced Vital Capacity (FVC)."( Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy.
Bargagli, E; Bergantini, L; Bini, L; Cameli, P; Carleo, A; d'Alessandro, M; Landi, C; Rottoli, P; Shaba, E, 2020
)
"Nintedanib is an oral antiangiogenic agent that has inhibitory effects on the fibroblast growth factor receptor, which is highly expressed in NETs."( Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors.
Attwood, K; Bies, R; Casucci, D; Fountzilas, C; Hicks, K; Iyer, RV; Konda, B; Maguire, O; Minderman, H; Mukherjee, S; Owen, D; Reidy-Lagunes, D; Shah, M; Suffren, SA; Wang, C; Wilton, J, 2020
)
"Nintedanib is a multi-kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF); however, its efficacy and safety for patients with IPF and restricted pulmonary function remain unclear. "( Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.
Fuchimoto, Y; Hara, N; Higo, H; Ichikawa, H; Itano, J; Kajimoto, K; Kanehiro, A; Kano, H; Kiura, K; Kudo, K; Kuyama, S; Maeda, Y; Miyahara, N; Oda, N; Senoo, S; Shibayama, T; Suwaki, T; Taniguchi, A; Tanimoto, Y; Watanabe, H, 2020
)
"Nintedanib is a triple angiokinase inhibitor of vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-3 and platelet-derived growth factor receptor-a/-b. "( Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111).
Berger, AW; Büchner-Steudel, P; Decker, T; Ettrich, TJ; Güthle, M; Hannig, CV; Hebart, HF; Heinemann, V; Hermann, PC; Herrmann, T; Hoffmann, T; Hofheinz, RD; Perkhofer, L; Seufferlein, T, 2021
)
"Nintedanib is a triple tyrosine kinase inhibitor and has an antifibrotic effect."( Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino, S, 2021
)
"Nintedanib is a multikinase inhibitor used for the treatment of pulmonary idiopathic fibrosis. "( Severe hepatotoxicity secondary to nintedanib.
Fernández Cano, MDC; Heredia Carrasco, C; Librero Jiménez, M, 2022
)
"Nintedanib is a synthetic orally active tyrosine kinase inhibitor, whose main action is to inhibit the receptors of the platelet-derived growth factor, fibroblast growth factor and vascular endothelial growth factor families. "( The Interactions of Nintedanib and Oral Anticoagulants-Molecular Mechanisms and Clinical Implications.
Błażejewski, J; Górny, B; Grześk, G; Nowaczyk, A; Rogowicz, D; Woźniak-Wiśniewska, A; Wołowiec, Ł, 2020
)
"Nintedanib is an orally available tyrosine kinase inhibitor that can treat CRC; however, drug resistance to nintedanib leads to unsatisfactory treatments for patients with CRC."( The microRNA-429/DUSP4 axis regulates the sensitivity of colorectal cancer cells to nintedanib.
Cheng, G; Li, Y; Liu, Z; Song, X, 2021
)
"Nintedanib is a multi-target receptor tyrosine kinase inhibitor that reduces the decline in forced vital capacity (FVC) and prevents acute exacerbations in idiopathic pulmonary fibrosis (IPF), which is a risk factor for lung cancer. "( Remarkable response of non-small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis.
Fukuoka, A; Hontsu, S; Kai, Y; Matsuda, M; Muro, S; Yamauchi, M; Yoshikawa, M, 2021
)
"Nintedanib is an approved treatment for IPF, which reduces the rate of decline in forced vital capacity (FVC)."( Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
Bargagli, E; Bendstrup, E; Bonella, F; Caro, F; Glaspole, I; Glassberg, MK; Orsatti, L; Quaresma, M; Stansen, W, 2021
)
"Nintedanib (NTB) is an FDA approved tyrosine kinase inhibitor for idiopathic pulmonary fibrosis (IPF) and chronic fibrosing interstitial lung diseases (ILD)."( Repurposing Nintedanib for pathological cardiac remodeling and dysfunction.
Lal, H; Sethu, P; Singh, AP; Tousif, S; Umbarkar, P; Zhang, Q, 2021
)
"Nintedanib is an antifibrotic agent approved by the United States Food and Drug Administration for the treatment of lung fibrosis. "( Nintedanib, a multitarget tyrosine kinase inhibitor, suppresses postoperative peritoneal adhesion formation in a rat model.
Fu, Y; Gong, T; Li, J; Li, X; Sang, M; Tsauo, J; Zhang, X; Zhao, H, 2021
)
"Nintedanib is a new antifibrotic agent that interferes with processes of pulmonary fibrosis."( Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study.
Fujimi, S; Minami, K; Mitsuyama, Y; Nishida, T; Nochioka, K; Okada, N; Umemura, Y; Watanabe, A; Yamakawa, K, 2021
)
"Nintedanib is an oral antiangiogenic agent that is approved in the EU and other countries in combination with docetaxel for the treatment of patients with advanced/metastatic lung adenocarcinoma after first-line chemotherapy."( Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma.
Atz, J; Azeh, I; Buchner, H; C Christoph, D; Hoffmann, C; Hoiczyk, M; Kambartel, K; Metzenmacher, M; Panse, J; Rizzo, F; Schaufler, D; Scheffler, M; Turki, AT, 2021
)
"Nintedanib (BIBF1120) is a triple kinase inhibitor of platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptors (FGFR), vascular endothelial growth factor receptor (VEGFR), and Src family kinase, which has recently been approved by FDA to treat idiopathic pulmonary fibrosis. "( Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
Jiang, W; Liu, F; Liu, N; Qi, H; Wang, J; Wang, L; Wang, Y; Xu, L; Zhuang, S, 2017
)
"Nintedanib is a new triple angiokinase oral inhibitor that potently blocks the proangiogenic pathways mediated by VEGFR, platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR)."( The potential role of nintedanib in treating colorectal cancer.
Chiarazzo, C; Di Maggio, G; Latiano, TP; Limosani, F; Maiello, E; Parente, P; Rossi, A, 2017
)
"Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF). "( Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
Assassi, S; Brown, KK; Coeck, C; Cottin, V; Distler, JHW; Distler, O; Gahlemann, M; Highland, KB; Maher, TM; Sauter, W; Schmidt, H; Varga, J,
)
"Nintedanib is an oral angiokinase inhibitor targeting multiple signaling pathways implicated in the pathogenesis of MPM, including the VEGF receptor."( LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Gaafar, R; Morsli, N; Nakano, T; Nowak, AK; Popat, S; Reck, M; Scagliotti, GV; Tsao, AS; van Meerbeeck, J; Velema, D; Vogelzang, NJ; von Wangenheim, U, 2017
)
"Nintedanib is a multi-tyrosine kinase receptor inhibitor recently approved for treatment of idiopathic pulmonary fibrosis. "( Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model.
Hur, J; Kang, JY; Kim, IK; Kim, YK; Kwon, SS; Lee, HY; Lee, SY; Rhee, CK; Yoon, HK,
)
"Nintedanib is a triple angiokinase inhibitor approved with docetaxel for adenocarcinoma non-small cell lung cancer after first-line chemotherapy (FLT). "( Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
Bennouna, J; Bondarenko, I; Douillard, JY; Gottfried, M; Heigener, DF; Kaiser, R; Krzakowski, M; Mellemgaard, A; Novello, S; Orlov, S; Reck, M; Stöhr, J; Summers, Y; von Pawel, J, 2017
)
"Nintedanib is an oral tyrosine kinase inhibitor targeting VEGF receptor 1-3, FGFR 1-3 and PDGFR α and β, which has entered phase III trial development in ovarian cancer."( Nintedanib in ovarian cancer.
Banerjee, S; Khalique, S, 2017
)
"Nintedanib is an inhibitor targeting platelet-derived growth factor receptor, fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases that has recently been approved for the treatment of idiopathic pulmonary fibrosis. "( Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
Beyer, C; Chen, CW; Dees, C; Distler, JHW; Distler, O; Harre, U; Huang, J; Maier, C; Schett, G; Soare, A; Wollin, L; Zhang, Y, 2017
)
"Nintedanib is a clinically approved multikinase receptor inhibitor to treat non-small cell lung cancer with adenocarcinoma (ADC) histology in combination with docetaxel, based on the clinical benefits reported on ADC but not on squamous cell carcinoma (SCC), which are the two most common histologic lung cancer subtypes."( Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.
Alcaraz, J; Gabasa, M; Hilberg, F; Ikemori, R; Reguart, N, 2017
)
"Nintedanib (BIBF 1200) is an oral tyrosine kinase inhibitor that targets the vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR) and fibroblast growth factor (FGFR) receptors. "( Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer.
Garcia-Carbonero, R; Riesco-Martinez, MC; Sanchez-Torre, A, 2017
)
"Nintedanib is a safe and effective treatment option for patients with IPF. "( Nintedanib for Idiopathic Pulmonary Fibrosis.
Tepede, A; Yogaratnam, D, 2019
)
"Nintedanib is a tyrosine-kinase inhibitor that blocks several profibrotic pathways, inhibiting proliferation and migration of fibroblasts and decreasing the synthesis of extracellular matrix proteins."( Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?
Cordeiro, A; Duarte, AC; Santos, MJ, 2018
)
"Nintedanib is an intracellular inhibitor of tyrosine kinases used in the treatment of non-small cell lung cancer and idiopathic pulmonary fibrosis (IPF). "( Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment.
Dallinger, C; Kraemer, S; Kretschmar, G; Kuelzer, R; Luedtke, D; Marzin, K; Schlenker-Herceg, R; Schmid, U; Schnell, D, 2018
)
"Nintedanib is a potent intracellular inhibitor of tyrosine kinases, including the receptor kinases vascular endothelial growth factor, platelet-derived growth factor and fibroblast growth factor. "( Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
Dallinger, C; Doege, C; Freiwald, M; Schmid, U, 2018
)
"Nintedanib is a tyrosine kinase inhibitor that efficiently slows idiopathic pulmonary fibrosis progression and has an acceptable tolerability profile."( Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
Rodríguez-Portal, JA, 2018
)
"Nintedanib is a substrate for p-glycoprotein which can impact bioavailability. "( Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects.
Dallinger, C; Jungnik, A; Luedtke, D; Marzin, K; von Wangenheim, U, 2018
)
"Nintedanib is an intracellular tyrosine kinase inhibitor approved in a treatment of idiopathic pulmonary fibrosis. "( [Nintedanib in the treatment of fibrosing interstital lung diseases].
Lewandowska, K, 2018
)
"Nintedanib is a multikinase inhibitor, and its efficacy on IPF was demonstrated in phase III trials."( Improvement in Patient-Reported Outcomes and Forced Vital Capacity during Nintedanib Treatment of Idiopathic Pulmonary Fibrosis.
Saitoh, M; Takeda, S; Takeda, T; Takeuchi, M, 2018
)
"Nintedanib is an approved treatment for idiopathic pulmonary fibrosis (IPF). "( Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Behr, J; Kolb, M; Martinez, FJ; Quaresma, M; Raghu, G; Richeldi, L; Schinzel, B; Stowasser, S; Wells, AU, 2018
)
"Nintedanib is a tyrosine kinase inhibitor with antifibrotic properties that has also been shown to significantly reduce the progression of the disease."( Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
Blaikley, J; Chaudhuri, N; Hayton, C; Leonard, C; Rivera-Ortega, P,
)
"Nintedanib is an oral multiple tyrosine kinases inhibitor, which targets angiogenesis."( Nintedanib for Advanced Epithelial Ovarian Cancer: A Change of Perspective? Summary of Evidence from a Systematic Review.
Barra, F; Casarin, J; Ferrero, S; Ghezzi, F; Laganà, AS, 2019
)
"Nintedanib is a new tyrosine kinase inhibitor and growth factor antagonist. "( A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology.
Du, K; Du, Y; Jiang, T; Li, D; Liu, H; Shen, Y; Webster, TJ; Xi, J; Xu, Y, 2018
)
"Nintedanib is an oral, triple kinase inhibitor that blocks these pathways and may improve anti-tumor activity by overcoming resistance to anti-VEGF therapies."( Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
Jerome, M; Jones, B; Keef, J; Li, P; Madan, A; Miley, D; Paluri, R; Robert, F; Saleh, M, 2019
)
"Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of adenocarcinoma tumour histology. "( Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Dallinger, C; Ebner, T; Freiwald, M; Lotz, R; Marzin, K; Schmid, U; Stopfer, P; Wind, S, 2019
)
"Nintedanib is a RET TKI that inhibits the vandetanib-resistant RET(G810A) mutant."( Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib.
Cai, J; Hilberg, F; Huang, Q; Liu, X; Mooers, BHM; Shen, T; Teng, P; Terzyan, SS; Wu, J; Zhou, M, 2019
)
"Nintedanib is an intracellular inhibitor of tyrosine kinases that has been approved for treatment of IPF and has recently been shown to reduce the rate of lung function decline in patients with ILD associated with systemic sclerosis (SSc-ILD)."( Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Distler, JHW; Kolb, M; Maher, TM; Redente, EF; Riches, DWH; Schlenker-Herceg, R; Stowasser, S; Wollin, L, 2019
)
"Nintedanib is a tyrosine kinase inhibitor whose targets include PDGF and FGF receptors."( Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation.
Harada, N; Kodama, Y; Kuriyama, S; Morio, Y; Nagaoka, T; Nagata, Y; Suzuki, Y; Takahashi, F; Takahashi, K; Tsutsumi, T; Wang, L; Yoshida, T, 2019
)
"Nintedanib is a triple angiokinase inhibitor that simultaneously acts on VEGFR, PDGFR and FGFR."( Nintedanib for the treatment of non-small-cell lung cancer.
Hanna, N; Rashdan, S, 2014
)
"Nintedanib is a triple-tyrosine kinase inhibitor and a potent antagonist of growth factors such as platelet-derived growth factor, vascular endothelial growth factor, and basic fibroblast growth factor, and it is currently evaluated in clinical trials as a potential IPF therapy."( Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis, IA, 2014
)
"Nintedanib is a potent, oral angiokinase inhibitor that targets VEGF, PDGF and FGF signalling, as well as RET and Flt3. "( Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis.
Büchert, M; Frost, A; Kaiser, R; Medinger, M; Mross, K; Stopfer, P; Studeny, M, 2014
)
"Nintedanib (Vargatef) is a potent, oral, triple angiokinase inhibitor of three distinct pro-angiogenic pathways."( Nintedanib for the treatment of patients with advanced non-small-cell lung cancer.
Heigener, D; Reck, M; Reinmuth, N, 2014
)
"Nintedanib is an oral, small-molecule tyrosine kinase inhibitor of PDGFR α/β, FGFR 1-3, and VEGFR 1-3 that may overcome resistance to anti-VEGF therapy."( Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.
Ahluwalia, MS; Dietrich, J; Doherty, LM; Gaffey, SC; LaFrankie, DC; Lee, EQ; Lesser, GJ; Ligon, KL; McCluskey, C; Muzikansky, A; Nayak, L; Norden, AD; Pulverenti, JR; Purow, B; Reardon, DA; Rifenburg, JA; Rinne, ML; Ruland, SF; Schiff, D; Smith, KH; Wen, PY, 2015
)
"Nintedanib (Ofev(®)) is an orally available, small, multiple receptor tyrosine kinase inhibitor developed by Boehringer Ingelheim for the treatment of idiopathic pulmonary fibrosis (IPF) and cancer. "( Nintedanib: first global approval.
McCormack, PL, 2015
)
"Nintedanib (BIBF1120) is a potent, oral, small-molecule tyrosine kinase inhibitor, also known as a triple angiokinase inhibitor, inhibiting three major signaling pathways involved in angiogenesis. "( Nintedanib: from discovery to the clinic.
Binder, R; Colbatzky, F; Dallinger, C; Hilberg, F; Kaiser, R; Roth, GJ; Schlenker-Herceg, R; Wollin, SL, 2015
)
"Nintedanib is a triple angiokinase inhibitor that targets VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β signaling."( Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.
Awasthi, N; Brekken, RA; Hinz, S; Schwarz, MA; Schwarz, RE, 2015
)
"Nintedanib is a potent small molecule inhibitor of the receptor tyrosine kinases PDGF receptor, FGF receptor and vascular endothelial growth factor receptor."( Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Hostettler, KE; Kolb, M; Pautsch, A; Schnapp, G; Stowasser, S; Wex, E; Wollin, L, 2015
)
"Nintedanib is a tyrosine kinase inhibitor that has recently been shown to slow disease progression in idiopathic pulmonary fibrosis in two replicate phase III clinical trials. "( Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Beyer, C; Distler, A; Distler, JH; Distler, O; Gelse, K; Huang, J; Palumbo-Zerr, K; Ramming, A; Schett, G; Wollin, L; Zhang, Y, 2016
)
"Nintedanib is a tyrosine kinase inhibitor that has recently been approved in the US and European Union for the treatment of IPF."( Nintedanib in the treatment of idiopathic pulmonary fibrosis.
Collard, HR; Mazzei, ME; Richeldi, L, 2015
)
"Nintedanib (Vargatef®) is a triple angiokinase inhibitor that potently blocks the proangiogenic pathways mediated by vascular endothelial growth factor receptors, platelet-derived growth factor receptors and fibroblast growth factor receptors. "( Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Dhillon, S, 2015
)
"Nintedanib is a novel triple angiokinase inhibitor that inhibits three growth factors simultaneously. "( Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties.
Chen, Y; Jiang, H; Pang, X; Peng, L; Xu, R; Yang, J; Zhan, M; Zhang, T; Zhao, L, 2015
)
"Nintedanib (BIBF-1120) is a multiple tyrosine kinase inhibitor recently approved by the U.S."( Novel Mechanisms for the Antifibrotic Action of Nintedanib.
Antony, VB; Bernard, K; Ding, Q; Kurundkar, A; Kurundkar, D; Rangarajan, S; Sanders, YY; Thannickal, VJ; Zhang, J; Zmijewski, J, 2016
)
"Nintedanib is a new tyrosine kinase inhibitor, which exerts its activity by blocking VEGF, FGF and PDGF receptors and inhibits the angiogenic signaling by preventing receptor dimerization."( Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.
Georgoulias, V; Nintos, G; Syrios, J, 2015
)
"Nintedanib is a novel, orally available triple angiokinase inhibitor that targets three important pathways involved in the initiation and propagation of angiogenesis in tumors, the VEGF, FGF and PDGFR pathways."( Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.
Jimeno, A; Man Wong, K; Noonan, S, 2015
)
"Nintedanib is a triple angiokinase inhibitor of VEGF, platelet-derived growth factor, and fibroblast growth factor signaling."( Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Stan
Hocke, J; Oum'Hamed, Z; Studeny, M; Tabernero, J; Van Cutsem, E; Yoshino, T, 2016
)
"Nintedanib (BIBF1120) is a multi-targeted angiokinase inhibitor and has been evaluated in idiopathic pulmonary fibrosis and advanced non-small cell lung cancer (NSCLC) patients in clinical studies. "( miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
Chiba, M; Gemma, A; Kubota, K; Matsumoto, M; Miyanaga, A; Nishijima, N; Noro, R; Seike, M; Soeno, C; Sugano, T, 2016
)
"Nintedanib is a multi-target receptor tyrosine kinase inhibitor. "( Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
Baba, T; Ikeda, S; Kitamura, H; Morita, M; Ogura, T; Sekine, A; Yamakawa, H, 2016
)
"Nintedanib is a potent, triple angiokinase inhibitor of vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor, and has been recently approved for the treatment of non-small cell lung cancer (NSCLC), following first-line chemotherapy. "( Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Epstein Shochet, G; Israeli-Shani, L; Koslow, M; Shitrit, D, 2016
)
"Nintedanib is an oral triple angiokinase inhibitor. "( A phase II study of nintedanib in patients with relapsed small cell lung cancer.
Han, JY; Hwangbo, B; Kim, HY; Lee, JS; Lim, KY, 2016
)
"Nintedanib is a triple angiokinase inhibitor that has been approved by the European Agency Medicines (EMA) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non small cell lung cancer (NSCLC) of adenocarcinoma tumour histology, after first-line chemotherapy. "( Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
Asensi Diez, R; Clopes Estela, A; Espinosa Bosch, M; García Agudo, S, 2016
)
"Nintedanib is a new anti-fibrosis agent that is an intracellular tyrosine kinase inhibitor targeting platelet derived growth factor receptor, fibroblast growth factor receptor and vascular endothelial growth factor receptor. "( Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.
Fukihara, J; Kondoh, Y, 2016
)
"Nintedanib is a potent small-molecule, triple-receptor tyrosine kinase inhibitor (VEGFR1, VEGFR2, and VEGFR3; fibroblast growth factor receptor 1 [FGFR1], FGFR2, and FGFR3; and PDGFRα and PDGFRß)."( Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Ahn, MJ; An, HJ; Cho, JY; Choi, MY; Kang, EJ; Keam, B; Kim, HR; Kim, J; Kim, Y; Lee, HY; Lee, JY; Lee, KE; Lee, KH; Lee, SH; Lee, SJ; Park, K; Sun, JM, 2017
)
"Nintedanib (BIBF 1120) is a small, orally available, triple angiokinase inhibitor in phase III development (various indications) that targets VEGFR 1-3, FGFR 1-3, and PDGFR-α/β. "( Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme.
Grunnet, K; Lassen, U; Muhic, A; Poulsen, HS; Sorensen, M, 2013
)

Effects

Nintedanib has a beneficial effect on slowing disease progression in patients with IPF. The drug has a low potential for drug-drug interactions, especially with drugs metabolised by cytochrome P450 enzymes.

Nintedanib (NTD) has been shown to be effective in systemic sclerosis (SSc)-interstitial lung disease (ILD) The drug has been approved for the treatment of idiopathic pulmonary fibrosis.

ExcerptReference
"Nintedanib has a low potential for drug-drug interactions, especially with drugs metabolised by cytochrome P450 enzymes."( Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Dallinger, C; Ebner, T; Freiwald, M; Lotz, R; Marzin, K; Schmid, U; Stopfer, P; Wind, S, 2019
)
"Nintedanib has a beneficial effect on slowing disease progression in patients with IPF."( Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Bailes, Z; Brown, KK; Cottin, V; du Bois, RM; Kimura, T; Richeldi, L; Schlenker-Herceg, R; Selman, M; Stowasser, S, 2016
)
"Nintedanib (NINT) has been used as a reference compound to investigate antifibrotic activity either for lung or skin fibrosis."( SSC-ILD mouse model induced by osmotic minipump delivered bleomycin: effect of Nintedanib.
Ferrini, E; Grandi, A; Khalajzeyqami, Z; Kleinjan, A; Nicastro, M; Ragionieri, L; Ravanetti, F; Ridwan, Y; Stellari, FF; Villetti, G, 2021
)
"Nintedanib (NTD) has been shown to be effective in systemic sclerosis (SSc)-interstitial lung disease (ILD). "( Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study.
Airo, P; Armentaro, G; Benfaremo, D; Beretta, L; Bosello, SL; Campochiaro, C; Confalonieri, M; Cuomo, G; Dagna, L; De Lorenzis, E; De Luca, G; Del Papa, N; Giuggioli, D; Lazzaroni, MG; Matucci-Cerinic, M; Moccaldi, B; Moroncini, G; Ruaro, B; Spinella, A; Stanziola, A; Vigone, B; Zanatta, E, 2023
)
"Nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis."( Combination treatment with Janus kinase inhibitor and nintedanib for rheumatoid arthritis with progressive interstitial lung disease: A case report.
Ikari, K; Mochizuki, T; Okazaki, K; Yano, K, 2023
)
"Nintedanib (Ninte) has been approved for the treatment of pulmonary fibrosis, and whether it can ameliorate chronic pancreatitis (CP) is unknown."( Nintedanib Alleviates Chronic Pancreatitis by Inhibiting the Activation of Pancreatic Stellate Cells via the JAK/STAT3 and ERK1/2 Pathways.
Dong, ZQ; Han, C; Hu, LH; Lv, YW; Wang, D; Wang, LJ; Wang, PY, 2023
)
"Nintedanib treatment has shown to be a promising approach for prostate cancer therapy, especially in the early stages of the disease, interfering in different carcinogenesis progression pathways."( Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
Agarwal, R; Alves, LF; Banzato, TP; Cagnon, VHA; Carvalho, JE; da Silva, RF, 2020
)
"Nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis (IPF). "( Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review.
Ishioka, Y; Itoga, M; Shiratori, T; Tabe, C; Taima, K; Takanashi, S; Tanaka, H; Tasaka, S; Tsuchiya, J, 2020
)
"Nintedanib (BIBF 1120) has been reported as being FGF and VEGF pathway inhibitors, exhibiting antitumor activity."( Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: contribution to the epithelial-stromal interaction balance.
Cagnon, VHA; da Silva, RF; Kido, LA; Montico, F; Nogueira Pangrazi, E, 2018
)
"Nintedanib has been shown to significantly reduce the annual rate of decline in the forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF) in previous randomized trials. "( Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib.
Fukuda, S; Fukumitsu, K; Ito, Y; Kanemitsu, Y; Maeno, K; Nakano, A; Niimi, A; Oguri, T; Ohkubo, H; Takemura, M, 2019
)
"Nintedanib has been clinically used to treat idiopathic pulmonary fibrosis for many years, but its effects in an animal model of NASH have not been tested."( Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
Imai, H; Kudo, H; Kuramoto, T; Kuranari, M; Li, L; Otani, N; Sekiguchi, A; Susutlertpanya, W; Uchida, T; Uemura, N; Wakuda, H, 2019
)
"Nintedanib (BIBF 1120) has been shown to block the vascular endothelial growth factor receptor (VEGFR), the platelet-derived growth factor receptor (PDGFR), and the fibroblast growth factor receptor (FGFR)."( What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
Capdevila, J; Carrato, A; Grande, E; Tabernero, J, 2014
)

Actions

Nintedanib can inhibit processes involved in the progression of fibrosis. It can reduce the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF)

ExcerptReference
"As nintedanib may cause foetal harm, patients taking nintedanib should avoid pregnancy."( A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Avis, M; Gahlemann, M; Guillén-Del-Castillo, A; Kreuter, M; Mack, SR; Marzin, K; Vonk, MC; Wind, S, 2022
)
"Nintedanib can inhibit processes involved in the progression of fibrosis and can reduce the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF) and fibrotic-interstitial lung disease (fibrotic-ILDs). "( The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials.
Chen, CH; Lai, CC; Lin, HC; Lin, YS; Wang, CY; Wang, YH, 2021
)

Treatment

Nintedanib is a licensed treatment for pulmonary fibrosis in adults. Treatment with nintedAnib may slow decline in lung function, decrease the frequency of exacerbations, and improve quality of life in subjects with IPF. Nintinganib treatment has shown to be a promising approach for prostate cancer therapy.

ExcerptReference
"Nintedanib treatment inhibited BLM-induced FAK activation and thus suppressed both in vivo and in vitro BLM-induced EndoMT."( Nintedanib Inhibits Endothelial Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis via Focal Adhesion Kinase Activity Reduction.
Chen, H; Chen, WC; Shen, HC; Su, VY; Wu, HH; Yang, KY; Yu, WK, 2022
)
"Nintedanib is a licensed treatment for pulmonary fibrosis in adults."( Nintedanib in children and adolescents with fibrosing interstitial lung diseases.
Bertulis, J; Brown, KK; Cunningham, S; DeBoer, EM; Deterding, R; Dumistracel, M; Erhardt, E; Flaherty, KR; Gahlemann, M; Griese, M; Schwerk, N; Stowasser, S; Warburton, D; Young, LR, 2023
)
"Nintedanib treatment has shown to be a promising approach for prostate cancer therapy, especially in the early stages of the disease, interfering in different carcinogenesis progression pathways."( Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
Agarwal, R; Alves, LF; Banzato, TP; Cagnon, VHA; Carvalho, JE; da Silva, RF, 2020
)
"Nintedanib treatment was able to significantly decrease the growth of PCa cell lines and also delay growth and progression of PCa lesions to higher grades of malignancy (without inducing any hepatotoxic effects) in TRAMP mice. "( Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
Agarwal, R; Arana, S; Cagnon, VHA; da Silva, RF; Kido, LA; Kumar, D; Montico, F; Nogueira-Pangrazi, E; Raina, K, 2017
)
"Nintedanib treatment did not affect right ventricular (RV) systolic pressure or total pulmonary resistance index in SuHx rats and had no effects on pulmonary vascular remodelling."( Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
Bogaard, HJ; da Silva Gonçalves Bos, D; de Man, FS; de Raaf, MA; Dickhoff, C; Goumans, MJ; Guignabert, C; Happé, C; Herrmann, FE; Koolwijk, P; Kuiper, VP; Kurakula, K; Lodder, K; Pan, X; Rol, N; Schalij, I; Sun, XQ; Szulcek, R; Thuillet, R; Tu, L; van Nieuw Amerongen, GP; Vonk-Noordegraaf, A; Wollin, L, 2019
)
"Nintedanib treatment resulted in modest disease stabilization in patients with metastatic esophagogastric cancer. "( Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer.
Basunia, A; Berger, MF; Boyar, MS; Capanu, M; Chalasani, SB; Chatila, WK; Chou, JF; Desai, AM; Goldberg, Z; Hechtman, JF; Ilson, DH; Janjigian, YY; Kelsen, DP; Ku, GY; Schattner, M; Schultz, N; Solit, DB; Tang, L; Tuvy, Y; Won, E, 2019
)
"Nintedanib-treated SKOV3 cells also showed colony compaction and decreases in EMT scores both in vitro and in vivo."( Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120).
Asad, M; Chung, VY; Huang, RY; Kuay, KT; Ng, AH; Tan, TZ; Tang, HM; Thiery, JP; Ye, J, 2015
)
"Nintedanib treatment did not increase local tumor invasiveness or metastasis to the liver and pancreatic lymph nodes--a phenomenon that has been observed with antiangiogenic treatments of Rip1Tag2 transgenic mice in other laboratories."( Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model.
Albrecht, I; Antoniadis, H; Bill, R; Christofori, G; Fagiani, E; Haefliger, S; Hilberg, F; Johansson, D; Zumsteg, A, 2015
)
"Nintedanib treatment was generally well tolerated and was associated with FVC stabilization in the majority of IPF patients in this CUP setting where most patients were not treatment naïve. "( Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis.
Bonella, F; Hagmeyer, L; Keller, C; Kohlhaeufl, MJ; Kreuter, M; Milger, K; Müller-Quernheim, J; Neurohr, C; Prasse, A, 2016
)
"Treatment with nintedanib blocked UUO-induced phosphorylation of PDGFRβ, FGFR1, FGFR2, VEGFR2, and several Src family kinases including Src, Lck, Lyn as well as activation of signal transducer and activator of transcription-3 (STAT3), nuclear factor-κB (NF-κB), and Smad-3 in the kidney."( Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
Jiang, W; Liu, F; Liu, N; Qi, H; Wang, J; Wang, L; Wang, Y; Xu, L; Zhuang, S, 2017
)
"Treatment with nintedanib/docetaxel significantly improved OS in European patients independently of age or prior therapy. "( Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study.
Bennouna, J; Bondarenko, I; Douillard, JY; Gottfried, M; Heigener, DF; Kaiser, R; Krzakowski, M; Mellemgaard, A; Novello, S; Orlov, S; Reck, M; Stöhr, J; Summers, Y; von Pawel, J, 2017
)
"Treatment with nintedanib also inhibited apoptosis of MVECs and blunted the capillary rarefaction in Fra2-transgenic mice."( Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
Beyer, C; Chen, CW; Dees, C; Distler, JHW; Distler, O; Harre, U; Huang, J; Maier, C; Schett, G; Soare, A; Wollin, L; Zhang, Y, 2017
)
"Treatment with nintedanib reduces the risk of acute exacerbations, and a combined analysis of data from clinical trials of nintedanib shows a trend towards a reduction in mortality."( Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
Rodríguez-Portal, JA, 2018
)
"Treatment with nintedanib resulted in an estimated total cost of €76,414 (vs €82,665 for pirfenidone). "( Health economic evaluation in idiopathic pulmonary fibrosis in France.
Bénard, S; Catella, L; Cottin, V; Le Lay, K; Luciani, L; Porte, F, 2018
)
"Treatment with nintedanib may slow decline in lung function, decrease the frequency of exacerbations, and improve quality of life in subjects with IPF."( Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis, IA, 2014
)

Toxicity

Nintedanib is effective and safe in patients with IPF aged >80 years. No significant differences were found when clinical outcomes were compared with those of younger patients. Placebo-controlled trials showed that the adverse event profile was characterised mainly by gastrointestinal events, particularly diarrhoea.

ExcerptReference
" Incidence and severity of adverse events (AEs) were reported."( A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.
Eschbach, C; Gatzemeier, U; Kaiser, R; Love, J; Reck, M; Stefanic, M; Stopfer, P; von Pawel, J, 2011
)
" The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61."( Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Azuma, A; Brown, KK; Brun, M; Collard, HR; Costabel, U; Cottin, V; Disse, B; du Bois, RM; Flaherty, KR; Girard, M; Hansell, DM; Inoue, Y; Kim, DS; Kolb, M; Le Maulf, F; Nicholson, AG; Noble, PW; Raghu, G; Richeldi, L; Schlenker-Herceg, R; Selman, M; Stowasser, S; Taniguchi, H, 2014
)
" Adverse events were reported in nine out of 17 patients receiving nintedanib alone and 10 out of 21 patients receiving nintedanib added to pirfenidone."( Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.
Abe, S; Azuma, A; Bando, M; Chida, K; Fujimoto, T; Hasegawa, Y; Inoue, Y; Klüglich, M; Kondoh, Y; Mochizuki, Y; Ogura, T; Okazaki, K; Sakamoto, W; Sugiyama, Y; Tadayasu, Y; Taniguchi, H, 2015
)
"Using pooled data from the replicate, randomized, 52-week, placebo-controlled INPULSIS(®) trials, we characterized the safety and tolerability of nintedanib 150 mg twice daily in patients with IPF and described how adverse events were managed during these trials."( Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
Bonella, F; Coeck, C; Corte, T; Crestani, B; Demedts, MG; Lasky, JA; Pelling, K; Quaresma, M; Richeldi, L, 2015
)
" Adverse events led to permanent treatment discontinuation in 19."( Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
Bonella, F; Coeck, C; Corte, T; Crestani, B; Demedts, MG; Lasky, JA; Pelling, K; Quaresma, M; Richeldi, L, 2015
)
" Recommendations for adverse event management minimized permanent treatment discontinuations in the INPULSIS(®) trials."( Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
Bonella, F; Coeck, C; Corte, T; Crestani, B; Demedts, MG; Lasky, JA; Pelling, K; Quaresma, M; Richeldi, L, 2015
)
" We evaluated the frequency of characteristic adverse events (AEs) commonly seen with existing anti-angiogenic agents."( Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
Aboshady, H; Barrueco, J; Bennouna, J; Bondarenko, I; Cheng, Y; Douillard, JY; Gottfried, M; Hocke, J; Kaiser, R; Luft, A; Mellemgaard, A; Reck, M; von Pawel, J; Zarogoulidis, K, 2015
)
"1%), and cutaneous adverse reactions (13."( Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
Aboshady, H; Barrueco, J; Bennouna, J; Bondarenko, I; Cheng, Y; Douillard, JY; Gottfried, M; Hocke, J; Kaiser, R; Luft, A; Mellemgaard, A; Reck, M; von Pawel, J; Zarogoulidis, K, 2015
)
" An increasing number of patients with IPF are receiving treatment with these novel therapies, and the risk of adverse events that may be associated with their use must be carefully evaluated."( The safety of new drug treatments for idiopathic pulmonary fibrosis.
Fletcher, S; Jones, MG; Limbrey, R; Marshall, BG; Richeldi, L; Sgalla, G; Spinks, K, 2016
)
" Areas covered: Most frequent adverse events reported in patients treated with nintedanib (gastrointestinal); additional adverse events of special interest (elevations in liver enzymes, bleeding, cardiovascular adverse events); recommendations for managing adverse events."( The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Cottin, V, 2017
)
"5%) also had a Common Terminology Criteria for Adverse Events (CTCAE) grade ≥2."( Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis.
Baba, T; Ikeda, S; Iwasawa, T; Kitamura, H; Oda, T; Ogura, T; Ohashi, K; Okuda, R; Okudela, K; Sadoyama, S; Sekine, A; Takemura, T; Yamakawa, H; Yamanaka, Y, 2017
)
" Nintedanib is well tolerated and has been shown to be safe for up to 51 months."( Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
Rodríguez-Portal, JA, 2018
)
"3%) was the most commonly reported adverse event."( Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.
Anagnostopoulos, A; Bouros, D; Bouros, E; Chrysikos, S; Dimakou, K; Granitsas, A; Karampitsakos, T; Kontou, M; Koulouris, N; Malliou, I; Ntolios, P; Steiropoulos, P; Tzilas, V; Tzouvelekis, A, 2018
)
"8%) had drug-related adverse events (AEs) or grade ≥ 3 AEs (67."( A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.
Deptala, A; Fartoux, L; Graham, J; Hocke, J; Loembé, AB; Ma, YT; Meyer, T; Palmer, DH; Peck-Radosavljevic, M; Ross, P; Schnell, D; Studeny, M, 2018
)
" Diarrhoea was the most frequent adverse event in INPULSIS-ON (60·1 events per 100 patient exposure-years in patients who continued nintedanib, 71·2 events per 100 patient exposure-years in patients who initiated nintedanib)."( Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Costabel, U; Crestani, B; Glaspole, I; Huggins, JT; Kaye, M; Kreuter, M; Ogura, T; Quaresma, M; Song, JW; Stansen, W; Stowasser, S, 2019
)
" Adverse events occurred in 97."( Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis.
Kim, DS; Park, S; Song, JW; Yoon, HY, 2018
)
" The aim of this study was to characterize IPF patients with a forced vital capacity (FVC) < 50% (group 1) and FVC 50-60% predicted (group 2) and analyze the effect and adverse events of nintedanib in Hungarian patients diagnosed between April 2015 and July 2017."( Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease.
Barczi, E; Bohacs, A; Eszes, N; Hejduk, K; Kolonics-Farkas, A; Müller, V; Starobinski, L; Vasakova, M, 2019
)
"The impact of nintedanib therapy on lung function, survival, and adverse events was analyzed longitudinally."( Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease.
Barczi, E; Bohacs, A; Eszes, N; Hejduk, K; Kolonics-Farkas, A; Müller, V; Starobinski, L; Vasakova, M, 2019
)
" Adverse events were less common than in clinical trials; dose reduction was necessary in three cases, drug discontinuation in two cases."( Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease.
Barczi, E; Bohacs, A; Eszes, N; Hejduk, K; Kolonics-Farkas, A; Müller, V; Starobinski, L; Vasakova, M, 2019
)
" Most G3 toxic events (5 out of 6: 2 diarrhea and 3 hypertransaminasemia) occurred subsequent to the DLT assessment period."( Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
Apala, JV; Colomer, R; Gonzalez-Cortijo, L; Guerra, J; Hornedo, J; Malon, D; Mouron, S; Quintela-Fandino, M, 2019
)
"Nintedanib slows disease progression in patients with idiopathic pulmonary fibrosis (IPF) by reducing the rate of decline in forced vital capacity, with an adverse event profile that is manageable for most patients."( Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
Crestani, B; Hernandez, P; Inoue, Y; Lancaster, L; Loaiza, L; Quaresma, M; Richeldi, L; Stowasser, S; Wachtlin, D, 2019
)
" All adverse events, irrespective of causality, were included in descriptive analyses."( Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
Crestani, B; Hernandez, P; Inoue, Y; Lancaster, L; Loaiza, L; Quaresma, M; Richeldi, L; Stowasser, S; Wachtlin, D, 2019
)
"Based on pooled data from six clinical trials, the adverse event profile of nintedanib was manageable for most patients."( Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
Crestani, B; Hernandez, P; Inoue, Y; Lancaster, L; Loaiza, L; Quaresma, M; Richeldi, L; Stowasser, S; Wachtlin, D, 2019
)
" Nausea was a significant adverse reaction (p < 0."( Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
Bast, A; Drent, M; Elfferich, MDP; Jessurun, NT; Proesmans, VLJ; Wijnen, PAHM, 2019
)
"Clinical trials have shown that nintedanib 150 mg twice daily (bid) reduces disease progression in patients with idiopathic pulmonary fibrosis (IPF), with an adverse event profile that is manageable for most patients."( Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil.
Alves, RLR; Baddini-Martinez, JA; Baldi, BG; Jezler, SFO; Pereira, CAC; Quaresma, M; Rabahi, MF; Rubin, AS; Trampisch, M; Zonzin, GA, 2019
)
" Safety assessments included adverse events leading to permanent discontinuation of nintedanib and serious adverse events."( Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil.
Alves, RLR; Baddini-Martinez, JA; Baldi, BG; Jezler, SFO; Pereira, CAC; Quaresma, M; Rabahi, MF; Rubin, AS; Trampisch, M; Zonzin, GA, 2019
)
" The most frequently reported adverse events considered by the investigator to be related to nintedanib treatment were diarrhea (45 patients, 78."( Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil.
Alves, RLR; Baddini-Martinez, JA; Baldi, BG; Jezler, SFO; Pereira, CAC; Quaresma, M; Rabahi, MF; Rubin, AS; Trampisch, M; Zonzin, GA, 2019
)
" Outcomes included the rate of decline in FVC over 24 weeks, the proportions of patients who had a confirmed or suspected idiopathic acute exacerbation over 24 weeks, deaths over 24 weeks, and adverse events."( Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
Jouneau, S; Kolb, M; Quaresma, M; Raghu, G; Richeldi, L; Schinzel, B; Stowasser, S; Wuyts, WA, 2020
)
" Diarrhoea adverse events were reported in 52."( Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
Jouneau, S; Kolb, M; Quaresma, M; Raghu, G; Richeldi, L; Schinzel, B; Stowasser, S; Wuyts, WA, 2020
)
" The most common grade 3 or 4 adverse reactions were fatigue (14%) and diarrhea (13%)."( Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma.
Acevedo-Delgado, JA; Acosta-Espinoza, A; Alatorre-Alexander, JA; Astorga-Ramos, AM; Barriguete-Parra, L; Campos-Gomez, S; Capdeville-García, D; Cázarez-Price, JC; Ceja-García, JP; Fernández-Garibay, VM; Flores-Anaya, N; Flores-Mariñelarena, RR; García-Montes, V; Gerson-Cwilich, R; González-Espinoza, IR; Gonzalez-Villanueva, JI; Kuri-Exsome, R; Magallanes-Maciel, M; Martínez-Barrera, L; Noriega-Iriondo, MF; Perales-Rodríguez, E; Perez-Lozano, Y; Rodríguez-Cid, JR; Rodríguez-Silva, C; Suárez-García, D; Vázquez-Cortés, L; Villalobos-Prieto, A; Zuloaga-Fernandez, CJ, 2020
)
"To characterise the safety and tolerability of nintedanib and the dose adjustments used to manage adverse events in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)."( Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Alves, M; Assassi, S; Azuma, A; Costabel, U; Distler, O; Gahlemann, M; Highland, KB; Hummers, LK; Kohlbrenner, V; Maher, TM; Seibold, JR; von Wangenheim, U, 2020
)
" To manage adverse events, treatment could be interrupted or the dose reduced to 100 mg two times per day."( Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Alves, M; Assassi, S; Azuma, A; Costabel, U; Distler, O; Gahlemann, M; Highland, KB; Hummers, LK; Kohlbrenner, V; Maher, TM; Seibold, JR; von Wangenheim, U, 2020
)
" The most common adverse event was diarrhoea, reported in 75."( Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Alves, M; Assassi, S; Azuma, A; Costabel, U; Distler, O; Gahlemann, M; Highland, KB; Hummers, LK; Kohlbrenner, V; Maher, TM; Seibold, JR; von Wangenheim, U, 2020
)
"The adverse event profile of nintedanib in patients with SSc-ILD is consistent with its established safety and tolerability profile in patients with idiopathic pulmonary fibrosis."( Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
Alves, M; Assassi, S; Azuma, A; Costabel, U; Distler, O; Gahlemann, M; Highland, KB; Hummers, LK; Kohlbrenner, V; Maher, TM; Seibold, JR; von Wangenheim, U, 2020
)
" The database included spontaneously reported adverse events and data collected via solicited reporting in patients treated with nintedanib from 15 October 2014 to 15 October 2018."( Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data.
Bender, S; Criner, GJ; Kohlbrenner, V; Lasky, JA; Lazarus, HM; Richeldi, L, 2020
)
" Major cardiovascular adverse events were reported at a rate of 13."( Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data.
Bender, S; Criner, GJ; Kohlbrenner, V; Lasky, JA; Lazarus, HM; Richeldi, L, 2020
)
" Adverse events were seen in all patients, and the rates of patients who discontinued nintedanib were also comparable (38."( Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis.
Fuchimoto, Y; Hara, N; Higo, H; Ichikawa, H; Itano, J; Kajimoto, K; Kanehiro, A; Kano, H; Kiura, K; Kudo, K; Kuyama, S; Maeda, Y; Miyahara, N; Oda, N; Senoo, S; Shibayama, T; Suwaki, T; Taniguchi, A; Tanimoto, Y; Watanabe, H, 2020
)
" Patient characteristics, treatment status, and adverse events (AEs) were compared between the elderly group and 126 patients with IPF, aged <75 years, with newly prescribed nintedanib during the same period (non-elderly group)."( Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis.
Baba, T; Ikeda, S; Katano, T; Kitamura, H; Komatsu, S; Oda, T; Ogura, T; Okuda, R; Sekine, A; Tabata, E; Uchida, Y, 2021
)
"In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks by 44% in comparison with placebo, with manageable adverse events in most patients."( Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
Alves, M; Azuma, A; Behera, D; Chung, L; Chung, M; Gahlemann, M; Kondoh, Y; Kuwana, M; Meng, X; Ogura, T; Okamoto, M; Swarnakar, R; Zeng, X; Zou, H, 2021
)
" Diarrhea was the most frequent adverse event and was reported in similar proportions of Asian and non-Asian patients in the nintedanib group (80."( Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
Alves, M; Azuma, A; Behera, D; Chung, L; Chung, M; Gahlemann, M; Kondoh, Y; Kuwana, M; Meng, X; Ogura, T; Okamoto, M; Swarnakar, R; Zeng, X; Zou, H, 2021
)
"In patients with SSc-ILD, nintedanib had a consistent benefit on slowing the progression of SSc-ILD in Asian and non-Asian patients, with a similar adverse event profile."( Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
Alves, M; Azuma, A; Behera, D; Chung, L; Chung, M; Gahlemann, M; Kondoh, Y; Kuwana, M; Meng, X; Ogura, T; Okamoto, M; Swarnakar, R; Zeng, X; Zou, H, 2021
)
" Adverse events were reported in subgroups by mycophenolate use at baseline."( Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Allanore, Y; Assassi, S; Azuma, A; Bourdin, A; Clerisme-Beaty, E; Denton, CP; Distler, JHW; Distler, O; Gahlemann, M; Girard, M; Highland, KB; Hoffmann-Vold, AM; Khanna, D; Kuwana, M; Maher, TM; Mayes, MD; Raghu, G; Stowasser, S; Vonk, MC; Zoz, D, 2021
)
" The adverse event profile of nintedanib was similar between the subgroups."( Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Allanore, Y; Assassi, S; Azuma, A; Bourdin, A; Clerisme-Beaty, E; Denton, CP; Distler, JHW; Distler, O; Gahlemann, M; Girard, M; Highland, KB; Hoffmann-Vold, AM; Khanna, D; Kuwana, M; Maher, TM; Mayes, MD; Raghu, G; Stowasser, S; Vonk, MC; Zoz, D, 2021
)
" The adverse event profile of nintedanib was similar in the subgroups by mycophenolate use."( Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Allanore, Y; Assassi, S; Azuma, A; Bourdin, A; Clerisme-Beaty, E; Denton, CP; Distler, JHW; Distler, O; Gahlemann, M; Girard, M; Highland, KB; Hoffmann-Vold, AM; Khanna, D; Kuwana, M; Maher, TM; Mayes, MD; Raghu, G; Stowasser, S; Vonk, MC; Zoz, D, 2021
)
" We review the evidence supporting this hypothesis and discuss possible actions for a safe implementation of nintedanib in clinical practice, building on the experience with tyrosine kinase inhibitors acquired in cardio-oncology."( Cardiovascular safety of the tyrosine kinase inhibitor nintedanib.
Ameri, P; Mercurio, V; Porto, I; Spallarossa, P; Tini, G; Tocchetti, CG, 2021
)
" Patient's counseling during treatment remains essential to manage emerging adverse events and eventually inform the decision of drug discontinuation."( An updated safety review of the drug treatments for idiopathic pulmonary fibrosis.
Comes, A; Richeldi, L; Sgalla, G, 2021
)
" The adverse event profile of nintedanib was generally similar across subgroups."( Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
Bargagli, E; Bendstrup, E; Bonella, F; Caro, F; Glaspole, I; Glassberg, MK; Orsatti, L; Quaresma, M; Stansen, W, 2021
)
" Proactive management of adverse events is important to reduce the impact of adverse events and help patients remain on therapy."( Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
Bargagli, E; Bendstrup, E; Bonella, F; Caro, F; Glaspole, I; Glassberg, MK; Orsatti, L; Quaresma, M; Stansen, W, 2021
)
" Although the adverse events associated with nintedanib in IPF patients are well known, its safety in other fibrotic-ILD patients remained unclear."( The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials.
Chen, CH; Lai, CC; Lin, HC; Lin, YS; Wang, CY; Wang, YH, 2021
)
" We estimated pooled odds ratios (ORs) and 95% confidence intervals (CIs) for adverse events using the DerSimonian-Laird random-effects model."( The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials.
Chen, CH; Lai, CC; Lin, HC; Lin, YS; Wang, CY; Wang, YH, 2021
)
"Compared to a placebo, nintedanib was associated with a higher risk of adverse events, especially for diarrhea, nausea, vomiting and weight loss, but it was also associated with a lower risk of cough and dyspnea in IPF and fibrotic-ILD patients."( The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials.
Chen, CH; Lai, CC; Lin, HC; Lin, YS; Wang, CY; Wang, YH, 2021
)
" Adverse events and adverse drug reactions (ADRs) were reported through a retrospective review of medical records."( Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan.
Bando, M; Hara, H; Hashimoto, S; Hisata, S; Homma, S; Inase, N; Izumi, S; Kataoka, K; Kato, M; Mukae, H; Nishioka, Y; Ogura, T; Saito, Y; Sakamoto, S; Shimizu, Y; Tanino, Y; Waseda, Y; Watanabe, K; Yatera, K, 2021
)
" The secondary endpoints were length of mechanical ventilation, volume of lung injury, and the incidence of gastrointestinal adverse events and acute liver failure."( Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study.
Fujimi, S; Minami, K; Mitsuyama, Y; Nishida, T; Nochioka, K; Okada, N; Umemura, Y; Watanabe, A; Yamakawa, K, 2021
)
" There were no significant differences in the adverse events."( Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study.
Fujimi, S; Minami, K; Mitsuyama, Y; Nishida, T; Nochioka, K; Okada, N; Umemura, Y; Watanabe, A; Yamakawa, K, 2021
)
" Common treatment-related adverse events (all grades) were diarrhoea (35."( Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-
Bovée, JVMG; Brahmi, M; Charon-Barra, C; Cousin, S; de Haan, J; De Meulemeester, L; Domènech, M; Dudzisz-Śledź, M; Estival, A; Gelderblom, H; Karavasilis, V; Litière, S; Marquina, G; Marreaud, S; Olungu, C; Schöffski, P; Steeghs, N; Toulmonde, M; Wozniak, A, 2021
)
" Although nintedanib has a manageable safety and tolerability profile over long-term use, it was discontinued in over 20% of patients because of adverse events such as diarrhoea and liver dysfunction."( Efficacy and safety of nintedanib in Japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study.
Hamada, N; Hosogaya, N; Ichikado, K; Ichiyasu, H; Ishii, H; Morimoto, S; Mukae, H; Okamoto, M; Sakamoto, N; Tobino, K, 2021
)
" The safety endpoint-occurrence of adverse events-will be assessed in each system organ class/preferred term."( Efficacy and safety of nintedanib in Japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study.
Hamada, N; Hosogaya, N; Ichikado, K; Ichiyasu, H; Ishii, H; Morimoto, S; Mukae, H; Okamoto, M; Sakamoto, N; Tobino, K, 2021
)
" In this study, we sought to determine whether switching treatment to nintedanib is feasible and safe in patients that had to discontinue treatment with pirfenidone due to side effects."( Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study.
Anevlavis, S; Archontogeorgis, K; Bonelis, K; Froudarakis, M; Ntolios, P; Paxinou, N; Steiropoulos, P; Voulgaris, A, 2021
)
" After the initiation of nintedanib, diarrhea was the most common side effect (66."( Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study.
Anevlavis, S; Archontogeorgis, K; Bonelis, K; Froudarakis, M; Ntolios, P; Paxinou, N; Steiropoulos, P; Voulgaris, A, 2021
)
"These results suggest that nintedanib is a safe option for the treatment of patients that had to discontinue pirfenidone due to adverse reactions."( Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study.
Anevlavis, S; Archontogeorgis, K; Bonelis, K; Froudarakis, M; Ntolios, P; Paxinou, N; Steiropoulos, P; Voulgaris, A, 2021
)
" To manage adverse events, treatment could be interrupted or the dose reduced to 100 mg twice daily."( Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
Belperio, JA; Coeck, C; Costabel, U; Cottin, V; Jenkins, RG; Kitamura, H; Lievens, D; Martinez, FJ; Molina-Molina, M; Tschoepe, I, 2022
)
" Adverse events led to treatment discontinuation in 22."( Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
Belperio, JA; Coeck, C; Costabel, U; Cottin, V; Jenkins, RG; Kitamura, H; Lievens, D; Martinez, FJ; Molina-Molina, M; Tschoepe, I, 2022
)
"The adverse event profile of nintedanib in patients with progressive fibrosing ILDs other than IPF is consistent with its established safety and tolerability profile in patients with IPF and characterized mainly by gastrointestinal events, particularly diarrhea."( Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
Belperio, JA; Coeck, C; Costabel, U; Cottin, V; Jenkins, RG; Kitamura, H; Lievens, D; Martinez, FJ; Molina-Molina, M; Tschoepe, I, 2022
)
" Four patients developed grade 1-2 immune related adverse events (irAE)."( Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Abbassi, A; Adam, J; Bahleda, R; Baldini, C; Bigorgne, A; Boselli, L; Bredel, D; Cassard, L; Champiat, S; Chaput, N; Danlos, FX; Escriou, G; Farhane, S; Gazzah, A; Grivel, J; Grynszpan, L; Halse, H; Hollebecque, A; Lacroix, L; Laghouati, S; Marabelle, A; Martin-Romano, P; Massard, C; Michot, JM; Mohamed-Djalim, C; Mouraud, S; Parpaleix, A; Postel-Vinay, S; Rafie, S; Ribrag, V; Signolle, N; Soria, JC; Susini, S; Texier, M; Varga, A; Vuagnat, P; Zitvogel, L, 2022
)
"While pirfenidone and nintedanib have greatly influenced the treatment of idiopathic pulmonary fibrosis (IPF), both drugs have significant early adverse drug reactions (ADRs) and almost nothing is known of their rare and delayed ADRs."( Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients.
Bouzillé, G; Fournier, D; Jouneau, S; Osmont, MN; Polard, E; Scailteux, LM, 2022
)
" The most common adverse event over the whole trial in nintedanib-treated Japanese patients was diarrhea, which was manageable for most patients by dose reduction and interruption."( Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.
Azuma, A; Inase, N; Inoue, Y; Ito, T; Nishioka, Y; Ogura, T; Okamoto, M; Rohr, KB; Suda, T; Takizawa, A, 2022
)
" Diarrhea was the most frequent adverse event (AE)."( Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years.
Alfano, F; Centanni, S; Chiesa, A; Conti, C; Di Marco, F; Mondoni, M; Muscato, G; Richeldi, L; Saderi, L; Sotgiu, G; Vancheri, C; Varone, F, 2023
)
"Nintedanib is effective and safe in patients with IPF aged >80 years, and no significant differences were found when clinical outcomes were compared with those of younger patients."( Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years.
Alfano, F; Centanni, S; Chiesa, A; Conti, C; Di Marco, F; Mondoni, M; Muscato, G; Richeldi, L; Saderi, L; Sotgiu, G; Vancheri, C; Varone, F, 2023
)
" Placebo-controlled trials showed that the adverse event profile of nintedanib was characterised mainly by gastrointestinal events, particularly diarrhoea."( A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Cottin, V; Podolanczuk, AJ, 2023
)
" NIN can frequently cause gastrointestinal adverse effects."( Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects.
Carrozzi, L; Da Rio, M; Della Rossa, A; Di Battista, M; Morganti, R; Mosca, M; Pistelli, F; Puccetti, L; Romei, C; Rossi, A; Tavanti, L; Tavoni, A, 2023
)
" Particular attention was paid to possible adverse effects and strategies adopted to manage them."( Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects.
Carrozzi, L; Da Rio, M; Della Rossa, A; Di Battista, M; Morganti, R; Mosca, M; Pistelli, F; Puccetti, L; Romei, C; Rossi, A; Tavanti, L; Tavoni, A, 2023
)
" No significant differences emerged between the two cohorts regarding the frequency of any possible adverse effect."( Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects.
Carrozzi, L; Da Rio, M; Della Rossa, A; Di Battista, M; Morganti, R; Mosca, M; Pistelli, F; Puccetti, L; Romei, C; Rossi, A; Tavanti, L; Tavoni, A, 2023
)
" A combination of multiple managing strategies and dose adjustment appears essential to cope optimally with NIN adverse effects."( Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects.
Carrozzi, L; Da Rio, M; Della Rossa, A; Di Battista, M; Morganti, R; Mosca, M; Pistelli, F; Puccetti, L; Romei, C; Rossi, A; Tavanti, L; Tavoni, A, 2023
)
"2%) experienced adverse events (AEs), most frequently gastrointestinal; diarrhea (n = 29, 30."( Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis.
Badovinac, S; Bitar, L; Jakopovic, M; Janzic, U; Korsic, M; Kukulj, S; Ljubicic, L; Mohorcic, K; Plestina, S; Samarzija, M; Seiwerth, F; Terglav, AS; Unk, M, 2023
)
" Adverse events (AEs) were also evaluated."( Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
Lorence, RM; Radonjic, D; Reck, M; Schuette, W; Urban, T; von Wangenheim, U; Westeel, V, 2023
)

Pharmacokinetics

A population pharmacokinetic model was developed for nintedanib in patients with non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF) Pharmacokinetic analysis indicated oral-delivered nintinganib plasma exposure and lung tissue partitioning were not dose-proportional and resulting lung levels were substantially higher than blood.

ExcerptReference
" We have done a phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamic biomarkers of BIBF 1120."( Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors.
Arao, T; Kaiser, R; Kaneda, H; Konishi, K; Miyazaki, M; Morinaga, R; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Sarashina, A; Satoh, T; Terashima, M; Tsuya, A; Ueda, S, 2010
)
" This study examined the antitumor effects of BIBF 1120 on hepatocellular carcinoma (HCC) and attempted to identify a pharmacodynamic biomarker for use in early clinical trials."( Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.
Aomatsu, K; Arao, T; De Velasco, MA; Fujita, Y; Furuta, K; Kaneda, H; Kudo, K; Kudo, M; Matsumoto, K; Nagai, T; Nishio, K; Saijo, N; Sakai, K; Tamura, D; Tanaka, K, 2011
)
" For the pharmacodynamic study, the phosphorylation levels of VEGFR2 in VEGF-stimulated peripheral blood leukocytes (PBL) were evaluated in mice inoculated with HCC cells and treated with BIBF 1120."( Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.
Aomatsu, K; Arao, T; De Velasco, MA; Fujita, Y; Furuta, K; Kaneda, H; Kudo, K; Kudo, M; Matsumoto, K; Nagai, T; Nishio, K; Saijo, N; Sakai, K; Tamura, D; Tanaka, K, 2011
)
" A flow cytometric analysis revealed that BIBF 1120 significantly decreased the phosphotyrosine (pTyr) levels of VEGFR2(+)CD45(dim) PBLs and the percentage of VEGFR2(+)pTyr(+) PBLs in vivo; the latter parameter seemed to be a more feasible pharmacodynamic biomarker."( Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.
Aomatsu, K; Arao, T; De Velasco, MA; Fujita, Y; Furuta, K; Kaneda, H; Kudo, K; Kudo, M; Matsumoto, K; Nagai, T; Nishio, K; Saijo, N; Sakai, K; Tamura, D; Tanaka, K, 2011
)
"We found that BIBF 1120 exhibited potent antitumor and antiangiogenic activity against HCC and identified VEGFR2(+)pTyr(+) PBLs as a feasible and noninvasive pharmacodynamic biomarker in vivo."( Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.
Aomatsu, K; Arao, T; De Velasco, MA; Fujita, Y; Furuta, K; Kaneda, H; Kudo, K; Kudo, M; Matsumoto, K; Nagai, T; Nishio, K; Saijo, N; Sakai, K; Tamura, D; Tanaka, K, 2011
)
"3 h and gMean terminal half-life was 13."( Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers.
Bischoff, D; Ebner, T; Kaiser, R; Lüdtke, S; Marzin, K; Rathgen, K; Stopfer, P; Wagner, K, 2011
)
" In particular, deuterated compound SKLB-C2202 had significantly improved pharmacokinetic properties compared with nintedanib."( Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties.
Chen, Y; Jiang, H; Pang, X; Peng, L; Xu, R; Yang, J; Zhan, M; Zhang, T; Zhao, L, 2015
)
" The method was successfully applied to a pharmacokinetic study of nintedanib and BIBF 1202 in rats after oral administration of nintedanib."( Simultaneous determination of nintedanib and its metabolite by UPLC-MS/MS in rat plasma and its application to a pharmacokinetic study.
Lin, D; Liu, XS; Liu, Y; Qiao, LM; Zhang, YN, 2016
)
"A population pharmacokinetic model was developed for nintedanib in patients with non-small cell lung cancer (NSCLC) or idiopathic pulmonary fibrosis (IPF)."( Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Dallinger, C; Fleury, A; Freiwald, M; Liesenfeld, KH; Schmid, U, 2018
)
"This model adequately described the pharmacokinetic profile of nintedanib in NSCLC and IPF populations and can be used for simulations exploring covariate effects and exposure-response analyses."( Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Dallinger, C; Fleury, A; Freiwald, M; Liesenfeld, KH; Schmid, U, 2018
)
"The magnitude of interindividual pharmacokinetic variability (IIV) of a drug and the factors responsible for this variability are intensively studied before-and sometimes after-registration as crucial information in anticipating and understanding variability in toxicity and efficacy."( Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.
Bruno, R; Chatelut, E; Ratain, MJ, 2018
)
" Studies in healthy volunteers and in patients with advanced cancer have shown that nintedanib has time-independent pharmacokinetic characteristics."( Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Dallinger, C; Ebner, T; Freiwald, M; Lotz, R; Marzin, K; Schmid, U; Stopfer, P; Wind, S, 2019
)
" However, no pharmacodynamic studies have addressed the effects of this combined target modulation."( Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
Apala, JV; Colomer, R; Gonzalez-Cortijo, L; Guerra, J; Hornedo, J; Malon, D; Mouron, S; Quintela-Fandino, M, 2019
)
" FGF23 and 17-B-estradiol levels were determined on days 0 and 15; pharmacokinetic parameters were assessed on days 1 and 28."( Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
Apala, JV; Colomer, R; Gonzalez-Cortijo, L; Guerra, J; Hornedo, J; Malon, D; Mouron, S; Quintela-Fandino, M, 2019
)
" Nintedanib and letrozole displayed a pharmacokinetic interaction that led to three- and twofold increases in their respective plasma concentrations."( Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition.
Apala, JV; Colomer, R; Gonzalez-Cortijo, L; Guerra, J; Hornedo, J; Malon, D; Mouron, S; Quintela-Fandino, M, 2019
)
" Pharmacokinetic analysis indicated oral-delivered nintedanib plasma exposure and lung tissue partitioning were not dose-proportional and resulting lung levels were substantially higher than blood."( Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship.
Ask, K; Bardestein-Wald, B; Beck, S; Epstein-Shochet, G; Hayat, A; Kolb, MR; Mekhael, O; Montgomery, AB; Naiel, S; Pham, S; Revill, S; Shitrit, D; Surber, MW; Vierhout, M, 2020
)
" To predict effectiveness treating IPF, inhalation was used as a tool to dissect the pharmacokinetic components required for nintedanib pulmonary anti-fibrotic activity."( Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis.
Baily, J; Beck, S; Gandi, SK; Marsden, AT; McElroy, MC; Pham, S; Surber, MW, 2020
)
" Pharmacokinetic data from 15 patients were analysed."( A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Avis, M; Gahlemann, M; Guillén-Del-Castillo, A; Kreuter, M; Mack, SR; Marzin, K; Vonk, MC; Wind, S, 2022
)
"23 times greater in Sprague-Dawley male rats compared to marketed formulation, according to in vivo pharmacokinetic data."( Bioavailability enhancement of vitamin E TPGS liposomes of nintedanib esylate: formulation optimization, cytotoxicity and pharmacokinetic studies.
Chinni, S; Kala, SG, 2022
)

Compound-Compound Interactions

Nintedanib is a triple angiokinase inhibitor that has been approved by the European Agency Medicines (EMA) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent lung cancer.

ExcerptReference
"The purpose of the phase I dose-escalation study was to evaluate the maximum tolerated dose (MTD) of BIBF 1120, an oral triple angiokinase inhibitor of vascular endothelial growth factor, platelet derived growth factor and fibroblast growth factor receptors, combined with paclitaxel and carboplatin."( A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.
du Bois, A; Harter, P; Huober, J; Loibl, S; Pfisterer, J; Reichardt, VL; Stopfer, P; Wimberger, P, 2010
)
") continuously at 100, 150, 200 or 250 mg, combined with paclitaxel (175 mg/m(2)) and carboplatin (area under the curve 5 min."( A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.
du Bois, A; Harter, P; Huober, J; Loibl, S; Pfisterer, J; Reichardt, VL; Stopfer, P; Wimberger, P, 2010
)
" This combination had an acceptable safety profile and no clinically relevant drug-drug interactions."( A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.
du Bois, A; Harter, P; Huober, J; Loibl, S; Pfisterer, J; Reichardt, VL; Stopfer, P; Wimberger, P, 2010
)
" This phase I, open-label dose-escalation study investigated BIBF 1120 combined with paclitaxel (Taxol) and carboplatin in first-line patients with advanced (IIIB/IV) non-small-cell lung cancer."( A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
Camidge, DR; Conkling, P; Doebele, RC; Kaiser, R; Otterson, GA; Stopfer, P; Traynor, AM; Wind, S; Zhao, Y, 2012
)
" in combination with paclitaxel and carboplatin."( A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
Camidge, DR; Conkling, P; Doebele, RC; Kaiser, R; Otterson, GA; Stopfer, P; Traynor, AM; Wind, S; Zhao, Y, 2012
)
"d when given with paclitaxel and carboplatin; this combination demonstrated an acceptable safety profile."( A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.
Camidge, DR; Conkling, P; Doebele, RC; Kaiser, R; Otterson, GA; Stopfer, P; Traynor, AM; Wind, S; Zhao, Y, 2012
)
"This phase I, open-label study evaluated the safety/tolerability and maximum tolerated dose of second-line nintedanib combined with docetaxel in Japanese patients with advanced non-small-cell lung cancer."( Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
Azuma, K; Hayashi, H; Hirai, F; Kaiser, R; Kaneda, H; Konishi, K; Kurata, T; Miyazaki, M; Nakagawa, K; Okamoto, I; Sarashina, A; Seto, T; Takeda, M; Terashima, M; Tsurutani, J; Yagi, N, 2015
)
"5), respectively, in combination with 75 mg/m(2) of docetaxel."( Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
Azuma, K; Hayashi, H; Hirai, F; Kaiser, R; Kaneda, H; Konishi, K; Kurata, T; Miyazaki, M; Nakagawa, K; Okamoto, I; Sarashina, A; Seto, T; Takeda, M; Terashima, M; Tsurutani, J; Yagi, N, 2015
)
"Continuous treatment with second-line nintedanib combined with docetaxel was manageable and showed promising signs of efficacy in Japanese patients with advanced non-small-cell lung cancer."( Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
Azuma, K; Hayashi, H; Hirai, F; Kaiser, R; Kaneda, H; Konishi, K; Kurata, T; Miyazaki, M; Nakagawa, K; Okamoto, I; Sarashina, A; Seto, T; Takeda, M; Terashima, M; Tsurutani, J; Yagi, N, 2015
)
"To evaluate the safety and maximum tolerated dose (MTD) of afatinib combined with nintedanib."( A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
Gordon, MS; LoRusso, PM; Ould-Kaci, M; Springett, GM; Su, YB; Wind, S; Zhao, Y, 2015
)
" This study determined the maximum tolerated dose (MTD) and pharmacokinetics of volasertib combined with nintedanib, a potent and orally bioavailable triple angiokinase inhibitor, in patients with advanced solid tumors."( A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
Cascinu, S; Clementi, L; de Braud, F; De Pas, T; Liu, D; Pilz, K; Sikken, P; Spitaleri, G, 2015
)
" The primary objective was the MTD of volasertib in combination with nintedanib."( A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
Cascinu, S; Clementi, L; de Braud, F; De Pas, T; Liu, D; Pilz, K; Sikken, P; Spitaleri, G, 2015
)
"Volasertib could be combined with fixed-dose nintedanib at the recommended single-agent dose."( A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
Cascinu, S; Clementi, L; de Braud, F; De Pas, T; Liu, D; Pilz, K; Sikken, P; Spitaleri, G, 2015
)
"This open-label, phase I, dose-escalation part of a phase I/II study evaluated the safety, pharmacokinetics, and preliminary efficacy of nintedanib, a triple angiokinase inhibitor, combined with pemetrexed in Japanese patients with advanced non-small cell lung cancer (NSCLC) after first-line chemotherapy."( Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.
Daga, H; Goto, K; Kaiser, R; Kaneda, H; Konishi, K; Miyazaki, M; Nakagawa, K; Okada, H; Okamoto, I; Sarashina, A; Takeda, K; Tanaka, T; Ueda, S; Yoh, K, 2015
)
"Nintedanib is a triple angiokinase inhibitor that has been approved by the European Agency Medicines (EMA) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non small cell lung cancer (NSCLC) of adenocarcinoma tumour histology, after first-line chemotherapy."( Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer; GENESIS-SEFH drug evaluation report.
Asensi Diez, R; Clopes Estela, A; Espinosa Bosch, M; García Agudo, S, 2016
)
"Nintedanib (BIBF 1120), a potent multikinase inhibitor of VEGFR-1/-2/-3, FGFR-1/-2/-3 and PDGFR-α/-β, exerts growth inhibitory and pro-apoptotic effects in myeloid leukemic cells, especially when used in combination with cytarabine."( A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.
Angenendt, L; Berdel, WE; Butterfass-Bahloul, T; Edemir, S; Gerss, J; Kewitz, T; Knoblauch, N; Krug, U; Mikesch, JH; Müller-Tidow, C; Sauer, T; Schliemann, C; Urban, M; Vehring, K; Wiebe, S, 2016
)
" The primary objective of this first in-human study was to evaluate the safety and tolerability of nintedanib in combination with bevacizumab."( Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
Jerome, M; Jones, B; Keef, J; Li, P; Madan, A; Miley, D; Paluri, R; Robert, F; Saleh, M, 2019
)
"In contrast to VEGF pathway-targeting antibodies, antiangiogenic tyrosine kinase inhibitors (TKIs) have failed to meet primary endpoints in almost all phase III clinical trials when combined with conventional chemotherapy."( Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity.
Hilberg, F; Kerbel, RS; Man, S; Reguera-Nuñez, E; Xu, P, 2019
)
"This was an open-label, two-period, fixed-sequence, drug-drug interaction study."( A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Avis, M; Gahlemann, M; Guillén-Del-Castillo, A; Kreuter, M; Mack, SR; Marzin, K; Vonk, MC; Wind, S, 2022
)
"We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 immunotherapy, in patients with advanced solid tumors (PEMBIB trial; NCT02856425)."( Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Abbassi, A; Adam, J; Bahleda, R; Baldini, C; Bigorgne, A; Boselli, L; Bredel, D; Cassard, L; Champiat, S; Chaput, N; Danlos, FX; Escriou, G; Farhane, S; Gazzah, A; Grivel, J; Grynszpan, L; Halse, H; Hollebecque, A; Lacroix, L; Laghouati, S; Marabelle, A; Martin-Romano, P; Massard, C; Michot, JM; Mohamed-Djalim, C; Mouraud, S; Parpaleix, A; Postel-Vinay, S; Rafie, S; Ribrag, V; Signolle, N; Soria, JC; Susini, S; Texier, M; Varga, A; Vuagnat, P; Zitvogel, L, 2022
)
"In this monocentric phase Ib dose escalation cohort, we evaluated escalating doses of nintedanib (Dose level 1 (DL1) = 150 mg bid [bis in die, as twice a day]; DL2 = 200 mg bid, oral delivery) in combination with pembrolizumab (200 mg Q3W, IV)."( Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Abbassi, A; Adam, J; Bahleda, R; Baldini, C; Bigorgne, A; Boselli, L; Bredel, D; Cassard, L; Champiat, S; Chaput, N; Danlos, FX; Escriou, G; Farhane, S; Gazzah, A; Grivel, J; Grynszpan, L; Halse, H; Hollebecque, A; Lacroix, L; Laghouati, S; Marabelle, A; Martin-Romano, P; Massard, C; Michot, JM; Mohamed-Djalim, C; Mouraud, S; Parpaleix, A; Postel-Vinay, S; Rafie, S; Ribrag, V; Signolle, N; Soria, JC; Susini, S; Texier, M; Varga, A; Vuagnat, P; Zitvogel, L, 2022
)
"Nintedanib 150 mg bid is the recommended dose for combination with pembrolizumab and is currently investigated in multiple expansion cohorts."( Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Abbassi, A; Adam, J; Bahleda, R; Baldini, C; Bigorgne, A; Boselli, L; Bredel, D; Cassard, L; Champiat, S; Chaput, N; Danlos, FX; Escriou, G; Farhane, S; Gazzah, A; Grivel, J; Grynszpan, L; Halse, H; Hollebecque, A; Lacroix, L; Laghouati, S; Marabelle, A; Martin-Romano, P; Massard, C; Michot, JM; Mohamed-Djalim, C; Mouraud, S; Parpaleix, A; Postel-Vinay, S; Rafie, S; Ribrag, V; Signolle, N; Soria, JC; Susini, S; Texier, M; Varga, A; Vuagnat, P; Zitvogel, L, 2022
)

Bioavailability

Nintedanib esylate is a kinase inhibitor designated for the cure of non-small cell lung cancer suffered from first-pass metabolism.

ExcerptReference
" We report here URMC-099 (1) an orally bioavailable (F = 41%), potent (IC50 = 14 nM) MLK3 inhibitor with excellent brain exposure in mouse PK models and minimal interference with key human CYP450 enzymes or hERG channels."( Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Dewhurst, S; Gelbard, HA; Goodfellow, VS; Loweth, CJ; Marker, DF; Nguyen, T; Polesskaya, O; Pollack, S; Ravula, SB; Sheppard, D; Todd, DE; Wiemann, T; Xu, Y, 2013
)
" This study determined the maximum tolerated dose (MTD) and pharmacokinetics of volasertib combined with nintedanib, a potent and orally bioavailable triple angiokinase inhibitor, in patients with advanced solid tumors."( A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
Cascinu, S; Clementi, L; de Braud, F; De Pas, T; Liu, D; Pilz, K; Sikken, P; Spitaleri, G, 2015
)
" It is a combination of two active pharmaceutical compounds, trifluridine, an antineoplastic thymidine-based nucleoside analog, and tipiracil, which enhances the bioavailability of trifluridine in vivo."( Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.
Matsuoka, K; Nakagawa, F; Suzuki, N; Takechi, T, 2016
)
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
"Exposure to nintedanib is increased by co-administration of ketoconazole and decreased by co-administration of rifampicin, likely due to effects on bioavailability of the absorbed fraction."( Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects.
Dallinger, C; Jungnik, A; Luedtke, D; Marzin, K; von Wangenheim, U, 2018
)
"The results suggested superior bioavailability and a sustained-release effect from nintedanib sustained-release capsules, as compared to the reference (commercial nintedanib soft capsule)."( A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology.
Du, K; Du, Y; Jiang, T; Li, D; Liu, H; Shen, Y; Webster, TJ; Xi, J; Xu, Y, 2018
)
" However, the poor solubility, rapid metabolism and low bioavailability of sorafenib greatly restricted its further clinical application."( Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.
Chen, F; Chen, Z; Fang, Y; Huang, R; Le, J; Shao, J; Zhang, B; Zhao, R, 2019
)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
" In addition, 9d demonstrated decent bioavailability (F = 39."( Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
Chen, L; Deng, D; Lan, T; Pei, H; Tang, M; Xue, L; Yang, Z; Ye, H; Zheng, S; Zhu, J, 2020
)
" In addition, 20f demonstrated good bioavailability (F = 41."( Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
Chen, L; Chen, Y; Deng, D; Liu, K; Pei, H; Tang, M; Xue, L; Yang, T; Yang, Z; Ye, H; Zheng, S, 2020
)
"The present research work was aimed to explore the ability of nanostructured lipid carriers (NLCs) to improve oral bioavailability of Nintedanib esylate (NE) via lymphatic uptake."( Enhanced oral bioavailability of nintedanib esylate with nanostructured lipid carriers by lymphatic targeting: In vitro, cell line and in vivo evaluation.
Patel, M; Patel, P, 2021
)
"B has the potential to act on multiple diseases that are still being discovered, but its extremely low bioavailability is a challenge that is to be dealt with for obtaining the full benefit."( Advances and challenges in nintedanib drug delivery.
Mehta, CH; Nayak, UY; Suresh, A; Velagacherla, V, 2021
)
"Nintedanib esylate is a kinase inhibitor designated for the cure of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability (~ 4."( Bioavailability enhancement of vitamin E TPGS liposomes of nintedanib esylate: formulation optimization, cytotoxicity and pharmacokinetic studies.
Chinni, S; Kala, SG, 2022
)
"In conclusion, NDNB/HP-β-CD complex gels combined with P-gp inhibitor were a potential strategy for enhancing the oral bioavailability and anti-tumor effect of NDNB."( Simultaneously Inhibiting P-gp Efflux and Drug Recrystallization Enhanced the Oral Bioavailability of Nintedanib.
Tan, C; Wang, J; Wei, Q; Xiong, S; Zhang, S, 2023
)

Dosage Studied

In children and adolescents with fibrosing ILD, a weight-based dosing regimen resulted in exposure to nintedanib similar to adults and an acceptable safety profile. Annual rate of decline in forced vital capacity and the duration of ninteganib administration were not significantly different between groups with and without dosage reduction.

ExcerptReference
" Although BIBF 1120 is rapidly metabolized in vivo by methylester cleavage, resulting in a short mean residence time, once daily oral dosing is fully efficacious in xenograft models."( BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Bader, G; Garin-Chesa, P; Heckel, A; Hilberg, F; Kautschitsch, S; Krssak, M; Quant, J; Rettig, WJ; Roth, GJ; Sommergruber, W; Tontsch-Grunt, U; Zoephel, A, 2008
)
"BIBF 1120 dosed continuously displayed a favorable safety and pharmacokinetics profile, and first efficacy signals were observed."( Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.
Baas, F; de Rossi, L; Frost, A; Gaschler-Markefski, B; Gmehling, D; Henning, J; Kaiser, R; Mross, K; Stefanic, M; Stopfer, P; Strecker, R; Unger, C, 2010
)
" On the other hand, the optimal combination and dosage of these drugs, selection of the apropriate biomarker and better understanding of the conflicting role of PDGFR and FGFR signaling in angiogenesis remain future challenges."( [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Döme, B; Török, S, 2012
)
" The true clinical benefit of nintedanib in ovarian cancer including its optimal treatment setting and dosage still need to be addressed."( Nintedanib in ovarian cancer.
Banerjee, S; Khalique, S, 2017
)
" Furthermore, currently the majority of new drugs are investigated in preclinical models of IPF are dosed using a prophylactic dosing regimen, whereas patients are almost always treated after the fibrosis is well established."( Use of animal models in IPF research.
Carrington, R; Jordan, S; Page, CP; Pitchford, SC, 2018
)
" Accumulation after repeated twice-daily dosing is negligible."( Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
Dallinger, C; Ebner, T; Freiwald, M; Lotz, R; Marzin, K; Schmid, U; Stopfer, P; Wind, S, 2019
)
" The re-escalated dosage of PSL improved the pneumonitis, and then nintedanib was started as additional therapy."( Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
Akasaka, K; Amano, M; Kawabe, R; Kida, G; Kuwano, K; Matsushima, H; Nishizawa, T; Oba, T; Ohta, H; Sato, S; Tsukahara, Y; Tsumiyama, E; Yamakawa, H, 2019
)
" The annual rate of decline in forced vital capacity and the duration of nintedanib administration were not significantly different between groups with and without dosage reduction."( Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis.
Abe, M; Hirasawa, Y; Kawasaki, T; Sakayori, M; Suzuki, K; Tatsumi, K; Terada, J; Tsushima, K; Yoshioka, K, 2020
)
" The patient benefited from a back-titrated regimen of methylprednisolone with the initial dosage of 2 mg/kg and anti-fibrotic effect of nintedanib and was successfully weaned from the ventilator."( Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab.
Chen, X; Hu, J; Li, Y; Luo, C; Zuo, X, 2020
)
"3%) and difficulty adhering to pirfenidone's dosage scheme (16."( Feasibility and safety of treatment switch from Pirfenidone to Nintedanib in patients with idiopathic pulmonary fibrosis: a real-world observational study.
Anevlavis, S; Archontogeorgis, K; Bonelis, K; Froudarakis, M; Ntolios, P; Paxinou, N; Steiropoulos, P; Voulgaris, A, 2021
)
" Dosing was based on weight-dependent allometric scaling."( Nintedanib in children and adolescents with fibrosing interstitial lung diseases.
Bertulis, J; Brown, KK; Cunningham, S; DeBoer, EM; Deterding, R; Dumistracel, M; Erhardt, E; Flaherty, KR; Gahlemann, M; Griese, M; Schwerk, N; Stowasser, S; Warburton, D; Young, LR, 2023
)
"In children and adolescents with fibrosing ILD, a weight-based dosing regimen resulted in exposure to nintedanib similar to adults and an acceptable safety profile."( Nintedanib in children and adolescents with fibrosing interstitial lung diseases.
Bertulis, J; Brown, KK; Cunningham, S; DeBoer, EM; Deterding, R; Dumistracel, M; Erhardt, E; Flaherty, KR; Gahlemann, M; Griese, M; Schwerk, N; Stowasser, S; Warburton, D; Young, LR, 2023
)
"In this retrospective cohort study, we enrolled 111 patients with ILDs treated with nintedanib and investigated the factors involved in starting dosage reduction, withdrawal, or discontinuation within 12 months, even with appropriate symptomatic treatment."( Clinical significance of high monocyte counts for the continuous treatment with nintedanib.
Hoshino, T; Matama, G; Murotani, K; Ohno, S; Okamoto, M; Takaki, R; Tominaga, M; Tsuneyoshi, S; Umemoto, S; Yano, R; Zaizen, Y, 2023
)
" Considering the risk of withdrawal periods and discontinuation, a reduced starting dosage may be acceptable in the patients with higher monocyte counts or small body sizes."( Clinical significance of high monocyte counts for the continuous treatment with nintedanib.
Hoshino, T; Matama, G; Murotani, K; Ohno, S; Okamoto, M; Takaki, R; Tominaga, M; Tsuneyoshi, S; Umemoto, S; Yano, R; Zaizen, Y, 2023
)
" Alongside epidemiological and disease-specific data, the period of NIN use and the need for dosage reduction and/or interruption were investigated."( Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects.
Carrozzi, L; Da Rio, M; Della Rossa, A; Di Battista, M; Morganti, R; Mosca, M; Pistelli, F; Puccetti, L; Romei, C; Rossi, A; Tavanti, L; Tavoni, A, 2023
)
" Although the rates of NIN dosage reduction or interruption were similar between the two subgroups, SSc-ILD presented a mean period before NIN dosage reduction and NIN interruption significantly shorter than IPF (3 ± 2."( Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects.
Carrozzi, L; Da Rio, M; Della Rossa, A; Di Battista, M; Morganti, R; Mosca, M; Pistelli, F; Puccetti, L; Romei, C; Rossi, A; Tavanti, L; Tavoni, A, 2023
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
Endometrial cancer04

Protein Targets (482)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency16.53880.00529.466132.9993AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency3.37860.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency1.42250.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
tyrosine-protein kinase YesHomo sapiens (human)Potency0.00560.00005.018279.2586AID686947; AID686948
Interferon betaHomo sapiens (human)Potency16.53880.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Serine/threonine-protein kinase Chk1Homo sapiens (human)IC50 (µMol)1.00000.00010.45308.8300AID1662309
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)30.00000.00000.536910.0000AID397043; AID507197
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)IC50 (µMol)30.00000.00010.545310.0000AID397044; AID507198
Platelet-derived growth factor receptor betaMus musculus (house mouse)IC50 (µMol)0.08500.00180.75529.5000AID1504565
Insulin receptorHomo sapiens (human)IC50 (µMol)7.00000.00170.847910.0000AID397040; AID507195
Tyrosine-protein kinase LckHomo sapiens (human)IC50 (µMol)0.01600.00021.317310.0000AID397077; AID507203
Cyclin-dependent kinase 1Homo sapiens (human)IC50 (µMol)10.00000.00041.345210.0000AID397041; AID507199
Tyrosine-protein kinase LynHomo sapiens (human)IC50 (µMol)0.14830.00020.55945.2000AID1662305; AID397078; AID507204
Insulin-like growth factor 1 receptorHomo sapiens (human)IC50 (µMol)5.50000.00030.43088.0000AID397039; AID507196
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)1.00000.00011.753610.0000AID1662309
Platelet-derived growth factor receptor betaHomo sapiens (human)IC50 (µMol)0.01330.00060.80078.5000AID1427154; AID1501068; AID1504563; AID1662299; AID507194; AID761354
Fibroblast growth factor receptor 1Homo sapiens (human)IC50 (µMol)0.06800.00020.942010.0000AID1427162; AID1501094; AID1504562; AID1662303; AID1845296; AID1876271; AID397047; AID507189; AID761353
Cyclin-dependent kinase 4Homo sapiens (human)IC50 (µMol)10.00000.00060.570610.0000AID397042; AID507201
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)IC50 (µMol)0.10930.00020.533510.0000AID1662304; AID397076; AID507205
Platelet-derived growth factor receptor alphaHomo sapiens (human)IC50 (µMol)0.01700.00010.491210.0000AID1427161; AID1501092; AID397048; AID507193; AID761356
Vascular endothelial growth factor receptor 1 Homo sapiens (human)IC50 (µMol)0.03950.00010.29147.0000AID1427159; AID1510861; AID1662300; AID397049; AID507185
Fibroblast growth factor receptor 2Homo sapiens (human)IC50 (µMol)0.03700.00040.32768.6200AID1845297; AID1876272; AID507190
Fibroblast growth factor receptor 4Homo sapiens (human)IC50 (µMol)0.61000.00080.62178.6200AID1845299; AID507192
Fibroblast growth factor receptor 3Homo sapiens (human)IC50 (µMol)0.10800.00040.28638.6200AID1845298; AID1876273; AID507191
Cyclin-dependent kinase 2Homo sapiens (human)IC50 (µMol)5.50000.00041.044410.0000AID1662307; AID507200
Platelet-derived growth factor receptor alpha Mus musculus (house mouse)IC50 (µMol)0.08500.00180.85729.5000AID1504565
Vascular endothelial growth factor receptor 3Homo sapiens (human)IC50 (µMol)0.01160.00010.22644.9000AID1427160; AID1501093; AID1510862; AID397050; AID507188
Vascular endothelial growth factor receptor 2Mus musculus (house mouse)IC50 (µMol)0.01300.00150.36725.1286AID507186
Vascular endothelial growth factor receptor 2Homo sapiens (human)IC50 (µMol)0.00900.00000.48308.8000AID1427153; AID1478069; AID1501066; AID1504564; AID1510860; AID1662298; AID397037; AID507187; AID761355
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)IC50 (µMol)0.02600.00010.32759.5480AID397079; AID507202
Serine/threonine-protein kinase PLK1Homo sapiens (human)IC50 (µMol)10.00000.00010.77349.0000AID397045
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)0.00260.00091.901410.0000AID1504566
Maternal embryonic leucine zipper kinaseHomo sapiens (human)IC50 (µMol)0.04300.00040.35770.7600AID1474637
Maternal embryonic leucine zipper kinaseHomo sapiens (human)Ki0.00560.00560.00560.0056AID1474637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Leukotriene C4 synthaseCavia porcellus (domestic guinea pig)Kd10.00000.93002.54785.7000AID625128
Bone morphogenetic protein receptor type-1BHomo sapiens (human)Kd20.00000.00091.14133.7000AID1424922; AID624825
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)Kd10.00000.00331.51757.6000AID624974
Serine/threonine-protein kinase PLK4Homo sapiens (human)Kd20.01770.00081.51449.0000AID1425121; AID625076
Serine/threonine-protein kinase 25Homo sapiens (human)Kd10.00000.01202.57349.2000AID625059
ATP-dependent RNA helicase DDX3XHomo sapiens (human)Kd30.00000.43500.43500.4350AID1424975
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)Kd10.00000.00051.01525.2000AID624877
Pyridoxal kinaseHomo sapiens (human)Kd30.00000.28605.076516.4040AID1425106
Citron Rho-interacting kinaseHomo sapiens (human)Kd20.00000.03303.064648.8760AID1424954; AID625065
Serine/threonine-protein kinase RIO3Homo sapiens (human)Kd0.03600.00771.40999.7000AID624926
Dual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)Kd10.00000.02701.44715.3000AID624722
Serine/threonine-protein kinase Chk1Homo sapiens (human)Kd2.38750.00281.47448.7000AID1424953; AID624831
Inhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)Kd10.00000.01201.58276.3000AID624836
Peripheral plasma membrane protein CASKHomo sapiens (human)Kd10.00000.01900.93302.8000AID624749
Aurora kinase AHomo sapiens (human)Kd20.00000.00010.73429.3000AID1424917; AID624919
Cyclin-G-associated kinaseHomo sapiens (human)Kd20.00000.00030.908628.6510AID1425009; AID625012
Serine/threonine-protein kinase DCLK1Homo sapiens (human)Kd0.54000.00491.83608.1000AID624966
Inhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)Kd4.50000.00581.50585.9000AID624832
Muscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)Kd0.59000.00310.61284.1000AID625022
Ephrin type-B receptor 6Homo sapiens (human)Kd15.07000.00001.07689.0000AID1424995; AID624957
Peroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)Kd30.00000.02601.31402.6020AID1424896
Mitogen-activated protein kinase 13Homo sapiens (human)Kd10.00000.00011.46676.6000AID624892
3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)Kd2.80000.00171.34323.5000AID624876
Mitogen-activated protein kinase kinase kinase 13Homo sapiens (human)Kd0.14000.01600.93165.3000AID624965
Death-associated protein kinase 3Homo sapiens (human)Kd2.10000.00101.82419.9000AID624834
Mitogen-activated protein kinase kinase kinase 7Homo sapiens (human)Kd0.00410.00151.66608.5000AID624724
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)Kd23.33330.00201.621211.4330AID1425155; AID624925
Mitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)Kd30.00000.09401.39103.5070AID1424926
NUAK family SNF1-like kinase 1Homo sapiens (human)Kd0.16000.00370.52145.9000AID625088
Dynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)Kd30.00000.01700.36100.7050AID1425097
Phosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)Kd10.00000.01802.48906.7000AID624751
Tyrosine-protein kinase JAK2Homo sapiens (human)Kd0.05950.00000.88517.0000AID1425031; AID624973
Rho-associated protein kinase 2Homo sapiens (human)Kd20.00000.00022.710556.0660AID1425158; AID624969
Serine/threonine-protein kinase ULK1Homo sapiens (human)Kd15.17000.00081.841023.2730AID1425208; AID624916
Serine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)Kd16.00000.00572.009512.2010AID1424997; AID624835
Ribosomal protein S6 kinase alpha-5Homo sapiens (human)Kd13.40000.01701.973729.9570AID1425162; AID624736; AID624967
U5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)Kd30.00001.38201.38201.3820AID1425174
Ribosomal protein S6 kinase alpha-4Homo sapiens (human)Kd13.54000.01201.63967.2000AID1425161; AID624806; AID624927
Serine/threonine-protein kinase 16Homo sapiens (human)Kd20.00600.00171.24839.9690AID1425179; AID624775
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)Kd10.00000.00321.00247.5000AID624958
Serine/threonine-protein kinase PAK 3Homo sapiens (human)Kd0.21000.00051.44835.7000AID624873
Cyclin-dependent kinase-like 5Homo sapiens (human)Kd20.00000.00171.47887.3000AID1424951; AID624905
Serine/threonine-protein kinase 17BHomo sapiens (human)Kd0.67000.00482.19829.4000AID624942
Serine/threonine-protein kinase 10Homo sapiens (human)Kd0.45500.00002.923457.4530AID1425177; AID625030
Serine/threonine-protein kinase D3Homo sapiens (human)Kd15.32000.00892.273823.3410AID1425137; AID625024
Cyclin-dependent kinase 14Homo sapiens (human)Kd0.47000.01600.99203.6000AID625070
Structural maintenance of chromosomes protein 2Homo sapiens (human)Kd30.00000.20900.65751.1060AID1425173
Mitogen-activated protein kinase kinase kinase 6Homo sapiens (human)Kd20.00000.17001.57818.0000AID1425050; AID624962
Serine/threonine-protein kinase OSR1Homo sapiens (human)Kd1.30000.04802.34988.0000AID624977
Mitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)Kd0.76150.00822.364562.7720AID1425054; AID624756
Serine/threonine-protein kinase LATS1Homo sapiens (human)Kd5.57650.01401.839310.7330AID1425033; AID624963
Serine/threonine-protein kinase PAK 4Homo sapiens (human)Kd16.50000.00272.569430.3710AID1425100; AID624811
Serine/threonine-protein kinase Chk2Homo sapiens (human)Kd10.00000.00711.27297.7000AID624803
Tyrosine-protein kinase ABL1Homo sapiens (human)Kd0.85920.00001.041113.4530AID1424890; AID624978; AID624979; AID624980; AID624981; AID624982; AID624983; AID624984; AID624985; AID624986; AID624987; AID624988; AID624989; AID624990; AID624991; AID624992
Epidermal growth factor receptorHomo sapiens (human)Kd11.53850.00011.351420.8270AID1424983; AID624996; AID624997; AID624998; AID624999; AID625000; AID625001; AID625002; AID625003; AID625004; AID625005; AID625006; AID625007
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)Kd10.00000.00661.14674.4000AID624897
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)Kd10.00000.00081.29315.1000AID624804
High affinity nerve growth factor receptorHomo sapiens (human)Kd1.47030.00201.34849.2000AID1425094; AID624808
Guanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)Kd30.00000.18400.18400.1840AID1425011
ADP/ATP translocase 2Homo sapiens (human)Kd30.00000.45100.45100.4510AID1425169
Protein kinase C beta typeHomo sapiens (human)Kd30.00000.00132.708126.3240AID1425130
Insulin receptorHomo sapiens (human)Kd15.01200.00171.08237.9060AID1425026; AID624784
Tyrosine-protein kinase LckHomo sapiens (human)Kd0.03760.00021.117424.2210AID1425034; AID625013
Tyrosine-protein kinase FynHomo sapiens (human)Kd1.14500.00081.42388.4000AID1425008; AID624727
Cyclin-dependent kinase 1Homo sapiens (human)Kd30.00000.28801.49523.0490AID1424937
Glycogen phosphorylase, liver formHomo sapiens (human)Kd30.00002.12102.12102.1210AID1425146
Tyrosine-protein kinase Fes/FpsHomo sapiens (human)Kd15.60000.00481.09867.4000AID1425003; AID624852
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)Kd0.04800.00060.69938.1000AID624995
Tyrosine-protein kinase YesHomo sapiens (human)Kd0.52450.00031.370817.1520AID1425212; AID625018
Tyrosine-protein kinase LynHomo sapiens (human)Kd15.47000.00061.04855.7000AID1425037; AID624862
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)Kd0.01670.00070.864227.5420AID1425154; AID625121; AID625122; AID625123; AID625124
Insulin-like growth factor 1 receptorHomo sapiens (human)Kd15.03100.00101.921119.2170AID1425022; AID624800
ATP-dependent translocase ABCB1Homo sapiens (human)EC50 (µMol)0.27600.01600.67863.1000AID1623456
Signal recognition particle receptor subunit alphaHomo sapiens (human)Kd30.00000.00800.00800.0080AID1425176
Cytochrome c1, heme protein, mitochondrialHomo sapiens (human)Kd30.00000.20200.20200.2020AID1424969
Hepatocyte growth factor receptorHomo sapiens (human)Kd7.75000.00021.62978.5000AID1425076; AID624794; AID624795; AID624796
Tyrosine-protein kinase HCKHomo sapiens (human)Kd3.40150.00032.034315.9930AID1425017; AID624857
Proto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)Kd3.70000.00051.17415.8000AID624899
Platelet-derived growth factor receptor betaHomo sapiens (human)Kd0.02300.00011.005011.1070AID1425104; AID624875
Tyrosine-protein kinase FgrHomo sapiens (human)Kd15.15000.00051.07217.8000AID1425005; AID625011
Wee1-like protein kinase 2Homo sapiens (human)Kd10.00000.00392.18749.4000AID624746
Uncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)Kd2.00000.02501.47395.8000AID624747
Serine/threonine-protein kinase A-RafHomo sapiens (human)Kd30.00000.04709.683233.6550AID1424915
Mast/stem cell growth factor receptor KitHomo sapiens (human)Kd3.38780.00020.81599.8000AID1425032; AID624786; AID624787; AID624788; AID624789; AID624790; AID624791; AID624792; AID624793
Glycogen phosphorylase, brain formHomo sapiens (human)Kd30.00003.56903.56903.5690AID1425145
Breakpoint cluster region proteinHomo sapiens (human)Kd0.30100.00301.219617.3640AID1424919
Serine/threonine-protein kinase pim-1Homo sapiens (human)Kd20.00000.00101.139319.3160AID1425111; AID624878
Fibroblast growth factor receptor 1Homo sapiens (human)Kd0.99750.00031.55816.2000AID1425004; AID625132
DNA topoisomerase 2-alphaHomo sapiens (human)Kd30.00000.06400.27500.4860AID1425202
Cyclin-dependent kinase 4Homo sapiens (human)Kd10.29330.00331.60508.6000AID1424946; AID624780; AID624781
ADP/ATP translocase 3Homo sapiens (human)Kd30.00000.00600.25050.4950AID1425170
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)Kd15.29000.00021.50779.6000AID1425175; AID625016
cAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)Kd30.00000.05201.75353.4550AID1425128
Insulin receptor-related proteinHomo sapiens (human)Kd0.02100.00621.38144.6000AID625075
Serine/threonine-protein kinase B-rafHomo sapiens (human)Kd16.66670.00021.625826.0180AID1424924; AID624946; AID624947
Phosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)Kd15.13000.00012.05699.5000AID1425110; AID624797
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)Kd30.00000.00406.755688.9030AID1425093
Platelet-derived growth factor receptor alphaHomo sapiens (human)Kd0.01600.00040.70908.8000AID625034
Tyrosine-protein kinase FerHomo sapiens (human)Kd2.44950.00141.36048.8000AID1425002; AID625010
Protein kinase C alpha typeHomo sapiens (human)Kd30.00000.00031.792221.3520AID1425129
cAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)Kd20.00000.00392.947923.2450AID1425123; AID624881
Vascular endothelial growth factor receptor 1 Homo sapiens (human)Kd0.06300.00070.95859.9000AID624853
General transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)Kd30.00000.00201.690612.0220AID1424996
Interferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)Kd10.00000.12002.32387.4000AID624896
Casein kinase II subunit alpha'Homo sapiens (human)Kd15.44500.00102.530928.8720AID1424968; AID624849
Ras-related protein Rab-6AHomo sapiens (human)Kd30.00000.03300.03300.0330AID1425150
Serine/threonine-protein kinase MAKHomo sapiens (human)Kd10.00000.02801.34612.6000AID625025
Cyclin-dependent kinase 11BHomo sapiens (human)Kd10.00000.00840.86792.1000AID624708
Ephrin type-A receptor 1Homo sapiens (human)Kd15.60000.00411.80009.8000AID1424987; AID625008
Fibroblast growth factor receptor 2Homo sapiens (human)Kd0.35000.03101.15795.5000AID625131
Receptor tyrosine-protein kinase erbB-3Homo sapiens (human)Kd10.00000.00082.25459.2000AID624851
Multifunctional protein ADE2Homo sapiens (human)Kd30.00005.48105.48105.4810AID1425098
Fibroblast growth factor receptor 4Homo sapiens (human)Kd1.80000.11002.67737.2000AID625130
Fibroblast growth factor receptor 3Homo sapiens (human)Kd0.11650.02301.26526.9000AID624782; AID624783
cAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)Kd30.00000.00208.557749.2780AID1425125
cAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)Kd20.00000.01300.74084.1000AID1425124; AID624882
Ferrochelatase, mitochondrialHomo sapiens (human)Kd16.60000.24306.434367.9140AID1425001; AID1801713
Ribosomal protein S6 kinase beta-1Homo sapiens (human)Kd15.09500.00131.18054.8000AID1425164; AID624906
Tyrosine-protein kinase JAK1Homo sapiens (human)Kd10.83490.00161.21667.8000AID1425030; AID624858; AID624859
Protein kinase C eta typeHomo sapiens (human)Kd10.00000.00040.28811.8000AID625049
Cyclin-dependent kinase 2Homo sapiens (human)Kd15.70000.00701.517910.4870AID1424944; AID624844
Beta-adrenergic receptor kinase 1Homo sapiens (human)Kd30.00000.17005.579122.4940AID1424908
Probable ATP-dependent RNA helicase DDX6Homo sapiens (human)Kd30.00004.10304.10304.1030AID1424977
Activin receptor type-2AHomo sapiens (human)Kd10.00000.01002.07898.9000AID624838
Mitogen-activated protein kinase 3 Homo sapiens (human)Kd20.00000.43005.27439.8000AID1425061; AID624885
MAP/microtubule affinity-regulating kinase 3Homo sapiens (human)Kd15.38500.00303.968958.2400AID1425069; AID624863
Deoxycytidine kinaseHomo sapiens (human)Kd30.00000.01201.08752.1630AID1424970
Mitogen-activated protein kinase 1Homo sapiens (human)Kd20.00000.00012.74417.3000AID1425056; AID624713
Ephrin type-A receptor 2Homo sapiens (human)Kd16.45000.00091.07528.1980AID1424988; AID624951
Ephrin type-A receptor 3Homo sapiens (human)Kd8.60000.00012.15218.6000AID625009
Ephrin type-A receptor 8Homo sapiens (human)Kd10.00000.00021.28757.7000AID625120
Ephrin type-B receptor 2Homo sapiens (human)Kd20.00000.00043.153653.1980AID1424992; AID625105
Leukocyte tyrosine kinase receptorHomo sapiens (human)Kd0.15000.00102.06317.5000AID624743
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)Kd10.17900.00091.55758.7000AID1425207; AID624912; AID624913
Wee1-like protein kinaseHomo sapiens (human)Kd16.45000.00143.538965.1580AID1425210; AID624914
Heme oxygenase 2Homo sapiens (human)Kd30.00000.11900.11900.1190AID1425018
Tyrosine-protein kinase receptor UFOHomo sapiens (human)Kd0.01200.00011.28916.3000AID624840
Mitogen-activated protein kinase 4Homo sapiens (human)Kd10.00001.10003.05565.4000AID624886
DnaJ homolog subfamily A member 1Homo sapiens (human)Kd30.00000.96200.96200.9620AID1424980
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)Kd20.00000.00061.06214.4000AID1424910; AID624994
RAC-beta serine/threonine-protein kinaseHomo sapiens (human)Kd20.00000.00211.61968.7000AID1424911; AID624839
G protein-coupled receptor kinase 4Homo sapiens (human)Kd0.01700.01201.68527.3000AID624739
Dual specificity protein kinase TTKHomo sapiens (human)Kd15.01100.00651.62698.5000AID1425205; AID624910
DNA replication licensing factor MCM4Homo sapiens (human)Kd30.00000.62900.62900.6290AID1425072
Prostaglandin G/H synthase 2Homo sapiens (human)Kd0.02300.00901.87258.4000AID625141
Myosin-10Homo sapiens (human)Kd30.00000.22900.49350.7580AID1425079
Tyrosine-protein kinase receptor Tie-1Homo sapiens (human)Kd2.20000.00031.06455.7000AID625017
Vascular endothelial growth factor receptor 3Homo sapiens (human)Kd0.09500.00150.94507.2000AID624854
Vascular endothelial growth factor receptor 2Homo sapiens (human)Kd0.00290.00020.80635.7000AID624860
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)Kd15.02100.00391.64299.6000AID1425039; AID625137
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)Kd0.00420.00020.95599.9000AID1425006; AID624934; AID624935; AID624936; AID624937; AID624938; AID624939; AID624940; AID775336
Bone morphogenetic protein receptor type-1AHomo sapiens (human)Kd20.00000.06001.50107.0000AID1424921; AID624945
Activin receptor type-1BHomo sapiens (human)Kd17.45000.00401.511015.2580AID1424901; AID624943
TGF-beta receptor type-1Homo sapiens (human)Kd3.03300.00502.27859.6000AID1425196; AID624961
Serine/threonine-protein kinase receptor R3Homo sapiens (human)Kd4.20000.00291.99369.5000AID624778
TGF-beta receptor type-2Homo sapiens (human)Kd20.00000.08001.83516.9000AID1425197; AID624909
Tyrosine-protein kinase CSKHomo sapiens (human)Kd20.00000.00103.457839.5530AID1424960; AID624948
Glycine--tRNA ligaseHomo sapiens (human)Kd30.00000.04000.04000.0400AID1425010
Protein kinase C iota typeHomo sapiens (human)Kd20.00000.02609.331651.0180AID1425133; AID624883
Exosome RNA helicase MTR4Homo sapiens (human)Kd30.00002.60702.60702.6070AID1425168
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)Kd10.00000.00060.84627.4000AID625036; AID625037; AID625038; AID625039; AID625040; AID625041; AID625042; AID625043; AID625044; AID625045
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)Kd10.00000.00170.83166.7000AID625046
Serine/threonine-protein kinase mTORHomo sapiens (human)Kd10.00000.00010.59939.2000AID624972
Megakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)Kd10.00000.26003.07007.7000AID624864
Tyrosine-protein kinase TecHomo sapiens (human)Kd20.00000.00101.00958.7000AID1425193; AID624908
Tyrosine-protein kinase TXKHomo sapiens (human)Kd0.86000.00061.91966.0000AID624911
Tyrosine-protein kinase ABL2Homo sapiens (human)Kd16.00000.00021.124914.9240AID1424891; AID624993
Tyrosine-protein kinase FRKHomo sapiens (human)Kd16.35000.00031.242410.8370AID1425007; AID624855
G protein-coupled receptor kinase 6Homo sapiens (human)Kd30.00001.18901.40201.6150AID1425012
Tyrosine-protein kinase ZAP-70Homo sapiens (human)Kd3.50000.01601.68444.2000AID624744
Tyrosine-protein kinase SYKHomo sapiens (human)Kd20.00000.00702.00529.2260AID1425188; AID624907
26S proteasome regulatory subunit 6BHomo sapiens (human)Kd30.00000.00500.00500.0050AID1425141
Mitogen-activated protein kinase 8Homo sapiens (human)Kd15.31500.01102.096526.0590AID1425063; AID624889
Mitogen-activated protein kinase 9Homo sapiens (human)Kd20.00000.00201.45968.1000AID1425064; AID624717
Dual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)Kd16.85000.00381.62649.9000AID1425041; AID624902
Dual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)Kd16.05000.00502.04626.6000AID1425040; AID624894
Phosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)Kd30.00000.20803.61257.0170AID1425113
Casein kinase I isoform alphaHomo sapiens (human)Kd20.00000.00102.575619.3520AID1424961; AID624846
Casein kinase I isoform deltaHomo sapiens (human)Kd15.65000.01502.227018.3960AID1424962; AID624716
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)Kd10.00000.00261.46028.4000AID624879
MAP kinase-activated protein kinase 2Homo sapiens (human)Kd20.00000.00032.027414.7420AID1425065; AID624703
Cyclin-dependent kinase 8Homo sapiens (human)Kd10.00000.00141.29088.0000AID624829
Elongation factor Tu, mitochondrialHomo sapiens (human)Kd30.00000.46400.46400.4640AID1425206
Choline-phosphate cytidylyltransferase AHomo sapiens (human)Kd30.00000.04100.04100.0410AID1425103
Casein kinase I isoform epsilonHomo sapiens (human)Kd15.11500.01301.408612.4090AID1424963; AID624847
Very long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)Kd30.00001.68901.68901.6890AID1424894
Dual specificity protein kinase CLK1Homo sapiens (human)Kd15.00440.00201.879129.8810AID1424955; AID624764
Dual specificity protein kinase CLK2Homo sapiens (human)Kd15.38000.00701.13846.5000AID1424956; AID624932
Dual specificity protein kinase CLK3Homo sapiens (human)Kd20.00000.01002.44999.0000AID1424957; AID624931
Glycogen synthase kinase-3 alphaHomo sapiens (human)Kd15.21500.00602.475422.5430AID1425013; AID625114
Glycogen synthase kinase-3 betaHomo sapiens (human)Kd15.04150.00701.00576.1680AID1425014; AID624856
Cyclin-dependent kinase 7Homo sapiens (human)Kd15.15000.00251.67837.7000AID1424949; AID624845
Cyclin-dependent kinase 9Homo sapiens (human)Kd20.00000.00101.61669.9010AID1424950; AID624830
Ras-related protein Rab-27AHomo sapiens (human)Kd30.00004.49304.49304.4930AID1425149
Tyrosine-protein kinase BlkHomo sapiens (human)Kd0.38000.00020.82287.9000AID624841
Interleukin-1 receptor-associated kinase 1Homo sapiens (human)Kd15.06000.00611.52528.5000AID1425027; AID624837
Ribosomal protein S6 kinase alpha-3Homo sapiens (human)Kd15.03250.01702.889637.6050AID1425160; AID624960
Cytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)Kd10.00000.00141.54897.4000AID624842
cAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)Kd10.00000.00721.30665.8000AID624976
Serine/threonine-protein kinase Nek2Homo sapiens (human)Kd20.00000.11001.56496.5000AID1425086; AID624869
Serine/threonine-protein kinase Nek3Homo sapiens (human)Kd20.00000.17005.936838.0880AID1425087; AID624870
Serine/threonine-protein kinase Nek4Homo sapiens (human)Kd10.00000.46001.53202.7000AID624904
Tyrosine-protein kinase JAK3Homo sapiens (human)Kd0.00820.00021.06888.7000AID624785
Dual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)Kd20.00000.00342.39436.5000AID1425043; AID624895
Serine/threonine-protein kinase PLK1Homo sapiens (human)Kd23.33330.00010.57115.0000AID1425120; AID624975
Death-associated protein kinase 1Homo sapiens (human)Kd10.00000.00141.25424.7000AID624971
LIM domain kinase 1Homo sapiens (human)Kd20.00000.02601.784021.0890AID1425035; AID624861
LIM domain kinase 2Homo sapiens (human)Kd20.00000.05704.971752.0560AID1425036; AID625021
Mitogen-activated protein kinase 12Homo sapiens (human)Kd10.00000.00012.21389.9000AID624766
Mitogen-activated protein kinase 10Homo sapiens (human)Kd15.13500.00101.63545.9000AID1425057; AID624891
5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)Kd30.00000.00601.468110.2120AID1425126
5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)Kd0.08400.01200.77985.0000AID625047
Ephrin type-B receptor 3Homo sapiens (human)Kd20.00000.00692.17136.4100AID1424993; AID624955
Ephrin type-A receptor 5Homo sapiens (human)Kd20.00000.00021.21005.9000AID1424990; AID624737
Ephrin type-B receptor 4Homo sapiens (human)Kd15.55000.00032.167826.3990AID1424994; AID624956
Ephrin type-B receptor 1Homo sapiens (human)Kd0.55000.00041.72167.3000AID624954
Ephrin type-A receptor 4Homo sapiens (human)Kd20.00000.00123.152543.9420AID1424989; AID624952
Adenylate kinase 2, mitochondrialHomo sapiens (human)Kd30.00001.03601.03601.0360AID1424909
Adenosine kinaseHomo sapiens (human)Kd30.00000.01301.83683.4930AID1424907
Hormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)Kd10.00000.00372.51399.8000AID625084
Serine/threonine-protein kinase SIK1Homo sapiens (human)Kd0.67000.00221.15303.2000AID624733
Receptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)Kd0.44000.01301.55069.8000AID624763
Ras-related protein Rab-10Homo sapiens (human)Kd30.00001.34801.34801.3480AID1425148
Cell division control protein 2 homologPlasmodium falciparum 3D7Kd10.00000.80003.23335.6000AID624760
Actin-related protein 3Homo sapiens (human)Kd30.00000.03602.77355.5110AID1424899
Actin-related protein 2Homo sapiens (human)Kd30.00000.00400.00400.0040AID1424898
Calcium-dependent protein kinase 1Plasmodium falciparum 3D7Kd1.20000.00030.85383.3000AID624759
GTP-binding nuclear protein RanHomo sapiens (human)Kd30.00000.75900.75900.7590AID1425153
Casein kinase II subunit alphaHomo sapiens (human)Kd7.50000.00061.76357.5000AID624848
Phosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)Kd0.01700.01700.86557.8000AID624915
SRSF protein kinase 2Homo sapiens (human)Kd0.03600.01500.28031.1000AID624768
Casein kinase I isoform gamma-2Homo sapiens (human)Kd20.00000.04601.45066.6000AID1424965; AID624833
Mitogen-activated protein kinase kinase kinase 9Homo sapiens (human)Kd0.22000.00352.20939.9000AID624706
Serine/threonine-protein kinase PknBMycobacterium tuberculosis H37RvKd0.00360.00321.27245.5000AID624753
Cyclin-dependent kinase 3Homo sapiens (human)Kd5.07250.00803.060263.6140AID1424945; AID624828
Cyclin-dependent kinase-like 1Homo sapiens (human)Kd10.00000.01300.73322.1000AID624941
Cyclin-dependent kinase 6Homo sapiens (human)Kd30.00000.03201.20073.3560AID1424948
Cyclin-dependent-like kinase 5 Homo sapiens (human)Kd20.00000.04301.37578.3000AID1424947; AID624970
Cyclin-dependent kinase 16Homo sapiens (human)Kd15.01050.00111.585510.0000AID1424941; AID625033
Cyclin-dependent kinase 17Homo sapiens (human)Kd15.04650.00100.82335.6000AID1424942; AID624776
ATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)Kd30.00000.98300.98300.9830AID1425108
Protein kinase C epsilon typeHomo sapiens (human)Kd10.00000.00020.58498.1000AID625014
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)Kd15.00500.00021.13868.7730AID1425038; AID624893
Angiopoietin-1 receptorHomo sapiens (human)Kd1.40000.00311.34646.7000AID624799
Mitogen-activated protein kinase kinase kinase 10Homo sapiens (human)Kd2.30000.00382.10746.9000AID624867
DNA topoisomerase 2-betaHomo sapiens (human)Kd30.00000.14801.22702.5970AID1425203
Protein kinase C theta typeHomo sapiens (human)Kd17.75000.00071.61407.2000AID1425134; AID625051
Activin receptor type-1Homo sapiens (human)Kd1.00750.00401.485316.1210AID1424900; AID624819
Macrophage-stimulating protein receptorHomo sapiens (human)Kd20.00000.00302.07188.4000AID1425078; AID624868
Focal adhesion kinase 1Homo sapiens (human)Kd15.10500.00051.225513.0390AID1425142; AID624729
Protein kinase C delta typeHomo sapiens (human)Kd20.00000.00021.12619.2060AID1425131; AID625048
Tyrosine-protein kinase BTKHomo sapiens (human)Kd1.87000.00061.529910.1530AID1424925; AID624779
Tyrosine-protein kinase receptor TYRO3Homo sapiens (human)Kd4.90000.00202.20669.3000AID625057
Cyclin-dependent kinase 18Homo sapiens (human)Kd0.51000.01401.49418.4000AID624874
Activated CDC42 kinase 1Homo sapiens (human)Kd15.80000.00201.71389.6000AID1425201; AID624807
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)Kd0.01600.00021.631471.4840AID1424972; AID624850
Tyrosine-protein kinase ITK/TSKHomo sapiens (human)Kd0.21000.01300.86005.6000AID625020
Myotonin-protein kinaseHomo sapiens (human)Kd10.00000.00352.05287.0000AID624950
Mitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)Kd15.14500.00311.468114.0430AID1425052; AID624959
Mitogen-activated protein kinase kinase kinase 12Homo sapiens (human)Kd0.14000.02201.05546.3000AID624762
Tyrosine-protein kinase MerHomo sapiens (human)Kd0.00850.00031.70556.8000AID624767
Serine/threonine-protein kinase 4Homo sapiens (human)Kd0.08900.00021.712025.9020AID1425185; AID625055
5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)Kd1.21550.00371.891315.3890AID1425122; AID624773
Serine/threonine-protein kinase PAK 1Homo sapiens (human)Kd10.00000.00061.62064.4000AID624871
Dual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)Kd0.09090.00022.659065.6770AID1425042; AID624721
Mitogen-activated protein kinase 7Homo sapiens (human)Kd16.25000.04202.00739.9000AID1425062; AID624888
Serine/threonine-protein kinase PAK 2Homo sapiens (human)Kd3.30000.00312.30456.0000AID624872
Serine/threonine-protein kinase 3Homo sapiens (human)Kd0.40000.00021.860217.5260AID1425182; AID625054
Mitogen-activated protein kinase kinase kinase 1Homo sapiens (human)Kd20.00000.09702.599512.4730AID1425044; AID625026
cGMP-dependent protein kinase 2Homo sapiens (human)Kd10.00000.00310.83103.6000AID625053
Integrin-linked protein kinaseHomo sapiens (human)Kd30.00000.02000.46031.3290AID1425024
Rho-associated protein kinase 1Homo sapiens (human)Kd20.00000.00031.755513.4620AID1425157; AID625015
Non-receptor tyrosine-protein kinase TNK1Homo sapiens (human)Kd15.10500.00181.006411.2690AID1425200; AID624930
Serine/threonine-protein kinase PRP4 homologHomo sapiens (human)Kd0.00840.00841.18997.6000AID624750
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)Kd0.24000.02001.14875.4000AID624924
Calcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)Kd10.00000.00131.72216.8000AID624827
Calcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)Kd20.00000.00051.02097.8000AID1424929; AID624731
Calcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)Kd20.00000.00031.504420.3010AID1424928; AID624770
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)Kd20.00000.00012.101640.2910AID1424981; AID624712
Activin receptor type-2BHomo sapiens (human)Kd20.00000.00762.73289.9000AID1424902; AID624820
Bone morphogenetic protein receptor type-2Homo sapiens (human)Kd15.02800.01902.591714.3770AID1424923; AID624826
Protein-tyrosine kinase 6Homo sapiens (human)Kd20.00000.00431.74309.0000AID1425144; AID625029
cGMP-dependent protein kinase 1 Homo sapiens (human)Kd15.00700.00160.70723.8000AID1425138; AID625052
Cyclin-dependent kinase 13Homo sapiens (human)Kd20.00000.00091.25714.5180AID1424940; AID624761
Calcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)Kd5.90000.02702.29257.0000AID624922
Inhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)Kd0.17150.00511.10938.3000AID1425023; AID625074
Protein-tyrosine kinase 2-betaHomo sapiens (human)Kd15.04050.00111.945030.4140AID1425143; AID624732
Maternal embryonic leucine zipper kinaseHomo sapiens (human)Kd0.02890.00492.283529.9330AID1425074; AID625087
Structural maintenance of chromosomes protein 1AHomo sapiens (human)Kd30.00000.36500.36500.3650AID1425172
Chromodomain-helicase-DNA-binding protein 4Homo sapiens (human)Kd30.00000.00300.00300.0030AID1424952
Peroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)Kd30.00000.01400.14250.2710AID1424895
Cyclin-dependent kinase 10Homo sapiens (human)Kd30.00000.00900.00900.0090AID1424938
Serine/threonine-protein kinase D1Homo sapiens (human)Kd0.99000.01401.41168.4000AID624884
Serine/threonine-protein kinase 38Homo sapiens (human)Kd20.00000.05601.56519.4000AID1425183; AID625067
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)Kd10.00000.00091.25487.0000AID624815
Ribosomal protein S6 kinase alpha-2Homo sapiens (human)Kd5.02900.00892.04219.6000AID624805; AID625127
Ephrin type-A receptor 7Homo sapiens (human)Kd20.00000.00251.44456.5000AID1424991; AID624953
Delta(24)-sterol reductaseHomo sapiens (human)Kd30.00000.43200.43200.4320AID1424978
Ribosomal protein S6 kinase alpha-1Homo sapiens (human)Kd4.06730.02802.528622.7260AID1425159; AID624900; AID624901
Dual specificity testis-specific protein kinase 1Homo sapiens (human)Kd20.00000.03301.75685.6000AID1425194; AID625056
Myosin light chain kinase, smooth muscleHomo sapiens (human)Kd15.14500.00301.20887.9000AID1425081; AID624709
Mitogen-activated protein kinase 11Homo sapiens (human)Kd20.00000.00010.46103.7430AID1425058; AID624890
Serine/threonine-protein kinase STK11Homo sapiens (human)Kd15.00900.00300.99495.9000AID1425178; AID624798
Rhodopsin kinase GRK1Homo sapiens (human)Kd1.00000.00100.68642.2000AID624898
NT-3 growth factor receptorHomo sapiens (human)Kd0.03200.00341.20208.6000AID624765
Serine/threonine-protein kinase N1Homo sapiens (human)Kd15.37000.00133.172949.8130AID1425117; AID624745
Serine/threonine-protein kinase N2Homo sapiens (human)Kd15.70000.00181.75279.9000AID1425118; AID625050
Mitogen-activated protein kinase 14Homo sapiens (human)Kd20.00000.00000.50368.5000AID1425059; AID624714
Calcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)Kd16.85000.03001.92155.4600AID1424930; AID624843
Mitogen-activated protein kinase kinase kinase 11Homo sapiens (human)Kd10.46670.01101.563917.9840AID1425045; AID624866; AID775337
BDNF/NT-3 growth factors receptorHomo sapiens (human)Kd0.01900.00380.78757.2000AID625032
Mitogen-activated protein kinase 6Homo sapiens (human)Kd10.00000.17001.91675.5000AID624887
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)Kd0.14000.00041.55897.1000AID625035
Discoidin domain-containing receptor 2Homo sapiens (human)Kd0.02900.00301.988842.2800AID1424973; AID624777
AP2-associated protein kinase 1Homo sapiens (human)Kd15.03150.00121.370713.7110AID1424889; AID625089
Myosin light chain kinase 3Homo sapiens (human)Kd5.26700.00201.618410.4240AID1425082; AID624738
Serine/threonine-protein kinase SBK1Homo sapiens (human)Kd0.11000.00320.90484.8000AID624812
Mitogen-activated protein kinase kinase kinase 19Homo sapiens (human)Kd0.00520.00050.84206.4000AID625136
Putative heat shock protein HSP 90-beta 2Homo sapiens (human)Kd30.00002.56602.56602.5660AID1425019
Serine/threonine-protein kinase TNNI3KHomo sapiens (human)Kd10.00000.01101.73457.2000AID625097
Rab-like protein 3Homo sapiens (human)Kd30.00004.83004.83004.8300AID1425151
Leucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)Kd0.04150.00041.20429.7000AID624740; AID624741
Serine/threonine-protein kinase MRCK alphaHomo sapiens (human)Kd20.00000.05704.554714.0200AID1424933; AID624920
Serine/threonine-protein kinase MRCK gammaHomo sapiens (human)Kd20.00000.03701.96259.5000AID1424935; AID625107
Acyl-CoA dehydrogenase family member 10Homo sapiens (human)Kd30.00000.07801.69973.9570AID1424892
Serine/threonine-protein kinase Nek5Homo sapiens (human)Kd10.00000.01302.41147.3000AID624742
Serine/threonine-protein kinase N3Homo sapiens (human)Kd30.00000.09900.73651.3740AID1425119
Serine/threonine-protein kinase ULK3Homo sapiens (human)Kd15.03000.00121.33509.9000AID1425209; AID624818
Dual serine/threonine and tyrosine protein kinaseHomo sapiens (human)Kd10.00000.00531.73376.4000AID624758
Mitogen-activated protein kinase kinase kinase 15Homo sapiens (human)Kd1.40000.00250.99092.8000AID624801
Uncharacterized protein FLJ45252Homo sapiens (human)Kd30.00000.00301.22929.3110AID1425147
Acyl-CoA dehydrogenase family member 11Homo sapiens (human)Kd30.00001.91603.07304.1470AID1424893
Serine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)Kd30.00000.11600.76041.5000AID1424998
Serine/threonine-protein kinase MARK2Homo sapiens (human)Kd15.70000.00011.842511.1030AID1425068; AID625106
ATP-dependent RNA helicase DHX30Homo sapiens (human)Kd30.00000.00600.00600.0060AID1424979
Serine/threonine-protein kinase TAO1Homo sapiens (human)Kd20.00000.00042.161218.7570AID1425189; AID625126
STE20-related kinase adapter protein alphaHomo sapiens (human)Kd30.00000.31601.72083.6720AID1425186
AarF domain-containing protein kinase 1Homo sapiens (human)Kd30.00000.02303.113722.7470AID1424904
Serine/threonine-protein kinase tousled-like 2Homo sapiens (human)Kd10.00000.01600.90122.6000AID624771
Serine/threonine-protein kinase 32CHomo sapiens (human)Kd10.00000.05502.16888.0000AID624734
Serine/threonine-protein kinase pim-3Homo sapiens (human)Kd10.00000.00051.34285.8000AID624802
Serine/threonine-protein kinase VRK2Homo sapiens (human)Kd10.00000.06301.99334.0000AID625058
Myosin light chain kinase family member 4Homo sapiens (human)Kd0.44000.01500.66593.4000AID624809
Homeodomain-interacting protein kinase 1Homo sapiens (human)Kd1.30000.05501.66266.8000AID624726
Calcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)Kd2.20000.00111.85475.9000AID625118
Mitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)Kd15.14500.00511.641315.4350AID1425053; AID624921
Cyclin-dependent kinase-like 3Homo sapiens (human)Kd10.00000.00391.45495.1000AID624822
MAP kinase-activated protein kinase 5Homo sapiens (human)Kd20.00000.00801.12413.1180AID1425067; AID624923
Serine/threonine-protein kinase BRSK2Homo sapiens (human)Kd10.00000.00351.98638.9000AID624929
Serine/threonine-protein kinase NIM1Homo sapiens (human)Kd10.00000.14002.61888.7000AID624728
Serine/threonine-protein kinase ULK2Homo sapiens (human)Kd0.38000.00081.08849.9000AID625085
Misshapen-like kinase 1Homo sapiens (human)Kd1.45650.00101.14258.9000AID1425077; AID624813
Serine/threonine-protein kinase DCLK2Homo sapiens (human)Kd10.00000.01601.69074.5000AID624814
Calcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)Kd0.63000.00001.14115.1000AID625143
Casein kinase I isoform alpha-likeHomo sapiens (human)Kd10.00000.25002.20567.1000AID624723
Homeodomain-interacting protein kinase 4Homo sapiens (human)Kd1.20000.00051.33398.1000AID624720
Myosin-IIIaHomo sapiens (human)Kd10.00000.04101.66266.3000AID625104
Ankyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)Kd10.00000.03201.65349.4000AID624735
Serine/threonine-protein kinase Nek11Homo sapiens (human)Kd10.00000.17001.23503.1000AID624725
Atypical kinase COQ8A, mitochondrialHomo sapiens (human)Kd20.00000.09405.167365.3020AID1424905; AID625116
Phosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)Kd20.00000.00302.75228.8000AID1425115; AID625134
Mitogen-activated protein kinase 15Homo sapiens (human)Kd20.00000.00490.68804.5000AID1425060; AID624715
Serine/threonine-protein kinase Nek9Homo sapiens (human)Kd20.00000.01602.742819.6170AID1425089; AID624704
Serine/threonine-protein kinase BRSK1Homo sapiens (human)Kd10.00000.01402.39248.4000AID624702
Serine/threonine-protein kinase 35Homo sapiens (human)Kd0.81000.00200.97065.4000AID624711
Serine/threonine-protein kinase Nek7Homo sapiens (human)Kd10.00000.00303.67198.7000AID624754
Rhodopsin kinase GRK7Homo sapiens (human)Kd1.20000.00091.27937.5000AID624719
Serine/threonine-protein kinase 32AHomo sapiens (human)Kd10.00000.01302.20435.5000AID624821
Myosin-IIIbHomo sapiens (human)Kd2.70000.08102.41557.1000AID624817
ATP-dependent RNA helicase DDX1Homo sapiens (human)Kd30.00000.08600.08600.0860AID1424974
Dual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)Kd10.00000.02202.36937.6000AID624918
Cyclin-dependent kinase-like 2Homo sapiens (human)Kd1.30000.00051.35195.9000AID624928
Mitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)Kd15.01750.00100.93785.5000AID1425051; AID624816
Serine/threonine-protein kinase Sgk3Homo sapiens (human)Kd1.00000.00341.35617.2000AID625073
Atypical kinase COQ8B, mitochondrialHomo sapiens (human)Kd10.00000.02702.32136.1000AID625135
Aurora kinase BHomo sapiens (human)Kd0.70100.00201.061422.8520AID1424918; AID624772
MAP/microtubule affinity-regulating kinase 4Homo sapiens (human)Kd16.00000.00541.10294.9000AID1425070; AID625140
Calcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)Kd0.26000.00101.91486.8000AID625119
Serine/threonine-protein kinase Nek1Homo sapiens (human)Kd20.00000.17002.42948.3000AID1425085; AID625068
Cyclin-dependent kinase 15Homo sapiens (human)Kd10.00000.03201.88868.6000AID624718
PAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)Kd30.00001.06701.06701.0670AID1425102
Calcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)Kd15.46000.00003.233152.8470AID1424931; AID625060
EKC/KEOPS complex subunit TP53RKHomo sapiens (human)Kd30.00000.31101.95193.8400AID1425204
SRSF protein kinase 1Homo sapiens (human)Kd0.03700.00551.08915.2000AID624903
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)Kd20.00000.04400.92852.9000AID1425116; AID624757
Mitogen-activated protein kinase kinase kinase 5Homo sapiens (human)Kd20.00000.07006.564750.5360AID1425049; AID625028
Phosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)Kd0.04900.03601.83819.7000AID624824
Mitogen-activated protein kinase kinase kinase 3Homo sapiens (human)Kd2.69150.00601.53319.9000AID1425047; AID624865
Eukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)Kd20.00000.05801.92244.8360AID1424984; AID625080
Serine/threonine-protein kinase RIO1Homo sapiens (human)Kd0.02300.00901.31958.4000AID625141
MAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)Kd10.00000.02601.97347.3000AID624823
Serine/threonine-protein kinase RIO2Homo sapiens (human)Kd10.00000.04901.76679.1000AID625111
Cyclin-dependent kinase 19Homo sapiens (human)Kd10.00000.00151.92047.2000AID625094
Transient receptor potential cation channel subfamily M member 6Homo sapiens (human)Kd10.00000.00790.00790.0079AID625110
Testis-specific serine/threonine-protein kinase 1Homo sapiens (human)Kd6.10000.02402.85776.3000AID625142
Serine/threonine-protein kinase 33Homo sapiens (human)Kd1.10000.00181.35424.9000AID625138
Nucleolar GTP-binding protein 1Homo sapiens (human)Kd30.00000.00904.10358.1980AID1425016
Serine/threonine-protein kinase D2Homo sapiens (human)Kd15.36000.00812.372325.0190AID1425136; AID625102
Serine/threonine-protein kinase DCLK3Homo sapiens (human)Kd0.77000.00451.40116.5000AID624707
NUAK family SNF1-like kinase 2Homo sapiens (human)Kd15.01050.00010.67744.6000AID1425095; AID625139
RNA cytidine acetyltransferaseHomo sapiens (human)Kd30.00001.24001.24001.2400AID1425083
Serine/threonine-protein kinase SIK2Homo sapiens (human)Kd0.20100.00111.816541.7950AID1425166; AID625095
Myosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)Kd4.00000.04301.13125.4000AID624705
STE20-like serine/threonine-protein kinase Homo sapiens (human)Kd1.93300.00003.857399.2320AID1425171; AID625086
Serine/threonine-protein kinase TAO3Homo sapiens (human)Kd20.00000.00022.713114.1960AID1425191; AID625101
Homeodomain-interacting protein kinase 2Homo sapiens (human)Kd0.79000.00731.37395.0000AID625129
Tyrosine-protein kinase SrmsHomo sapiens (human)Kd10.00000.01302.60079.8000AID624710
Homeodomain-interacting protein kinase 3Homo sapiens (human)Kd0.85000.00401.70469.7000AID625023
Serine/threonine-protein kinase PLK3Homo sapiens (human)Kd10.00000.00402.90568.5000AID624933
dCTP pyrophosphatase 1Homo sapiens (human)Kd30.00000.57301.74033.0540AID1424971
Dual specificity protein kinase CLK4Homo sapiens (human)Kd15.00900.00201.41228.3000AID1424958; AID625125
MAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)Kd10.00000.00141.41315.7000AID625108
Serine/threonine-protein kinase Nek6Homo sapiens (human)Kd10.00000.00631.33854.4000AID625079
Casein kinase I isoform gamma-1Homo sapiens (human)Kd23.33330.05302.06225.7000AID1424964; AID625128
Serine/threonine-protein kinase PAK 6Homo sapiens (human)Kd20.00000.00041.91949.7000AID1425101; AID625115
SNF-related serine/threonine-protein kinaseHomo sapiens (human)Kd10.00000.09000.55201.5000AID624752
Serine/threonine-protein kinase LATS2Homo sapiens (human)Kd0.38000.00101.68798.0000AID625083
Serine/threonine-protein kinase 36Homo sapiens (human)Kd10.00000.18002.76518.3000AID625096
Phenylalanine--tRNA ligase beta subunitHomo sapiens (human)Kd30.00000.00300.00450.0060AID1425000
BMP-2-inducible protein kinaseHomo sapiens (human)Kd1.30660.00222.409756.0320AID1424920; AID625109
Interleukin-1 receptor-associated kinase 4Homo sapiens (human)Kd15.40500.00173.471934.1450AID1425029; AID625098
Serine/threonine-protein kinase 32BHomo sapiens (human)Kd10.00000.02402.70406.4000AID625112
Mitogen-activated protein kinase kinase kinase 20Homo sapiens (human)Kd20.00000.00231.703413.6380AID1425213; AID624755
Cyclin-dependent kinase 12Homo sapiens (human)Kd30.00000.03201.80325.6350AID1424939
Serine/threonine-protein kinase PLK2Homo sapiens (human)Kd10.00000.00081.80838.3000AID625063
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)Kd30.00003.92003.92003.9200AID1425084
Serine/threonine-protein kinase MARK1Homo sapiens (human)Kd1.40000.00401.26154.9000AID625113
Serine/threonine-protein kinase pim-2Homo sapiens (human)Kd20.00000.00190.84155.0000AID1425112; AID625064
Serine/threonine-protein kinase PAK 5Homo sapiens (human)Kd1.30000.00120.88013.3000AID625117
Serine/threonine-protein kinase 26Homo sapiens (human)Kd1.38500.00741.73808.3000AID1425181; AID625103
eIF-2-alpha kinase GCN2Homo sapiens (human)Kd2.00000.00331.18284.4000AID624810
Serine/threonine-protein kinase NLKHomo sapiens (human)Kd23.33330.00601.02264.4000AID1425090; AID625100
Phosphatidylinositol 4-kinase betaHomo sapiens (human)Kd10.00000.03901.19823.5000AID624880
Serine/threonine-protein kinase 17AHomo sapiens (human)Kd0.11000.00101.72189.0000AID624968
STE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)Kd0.52000.13000.98793.7000AID625071
Ephrin type-A receptor 6Homo sapiens (human)Kd0.94000.00111.02559.1000AID624748
5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)Kd30.00000.00501.15819.1280AID1425127
Serine/threonine-protein kinase TBK1Homo sapiens (human)Kd2.72800.00091.767449.6010AID1425192; AID625072
Septin-9Homo sapiens (human)Kd30.00000.01000.24300.6350AID1425165
Death-associated protein kinase 2Homo sapiens (human)Kd3.20000.00161.12619.1000AID625077
Ribosomal protein S6 kinase alpha-6Homo sapiens (human)Kd13.41000.00402.415323.7620AID1425163; AID625081; AID625082
TRAF2 and NCK-interacting protein kinaseHomo sapiens (human)Kd0.59150.00471.393510.0000AID1425199; AID625093
Serine/threonine-protein kinase tousled-like 1Homo sapiens (human)Kd10.00000.02701.05134.0000AID625069
Serine/threonine-protein kinase TAO2Homo sapiens (human)Kd20.00000.01002.017612.9420AID1425190; AID625099
Long-chain-fatty-acid--CoA ligase 5Homo sapiens (human)Kd30.00000.00800.63531.6900AID1424897
ALK tyrosine kinase receptorHomo sapiens (human)Kd20.01030.00051.35077.7000AID1424913; AID624944
SRSF protein kinase 3Homo sapiens (human)Kd0.01200.01202.11549.3000AID625078
Serine/threonine-protein kinase ICKHomo sapiens (human)Kd15.85000.00071.47179.3000AID1425021; AID625090
Cyclin-dependent kinase 11AHomo sapiens (human)Kd10.00000.00520.66171.3000AID625133
Aurora kinase CHomo sapiens (human)Kd0.19000.00131.08488.7000AID624769
Calcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)Kd3.60000.00011.69969.6000AID624730
RAC-gamma serine/threonine-protein kinaseHomo sapiens (human)Kd23.33330.00251.76466.2000AID1424912; AID625019
Serine/threonine-protein kinase 38-likeHomo sapiens (human)Kd10.00000.02801.46926.9000AID625092
Microtubule-associated serine/threonine-protein kinase 1Homo sapiens (human)Kd4.60000.01901.54206.2000AID625091
Serine/threonine-protein kinase SIK3Homo sapiens (human)Kd20.00000.00051.508610.3180AID1425167; AID624774
Mitogen-activated protein kinase kinase kinase 2Homo sapiens (human)Kd0.75520.00241.32986.9000AID1425046; AID625062
Thyroid hormone receptor-associated protein 3Homo sapiens (human)Kd30.00002.74602.74602.7460AID1425198
Dual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)Kd1.60000.02801.81299.5000AID624964
Mitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)Kd1.94100.00051.949450.2140AID1425055; AID625061
Receptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)Kd30.00000.01101.47976.7000AID1425156
Serine/threonine-protein kinase MRCK betaHomo sapiens (human)Kd20.00000.03403.625250.0050AID1424934; AID625031
Interleukin-1 receptor-associated kinase 3Homo sapiens (human)Kd17.65000.00701.713725.5810AID1425028; AID625066
Serine/threonine-protein kinase 24Homo sapiens (human)Kd0.11000.00650.89204.0840AID624917
Casein kinase I isoform gamma-3Homo sapiens (human)Kd23.33330.09702.39788.7000AID1424966; AID624949
Mitogen-activated protein kinase kinase kinase 4Homo sapiens (human)Kd20.00000.03902.39708.4000AID1425048; AID625027
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3069)

Processvia Protein(s)Taxonomy
positive regulation of gene expressionBone morphogenetic protein receptor type-1BHomo sapiens (human)
cartilage condensationBone morphogenetic protein receptor type-1BHomo sapiens (human)
ovarian cumulus expansionBone morphogenetic protein receptor type-1BHomo sapiens (human)
osteoblast differentiationBone morphogenetic protein receptor type-1BHomo sapiens (human)
eye developmentBone morphogenetic protein receptor type-1BHomo sapiens (human)
chondrocyte developmentBone morphogenetic protein receptor type-1BHomo sapiens (human)
inflammatory responseBone morphogenetic protein receptor type-1BHomo sapiens (human)
central nervous system neuron differentiationBone morphogenetic protein receptor type-1BHomo sapiens (human)
proteoglycan biosynthetic processBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of bone mineralizationBone morphogenetic protein receptor type-1BHomo sapiens (human)
BMP signaling pathwayBone morphogenetic protein receptor type-1BHomo sapiens (human)
retinal ganglion cell axon guidanceBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of chondrocyte differentiationBone morphogenetic protein receptor type-1BHomo sapiens (human)
ovulation cycleBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of osteoblast differentiationBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBone morphogenetic protein receptor type-1BHomo sapiens (human)
retina development in camera-type eyeBone morphogenetic protein receptor type-1BHomo sapiens (human)
endochondral bone morphogenesisBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of cartilage developmentBone morphogenetic protein receptor type-1BHomo sapiens (human)
cellular response to BMP stimulusBone morphogenetic protein receptor type-1BHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptorsBone morphogenetic protein receptor type-1BHomo sapiens (human)
negative regulation of chondrocyte proliferationBone morphogenetic protein receptor type-1BHomo sapiens (human)
dorsal/ventral pattern formationBone morphogenetic protein receptor type-1BHomo sapiens (human)
protein phosphorylationBone morphogenetic protein receptor type-1BHomo sapiens (human)
cellular response to growth factor stimulusBone morphogenetic protein receptor type-1BHomo sapiens (human)
phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
natural killer cell differentiationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of cytokine productionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of endothelial cell proliferationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
adaptive immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
mast cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
respiratory burst involved in defense responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
protein phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
inflammatory responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of endothelial cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of gene expressionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
T cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
natural killer cell activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
B cell differentiationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
T cell differentiationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
neutrophil chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of neutrophil apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
natural killer cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
B cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
vascular endothelial growth factor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
T cell activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
B cell activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
mast cell degranulationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
innate immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
T cell receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
B cell receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
mast cell differentiationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
neutrophil extravasationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of epithelial tube formationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
positive regulation of centriole replicationSerine/threonine-protein kinase PLK4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK4Homo sapiens (human)
centriole replicationSerine/threonine-protein kinase PLK4Homo sapiens (human)
positive regulation of centriole replicationSerine/threonine-protein kinase PLK4Homo sapiens (human)
cilium assemblySerine/threonine-protein kinase PLK4Homo sapiens (human)
trophoblast giant cell differentiationSerine/threonine-protein kinase PLK4Homo sapiens (human)
de novo centriole assembly involved in multi-ciliated epithelial cell differentiationSerine/threonine-protein kinase PLK4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 25Homo sapiens (human)
response to oxidative stressSerine/threonine-protein kinase 25Homo sapiens (human)
establishment or maintenance of cell polaritySerine/threonine-protein kinase 25Homo sapiens (human)
signal transductionSerine/threonine-protein kinase 25Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase 25Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeSerine/threonine-protein kinase 25Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase 25Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hydrogen peroxideSerine/threonine-protein kinase 25Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 25Homo sapiens (human)
positive regulation of axonogenesisSerine/threonine-protein kinase 25Homo sapiens (human)
Golgi localizationSerine/threonine-protein kinase 25Homo sapiens (human)
establishment of Golgi localizationSerine/threonine-protein kinase 25Homo sapiens (human)
Golgi reassemblySerine/threonine-protein kinase 25Homo sapiens (human)
translational initiationATP-dependent RNA helicase DDX3XHomo sapiens (human)
chromosome segregationATP-dependent RNA helicase DDX3XHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsATP-dependent RNA helicase DDX3XHomo sapiens (human)
response to virusATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA secondary structure unwindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of gene expressionATP-dependent RNA helicase DDX3XHomo sapiens (human)
Wnt signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of translationATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of cell growthATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of cell growthATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of protein-containing complex assemblyATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of protein autophosphorylationATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of type I interferon productionATP-dependent RNA helicase DDX3XHomo sapiens (human)
DNA duplex unwindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of interferon-alpha productionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of interferon-beta productionATP-dependent RNA helicase DDX3XHomo sapiens (human)
stress granule assemblyATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of toll-like receptor 7 signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of toll-like receptor 8 signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
intracellular signal transductionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of translation in response to endoplasmic reticulum stressATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytosolic ribosome assemblyATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of apoptotic processATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of apoptotic processATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of viral genome replicationATP-dependent RNA helicase DDX3XHomo sapiens (human)
innate immune responseATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of translationATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of translational initiationATP-dependent RNA helicase DDX3XHomo sapiens (human)
lipid homeostasisATP-dependent RNA helicase DDX3XHomo sapiens (human)
cellular response to arsenic-containing substanceATP-dependent RNA helicase DDX3XHomo sapiens (human)
cellular response to osmotic stressATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of chemokine (C-C motif) ligand 5 productionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
intrinsic apoptotic signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
cellular response to virusATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of protein acetylationATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsATP-dependent RNA helicase DDX3XHomo sapiens (human)
positive regulation of protein K63-linked ubiquitinationATP-dependent RNA helicase DDX3XHomo sapiens (human)
protein localization to cytoplasmic stress granuleATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayATP-dependent RNA helicase DDX3XHomo sapiens (human)
negative regulation of gene expressionATP-dependent RNA helicase DDX3XHomo sapiens (human)
gamete generationATP-dependent RNA helicase DDX3XHomo sapiens (human)
cell differentiationATP-dependent RNA helicase DDX3XHomo sapiens (human)
biological_processPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
cellular response to starvationPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
autophagosome organizationPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
cell migrationPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
pyridoxal 5'-phosphate salvagePyridoxal kinaseHomo sapiens (human)
pyridoxal metabolic processPyridoxal kinaseHomo sapiens (human)
pyridoxamine metabolic processPyridoxal kinaseHomo sapiens (human)
mitotic cell cycleCitron Rho-interacting kinaseHomo sapiens (human)
mitotic cytokinesisCitron Rho-interacting kinaseHomo sapiens (human)
positive regulation of cytokinesisCitron Rho-interacting kinaseHomo sapiens (human)
negative regulation of hippo signalingCitron Rho-interacting kinaseHomo sapiens (human)
generation of neuronsCitron Rho-interacting kinaseHomo sapiens (human)
neuron apoptotic processCitron Rho-interacting kinaseHomo sapiens (human)
chromosome segregationSerine/threonine-protein kinase RIO3Homo sapiens (human)
maturation of SSU-rRNASerine/threonine-protein kinase RIO3Homo sapiens (human)
negative regulation of protein-containing complex assemblySerine/threonine-protein kinase RIO3Homo sapiens (human)
positive regulation of interferon-beta productionSerine/threonine-protein kinase RIO3Homo sapiens (human)
negative regulation of MDA-5 signaling pathwaySerine/threonine-protein kinase RIO3Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase RIO3Homo sapiens (human)
innate immune responseSerine/threonine-protein kinase RIO3Homo sapiens (human)
positive regulation of innate immune responseSerine/threonine-protein kinase RIO3Homo sapiens (human)
defense response to virusSerine/threonine-protein kinase RIO3Homo sapiens (human)
cellular response to dsRNASerine/threonine-protein kinase RIO3Homo sapiens (human)
cellular response to virusSerine/threonine-protein kinase RIO3Homo sapiens (human)
cellular response to dsDNASerine/threonine-protein kinase RIO3Homo sapiens (human)
apoptotic processDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to osmotic stressDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
JNK cascadeDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to heatDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to UVDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to woundingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
response to tumor necrosis factorDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
Fc-epsilon receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of JUN kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of JNK cascadeDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of telomerase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cellular response to lipopolysaccharideDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cellular response to interleukin-1Dual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
positive regulation of telomere cappingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
regulation of motor neuron apoptotic processDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
DNA damage checkpoint signalingSerine/threonine-protein kinase Chk1Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase Chk1Homo sapiens (human)
inner cell mass cell proliferationSerine/threonine-protein kinase Chk1Homo sapiens (human)
DNA replicationSerine/threonine-protein kinase Chk1Homo sapiens (human)
DNA repairSerine/threonine-protein kinase Chk1Homo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase Chk1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Chk1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase Chk1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Chk1Homo sapiens (human)
nucleus organizationSerine/threonine-protein kinase Chk1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase Chk1Homo sapiens (human)
regulation of double-strand break repair via homologous recombinationSerine/threonine-protein kinase Chk1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase Chk1Homo sapiens (human)
regulation of cell population proliferationSerine/threonine-protein kinase Chk1Homo sapiens (human)
signal transduction in response to DNA damageSerine/threonine-protein kinase Chk1Homo sapiens (human)
mitotic G2/M transition checkpointSerine/threonine-protein kinase Chk1Homo sapiens (human)
positive regulation of cell cycleSerine/threonine-protein kinase Chk1Homo sapiens (human)
negative regulation of gene expression, epigeneticSerine/threonine-protein kinase Chk1Homo sapiens (human)
negative regulation of mitotic nuclear divisionSerine/threonine-protein kinase Chk1Homo sapiens (human)
regulation of mitotic centrosome separationSerine/threonine-protein kinase Chk1Homo sapiens (human)
negative regulation of G0 to G1 transitionSerine/threonine-protein kinase Chk1Homo sapiens (human)
cellular response to mechanical stimulusSerine/threonine-protein kinase Chk1Homo sapiens (human)
cellular response to caffeineSerine/threonine-protein kinase Chk1Homo sapiens (human)
replicative senescenceSerine/threonine-protein kinase Chk1Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase Chk1Homo sapiens (human)
apoptotic process involved in developmentSerine/threonine-protein kinase Chk1Homo sapiens (human)
negative regulation of DNA biosynthetic processSerine/threonine-protein kinase Chk1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependentInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
inflammatory responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
response to virusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cortical actin cytoskeleton organizationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
toll-like receptor 3 signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
TRIF-dependent toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
Fc-epsilon receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of phosphorylationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
innate immune responseInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
T cell receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
stress-activated MAPK cascadeInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein maturationInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
interleukin-1-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cellular response to tumor necrosis factorInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein localization to plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of establishment of endothelial barrierInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of bicellular tight junction assemblyInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
regulation of toll-like receptor signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
negative regulation of cell-matrix adhesionPeripheral plasma membrane protein CASKHomo sapiens (human)
cell adhesionPeripheral plasma membrane protein CASKHomo sapiens (human)
negative regulation of keratinocyte proliferationPeripheral plasma membrane protein CASKHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeripheral plasma membrane protein CASKHomo sapiens (human)
GMP metabolic processPeripheral plasma membrane protein CASKHomo sapiens (human)
GDP metabolic processPeripheral plasma membrane protein CASKHomo sapiens (human)
establishment of localization in cellPeripheral plasma membrane protein CASKHomo sapiens (human)
negative regulation of wound healingPeripheral plasma membrane protein CASKHomo sapiens (human)
calcium ion importPeripheral plasma membrane protein CASKHomo sapiens (human)
positive regulation of calcium ion importPeripheral plasma membrane protein CASKHomo sapiens (human)
negative regulation of cellular response to growth factor stimulusPeripheral plasma membrane protein CASKHomo sapiens (human)
regulation of synaptic vesicle exocytosisPeripheral plasma membrane protein CASKHomo sapiens (human)
protein localizationPeripheral plasma membrane protein CASKHomo sapiens (human)
regulation of neurotransmitter secretionPeripheral plasma membrane protein CASKHomo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
response to woundingAurora kinase AHomo sapiens (human)
liver regenerationAurora kinase AHomo sapiens (human)
G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
mitotic cell cycleAurora kinase AHomo sapiens (human)
chromatin remodelingAurora kinase AHomo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
apoptotic processAurora kinase AHomo sapiens (human)
spindle organizationAurora kinase AHomo sapiens (human)
spindle assembly involved in female meiosis IAurora kinase AHomo sapiens (human)
mitotic centrosome separationAurora kinase AHomo sapiens (human)
anterior/posterior axis specificationAurora kinase AHomo sapiens (human)
regulation of G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
negative regulation of gene expressionAurora kinase AHomo sapiens (human)
peptidyl-serine phosphorylationAurora kinase AHomo sapiens (human)
regulation of protein stabilityAurora kinase AHomo sapiens (human)
negative regulation of protein bindingAurora kinase AHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
negative regulation of apoptotic processAurora kinase AHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
positive regulation of mitotic nuclear divisionAurora kinase AHomo sapiens (human)
positive regulation of mitotic cell cycleAurora kinase AHomo sapiens (human)
regulation of centrosome cycleAurora kinase AHomo sapiens (human)
protein autophosphorylationAurora kinase AHomo sapiens (human)
cell divisionAurora kinase AHomo sapiens (human)
centrosome localizationAurora kinase AHomo sapiens (human)
cilium disassemblyAurora kinase AHomo sapiens (human)
protein localization to centrosomeAurora kinase AHomo sapiens (human)
positive regulation of mitochondrial fissionAurora kinase AHomo sapiens (human)
positive regulation of oocyte maturationAurora kinase AHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase AHomo sapiens (human)
neuron projection extensionAurora kinase AHomo sapiens (human)
mitotic spindle organizationAurora kinase AHomo sapiens (human)
regulation of cytokinesisAurora kinase AHomo sapiens (human)
receptor-mediated endocytosisCyclin-G-associated kinaseHomo sapiens (human)
endoplasmic reticulum organizationCyclin-G-associated kinaseHomo sapiens (human)
Golgi organizationCyclin-G-associated kinaseHomo sapiens (human)
negative regulation of neuron projection developmentCyclin-G-associated kinaseHomo sapiens (human)
synaptic vesicle uncoatingCyclin-G-associated kinaseHomo sapiens (human)
protein localization to Golgi apparatusCyclin-G-associated kinaseHomo sapiens (human)
intracellular transportCyclin-G-associated kinaseHomo sapiens (human)
clathrin coat assemblyCyclin-G-associated kinaseHomo sapiens (human)
chaperone cofactor-dependent protein refoldingCyclin-G-associated kinaseHomo sapiens (human)
clathrin coat disassemblyCyclin-G-associated kinaseHomo sapiens (human)
clathrin-dependent endocytosisCyclin-G-associated kinaseHomo sapiens (human)
protein localization to plasma membraneCyclin-G-associated kinaseHomo sapiens (human)
Golgi to lysosome transportCyclin-G-associated kinaseHomo sapiens (human)
regulation of clathrin coat assemblyCyclin-G-associated kinaseHomo sapiens (human)
neuron migrationSerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase DCLK1Homo sapiens (human)
nervous system developmentSerine/threonine-protein kinase DCLK1Homo sapiens (human)
central nervous system developmentSerine/threonine-protein kinase DCLK1Homo sapiens (human)
response to virusSerine/threonine-protein kinase DCLK1Homo sapiens (human)
endosomal transportSerine/threonine-protein kinase DCLK1Homo sapiens (human)
central nervous system projection neuron axonogenesisSerine/threonine-protein kinase DCLK1Homo sapiens (human)
forebrain developmentSerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein localization to nucleusSerine/threonine-protein kinase DCLK1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase DCLK1Homo sapiens (human)
axon extensionSerine/threonine-protein kinase DCLK1Homo sapiens (human)
dendrite morphogenesisSerine/threonine-protein kinase DCLK1Homo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase DCLK1Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase DCLK1Homo sapiens (human)
skeletal muscle contractionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein phosphorylationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
inflammatory responseInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
immune responseInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
I-kappaB phosphorylationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
Rho protein signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to xenobiotic stimulusInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to virusInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to toxic substanceInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
anatomical structure morphogenesisInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to acetateInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
negative regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to lipopolysaccharideInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of interferon-alpha productionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to hydroperoxideInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
toll-like receptor 4 signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to reactive oxygen speciesInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
non-canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to amino acidInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
innate immune responseInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
striated muscle cell differentiationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
response to cholecystokininInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to cadmium ionInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to tumor necrosis factorInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cellular response to virusInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
positive regulation of protein phosphorylationMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
neuromuscular junction developmentMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
memoryMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
regulation of synaptic assembly at neuromuscular junctionMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of gene expressionMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
cell differentiationMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
protein autophosphorylationMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
skeletal muscle acetylcholine-gated channel clusteringMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of protein geranylgeranylationMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
multicellular organism developmentMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of kinase activityMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
positive regulation of neuron projection developmentMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
protein phosphorylationEphrin type-B receptor 6Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 6Homo sapiens (human)
axon guidanceEphrin type-B receptor 6Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA oxidasePeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
lipid homeostasisPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
response to osmotic stressMitogen-activated protein kinase 13Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 13Homo sapiens (human)
positive regulation of interleukin-6 productionMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to UVMitogen-activated protein kinase 13Homo sapiens (human)
positive regulation of inflammatory responseMitogen-activated protein kinase 13Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to hydrogen peroxideMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to interleukin-1Mitogen-activated protein kinase 13Homo sapiens (human)
cellular response to sorbitolMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to anisomycinMitogen-activated protein kinase 13Homo sapiens (human)
cellular response to sodium arseniteMitogen-activated protein kinase 13Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 13Homo sapiens (human)
intracellular signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
type B pancreatic cell development3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of protein kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
hyperosmotic response3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
epidermal growth factor receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
insulin receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of phospholipase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic process3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cell migration3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
calcium-mediated signaling3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
actin cytoskeleton organization3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
T cell costimulation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
activation of protein kinase B activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cellular response to insulin stimulus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of toll-like receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
regulation of canonical NF-kappaB signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
regulation of mast cell degranulation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of angiogenesis3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein autophosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosol3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cellular response to epidermal growth factor stimulus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathway3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of protein localization to plasma membrane3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of sprouting angiogenesis3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
negative regulation of endothelial cell apoptotic process3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylation3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
intracellular signal transduction3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of neuron maturationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of axon extensionMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of neuron projection arborizationMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
positive regulation of branching morphogenesis of a nerveMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
chromatin organizationDeath-associated protein kinase 3Homo sapiens (human)
regulation of DNA-templated transcriptionDeath-associated protein kinase 3Homo sapiens (human)
protein phosphorylationDeath-associated protein kinase 3Homo sapiens (human)
apoptotic processDeath-associated protein kinase 3Homo sapiens (human)
regulation of smooth muscle contractionDeath-associated protein kinase 3Homo sapiens (human)
regulation of mitotic nuclear divisionDeath-associated protein kinase 3Homo sapiens (human)
regulation of mitotic cell cycleDeath-associated protein kinase 3Homo sapiens (human)
regulation of cell shapeDeath-associated protein kinase 3Homo sapiens (human)
regulation of autophagyDeath-associated protein kinase 3Homo sapiens (human)
negative regulation of translationDeath-associated protein kinase 3Homo sapiens (human)
positive regulation of cell migrationDeath-associated protein kinase 3Homo sapiens (human)
regulation of actin cytoskeleton organizationDeath-associated protein kinase 3Homo sapiens (human)
intracellular signal transductionDeath-associated protein kinase 3Homo sapiens (human)
regulation of apoptotic processDeath-associated protein kinase 3Homo sapiens (human)
positive regulation of apoptotic processDeath-associated protein kinase 3Homo sapiens (human)
regulation of myosin II filament organizationDeath-associated protein kinase 3Homo sapiens (human)
protein autophosphorylationDeath-associated protein kinase 3Homo sapiens (human)
regulation of focal adhesion assemblyDeath-associated protein kinase 3Homo sapiens (human)
cellular response to type II interferonDeath-associated protein kinase 3Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayDeath-associated protein kinase 3Homo sapiens (human)
apoptotic signaling pathwayDeath-associated protein kinase 3Homo sapiens (human)
regulation of cell motilityDeath-associated protein kinase 3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of T cell cytokine productionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
chromatin remodelingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
inflammatory responseMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
canonical NF-kappaB signal transductionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
I-kappaB phosphorylationMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
negative regulation of gene expressionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of macroautophagyMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of interleukin-2 productionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
toll-like receptor 3 signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
toll-like receptor 4 signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
TRIF-dependent toll-like receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
interleukin-33-mediated signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
interleukin-17A-mediated signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
defense response to bacteriumMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
anoikisMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of cell cycleMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of cell sizeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
T cell receptor signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
interleukin-1-mediated signaling pathwayMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cellular response to hypoxiaMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cellular response to angiotensinMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
immune responseMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
toll-like receptor 2 signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of cytokine-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
adaptive immune responseReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of T-helper 1 type immune responseReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
apoptotic processReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
inflammatory responseReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
signal transductionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
JNK cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytokine-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein ubiquitinationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of chemokine productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interferon-alpha productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interferon-beta productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of type II interferon productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interleukin-1 beta productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interleukin-12 productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interleukin-2 productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of interleukin-6 productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
immature T cell proliferation in thymusReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of immature T cell proliferation in thymusReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
toll-like receptor 4 signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
CD4-positive, alpha-beta T cell proliferationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
defense response to bacteriumReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of apoptotic processReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
response to exogenous dsRNAReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
innate immune responseReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of T-helper 1 cell differentiationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of JNK cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
defense response to Gram-positive bacteriumReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
T cell receptor signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein homooligomerizationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
stress-activated MAPK cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of macrophage cytokine productionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
ERK1 and ERK2 cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nucleotide-binding oligomerization domain containing 1 signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
response to interleukin-1Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
response to interleukin-12Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
response to interleukin-18Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to lipoteichoic acidReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to peptidoglycanReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to muramyl dipeptideReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
activation of cysteine-type endopeptidase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
xenophagyReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein K63-linked ubiquitinationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of xenophagyReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
chromatin remodelingMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
apoptotic processMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
chromosome segregationMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
regulation of sister chromatid cohesionMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
mitotic spindle assembly checkpoint signalingMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
cell divisionMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
regulation of chromosome segregationMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
positive regulation of maintenance of mitotic sister chromatid cohesion, centromericMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
meiotic sister chromatid cohesion, centromericMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
protein phosphorylationNUAK family SNF1-like kinase 1Homo sapiens (human)
DNA damage responseNUAK family SNF1-like kinase 1Homo sapiens (human)
cell adhesionNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of cell adhesionNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of myosin-light-chain-phosphatase activityNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of cell population proliferationNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of signal transduction by p53 class mediatorNUAK family SNF1-like kinase 1Homo sapiens (human)
regulation of cellular senescenceNUAK family SNF1-like kinase 1Homo sapiens (human)
mitochondrion organizationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial genome maintenanceDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial fissionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
neural tube closureDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
apoptotic processDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrion organizationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
inner mitochondrial membrane organizationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
visual perceptionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial fusionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
axonal transport of mitochondrionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-17 productionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cristae formationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic processDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
GTP metabolic processDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
protein complex oligomerizationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
membrane fusionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cellular senescenceDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
membrane tubulationDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane fusionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
phagocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
synaptic vesicle exocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
actin cytoskeleton organizationPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
neutrophil chemotaxisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
adherens junction assemblyPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
synaptic vesicle endocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
membrane organizationPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
clathrin-dependent endocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
cell-cell adhesionPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
positive regulation of platelet aggregationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of platelet activationTyrosine-protein kinase JAK2Homo sapiens (human)
response to antibioticTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of SMAD protein signal transductionTyrosine-protein kinase JAK2Homo sapiens (human)
microglial cell activationTyrosine-protein kinase JAK2Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase JAK2Homo sapiens (human)
chromatin remodelingTyrosine-protein kinase JAK2Homo sapiens (human)
transcription by RNA polymerase IITyrosine-protein kinase JAK2Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK2Homo sapiens (human)
apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
immune responseTyrosine-protein kinase JAK2Homo sapiens (human)
signal transductionTyrosine-protein kinase JAK2Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
G protein-coupled receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTyrosine-protein kinase JAK2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK2Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK2Homo sapiens (human)
mesoderm developmentTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of cardiac muscle cell apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cell-substrate adhesionTyrosine-protein kinase JAK2Homo sapiens (human)
response to amineTyrosine-protein kinase JAK2Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase JAK2Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of cell-cell adhesionTyrosine-protein kinase JAK2Homo sapiens (human)
actin filament polymerizationTyrosine-protein kinase JAK2Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK2Homo sapiens (human)
erythrocyte differentiationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cell migrationTyrosine-protein kinase JAK2Homo sapiens (human)
axon regenerationTyrosine-protein kinase JAK2Homo sapiens (human)
intracellular mineralocorticoid receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of insulin secretionTyrosine-protein kinase JAK2Homo sapiens (human)
response to lipopolysaccharideTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of interleukin-1 beta productionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of interleukin-17 productionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of natural killer cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
response to hydroperoxideTyrosine-protein kinase JAK2Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
symbiont-induced defense-related programmed cell deathTyrosine-protein kinase JAK2Homo sapiens (human)
response to tumor necrosis factorTyrosine-protein kinase JAK2Homo sapiens (human)
post-embryonic hemopoiesisTyrosine-protein kinase JAK2Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-12-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
cellular response to interleukin-3Tyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-5-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
collagen-activated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-3-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
granulocyte-macrophage colony-stimulating factor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of T cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of protein import into nucleusTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK2Homo sapiens (human)
activation of Janus kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of DNA bindingTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of MAPK cascadeTyrosine-protein kinase JAK2Homo sapiens (human)
negative regulation of neuron apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
post-translational protein modificationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of MHC class II biosynthetic processTyrosine-protein kinase JAK2Homo sapiens (human)
regulation of nitric oxide biosynthetic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cell differentiationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase JAK2Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK2Homo sapiens (human)
protein autophosphorylationTyrosine-protein kinase JAK2Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
regulation of inflammatory responseTyrosine-protein kinase JAK2Homo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of NK T cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase JAK2Homo sapiens (human)
type II interferon-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
growth hormone receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of growth hormone receptor signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
mammary gland epithelium developmentTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-6-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of leukocyte proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
response to interleukin-12Tyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-35-mediated signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
cellular response to lipopolysaccharideTyrosine-protein kinase JAK2Homo sapiens (human)
cellular response to dexamethasone stimulusTyrosine-protein kinase JAK2Homo sapiens (human)
extrinsic apoptotic signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
cellular response to virusTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of cold-induced thermogenesisTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of growth factor dependent skeletal muscle satellite cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of epithelial cell apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTyrosine-protein kinase JAK2Homo sapiens (human)
regulation of postsynapse to nucleus signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of signaling receptor activityTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of T-helper 17 type immune responseTyrosine-protein kinase JAK2Homo sapiens (human)
positive regulation of apoptotic signaling pathwayTyrosine-protein kinase JAK2Homo sapiens (human)
regulation of apoptotic processTyrosine-protein kinase JAK2Homo sapiens (human)
epithelial to mesenchymal transitionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationRho-associated protein kinase 2Homo sapiens (human)
response to ischemiaRho-associated protein kinase 2Homo sapiens (human)
aortic valve morphogenesisRho-associated protein kinase 2Homo sapiens (human)
protein phosphorylationRho-associated protein kinase 2Homo sapiens (human)
smooth muscle contractionRho-associated protein kinase 2Homo sapiens (human)
canonical NF-kappaB signal transductionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of endothelial cell migrationRho-associated protein kinase 2Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyRho-associated protein kinase 2Homo sapiens (human)
positive regulation of gene expressionRho-associated protein kinase 2Homo sapiens (human)
negative regulation of gene expressionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of centrosome duplicationRho-associated protein kinase 2Homo sapiens (human)
negative regulation of angiogenesisRho-associated protein kinase 2Homo sapiens (human)
actin cytoskeleton organizationRho-associated protein kinase 2Homo sapiens (human)
regulation of cell adhesionRho-associated protein kinase 2Homo sapiens (human)
positive regulation of cell migrationRho-associated protein kinase 2Homo sapiens (human)
cortical actin cytoskeleton organizationRho-associated protein kinase 2Homo sapiens (human)
regulation of nervous system processRho-associated protein kinase 2Homo sapiens (human)
positive regulation of connective tissue growth factor productionRho-associated protein kinase 2Homo sapiens (human)
regulation of actin cytoskeleton organizationRho-associated protein kinase 2Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityRho-associated protein kinase 2Homo sapiens (human)
regulation of circadian rhythmRho-associated protein kinase 2Homo sapiens (human)
positive regulation of MAPK cascadeRho-associated protein kinase 2Homo sapiens (human)
modulation by host of viral processRho-associated protein kinase 2Homo sapiens (human)
negative regulation of nitric oxide biosynthetic processRho-associated protein kinase 2Homo sapiens (human)
regulation of keratinocyte differentiationRho-associated protein kinase 2Homo sapiens (human)
rhythmic processRho-associated protein kinase 2Homo sapiens (human)
centrosome duplicationRho-associated protein kinase 2Homo sapiens (human)
regulation of stress fiber assemblyRho-associated protein kinase 2Homo sapiens (human)
positive regulation of stress fiber assemblyRho-associated protein kinase 2Homo sapiens (human)
regulation of focal adhesion assemblyRho-associated protein kinase 2Homo sapiens (human)
mRNA destabilizationRho-associated protein kinase 2Homo sapiens (human)
negative regulation of biomineral tissue developmentRho-associated protein kinase 2Homo sapiens (human)
cellular response to testosterone stimulusRho-associated protein kinase 2Homo sapiens (human)
response to transforming growth factor betaRho-associated protein kinase 2Homo sapiens (human)
protein localization to plasma membraneRho-associated protein kinase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionRho-associated protein kinase 2Homo sapiens (human)
blood vessel diameter maintenanceRho-associated protein kinase 2Homo sapiens (human)
regulation of angiotensin-activated signaling pathwayRho-associated protein kinase 2Homo sapiens (human)
negative regulation of protein localization to lysosomeRho-associated protein kinase 2Homo sapiens (human)
regulation of cellular response to hypoxiaRho-associated protein kinase 2Homo sapiens (human)
positive regulation of amyloid-beta formationRho-associated protein kinase 2Homo sapiens (human)
positive regulation of protein localization to early endosomeRho-associated protein kinase 2Homo sapiens (human)
positive regulation of amyloid precursor protein catabolic processRho-associated protein kinase 2Homo sapiens (human)
regulation of establishment of endothelial barrierRho-associated protein kinase 2Homo sapiens (human)
negative regulation of bicellular tight junction assemblyRho-associated protein kinase 2Homo sapiens (human)
cellular response to acetylcholineRho-associated protein kinase 2Homo sapiens (human)
positive regulation of connective tissue replacementRho-associated protein kinase 2Homo sapiens (human)
response to angiotensinRho-associated protein kinase 2Homo sapiens (human)
regulation of establishment of cell polarityRho-associated protein kinase 2Homo sapiens (human)
regulation of cell motilityRho-associated protein kinase 2Homo sapiens (human)
actomyosin structure organizationRho-associated protein kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationRho-associated protein kinase 2Homo sapiens (human)
mitotic cytokinesisRho-associated protein kinase 2Homo sapiens (human)
embryonic morphogenesisRho-associated protein kinase 2Homo sapiens (human)
regulation of cell junction assemblyRho-associated protein kinase 2Homo sapiens (human)
Rho protein signal transductionRho-associated protein kinase 2Homo sapiens (human)
autophagosome assemblySerine/threonine-protein kinase ULK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein localizationSerine/threonine-protein kinase ULK1Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase ULK1Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwaySerine/threonine-protein kinase ULK1Homo sapiens (human)
macroautophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
regulation of macroautophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
neuron projection regenerationSerine/threonine-protein kinase ULK1Homo sapiens (human)
neuron projection developmentSerine/threonine-protein kinase ULK1Homo sapiens (human)
negative regulation of protein-containing complex assemblySerine/threonine-protein kinase ULK1Homo sapiens (human)
cellular response to nutrient levelsSerine/threonine-protein kinase ULK1Homo sapiens (human)
response to starvationSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ULK1Homo sapiens (human)
regulation of protein lipidationSerine/threonine-protein kinase ULK1Homo sapiens (human)
positive regulation of autophagosome assemblySerine/threonine-protein kinase ULK1Homo sapiens (human)
axon extensionSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase ULK1Homo sapiens (human)
reticulophagySerine/threonine-protein kinase ULK1Homo sapiens (human)
piecemeal microautophagy of the nucleusSerine/threonine-protein kinase ULK1Homo sapiens (human)
negative regulation of collateral sproutingSerine/threonine-protein kinase ULK1Homo sapiens (human)
endothelial cell proliferationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mRNA catabolic processSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
regulation of macroautophagySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of RNA splicingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to unfolded proteinSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
peptidyl-serine autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-mediated unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of JUN kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mRNA splicing, via endonucleolytic cleavage and ligationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to hydrogen peroxideSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cellular response to glucose stimulusSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of endoplasmic reticulum unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
insulin metabolic processSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
peptidyl-serine trans-autophosphorylationSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
negative regulation of cytokine productionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
chromatin remodelingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein phosphorylationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
inflammatory responseRibosomal protein S6 kinase alpha-5Homo sapiens (human)
axon guidanceRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of CREB transcription factor activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
post-translational protein modificationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
negative regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-5Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
interleukin-1-mediated signaling pathwayRibosomal protein S6 kinase alpha-5Homo sapiens (human)
regulation of postsynapse organizationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cis assembly of pre-catalytic spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
spliceosome conformational change to release U4 (or U4atac) and U1 (or U11)U5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
mRNA splicing, via spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
osteoblast differentiationU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
negative regulation of cytokine productionRibosomal protein S6 kinase alpha-4Homo sapiens (human)
chromatin remodelingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein phosphorylationRibosomal protein S6 kinase alpha-4Homo sapiens (human)
inflammatory responseRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of CREB transcription factor activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-4Homo sapiens (human)
post-translational protein modificationRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
interleukin-1-mediated signaling pathwayRibosomal protein S6 kinase alpha-4Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase 16Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 16Homo sapiens (human)
cellular response to transforming growth factor beta stimulusSerine/threonine-protein kinase 16Homo sapiens (human)
chemotaxisPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
modulation by host of viral processPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
cell migrationPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase PAK 3Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwaySerine/threonine-protein kinase PAK 3Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase PAK 3Homo sapiens (human)
dendrite developmentSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of actin filament polymerizationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
ephrin receptor signaling pathwaySerine/threonine-protein kinase PAK 3Homo sapiens (human)
synapse organizationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
dendritic spine morphogenesisSerine/threonine-protein kinase PAK 3Homo sapiens (human)
cellular response to organic cyclic compoundSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of postsynapse organizationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase PAK 3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 3Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase PAK 3Homo sapiens (human)
neuron migrationCyclin-dependent kinase-like 5Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase-like 5Homo sapiens (human)
positive regulation of GTPase activityCyclin-dependent kinase-like 5Homo sapiens (human)
positive regulation of axon extensionCyclin-dependent kinase-like 5Homo sapiens (human)
protein autophosphorylationCyclin-dependent kinase-like 5Homo sapiens (human)
regulation of dendrite developmentCyclin-dependent kinase-like 5Homo sapiens (human)
positive regulation of dendrite morphogenesisCyclin-dependent kinase-like 5Homo sapiens (human)
modulation of chemical synaptic transmissionCyclin-dependent kinase-like 5Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase-like 5Homo sapiens (human)
positive regulation of dendritic spine developmentCyclin-dependent kinase-like 5Homo sapiens (human)
regulation of postsynapse organizationCyclin-dependent kinase-like 5Homo sapiens (human)
regulation of cilium assemblyCyclin-dependent kinase-like 5Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 17BHomo sapiens (human)
apoptotic processSerine/threonine-protein kinase 17BHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 17BHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 17BHomo sapiens (human)
positive regulation of fibroblast apoptotic processSerine/threonine-protein kinase 17BHomo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 17BHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 10Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 10Homo sapiens (human)
lymphocyte aggregationSerine/threonine-protein kinase 10Homo sapiens (human)
regulation of lymphocyte migrationSerine/threonine-protein kinase 10Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase D3Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D3Homo sapiens (human)
sphingolipid biosynthetic processSerine/threonine-protein kinase D3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase D3Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D3Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 14Homo sapiens (human)
Wnt signaling pathwayCyclin-dependent kinase 14Homo sapiens (human)
cell divisionCyclin-dependent kinase 14Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 14Homo sapiens (human)
regulation of canonical Wnt signaling pathwayCyclin-dependent kinase 14Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 14Homo sapiens (human)
mitotic chromosome condensationStructural maintenance of chromosomes protein 2Homo sapiens (human)
meiotic chromosome condensationStructural maintenance of chromosomes protein 2Homo sapiens (human)
meiotic chromosome segregationStructural maintenance of chromosomes protein 2Homo sapiens (human)
cell divisionStructural maintenance of chromosomes protein 2Homo sapiens (human)
kinetochore organizationStructural maintenance of chromosomes protein 2Homo sapiens (human)
positive regulation of chromosome segregationStructural maintenance of chromosomes protein 2Homo sapiens (human)
positive regulation of chromosome separationStructural maintenance of chromosomes protein 2Homo sapiens (human)
positive regulation of chromosome condensationStructural maintenance of chromosomes protein 2Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
signal transductionMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
cellular response to stressMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase OSR1Homo sapiens (human)
cell volume homeostasisSerine/threonine-protein kinase OSR1Homo sapiens (human)
response to oxidative stressSerine/threonine-protein kinase OSR1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase OSR1Homo sapiens (human)
osmosensory signaling pathwaySerine/threonine-protein kinase OSR1Homo sapiens (human)
response to xenobiotic stimulusSerine/threonine-protein kinase OSR1Homo sapiens (human)
positive regulation of T cell chemotaxisSerine/threonine-protein kinase OSR1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase OSR1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase OSR1Homo sapiens (human)
chemokine (C-C motif) ligand 21 signaling pathwaySerine/threonine-protein kinase OSR1Homo sapiens (human)
chemokine (C-X-C motif) ligand 12 signaling pathwaySerine/threonine-protein kinase OSR1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase OSR1Homo sapiens (human)
renal sodium ion absorptionSerine/threonine-protein kinase OSR1Homo sapiens (human)
cellular hyperosmotic responseSerine/threonine-protein kinase OSR1Homo sapiens (human)
cellular hypotonic responseSerine/threonine-protein kinase OSR1Homo sapiens (human)
negative regulation of potassium ion transmembrane transportSerine/threonine-protein kinase OSR1Homo sapiens (human)
cellular response to chemokineSerine/threonine-protein kinase OSR1Homo sapiens (human)
negative regulation of potassium ion transmembrane transporter activitySerine/threonine-protein kinase OSR1Homo sapiens (human)
microvillus assemblyMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
negative regulation of cell-matrix adhesionMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of cell migrationMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of ARF protein signal transductionMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of hippo signalingMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
negative regulation of apoptotic processMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of GTPase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
regulation of JNK cascadeMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of keratinocyte migrationMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of focal adhesion assemblyMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
positive regulation of focal adhesion disassemblyMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
regulation of MAPK cascadeMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
neuron projection morphogenesisMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase LATS1Homo sapiens (human)
sister chromatid segregationSerine/threonine-protein kinase LATS1Homo sapiens (human)
inner cell mass cell fate commitmentSerine/threonine-protein kinase LATS1Homo sapiens (human)
inner cell mass cellular morphogenesisSerine/threonine-protein kinase LATS1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase LATS1Homo sapiens (human)
hormone-mediated signaling pathwaySerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase LATS1Homo sapiens (human)
keratinocyte differentiationSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of actin filament polymerizationSerine/threonine-protein kinase LATS1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of intracellular estrogen receptor signaling pathwaySerine/threonine-protein kinase LATS1Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of protein-containing complex assemblySerine/threonine-protein kinase LATS1Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activitySerine/threonine-protein kinase LATS1Homo sapiens (human)
cytoplasmic sequestering of proteinSerine/threonine-protein kinase LATS1Homo sapiens (human)
cell divisionSerine/threonine-protein kinase LATS1Homo sapiens (human)
mammary gland epithelial cell differentiationSerine/threonine-protein kinase LATS1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase LATS1Homo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of ubiquitin-dependent protein catabolic processSerine/threonine-protein kinase LATS1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase LATS1Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase LATS1Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of organ growthSerine/threonine-protein kinase LATS1Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase PAK 4Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase PAK 4Homo sapiens (human)
signal transductionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cell migrationSerine/threonine-protein kinase PAK 4Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase PAK 4Homo sapiens (human)
dendritic spine developmentSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cellular response to organic cyclic compoundSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cell-cell adhesionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
negative regulation of endothelial cell apoptotic processSerine/threonine-protein kinase PAK 4Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 4Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Chk2Homo sapiens (human)
signal transduction in response to DNA damageSerine/threonine-protein kinase Chk2Homo sapiens (human)
DNA damage checkpoint signalingSerine/threonine-protein kinase Chk2Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase Chk2Homo sapiens (human)
double-strand break repairSerine/threonine-protein kinase Chk2Homo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Chk2Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Chk2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestSerine/threonine-protein kinase Chk2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorSerine/threonine-protein kinase Chk2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein catabolic processSerine/threonine-protein kinase Chk2Homo sapiens (human)
mitotic intra-S DNA damage checkpoint signalingSerine/threonine-protein kinase Chk2Homo sapiens (human)
regulation of protein catabolic processSerine/threonine-protein kinase Chk2Homo sapiens (human)
signal transduction in response to DNA damageSerine/threonine-protein kinase Chk2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorSerine/threonine-protein kinase Chk2Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase Chk2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Chk2Homo sapiens (human)
thymocyte apoptotic processSerine/threonine-protein kinase Chk2Homo sapiens (human)
cellular response to gamma radiationSerine/threonine-protein kinase Chk2Homo sapiens (human)
mitotic spindle assemblySerine/threonine-protein kinase Chk2Homo sapiens (human)
replicative senescenceSerine/threonine-protein kinase Chk2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase Chk2Homo sapiens (human)
regulation of autophagosome assemblySerine/threonine-protein kinase Chk2Homo sapiens (human)
mitotic DNA damage checkpoint signalingSerine/threonine-protein kinase Chk2Homo sapiens (human)
response to oxidative stressTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of phospholipase C activityTyrosine-protein kinase ABL1Homo sapiens (human)
mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
neural tube closureTyrosine-protein kinase ABL1Homo sapiens (human)
B-1 B cell homeostasisTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of protein phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
B cell proliferation involved in immune responseTyrosine-protein kinase ABL1Homo sapiens (human)
transitional one stage B cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
mismatch repairTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of DNA-templated transcriptionTyrosine-protein kinase ABL1Homo sapiens (human)
autophagyTyrosine-protein kinase ABL1Homo sapiens (human)
DNA damage responseTyrosine-protein kinase ABL1Homo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
canonical NF-kappaB signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
associative learningTyrosine-protein kinase ABL1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageTyrosine-protein kinase ABL1Homo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase ABL1Homo sapiens (human)
post-embryonic developmentTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of autophagyTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of endothelial cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
cerebellum morphogenesisTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of cell-cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
microspike assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein kinase ABL1Homo sapiens (human)
actin filament polymerizationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of endocytosisTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
neuron differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
BMP signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of BMP signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of axon extensionTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of microtubule polymerizationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of Cdc42 protein signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of interleukin-2 productionTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of actin cytoskeleton organizationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of osteoblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to oxidative stressTyrosine-protein kinase ABL1Homo sapiens (human)
response to endoplasmic reticulum stressTyrosine-protein kinase ABL1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
protein modification processTyrosine-protein kinase ABL1Homo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase ABL1Homo sapiens (human)
neuropilin signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
signal transduction in response to DNA damageTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of neuron apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
endothelial cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of T cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of vasoconstrictionTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of mitotic cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase ABL1Homo sapiens (human)
alpha-beta T cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
protein autophosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of fibroblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
spleen developmentTyrosine-protein kinase ABL1Homo sapiens (human)
thymus developmentTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
activated T cell proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
neuromuscular process controlling balanceTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of oxidoreductase activityTyrosine-protein kinase ABL1Homo sapiens (human)
neuron apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
myoblast proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of stress fiber assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
establishment of localization in cellTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell cycleTyrosine-protein kinase ABL1Homo sapiens (human)
mitochondrial depolarizationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of focal adhesion assemblyTyrosine-protein kinase ABL1Homo sapiens (human)
Bergmann glial cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
cardiac muscle cell proliferationTyrosine-protein kinase ABL1Homo sapiens (human)
neuroepithelial cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase ABL1Homo sapiens (human)
ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase ABL1Homo sapiens (human)
DNA conformation changeTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to lipopolysaccharideTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase ABL1Homo sapiens (human)
response to epinephrineTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of protein serine/threonine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisTyrosine-protein kinase ABL1Homo sapiens (human)
cellular senescenceTyrosine-protein kinase ABL1Homo sapiens (human)
cell-cell adhesionTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of dendrite developmentTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of long-term synaptic potentiationTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of hematopoietic stem cell differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of extracellular matrix organizationTyrosine-protein kinase ABL1Homo sapiens (human)
podocyte apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
cellular response to dopamineTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of establishment of T cell polarityTyrosine-protein kinase ABL1Homo sapiens (human)
DN4 thymocyte differentiationTyrosine-protein kinase ABL1Homo sapiens (human)
protein localization to cytoplasmic microtubule plus-endTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of microtubule bindingTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of actin filament bindingTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of modification of synaptic structureTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of blood vessel branchingTyrosine-protein kinase ABL1Homo sapiens (human)
activation of protein kinase C activityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of Wnt signaling pathway, planar cell polarity pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
regulation of cell motilityTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of endothelial cell apoptotic processTyrosine-protein kinase ABL1Homo sapiens (human)
positive regulation of T cell migrationTyrosine-protein kinase ABL1Homo sapiens (human)
negative regulation of cellular senescenceTyrosine-protein kinase ABL1Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein kinase ABL1Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase ABL1Homo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
activation of adenylate cyclase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cell population proliferationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
insulin receptor signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
Schwann cell developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
thyroid gland developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein-containing complex assemblyRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
somatic stem cell population maintenanceRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of Rho protein signal transductionRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
insulin secretion involved in cellular response to glucose stimulusRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
response to muscle stretchRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
ERBB2-ERBB3 signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
wound healingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
myelinationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of MAPK cascadeRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
type B pancreatic cell proliferationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
intermediate filament cytoskeleton organizationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell differentiationRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
thymus developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
face developmentRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
type II interferon-mediated signaling pathwayRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
death-inducing signaling complex assemblyRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell motilityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
MAPK cascadeRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cell surface receptor signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junction developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
motor neuron axon guidanceReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
Schwann cell developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell growthReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of microtubule-based processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of immature T cell proliferation in thymusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of Rho protein signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
intracellular signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-EGFR signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
wound healingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelinationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAP kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of translationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of angiogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell adhesionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
oligodendrocyte differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of epithelial cell proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
semaphorin-plexin signaling pathwayReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of protein targeting to membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of MAPK cascadeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuron differentiationReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cellular response to amyloid-betaHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
protein phosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
axon guidanceHigh affinity nerve growth factor receptorHomo sapiens (human)
learning or memoryHigh affinity nerve growth factor receptorHomo sapiens (human)
circadian rhythmHigh affinity nerve growth factor receptorHomo sapiens (human)
negative regulation of cell population proliferationHigh affinity nerve growth factor receptorHomo sapiens (human)
response to xenobiotic stimulusHigh affinity nerve growth factor receptorHomo sapiens (human)
programmed cell death involved in cell developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of neuron projection developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
olfactory nerve developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
B cell differentiationHigh affinity nerve growth factor receptorHomo sapiens (human)
response to nutrient levelsHigh affinity nerve growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
nerve growth factor signaling pathwayHigh affinity nerve growth factor receptorHomo sapiens (human)
mechanoreceptor differentiationHigh affinity nerve growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of programmed cell deathHigh affinity nerve growth factor receptorHomo sapiens (human)
negative regulation of neuron apoptotic processHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of GTPase activityHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of Ras protein signal transductionHigh affinity nerve growth factor receptorHomo sapiens (human)
protein autophosphorylationHigh affinity nerve growth factor receptorHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayHigh affinity nerve growth factor receptorHomo sapiens (human)
ephrin receptor signaling pathwayHigh affinity nerve growth factor receptorHomo sapiens (human)
sympathetic nervous system developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
response to axon injuryHigh affinity nerve growth factor receptorHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painHigh affinity nerve growth factor receptorHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityHigh affinity nerve growth factor receptorHomo sapiens (human)
neuron apoptotic processHigh affinity nerve growth factor receptorHomo sapiens (human)
response to hydrostatic pressureHigh affinity nerve growth factor receptorHomo sapiens (human)
response to electrical stimulusHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of synapse assemblyHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicHigh affinity nerve growth factor receptorHomo sapiens (human)
Sertoli cell developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
axonogenesis involved in innervationHigh affinity nerve growth factor receptorHomo sapiens (human)
behavioral response to formalin induced painHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHigh affinity nerve growth factor receptorHomo sapiens (human)
cellular response to nicotineHigh affinity nerve growth factor receptorHomo sapiens (human)
cellular response to nerve growth factor stimulusHigh affinity nerve growth factor receptorHomo sapiens (human)
multicellular organism developmentHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of kinase activityHigh affinity nerve growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHigh affinity nerve growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionHigh affinity nerve growth factor receptorHomo sapiens (human)
signal transductionGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of adenylate cyclase activityGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
response to nutrientGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cell population proliferationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of cell population proliferationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of cell migrationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of superoxide anion generationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of urine volumeGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of calcium ion-dependent exocytosisGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of insulin receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of synaptic transmissionGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cell divisionGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
regulation of calcium ion transportGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway involved in heart processGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
positive regulation of neural precursor cell proliferationGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
chromosome segregationADP/ATP translocase 2Homo sapiens (human)
positive regulation of cell population proliferationADP/ATP translocase 2Homo sapiens (human)
adenine transportADP/ATP translocase 2Homo sapiens (human)
B cell differentiationADP/ATP translocase 2Homo sapiens (human)
erythrocyte differentiationADP/ATP translocase 2Homo sapiens (human)
regulation of mitochondrial membrane permeabilityADP/ATP translocase 2Homo sapiens (human)
adenine nucleotide transportADP/ATP translocase 2Homo sapiens (human)
mitochondrial ADP transmembrane transportADP/ATP translocase 2Homo sapiens (human)
negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayADP/ATP translocase 2Homo sapiens (human)
positive regulation of mitophagyADP/ATP translocase 2Homo sapiens (human)
proton transmembrane transportADP/ATP translocase 2Homo sapiens (human)
mitochondrial ATP transmembrane transportADP/ATP translocase 2Homo sapiens (human)
cellular response to leukemia inhibitory factorADP/ATP translocase 2Homo sapiens (human)
adaptive thermogenesisADP/ATP translocase 2Homo sapiens (human)
adaptive immune responseProtein kinase C beta typeHomo sapiens (human)
chromatin remodelingProtein kinase C beta typeHomo sapiens (human)
regulation of transcription by RNA polymerase IIProtein kinase C beta typeHomo sapiens (human)
protein phosphorylationProtein kinase C beta typeHomo sapiens (human)
calcium ion transportProtein kinase C beta typeHomo sapiens (human)
intracellular calcium ion homeostasisProtein kinase C beta typeHomo sapiens (human)
apoptotic processProtein kinase C beta typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C beta typeHomo sapiens (human)
signal transductionProtein kinase C beta typeHomo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
response to xenobiotic stimulusProtein kinase C beta typeHomo sapiens (human)
response to glucoseProtein kinase C beta typeHomo sapiens (human)
regulation of glucose transmembrane transportProtein kinase C beta typeHomo sapiens (human)
negative regulation of glucose transmembrane transportProtein kinase C beta typeHomo sapiens (human)
regulation of dopamine secretionProtein kinase C beta typeHomo sapiens (human)
dibenzo-p-dioxin metabolic processProtein kinase C beta typeHomo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C beta typeHomo sapiens (human)
response to vitamin DProtein kinase C beta typeHomo sapiens (human)
regulation of growthProtein kinase C beta typeHomo sapiens (human)
B cell activationProtein kinase C beta typeHomo sapiens (human)
positive regulation of odontogenesis of dentin-containing toothProtein kinase C beta typeHomo sapiens (human)
lipoprotein transportProtein kinase C beta typeHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProtein kinase C beta typeHomo sapiens (human)
post-translational protein modificationProtein kinase C beta typeHomo sapiens (human)
response to ethanolProtein kinase C beta typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C beta typeHomo sapiens (human)
positive regulation of DNA-templated transcriptionProtein kinase C beta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
B cell receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
positive regulation of B cell receptor signaling pathwayProtein kinase C beta typeHomo sapiens (human)
cellular response to carbohydrate stimulusProtein kinase C beta typeHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionProtein kinase C beta typeHomo sapiens (human)
regulation of synaptic vesicle exocytosisProtein kinase C beta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C beta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C beta typeHomo sapiens (human)
positive regulation of MAP kinase activityInsulin receptorHomo sapiens (human)
positive regulation of protein phosphorylationInsulin receptorHomo sapiens (human)
positive regulation of receptor internalizationInsulin receptorHomo sapiens (human)
heart morphogenesisInsulin receptorHomo sapiens (human)
regulation of DNA-templated transcriptionInsulin receptorHomo sapiens (human)
protein phosphorylationInsulin receptorHomo sapiens (human)
receptor-mediated endocytosisInsulin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayInsulin receptorHomo sapiens (human)
learningInsulin receptorHomo sapiens (human)
memoryInsulin receptorHomo sapiens (human)
positive regulation of cell population proliferationInsulin receptorHomo sapiens (human)
insulin receptor signaling pathwayInsulin receptorHomo sapiens (human)
epidermis developmentInsulin receptorHomo sapiens (human)
male gonad developmentInsulin receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationInsulin receptorHomo sapiens (human)
male sex determinationInsulin receptorHomo sapiens (human)
adrenal gland developmentInsulin receptorHomo sapiens (human)
positive regulation of cell migrationInsulin receptorHomo sapiens (human)
exocrine pancreas developmentInsulin receptorHomo sapiens (human)
receptor internalizationInsulin receptorHomo sapiens (human)
activation of protein kinase activityInsulin receptorHomo sapiens (human)
activation of protein kinase B activityInsulin receptorHomo sapiens (human)
cellular response to insulin stimulusInsulin receptorHomo sapiens (human)
glucose homeostasisInsulin receptorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyInsulin receptorHomo sapiens (human)
positive regulation of MAPK cascadeInsulin receptorHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processInsulin receptorHomo sapiens (human)
positive regulation of glycogen biosynthetic processInsulin receptorHomo sapiens (human)
positive regulation of glycolytic processInsulin receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionInsulin receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionInsulin receptorHomo sapiens (human)
regulation of embryonic developmentInsulin receptorHomo sapiens (human)
positive regulation of glucose importInsulin receptorHomo sapiens (human)
symbiont entry into host cellInsulin receptorHomo sapiens (human)
protein autophosphorylationInsulin receptorHomo sapiens (human)
positive regulation of developmental growthInsulin receptorHomo sapiens (human)
positive regulation of meiotic cell cycleInsulin receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin receptorHomo sapiens (human)
positive regulation of respiratory burstInsulin receptorHomo sapiens (human)
cellular response to growth factor stimulusInsulin receptorHomo sapiens (human)
dendritic spine maintenanceInsulin receptorHomo sapiens (human)
amyloid-beta clearanceInsulin receptorHomo sapiens (human)
transport across blood-brain barrierInsulin receptorHomo sapiens (human)
neuron projection maintenanceInsulin receptorHomo sapiens (human)
regulation of female gonad developmentInsulin receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayInsulin receptorHomo sapiens (human)
multicellular organism developmentInsulin receptorHomo sapiens (human)
positive regulation of kinase activityInsulin receptorHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
intracellular zinc ion homeostasisTyrosine-protein kinase LckHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase LckHomo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase LckHomo sapiens (human)
hemopoiesisTyrosine-protein kinase LckHomo sapiens (human)
platelet activationTyrosine-protein kinase LckHomo sapiens (human)
T cell differentiationTyrosine-protein kinase LckHomo sapiens (human)
T cell costimulationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase LckHomo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase LckHomo sapiens (human)
Fc-gamma receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of T cell activationTyrosine-protein kinase LckHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase LckHomo sapiens (human)
release of sequestered calcium ion into cytosolTyrosine-protein kinase LckHomo sapiens (human)
regulation of lymphocyte activationTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of leukocyte cell-cell adhesionTyrosine-protein kinase LckHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
innate immune responseTyrosine-protein kinase LckHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase LckHomo sapiens (human)
response to singlet oxygenTyrosine-protein kinase FynHomo sapiens (human)
neuron migrationTyrosine-protein kinase FynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FynHomo sapiens (human)
heart processTyrosine-protein kinase FynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
calcium ion transportTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
axon guidanceTyrosine-protein kinase FynHomo sapiens (human)
learningTyrosine-protein kinase FynHomo sapiens (human)
feeding behaviorTyrosine-protein kinase FynHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FynHomo sapiens (human)
gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase FynHomo sapiens (human)
protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
forebrain developmentTyrosine-protein kinase FynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FynHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase FynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FynHomo sapiens (human)
response to ethanolTyrosine-protein kinase FynHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
dendrite morphogenesisTyrosine-protein kinase FynHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
activated T cell proliferationTyrosine-protein kinase FynHomo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase FynHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase FynHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTyrosine-protein kinase FynHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase FynHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein targeting to membraneTyrosine-protein kinase FynHomo sapiens (human)
dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase FynHomo sapiens (human)
regulation of glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to L-glutamateTyrosine-protein kinase FynHomo sapiens (human)
cellular response to glycineTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to membraneTyrosine-protein kinase FynHomo sapiens (human)
regulation of calcium ion import across plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityTyrosine-protein kinase FynHomo sapiens (human)
innate immune responseTyrosine-protein kinase FynHomo sapiens (human)
cell differentiationTyrosine-protein kinase FynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 1Homo sapiens (human)
microtubule cytoskeleton organizationCyclin-dependent kinase 1Homo sapiens (human)
DNA replicationCyclin-dependent kinase 1Homo sapiens (human)
DNA repairCyclin-dependent kinase 1Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IICyclin-dependent kinase 1Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 1Homo sapiens (human)
apoptotic processCyclin-dependent kinase 1Homo sapiens (human)
DNA damage responseCyclin-dependent kinase 1Homo sapiens (human)
mitotic nuclear membrane disassemblyCyclin-dependent kinase 1Homo sapiens (human)
centrosome cycleCyclin-dependent kinase 1Homo sapiens (human)
pronuclear fusionCyclin-dependent kinase 1Homo sapiens (human)
response to xenobiotic stimulusCyclin-dependent kinase 1Homo sapiens (human)
response to toxic substanceCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of gene expressionCyclin-dependent kinase 1Homo sapiens (human)
negative regulation of gene expressionCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 1Homo sapiens (human)
regulation of Schwann cell differentiationCyclin-dependent kinase 1Homo sapiens (human)
response to amineCyclin-dependent kinase 1Homo sapiens (human)
response to activityCyclin-dependent kinase 1Homo sapiens (human)
cell migrationCyclin-dependent kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationCyclin-dependent kinase 1Homo sapiens (human)
chromosome condensationCyclin-dependent kinase 1Homo sapiens (human)
epithelial cell differentiationCyclin-dependent kinase 1Homo sapiens (human)
animal organ regenerationCyclin-dependent kinase 1Homo sapiens (human)
protein localization to kinetochoreCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of protein import into nucleusCyclin-dependent kinase 1Homo sapiens (human)
regulation of circadian rhythmCyclin-dependent kinase 1Homo sapiens (human)
negative regulation of apoptotic processCyclin-dependent kinase 1Homo sapiens (human)
response to ethanolCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 1Homo sapiens (human)
regulation of embryonic developmentCyclin-dependent kinase 1Homo sapiens (human)
response to cadmium ionCyclin-dependent kinase 1Homo sapiens (human)
response to copper ionCyclin-dependent kinase 1Homo sapiens (human)
symbiont entry into host cellCyclin-dependent kinase 1Homo sapiens (human)
fibroblast proliferationCyclin-dependent kinase 1Homo sapiens (human)
rhythmic processCyclin-dependent kinase 1Homo sapiens (human)
response to axon injuryCyclin-dependent kinase 1Homo sapiens (human)
cell divisionCyclin-dependent kinase 1Homo sapiens (human)
ventricular cardiac muscle cell developmentCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of mitotic sister chromatid segregationCyclin-dependent kinase 1Homo sapiens (human)
protein-containing complex assemblyCyclin-dependent kinase 1Homo sapiens (human)
cellular response to hydrogen peroxideCyclin-dependent kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeCyclin-dependent kinase 1Homo sapiens (human)
cellular response to organic cyclic compoundCyclin-dependent kinase 1Homo sapiens (human)
Golgi disassemblyCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of protein localization to nucleusCyclin-dependent kinase 1Homo sapiens (human)
regulation of attachment of mitotic spindle microtubules to kinetochoreCyclin-dependent kinase 1Homo sapiens (human)
microtubule cytoskeleton organization involved in mitosisCyclin-dependent kinase 1Homo sapiens (human)
positive regulation of mitochondrial ATP synthesis coupled electron transportCyclin-dependent kinase 1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingCyclin-dependent kinase 1Homo sapiens (human)
protein deubiquitinationCyclin-dependent kinase 1Homo sapiens (human)
glycogen metabolic processGlycogen phosphorylase, liver formHomo sapiens (human)
5-phosphoribose 1-diphosphate biosynthetic processGlycogen phosphorylase, liver formHomo sapiens (human)
response to bacteriumGlycogen phosphorylase, liver formHomo sapiens (human)
glucose homeostasisGlycogen phosphorylase, liver formHomo sapiens (human)
necroptotic processGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, liver formHomo sapiens (human)
microtubule bundle formationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
centrosome cycleTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase Fes/FpsHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell adhesionTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of microtubule polymerizationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell population proliferationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of mast cell degranulationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell differentiationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of myeloid cell differentiationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of monocyte differentiationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
myoblast proliferationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cardiac muscle cell proliferationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of vesicle-mediated transportTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cellular response to vitamin DTyrosine-protein kinase Fes/FpsHomo sapiens (human)
regulation of cell motilityTyrosine-protein kinase Fes/FpsHomo sapiens (human)
chemotaxisTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cell adhesionTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase Fes/FpsHomo sapiens (human)
positive regulation of macrophage chemotaxisMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of macrophage proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of protein phosphorylationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
response to ischemiaMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
inflammatory responseMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
signal transductionMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
axon guidanceMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cell population proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
negative regulation of cell population proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of cell shapeMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cytokine-mediated signaling pathwayMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
olfactory bulb developmentMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
forebrain neuron differentiationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
hemopoiesisMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
monocyte differentiationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
macrophage differentiationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
osteoclast differentiationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
ruffle organizationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of chemokine productionMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of actin cytoskeleton organizationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulusMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
macrophage colony-stimulating factor signaling pathwayMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
negative regulation of apoptotic processMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation by host of viral processMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
innate immune responseMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of bone resorptionMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cell-cell junction maintenanceMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
protein autophosphorylationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
mammary gland duct morphogenesisMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of protein tyrosine kinase activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
microglial cell proliferationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cellular response to cytokine stimulusMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of macrophage migrationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of cell motilityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of cell migrationMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
regulation of MAPK cascadeMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
positive regulation of kinase activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
multicellular organism developmentMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase YesHomo sapiens (human)
regulation of glucose transmembrane transportTyrosine-protein kinase YesHomo sapiens (human)
T cell costimulationTyrosine-protein kinase YesHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase YesHomo sapiens (human)
protein modification processTyrosine-protein kinase YesHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase YesHomo sapiens (human)
regulation of vascular permeabilityTyrosine-protein kinase YesHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase YesHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase YesHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase YesHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase YesHomo sapiens (human)
cellular response to retinoic acidTyrosine-protein kinase YesHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase YesHomo sapiens (human)
innate immune responseTyrosine-protein kinase YesHomo sapiens (human)
cell differentiationTyrosine-protein kinase YesHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase YesHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase YesHomo sapiens (human)
DNA damage checkpoint signalingTyrosine-protein kinase LynHomo sapiens (human)
B cell homeostasisTyrosine-protein kinase LynHomo sapiens (human)
regulation of cytokine productionTyrosine-protein kinase LynHomo sapiens (human)
regulation of protein phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of protein phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of protein phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
hematopoietic progenitor cell differentiationTyrosine-protein kinase LynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase LynHomo sapiens (human)
Fc receptor mediated stimulatory signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
tolerance induction to self antigenTyrosine-protein kinase LynHomo sapiens (human)
histamine secretion by mast cellTyrosine-protein kinase LynHomo sapiens (human)
platelet degranulationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of myeloid leukocyte differentiationTyrosine-protein kinase LynHomo sapiens (human)
immune response-regulating cell surface receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
Fc receptor mediated inhibitory signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase LynHomo sapiens (human)
regulation of B cell apoptotic processTyrosine-protein kinase LynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
DNA damage responseTyrosine-protein kinase LynHomo sapiens (human)
response to sterol depletionTyrosine-protein kinase LynHomo sapiens (human)
signal transductionTyrosine-protein kinase LynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein kinase LynHomo sapiens (human)
response to xenobiotic stimulusTyrosine-protein kinase LynHomo sapiens (human)
response to toxic substanceTyrosine-protein kinase LynHomo sapiens (human)
response to hormoneTyrosine-protein kinase LynHomo sapiens (human)
response to carbohydrateTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase LynHomo sapiens (human)
oligodendrocyte developmentTyrosine-protein kinase LynHomo sapiens (human)
response to organic cyclic compoundTyrosine-protein kinase LynHomo sapiens (human)
fatty acid transportTyrosine-protein kinase LynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase LynHomo sapiens (human)
erythrocyte differentiationTyrosine-protein kinase LynHomo sapiens (human)
eosinophil differentiationTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of cell migrationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of B cell proliferationTyrosine-protein kinase LynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase LynHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
response to insulinTyrosine-protein kinase LynHomo sapiens (human)
regulation of mast cell activationTyrosine-protein kinase LynHomo sapiens (human)
regulation of cell adhesion mediated by integrinTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of toll-like receptor 2 signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
toll-like receptor 4 signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of toll-like receptor 4 signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
cellular response to heatTyrosine-protein kinase LynHomo sapiens (human)
interleukin-5-mediated signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase LynHomo sapiens (human)
C-X-C chemokine receptor CXCR4 signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase LynHomo sapiens (human)
response to amino acidTyrosine-protein kinase LynHomo sapiens (human)
regulation of mast cell degranulationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of MAPK cascadeTyrosine-protein kinase LynHomo sapiens (human)
regulation of erythrocyte differentiationTyrosine-protein kinase LynHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase LynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
response to axon injuryTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of immune responseTyrosine-protein kinase LynHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
regulation of B cell receptor signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase LynHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosolTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of glial cell proliferationTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of Fc receptor mediated stimulatory signaling pathwayTyrosine-protein kinase LynHomo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase LynHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of oligodendrocyte progenitor proliferationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of mast cell proliferationTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of mast cell proliferationTyrosine-protein kinase LynHomo sapiens (human)
cellular response to retinoic acidTyrosine-protein kinase LynHomo sapiens (human)
regulation of monocyte chemotaxisTyrosine-protein kinase LynHomo sapiens (human)
regulation of platelet aggregationTyrosine-protein kinase LynHomo sapiens (human)
dendritic cell differentiationTyrosine-protein kinase LynHomo sapiens (human)
negative regulation of intracellular signal transductionTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic processTyrosine-protein kinase LynHomo sapiens (human)
positive regulation of dendritic cell apoptotic processTyrosine-protein kinase LynHomo sapiens (human)
neuron projection developmentTyrosine-protein kinase LynHomo sapiens (human)
innate immune responseTyrosine-protein kinase LynHomo sapiens (human)
MAPK cascadeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
ureteric bud developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
neural crest cell migrationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
embryonic epithelial tube formationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion moleculesProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
neuron cell-cell adhesionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
signal transductionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
axon guidanceProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
posterior midgut developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
response to xenobiotic stimulusProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of gene expressionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of neuron projection developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of neuron maturationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
regulation of cell adhesionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of cell migrationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
membrane protein proteolysisProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of cell adhesion mediated by integrinProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
ureter maturationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
glial cell-derived neurotrophic factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
neuron maturationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of MAPK cascadeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of cell sizeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of DNA-templated transcriptionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
response to painProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
enteric nervous system developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
regulation of axonogenesisProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
retina development in camera-type eyeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
innervationProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
Peyer's patch morphogenesisProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
cellular response to retinoic acidProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of metanephric glomerulus developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
lymphocyte migration into lymphoid organsProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
GDF15-GFRAL signaling pathwayProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway in absence of ligandProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
positive regulation of kinase activityProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
multicellular organism developmentProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
peptidyl-tyrosine autophosphorylationInsulin-like growth factor 1 receptorHomo sapiens (human)
cardiac atrium developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
immune responseInsulin-like growth factor 1 receptorHomo sapiens (human)
signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
axonogenesisInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cell population proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor signaling pathwayInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of muscle cell apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cerebellum developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
hippocampus developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
establishment of cell polarityInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cell migrationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cytokinesisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to vitamin EInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of osteoblast proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to zinc ion starvationInsulin-like growth factor 1 receptorHomo sapiens (human)
response to nicotineInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyInsulin-like growth factor 1 receptorHomo sapiens (human)
response to alkaloidInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of MAPK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
estrous cycleInsulin-like growth factor 1 receptorHomo sapiens (human)
transcytosisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to ethanolInsulin-like growth factor 1 receptorHomo sapiens (human)
regulation of JNK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
protein autophosphorylationInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of axon regenerationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of DNA metabolic processInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to mechanical stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to estradiol stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to progesterone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to testosterone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to dexamethasone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of steroid hormone biosynthetic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular senescenceInsulin-like growth factor 1 receptorHomo sapiens (human)
dendritic spine maintenanceInsulin-like growth factor 1 receptorHomo sapiens (human)
amyloid-beta clearanceInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to L-glutamateInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of hepatocyte apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to aldosteroneInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of cholangiocyte apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to angiotensinInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to amyloid-betaInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to insulin-like growth factor stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
multicellular organism developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of kinase activityInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to glucose stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of MAPK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
cotranslational protein targeting to membraneSignal recognition particle receptor subunit alphaHomo sapiens (human)
SRP-dependent cotranslational protein targeting to membrane, signal sequence recognitionSignal recognition particle receptor subunit alphaHomo sapiens (human)
intracellular protein transportSignal recognition particle receptor subunit alphaHomo sapiens (human)
protein targeting to ERSignal recognition particle receptor subunit alphaHomo sapiens (human)
mitochondrial electron transport, ubiquinol to cytochrome cCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
response to glucagonCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
cellular respirationCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
proton transmembrane transportCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
endothelial cell morphogenesisHepatocyte growth factor receptorHomo sapiens (human)
signal transductionHepatocyte growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of autophagyHepatocyte growth factor receptorHomo sapiens (human)
positive regulation of microtubule polymerizationHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of Rho protein signal transductionHepatocyte growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIHepatocyte growth factor receptorHomo sapiens (human)
hepatocyte growth factor receptor signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
branching morphogenesis of an epithelial tubeHepatocyte growth factor receptorHomo sapiens (human)
positive chemotaxisHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of stress fiber assemblyHepatocyte growth factor receptorHomo sapiens (human)
excitatory postsynaptic potentialHepatocyte growth factor receptorHomo sapiens (human)
establishment of skin barrierHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
semaphorin-plexin signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of hydrogen peroxide-mediated programmed cell deathHepatocyte growth factor receptorHomo sapiens (human)
negative regulation of guanyl-nucleotide exchange factor activityHepatocyte growth factor receptorHomo sapiens (human)
positive regulation of endothelial cell chemotaxisHepatocyte growth factor receptorHomo sapiens (human)
liver developmentHepatocyte growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayHepatocyte growth factor receptorHomo sapiens (human)
phagocytosisHepatocyte growth factor receptorHomo sapiens (human)
multicellular organism developmentHepatocyte growth factor receptorHomo sapiens (human)
neuron differentiationHepatocyte growth factor receptorHomo sapiens (human)
positive regulation of kinase activityHepatocyte growth factor receptorHomo sapiens (human)
cell migrationHepatocyte growth factor receptorHomo sapiens (human)
pancreas developmentHepatocyte growth factor receptorHomo sapiens (human)
nervous system developmentHepatocyte growth factor receptorHomo sapiens (human)
leukocyte migration involved in immune responseTyrosine-protein kinase HCKHomo sapiens (human)
innate immune response-activating signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase HCKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase HCKHomo sapiens (human)
inflammatory responseTyrosine-protein kinase HCKHomo sapiens (human)
cell adhesionTyrosine-protein kinase HCKHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
mesoderm developmentTyrosine-protein kinase HCKHomo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein kinase HCKHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase HCKHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase HCKHomo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
positive regulation of actin filament polymerizationTyrosine-protein kinase HCKHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
regulation of actin cytoskeleton organizationTyrosine-protein kinase HCKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase HCKHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase HCKHomo sapiens (human)
negative regulation of apoptotic processTyrosine-protein kinase HCKHomo sapiens (human)
leukocyte degranulationTyrosine-protein kinase HCKHomo sapiens (human)
respiratory burst after phagocytosisTyrosine-protein kinase HCKHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase HCKHomo sapiens (human)
regulation of inflammatory responseTyrosine-protein kinase HCKHomo sapiens (human)
regulation of phagocytosisTyrosine-protein kinase HCKHomo sapiens (human)
regulation of DNA-binding transcription factor activityTyrosine-protein kinase HCKHomo sapiens (human)
type II interferon-mediated signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
regulation of podosome assemblyTyrosine-protein kinase HCKHomo sapiens (human)
cell differentiationTyrosine-protein kinase HCKHomo sapiens (human)
innate immune responseTyrosine-protein kinase HCKHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase HCKHomo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
regulation of cell growthProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
columnar/cuboidal epithelial cell developmentProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
spermatogenesisProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
cell differentiationProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
regulation of TOR signalingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
positive regulation of kinase activityProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
multicellular organism developmentProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
signal transductionPlatelet-derived growth factor receptor betaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell population proliferationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of phospholipase C activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of smooth muscle cell migrationPlatelet-derived growth factor receptor betaHomo sapiens (human)
peptidyl-tyrosine phosphorylationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell migrationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
regulation of actin cytoskeleton organizationPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell migration involved in vasculogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
aorta morphogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of MAP kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of mitotic nuclear divisionPlatelet-derived growth factor receptor betaHomo sapiens (human)
phosphatidylinositol metabolic processPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein autophosphorylationPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of calcium-mediated signalingPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of chemotaxisPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPlatelet-derived growth factor receptor betaHomo sapiens (human)
cardiac myofibril assemblyPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell chemotaxisPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell migration involved in coronary angiogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
retina vasculature development in camera-type eyePlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePlatelet-derived growth factor receptor betaHomo sapiens (human)
smooth muscle cell chemotaxisPlatelet-derived growth factor receptor betaHomo sapiens (human)
metanephric glomerular mesangial cell proliferation involved in metanephros developmentPlatelet-derived growth factor receptor betaHomo sapiens (human)
metanephric glomerular capillary formationPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of calcium ion importPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of DNA biosynthetic processPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
angiogenesisPlatelet-derived growth factor receptor betaHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayPlatelet-derived growth factor receptor betaHomo sapiens (human)
multicellular organism developmentPlatelet-derived growth factor receptor betaHomo sapiens (human)
positive regulation of cytokine productionTyrosine-protein kinase FgrHomo sapiens (human)
immune response-regulating cell surface receptor signaling pathwayTyrosine-protein kinase FgrHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FgrHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FgrHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase FgrHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FgrHomo sapiens (human)
response to virusTyrosine-protein kinase FgrHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FgrHomo sapiens (human)
bone mineralizationTyrosine-protein kinase FgrHomo sapiens (human)
positive regulation of cell migrationTyrosine-protein kinase FgrHomo sapiens (human)
negative regulation of natural killer cell activationTyrosine-protein kinase FgrHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FgrHomo sapiens (human)
positive regulation of mast cell degranulationTyrosine-protein kinase FgrHomo sapiens (human)
regulation of innate immune responseTyrosine-protein kinase FgrHomo sapiens (human)
regulation of protein kinase activityTyrosine-protein kinase FgrHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase FgrHomo sapiens (human)
skeletal system morphogenesisTyrosine-protein kinase FgrHomo sapiens (human)
regulation of phagocytosisTyrosine-protein kinase FgrHomo sapiens (human)
defense response to Gram-positive bacteriumTyrosine-protein kinase FgrHomo sapiens (human)
myoblast proliferationTyrosine-protein kinase FgrHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase FgrHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FgrHomo sapiens (human)
cell differentiationTyrosine-protein kinase FgrHomo sapiens (human)
innate immune responseTyrosine-protein kinase FgrHomo sapiens (human)
mitotic cell cycleWee1-like protein kinase 2Homo sapiens (human)
female meiotic nuclear divisionWee1-like protein kinase 2Homo sapiens (human)
female pronucleus assemblyWee1-like protein kinase 2Homo sapiens (human)
positive regulation of phosphorylationWee1-like protein kinase 2Homo sapiens (human)
regulation of meiosis IWee1-like protein kinase 2Homo sapiens (human)
regulation of fertilizationWee1-like protein kinase 2Homo sapiens (human)
negative regulation of oocyte maturationWee1-like protein kinase 2Homo sapiens (human)
protein phosphorylationWee1-like protein kinase 2Homo sapiens (human)
regulation of TOR signalingSerine/threonine-protein kinase A-RafHomo sapiens (human)
regulation of proteasomal ubiquitin-dependent protein catabolic processSerine/threonine-protein kinase A-RafHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase A-RafHomo sapiens (human)
protein modification processSerine/threonine-protein kinase A-RafHomo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase A-RafHomo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase A-RafHomo sapiens (human)
ovarian follicle developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
myeloid progenitor cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
lymphoid progenitor cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
immature B cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
mast cell chemotaxisMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of dendritic cell cytokine productionMast/stem cell growth factor receptor KitHomo sapiens (human)
glycosphingolipid metabolic processMast/stem cell growth factor receptor KitHomo sapiens (human)
inflammatory responseMast/stem cell growth factor receptor KitHomo sapiens (human)
signal transductionMast/stem cell growth factor receptor KitHomo sapiens (human)
spermatogenesisMast/stem cell growth factor receptor KitHomo sapiens (human)
spermatid developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
germ cell migrationMast/stem cell growth factor receptor KitHomo sapiens (human)
regulation of cell shapeMast/stem cell growth factor receptor KitHomo sapiens (human)
visual learningMast/stem cell growth factor receptor KitHomo sapiens (human)
male gonad developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of phospholipase C activityMast/stem cell growth factor receptor KitHomo sapiens (human)
cytokine-mediated signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
stem cell population maintenanceMast/stem cell growth factor receptor KitHomo sapiens (human)
lamellipodium assemblyMast/stem cell growth factor receptor KitHomo sapiens (human)
actin cytoskeleton organizationMast/stem cell growth factor receptor KitHomo sapiens (human)
hemopoiesisMast/stem cell growth factor receptor KitHomo sapiens (human)
T cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
erythrocyte differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
melanocyte differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of pseudopodium assemblyMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of mast cell cytokine productionMast/stem cell growth factor receptor KitHomo sapiens (human)
somatic stem cell population maintenanceMast/stem cell growth factor receptor KitHomo sapiens (human)
embryonic hemopoiesisMast/stem cell growth factor receptor KitHomo sapiens (human)
ectopic germ cell programmed cell deathMast/stem cell growth factor receptor KitHomo sapiens (human)
intracellular signal transductionMast/stem cell growth factor receptor KitHomo sapiens (human)
hematopoietic stem cell migrationMast/stem cell growth factor receptor KitHomo sapiens (human)
megakaryocyte developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
Fc receptor signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
Kit signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
erythropoietin-mediated signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
regulation of cell population proliferationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinMast/stem cell growth factor receptor KitHomo sapiens (human)
negative regulation of programmed cell deathMast/stem cell growth factor receptor KitHomo sapiens (human)
mast cell degranulationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of MAPK cascadeMast/stem cell growth factor receptor KitHomo sapiens (human)
pigmentationMast/stem cell growth factor receptor KitHomo sapiens (human)
tongue developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of Notch signaling pathwayMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATMast/stem cell growth factor receptor KitHomo sapiens (human)
response to cadmium ionMast/stem cell growth factor receptor KitHomo sapiens (human)
protein autophosphorylationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of long-term neuronal synaptic plasticityMast/stem cell growth factor receptor KitHomo sapiens (human)
digestive tract developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
stem cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
epithelial cell proliferationMast/stem cell growth factor receptor KitHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of soundMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityMast/stem cell growth factor receptor KitHomo sapiens (human)
negative regulation of developmental processMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMast/stem cell growth factor receptor KitHomo sapiens (human)
cell chemotaxisMast/stem cell growth factor receptor KitHomo sapiens (human)
mast cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
mast cell proliferationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of mast cell proliferationMast/stem cell growth factor receptor KitHomo sapiens (human)
melanocyte migrationMast/stem cell growth factor receptor KitHomo sapiens (human)
melanocyte adhesionMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of pyloric antrum smooth muscle contractionMast/stem cell growth factor receptor KitHomo sapiens (human)
regulation of bile acid metabolic processMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of colon smooth muscle contractionMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of small intestine smooth muscle contractionMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
negative regulation of reproductive processMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of cell migrationMast/stem cell growth factor receptor KitHomo sapiens (human)
positive regulation of MAP kinase activityMast/stem cell growth factor receptor KitHomo sapiens (human)
multicellular organism developmentMast/stem cell growth factor receptor KitHomo sapiens (human)
B cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
hematopoietic progenitor cell differentiationMast/stem cell growth factor receptor KitHomo sapiens (human)
glycogen catabolic processGlycogen phosphorylase, brain formHomo sapiens (human)
negative regulation of cellular extravasationBreakpoint cluster region proteinHomo sapiens (human)
renal system processBreakpoint cluster region proteinHomo sapiens (human)
protein phosphorylationBreakpoint cluster region proteinHomo sapiens (human)
phagocytosisBreakpoint cluster region proteinHomo sapiens (human)
signal transductionBreakpoint cluster region proteinHomo sapiens (human)
small GTPase-mediated signal transductionBreakpoint cluster region proteinHomo sapiens (human)
brain developmentBreakpoint cluster region proteinHomo sapiens (human)
actin cytoskeleton organizationBreakpoint cluster region proteinHomo sapiens (human)
keratinocyte differentiationBreakpoint cluster region proteinHomo sapiens (human)
regulation of Rho protein signal transductionBreakpoint cluster region proteinHomo sapiens (human)
inner ear morphogenesisBreakpoint cluster region proteinHomo sapiens (human)
regulation of vascular permeabilityBreakpoint cluster region proteinHomo sapiens (human)
neutrophil degranulationBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of neutrophil degranulationBreakpoint cluster region proteinHomo sapiens (human)
focal adhesion assemblyBreakpoint cluster region proteinHomo sapiens (human)
homeostasis of number of cellsBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of inflammatory responseBreakpoint cluster region proteinHomo sapiens (human)
positive regulation of phagocytosisBreakpoint cluster region proteinHomo sapiens (human)
modulation of chemical synaptic transmissionBreakpoint cluster region proteinHomo sapiens (human)
neuromuscular process controlling balanceBreakpoint cluster region proteinHomo sapiens (human)
regulation of small GTPase mediated signal transductionBreakpoint cluster region proteinHomo sapiens (human)
regulation of cell cycleBreakpoint cluster region proteinHomo sapiens (human)
definitive hemopoiesisBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of respiratory burstBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of blood vessel remodelingBreakpoint cluster region proteinHomo sapiens (human)
intracellular protein transmembrane transportBreakpoint cluster region proteinHomo sapiens (human)
cellular response to lipopolysaccharideBreakpoint cluster region proteinHomo sapiens (human)
activation of GTPase activityBreakpoint cluster region proteinHomo sapiens (human)
macrophage migrationBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of macrophage migrationBreakpoint cluster region proteinHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processBreakpoint cluster region proteinHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of transmembrane transporter activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of innate immune responseSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
vitamin D receptor signaling pathwaySerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular response to type II interferonSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of brown fat cell differentiationSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of hematopoietic stem cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardioblast proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular detoxificationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 1Homo sapiens (human)
MAPK cascadeFibroblast growth factor receptor 1Homo sapiens (human)
skeletal system developmentFibroblast growth factor receptor 1Homo sapiens (human)
angiogenesisFibroblast growth factor receptor 1Homo sapiens (human)
ureteric bud developmentFibroblast growth factor receptor 1Homo sapiens (human)
in utero embryonic developmentFibroblast growth factor receptor 1Homo sapiens (human)
organ inductionFibroblast growth factor receptor 1Homo sapiens (human)
neuron migrationFibroblast growth factor receptor 1Homo sapiens (human)
epithelial to mesenchymal transitionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of mesenchymal cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
chondrocyte differentiationFibroblast growth factor receptor 1Homo sapiens (human)
protein phosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
sensory perception of soundFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
mesenchymal cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
gene expressionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phospholipase C activityFibroblast growth factor receptor 1Homo sapiens (human)
regulation of phosphate transportFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentFibroblast growth factor receptor 1Homo sapiens (human)
cell migrationFibroblast growth factor receptor 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
ventricular zone neuroblast divisionFibroblast growth factor receptor 1Homo sapiens (human)
cell projection assemblyFibroblast growth factor receptor 1Homo sapiens (human)
embryonic limb morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
midbrain developmentFibroblast growth factor receptor 1Homo sapiens (human)
neuron projection developmentFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex developmentFibroblast growth factor receptor 1Homo sapiens (human)
inner ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
outer ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
middle ear morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
chordate embryonic developmentFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAP kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationFibroblast growth factor receptor 1Homo sapiens (human)
cellular response to fibroblast growth factor stimulusFibroblast growth factor receptor 1Homo sapiens (human)
regulation of cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of neuron differentiationFibroblast growth factor receptor 1Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 1Homo sapiens (human)
phosphatidylinositol-mediated signalingFibroblast growth factor receptor 1Homo sapiens (human)
paraxial mesoderm developmentFibroblast growth factor receptor 1Homo sapiens (human)
regulation of lateral mesodermal cell fate specificationFibroblast growth factor receptor 1Homo sapiens (human)
cell maturationFibroblast growth factor receptor 1Homo sapiens (human)
skeletal system morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
stem cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFibroblast growth factor receptor 1Homo sapiens (human)
calcium ion homeostasisFibroblast growth factor receptor 1Homo sapiens (human)
cardiac muscle cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
auditory receptor cell developmentFibroblast growth factor receptor 1Homo sapiens (human)
branching involved in salivary gland morphogenesisFibroblast growth factor receptor 1Homo sapiens (human)
lung-associated mesenchyme developmentFibroblast growth factor receptor 1Homo sapiens (human)
regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signalingFibroblast growth factor receptor 1Homo sapiens (human)
vitamin D3 metabolic processFibroblast growth factor receptor 1Homo sapiens (human)
diphosphate metabolic processFibroblast growth factor receptor 1Homo sapiens (human)
cementum mineralizationFibroblast growth factor receptor 1Homo sapiens (human)
stem cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
negative regulation of fibroblast growth factor productionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of mitotic cell cycle DNA replicationFibroblast growth factor receptor 1Homo sapiens (human)
response to sodium phosphateFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of stem cell proliferationFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of parathyroid hormone secretionFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of endothelial cell chemotaxisFibroblast growth factor receptor 1Homo sapiens (human)
regulation of extrinsic apoptotic signaling pathway in absence of ligandFibroblast growth factor receptor 1Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of cell differentiationFibroblast growth factor receptor 1Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 1Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 4Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 4Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 4Homo sapiens (human)
response to xenobiotic stimulusCyclin-dependent kinase 4Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 4Homo sapiens (human)
positive regulation of fibroblast proliferationCyclin-dependent kinase 4Homo sapiens (human)
cell divisionCyclin-dependent kinase 4Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 4Homo sapiens (human)
regulation of transcription initiation by RNA polymerase IICyclin-dependent kinase 4Homo sapiens (human)
regulation of type B pancreatic cell proliferationCyclin-dependent kinase 4Homo sapiens (human)
cellular response to lipopolysaccharideCyclin-dependent kinase 4Homo sapiens (human)
cellular response to interleukin-4Cyclin-dependent kinase 4Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateCyclin-dependent kinase 4Homo sapiens (human)
cellular response to ionomycinCyclin-dependent kinase 4Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 4Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 4Homo sapiens (human)
signal transductionCyclin-dependent kinase 4Homo sapiens (human)
apoptotic processADP/ATP translocase 3Homo sapiens (human)
mitochondrial ADP transmembrane transportADP/ATP translocase 3Homo sapiens (human)
mitochondrial ATP transmembrane transportADP/ATP translocase 3Homo sapiens (human)
negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayADP/ATP translocase 3Homo sapiens (human)
GMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
GTP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
circadian rhythmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
lymphocyte proliferationInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cellular response to interleukin-4Inosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
'de novo' XMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
primary ovarian follicle growthProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of cytokine productionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
epidermal growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
spermatogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
learning or memoryProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to xenobiotic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mechanical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to acidic pHProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of gene expressionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of glucose metabolic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein processingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
skeletal muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of smooth muscle cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
macroautophagyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
forebrain developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
T cell costimulationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of protein-containing complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein destabilizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to nutrient levelsProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomere maintenance via telomeraseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to insulin stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of intracellular estrogen receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of integrin activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of toll-like receptor 3 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
adherens junction organizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
substrate adhesion-dependent cell spreadingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of dephosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of hippo signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intracellular signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
entry of bacterium into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
osteoclast developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ERBB2 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
angiotensin-activated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
odontogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of vascular permeabilityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stress fiber assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transcytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Notch signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Ras protein signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein autophosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
oogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
progesterone receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
leukocyte migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of small GTPase mediated signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mineralocorticoidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
myoblast proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to electrical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of mitochondrial depolarizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomerase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
uterus developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
branching involved in mammary gland duct morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell projection assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intestinal epithelial cell developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
interleukin-6-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hydrogen peroxideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to interleukin-1Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to lipopolysaccharideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to peptide hormone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to progesterone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fatty acidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hypoxiaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fluid shear stressProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of podosome assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
DNA biosynthetic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of heart rate by cardiac conductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein localization to nucleusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of TORC1 signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to prolactinProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of male germ cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ovarian follicle developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of lamellipodium morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor-beta signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of early endosome to late endosome transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of anoikisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of caveolin-mediated endocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell differentiationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
innate immune responseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
symbiont entry into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of protein phosphorylationcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
intracellular signal transductioncAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
negative regulation of cAMP/PKA signal transductioncAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
negative regulation of cAMP-dependent protein kinase activitycAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayInsulin receptor-related proteinHomo sapiens (human)
insulin receptor signaling pathwayInsulin receptor-related proteinHomo sapiens (human)
actin cytoskeleton organizationInsulin receptor-related proteinHomo sapiens (human)
male sex determinationInsulin receptor-related proteinHomo sapiens (human)
protein autophosphorylationInsulin receptor-related proteinHomo sapiens (human)
cellular response to alkaline pHInsulin receptor-related proteinHomo sapiens (human)
positive regulation of kinase activityInsulin receptor-related proteinHomo sapiens (human)
multicellular organism developmentInsulin receptor-related proteinHomo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase B-rafHomo sapiens (human)
myeloid progenitor cell differentiationSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase B-rafHomo sapiens (human)
epidermal growth factor receptor signaling pathwaySerine/threonine-protein kinase B-rafHomo sapiens (human)
visual learningSerine/threonine-protein kinase B-rafHomo sapiens (human)
animal organ morphogenesisSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of fibroblast migrationSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of glucose transmembrane transportSerine/threonine-protein kinase B-rafHomo sapiens (human)
synaptic vesicle exocytosisSerine/threonine-protein kinase B-rafHomo sapiens (human)
thyroid gland developmentSerine/threonine-protein kinase B-rafHomo sapiens (human)
T cell differentiation in thymusSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase B-rafHomo sapiens (human)
substrate adhesion-dependent cell spreadingSerine/threonine-protein kinase B-rafHomo sapiens (human)
somatic stem cell population maintenanceSerine/threonine-protein kinase B-rafHomo sapiens (human)
regulation of cell population proliferationSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase B-rafHomo sapiens (human)
stress fiber assemblySerine/threonine-protein kinase B-rafHomo sapiens (human)
CD4-positive, alpha-beta T cell differentiationSerine/threonine-protein kinase B-rafHomo sapiens (human)
CD4-positive or CD8-positive, alpha-beta T cell lineage commitmentSerine/threonine-protein kinase B-rafHomo sapiens (human)
response to peptide hormoneSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of neuron apoptotic processSerine/threonine-protein kinase B-rafHomo sapiens (human)
regulation of T cell differentiationSerine/threonine-protein kinase B-rafHomo sapiens (human)
thymus developmentSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of axon regenerationSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of axonogenesisSerine/threonine-protein kinase B-rafHomo sapiens (human)
T cell receptor signaling pathwaySerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of stress fiber assemblySerine/threonine-protein kinase B-rafHomo sapiens (human)
response to cAMPSerine/threonine-protein kinase B-rafHomo sapiens (human)
long-term synaptic potentiationSerine/threonine-protein kinase B-rafHomo sapiens (human)
head morphogenesisSerine/threonine-protein kinase B-rafHomo sapiens (human)
face developmentSerine/threonine-protein kinase B-rafHomo sapiens (human)
ERK1 and ERK2 cascadeSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeSerine/threonine-protein kinase B-rafHomo sapiens (human)
cellular response to calcium ionSerine/threonine-protein kinase B-rafHomo sapiens (human)
cellular response to xenobiotic stimulusSerine/threonine-protein kinase B-rafHomo sapiens (human)
endothelial cell apoptotic processSerine/threonine-protein kinase B-rafHomo sapiens (human)
establishment of protein localization to membraneSerine/threonine-protein kinase B-rafHomo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingSerine/threonine-protein kinase B-rafHomo sapiens (human)
cellular response to nerve growth factor stimulusSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of synaptic vesicle exocytosisSerine/threonine-protein kinase B-rafHomo sapiens (human)
negative regulation of endothelial cell apoptotic processSerine/threonine-protein kinase B-rafHomo sapiens (human)
glycogen metabolic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
glycogen biosynthetic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
glycogen catabolic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
generation of precursor metabolites and energyPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
protein phosphorylationPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
positive regulation of glycogen catabolic processPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
quinone catabolic processRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cellular response to reactive oxygen speciesPlatelet-derived growth factor receptor alphaHomo sapiens (human)
luteinizationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
in utero embryonic developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cell activationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
hematopoietic progenitor cell differentiationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
estrogen metabolic processPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of cell population proliferationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
negative regulation of platelet activationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of phospholipase C activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
peptidyl-tyrosine phosphorylationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
signal transduction involved in regulation of gene expressionPlatelet-derived growth factor receptor alphaHomo sapiens (human)
extracellular matrix organizationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
lung developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
adrenal gland developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of cell migrationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
male genitalia developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
regulation of actin cytoskeleton organizationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
Leydig cell differentiationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor receptor-alpha signaling pathwayPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor alphaHomo sapiens (human)
wound healingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
odontogenesis of dentin-containing toothPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein autophosphorylationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of fibroblast proliferationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
embryonic digestive tract morphogenesisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
embryonic cranial skeleton morphogenesisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
embryonic skeletal system morphogenesisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of calcium-mediated signalingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
white fat cell differentiationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of chemotaxisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cardiac myofibril assemblyPlatelet-derived growth factor receptor alphaHomo sapiens (human)
roof of mouth developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
face morphogenesisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cell chemotaxisPlatelet-derived growth factor receptor alphaHomo sapiens (human)
retina vasculature development in camera-type eyePlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet aggregationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cellular response to amino acid stimulusPlatelet-derived growth factor receptor alphaHomo sapiens (human)
metanephric glomerular capillary formationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
regulation of mesenchymal stem cell differentiationPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayPlatelet-derived growth factor receptor alphaHomo sapiens (human)
positive regulation of kinase activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
multicellular organism developmentPlatelet-derived growth factor receptor alphaHomo sapiens (human)
microtubule cytoskeleton organizationTyrosine-protein kinase FerHomo sapiens (human)
regulation of protein phosphorylationTyrosine-protein kinase FerHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FerHomo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FerHomo sapiens (human)
germ cell developmentTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of cell population proliferationTyrosine-protein kinase FerHomo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
regulation of lamellipodium assemblyTyrosine-protein kinase FerHomo sapiens (human)
regulation of fibroblast migrationTyrosine-protein kinase FerHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FerHomo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
actin cytoskeleton organizationTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of cell migrationTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of actin filament polymerizationTyrosine-protein kinase FerHomo sapiens (human)
response to lipopolysaccharideTyrosine-protein kinase FerHomo sapiens (human)
negative regulation of mast cell activation involved in immune responseTyrosine-protein kinase FerHomo sapiens (human)
adherens junction assemblyTyrosine-protein kinase FerHomo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase FerHomo sapiens (human)
cellular response to reactive oxygen speciesTyrosine-protein kinase FerHomo sapiens (human)
extracellular matrix-cell signalingTyrosine-protein kinase FerHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FerHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulusTyrosine-protein kinase FerHomo sapiens (human)
response to platelet-derived growth factorTyrosine-protein kinase FerHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
Kit signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
regulation of epidermal growth factor receptor signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
cell-cell adhesion mediated by cadherinTyrosine-protein kinase FerHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase FerHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
diapedesisTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTyrosine-protein kinase FerHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase FerHomo sapiens (human)
Sertoli cell developmentTyrosine-protein kinase FerHomo sapiens (human)
interleukin-6-mediated signaling pathwayTyrosine-protein kinase FerHomo sapiens (human)
seminiferous tubule developmentTyrosine-protein kinase FerHomo sapiens (human)
adherens junction disassemblyTyrosine-protein kinase FerHomo sapiens (human)
cell adhesionTyrosine-protein kinase FerHomo sapiens (human)
chemotaxisTyrosine-protein kinase FerHomo sapiens (human)
angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell proliferationProtein kinase C alpha typeHomo sapiens (human)
desmosome assemblyProtein kinase C alpha typeHomo sapiens (human)
chromatin remodelingProtein kinase C alpha typeHomo sapiens (human)
protein phosphorylationProtein kinase C alpha typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C alpha typeHomo sapiens (human)
cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyProtein kinase C alpha typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C alpha typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C alpha typeHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
post-translational protein modificationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of macrophage differentiationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of bone resorptionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of mitotic cell cycleProtein kinase C alpha typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C alpha typeHomo sapiens (human)
response to interleukin-1Protein kinase C alpha typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C alpha typeHomo sapiens (human)
apoptotic signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiotensin-activated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of dense core granule biogenesisProtein kinase C alpha typeHomo sapiens (human)
intracellular signal transductionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C alpha typeHomo sapiens (human)
mesoderm formationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
neural tube closurecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of heart ratecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
renal water homeostasiscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
mRNA processingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein phosphorylationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein export from nucleuscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of macroautophagycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytokine-mediated signaling pathwaycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
positive regulation of insulin secretioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
negative regulation of interleukin-2 productioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
high-density lipoprotein particle assemblycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to heatcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
mitochondrial protein catabolic processcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of osteoblast differentiationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
positive regulation of gluconeogenesiscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
negative regulation of smoothened signaling pathwaycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
positive regulation of protein export from nucleuscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
sperm capacitationcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
positive regulation of calcium-mediated signalingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of cell cyclecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of cardiac muscle contractioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of proteasomal protein catabolic processcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to coldcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of protein processingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to glucose stimuluscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to parathyroid hormone stimuluscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to glucagon stimuluscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cellular response to epinephrine stimuluscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of cardiac conductioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
negative regulation of TORC1 signalingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
negative regulation of glycolytic process through fructose-6-phosphatecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein localization to lipid dropletcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
regulation of bicellular tight junction assemblycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein kinase A signalingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
monocyte chemotaxisVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of phospholipase C activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell migrationVascular endothelial growth factor receptor 1 Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 1 Homo sapiens (human)
cell differentiationVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 1 Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor-1 signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of MAP kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of angiogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 1 Homo sapiens (human)
blood vessel morphogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
embryonic morphogenesisVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionVascular endothelial growth factor receptor 1 Homo sapiens (human)
negative regulation of vascular endothelial cell proliferationVascular endothelial growth factor receptor 1 Homo sapiens (human)
hyaloid vascular plexus regressionVascular endothelial growth factor receptor 1 Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 1 Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)General transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
response to hypoxiaGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
in utero embryonic developmentGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription-coupled nucleotide-excision repairGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
nucleotide-excision repairGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
regulation of transcription by RNA polymerase IIGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription elongation by RNA polymerase IGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription by RNA polymerase IIGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription initiation at RNA polymerase II promoterGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
apoptotic processGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
response to oxidative stressGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
chromosome segregationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
determination of adult lifespanGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
UV protectionGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
post-embryonic developmentGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
spinal cord developmentGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
extracellular matrix organizationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
bone mineralizationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
central nervous system myelin formationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
DNA duplex unwindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
multicellular organism growthGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
hair cell differentiationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
embryonic cleavageGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
erythrocyte maturationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
embryonic organ developmentGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
hair follicle maturationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
hematopoietic stem cell differentiationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
hematopoietic stem cell proliferationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
regulation of mitotic cell cycle phase transitionGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
positive regulation of mitotic recombinationGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
positive regulation of cytokine productionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
translationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein phosphorylationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of cell population proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
response to virusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of translationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
endoplasmic reticulum unfolded protein responseInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of chemokine productionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of stress-activated MAPK cascadeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of osteoblast proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cellular response to amino acid starvationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
response to interferon-alphaInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of apoptotic processInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of MAPK cascadeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
negative regulation of viral genome replicationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein autophosphorylationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
defense response to virusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
antiviral innate immune responseInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of NLRP3 inflammasome complex assemblyInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic progenitor cell differentiationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic stem cell proliferationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
regulation of hematopoietic stem cell differentiationInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
eiF2alpha phosphorylation in response to endoplasmic reticulum stressInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
double-strand break repairCasein kinase II subunit alpha'Homo sapiens (human)
apoptotic processCasein kinase II subunit alpha'Homo sapiens (human)
spermatogenesisCasein kinase II subunit alpha'Homo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
cerebral cortex developmentCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alpha'Homo sapiens (human)
liver regenerationCasein kinase II subunit alpha'Homo sapiens (human)
regulation of mitophagyCasein kinase II subunit alpha'Homo sapiens (human)
positive regulation of protein targeting to mitochondrionCasein kinase II subunit alpha'Homo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-cysteine methylationRas-related protein Rab-6AHomo sapiens (human)
retrograde vesicle-mediated transport, Golgi to endoplasmic reticulumRas-related protein Rab-6AHomo sapiens (human)
antigen processing and presentationRas-related protein Rab-6AHomo sapiens (human)
neuron projection developmentRas-related protein Rab-6AHomo sapiens (human)
protein localization to Golgi apparatusRas-related protein Rab-6AHomo sapiens (human)
early endosome to Golgi transportRas-related protein Rab-6AHomo sapiens (human)
minus-end-directed organelle transport along microtubuleRas-related protein Rab-6AHomo sapiens (human)
protein localization to Golgi membraneRas-related protein Rab-6AHomo sapiens (human)
intracellular protein transportRas-related protein Rab-6AHomo sapiens (human)
intra-Golgi vesicle-mediated transportRas-related protein Rab-6AHomo sapiens (human)
retrograde transport, endosome to GolgiRas-related protein Rab-6AHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MAKHomo sapiens (human)
spermatogenesisSerine/threonine-protein kinase MAKHomo sapiens (human)
cell differentiationSerine/threonine-protein kinase MAKHomo sapiens (human)
photoreceptor cell maintenanceSerine/threonine-protein kinase MAKHomo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase MAKHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase MAKHomo sapiens (human)
negative regulation of non-motile cilium assemblySerine/threonine-protein kinase MAKHomo sapiens (human)
non-motile cilium assemblySerine/threonine-protein kinase MAKHomo sapiens (human)
intraciliary transportSerine/threonine-protein kinase MAKHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase MAKHomo sapiens (human)
cilium assemblySerine/threonine-protein kinase MAKHomo sapiens (human)
mitotic cell cycleCyclin-dependent kinase 11BHomo sapiens (human)
regulation of cell growthCyclin-dependent kinase 11BHomo sapiens (human)
regulation of DNA-templated transcriptionCyclin-dependent kinase 11BHomo sapiens (human)
protein phosphorylationCyclin-dependent kinase 11BHomo sapiens (human)
apoptotic processCyclin-dependent kinase 11BHomo sapiens (human)
regulation of mRNA processingCyclin-dependent kinase 11BHomo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 11BHomo sapiens (human)
positive regulation of cell-matrix adhesionEphrin type-A receptor 1Homo sapiens (human)
negative regulation of protein kinase activityEphrin type-A receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayEphrin type-A receptor 1Homo sapiens (human)
positive regulation of cell population proliferationEphrin type-A receptor 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-A receptor 1Homo sapiens (human)
positive regulation of cell migrationEphrin type-A receptor 1Homo sapiens (human)
negative regulation of cell migrationEphrin type-A receptor 1Homo sapiens (human)
substrate adhesion-dependent cell spreadingEphrin type-A receptor 1Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 1Homo sapiens (human)
positive regulation of angiogenesisEphrin type-A receptor 1Homo sapiens (human)
protein autophosphorylationEphrin type-A receptor 1Homo sapiens (human)
positive regulation of stress fiber assemblyEphrin type-A receptor 1Homo sapiens (human)
activation of GTPase activityEphrin type-A receptor 1Homo sapiens (human)
positive regulation of kinase activityEphrin type-A receptor 1Homo sapiens (human)
multicellular organism developmentEphrin type-A receptor 1Homo sapiens (human)
angiogenesisEphrin type-A receptor 1Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 1Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 2Homo sapiens (human)
angiogenesisFibroblast growth factor receptor 2Homo sapiens (human)
ureteric bud developmentFibroblast growth factor receptor 2Homo sapiens (human)
in utero embryonic developmentFibroblast growth factor receptor 2Homo sapiens (human)
epithelial to mesenchymal transitionFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
outflow tract septum morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
membranous septum morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
endochondral bone growthFibroblast growth factor receptor 2Homo sapiens (human)
apoptotic processFibroblast growth factor receptor 2Homo sapiens (human)
cell-cell signalingFibroblast growth factor receptor 2Homo sapiens (human)
axonogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
regulation of smoothened signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
post-embryonic developmentFibroblast growth factor receptor 2Homo sapiens (human)
embryonic pattern specificationFibroblast growth factor receptor 2Homo sapiens (human)
animal organ morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 2Homo sapiens (human)
negative regulation of keratinocyte proliferationFibroblast growth factor receptor 2Homo sapiens (human)
morphogenesis of embryonic epitheliumFibroblast growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 2Homo sapiens (human)
orbitofrontal cortex developmentFibroblast growth factor receptor 2Homo sapiens (human)
ventricular zone neuroblast divisionFibroblast growth factor receptor 2Homo sapiens (human)
pyramidal neuron developmentFibroblast growth factor receptor 2Homo sapiens (human)
gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of Wnt signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
bone mineralizationFibroblast growth factor receptor 2Homo sapiens (human)
lung developmentFibroblast growth factor receptor 2Homo sapiens (human)
epithelial cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
midbrain developmentFibroblast growth factor receptor 2Homo sapiens (human)
otic vesicle formationFibroblast growth factor receptor 2Homo sapiens (human)
hair follicle morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
response to lipopolysaccharideFibroblast growth factor receptor 2Homo sapiens (human)
lacrimal gland developmentFibroblast growth factor receptor 2Homo sapiens (human)
regulation of osteoblast proliferationFibroblast growth factor receptor 2Homo sapiens (human)
organ growthFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow cellFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in hemopoiesisFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrowFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex developmentFibroblast growth factor receptor 2Homo sapiens (human)
inner ear morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
odontogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 2Homo sapiens (human)
cell fate commitmentFibroblast growth factor receptor 2Homo sapiens (human)
response to ethanolFibroblast growth factor receptor 2Homo sapiens (human)
regulation of osteoblast differentiationFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cell cycleFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIFibroblast growth factor receptor 2Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 2Homo sapiens (human)
lung alveolus developmentFibroblast growth factor receptor 2Homo sapiens (human)
mesodermal cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
embryonic digestive tract morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
embryonic organ morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
digestive tract developmentFibroblast growth factor receptor 2Homo sapiens (human)
embryonic organ developmentFibroblast growth factor receptor 2Homo sapiens (human)
reproductive structure developmentFibroblast growth factor receptor 2Homo sapiens (human)
embryonic cranial skeleton morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
skeletal system morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
epidermis morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching morphogenesis of a nerveFibroblast growth factor receptor 2Homo sapiens (human)
mesenchymal cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of epithelial cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
regulation of smooth muscle cell differentiationFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cell divisionFibroblast growth factor receptor 2Homo sapiens (human)
ventricular cardiac muscle tissue morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
limb bud formationFibroblast growth factor receptor 2Homo sapiens (human)
bone developmentFibroblast growth factor receptor 2Homo sapiens (human)
bone morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching involved in prostate gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching involved in salivary gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
bud elongation involved in lung branchingFibroblast growth factor receptor 2Homo sapiens (human)
lung lobe morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
lung-associated mesenchyme developmentFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of epithelial cell proliferation involved in lung morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
prostate gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
prostate epithelial cord elongationFibroblast growth factor receptor 2Homo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
squamous basal epithelial stem cell differentiation involved in prostate gland acinus developmentFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor signaling pathway involved in mammary gland specificationFibroblast growth factor receptor 2Homo sapiens (human)
lateral sprouting from an epitheliumFibroblast growth factor receptor 2Homo sapiens (human)
mammary gland bud formationFibroblast growth factor receptor 2Homo sapiens (human)
epithelial cell proliferation involved in salivary gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branch elongation involved in salivary gland morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
branching involved in labyrinthine layer morphogenesisFibroblast growth factor receptor 2Homo sapiens (human)
regulation of morphogenesis of a branching structureFibroblast growth factor receptor 2Homo sapiens (human)
mesenchymal cell differentiation involved in lung developmentFibroblast growth factor receptor 2Homo sapiens (human)
mesenchymal cell proliferation involved in lung developmentFibroblast growth factor receptor 2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 2Homo sapiens (human)
cellular response to retinoic acidFibroblast growth factor receptor 2Homo sapiens (human)
cellular response to hypoxiaFibroblast growth factor receptor 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationFibroblast growth factor receptor 2Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 2Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 2Homo sapiens (human)
endocardial cushion developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of cell adhesionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
peripheral nervous system developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of gene expressionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
Schwann cell differentiationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
Schwann cell developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
cranial nerve developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
wound healingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
myelinationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of secretionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of cardiac muscle tissue developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
motor neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of motor neuron apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
GMP biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
'de novo' IMP biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
purine nucleobase biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
'de novo' AMP biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
'de novo' XMP biosynthetic processMultifunctional protein ADE2Homo sapiens (human)
response to bile acidFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 4Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 4Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of gene expressionFibroblast growth factor receptor 4Homo sapiens (human)
regulation of extracellular matrix disassemblyFibroblast growth factor receptor 4Homo sapiens (human)
cell migrationFibroblast growth factor receptor 4Homo sapiens (human)
peptidyl-tyrosine phosphorylationFibroblast growth factor receptor 4Homo sapiens (human)
regulation of lipid metabolic processFibroblast growth factor receptor 4Homo sapiens (human)
glucose homeostasisFibroblast growth factor receptor 4Homo sapiens (human)
cholesterol homeostasisFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of catalytic activityFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of proteolysisFibroblast growth factor receptor 4Homo sapiens (human)
protein autophosphorylationFibroblast growth factor receptor 4Homo sapiens (human)
phosphate ion homeostasisFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 4Homo sapiens (human)
regulation of bile acid biosynthetic processFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of DNA biosynthetic processFibroblast growth factor receptor 4Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 4Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 4Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
MAPK cascadeFibroblast growth factor receptor 3Homo sapiens (human)
skeletal system developmentFibroblast growth factor receptor 3Homo sapiens (human)
endochondral ossificationFibroblast growth factor receptor 3Homo sapiens (human)
chondrocyte differentiationFibroblast growth factor receptor 3Homo sapiens (human)
endochondral bone growthFibroblast growth factor receptor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATFibroblast growth factor receptor 3Homo sapiens (human)
cell-cell signalingFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of cell population proliferationFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of phospholipase activityFibroblast growth factor receptor 3Homo sapiens (human)
bone mineralizationFibroblast growth factor receptor 3Homo sapiens (human)
chondrocyte proliferationFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of MAPK cascadeFibroblast growth factor receptor 3Homo sapiens (human)
negative regulation of developmental growthFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFibroblast growth factor receptor 3Homo sapiens (human)
bone morphogenesisFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeFibroblast growth factor receptor 3Homo sapiens (human)
bone maturationFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor apoptotic signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayFibroblast growth factor receptor 3Homo sapiens (human)
multicellular organism developmentFibroblast growth factor receptor 3Homo sapiens (human)
positive regulation of kinase activityFibroblast growth factor receptor 3Homo sapiens (human)
renal water homeostasiscAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
spermatogenesiscAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
male gonad developmentcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
high-density lipoprotein particle assemblycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
protein kinase A signalingcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
neural tube closurecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
renal water homeostasiscAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein phosphorylationcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
signal transductioncAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwaycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
high-density lipoprotein particle assemblycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
negative regulation of smoothened signaling pathwaycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
regulation of protein processingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
negative regulation of TORC1 signalingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein kinase A signalingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
generation of precursor metabolites and energyFerrochelatase, mitochondrialHomo sapiens (human)
heme biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
heme A biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
heme B biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
cholesterol metabolic processFerrochelatase, mitochondrialHomo sapiens (human)
response to xenobiotic stimulusFerrochelatase, mitochondrialHomo sapiens (human)
response to light stimulusFerrochelatase, mitochondrialHomo sapiens (human)
detection of UVFerrochelatase, mitochondrialHomo sapiens (human)
response to lead ionFerrochelatase, mitochondrialHomo sapiens (human)
regulation of eIF2 alpha phosphorylation by hemeFerrochelatase, mitochondrialHomo sapiens (human)
response to insecticideFerrochelatase, mitochondrialHomo sapiens (human)
erythrocyte differentiationFerrochelatase, mitochondrialHomo sapiens (human)
very-low-density lipoprotein particle assemblyFerrochelatase, mitochondrialHomo sapiens (human)
response to ethanolFerrochelatase, mitochondrialHomo sapiens (human)
protoporphyrinogen IX metabolic processFerrochelatase, mitochondrialHomo sapiens (human)
response to arsenic-containing substanceFerrochelatase, mitochondrialHomo sapiens (human)
regulation of hemoglobin biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
heme O biosynthetic processFerrochelatase, mitochondrialHomo sapiens (human)
response to methylmercuryFerrochelatase, mitochondrialHomo sapiens (human)
multicellular organismal-level iron ion homeostasisFerrochelatase, mitochondrialHomo sapiens (human)
response to platinum ionFerrochelatase, mitochondrialHomo sapiens (human)
cellular response to dexamethasone stimulusFerrochelatase, mitochondrialHomo sapiens (human)
G1/S transition of mitotic cell cycleRibosomal protein S6 kinase beta-1Homo sapiens (human)
behavioral fear responseRibosomal protein S6 kinase beta-1Homo sapiens (human)
skeletal muscle contractionRibosomal protein S6 kinase beta-1Homo sapiens (human)
apoptotic processRibosomal protein S6 kinase beta-1Homo sapiens (human)
signal transductionRibosomal protein S6 kinase beta-1Homo sapiens (human)
germ cell developmentRibosomal protein S6 kinase beta-1Homo sapiens (human)
long-term memoryRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to xenobiotic stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to mechanical stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to toxic substanceRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to glucoseRibosomal protein S6 kinase beta-1Homo sapiens (human)
skeletal muscle atrophyRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to electrical stimulus involved in regulation of muscle adaptationRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of smooth muscle cell migrationRibosomal protein S6 kinase beta-1Homo sapiens (human)
cell migrationRibosomal protein S6 kinase beta-1Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to nutrient levelsRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to nutrientRibosomal protein S6 kinase beta-1Homo sapiens (human)
TOR signalingRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to lipopolysaccharideRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to testosteroneRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to glucagonRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to tumor necrosis factorRibosomal protein S6 kinase beta-1Homo sapiens (human)
negative regulation of apoptotic processRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to L-leucineRibosomal protein S6 kinase beta-1Homo sapiens (human)
long-chain fatty acid import into cellRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to ethanolRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of translationRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of mitotic cell cycleRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of translational initiationRibosomal protein S6 kinase beta-1Homo sapiens (human)
regulation of glucose importRibosomal protein S6 kinase beta-1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayRibosomal protein S6 kinase beta-1Homo sapiens (human)
phosphatidylinositol-mediated signalingRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of skeletal muscle tissue growthRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationRibosomal protein S6 kinase beta-1Homo sapiens (human)
modulation of chemical synaptic transmissionRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to type II interferonRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to growth factor stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to dexamethasone stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
positive regulation of TORC1 signalingRibosomal protein S6 kinase beta-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayRibosomal protein S6 kinase beta-1Homo sapiens (human)
cellular response to insulin stimulusRibosomal protein S6 kinase beta-1Homo sapiens (human)
response to antibioticTyrosine-protein kinase JAK1Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK1Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK1Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
positive regulation of homotypic cell-cell adhesionTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-15-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-4-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-2-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-9-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-11-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
type III interferon-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
type II interferon-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
type I interferon-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-6-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
T-helper 17 cell lineage commitmentTyrosine-protein kinase JAK1Homo sapiens (human)
cellular response to virusTyrosine-protein kinase JAK1Homo sapiens (human)
interleukin-10-mediated signaling pathwayTyrosine-protein kinase JAK1Homo sapiens (human)
protein localization to cell-cell junctionTyrosine-protein kinase JAK1Homo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase JAK1Homo sapiens (human)
positive regulation of sprouting angiogenesisTyrosine-protein kinase JAK1Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK1Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK1Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK1Homo sapiens (human)
protein phosphorylationProtein kinase C eta typeHomo sapiens (human)
signal transductionProtein kinase C eta typeHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationProtein kinase C eta typeHomo sapiens (human)
cell differentiationProtein kinase C eta typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C eta typeHomo sapiens (human)
positive regulation of keratinocyte differentiationProtein kinase C eta typeHomo sapiens (human)
positive regulation of B cell receptor signaling pathwayProtein kinase C eta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C eta typeHomo sapiens (human)
positive regulation of glial cell proliferationProtein kinase C eta typeHomo sapiens (human)
protein kinase C signalingProtein kinase C eta typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C eta typeHomo sapiens (human)
regulation of bicellular tight junction assemblyProtein kinase C eta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C eta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C eta typeHomo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 2Homo sapiens (human)
DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
DNA repairCyclin-dependent kinase 2Homo sapiens (human)
chromatin remodelingCyclin-dependent kinase 2Homo sapiens (human)
DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
potassium ion transportCyclin-dependent kinase 2Homo sapiens (human)
centriole replicationCyclin-dependent kinase 2Homo sapiens (human)
Ras protein signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of cell population proliferationCyclin-dependent kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of heterochromatin formationCyclin-dependent kinase 2Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated DNA replication initiationCyclin-dependent kinase 2Homo sapiens (human)
telomere maintenance in response to DNA damageCyclin-dependent kinase 2Homo sapiens (human)
post-translational protein modificationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA replicationCyclin-dependent kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCyclin-dependent kinase 2Homo sapiens (human)
centrosome duplicationCyclin-dependent kinase 2Homo sapiens (human)
cell divisionCyclin-dependent kinase 2Homo sapiens (human)
meiotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
cellular response to nitric oxideCyclin-dependent kinase 2Homo sapiens (human)
cellular senescenceCyclin-dependent kinase 2Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processCyclin-dependent kinase 2Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase 2Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 2Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 2Homo sapiens (human)
desensitization of G protein-coupled receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of the force of heart contraction by chemical signalBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
tachykinin receptor signaling pathwayBeta-adrenergic receptor kinase 1Homo sapiens (human)
heart developmentBeta-adrenergic receptor kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationBeta-adrenergic receptor kinase 1Homo sapiens (human)
viral genome replicationBeta-adrenergic receptor kinase 1Homo sapiens (human)
receptor internalizationBeta-adrenergic receptor kinase 1Homo sapiens (human)
positive regulation of catecholamine secretionBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of striated muscle contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
symbiont entry into host cellBeta-adrenergic receptor kinase 1Homo sapiens (human)
cardiac muscle contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
negative regulation of relaxation of smooth muscleBeta-adrenergic receptor kinase 1Homo sapiens (human)
regulation of the force of heart contractionBeta-adrenergic receptor kinase 1Homo sapiens (human)
protein phosphorylationBeta-adrenergic receptor kinase 1Homo sapiens (human)
P-body assemblyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
miRNA-mediated gene silencing by inhibition of translationProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
negative regulation of translationProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
viral RNA genome packagingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
stem cell population maintenanceProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
neuron differentiationProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
P-body assemblyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
negative regulation of neuron differentiationProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
stress granule assemblyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
positive regulation of protein phosphorylationActivin receptor type-2AHomo sapiens (human)
BMP signaling pathwayActivin receptor type-2AHomo sapiens (human)
gastrulation with mouth forming secondActivin receptor type-2AHomo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayActivin receptor type-2AHomo sapiens (human)
spermatogenesisActivin receptor type-2AHomo sapiens (human)
determination of left/right symmetryActivin receptor type-2AHomo sapiens (human)
mesoderm developmentActivin receptor type-2AHomo sapiens (human)
anterior/posterior pattern specificationActivin receptor type-2AHomo sapiens (human)
positive regulation of bone mineralizationActivin receptor type-2AHomo sapiens (human)
BMP signaling pathwayActivin receptor type-2AHomo sapiens (human)
activin receptor signaling pathwayActivin receptor type-2AHomo sapiens (human)
positive regulation of activin receptor signaling pathwayActivin receptor type-2AHomo sapiens (human)
odontogenesis of dentin-containing toothActivin receptor type-2AHomo sapiens (human)
sperm ejaculationActivin receptor type-2AHomo sapiens (human)
penile erectionActivin receptor type-2AHomo sapiens (human)
regulation of nitric oxide biosynthetic processActivin receptor type-2AHomo sapiens (human)
positive regulation of erythrocyte differentiationActivin receptor type-2AHomo sapiens (human)
positive regulation of osteoblast differentiationActivin receptor type-2AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIActivin receptor type-2AHomo sapiens (human)
embryonic skeletal system developmentActivin receptor type-2AHomo sapiens (human)
Sertoli cell proliferationActivin receptor type-2AHomo sapiens (human)
positive regulation of SMAD protein signal transductionActivin receptor type-2AHomo sapiens (human)
cellular response to BMP stimulusActivin receptor type-2AHomo sapiens (human)
protein phosphorylationActivin receptor type-2AHomo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-2AHomo sapiens (human)
positive regulation of macrophage chemotaxisMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of macrophage proliferationMitogen-activated protein kinase 3 Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
DNA-templated transcriptionMitogen-activated protein kinase 3 Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 3 Homo sapiens (human)
insulin receptor signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
Schwann cell developmentMitogen-activated protein kinase 3 Homo sapiens (human)
phosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
sensory perception of painMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 3 Homo sapiens (human)
BMP signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of cellular pHMitogen-activated protein kinase 3 Homo sapiens (human)
thyroid gland developmentMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 3 Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of stress-activated MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 3 Homo sapiens (human)
peptidyl-tyrosine autophosphorylationMitogen-activated protein kinase 3 Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
outer ear morphogenesisMitogen-activated protein kinase 3 Homo sapiens (human)
myelinationMitogen-activated protein kinase 3 Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 3 Homo sapiens (human)
response to exogenous dsRNAMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 3 Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
thymus developmentMitogen-activated protein kinase 3 Homo sapiens (human)
modulation of chemical synaptic transmissionMitogen-activated protein kinase 3 Homo sapiens (human)
cartilage developmentMitogen-activated protein kinase 3 Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of cytoskeleton organizationMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase 3 Homo sapiens (human)
Bergmann glial cell differentiationMitogen-activated protein kinase 3 Homo sapiens (human)
face developmentMitogen-activated protein kinase 3 Homo sapiens (human)
lung morphogenesisMitogen-activated protein kinase 3 Homo sapiens (human)
trachea formationMitogen-activated protein kinase 3 Homo sapiens (human)
cardiac neural crest cell development involved in heart developmentMitogen-activated protein kinase 3 Homo sapiens (human)
ERK1 and ERK2 cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMitogen-activated protein kinase 3 Homo sapiens (human)
interleukin-1-mediated signaling pathwayMitogen-activated protein kinase 3 Homo sapiens (human)
response to epidermal growth factorMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 3 Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 3 Homo sapiens (human)
caveolin-mediated endocytosisMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of Golgi inheritanceMitogen-activated protein kinase 3 Homo sapiens (human)
xenophagyMitogen-activated protein kinase 3 Homo sapiens (human)
negative regulation of TORC1 signalingMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase 3 Homo sapiens (human)
positive regulation of xenophagyMitogen-activated protein kinase 3 Homo sapiens (human)
regulation of early endosome to late endosome transportMitogen-activated protein kinase 3 Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 3 Homo sapiens (human)
protein phosphorylationMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
peptidyl-serine phosphorylationMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
positive regulation of protein bindingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
negative regulation of hippo signalingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
peptidyl-serine autophosphorylationMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
negative regulation of protein localization to nucleusMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
intracellular signal transductionMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
pyrimidine nucleotide metabolic processDeoxycytidine kinaseHomo sapiens (human)
CMP biosynthetic processDeoxycytidine kinaseHomo sapiens (human)
dAMP salvageDeoxycytidine kinaseHomo sapiens (human)
nucleoside phosphate biosynthetic processDeoxycytidine kinaseHomo sapiens (human)
positive regulation of macrophage chemotaxisMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of macrophage proliferationMitogen-activated protein kinase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 1Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 1Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 1Homo sapiens (human)
DNA damage responseMitogen-activated protein kinase 1Homo sapiens (human)
signal transductionMitogen-activated protein kinase 1Homo sapiens (human)
chemical synaptic transmissionMitogen-activated protein kinase 1Homo sapiens (human)
learning or memoryMitogen-activated protein kinase 1Homo sapiens (human)
insulin receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
Schwann cell developmentMitogen-activated protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationMitogen-activated protein kinase 1Homo sapiens (human)
cytosine metabolic processMitogen-activated protein kinase 1Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 1Homo sapiens (human)
androgen receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
regulation of cellular pHMitogen-activated protein kinase 1Homo sapiens (human)
thyroid gland developmentMitogen-activated protein kinase 1Homo sapiens (human)
regulation of protein stabilityMitogen-activated protein kinase 1Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase 1Homo sapiens (human)
regulation of stress-activated MAPK cascadeMitogen-activated protein kinase 1Homo sapiens (human)
mammary gland epithelial cell proliferationMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 1Homo sapiens (human)
response to nicotineMitogen-activated protein kinase 1Homo sapiens (human)
ERBB signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
outer ear morphogenesisMitogen-activated protein kinase 1Homo sapiens (human)
myelinationMitogen-activated protein kinase 1Homo sapiens (human)
response to exogenous dsRNAMitogen-activated protein kinase 1Homo sapiens (human)
steroid hormone mediated signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
negative regulation of cell differentiationMitogen-activated protein kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
thymus developmentMitogen-activated protein kinase 1Homo sapiens (human)
progesterone receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
T cell receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
B cell receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 1Homo sapiens (human)
regulation of cytoskeleton organizationMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase 1Homo sapiens (human)
Bergmann glial cell differentiationMitogen-activated protein kinase 1Homo sapiens (human)
long-term synaptic potentiationMitogen-activated protein kinase 1Homo sapiens (human)
face developmentMitogen-activated protein kinase 1Homo sapiens (human)
lung morphogenesisMitogen-activated protein kinase 1Homo sapiens (human)
trachea formationMitogen-activated protein kinase 1Homo sapiens (human)
labyrinthine layer blood vessel developmentMitogen-activated protein kinase 1Homo sapiens (human)
cardiac neural crest cell development involved in heart developmentMitogen-activated protein kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeMitogen-activated protein kinase 1Homo sapiens (human)
response to epidermal growth factorMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 1Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 1Homo sapiens (human)
caveolin-mediated endocytosisMitogen-activated protein kinase 1Homo sapiens (human)
regulation of Golgi inheritanceMitogen-activated protein kinase 1Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase 1Homo sapiens (human)
regulation of early endosome to late endosome transportMitogen-activated protein kinase 1Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 1Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 1Homo sapiens (human)
skeletal system developmentEphrin type-A receptor 2Homo sapiens (human)
vasculogenesisEphrin type-A receptor 2Homo sapiens (human)
osteoblast differentiationEphrin type-A receptor 2Homo sapiens (human)
blood vessel endothelial cell proliferation involved in sprouting angiogenesisEphrin type-A receptor 2Homo sapiens (human)
inflammatory responseEphrin type-A receptor 2Homo sapiens (human)
cell adhesionEphrin type-A receptor 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageEphrin type-A receptor 2Homo sapiens (human)
regulation of lamellipodium assemblyEphrin type-A receptor 2Homo sapiens (human)
notochord formationEphrin type-A receptor 2Homo sapiens (human)
cell migrationEphrin type-A receptor 2Homo sapiens (human)
negative regulation of angiogenesisEphrin type-A receptor 2Homo sapiens (human)
neural tube developmentEphrin type-A receptor 2Homo sapiens (human)
neuron differentiationEphrin type-A receptor 2Homo sapiens (human)
keratinocyte differentiationEphrin type-A receptor 2Homo sapiens (human)
osteoclast differentiationEphrin type-A receptor 2Homo sapiens (human)
positive regulation of cell migrationEphrin type-A receptor 2Homo sapiens (human)
negative regulation of chemokine productionEphrin type-A receptor 2Homo sapiens (human)
mammary gland epithelial cell proliferationEphrin type-A receptor 2Homo sapiens (human)
regulation of cell adhesion mediated by integrinEphrin type-A receptor 2Homo sapiens (human)
post-anal tail morphogenesisEphrin type-A receptor 2Homo sapiens (human)
regulation of blood vessel endothelial cell migrationEphrin type-A receptor 2Homo sapiens (human)
regulation of angiogenesisEphrin type-A receptor 2Homo sapiens (human)
cAMP metabolic processEphrin type-A receptor 2Homo sapiens (human)
symbiont entry into host cellEphrin type-A receptor 2Homo sapiens (human)
bone remodelingEphrin type-A receptor 2Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 2Homo sapiens (human)
axial mesoderm formationEphrin type-A receptor 2Homo sapiens (human)
cell motilityEphrin type-A receptor 2Homo sapiens (human)
defense response to Gram-positive bacteriumEphrin type-A receptor 2Homo sapiens (human)
notochord cell developmentEphrin type-A receptor 2Homo sapiens (human)
cell chemotaxisEphrin type-A receptor 2Homo sapiens (human)
branching involved in mammary gland duct morphogenesisEphrin type-A receptor 2Homo sapiens (human)
lens fiber cell morphogenesisEphrin type-A receptor 2Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeEphrin type-A receptor 2Homo sapiens (human)
response to growth factorEphrin type-A receptor 2Homo sapiens (human)
protein localization to plasma membraneEphrin type-A receptor 2Homo sapiens (human)
activation of GTPase activityEphrin type-A receptor 2Homo sapiens (human)
negative regulation of lymphangiogenesisEphrin type-A receptor 2Homo sapiens (human)
positive regulation of protein localization to plasma membraneEphrin type-A receptor 2Homo sapiens (human)
positive regulation of bicellular tight junction assemblyEphrin type-A receptor 2Homo sapiens (human)
pericyte cell differentiationEphrin type-A receptor 2Homo sapiens (human)
positive regulation of kinase activityEphrin type-A receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEphrin type-A receptor 2Homo sapiens (human)
multicellular organism developmentEphrin type-A receptor 2Homo sapiens (human)
cell adhesionEphrin type-A receptor 3Homo sapiens (human)
regulation of epithelial to mesenchymal transitionEphrin type-A receptor 3Homo sapiens (human)
positive regulation of neuron projection developmentEphrin type-A receptor 3Homo sapiens (human)
cell migrationEphrin type-A receptor 3Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-A receptor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationEphrin type-A receptor 3Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 3Homo sapiens (human)
negative regulation of endocytosisEphrin type-A receptor 3Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 3Homo sapiens (human)
regulation of focal adhesion assemblyEphrin type-A receptor 3Homo sapiens (human)
regulation of microtubule cytoskeleton organizationEphrin type-A receptor 3Homo sapiens (human)
cellular response to retinoic acidEphrin type-A receptor 3Homo sapiens (human)
fasciculation of sensory neuron axonEphrin type-A receptor 3Homo sapiens (human)
fasciculation of motor neuron axonEphrin type-A receptor 3Homo sapiens (human)
positive regulation of protein localization to plasma membraneEphrin type-A receptor 3Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 3Homo sapiens (human)
axon guidanceEphrin type-A receptor 3Homo sapiens (human)
substrate-dependent cell migrationEphrin type-A receptor 8Homo sapiens (human)
cell adhesionEphrin type-A receptor 8Homo sapiens (human)
axon guidanceEphrin type-A receptor 8Homo sapiens (human)
neuron remodelingEphrin type-A receptor 8Homo sapiens (human)
regulation of cell adhesionEphrin type-A receptor 8Homo sapiens (human)
neuron projection developmentEphrin type-A receptor 8Homo sapiens (human)
regulation of cell adhesion mediated by integrinEphrin type-A receptor 8Homo sapiens (human)
positive regulation of MAPK cascadeEphrin type-A receptor 8Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 8Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEphrin type-A receptor 8Homo sapiens (human)
cellular response to follicle-stimulating hormone stimulusEphrin type-A receptor 8Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 8Homo sapiens (human)
negative regulation of protein kinase activityEphrin type-B receptor 2Homo sapiens (human)
regulation of autophagosome assemblyEphrin type-B receptor 2Homo sapiens (human)
angiogenesisEphrin type-B receptor 2Homo sapiens (human)
urogenital system developmentEphrin type-B receptor 2Homo sapiens (human)
negative regulation of protein phosphorylationEphrin type-B receptor 2Homo sapiens (human)
positive regulation of immunoglobulin productionEphrin type-B receptor 2Homo sapiens (human)
negative regulation of cell adhesionEphrin type-B receptor 2Homo sapiens (human)
nervous system developmentEphrin type-B receptor 2Homo sapiens (human)
axon guidanceEphrin type-B receptor 2Homo sapiens (human)
axonal fasciculationEphrin type-B receptor 2Homo sapiens (human)
learning or memoryEphrin type-B receptor 2Homo sapiens (human)
learningEphrin type-B receptor 2Homo sapiens (human)
positive regulation of gene expressionEphrin type-B receptor 2Homo sapiens (human)
phosphorylationEphrin type-B receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-B receptor 2Homo sapiens (human)
optic nerve morphogenesisEphrin type-B receptor 2Homo sapiens (human)
hindbrain tangential cell migrationEphrin type-B receptor 2Homo sapiens (human)
central nervous system projection neuron axonogenesisEphrin type-B receptor 2Homo sapiens (human)
corpus callosum developmentEphrin type-B receptor 2Homo sapiens (human)
regulation of blood coagulationEphrin type-B receptor 2Homo sapiens (human)
positive regulation of cell migrationEphrin type-B receptor 2Homo sapiens (human)
positive regulation of B cell proliferationEphrin type-B receptor 2Homo sapiens (human)
retinal ganglion cell axon guidanceEphrin type-B receptor 2Homo sapiens (human)
positive regulation of synaptic plasticityEphrin type-B receptor 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionEphrin type-B receptor 2Homo sapiens (human)
B cell activationEphrin type-B receptor 2Homo sapiens (human)
inner ear morphogenesisEphrin type-B receptor 2Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATEphrin type-B receptor 2Homo sapiens (human)
negative regulation of Ras protein signal transductionEphrin type-B receptor 2Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 2Homo sapiens (human)
regulation of neuronal synaptic plasticityEphrin type-B receptor 2Homo sapiens (human)
positive regulation of long-term neuronal synaptic plasticityEphrin type-B receptor 2Homo sapiens (human)
camera-type eye morphogenesisEphrin type-B receptor 2Homo sapiens (human)
negative regulation of axonogenesisEphrin type-B receptor 2Homo sapiens (human)
regulation of body fluid levelsEphrin type-B receptor 2Homo sapiens (human)
regulation of filopodium assemblyEphrin type-B receptor 2Homo sapiens (human)
positive regulation of synapse assemblyEphrin type-B receptor 2Homo sapiens (human)
roof of mouth developmentEphrin type-B receptor 2Homo sapiens (human)
dendritic spine developmentEphrin type-B receptor 2Homo sapiens (human)
dendritic spine morphogenesisEphrin type-B receptor 2Homo sapiens (human)
positive regulation of dendritic spine morphogenesisEphrin type-B receptor 2Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeEphrin type-B receptor 2Homo sapiens (human)
cellular response to lipopolysaccharideEphrin type-B receptor 2Homo sapiens (human)
commissural neuron axon guidanceEphrin type-B receptor 2Homo sapiens (human)
postsynaptic membrane assemblyEphrin type-B receptor 2Homo sapiens (human)
trans-synaptic signaling by trans-synaptic complex, modulating synaptic transmissionEphrin type-B receptor 2Homo sapiens (human)
neuron projection retractionEphrin type-B receptor 2Homo sapiens (human)
vesicle-mediated intercellular transportEphrin type-B receptor 2Homo sapiens (human)
tight junction assemblyEphrin type-B receptor 2Homo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseEphrin type-B receptor 2Homo sapiens (human)
positive regulation of long-term synaptic potentiationEphrin type-B receptor 2Homo sapiens (human)
positive regulation of protein localization to plasma membraneEphrin type-B receptor 2Homo sapiens (human)
cellular response to amyloid-betaEphrin type-B receptor 2Homo sapiens (human)
negative regulation of NMDA glutamate receptor activityEphrin type-B receptor 2Homo sapiens (human)
positive regulation of NMDA glutamate receptor activityEphrin type-B receptor 2Homo sapiens (human)
positive regulation of protein localization to cell surfaceEphrin type-B receptor 2Homo sapiens (human)
regulation of T-helper 17 type immune responseEphrin type-B receptor 2Homo sapiens (human)
regulation of behavioral fear responseEphrin type-B receptor 2Homo sapiens (human)
protein phosphorylationEphrin type-B receptor 2Homo sapiens (human)
protein phosphorylationLeukocyte tyrosine kinase receptorHomo sapiens (human)
signal transductionLeukocyte tyrosine kinase receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayLeukocyte tyrosine kinase receptorHomo sapiens (human)
cell population proliferationLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of neuron projection developmentLeukocyte tyrosine kinase receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationLeukocyte tyrosine kinase receptorHomo sapiens (human)
negative regulation of apoptotic processLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionLeukocyte tyrosine kinase receptorHomo sapiens (human)
cellular response to retinoic acidLeukocyte tyrosine kinase receptorHomo sapiens (human)
regulation of cell population proliferationLeukocyte tyrosine kinase receptorHomo sapiens (human)
positive regulation of kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
regulation of neuron differentiationLeukocyte tyrosine kinase receptorHomo sapiens (human)
multicellular organism developmentLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein phosphorylationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
immune responseNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytokine-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of type II interferon productionNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of interleukin-17 productionNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of natural killer cell proliferationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-12-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type III interferon-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of T cell proliferationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of NK T cell proliferationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type II interferon-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type I interferon-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cellular response to virusNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-10-mediated signaling pathwayNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of protein localization to nucleusNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
positive regulation of T-helper 17 type immune responseNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
intracellular signal transductionNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cell differentiationNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
G2/M transition of mitotic cell cycleWee1-like protein kinaseHomo sapiens (human)
microtubule cytoskeleton organizationWee1-like protein kinaseHomo sapiens (human)
negative regulation of G2/M transition of mitotic cell cycleWee1-like protein kinaseHomo sapiens (human)
establishment of cell polarityWee1-like protein kinaseHomo sapiens (human)
positive regulation of DNA replicationWee1-like protein kinaseHomo sapiens (human)
neuron projection morphogenesisWee1-like protein kinaseHomo sapiens (human)
cell divisionWee1-like protein kinaseHomo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleWee1-like protein kinaseHomo sapiens (human)
protein phosphorylationWee1-like protein kinaseHomo sapiens (human)
response to hypoxiaHeme oxygenase 2Homo sapiens (human)
response to oxidative stressHeme oxygenase 2Homo sapiens (human)
heme catabolic processHeme oxygenase 2Homo sapiens (human)
heme oxidationHeme oxygenase 2Homo sapiens (human)
neuron migrationTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of cytokine-mediated signaling pathwayTyrosine-protein kinase receptor UFOHomo sapiens (human)
blood vessel remodelingTyrosine-protein kinase receptor UFOHomo sapiens (human)
phagocytosisTyrosine-protein kinase receptor UFOHomo sapiens (human)
inflammatory responseTyrosine-protein kinase receptor UFOHomo sapiens (human)
signal transductionTyrosine-protein kinase receptor UFOHomo sapiens (human)
spermatogenesisTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of macrophage cytokine productionTyrosine-protein kinase receptor UFOHomo sapiens (human)
forebrain cell migrationTyrosine-protein kinase receptor UFOHomo sapiens (human)
animal organ regenerationTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of type II interferon productionTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of tumor necrosis factor productionTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of natural killer cell differentiationTyrosine-protein kinase receptor UFOHomo sapiens (human)
secretion by cellTyrosine-protein kinase receptor UFOHomo sapiens (human)
erythrocyte homeostasisTyrosine-protein kinase receptor UFOHomo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase receptor UFOHomo sapiens (human)
cellular response to interferon-alphaTyrosine-protein kinase receptor UFOHomo sapiens (human)
ovulation cycleTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of neuron apoptotic processTyrosine-protein kinase receptor UFOHomo sapiens (human)
innate immune responseTyrosine-protein kinase receptor UFOHomo sapiens (human)
symbiont entry into host cellTyrosine-protein kinase receptor UFOHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase receptor UFOHomo sapiens (human)
cell maturationTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of pinocytosisTyrosine-protein kinase receptor UFOHomo sapiens (human)
response to axon injuryTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of lymphocyte activationTyrosine-protein kinase receptor UFOHomo sapiens (human)
neuron apoptotic processTyrosine-protein kinase receptor UFOHomo sapiens (human)
establishment of localization in cellTyrosine-protein kinase receptor UFOHomo sapiens (human)
vagina developmentTyrosine-protein kinase receptor UFOHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase receptor UFOHomo sapiens (human)
cellular response to lipopolysaccharideTyrosine-protein kinase receptor UFOHomo sapiens (human)
dendritic cell differentiationTyrosine-protein kinase receptor UFOHomo sapiens (human)
neutrophil clearanceTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of viral life cycleTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of dendritic cell apoptotic processTyrosine-protein kinase receptor UFOHomo sapiens (human)
platelet activationTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase receptor UFOHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase receptor UFOHomo sapiens (human)
natural killer cell differentiationTyrosine-protein kinase receptor UFOHomo sapiens (human)
cell migrationTyrosine-protein kinase receptor UFOHomo sapiens (human)
positive regulation of kinase activityTyrosine-protein kinase receptor UFOHomo sapiens (human)
nervous system developmentTyrosine-protein kinase receptor UFOHomo sapiens (human)
multicellular organism developmentTyrosine-protein kinase receptor UFOHomo sapiens (human)
negative regulation of apoptotic processTyrosine-protein kinase receptor UFOHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 4Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 4Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 4Homo sapiens (human)
S-adenosylmethionine biosynthetic processS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
one-carbon metabolic processS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
protein hexamerizationS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
protein heterooligomerizationS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
cellular response to methionineS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
positive regulation of TORC1 signalingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
cellular response to leukemia inhibitory factorS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
protein foldingDnaJ homolog subfamily A member 1Homo sapiens (human)
response to unfolded proteinDnaJ homolog subfamily A member 1Homo sapiens (human)
spermatogenesisDnaJ homolog subfamily A member 1Homo sapiens (human)
response to heatDnaJ homolog subfamily A member 1Homo sapiens (human)
flagellated sperm motilityDnaJ homolog subfamily A member 1Homo sapiens (human)
androgen receptor signaling pathwayDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of protein ubiquitinationDnaJ homolog subfamily A member 1Homo sapiens (human)
positive regulation of apoptotic processDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of apoptotic processDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of JUN kinase activityDnaJ homolog subfamily A member 1Homo sapiens (human)
regulation of protein transportDnaJ homolog subfamily A member 1Homo sapiens (human)
protein localization to mitochondrionDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of establishment of protein localization to mitochondrionDnaJ homolog subfamily A member 1Homo sapiens (human)
negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathwayDnaJ homolog subfamily A member 1Homo sapiens (human)
protein refoldingDnaJ homolog subfamily A member 1Homo sapiens (human)
protein phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
activation-induced cell death of T cellsRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
osteoblast differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
maternal placenta developmentRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of endothelial cell proliferationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell migration involved in sprouting angiogenesisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glycogen biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of glycogen biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glucose metabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of translationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein import into nucleusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nitric oxide biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
inflammatory responseRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to oxidative stressRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
epidermal growth factor receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
G protein-coupled receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
canonical NF-kappaB signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell population proliferationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
insulin receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
apoptotic mitochondrial changesRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to heatRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
gene expressionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of autophagyRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of endothelial cell migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of gene expressionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of gene expressionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of long-chain fatty acid import across plasma membraneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
fibroblast migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of fibroblast migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of sodium ion transportRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glucose metabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of endopeptidase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of neuron projection developmentRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of macroautophagyRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein ubiquitinationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
peptidyl-threonine phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
virus-mediated perturbation of host defense responseRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cytokine-mediated signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
mammalian oogenesis stageRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell growthRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
T cell costimulationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein ubiquitinationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of myelinationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
TOR signalingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of fatty acid beta-oxidationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of endodeoxyribonuclease activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to foodRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
peripheral nervous system myelin maintenanceRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to insulin stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to fluid shear stressRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to reactive oxygen speciesRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
interleukin-18-mediated signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to vascular endothelial growth factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to decreased oxygen levelsRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
non-canonical NF-kappaB signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glucose homeostasisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of apoptotic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of apoptotic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
anoikisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of mRNA stabilityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of fat cell differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glycogen biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of Notch signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of proteolysisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of DNA-templated transcriptionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glucose importRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of organ growthRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein autophosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of lipid biosynthetic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
behavioral response to painRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of nitric-oxide synthase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
striated muscle cell differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein metabolic processRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
excitatory postsynaptic potentialRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to growth hormoneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
mammary gland epithelial cell differentiationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
labyrinthine layer blood vessel developmentRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to UV-ARAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to growth factorRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to cadmium ionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to tumor necrosis factorRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to epidermal growth factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to prostaglandin E stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein serine/threonine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
establishment of protein localization to mitochondrionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
maintenance of protein location in mitochondrionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to granulocyte macrophage colony-stimulating factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
execution phase of apoptosisRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of postsynapse organizationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of tRNA methylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to oxidised low-density lipoprotein particle stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of protein localization to lysosomeRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein localization to nucleusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to peptideRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of signal transduction by p53 class mediatorRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cilium assemblyRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein localization to plasma membraneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of I-kappaB phosphorylationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of TORC1 signalingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein localization to endoplasmic reticulumRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cellular response to nerve growth factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
response to insulin-like growth factor stimulusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein localization to cell surfaceRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
regulation of type B pancreatic cell developmentRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of lymphocyte migrationRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glycogen biosynthetic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
glucose metabolic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
regulation of translationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
insulin receptor signaling pathwayRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of long-chain fatty acid import across plasma membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glucose metabolic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell migrationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell migrationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of fatty acid beta-oxidationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
peripheral nervous system myelin maintenanceRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cellular response to insulin stimulusRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
protein modification processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
fat cell differentiationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glycogen biosynthetic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of glucose importRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
regulation of cell cycleRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
mammary gland epithelial cell differentiationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cellular response to high light intensityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
organic substance transportRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
protein localization to plasma membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of protein targeting to membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
retinal rod cell apoptotic processRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell motilityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
signal transductionG protein-coupled receptor kinase 4Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathwayG protein-coupled receptor kinase 4Homo sapiens (human)
regulation of opsin-mediated signaling pathwayG protein-coupled receptor kinase 4Homo sapiens (human)
receptor internalizationG protein-coupled receptor kinase 4Homo sapiens (human)
protein phosphorylationG protein-coupled receptor kinase 4Homo sapiens (human)
regulation of signal transductionG protein-coupled receptor kinase 4Homo sapiens (human)
spindle organizationDual specificity protein kinase TTKHomo sapiens (human)
mitotic spindle organizationDual specificity protein kinase TTKHomo sapiens (human)
positive regulation of cell population proliferationDual specificity protein kinase TTKHomo sapiens (human)
female meiosis chromosome segregationDual specificity protein kinase TTKHomo sapiens (human)
protein localization to meiotic spindle midzoneDual specificity protein kinase TTKHomo sapiens (human)
chromosome segregationDual specificity protein kinase TTKHomo sapiens (human)
peptidyl-serine phosphorylationDual specificity protein kinase TTKHomo sapiens (human)
protein localization to kinetochoreDual specificity protein kinase TTKHomo sapiens (human)
mitotic spindle assembly checkpoint signalingDual specificity protein kinase TTKHomo sapiens (human)
meiotic spindle assembly checkpoint signalingDual specificity protein kinase TTKHomo sapiens (human)
DNA replicationDNA replication licensing factor MCM4Homo sapiens (human)
DNA unwinding involved in DNA replicationDNA replication licensing factor MCM4Homo sapiens (human)
regulation of DNA-templated DNA replication initiationDNA replication licensing factor MCM4Homo sapiens (human)
double-strand break repair via break-induced replicationDNA replication licensing factor MCM4Homo sapiens (human)
DNA strand elongation involved in DNA replicationDNA replication licensing factor MCM4Homo sapiens (human)
mitotic DNA replication initiationDNA replication licensing factor MCM4Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
mitotic cytokinesisMyosin-10Homo sapiens (human)
actin filament-based movementMyosin-10Homo sapiens (human)
cell adhesionMyosin-10Homo sapiens (human)
actomyosin structure organizationMyosin-10Homo sapiens (human)
positive regulation of protein secretionMyosin-10Homo sapiens (human)
mitotic cytokinesisMyosin-10Homo sapiens (human)
regulation of cell shapeMyosin-10Homo sapiens (human)
regulation of extracellular matrix assemblyTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
regulation of endothelial cell proliferationTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
lymphatic endothelial cell differentiationTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
angiogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
vasculogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
in utero embryonic developmentTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
aortic valve morphogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
signal transductionTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
mesoderm developmentTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
negative regulation of angiogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
negative regulation of cell migrationTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
response to retinoic acidTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
plasma membrane fusionTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
tissue remodelingTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
branching involved in lymph vessel morphogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
positive regulation of angiogenesisTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
positive regulation of kinase activityTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
multicellular organism developmentTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of protein phosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of endothelial cell proliferationVascular endothelial growth factor receptor 3Homo sapiens (human)
vasculature developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
lymph vessel developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
lymphangiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
sprouting angiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
respiratory system processVascular endothelial growth factor receptor 3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of endothelial cell migrationVascular endothelial growth factor receptor 3Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
negative regulation of apoptotic processVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of JNK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 3Homo sapiens (human)
lung alveolus developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
blood vessel morphogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
regulation of blood vessel remodelingVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of protein kinase C signalingVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 3Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 3Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 3Homo sapiens (human)
regulation of MAPK cascadeVascular endothelial growth factor receptor 3Homo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 3Homo sapiens (human)
branching involved in blood vessel morphogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of macroautophagyVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mitochondrial depolarizationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mitochondrial fissionVascular endothelial growth factor receptor 2Homo sapiens (human)
angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
ovarian follicle developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
vasculogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of protein phosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
lymph vessel developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell migration involved in sprouting angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
epithelial cell maturationVascular endothelial growth factor receptor 2Homo sapiens (human)
endocardium developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
endothelium developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell population proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of cell shapeVascular endothelial growth factor receptor 2Homo sapiens (human)
mesenchymal cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of gene expressionVascular endothelial growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of BMP signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
embryonic hemopoiesisVascular endothelial growth factor receptor 2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor-2 signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
peptidyl-tyrosine autophosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
surfactant homeostasisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of MAPK cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of neuron apoptotic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
cell fate commitmentVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
protein autophosphorylationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
lung alveolus developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
post-embryonic camera-type eye morphogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
epithelial cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of positive chemotaxisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of focal adhesion assemblyVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionVascular endothelial growth factor receptor 2Homo sapiens (human)
calcium ion homeostasisVascular endothelial growth factor receptor 2Homo sapiens (human)
blood vessel endothelial cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular wound healingVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
semaphorin-plexin signaling pathwayVascular endothelial growth factor receptor 2Homo sapiens (human)
stem cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of hematopoietic progenitor cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of bone developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cellular response to hydrogen sulfideVascular endothelial growth factor receptor 2Homo sapiens (human)
negative regulation of endothelial cell apoptotic processVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of stem cell proliferationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of endothelial cell chemotaxisVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of vasculogenesisVascular endothelial growth factor receptor 2Homo sapiens (human)
regulation of MAPK cascadeVascular endothelial growth factor receptor 2Homo sapiens (human)
multicellular organism developmentVascular endothelial growth factor receptor 2Homo sapiens (human)
cell migrationVascular endothelial growth factor receptor 2Homo sapiens (human)
endothelial cell differentiationVascular endothelial growth factor receptor 2Homo sapiens (human)
positive regulation of kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of gene expressionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
Schwann cell developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
thyroid gland developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
regulation of stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
peptidyl-serine autophosphorylationDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
myelinationDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
thymus developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
regulation of axon regenerationDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of axonogenesisDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
face developmentDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
trachea formationDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
epithelial cell proliferation involved in lung morphogenesisDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
regulation of Golgi inheritanceDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
positive regulation of cell motilityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
regulation of early endosome to late endosome transportDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
hemopoiesisReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
leukocyte homeostasisReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
myeloid progenitor cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
pro-B cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of cell population proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
response to organonitrogen compoundReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cytokine-mediated signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
B cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
animal organ regenerationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
common myeloid progenitor cell proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
vascular endothelial growth factor signaling pathwayReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
regulation of apoptotic processReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of MAP kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of MAPK cascadeReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
lymphocyte proliferationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein autophosphorylationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cellular response to cytokine stimulusReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cellular response to glucocorticoid stimulusReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
dendritic cell differentiationReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
positive regulation of kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
multicellular organism developmentReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
regulation of cardiac muscle cell apoptotic processBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of neural crest cell differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of gene expressionBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of gene expressionBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of transforming growth factor beta2 productionBone morphogenetic protein receptor type-1AHomo sapiens (human)
angiogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
osteoblast differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
in utero embryonic developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
mesoderm formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
somitogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
Mullerian duct regressionBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of mesenchymal cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
chondrocyte differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
outflow tract septum morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
outflow tract morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
cardiac conduction system developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
atrioventricular valve developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
mitral valve morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
tricuspid valve morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
endocardial cushion morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
cardiac right ventricle morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
ventricular trabecula myocardium morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
ventricular compact myocardium morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
endocardial cushion formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
immune responseBone morphogenetic protein receptor type-1AHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayBone morphogenetic protein receptor type-1AHomo sapiens (human)
ectoderm developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
dorsal/ventral axis specificationBone morphogenetic protein receptor type-1AHomo sapiens (human)
neural crest cell developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of smooth muscle cell migrationBone morphogenetic protein receptor type-1AHomo sapiens (human)
central nervous system neuron differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
pituitary gland developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
neural plate mediolateral regionalizationBone morphogenetic protein receptor type-1AHomo sapiens (human)
lung developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of bone mineralizationBone morphogenetic protein receptor type-1AHomo sapiens (human)
BMP signaling pathwayBone morphogenetic protein receptor type-1AHomo sapiens (human)
somatic stem cell population maintenanceBone morphogenetic protein receptor type-1AHomo sapiens (human)
hindlimb morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
dorsal aorta morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
odontogenesis of dentin-containing toothBone morphogenetic protein receptor type-1AHomo sapiens (human)
embryonic digit morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of osteoblast differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBone morphogenetic protein receptor type-1AHomo sapiens (human)
paraxial mesoderm structural organizationBone morphogenetic protein receptor type-1AHomo sapiens (human)
lateral mesoderm developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of lateral mesodermal cell fate specificationBone morphogenetic protein receptor type-1AHomo sapiens (human)
mesendoderm developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
embryonic organ developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
developmental growthBone morphogenetic protein receptor type-1AHomo sapiens (human)
epithelial cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of epithelial cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of neurogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
negative regulation of muscle cell differentiationBone morphogenetic protein receptor type-1AHomo sapiens (human)
roof of mouth developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of cardiac muscle cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of cardiac muscle cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of SMAD protein signal transductionBone morphogenetic protein receptor type-1AHomo sapiens (human)
ventricular septum morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
heart formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
atrioventricular node cell developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
pharyngeal arch artery morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
cellular response to BMP stimulusBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of miRNA transcriptionBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of cardiac ventricle developmentBone morphogenetic protein receptor type-1AHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationBone morphogenetic protein receptor type-1AHomo sapiens (human)
fibrous ring of heart morphogenesisBone morphogenetic protein receptor type-1AHomo sapiens (human)
regulation of cellular senescenceBone morphogenetic protein receptor type-1AHomo sapiens (human)
protein phosphorylationBone morphogenetic protein receptor type-1AHomo sapiens (human)
dorsal/ventral pattern formationBone morphogenetic protein receptor type-1AHomo sapiens (human)
cellular response to growth factor stimulusBone morphogenetic protein receptor type-1AHomo sapiens (human)
G1/S transition of mitotic cell cycleActivin receptor type-1BHomo sapiens (human)
in utero embryonic developmentActivin receptor type-1BHomo sapiens (human)
hair follicle developmentActivin receptor type-1BHomo sapiens (human)
regulation of DNA-templated transcriptionActivin receptor type-1BHomo sapiens (human)
signal transductionActivin receptor type-1BHomo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayActivin receptor type-1BHomo sapiens (human)
positive regulation of gene expressionActivin receptor type-1BHomo sapiens (human)
negative regulation of gene expressionActivin receptor type-1BHomo sapiens (human)
peptidyl-threonine phosphorylationActivin receptor type-1BHomo sapiens (human)
negative regulation of cell growthActivin receptor type-1BHomo sapiens (human)
activin receptor signaling pathwayActivin receptor type-1BHomo sapiens (human)
positive regulation of activin receptor signaling pathwayActivin receptor type-1BHomo sapiens (human)
nodal signaling pathwayActivin receptor type-1BHomo sapiens (human)
positive regulation of erythrocyte differentiationActivin receptor type-1BHomo sapiens (human)
protein autophosphorylationActivin receptor type-1BHomo sapiens (human)
extrinsic apoptotic signaling pathwayActivin receptor type-1BHomo sapiens (human)
positive regulation of trophoblast cell migrationActivin receptor type-1BHomo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-1BHomo sapiens (human)
protein phosphorylationActivin receptor type-1BHomo sapiens (human)
nervous system developmentActivin receptor type-1BHomo sapiens (human)
proepicardium developmentTGF-beta receptor type-1Homo sapiens (human)
negative regulation of cell migrationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of extracellular matrix assemblyTGF-beta receptor type-1Homo sapiens (human)
skeletal system developmentTGF-beta receptor type-1Homo sapiens (human)
in utero embryonic developmentTGF-beta receptor type-1Homo sapiens (human)
kidney developmentTGF-beta receptor type-1Homo sapiens (human)
blastocyst developmentTGF-beta receptor type-1Homo sapiens (human)
epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
endothelial cell proliferationTGF-beta receptor type-1Homo sapiens (human)
negative regulation of endothelial cell proliferationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of endothelial cell proliferationTGF-beta receptor type-1Homo sapiens (human)
lens development in camera-type eyeTGF-beta receptor type-1Homo sapiens (human)
ventricular trabecula myocardium morphogenesisTGF-beta receptor type-1Homo sapiens (human)
ventricular compact myocardium morphogenesisTGF-beta receptor type-1Homo sapiens (human)
regulation of DNA-templated transcriptionTGF-beta receptor type-1Homo sapiens (human)
apoptotic processTGF-beta receptor type-1Homo sapiens (human)
signal transductionTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
heart developmentTGF-beta receptor type-1Homo sapiens (human)
positive regulation of cell population proliferationTGF-beta receptor type-1Homo sapiens (human)
germ cell migrationTGF-beta receptor type-1Homo sapiens (human)
male gonad developmentTGF-beta receptor type-1Homo sapiens (human)
post-embryonic developmentTGF-beta receptor type-1Homo sapiens (human)
anterior/posterior pattern specificationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of gene expressionTGF-beta receptor type-1Homo sapiens (human)
regulation of epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
peptidyl-serine phosphorylationTGF-beta receptor type-1Homo sapiens (human)
collagen fibril organizationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of cell growthTGF-beta receptor type-1Homo sapiens (human)
positive regulation of cell migrationTGF-beta receptor type-1Homo sapiens (human)
regulation of protein ubiquitinationTGF-beta receptor type-1Homo sapiens (human)
negative regulation of chondrocyte differentiationTGF-beta receptor type-1Homo sapiens (human)
activin receptor signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
intracellular signal transductionTGF-beta receptor type-1Homo sapiens (human)
myofibroblast differentiationTGF-beta receptor type-1Homo sapiens (human)
wound healingTGF-beta receptor type-1Homo sapiens (human)
endothelial cell activationTGF-beta receptor type-1Homo sapiens (human)
extracellular structure organizationTGF-beta receptor type-1Homo sapiens (human)
endothelial cell migrationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionTGF-beta receptor type-1Homo sapiens (human)
filopodium assemblyTGF-beta receptor type-1Homo sapiens (human)
thymus developmentTGF-beta receptor type-1Homo sapiens (human)
neuron fate commitmentTGF-beta receptor type-1Homo sapiens (human)
embryonic cranial skeleton morphogenesisTGF-beta receptor type-1Homo sapiens (human)
skeletal system morphogenesisTGF-beta receptor type-1Homo sapiens (human)
mesenchymal cell differentiationTGF-beta receptor type-1Homo sapiens (human)
artery morphogenesisTGF-beta receptor type-1Homo sapiens (human)
cell motilityTGF-beta receptor type-1Homo sapiens (human)
positive regulation of filopodium assemblyTGF-beta receptor type-1Homo sapiens (human)
positive regulation of stress fiber assemblyTGF-beta receptor type-1Homo sapiens (human)
regulation of cell cycleTGF-beta receptor type-1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTGF-beta receptor type-1Homo sapiens (human)
parathyroid gland developmentTGF-beta receptor type-1Homo sapiens (human)
roof of mouth developmentTGF-beta receptor type-1Homo sapiens (human)
pharyngeal system developmentTGF-beta receptor type-1Homo sapiens (human)
regulation of cardiac muscle cell proliferationTGF-beta receptor type-1Homo sapiens (human)
cardiac epithelial to mesenchymal transitionTGF-beta receptor type-1Homo sapiens (human)
positive regulation of SMAD protein signal transductionTGF-beta receptor type-1Homo sapiens (human)
ventricular septum morphogenesisTGF-beta receptor type-1Homo sapiens (human)
angiogenesis involved in coronary vascular morphogenesisTGF-beta receptor type-1Homo sapiens (human)
coronary artery morphogenesisTGF-beta receptor type-1Homo sapiens (human)
response to cholesterolTGF-beta receptor type-1Homo sapiens (human)
cellular response to transforming growth factor beta stimulusTGF-beta receptor type-1Homo sapiens (human)
positive regulation of mesenchymal stem cell proliferationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of vasculature developmentTGF-beta receptor type-1Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formationTGF-beta receptor type-1Homo sapiens (human)
positive regulation of tight junction disassemblyTGF-beta receptor type-1Homo sapiens (human)
epicardium morphogenesisTGF-beta receptor type-1Homo sapiens (human)
positive regulation of apoptotic signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayTGF-beta receptor type-1Homo sapiens (human)
protein phosphorylationTGF-beta receptor type-1Homo sapiens (human)
cellular response to growth factor stimulusTGF-beta receptor type-1Homo sapiens (human)
nervous system developmentTGF-beta receptor type-1Homo sapiens (human)
endocardial cushion to mesenchymal transitionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of epithelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of Notch signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
angiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
response to hypoxiaSerine/threonine-protein kinase receptor R3Homo sapiens (human)
in utero embryonic developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of endothelial cell proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of endothelial cell proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of endothelial cell proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
lymphangiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood vessel maturationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood vessel remodelingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood vessel endothelial cell proliferation involved in sprouting angiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
endocardial cushion morphogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of DNA replicationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell adhesionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
signal transductionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
blood circulationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of blood pressureSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of endothelial cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of gene expressionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell growthSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
BMP signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of BMP signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of chondrocyte differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin receptor signaling pathwaySerine/threonine-protein kinase receptor R3Homo sapiens (human)
wound healing, spreading of epidermal cellsSerine/threonine-protein kinase receptor R3Homo sapiens (human)
dorsal aorta morphogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of endothelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of endothelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase receptor R3Homo sapiens (human)
negative regulation of focal adhesion assemblySerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of SMAD protein signal transductionSerine/threonine-protein kinase receptor R3Homo sapiens (human)
lymphatic endothelial cell differentiationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
artery developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
venous blood vessel developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
endothelial tube morphogenesisSerine/threonine-protein kinase receptor R3Homo sapiens (human)
retina vasculature development in camera-type eyeSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cellular response to transforming growth factor beta stimulusSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cellular response to BMP stimulusSerine/threonine-protein kinase receptor R3Homo sapiens (human)
positive regulation of bicellular tight junction assemblySerine/threonine-protein kinase receptor R3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
dorsal/ventral pattern formationSerine/threonine-protein kinase receptor R3Homo sapiens (human)
heart developmentSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cellular response to growth factor stimulusSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cell proliferation involved in endocardial cushion morphogenesisTGF-beta receptor type-2Homo sapiens (human)
superior endocardial cushion morphogenesisTGF-beta receptor type-2Homo sapiens (human)
blood vessel developmentTGF-beta receptor type-2Homo sapiens (human)
branching involved in blood vessel morphogenesisTGF-beta receptor type-2Homo sapiens (human)
vasculogenesisTGF-beta receptor type-2Homo sapiens (human)
in utero embryonic developmentTGF-beta receptor type-2Homo sapiens (human)
epithelial to mesenchymal transitionTGF-beta receptor type-2Homo sapiens (human)
heart loopingTGF-beta receptor type-2Homo sapiens (human)
positive regulation of mesenchymal cell proliferationTGF-beta receptor type-2Homo sapiens (human)
lens development in camera-type eyeTGF-beta receptor type-2Homo sapiens (human)
positive regulation of tolerance induction to self antigenTGF-beta receptor type-2Homo sapiens (human)
positive regulation of B cell tolerance inductionTGF-beta receptor type-2Homo sapiens (human)
positive regulation of T cell tolerance inductionTGF-beta receptor type-2Homo sapiens (human)
outflow tract septum morphogenesisTGF-beta receptor type-2Homo sapiens (human)
membranous septum morphogenesisTGF-beta receptor type-2Homo sapiens (human)
outflow tract morphogenesisTGF-beta receptor type-2Homo sapiens (human)
aortic valve morphogenesisTGF-beta receptor type-2Homo sapiens (human)
atrioventricular valve morphogenesisTGF-beta receptor type-2Homo sapiens (human)
tricuspid valve morphogenesisTGF-beta receptor type-2Homo sapiens (human)
cardiac left ventricle morphogenesisTGF-beta receptor type-2Homo sapiens (human)
endocardial cushion fusionTGF-beta receptor type-2Homo sapiens (human)
growth plate cartilage chondrocyte growthTGF-beta receptor type-2Homo sapiens (human)
apoptotic processTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayTGF-beta receptor type-2Homo sapiens (human)
Notch signaling pathwayTGF-beta receptor type-2Homo sapiens (human)
smoothened signaling pathwayTGF-beta receptor type-2Homo sapiens (human)
gastrulationTGF-beta receptor type-2Homo sapiens (human)
brain developmentTGF-beta receptor type-2Homo sapiens (human)
heart developmentTGF-beta receptor type-2Homo sapiens (human)
positive regulation of cell population proliferationTGF-beta receptor type-2Homo sapiens (human)
response to xenobiotic stimulusTGF-beta receptor type-2Homo sapiens (human)
regulation of gene expressionTGF-beta receptor type-2Homo sapiens (human)
positive regulation of epithelial cell migrationTGF-beta receptor type-2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionTGF-beta receptor type-2Homo sapiens (human)
activation of protein kinase activityTGF-beta receptor type-2Homo sapiens (human)
activin receptor signaling pathwayTGF-beta receptor type-2Homo sapiens (human)
embryonic hemopoiesisTGF-beta receptor type-2Homo sapiens (human)
aorta morphogenesisTGF-beta receptor type-2Homo sapiens (human)
regulation of cell population proliferationTGF-beta receptor type-2Homo sapiens (human)
myeloid dendritic cell differentiationTGF-beta receptor type-2Homo sapiens (human)
positive regulation of angiogenesisTGF-beta receptor type-2Homo sapiens (human)
embryonic cranial skeleton morphogenesisTGF-beta receptor type-2Homo sapiens (human)
artery morphogenesisTGF-beta receptor type-2Homo sapiens (human)
positive regulation of NK T cell differentiationTGF-beta receptor type-2Homo sapiens (human)
roof of mouth developmentTGF-beta receptor type-2Homo sapiens (human)
positive regulation of SMAD protein signal transductionTGF-beta receptor type-2Homo sapiens (human)
SMAD protein signal transductionTGF-beta receptor type-2Homo sapiens (human)
ventricular septum morphogenesisTGF-beta receptor type-2Homo sapiens (human)
bronchus morphogenesisTGF-beta receptor type-2Homo sapiens (human)
trachea formationTGF-beta receptor type-2Homo sapiens (human)
mammary gland morphogenesisTGF-beta receptor type-2Homo sapiens (human)
lung lobe morphogenesisTGF-beta receptor type-2Homo sapiens (human)
Langerhans cell differentiationTGF-beta receptor type-2Homo sapiens (human)
secondary palate developmentTGF-beta receptor type-2Homo sapiens (human)
response to cholesterolTGF-beta receptor type-2Homo sapiens (human)
regulation of stem cell proliferationTGF-beta receptor type-2Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formationTGF-beta receptor type-2Homo sapiens (human)
inferior endocardial cushion morphogenesisTGF-beta receptor type-2Homo sapiens (human)
lens fiber cell apoptotic processTGF-beta receptor type-2Homo sapiens (human)
miRNA transportTGF-beta receptor type-2Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processTGF-beta receptor type-2Homo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationTGF-beta receptor type-2Homo sapiens (human)
regulation of stem cell differentiationTGF-beta receptor type-2Homo sapiens (human)
cellular response to growth factor stimulusTGF-beta receptor type-2Homo sapiens (human)
protein phosphorylationTGF-beta receptor type-2Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase CSKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of cell population proliferationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of low-density lipoprotein particle clearanceTyrosine-protein kinase CSKHomo sapiens (human)
T cell costimulationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of Golgi to plasma membrane protein transportTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of bone resorptionTyrosine-protein kinase CSKHomo sapiens (human)
oligodendrocyte differentiationTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of phagocytosisTyrosine-protein kinase CSKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase CSKHomo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase CSKHomo sapiens (human)
cellular response to peptide hormone stimulusTyrosine-protein kinase CSKHomo sapiens (human)
regulation of Fc receptor mediated stimulatory signaling pathwayTyrosine-protein kinase CSKHomo sapiens (human)
adherens junction organizationTyrosine-protein kinase CSKHomo sapiens (human)
tRNA aminoacylation for protein translationGlycine--tRNA ligaseHomo sapiens (human)
diadenosine tetraphosphate biosynthetic processGlycine--tRNA ligaseHomo sapiens (human)
mitochondrial glycyl-tRNA aminoacylationGlycine--tRNA ligaseHomo sapiens (human)
protein phosphorylationProtein kinase C iota typeHomo sapiens (human)
protein targeting to membraneProtein kinase C iota typeHomo sapiens (human)
cytoskeleton organizationProtein kinase C iota typeHomo sapiens (human)
actin filament organizationProtein kinase C iota typeHomo sapiens (human)
positive regulation of neuron projection developmentProtein kinase C iota typeHomo sapiens (human)
vesicle-mediated transportProtein kinase C iota typeHomo sapiens (human)
cell migrationProtein kinase C iota typeHomo sapiens (human)
cellular response to insulin stimulusProtein kinase C iota typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C iota typeHomo sapiens (human)
establishment of apical/basal cell polarityProtein kinase C iota typeHomo sapiens (human)
eye photoreceptor cell developmentProtein kinase C iota typeHomo sapiens (human)
negative regulation of apoptotic processProtein kinase C iota typeHomo sapiens (human)
negative regulation of neuron apoptotic processProtein kinase C iota typeHomo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarityProtein kinase C iota typeHomo sapiens (human)
cell-cell junction organizationProtein kinase C iota typeHomo sapiens (human)
positive regulation of Notch signaling pathwayProtein kinase C iota typeHomo sapiens (human)
positive regulation of glucose importProtein kinase C iota typeHomo sapiens (human)
secretionProtein kinase C iota typeHomo sapiens (human)
Golgi vesicle buddingProtein kinase C iota typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C iota typeHomo sapiens (human)
positive regulation of glial cell proliferationProtein kinase C iota typeHomo sapiens (human)
membrane organizationProtein kinase C iota typeHomo sapiens (human)
cellular response to chemical stressProtein kinase C iota typeHomo sapiens (human)
response to interleukin-1Protein kinase C iota typeHomo sapiens (human)
regulation of postsynaptic membrane neurotransmitter receptor levelsProtein kinase C iota typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C iota typeHomo sapiens (human)
positive regulation of endothelial cell apoptotic processProtein kinase C iota typeHomo sapiens (human)
intracellular signal transductionProtein kinase C iota typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C iota typeHomo sapiens (human)
mRNA splicing, via spliceosomeExosome RNA helicase MTR4Homo sapiens (human)
maturation of 5.8S rRNAExosome RNA helicase MTR4Homo sapiens (human)
rRNA processingExosome RNA helicase MTR4Homo sapiens (human)
RNA catabolic processExosome RNA helicase MTR4Homo sapiens (human)
DNA damage responseExosome RNA helicase MTR4Homo sapiens (human)
snRNA catabolic processExosome RNA helicase MTR4Homo sapiens (human)
phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
liver developmentPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of protein phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
vasculature developmentPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
glucose metabolic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phagocytosisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
epidermal growth factor receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
insulin receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of lamellipodium assemblyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of gene expressionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to muscle inactivityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of macroautophagyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
actin cytoskeleton organizationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
platelet activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of actin filament depolymerizationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
T cell costimulationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of TOR signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cellular response to insulin stimulusPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to muscle stretchPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
vascular endothelial growth factor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of multicellular organism growthPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to L-leucinePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
anoikisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of cellular respirationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of neuron apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
endothelial cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of smooth muscle cell proliferationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
T cell receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
relaxation of cardiac musclePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cardiac muscle contractionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
adipose tissue developmentPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cellular response to glucose stimulusPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cellular response to hydrostatic pressurePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to dexamethasonePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cardiac muscle cell contractionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
energy homeostasisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of actin filament organizationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
autosome genomic imprintingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
response to butyratePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
positive regulation of protein localization to membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of fibroblast apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
negative regulation of anoikisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
regulation of cell-matrix adhesionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of gene expressionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
endothelial cell proliferationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
response to ischemiaPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
intracellular calcium ion homeostasisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
endocytosisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
autophagyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion moleculesPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
G protein-coupled receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of autophagyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of endothelial cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
platelet activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of neutrophil apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
positive regulation of Rac protein signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
embryonic cleavagePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of MAPK cascadePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
angiogenesis involved in wound healingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
platelet aggregationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of hypoxia-induced intrinsic apoptotic signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
negative regulation of sprouting angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
regulation of clathrin-dependent endocytosisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
protein destabilizationSerine/threonine-protein kinase mTORHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of macroautophagySerine/threonine-protein kinase mTORHomo sapiens (human)
phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase mTORHomo sapiens (human)
T-helper 1 cell lineage commitmentSerine/threonine-protein kinase mTORHomo sapiens (human)
heart morphogenesisSerine/threonine-protein kinase mTORHomo sapiens (human)
heart valve morphogenesisSerine/threonine-protein kinase mTORHomo sapiens (human)
energy reserve metabolic processSerine/threonine-protein kinase mTORHomo sapiens (human)
'de novo' pyrimidine nucleobase biosynthetic processSerine/threonine-protein kinase mTORHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
inflammatory responseSerine/threonine-protein kinase mTORHomo sapiens (human)
DNA damage responseSerine/threonine-protein kinase mTORHomo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
lysosome organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
germ cell developmentSerine/threonine-protein kinase mTORHomo sapiens (human)
response to nutrientSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of cell sizeSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to starvationSerine/threonine-protein kinase mTORHomo sapiens (human)
response to heatSerine/threonine-protein kinase mTORHomo sapiens (human)
post-embryonic developmentSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of autophagySerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of lamellipodium assemblySerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of epithelial to mesenchymal transitionSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of myotube differentiationSerine/threonine-protein kinase mTORHomo sapiens (human)
macroautophagySerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of macroautophagySerine/threonine-protein kinase mTORHomo sapiens (human)
phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
neuronal action potentialSerine/threonine-protein kinase mTORHomo sapiens (human)
protein catabolic processSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of cell growthSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of actin filament polymerizationSerine/threonine-protein kinase mTORHomo sapiens (human)
T cell costimulationSerine/threonine-protein kinase mTORHomo sapiens (human)
ruffle organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of myelinationSerine/threonine-protein kinase mTORHomo sapiens (human)
response to nutrient levelsSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to nutrient levelsSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to nutrientSerine/threonine-protein kinase mTORHomo sapiens (human)
TOR signalingSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of phosphoprotein phosphatase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to insulin stimulusSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
calcineurin-NFAT signaling cascadeSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to amino acid starvationSerine/threonine-protein kinase mTORHomo sapiens (human)
multicellular organism growthSerine/threonine-protein kinase mTORHomo sapiens (human)
TORC1 signalingSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of circadian rhythmSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase mTORHomo sapiens (human)
response to amino acidSerine/threonine-protein kinase mTORHomo sapiens (human)
anoikisSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of osteoclast differentiationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of translationSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of cell sizeSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of glycolytic processSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIISerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of translational initiationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of lipid biosynthetic processSerine/threonine-protein kinase mTORHomo sapiens (human)
behavioral response to painSerine/threonine-protein kinase mTORHomo sapiens (human)
rhythmic processSerine/threonine-protein kinase mTORHomo sapiens (human)
oligodendrocyte differentiationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of oligodendrocyte differentiationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationSerine/threonine-protein kinase mTORHomo sapiens (human)
voluntary musculoskeletal movementSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of stress fiber assemblySerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of keratinocyte migrationSerine/threonine-protein kinase mTORHomo sapiens (human)
nucleus localizationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase mTORHomo sapiens (human)
cardiac muscle cell developmentSerine/threonine-protein kinase mTORHomo sapiens (human)
cardiac muscle contractionSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to methionineSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to amino acid stimulusSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to L-leucineSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to hypoxiaSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to osmotic stressSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of membrane permeabilitySerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of cellular response to heatSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of transcription of nucleolar large rRNA by RNA polymerase ISerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of wound healing, spreading of epidermal cellsSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of locomotor rhythmSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of cytoplasmic translational initiationSerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of lysosome organizationSerine/threonine-protein kinase mTORHomo sapiens (human)
positive regulation of pentose-phosphate shuntSerine/threonine-protein kinase mTORHomo sapiens (human)
cellular response to leucine starvationSerine/threonine-protein kinase mTORHomo sapiens (human)
regulation of autophagosome assemblySerine/threonine-protein kinase mTORHomo sapiens (human)
negative regulation of macroautophagySerine/threonine-protein kinase mTORHomo sapiens (human)
protein phosphorylationMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
positive regulation of cell population proliferationMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase TecHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase TecHomo sapiens (human)
regulation of platelet activationTyrosine-protein kinase TecHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase TecHomo sapiens (human)
tissue regenerationTyrosine-protein kinase TecHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase TecHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase TecHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase TecHomo sapiens (human)
positive regulation of cytokine productionTyrosine-protein kinase TXKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase TXKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase TXKHomo sapiens (human)
activation of phospholipase C activityTyrosine-protein kinase TXKHomo sapiens (human)
regulation of gene expressionTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of transcription by RNA polymerase IITyrosine-protein kinase TXKHomo sapiens (human)
protein autophosphorylationTyrosine-protein kinase TXKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of type II interferon-mediated signaling pathwayTyrosine-protein kinase TXKHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of phospholipase C activityTyrosine-protein kinase ABL2Homo sapiens (human)
negative regulation of Rho protein signal transductionTyrosine-protein kinase ABL2Homo sapiens (human)
exploration behaviorTyrosine-protein kinase ABL2Homo sapiens (human)
cell adhesionTyrosine-protein kinase ABL2Homo sapiens (human)
signal transductionTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of autophagyTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase ABL2Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of endocytosisTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of cell adhesionTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of actin cytoskeleton organizationTyrosine-protein kinase ABL2Homo sapiens (human)
protein modification processTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of oxidoreductase activityTyrosine-protein kinase ABL2Homo sapiens (human)
cellular response to retinoic acidTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of establishment of T cell polarityTyrosine-protein kinase ABL2Homo sapiens (human)
regulation of cell motilityTyrosine-protein kinase ABL2Homo sapiens (human)
positive regulation of T cell migrationTyrosine-protein kinase ABL2Homo sapiens (human)
epidermal growth factor receptor signaling pathwayTyrosine-protein kinase ABL2Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase ABL2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITyrosine-protein kinase FRKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FRKHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FRKHomo sapiens (human)
cell differentiationTyrosine-protein kinase FRKHomo sapiens (human)
innate immune responseTyrosine-protein kinase FRKHomo sapiens (human)
G protein-coupled receptor signaling pathwayG protein-coupled receptor kinase 6Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathwayG protein-coupled receptor kinase 6Homo sapiens (human)
Wnt signaling pathwayG protein-coupled receptor kinase 6Homo sapiens (human)
regulation of signal transductionG protein-coupled receptor kinase 6Homo sapiens (human)
protein phosphorylationG protein-coupled receptor kinase 6Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive thymic T cell selectionTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive regulation of T cell differentiationTyrosine-protein kinase ZAP-70Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase ZAP-70Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase ZAP-70Homo sapiens (human)
immune responseTyrosine-protein kinase ZAP-70Homo sapiens (human)
calcium-mediated signalingTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell differentiationTyrosine-protein kinase ZAP-70Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell activationTyrosine-protein kinase ZAP-70Homo sapiens (human)
B cell activationTyrosine-protein kinase ZAP-70Homo sapiens (human)
beta selectionTyrosine-protein kinase ZAP-70Homo sapiens (human)
negative thymic T cell selectionTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive regulation of alpha-beta T cell differentiationTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive regulation of alpha-beta T cell proliferationTyrosine-protein kinase ZAP-70Homo sapiens (human)
positive regulation of calcium-mediated signalingTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell aggregationTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell migrationTyrosine-protein kinase ZAP-70Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase ZAP-70Homo sapiens (human)
cell differentiationTyrosine-protein kinase ZAP-70Homo sapiens (human)
innate immune responseTyrosine-protein kinase ZAP-70Homo sapiens (human)
protein import into nucleusTyrosine-protein kinase SYKHomo sapiens (human)
regulation of DNA-binding transcription factor activityTyrosine-protein kinase SYKHomo sapiens (human)
angiogenesisTyrosine-protein kinase SYKHomo sapiens (human)
cell activationTyrosine-protein kinase SYKHomo sapiens (human)
lymph vessel developmentTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of receptor internalizationTyrosine-protein kinase SYKHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase SYKHomo sapiens (human)
macrophage activation involved in immune responseTyrosine-protein kinase SYKHomo sapiens (human)
neutrophil activation involved in immune responseTyrosine-protein kinase SYKHomo sapiens (human)
leukocyte activation involved in immune responseTyrosine-protein kinase SYKHomo sapiens (human)
serotonin secretion by plateletTyrosine-protein kinase SYKHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase SYKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase SYKHomo sapiens (human)
leukocyte cell-cell adhesionTyrosine-protein kinase SYKHomo sapiens (human)
integrin-mediated signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
animal organ morphogenesisTyrosine-protein kinase SYKHomo sapiens (human)
regulation of platelet activationTyrosine-protein kinase SYKHomo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase SYKHomo sapiens (human)
leukotriene biosynthetic processTyrosine-protein kinase SYKHomo sapiens (human)
calcium-mediated signalingTyrosine-protein kinase SYKHomo sapiens (human)
platelet activationTyrosine-protein kinase SYKHomo sapiens (human)
B cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
neutrophil chemotaxisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of protein-containing complex assemblyTyrosine-protein kinase SYKHomo sapiens (human)
receptor internalizationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of type I interferon productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of granulocyte macrophage colony-stimulating factor productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-10 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-12 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-3 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-4 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of interleukin-8 productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of mast cell cytokine productionTyrosine-protein kinase SYKHomo sapiens (human)
regulation of superoxide anion generationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of superoxide anion generationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of cell adhesion mediated by integrinTyrosine-protein kinase SYKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase SYKHomo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase SYKHomo sapiens (human)
interleukin-3-mediated signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
gamma-delta T cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
defense response to bacteriumTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processTyrosine-protein kinase SYKHomo sapiens (human)
mast cell degranulationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of mast cell degranulationTyrosine-protein kinase SYKHomo sapiens (human)
regulation of neutrophil degranulationTyrosine-protein kinase SYKHomo sapiens (human)
beta selectionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of MAPK cascadeTyrosine-protein kinase SYKHomo sapiens (human)
innate immune responseTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of B cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of gamma-delta T cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of bone resorptionTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of alpha-beta T cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of alpha-beta T cell proliferationTyrosine-protein kinase SYKHomo sapiens (human)
blood vessel morphogenesisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase SYKHomo sapiens (human)
regulation of phagocytosisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of calcium-mediated signalingTyrosine-protein kinase SYKHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of killing of cells of another organismTyrosine-protein kinase SYKHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to molecule of fungal originTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to lipidTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of monocyte chemotactic protein-1 productionTyrosine-protein kinase SYKHomo sapiens (human)
regulation of arachidonic acid secretionTyrosine-protein kinase SYKHomo sapiens (human)
regulation of platelet aggregationTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of cold-induced thermogenesisTyrosine-protein kinase SYKHomo sapiens (human)
positive regulation of TORC1 signalingTyrosine-protein kinase SYKHomo sapiens (human)
cellular response to lectinTyrosine-protein kinase SYKHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase SYKHomo sapiens (human)
cell differentiationTyrosine-protein kinase SYKHomo sapiens (human)
blastocyst development26S proteasome regulatory subunit 6BHomo sapiens (human)
proteolysis26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process26S proteasome regulatory subunit 6BHomo sapiens (human)
positive regulation of proteasomal protein catabolic process26S proteasome regulatory subunit 6BHomo sapiens (human)
JUN phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
response to UVMitogen-activated protein kinase 8Homo sapiens (human)
negative regulation of apoptotic processMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 8Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
response to oxidative stressMitogen-activated protein kinase 8Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 8Homo sapiens (human)
JUN phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 8Homo sapiens (human)
regulation of macroautophagyMitogen-activated protein kinase 8Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
peptidyl-threonine phosphorylationMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of cell killingMitogen-activated protein kinase 8Homo sapiens (human)
negative regulation of protein bindingMitogen-activated protein kinase 8Homo sapiens (human)
regulation of protein localizationMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to oxidative stressMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 8Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 8Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase 8Homo sapiens (human)
negative regulation of apoptotic processMitogen-activated protein kinase 8Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of protein metabolic processMitogen-activated protein kinase 8Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase 8Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 8Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 8Homo sapiens (human)
energy homeostasisMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyMitogen-activated protein kinase 8Homo sapiens (human)
response to mechanical stimulusMitogen-activated protein kinase 8Homo sapiens (human)
positive regulation of establishment of protein localization to mitochondrionMitogen-activated protein kinase 8Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 9Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiationMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of protein ubiquitinationMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processMitogen-activated protein kinase 9Homo sapiens (human)
cellular response to reactive oxygen speciesMitogen-activated protein kinase 9Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 9Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 9Homo sapiens (human)
modulation of chemical synaptic transmissionMitogen-activated protein kinase 9Homo sapiens (human)
protein localization to tricellular tight junctionMitogen-activated protein kinase 9Homo sapiens (human)
cellular response to cadmium ionMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of podosome assemblyMitogen-activated protein kinase 9Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 9Homo sapiens (human)
inflammatory response to woundingMitogen-activated protein kinase 9Homo sapiens (human)
apoptotic signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of apoptotic signaling pathwayMitogen-activated protein kinase 9Homo sapiens (human)
positive regulation of protein phosphorylationDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
JNK cascadeDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
response to woundingDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
smooth muscle cell apoptotic processDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hydrogen peroxideDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
Fc-epsilon receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
positive regulation of neuron apoptotic processDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
positive regulation of DNA replicationDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
positive regulation of JNK cascadeDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cell growth involved in cardiac muscle cell developmentDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cellular response to mechanical stimulusDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cellular response to sorbitolDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
negative regulation of motor neuron apoptotic processDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
regulation of cytokine productionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
response to ischemiaDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
inflammatory responseDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
stress-activated protein kinase signaling cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
negative regulation of hippo signalingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
p38MAPK cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of MAPK cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of protein kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cardiac muscle contractionDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular response to lipopolysaccharideDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular response to sorbitolDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
regulation of autophagyPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
megakaryocyte developmentPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
autophagosome-lysosome fusionPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
vesicle-mediated cholesterol transportPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
positive regulation of autophagosome assemblyPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
protein phosphorylationCasein kinase I isoform alphaHomo sapiens (human)
Golgi organizationCasein kinase I isoform alphaHomo sapiens (human)
cell surface receptor signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform alphaHomo sapiens (human)
viral protein processingCasein kinase I isoform alphaHomo sapiens (human)
cellular response to nutrientCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of Rho protein signal transductionCasein kinase I isoform alphaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processCasein kinase I isoform alphaHomo sapiens (human)
intermediate filament cytoskeleton organizationCasein kinase I isoform alphaHomo sapiens (human)
cell divisionCasein kinase I isoform alphaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayCasein kinase I isoform alphaHomo sapiens (human)
negative regulation of NLRP3 inflammasome complex assemblyCasein kinase I isoform alphaHomo sapiens (human)
positive regulation of TORC1 signalingCasein kinase I isoform alphaHomo sapiens (human)
signal transductionCasein kinase I isoform alphaHomo sapiens (human)
microtubule nucleationCasein kinase I isoform deltaHomo sapiens (human)
Golgi organizationCasein kinase I isoform deltaHomo sapiens (human)
protein localization to Golgi apparatusCasein kinase I isoform deltaHomo sapiens (human)
protein localization to ciliumCasein kinase I isoform deltaHomo sapiens (human)
protein localization to centrosomeCasein kinase I isoform deltaHomo sapiens (human)
non-motile cilium assemblyCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of protein phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
protein phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform deltaHomo sapiens (human)
circadian regulation of gene expressionCasein kinase I isoform deltaHomo sapiens (human)
regulation of circadian rhythmCasein kinase I isoform deltaHomo sapiens (human)
COPII vesicle coatingCasein kinase I isoform deltaHomo sapiens (human)
spindle assemblyCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
midbrain dopaminergic neuron differentiationCasein kinase I isoform deltaHomo sapiens (human)
cellular response to nerve growth factor stimulusCasein kinase I isoform deltaHomo sapiens (human)
positive regulation of non-canonical Wnt signaling pathwayCasein kinase I isoform deltaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform deltaHomo sapiens (human)
signal transductionCasein kinase I isoform deltaHomo sapiens (human)
non-motile cilium assemblyCasein kinase I isoform deltaHomo sapiens (human)
endocytosisCasein kinase I isoform deltaHomo sapiens (human)
phosphorylationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of cytokine productionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
adaptive immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
dendritic cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of acute inflammatory responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
respiratory burst involved in defense responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
endocytosisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
inflammatory responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
G protein-coupled receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of endothelial cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
T cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
negative regulation of triglyceride catabolic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
neutrophil chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
secretory granule localizationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
regulation of cell adhesion mediated by integrinPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of Rac protein signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
natural killer cell chemotaxisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
T cell proliferationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
T cell activationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
mast cell degranulationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of MAP kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
innate immune responsePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
regulation of angiogenesisPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
negative regulation of cardiac muscle contractionPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
platelet aggregationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
cellular response to cAMPPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
neutrophil extravasationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
hepatocyte apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
regulation of calcium ion transmembrane transportPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
negative regulation of fibroblast apoptotic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
cell migrationPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic processPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
MAPK cascadeMAP kinase-activated protein kinase 2Homo sapiens (human)
toll-like receptor signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
protein phosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
leukotriene metabolic processMAP kinase-activated protein kinase 2Homo sapiens (human)
inflammatory responseMAP kinase-activated protein kinase 2Homo sapiens (human)
DNA damage responseMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
response to lipopolysaccharideMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of interleukin-6 productionMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of tumor necrosis factor productionMAP kinase-activated protein kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionMAP kinase-activated protein kinase 2Homo sapiens (human)
response to cytokineMAP kinase-activated protein kinase 2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMAP kinase-activated protein kinase 2Homo sapiens (human)
p38MAPK cascadeMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of mRNA stabilityMAP kinase-activated protein kinase 2Homo sapiens (human)
macropinocytosisMAP kinase-activated protein kinase 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMAP kinase-activated protein kinase 2Homo sapiens (human)
inner ear developmentMAP kinase-activated protein kinase 2Homo sapiens (human)
positive regulation of macrophage cytokine productionMAP kinase-activated protein kinase 2Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMAP kinase-activated protein kinase 2Homo sapiens (human)
regulation of cellular response to heatMAP kinase-activated protein kinase 2Homo sapiens (human)
protein autophosphorylationMAP kinase-activated protein kinase 2Homo sapiens (human)
intracellular signal transductionMAP kinase-activated protein kinase 2Homo sapiens (human)
protein ubiquitinationCyclin-dependent kinase 8Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 8Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 8Homo sapiens (human)
negative regulation of triglyceride metabolic processCyclin-dependent kinase 8Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 8Homo sapiens (human)
translational elongationElongation factor Tu, mitochondrialHomo sapiens (human)
response to ethanolElongation factor Tu, mitochondrialHomo sapiens (human)
mitochondrial translational elongationElongation factor Tu, mitochondrialHomo sapiens (human)
phosphatidylcholine biosynthetic processCholine-phosphate cytidylyltransferase AHomo sapiens (human)
CDP-choline pathwayCholine-phosphate cytidylyltransferase AHomo sapiens (human)
DNA repairCasein kinase I isoform epsilonHomo sapiens (human)
protein phosphorylationCasein kinase I isoform epsilonHomo sapiens (human)
protein localizationCasein kinase I isoform epsilonHomo sapiens (human)
negative regulation of Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
negative regulation of protein bindingCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase I isoform epsilonHomo sapiens (human)
regulation of protein localizationCasein kinase I isoform epsilonHomo sapiens (human)
circadian regulation of gene expressionCasein kinase I isoform epsilonHomo sapiens (human)
regulation of circadian rhythmCasein kinase I isoform epsilonHomo sapiens (human)
circadian behaviorCasein kinase I isoform epsilonHomo sapiens (human)
canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of amyloid-beta formationCasein kinase I isoform epsilonHomo sapiens (human)
cellular response to nerve growth factor stimulusCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of non-canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform epsilonHomo sapiens (human)
endocytosisCasein kinase I isoform epsilonHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform epsilonHomo sapiens (human)
signal transductionCasein kinase I isoform epsilonHomo sapiens (human)
temperature homeostasisVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
response to coldVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
energy derivation by oxidation of organic compoundsVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
epithelial cell differentiationVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenaseVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
negative regulation of fatty acid biosynthetic processVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
negative regulation of fatty acid oxidationVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
regulation of cholesterol metabolic processVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK1Homo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity protein kinase CLK1Homo sapiens (human)
protein phosphorylationDual specificity protein kinase CLK2Homo sapiens (human)
response to ionizing radiationDual specificity protein kinase CLK2Homo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK2Homo sapiens (human)
negative regulation of gluconeogenesisDual specificity protein kinase CLK2Homo sapiens (human)
protein autophosphorylationDual specificity protein kinase CLK2Homo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity protein kinase CLK2Homo sapiens (human)
protein phosphorylationDual specificity protein kinase CLK3Homo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK3Homo sapiens (human)
regulation of systemic arterial blood pressureGlycogen synthase kinase-3 alphaHomo sapiens (human)
cardiac left ventricle morphogenesisGlycogen synthase kinase-3 alphaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
nervous system developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of UDP-glucose catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
Wnt signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
cell migrationGlycogen synthase kinase-3 alphaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to insulin stimulusGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 alphaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of heart contractionGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glucose importGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to lithium ionGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to glucocorticoid stimulusGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
autosome genomic imprintingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of mitophagyGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of amyloid-beta formationGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein targeting to mitochondrionGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen synthase activity, transferring glucose-1-phosphateGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
ER overload responseGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of apoptotic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
epithelial to mesenchymal transitionGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell-matrix adhesionGlycogen synthase kinase-3 betaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrion organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 betaHomo sapiens (human)
hippocampus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
establishment of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
maintenance of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of cell migrationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axon extensionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of phosphoprotein phosphatase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule-based processGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 betaHomo sapiens (human)
regulation of circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of GTPase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of osteoblast differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cilium assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein autophosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of dendrite morphogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axonogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeGlycogen synthase kinase-3 betaHomo sapiens (human)
superior temporal gyrus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to retinoic acidGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 betaHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule anchoring at centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of cellular response to heatGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein localization to nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of long-term synaptic potentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein acetylationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to ciliumGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of dopaminergic neuron differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to amyloid-betaGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complex disassemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of mesenchymal stem cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
DNA repairCyclin-dependent kinase 7Homo sapiens (human)
transcription by RNA polymerase IICyclin-dependent kinase 7Homo sapiens (human)
transcription initiation at RNA polymerase II promoterCyclin-dependent kinase 7Homo sapiens (human)
snRNA transcription by RNA polymerase IICyclin-dependent kinase 7Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 7Homo sapiens (human)
protein stabilizationCyclin-dependent kinase 7Homo sapiens (human)
cell divisionCyclin-dependent kinase 7Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 7Homo sapiens (human)
regulation of G1/S transition of mitotic cell cycleCyclin-dependent kinase 7Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 7Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 9Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 9Homo sapiens (human)
DNA repairCyclin-dependent kinase 9Homo sapiens (human)
regulation of DNA repairCyclin-dependent kinase 9Homo sapiens (human)
transcription by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
transcription initiation at RNA polymerase II promoterCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
cell population proliferationCyclin-dependent kinase 9Homo sapiens (human)
replication fork processingCyclin-dependent kinase 9Homo sapiens (human)
regulation of mRNA 3'-end processingCyclin-dependent kinase 9Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
positive regulation by host of viral transcriptionCyclin-dependent kinase 9Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 9Homo sapiens (human)
regulation of muscle cell differentiationCyclin-dependent kinase 9Homo sapiens (human)
nucleus localizationCyclin-dependent kinase 9Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 9Homo sapiens (human)
cellular response to cytokine stimulusCyclin-dependent kinase 9Homo sapiens (human)
negative regulation of protein localization to chromatinCyclin-dependent kinase 9Homo sapiens (human)
positive regulation of protein localization to chromatinCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation-coupled chromatin remodelingCyclin-dependent kinase 9Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 9Homo sapiens (human)
exocytosisRas-related protein Rab-27AHomo sapiens (human)
blood coagulationRas-related protein Rab-27AHomo sapiens (human)
protein secretionRas-related protein Rab-27AHomo sapiens (human)
positive regulation of gene expressionRas-related protein Rab-27AHomo sapiens (human)
antigen processing and presentationRas-related protein Rab-27AHomo sapiens (human)
melanocyte differentiationRas-related protein Rab-27AHomo sapiens (human)
melanosome localizationRas-related protein Rab-27AHomo sapiens (human)
melanosome transportRas-related protein Rab-27AHomo sapiens (human)
multivesicular body organizationRas-related protein Rab-27AHomo sapiens (human)
cytotoxic T cell degranulationRas-related protein Rab-27AHomo sapiens (human)
natural killer cell degranulationRas-related protein Rab-27AHomo sapiens (human)
positive regulation of exocytosisRas-related protein Rab-27AHomo sapiens (human)
synaptic vesicle transportRas-related protein Rab-27AHomo sapiens (human)
positive regulation of phagocytosisRas-related protein Rab-27AHomo sapiens (human)
multivesicular body sorting pathwayRas-related protein Rab-27AHomo sapiens (human)
complement-dependent cytotoxicityRas-related protein Rab-27AHomo sapiens (human)
positive regulation of regulated secretory pathwayRas-related protein Rab-27AHomo sapiens (human)
positive regulation of reactive oxygen species biosynthetic processRas-related protein Rab-27AHomo sapiens (human)
positive regulation of constitutive secretory pathwayRas-related protein Rab-27AHomo sapiens (human)
exosomal secretionRas-related protein Rab-27AHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase BlkHomo sapiens (human)
positive regulation of insulin secretionTyrosine-protein kinase BlkHomo sapiens (human)
positive regulation of protein bindingTyrosine-protein kinase BlkHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase BlkHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase BlkHomo sapiens (human)
innate immune responseTyrosine-protein kinase BlkHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase BlkHomo sapiens (human)
cell differentiationTyrosine-protein kinase BlkHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase BlkHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein autophosphorylationInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
regulation of cytokine-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
JNK cascadeInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of type I interferon productionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
response to lipopolysaccharideInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
toll-like receptor 2 signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
toll-like receptor 9 signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
cellular response to heatInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
interleukin-33-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein autophosphorylationInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
type I interferon-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
interleukin-1-mediated signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
response to interleukin-1Interleukin-1 receptor-associated kinase 1Homo sapiens (human)
cellular response to hypoxiaInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
toll-like receptor 4 signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
positive regulation of MAP kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
cellular response to lipopolysaccharideInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
intracellular signal transductionInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
Toll signaling pathwayInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
innate immune responseInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
skeletal system developmentRibosomal protein S6 kinase alpha-3Homo sapiens (human)
toll-like receptor signaling pathwayRibosomal protein S6 kinase alpha-3Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-3Homo sapiens (human)
chemical synaptic transmissionRibosomal protein S6 kinase alpha-3Homo sapiens (human)
central nervous system developmentRibosomal protein S6 kinase alpha-3Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-3Homo sapiens (human)
positive regulation of cell growthRibosomal protein S6 kinase alpha-3Homo sapiens (human)
response to lipopolysaccharideRibosomal protein S6 kinase alpha-3Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-3Homo sapiens (human)
negative regulation of apoptotic processRibosomal protein S6 kinase alpha-3Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRibosomal protein S6 kinase alpha-3Homo sapiens (human)
regulation of translation in response to stressRibosomal protein S6 kinase alpha-3Homo sapiens (human)
positive regulation of cell differentiationRibosomal protein S6 kinase alpha-3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein phosphorylationCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
phosphatidylinositol biosynthetic processCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
apoptotic processCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
cell adhesionCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
signal transductionCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
mesoderm developmentCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
intracellular signal transductionCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
protein autophosphorylationCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
B cell receptor signaling pathwayCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
adaptive immune responseCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
angiogenesiscAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
endothelial cell proliferationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
cell adhesioncAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
peptidyl-serine phosphorylationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
myeloid cell differentiationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
regulation of cell adhesioncAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
regulation of cell migrationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
cell-substrate adhesioncAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
endothelial cell migrationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein autophosphorylationcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
epithelial tube morphogenesiscAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
kidney morphogenesiscAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
regulation of epithelial cell differentiation involved in kidney developmentcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein kinase A signalingcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase Nek2Homo sapiens (human)
blastocyst developmentSerine/threonine-protein kinase Nek2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek2Homo sapiens (human)
chromosome segregationSerine/threonine-protein kinase Nek2Homo sapiens (human)
regulation of mitotic nuclear divisionSerine/threonine-protein kinase Nek2Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseSerine/threonine-protein kinase Nek2Homo sapiens (human)
regulation of mitotic centrosome separationSerine/threonine-protein kinase Nek2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase Nek2Homo sapiens (human)
spindle assemblySerine/threonine-protein kinase Nek2Homo sapiens (human)
centrosome separationSerine/threonine-protein kinase Nek2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek2Homo sapiens (human)
meiotic cell cycleSerine/threonine-protein kinase Nek2Homo sapiens (human)
positive regulation of telomerase activitySerine/threonine-protein kinase Nek2Homo sapiens (human)
regulation of attachment of spindle microtubules to kinetochoreSerine/threonine-protein kinase Nek2Homo sapiens (human)
mitotic spindle assemblySerine/threonine-protein kinase Nek2Homo sapiens (human)
negative regulation of centriole-centriole cohesionSerine/threonine-protein kinase Nek2Homo sapiens (human)
positive regulation of telomere cappingSerine/threonine-protein kinase Nek2Homo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase Nek3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek3Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase Nek3Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase Nek3Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek3Homo sapiens (human)
regulation of tubulin deacetylationSerine/threonine-protein kinase Nek3Homo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase Nek4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek4Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase Nek4Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase Nek4Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek4Homo sapiens (human)
regulation of cellular senescenceSerine/threonine-protein kinase Nek4Homo sapiens (human)
adaptive immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of dendritic cell cytokine productionTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
enzyme-linked receptor protein signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
tyrosine phosphorylation of STAT proteinTyrosine-protein kinase JAK3Homo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase JAK3Homo sapiens (human)
B cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-10 productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of interleukin-12 productionTyrosine-protein kinase JAK3Homo sapiens (human)
intracellular signal transductionTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-15-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-4-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-2-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
interleukin-9-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
T cell homeostasisTyrosine-protein kinase JAK3Homo sapiens (human)
innate immune responseTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of FasL productionTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T-helper 1 cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of T cell activationTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
regulation of T cell apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
negative regulation of thymocyte apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-2Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-4Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-15Tyrosine-protein kinase JAK3Homo sapiens (human)
response to interleukin-9Tyrosine-protein kinase JAK3Homo sapiens (human)
regulation of apoptotic processTyrosine-protein kinase JAK3Homo sapiens (human)
cell differentiationTyrosine-protein kinase JAK3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATTyrosine-protein kinase JAK3Homo sapiens (human)
cytokine-mediated signaling pathwayTyrosine-protein kinase JAK3Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
osteoblast differentiationDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of protein phosphorylationDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
response to ischemiaDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
apoptotic processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
response to xenobiotic stimulusDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
ovulation cycle processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
stress-activated protein kinase signaling cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of prostaglandin secretionDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
p38MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
signal transduction in response to DNA damageDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of apoptotic processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
regulation of cell cycleDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cardiac muscle contractionDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
bone developmentDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cellular response to sorbitolDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
negative regulation of cold-induced thermogenesisDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
regulation of signal transduction by p53 class mediatorDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
establishment of protein localizationSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic sister chromatid segregationSerine/threonine-protein kinase PLK1Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IISerine/threonine-protein kinase PLK1Homo sapiens (human)
establishment of mitotic spindle orientationSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic cytokinesisSerine/threonine-protein kinase PLK1Homo sapiens (human)
microtubule bundle formationSerine/threonine-protein kinase PLK1Homo sapiens (human)
double-strand break repairSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic spindle organizationSerine/threonine-protein kinase PLK1Homo sapiens (human)
sister chromatid cohesionSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic chromosome condensationSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic nuclear membrane disassemblySerine/threonine-protein kinase PLK1Homo sapiens (human)
metaphase/anaphase transition of mitotic cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic spindle assembly checkpoint signalingSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase PLK1Homo sapiens (human)
centrosome cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationSerine/threonine-protein kinase PLK1Homo sapiens (human)
female meiosis chromosome segregationSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein ubiquitinationSerine/threonine-protein kinase PLK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein destabilizationSerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of cytokinesisSerine/threonine-protein kinase PLK1Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of protein bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
homologous chromosome segregationSerine/threonine-protein kinase PLK1Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of proteolysisSerine/threonine-protein kinase PLK1Homo sapiens (human)
Golgi inheritanceSerine/threonine-protein kinase PLK1Homo sapiens (human)
nuclear membrane disassemblySerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of ubiquitin-protein transferase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of cell cycleSerine/threonine-protein kinase PLK1Homo sapiens (human)
synaptonemal complex disassemblySerine/threonine-protein kinase PLK1Homo sapiens (human)
protein localization to chromatinSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein localization to nuclear envelopeSerine/threonine-protein kinase PLK1Homo sapiens (human)
double-strand break repair via alternative nonhomologous end joiningSerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of protein localization to nucleusSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of mitotic spindle assemblySerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of mitotic cell cycle phase transitionSerine/threonine-protein kinase PLK1Homo sapiens (human)
positive regulation of ubiquitin protein ligase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of protein localization to cell cortexSerine/threonine-protein kinase PLK1Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic processSerine/threonine-protein kinase PLK1Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationSerine/threonine-protein kinase PLK1Homo sapiens (human)
apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
defense response to tumor cellDeath-associated protein kinase 1Homo sapiens (human)
regulation of response to tumor cellDeath-associated protein kinase 1Homo sapiens (human)
protein phosphorylationDeath-associated protein kinase 1Homo sapiens (human)
apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsDeath-associated protein kinase 1Homo sapiens (human)
regulation of autophagyDeath-associated protein kinase 1Homo sapiens (human)
positive regulation of autophagyDeath-associated protein kinase 1Homo sapiens (human)
negative regulation of translationDeath-associated protein kinase 1Homo sapiens (human)
intracellular signal transductionDeath-associated protein kinase 1Homo sapiens (human)
regulation of apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
positive regulation of apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
negative regulation of apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processDeath-associated protein kinase 1Homo sapiens (human)
protein autophosphorylationDeath-associated protein kinase 1Homo sapiens (human)
cellular response to type II interferonDeath-associated protein kinase 1Homo sapiens (human)
cellular response to hydroperoxideDeath-associated protein kinase 1Homo sapiens (human)
apoptotic signaling pathwayDeath-associated protein kinase 1Homo sapiens (human)
positive regulation of autophagic cell deathDeath-associated protein kinase 1Homo sapiens (human)
regulation of NMDA receptor activityDeath-associated protein kinase 1Homo sapiens (human)
protein phosphorylationLIM domain kinase 1Homo sapiens (human)
signal transductionLIM domain kinase 1Homo sapiens (human)
Rho protein signal transductionLIM domain kinase 1Homo sapiens (human)
nervous system developmentLIM domain kinase 1Homo sapiens (human)
positive regulation of actin filament bundle assemblyLIM domain kinase 1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisLIM domain kinase 1Homo sapiens (human)
stress fiber assemblyLIM domain kinase 1Homo sapiens (human)
positive regulation of axon extensionLIM domain kinase 1Homo sapiens (human)
axon extensionLIM domain kinase 1Homo sapiens (human)
negative regulation of ubiquitin-protein transferase activityLIM domain kinase 1Homo sapiens (human)
positive regulation of stress fiber assemblyLIM domain kinase 1Homo sapiens (human)
actin cytoskeleton organizationLIM domain kinase 1Homo sapiens (human)
positive regulation of protein phosphorylationLIM domain kinase 2Homo sapiens (human)
protein phosphorylationLIM domain kinase 2Homo sapiens (human)
spermatogenesisLIM domain kinase 2Homo sapiens (human)
phosphorylationLIM domain kinase 2Homo sapiens (human)
astral microtubule organizationLIM domain kinase 2Homo sapiens (human)
establishment of vesicle localizationLIM domain kinase 2Homo sapiens (human)
head developmentLIM domain kinase 2Homo sapiens (human)
cornea development in camera-type eyeLIM domain kinase 2Homo sapiens (human)
positive regulation of protein localization to nucleusLIM domain kinase 2Homo sapiens (human)
negative regulation of cilium assemblyLIM domain kinase 2Homo sapiens (human)
actin cytoskeleton organizationLIM domain kinase 2Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 12Homo sapiens (human)
signal transductionMitogen-activated protein kinase 12Homo sapiens (human)
muscle organ developmentMitogen-activated protein kinase 12Homo sapiens (human)
positive regulation of peptidase activityMitogen-activated protein kinase 12Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 12Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 12Homo sapiens (human)
myoblast differentiationMitogen-activated protein kinase 12Homo sapiens (human)
negative regulation of cell cycleMitogen-activated protein kinase 12Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 12Homo sapiens (human)
regulation of cell cycleMitogen-activated protein kinase 12Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 12Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 10Homo sapiens (human)
signal transductionMitogen-activated protein kinase 10Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 10Homo sapiens (human)
response to light stimulusMitogen-activated protein kinase 10Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 10Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 10Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 10Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 10Homo sapiens (human)
regulation of glycolytic process5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
spermatogenesis5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
positive regulation of gene expression5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
positive regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
import into nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
regulation of catalytic activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
lipid droplet disassembly5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
chromatin remodeling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
autophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
lipid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of autophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
response to muscle activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
Wnt signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of macroautophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of macroautophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of TOR signaling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to oxidative stress5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to glucose starvation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
glucose homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of circadian rhythm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of glycolytic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
rhythmic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
fatty acid homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of stress granule assembly5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of microtubule cytoskeleton organization5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to calcium ion5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to glucose stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to prostaglandin E stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to xenobiotic stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
energy homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of protein localization5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of hepatocyte apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of TORC1 signaling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of tubulin deacetylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein localization to lipid droplet5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of peptidyl-lysine acetylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
angiogenesisEphrin type-B receptor 3Homo sapiens (human)
urogenital system developmentEphrin type-B receptor 3Homo sapiens (human)
axon guidanceEphrin type-B receptor 3Homo sapiens (human)
axonal fasciculationEphrin type-B receptor 3Homo sapiens (human)
cell migrationEphrin type-B receptor 3Homo sapiens (human)
central nervous system projection neuron axonogenesisEphrin type-B receptor 3Homo sapiens (human)
corpus callosum developmentEphrin type-B receptor 3Homo sapiens (human)
regulation of cell-cell adhesionEphrin type-B receptor 3Homo sapiens (human)
retinal ganglion cell axon guidanceEphrin type-B receptor 3Homo sapiens (human)
substrate adhesion-dependent cell spreadingEphrin type-B receptor 3Homo sapiens (human)
regulation of GTPase activityEphrin type-B receptor 3Homo sapiens (human)
protein autophosphorylationEphrin type-B receptor 3Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 3Homo sapiens (human)
thymus developmentEphrin type-B receptor 3Homo sapiens (human)
digestive tract morphogenesisEphrin type-B receptor 3Homo sapiens (human)
regulation of axonogenesisEphrin type-B receptor 3Homo sapiens (human)
positive regulation of synapse assemblyEphrin type-B receptor 3Homo sapiens (human)
roof of mouth developmentEphrin type-B receptor 3Homo sapiens (human)
dendritic spine developmentEphrin type-B receptor 3Homo sapiens (human)
dendritic spine morphogenesisEphrin type-B receptor 3Homo sapiens (human)
protein phosphorylationEphrin type-B receptor 3Homo sapiens (human)
axon guidanceEphrin type-A receptor 5Homo sapiens (human)
cAMP-mediated signalingEphrin type-A receptor 5Homo sapiens (human)
hippocampus developmentEphrin type-A receptor 5Homo sapiens (human)
positive regulation of CREB transcription factor activityEphrin type-A receptor 5Homo sapiens (human)
regulation of actin cytoskeleton organizationEphrin type-A receptor 5Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 5Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 5Homo sapiens (human)
neuron developmentEphrin type-A receptor 5Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusEphrin type-A receptor 5Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 5Homo sapiens (human)
angiogenesisEphrin type-B receptor 4Homo sapiens (human)
cell migration involved in sprouting angiogenesisEphrin type-B receptor 4Homo sapiens (human)
heart morphogenesisEphrin type-B receptor 4Homo sapiens (human)
cell adhesionEphrin type-B receptor 4Homo sapiens (human)
protein autophosphorylationEphrin type-B receptor 4Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 4Homo sapiens (human)
multicellular organism developmentEphrin type-B receptor 4Homo sapiens (human)
positive regulation of kinase activityEphrin type-B receptor 4Homo sapiens (human)
angiogenesisEphrin type-B receptor 1Homo sapiens (human)
immunological synapse formationEphrin type-B receptor 1Homo sapiens (human)
axon guidanceEphrin type-B receptor 1Homo sapiens (human)
skeletal muscle satellite cell activationEphrin type-B receptor 1Homo sapiens (human)
optic nerve morphogenesisEphrin type-B receptor 1Homo sapiens (human)
hindbrain tangential cell migrationEphrin type-B receptor 1Homo sapiens (human)
central nervous system projection neuron axonogenesisEphrin type-B receptor 1Homo sapiens (human)
neurogenesisEphrin type-B receptor 1Homo sapiens (human)
establishment of cell polarityEphrin type-B receptor 1Homo sapiens (human)
retinal ganglion cell axon guidanceEphrin type-B receptor 1Homo sapiens (human)
cell-substrate adhesionEphrin type-B receptor 1Homo sapiens (human)
regulation of JNK cascadeEphrin type-B receptor 1Homo sapiens (human)
protein autophosphorylationEphrin type-B receptor 1Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-B receptor 1Homo sapiens (human)
camera-type eye morphogenesisEphrin type-B receptor 1Homo sapiens (human)
modulation of chemical synaptic transmissionEphrin type-B receptor 1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painEphrin type-B receptor 1Homo sapiens (human)
positive regulation of synapse assemblyEphrin type-B receptor 1Homo sapiens (human)
cell chemotaxisEphrin type-B receptor 1Homo sapiens (human)
dendritic spine developmentEphrin type-B receptor 1Homo sapiens (human)
dendritic spine morphogenesisEphrin type-B receptor 1Homo sapiens (human)
neural precursor cell proliferationEphrin type-B receptor 1Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeEphrin type-B receptor 1Homo sapiens (human)
negative regulation of skeletal muscle satellite cell proliferationEphrin type-B receptor 1Homo sapiens (human)
negative regulation of satellite cell differentiationEphrin type-B receptor 1Homo sapiens (human)
protein phosphorylationEphrin type-B receptor 1Homo sapiens (human)
negative regulation of cellular response to hypoxiaEphrin type-A receptor 4Homo sapiens (human)
cell adhesionEphrin type-A receptor 4Homo sapiens (human)
negative regulation of cell adhesionEphrin type-A receptor 4Homo sapiens (human)
adult walking behaviorEphrin type-A receptor 4Homo sapiens (human)
motor neuron axon guidanceEphrin type-A receptor 4Homo sapiens (human)
positive regulation of cell population proliferationEphrin type-A receptor 4Homo sapiens (human)
glial cell migrationEphrin type-A receptor 4Homo sapiens (human)
negative regulation of epithelial to mesenchymal transitionEphrin type-A receptor 4Homo sapiens (human)
negative regulation of neuron projection developmentEphrin type-A receptor 4Homo sapiens (human)
negative regulation of translationEphrin type-A receptor 4Homo sapiens (human)
peptidyl-tyrosine phosphorylationEphrin type-A receptor 4Homo sapiens (human)
corticospinal tract morphogenesisEphrin type-A receptor 4Homo sapiens (human)
positive regulation of cell migrationEphrin type-A receptor 4Homo sapiens (human)
negative regulation of cell migrationEphrin type-A receptor 4Homo sapiens (human)
adherens junction organizationEphrin type-A receptor 4Homo sapiens (human)
regulation of GTPase activityEphrin type-A receptor 4Homo sapiens (human)
positive regulation of cell adhesionEphrin type-A receptor 4Homo sapiens (human)
protein autophosphorylationEphrin type-A receptor 4Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 4Homo sapiens (human)
negative regulation of axon regenerationEphrin type-A receptor 4Homo sapiens (human)
regulation of astrocyte differentiationEphrin type-A receptor 4Homo sapiens (human)
regulation of axonogenesisEphrin type-A receptor 4Homo sapiens (human)
positive regulation of dendrite morphogenesisEphrin type-A receptor 4Homo sapiens (human)
protein stabilizationEphrin type-A receptor 4Homo sapiens (human)
regulation of dendritic spine morphogenesisEphrin type-A receptor 4Homo sapiens (human)
positive regulation of protein tyrosine kinase activityEphrin type-A receptor 4Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeEphrin type-A receptor 4Homo sapiens (human)
nephric duct morphogenesisEphrin type-A receptor 4Homo sapiens (human)
cochlea developmentEphrin type-A receptor 4Homo sapiens (human)
fasciculation of sensory neuron axonEphrin type-A receptor 4Homo sapiens (human)
fasciculation of motor neuron axonEphrin type-A receptor 4Homo sapiens (human)
neuron projection guidanceEphrin type-A receptor 4Homo sapiens (human)
synapse pruningEphrin type-A receptor 4Homo sapiens (human)
neuron projection fasciculationEphrin type-A receptor 4Homo sapiens (human)
negative regulation of long-term synaptic potentiationEphrin type-A receptor 4Homo sapiens (human)
positive regulation of amyloid-beta formationEphrin type-A receptor 4Homo sapiens (human)
positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic processEphrin type-A receptor 4Homo sapiens (human)
negative regulation of proteolysis involved in protein catabolic processEphrin type-A receptor 4Homo sapiens (human)
cellular response to amyloid-betaEphrin type-A receptor 4Homo sapiens (human)
regulation of modification of synaptic structureEphrin type-A receptor 4Homo sapiens (human)
regulation of synapse pruningEphrin type-A receptor 4Homo sapiens (human)
positive regulation of Rho guanyl-nucleotide exchange factor activityEphrin type-A receptor 4Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 4Homo sapiens (human)
axon guidanceEphrin type-A receptor 4Homo sapiens (human)
ADP biosynthetic processAdenylate kinase 2, mitochondrialHomo sapiens (human)
nucleobase-containing small molecule interconversionAdenylate kinase 2, mitochondrialHomo sapiens (human)
AMP metabolic processAdenylate kinase 2, mitochondrialHomo sapiens (human)
ATP metabolic processAdenylate kinase 2, mitochondrialHomo sapiens (human)
nucleoside monophosphate phosphorylationAdenylate kinase 2, mitochondrialHomo sapiens (human)
purine ribonucleoside salvageAdenosine kinaseHomo sapiens (human)
dATP biosynthetic processAdenosine kinaseHomo sapiens (human)
ribonucleoside monophosphate biosynthetic processAdenosine kinaseHomo sapiens (human)
GMP salvageAdenosine kinaseHomo sapiens (human)
AMP salvageAdenosine kinaseHomo sapiens (human)
dAMP salvageAdenosine kinaseHomo sapiens (human)
purine nucleobase metabolic processAdenosine kinaseHomo sapiens (human)
signal transductionHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
intracellular signal transductionHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
regulation of sodium ion transportSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase SIK1Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase SIK1Homo sapiens (human)
regulation of myotube differentiationSerine/threonine-protein kinase SIK1Homo sapiens (human)
negative regulation of triglyceride biosynthetic processSerine/threonine-protein kinase SIK1Homo sapiens (human)
negative regulation of CREB transcription factor activitySerine/threonine-protein kinase SIK1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase SIK1Homo sapiens (human)
entrainment of circadian clock by photoperiodSerine/threonine-protein kinase SIK1Homo sapiens (human)
anoikisSerine/threonine-protein kinase SIK1Homo sapiens (human)
regulation of cell differentiationSerine/threonine-protein kinase SIK1Homo sapiens (human)
negative regulation of gluconeogenesisSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase SIK1Homo sapiens (human)
rhythmic processSerine/threonine-protein kinase SIK1Homo sapiens (human)
cardiac muscle cell differentiationSerine/threonine-protein kinase SIK1Homo sapiens (human)
positive regulation of anoikisSerine/threonine-protein kinase SIK1Homo sapiens (human)
morphogenesis of an epitheliumReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
Golgi to plasma membrane transportRas-related protein Rab-10Homo sapiens (human)
axonogenesisRas-related protein Rab-10Homo sapiens (human)
vesicle-mediated transportRas-related protein Rab-10Homo sapiens (human)
endosomal transportRas-related protein Rab-10Homo sapiens (human)
antigen processing and presentationRas-related protein Rab-10Homo sapiens (human)
polarized epithelial cell differentiationRas-related protein Rab-10Homo sapiens (human)
cellular response to insulin stimulusRas-related protein Rab-10Homo sapiens (human)
Golgi to plasma membrane protein transportRas-related protein Rab-10Homo sapiens (human)
regulated exocytosisRas-related protein Rab-10Homo sapiens (human)
establishment of neuroblast polarityRas-related protein Rab-10Homo sapiens (human)
endoplasmic reticulum tubular network organizationRas-related protein Rab-10Homo sapiens (human)
protein localization to plasma membraneRas-related protein Rab-10Homo sapiens (human)
establishment of protein localization to membraneRas-related protein Rab-10Homo sapiens (human)
establishment of protein localization to endoplasmic reticulum membraneRas-related protein Rab-10Homo sapiens (human)
cell-cell adhesionRas-related protein Rab-10Homo sapiens (human)
protein localization to basolateral plasma membraneRas-related protein Rab-10Homo sapiens (human)
exocytosisRas-related protein Rab-10Homo sapiens (human)
protein secretionRas-related protein Rab-10Homo sapiens (human)
establishment or maintenance of cell polarityActin-related protein 3Homo sapiens (human)
asymmetric cell divisionActin-related protein 3Homo sapiens (human)
positive regulation of lamellipodium assemblyActin-related protein 3Homo sapiens (human)
meiotic chromosome movement towards spindle poleActin-related protein 3Homo sapiens (human)
meiotic cytokinesisActin-related protein 3Homo sapiens (human)
Arp2/3 complex-mediated actin nucleationActin-related protein 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIActin-related protein 3Homo sapiens (human)
spindle localizationActin-related protein 3Homo sapiens (human)
cilium assemblyActin-related protein 3Homo sapiens (human)
actin polymerization-dependent cell motilityActin-related protein 3Homo sapiens (human)
cellular response to type II interferonActin-related protein 3Homo sapiens (human)
regulation of double-strand break repair via nonhomologous end joiningActin-related protein 2Homo sapiens (human)
cilium assemblyActin-related protein 2Homo sapiens (human)
establishment or maintenance of cell polarityActin-related protein 2Homo sapiens (human)
asymmetric cell divisionActin-related protein 2Homo sapiens (human)
positive regulation of lamellipodium assemblyActin-related protein 2Homo sapiens (human)
meiotic chromosome movement towards spindle poleActin-related protein 2Homo sapiens (human)
cytosolic transportActin-related protein 2Homo sapiens (human)
meiotic cytokinesisActin-related protein 2Homo sapiens (human)
Arp2/3 complex-mediated actin nucleationActin-related protein 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIActin-related protein 2Homo sapiens (human)
spindle localizationActin-related protein 2Homo sapiens (human)
cellular response to type II interferonActin-related protein 2Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationActin-related protein 2Homo sapiens (human)
ribosomal large subunit export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
ribosomal small subunit export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
mitotic sister chromatid segregationGTP-binding nuclear protein RanHomo sapiens (human)
mitotic cell cycleGTP-binding nuclear protein RanHomo sapiens (human)
DNA metabolic processGTP-binding nuclear protein RanHomo sapiens (human)
protein import into nucleusGTP-binding nuclear protein RanHomo sapiens (human)
protein export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
mitotic spindle organizationGTP-binding nuclear protein RanHomo sapiens (human)
spermatid developmentGTP-binding nuclear protein RanHomo sapiens (human)
viral processGTP-binding nuclear protein RanHomo sapiens (human)
hippocampus developmentGTP-binding nuclear protein RanHomo sapiens (human)
actin cytoskeleton organizationGTP-binding nuclear protein RanHomo sapiens (human)
positive regulation of protein bindingGTP-binding nuclear protein RanHomo sapiens (human)
pre-miRNA export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
positive regulation of protein import into nucleusGTP-binding nuclear protein RanHomo sapiens (human)
GTP metabolic processGTP-binding nuclear protein RanHomo sapiens (human)
cell divisionGTP-binding nuclear protein RanHomo sapiens (human)
snRNA import into nucleusGTP-binding nuclear protein RanHomo sapiens (human)
cellular response to mineralocorticoid stimulusGTP-binding nuclear protein RanHomo sapiens (human)
protein localization to nucleolusGTP-binding nuclear protein RanHomo sapiens (human)
ribosomal subunit export from nucleusGTP-binding nuclear protein RanHomo sapiens (human)
double-strand break repairCasein kinase II subunit alphaHomo sapiens (human)
protein phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
DNA damage responseCasein kinase II subunit alphaHomo sapiens (human)
signal transductionCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell population proliferationCasein kinase II subunit alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of translationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell growthCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
rhythmic processCasein kinase II subunit alphaHomo sapiens (human)
protein stabilizationCasein kinase II subunit alphaHomo sapiens (human)
chaperone-mediated protein foldingCasein kinase II subunit alphaHomo sapiens (human)
symbiont-mediated disruption of host cell PML bodyCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of aggrephagyCasein kinase II subunit alphaHomo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
regulation of cell cycleCasein kinase II subunit alphaHomo sapiens (human)
cell surface receptor signaling pathwayPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
regulation of autophagyPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
autophagosome-lysosome fusionPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
positive regulation of autophagosome assemblyPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
spliceosomal complex assemblySRSF protein kinase 2Homo sapiens (human)
angiogenesisSRSF protein kinase 2Homo sapiens (human)
protein phosphorylationSRSF protein kinase 2Homo sapiens (human)
positive regulation of cell population proliferationSRSF protein kinase 2Homo sapiens (human)
RNA splicingSRSF protein kinase 2Homo sapiens (human)
positive regulation of gene expressionSRSF protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationSRSF protein kinase 2Homo sapiens (human)
cell differentiationSRSF protein kinase 2Homo sapiens (human)
nuclear speck organizationSRSF protein kinase 2Homo sapiens (human)
intracellular signal transductionSRSF protein kinase 2Homo sapiens (human)
positive regulation of neuron apoptotic processSRSF protein kinase 2Homo sapiens (human)
positive regulation of viral genome replicationSRSF protein kinase 2Homo sapiens (human)
negative regulation of viral genome replicationSRSF protein kinase 2Homo sapiens (human)
innate immune responseSRSF protein kinase 2Homo sapiens (human)
positive regulation of cell cycleSRSF protein kinase 2Homo sapiens (human)
regulation of mRNA splicing, via spliceosomeSRSF protein kinase 2Homo sapiens (human)
R-loop processingSRSF protein kinase 2Homo sapiens (human)
regulation of mRNA processingSRSF protein kinase 2Homo sapiens (human)
protein phosphorylationCasein kinase I isoform gamma-2Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform gamma-2Homo sapiens (human)
sphingolipid biosynthetic processCasein kinase I isoform gamma-2Homo sapiens (human)
signal transductionCasein kinase I isoform gamma-2Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform gamma-2Homo sapiens (human)
endocytosisCasein kinase I isoform gamma-2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform gamma-2Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
apoptotic processMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
DNA damage responseCyclin-dependent kinase 3Homo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 3Homo sapiens (human)
cell population proliferationCyclin-dependent kinase 3Homo sapiens (human)
G0 to G1 transitionCyclin-dependent kinase 3Homo sapiens (human)
negative regulation of Notch signaling pathwayCyclin-dependent kinase 3Homo sapiens (human)
cell divisionCyclin-dependent kinase 3Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 3Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 3Homo sapiens (human)
signal transductionCyclin-dependent kinase 3Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 3Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 3Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase-like 1Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase-like 1Homo sapiens (human)
regulation of cilium assemblyCyclin-dependent kinase-like 1Homo sapiens (human)
G1/S transition of mitotic cell cycleCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICyclin-dependent kinase 6Homo sapiens (human)
positive regulation of cell-matrix adhesionCyclin-dependent kinase 6Homo sapiens (human)
type B pancreatic cell developmentCyclin-dependent kinase 6Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 6Homo sapiens (human)
Notch signaling pathwayCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cell population proliferationCyclin-dependent kinase 6Homo sapiens (human)
response to virusCyclin-dependent kinase 6Homo sapiens (human)
regulation of gene expressionCyclin-dependent kinase 6Homo sapiens (human)
positive regulation of gene expressionCyclin-dependent kinase 6Homo sapiens (human)
astrocyte developmentCyclin-dependent kinase 6Homo sapiens (human)
dentate gyrus developmentCyclin-dependent kinase 6Homo sapiens (human)
lateral ventricle developmentCyclin-dependent kinase 6Homo sapiens (human)
T cell differentiation in thymusCyclin-dependent kinase 6Homo sapiens (human)
gliogenesisCyclin-dependent kinase 6Homo sapiens (human)
cell dedifferentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of myeloid cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
regulation of erythrocyte differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of monocyte differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of osteoblast differentiationCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cell cycleCyclin-dependent kinase 6Homo sapiens (human)
positive regulation of fibroblast proliferationCyclin-dependent kinase 6Homo sapiens (human)
generation of neuronsCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of epithelial cell proliferationCyclin-dependent kinase 6Homo sapiens (human)
cell divisionCyclin-dependent kinase 6Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 6Homo sapiens (human)
hematopoietic stem cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
regulation of hematopoietic stem cell differentiationCyclin-dependent kinase 6Homo sapiens (human)
regulation of cell motilityCyclin-dependent kinase 6Homo sapiens (human)
negative regulation of cellular senescenceCyclin-dependent kinase 6Homo sapiens (human)
regulation of G2/M transition of mitotic cell cycleCyclin-dependent kinase 6Homo sapiens (human)
response to organic substanceCyclin-dependent kinase 6Homo sapiens (human)
signal transductionCyclin-dependent kinase 6Homo sapiens (human)
microtubule cytoskeleton organizationCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron migrationCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic transmission, dopaminergicCyclin-dependent-like kinase 5 Homo sapiens (human)
protein phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
intracellular protein transportCyclin-dependent-like kinase 5 Homo sapiens (human)
cell-matrix adhesionCyclin-dependent-like kinase 5 Homo sapiens (human)
chemical synaptic transmissionCyclin-dependent-like kinase 5 Homo sapiens (human)
synapse assemblyCyclin-dependent-like kinase 5 Homo sapiens (human)
skeletal muscle tissue developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
motor neuron axon guidanceCyclin-dependent-like kinase 5 Homo sapiens (human)
visual learningCyclin-dependent-like kinase 5 Homo sapiens (human)
Schwann cell developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle exocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of macroautophagyCyclin-dependent-like kinase 5 Homo sapiens (human)
phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
peptidyl-serine phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
peptidyl-threonine phosphorylationCyclin-dependent-like kinase 5 Homo sapiens (human)
sensory perception of painCyclin-dependent-like kinase 5 Homo sapiens (human)
cerebellar cortex formationCyclin-dependent-like kinase 5 Homo sapiens (human)
hippocampus developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
layer formation in cerebral cortexCyclin-dependent-like kinase 5 Homo sapiens (human)
central nervous system neuron developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
corpus callosum developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron differentiationCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of cell migrationCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of axon extensionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron projection developmentCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of protein ubiquitinationCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of synaptic plasticityCyclin-dependent-like kinase 5 Homo sapiens (human)
receptor catabolic processCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic transmission, glutamatergicCyclin-dependent-like kinase 5 Homo sapiens (human)
protein localization to synapseCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
receptor clusteringCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of neuron apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of cell cycleCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of proteolysisCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of DNA-templated transcriptionCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of calcium ion-dependent exocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
negative regulation of protein export from nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
behavioral response to cocaineCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic plasticityCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle endocytosisCyclin-dependent-like kinase 5 Homo sapiens (human)
rhythmic processCyclin-dependent-like kinase 5 Homo sapiens (human)
axon extensionCyclin-dependent-like kinase 5 Homo sapiens (human)
oligodendrocyte differentiationCyclin-dependent-like kinase 5 Homo sapiens (human)
dendrite morphogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
cell divisionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron apoptotic processCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of cell cycleCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCyclin-dependent-like kinase 5 Homo sapiens (human)
excitatory postsynaptic potentialCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of dendritic spine morphogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
calcium ion importCyclin-dependent-like kinase 5 Homo sapiens (human)
positive regulation of protein targeting to membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of protein localization to plasma membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
regulation of synaptic vesicle recyclingCyclin-dependent-like kinase 5 Homo sapiens (human)
cellular response to amyloid-betaCyclin-dependent-like kinase 5 Homo sapiens (human)
axonogenesisCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicle transportCyclin-dependent-like kinase 5 Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 16Homo sapiens (human)
exocytosisCyclin-dependent kinase 16Homo sapiens (human)
spermatogenesisCyclin-dependent kinase 16Homo sapiens (human)
positive regulation of autophagyCyclin-dependent kinase 16Homo sapiens (human)
growth hormone secretionCyclin-dependent kinase 16Homo sapiens (human)
neuron projection developmentCyclin-dependent kinase 16Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 16Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusCyclin-dependent kinase 16Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 17Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 17Homo sapiens (human)
cellular response to leukemia inhibitory factorATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
canonical glycolysisATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
fructose 1,6-bisphosphate metabolic processATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
fructose 6-phosphate metabolic processATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
MAPK cascadeProtein kinase C epsilon typeHomo sapiens (human)
macrophage activation involved in immune responseProtein kinase C epsilon typeHomo sapiens (human)
protein phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
apoptotic processProtein kinase C epsilon typeHomo sapiens (human)
signal transductionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of epithelial cell migrationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of fibroblast migrationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cell-substrate adhesionProtein kinase C epsilon typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
insulin secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of actin filament polymerizationProtein kinase C epsilon typeHomo sapiens (human)
negative regulation of protein ubiquitinationProtein kinase C epsilon typeHomo sapiens (human)
cell-substrate adhesionProtein kinase C epsilon typeHomo sapiens (human)
lipopolysaccharide-mediated signaling pathwayProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cytokinesisProtein kinase C epsilon typeHomo sapiens (human)
locomotory exploration behaviorProtein kinase C epsilon typeHomo sapiens (human)
TRAM-dependent toll-like receptor 4 signaling pathwayProtein kinase C epsilon typeHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionProtein kinase C epsilon typeHomo sapiens (human)
response to morphineProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of MAPK cascadeProtein kinase C epsilon typeHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of lipid catabolic processProtein kinase C epsilon typeHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosolProtein kinase C epsilon typeHomo sapiens (human)
cell divisionProtein kinase C epsilon typeHomo sapiens (human)
establishment of localization in cellProtein kinase C epsilon typeHomo sapiens (human)
synaptic transmission, GABAergicProtein kinase C epsilon typeHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusProtein kinase C epsilon typeHomo sapiens (human)
mucus secretionProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of mucus secretionProtein kinase C epsilon typeHomo sapiens (human)
cellular response to ethanolProtein kinase C epsilon typeHomo sapiens (human)
cellular response to prostaglandin E stimulusProtein kinase C epsilon typeHomo sapiens (human)
cellular response to hypoxiaProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of wound healingProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of protein localization to plasma membraneProtein kinase C epsilon typeHomo sapiens (human)
negative regulation of sodium ion transmembrane transporter activityProtein kinase C epsilon typeHomo sapiens (human)
positive regulation of cellular glucuronidationProtein kinase C epsilon typeHomo sapiens (human)
intracellular signal transductionProtein kinase C epsilon typeHomo sapiens (human)
chemotaxisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
negative regulation of cell population proliferationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of gene expressionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Schwann cell developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cerebellar cortex formationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
keratinocyte differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
thyroid gland developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of stress-activated MAPK cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
endodermal cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ERBB2-ERBB3 signaling pathwayDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
myelinationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
type B pancreatic cell proliferationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
thymus developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of axon regenerationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cell motilityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of axonogenesisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Bergmann glial cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
face developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
trachea formationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
epithelial cell proliferation involved in lung morphogenesisDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
placenta blood vessel developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
labyrinthine layer developmentDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of Golgi inheritanceDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cellular senescenceDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of endodermal cell differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
regulation of early endosome to late endosome transportDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
neuron differentiationDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAngiopoietin-1 receptorHomo sapiens (human)
angiogenesisAngiopoietin-1 receptorHomo sapiens (human)
response to hypoxiaAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of protein phosphorylationAngiopoietin-1 receptorHomo sapiens (human)
endothelial cell proliferationAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of endothelial cell proliferationAngiopoietin-1 receptorHomo sapiens (human)
endochondral ossificationAngiopoietin-1 receptorHomo sapiens (human)
sprouting angiogenesisAngiopoietin-1 receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayAngiopoietin-1 receptorHomo sapiens (human)
cell-cell signalingAngiopoietin-1 receptorHomo sapiens (human)
heart developmentAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of endothelial cell migrationAngiopoietin-1 receptorHomo sapiens (human)
negative regulation of angiogenesisAngiopoietin-1 receptorHomo sapiens (human)
regulation of establishment or maintenance of cell polarityAngiopoietin-1 receptorHomo sapiens (human)
substrate adhesion-dependent cell spreadingAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of Rac protein signal transductionAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of Rho protein signal transductionAngiopoietin-1 receptorHomo sapiens (human)
negative regulation of apoptotic processAngiopoietin-1 receptorHomo sapiens (human)
regulation of vascular permeabilityAngiopoietin-1 receptorHomo sapiens (human)
response to peptide hormoneAngiopoietin-1 receptorHomo sapiens (human)
response to estrogenAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of angiogenesisAngiopoietin-1 receptorHomo sapiens (human)
Tie signaling pathwayAngiopoietin-1 receptorHomo sapiens (human)
negative regulation of inflammatory responseAngiopoietin-1 receptorHomo sapiens (human)
response to cAMPAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of focal adhesion assemblyAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionAngiopoietin-1 receptorHomo sapiens (human)
definitive hemopoiesisAngiopoietin-1 receptorHomo sapiens (human)
heart trabecula formationAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAngiopoietin-1 receptorHomo sapiens (human)
glomerulus vasculature developmentAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of intracellular signal transductionAngiopoietin-1 receptorHomo sapiens (human)
regulation of endothelial cell apoptotic processAngiopoietin-1 receptorHomo sapiens (human)
negative regulation of endothelial cell apoptotic processAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of MAPK cascadeAngiopoietin-1 receptorHomo sapiens (human)
positive regulation of kinase activityAngiopoietin-1 receptorHomo sapiens (human)
multicellular organism developmentAngiopoietin-1 receptorHomo sapiens (human)
apoptotic processMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
signal transductionMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
smoothened signaling pathwayMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
peptidyl-threonine phosphorylationMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
negative regulation of DNA-templated transcriptionMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
positive regulation of JNK cascadeMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
neuron migrationDNA topoisomerase 2-betaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-betaHomo sapiens (human)
axonogenesisDNA topoisomerase 2-betaHomo sapiens (human)
B cell differentiationDNA topoisomerase 2-betaHomo sapiens (human)
forebrain developmentDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to hydrogen peroxideDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to ATPDNA topoisomerase 2-betaHomo sapiens (human)
cellular senescenceDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA topoisomerase 2-betaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-betaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-betaHomo sapiens (human)
regulation of cell growthProtein kinase C theta typeHomo sapiens (human)
regulation of DNA-templated transcriptionProtein kinase C theta typeHomo sapiens (human)
protein phosphorylationProtein kinase C theta typeHomo sapiens (human)
membrane protein ectodomain proteolysisProtein kinase C theta typeHomo sapiens (human)
inflammatory responseProtein kinase C theta typeHomo sapiens (human)
axon guidanceProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-17 productionProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-2 productionProtein kinase C theta typeHomo sapiens (human)
positive regulation of interleukin-4 productionProtein kinase C theta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C theta typeHomo sapiens (human)
CD4-positive, alpha-beta T cell proliferationProtein kinase C theta typeHomo sapiens (human)
Fc-epsilon receptor signaling pathwayProtein kinase C theta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C theta typeHomo sapiens (human)
positive regulation of T cell activationProtein kinase C theta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomerase activityProtein kinase C theta typeHomo sapiens (human)
cell chemotaxisProtein kinase C theta typeHomo sapiens (human)
negative regulation of T cell apoptotic processProtein kinase C theta typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C theta typeHomo sapiens (human)
positive regulation of telomere cappingProtein kinase C theta typeHomo sapiens (human)
positive regulation of T-helper 17 type immune responseProtein kinase C theta typeHomo sapiens (human)
positive regulation of CD4-positive, alpha-beta T cell proliferationProtein kinase C theta typeHomo sapiens (human)
positive regulation of T-helper 2 cell activationProtein kinase C theta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C theta typeHomo sapiens (human)
outflow tract septum morphogenesisActivin receptor type-1Homo sapiens (human)
branching involved in blood vessel morphogenesisActivin receptor type-1Homo sapiens (human)
in utero embryonic developmentActivin receptor type-1Homo sapiens (human)
gastrulation with mouth forming secondActivin receptor type-1Homo sapiens (human)
mesoderm formationActivin receptor type-1Homo sapiens (human)
neural crest cell migrationActivin receptor type-1Homo sapiens (human)
acute inflammatory responseActivin receptor type-1Homo sapiens (human)
embryonic heart tube morphogenesisActivin receptor type-1Homo sapiens (human)
atrioventricular valve morphogenesisActivin receptor type-1Homo sapiens (human)
mitral valve morphogenesisActivin receptor type-1Homo sapiens (human)
endocardial cushion formationActivin receptor type-1Homo sapiens (human)
endocardial cushion fusionActivin receptor type-1Homo sapiens (human)
atrial septum primum morphogenesisActivin receptor type-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayActivin receptor type-1Homo sapiens (human)
germ cell developmentActivin receptor type-1Homo sapiens (human)
determination of left/right symmetryActivin receptor type-1Homo sapiens (human)
negative regulation of signal transductionActivin receptor type-1Homo sapiens (human)
regulation of ossificationActivin receptor type-1Homo sapiens (human)
positive regulation of cell migrationActivin receptor type-1Homo sapiens (human)
positive regulation of bone mineralizationActivin receptor type-1Homo sapiens (human)
BMP signaling pathwayActivin receptor type-1Homo sapiens (human)
activin receptor signaling pathwayActivin receptor type-1Homo sapiens (human)
negative regulation of activin receptor signaling pathwayActivin receptor type-1Homo sapiens (human)
positive regulation of osteoblast differentiationActivin receptor type-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionActivin receptor type-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIActivin receptor type-1Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationActivin receptor type-1Homo sapiens (human)
smooth muscle cell differentiationActivin receptor type-1Homo sapiens (human)
pharyngeal system developmentActivin receptor type-1Homo sapiens (human)
positive regulation of SMAD protein signal transductionActivin receptor type-1Homo sapiens (human)
ventricular septum morphogenesisActivin receptor type-1Homo sapiens (human)
cardiac muscle cell fate commitmentActivin receptor type-1Homo sapiens (human)
endocardial cushion cell fate commitmentActivin receptor type-1Homo sapiens (human)
positive regulation of cardiac epithelial to mesenchymal transitionActivin receptor type-1Homo sapiens (human)
cellular response to BMP stimulusActivin receptor type-1Homo sapiens (human)
positive regulation of determination of dorsal identityActivin receptor type-1Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleActivin receptor type-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayActivin receptor type-1Homo sapiens (human)
dorsal/ventral pattern formationActivin receptor type-1Homo sapiens (human)
heart developmentActivin receptor type-1Homo sapiens (human)
protein phosphorylationActivin receptor type-1Homo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-1Homo sapiens (human)
defense responseMacrophage-stimulating protein receptorHomo sapiens (human)
signal transductionMacrophage-stimulating protein receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayMacrophage-stimulating protein receptorHomo sapiens (human)
single fertilizationMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of cell population proliferationMacrophage-stimulating protein receptorHomo sapiens (human)
response to virusMacrophage-stimulating protein receptorHomo sapiens (human)
macrophage colony-stimulating factor signaling pathwayMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of MAP kinase activityMacrophage-stimulating protein receptorHomo sapiens (human)
innate immune responseMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMacrophage-stimulating protein receptorHomo sapiens (human)
nervous system developmentMacrophage-stimulating protein receptorHomo sapiens (human)
cell migrationMacrophage-stimulating protein receptorHomo sapiens (human)
phagocytosisMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of kinase activityMacrophage-stimulating protein receptorHomo sapiens (human)
multicellular organism developmentMacrophage-stimulating protein receptorHomo sapiens (human)
positive regulation of macrophage chemotaxisFocal adhesion kinase 1Homo sapiens (human)
positive regulation of macrophage proliferationFocal adhesion kinase 1Homo sapiens (human)
angiogenesisFocal adhesion kinase 1Homo sapiens (human)
placenta developmentFocal adhesion kinase 1Homo sapiens (human)
regulation of protein phosphorylationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of protein phosphorylationFocal adhesion kinase 1Homo sapiens (human)
heart morphogenesisFocal adhesion kinase 1Homo sapiens (human)
signal complex assemblyFocal adhesion kinase 1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
integrin-mediated signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
axon guidanceFocal adhesion kinase 1Homo sapiens (human)
positive regulation of cell population proliferationFocal adhesion kinase 1Homo sapiens (human)
regulation of cell shapeFocal adhesion kinase 1Homo sapiens (human)
regulation of endothelial cell migrationFocal adhesion kinase 1Homo sapiens (human)
regulation of epithelial cell migrationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of epithelial cell migrationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of epithelial to mesenchymal transitionFocal adhesion kinase 1Homo sapiens (human)
positive regulation of fibroblast migrationFocal adhesion kinase 1Homo sapiens (human)
cell migrationFocal adhesion kinase 1Homo sapiens (human)
peptidyl-tyrosine phosphorylationFocal adhesion kinase 1Homo sapiens (human)
negative regulation of cell-cell adhesionFocal adhesion kinase 1Homo sapiens (human)
establishment of cell polarityFocal adhesion kinase 1Homo sapiens (human)
positive regulation of cell migrationFocal adhesion kinase 1Homo sapiens (human)
regulation of cell adhesion mediated by integrinFocal adhesion kinase 1Homo sapiens (human)
detection of muscle stretchFocal adhesion kinase 1Homo sapiens (human)
netrin-activated signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisFocal adhesion kinase 1Homo sapiens (human)
regulation of cell population proliferationFocal adhesion kinase 1Homo sapiens (human)
negative regulation of apoptotic processFocal adhesion kinase 1Homo sapiens (human)
regulation of GTPase activityFocal adhesion kinase 1Homo sapiens (human)
regulation of osteoblast differentiationFocal adhesion kinase 1Homo sapiens (human)
positive regulation of protein kinase activityFocal adhesion kinase 1Homo sapiens (human)
protein autophosphorylationFocal adhesion kinase 1Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
ephrin receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
cell motilityFocal adhesion kinase 1Homo sapiens (human)
regulation of cytoskeleton organizationFocal adhesion kinase 1Homo sapiens (human)
regulation of focal adhesion assemblyFocal adhesion kinase 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionFocal adhesion kinase 1Homo sapiens (human)
growth hormone receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
positive regulation of wound healingFocal adhesion kinase 1Homo sapiens (human)
regulation of substrate adhesion-dependent cell spreadingFocal adhesion kinase 1Homo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic processFocal adhesion kinase 1Homo sapiens (human)
negative regulation of anoikisFocal adhesion kinase 1Homo sapiens (human)
protein phosphorylationFocal adhesion kinase 1Homo sapiens (human)
epidermal growth factor receptor signaling pathwayFocal adhesion kinase 1Homo sapiens (human)
regulation of cell adhesionFocal adhesion kinase 1Homo sapiens (human)
microtubule cytoskeleton organizationProtein kinase C zeta typeHomo sapiens (human)
positive regulation of cell-matrix adhesionProtein kinase C zeta typeHomo sapiens (human)
protein phosphorylationProtein kinase C zeta typeHomo sapiens (human)
inflammatory responseProtein kinase C zeta typeHomo sapiens (human)
signal transductionProtein kinase C zeta typeHomo sapiens (human)
cell surface receptor signaling pathwayProtein kinase C zeta typeHomo sapiens (human)
long-term memoryProtein kinase C zeta typeHomo sapiens (human)
positive regulation of cell population proliferationProtein kinase C zeta typeHomo sapiens (human)
cell migrationProtein kinase C zeta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C zeta typeHomo sapiens (human)
establishment of cell polarityProtein kinase C zeta typeHomo sapiens (human)
negative regulation of protein-containing complex assemblyProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-10 productionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-13 productionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-4 productionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of interleukin-5 productionProtein kinase C zeta typeHomo sapiens (human)
cellular response to insulin stimulusProtein kinase C zeta typeHomo sapiens (human)
negative regulation of apoptotic processProtein kinase C zeta typeHomo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarityProtein kinase C zeta typeHomo sapiens (human)
positive regulation of T-helper 2 cell differentiationProtein kinase C zeta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C zeta typeHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayProtein kinase C zeta typeHomo sapiens (human)
vesicle transport along microtubuleProtein kinase C zeta typeHomo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationProtein kinase C zeta typeHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProtein kinase C zeta typeHomo sapiens (human)
positive regulation of protein transportProtein kinase C zeta typeHomo sapiens (human)
membrane depolarizationProtein kinase C zeta typeHomo sapiens (human)
membrane hyperpolarizationProtein kinase C zeta typeHomo sapiens (human)
long-term synaptic potentiationProtein kinase C zeta typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C zeta typeHomo sapiens (human)
protein kinase C signalingProtein kinase C zeta typeHomo sapiens (human)
protein localization to plasma membraneProtein kinase C zeta typeHomo sapiens (human)
regulation of neurotransmitter receptor localization to postsynaptic specialization membraneProtein kinase C zeta typeHomo sapiens (human)
neuron projection extensionProtein kinase C zeta typeHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialProtein kinase C zeta typeHomo sapiens (human)
positive regulation of T-helper 2 cell cytokine productionProtein kinase C zeta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C zeta typeHomo sapiens (human)
protein phosphorylationProtein kinase C delta typeHomo sapiens (human)
apoptotic processProtein kinase C delta typeHomo sapiens (human)
DNA damage responseProtein kinase C delta typeHomo sapiens (human)
signal transductionProtein kinase C delta typeHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressProtein kinase C delta typeHomo sapiens (human)
regulation of signaling receptor activityProtein kinase C delta typeHomo sapiens (human)
immunoglobulin mediated immune responseProtein kinase C delta typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C delta typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C delta typeHomo sapiens (human)
termination of signal transductionProtein kinase C delta typeHomo sapiens (human)
negative regulation of actin filament polymerizationProtein kinase C delta typeHomo sapiens (human)
positive regulation of endodeoxyribonuclease activityProtein kinase C delta typeHomo sapiens (human)
negative regulation of protein bindingProtein kinase C delta typeHomo sapiens (human)
activation of protein kinase activityProtein kinase C delta typeHomo sapiens (human)
positive regulation of superoxide anion generationProtein kinase C delta typeHomo sapiens (human)
regulation of actin cytoskeleton organizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C delta typeHomo sapiens (human)
cellular response to UVProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein dephosphorylationProtein kinase C delta typeHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProtein kinase C delta typeHomo sapiens (human)
B cell proliferationProtein kinase C delta typeHomo sapiens (human)
neutrophil activationProtein kinase C delta typeHomo sapiens (human)
positive regulation of protein import into nucleusProtein kinase C delta typeHomo sapiens (human)
defense response to bacteriumProtein kinase C delta typeHomo sapiens (human)
negative regulation of MAP kinase activityProtein kinase C delta typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C delta typeHomo sapiens (human)
post-translational protein modificationProtein kinase C delta typeHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayProtein kinase C delta typeHomo sapiens (human)
negative regulation of inflammatory responseProtein kinase C delta typeHomo sapiens (human)
negative regulation of peptidyl-tyrosine phosphorylationProtein kinase C delta typeHomo sapiens (human)
protein stabilizationProtein kinase C delta typeHomo sapiens (human)
negative regulation of filopodium assemblyProtein kinase C delta typeHomo sapiens (human)
cell chemotaxisProtein kinase C delta typeHomo sapiens (human)
cellular response to hydrogen peroxideProtein kinase C delta typeHomo sapiens (human)
cellular response to hydroperoxideProtein kinase C delta typeHomo sapiens (human)
negative regulation of platelet aggregationProtein kinase C delta typeHomo sapiens (human)
cellular senescenceProtein kinase C delta typeHomo sapiens (human)
positive regulation of phospholipid scramblase activityProtein kinase C delta typeHomo sapiens (human)
cellular response to angiotensinProtein kinase C delta typeHomo sapiens (human)
regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of ceramide biosynthetic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of glucosylceramide catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of sphingomyelin catabolic processProtein kinase C delta typeHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProtein kinase C delta typeHomo sapiens (human)
intracellular signal transductionProtein kinase C delta typeHomo sapiens (human)
neutrophil homeostasisTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of type III hypersensitivityTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of type I hypersensitivityTyrosine-protein kinase BTKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase BTKHomo sapiens (human)
B cell affinity maturationTyrosine-protein kinase BTKHomo sapiens (human)
histamine secretion by mast cellTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of immunoglobulin productionTyrosine-protein kinase BTKHomo sapiens (human)
regulation of B cell cytokine productionTyrosine-protein kinase BTKHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
regulation of B cell apoptotic processTyrosine-protein kinase BTKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase BTKHomo sapiens (human)
mesoderm developmentTyrosine-protein kinase BTKHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase BTKHomo sapiens (human)
calcium-mediated signalingTyrosine-protein kinase BTKHomo sapiens (human)
proteoglycan catabolic processTyrosine-protein kinase BTKHomo sapiens (human)
negative regulation of B cell proliferationTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of B cell proliferationTyrosine-protein kinase BTKHomo sapiens (human)
response to lipopolysaccharideTyrosine-protein kinase BTKHomo sapiens (human)
negative regulation of interleukin-10 productionTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of interleukin-6 productionTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of tumor necrosis factor productionTyrosine-protein kinase BTKHomo sapiens (human)
cellular response to reactive oxygen speciesTyrosine-protein kinase BTKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase BTKHomo sapiens (human)
Fc-epsilon receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
B cell activationTyrosine-protein kinase BTKHomo sapiens (human)
innate immune responseTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of B cell differentiationTyrosine-protein kinase BTKHomo sapiens (human)
cell maturationTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of phagocytosisTyrosine-protein kinase BTKHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityTyrosine-protein kinase BTKHomo sapiens (human)
monocyte proliferationTyrosine-protein kinase BTKHomo sapiens (human)
cellular response to molecule of fungal originTyrosine-protein kinase BTKHomo sapiens (human)
apoptotic signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
cellular response to interleukin-7Tyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of interleukin-17A productionTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyTyrosine-protein kinase BTKHomo sapiens (human)
positive regulation of synoviocyte proliferationTyrosine-protein kinase BTKHomo sapiens (human)
eosinophil homeostasisTyrosine-protein kinase BTKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase BTKHomo sapiens (human)
neuron migrationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
natural killer cell differentiationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cell adhesionTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
signal transductionTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
neuropeptide signaling pathwayTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
spermatogenesisTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
forebrain cell migrationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
platelet activationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
secretion by cellTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of toll-like receptor signaling pathwayTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
ovulation cycleTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
apoptotic cell clearanceTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of neuron apoptotic processTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of innate immune responseTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
symbiont entry into host cellTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
protein autophosphorylationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of inflammatory responseTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
negative regulation of lymphocyte activationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
neuron apoptotic processTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
establishment of localization in cellTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
vagina developmentTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
neuron cellular homeostasisTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
platelet aggregationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
positive regulation of viral life cycleTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
nervous system developmentTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
phagocytosisTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
multicellular organism developmentTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
positive regulation of kinase activityTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cell migrationTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
positive regulation of myelinationCyclin-dependent kinase 18Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 18Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 18Homo sapiens (human)
endocytosisActivated CDC42 kinase 1Homo sapiens (human)
cell surface receptor signaling pathwayActivated CDC42 kinase 1Homo sapiens (human)
small GTPase-mediated signal transductionActivated CDC42 kinase 1Homo sapiens (human)
phosphorylationActivated CDC42 kinase 1Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationActivated CDC42 kinase 1Homo sapiens (human)
regulation of clathrin-dependent endocytosisActivated CDC42 kinase 1Homo sapiens (human)
protein phosphorylationActivated CDC42 kinase 1Homo sapiens (human)
regulation of cell growthEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
regulation of cell-matrix adhesionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
cell adhesionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
embryo implantationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
lactationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
cell population proliferationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
negative regulation of cell population proliferationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
regulation of extracellular matrix disassemblyEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
smooth muscle cell migrationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
peptidyl-tyrosine autophosphorylationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
ear developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
wound healing, spreading of cellsEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
protein autophosphorylationEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
branching involved in mammary gland duct morphogenesisEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
mammary gland alveolus developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
smooth muscle cell-matrix adhesionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
axon developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
neuron projection extensionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
multicellular organism developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of kinase activityEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
positive regulation of cytokine productionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase ITK/TSKHomo sapiens (human)
cellular defense responseTyrosine-protein kinase ITK/TSKHomo sapiens (human)
signal transductionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
activation of phospholipase C activityTyrosine-protein kinase ITK/TSKHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
T cell activationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
gamma-delta T cell activationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase ITK/TSKHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
B cell receptor signaling pathwayTyrosine-protein kinase ITK/TSKHomo sapiens (human)
NK T cell differentiationTyrosine-protein kinase ITK/TSKHomo sapiens (human)
regulation of sodium ion transportMyotonin-protein kinaseHomo sapiens (human)
protein phosphorylationMyotonin-protein kinaseHomo sapiens (human)
intracellular calcium ion homeostasisMyotonin-protein kinaseHomo sapiens (human)
nuclear envelope organizationMyotonin-protein kinaseHomo sapiens (human)
regulation of heart contractionMyotonin-protein kinaseHomo sapiens (human)
muscle cell apoptotic processMyotonin-protein kinaseHomo sapiens (human)
regulation of myotube differentiationMyotonin-protein kinaseHomo sapiens (human)
regulation of excitatory postsynaptic membrane potential involved in skeletal muscle contractionMyotonin-protein kinaseHomo sapiens (human)
regulation of synapse structural plasticityMyotonin-protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationMyotonin-protein kinaseHomo sapiens (human)
regulation of skeletal muscle contraction by calcium ion signalingMyotonin-protein kinaseHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
vesicle targetingMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
immune responseMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
innate immune responseMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
positive regulation of JNK cascadeMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
post-translational protein modificationMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
positive regulation of protein kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
positive regulation of DNA-templated transcriptionMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
negative regulation of motor neuron apoptotic processMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
natural killer cell differentiationTyrosine-protein kinase MerHomo sapiens (human)
negative regulation of cytokine productionTyrosine-protein kinase MerHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase MerHomo sapiens (human)
phagocytosisTyrosine-protein kinase MerHomo sapiens (human)
cell surface receptor signaling pathwayTyrosine-protein kinase MerHomo sapiens (human)
cell-cell signalingTyrosine-protein kinase MerHomo sapiens (human)
spermatogenesisTyrosine-protein kinase MerHomo sapiens (human)
platelet activationTyrosine-protein kinase MerHomo sapiens (human)
secretion by cellTyrosine-protein kinase MerHomo sapiens (human)
substrate adhesion-dependent cell spreadingTyrosine-protein kinase MerHomo sapiens (human)
positive regulation of phagocytosisTyrosine-protein kinase MerHomo sapiens (human)
negative regulation of lymphocyte activationTyrosine-protein kinase MerHomo sapiens (human)
establishment of localization in cellTyrosine-protein kinase MerHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionTyrosine-protein kinase MerHomo sapiens (human)
retina development in camera-type eyeTyrosine-protein kinase MerHomo sapiens (human)
vagina developmentTyrosine-protein kinase MerHomo sapiens (human)
neutrophil clearanceTyrosine-protein kinase MerHomo sapiens (human)
negative regulation of leukocyte apoptotic processTyrosine-protein kinase MerHomo sapiens (human)
nervous system developmentTyrosine-protein kinase MerHomo sapiens (human)
positive regulation of kinase activityTyrosine-protein kinase MerHomo sapiens (human)
cell migrationTyrosine-protein kinase MerHomo sapiens (human)
multicellular organism developmentTyrosine-protein kinase MerHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase MerHomo sapiens (human)
cell morphogenesisSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of protein phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of protein bindingSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase 4Homo sapiens (human)
branching involved in blood vessel morphogenesisSerine/threonine-protein kinase 4Homo sapiens (human)
neural tube formationSerine/threonine-protein kinase 4Homo sapiens (human)
endocardium developmentSerine/threonine-protein kinase 4Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
protein import into nucleusSerine/threonine-protein kinase 4Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
signal transductionSerine/threonine-protein kinase 4Homo sapiens (human)
central nervous system developmentSerine/threonine-protein kinase 4Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 4Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 4Homo sapiens (human)
keratinocyte differentiationSerine/threonine-protein kinase 4Homo sapiens (human)
organ growthSerine/threonine-protein kinase 4Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase 4Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of fat cell differentiationSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of organ growthSerine/threonine-protein kinase 4Homo sapiens (human)
epithelial cell proliferationSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of epithelial cell proliferationSerine/threonine-protein kinase 4Homo sapiens (human)
protein tetramerizationSerine/threonine-protein kinase 4Homo sapiens (human)
canonical Wnt signaling pathwaySerine/threonine-protein kinase 4Homo sapiens (human)
primitive hemopoiesisSerine/threonine-protein kinase 4Homo sapiens (human)
cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 4Homo sapiens (human)
regulation of cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 4Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase 4Homo sapiens (human)
hepatocyte apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of hepatocyte apoptotic processSerine/threonine-protein kinase 4Homo sapiens (human)
positive regulation of substrate-dependent cell migration, cell attachment to substrateSerine/threonine-protein kinase 4Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase 4Homo sapiens (human)
lipid droplet disassembly5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to hypoxia5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
glucose metabolic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
chromatin remodeling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
autophagy5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of cell population proliferation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
lipid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to UV5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cold acclimation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to gamma radiation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of autophagy5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
bile acid and bile salt transport5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
Wnt signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid oxidation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to caffeine5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of TOR signaling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of peptidyl-serine phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to oxidative stress5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
bile acid signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to glucose starvation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
glucose homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of circadian rhythm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
response to estrogen5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of glycolytic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of DNA-templated transcription5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of glucosylceramide biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of insulin receptor signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
rhythmic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of skeletal muscle tissue development5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of lipid catabolic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
fatty acid homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of vesicle-mediated transport5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
motor behavior5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
CAMKK-AMPK signaling cascade5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of stress granule assembly5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
neuron cellular homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to hydrogen peroxide5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of microtubule cytoskeleton organization5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to calcium ion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to glucose stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to ethanol5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to prostaglandin E stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to organonitrogen compound5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to hypoxia5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cellular response to xenobiotic stimulus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
energy homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
regulation of bile acid secretion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of mitochondrial transcription5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of protein localization5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of hepatocyte apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of protein targeting to mitochondrion5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of adipose tissue development5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of TORC1 signaling5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
negative regulation of tubulin deacetylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein localization to lipid droplet5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
positive regulation of peptidyl-lysine acetylation5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cell migrationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of protein phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
exocytosisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of cell population proliferationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of cell migrationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of microtubule polymerizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
wound healingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of JUN kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
hepatocyte growth factor receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
ephrin receptor signaling pathwaySerine/threonine-protein kinase PAK 1Homo sapiens (human)
branching morphogenesis of an epithelial tubeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of stress fiber assemblySerine/threonine-protein kinase PAK 1Homo sapiens (human)
negative regulation of cell proliferation involved in contact inhibitionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
positive regulation of microtubule nucleationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein localization to cytoplasmic stress granuleSerine/threonine-protein kinase PAK 1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase PAK 1Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase PAK 1Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
MAPK cascadeDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
signal transductionDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
heart developmentDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of cell growthDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of interleukin-8 productionDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of heterotypic cell-cell adhesionDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic processDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of MAP kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of epithelial cell proliferationDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
positive regulation of protein metabolic processDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of response to cytokine stimulusDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
ERK5 cascadeDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
cellular response to growth factor stimulusDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
cellular response to laminar fluid shear stressDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of chemokine (C-X-C motif) ligand 2 productionDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 7Homo sapiens (human)
signal transductionMitogen-activated protein kinase 7Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayMitogen-activated protein kinase 7Homo sapiens (human)
cell differentiationMitogen-activated protein kinase 7Homo sapiens (human)
calcineurin-NFAT signaling cascadeMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of heterotypic cell-cell adhesionMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of smooth muscle cell apoptotic processMitogen-activated protein kinase 7Homo sapiens (human)
regulation of angiogenesisMitogen-activated protein kinase 7Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of inflammatory responseMitogen-activated protein kinase 7Homo sapiens (human)
positive regulation of protein metabolic processMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of response to cytokine stimulusMitogen-activated protein kinase 7Homo sapiens (human)
cellular response to hydrogen peroxideMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeMitogen-activated protein kinase 7Homo sapiens (human)
cellular response to growth factor stimulusMitogen-activated protein kinase 7Homo sapiens (human)
cellular response to laminar fluid shear stressMitogen-activated protein kinase 7Homo sapiens (human)
cellular response to transforming growth factor beta stimulusMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of endothelial cell apoptotic processMitogen-activated protein kinase 7Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandMitogen-activated protein kinase 7Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 7Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwaySerine/threonine-protein kinase PAK 2Homo sapiens (human)
cardiac muscle hypertrophySerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of protein kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
adherens junction assemblySerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PAK 2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase PAK 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
regulation of cytoskeleton organizationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of stress fiber assemblySerine/threonine-protein kinase PAK 2Homo sapiens (human)
dendritic spine developmentSerine/threonine-protein kinase PAK 2Homo sapiens (human)
bicellular tight junction assemblySerine/threonine-protein kinase PAK 2Homo sapiens (human)
cellular response to organic cyclic compoundSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein localization to cell-cell junctionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwaySerine/threonine-protein kinase PAK 2Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in execution phase of apoptosisSerine/threonine-protein kinase PAK 2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase PAK 2Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
positive regulation of protein bindingSerine/threonine-protein kinase 3Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase 3Homo sapiens (human)
neural tube formationSerine/threonine-protein kinase 3Homo sapiens (human)
endocardium developmentSerine/threonine-protein kinase 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 3Homo sapiens (human)
protein import into nucleusSerine/threonine-protein kinase 3Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase 3Homo sapiens (human)
JNK cascadeSerine/threonine-protein kinase 3Homo sapiens (human)
central nervous system developmentSerine/threonine-protein kinase 3Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 3Homo sapiens (human)
organ growthSerine/threonine-protein kinase 3Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase 3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of fat cell differentiationSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of JNK cascadeSerine/threonine-protein kinase 3Homo sapiens (human)
negative regulation of organ growthSerine/threonine-protein kinase 3Homo sapiens (human)
epithelial cell proliferationSerine/threonine-protein kinase 3Homo sapiens (human)
negative regulation of epithelial cell proliferationSerine/threonine-protein kinase 3Homo sapiens (human)
protein tetramerizationSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase 3Homo sapiens (human)
canonical Wnt signaling pathwaySerine/threonine-protein kinase 3Homo sapiens (human)
primitive hemopoiesisSerine/threonine-protein kinase 3Homo sapiens (human)
cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 3Homo sapiens (human)
regulation of cell differentiation involved in embryonic placenta developmentSerine/threonine-protein kinase 3Homo sapiens (human)
protein localization to centrosomeSerine/threonine-protein kinase 3Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase 3Homo sapiens (human)
hepatocyte apoptotic processSerine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathway via death domain receptorsSerine/threonine-protein kinase 3Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase 3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein phosphorylationcGMP-dependent protein kinase 2Homo sapiens (human)
signal transductioncGMP-dependent protein kinase 2Homo sapiens (human)
positive regulation of chondrocyte differentiationcGMP-dependent protein kinase 2Homo sapiens (human)
tetrahydrobiopterin metabolic processcGMP-dependent protein kinase 2Homo sapiens (human)
protein localization to plasma membranecGMP-dependent protein kinase 2Homo sapiens (human)
positive regulation of protein localizationcGMP-dependent protein kinase 2Homo sapiens (human)
negative regulation of chloride transportcGMP-dependent protein kinase 2Homo sapiens (human)
protein kinase A signalingcGMP-dependent protein kinase 2Homo sapiens (human)
cell morphogenesisIntegrin-linked protein kinaseHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
branching involved in ureteric bud morphogenesisIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of protein phosphorylationIntegrin-linked protein kinaseHomo sapiens (human)
outflow tract morphogenesisIntegrin-linked protein kinaseHomo sapiens (human)
protein phosphorylationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of cell population proliferationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of signal transductionIntegrin-linked protein kinaseHomo sapiens (human)
fibroblast migrationIntegrin-linked protein kinaseHomo sapiens (human)
nerve developmentIntegrin-linked protein kinaseHomo sapiens (human)
myelination in peripheral nervous systemIntegrin-linked protein kinaseHomo sapiens (human)
cell projection organizationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of BMP signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of phosphorylationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionIntegrin-linked protein kinaseHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionIntegrin-linked protein kinaseHomo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polarityIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of osteoblast differentiationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of DNA-templated transcriptionIntegrin-linked protein kinaseHomo sapiens (human)
neural precursor cell proliferationIntegrin-linked protein kinaseHomo sapiens (human)
platelet aggregationIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin-linked protein kinaseHomo sapiens (human)
negative regulation of neural precursor cell proliferationIntegrin-linked protein kinaseHomo sapiens (human)
cell-matrix adhesionIntegrin-linked protein kinaseHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin-linked protein kinaseHomo sapiens (human)
epithelial to mesenchymal transitionRho-associated protein kinase 1Homo sapiens (human)
aortic valve morphogenesisRho-associated protein kinase 1Homo sapiens (human)
apical constrictionRho-associated protein kinase 1Homo sapiens (human)
protein phosphorylationRho-associated protein kinase 1Homo sapiens (human)
smooth muscle contractionRho-associated protein kinase 1Homo sapiens (human)
leukocyte cell-cell adhesionRho-associated protein kinase 1Homo sapiens (human)
signal transductionRho-associated protein kinase 1Homo sapiens (human)
canonical NF-kappaB signal transductionRho-associated protein kinase 1Homo sapiens (human)
Rho protein signal transductionRho-associated protein kinase 1Homo sapiens (human)
positive regulation of autophagyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of gene expressionRho-associated protein kinase 1Homo sapiens (human)
positive regulation of phosphatase activityRho-associated protein kinase 1Homo sapiens (human)
negative regulation of angiogenesisRho-associated protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationRho-associated protein kinase 1Homo sapiens (human)
membrane to membrane dockingRho-associated protein kinase 1Homo sapiens (human)
actin cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
regulation of cell adhesionRho-associated protein kinase 1Homo sapiens (human)
regulation of cell migrationRho-associated protein kinase 1Homo sapiens (human)
cortical actin cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
neuron projection developmentRho-associated protein kinase 1Homo sapiens (human)
bleb assemblyRho-associated protein kinase 1Homo sapiens (human)
negative regulation of protein bindingRho-associated protein kinase 1Homo sapiens (human)
regulation of actin cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
positive regulation of dephosphorylationRho-associated protein kinase 1Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activityRho-associated protein kinase 1Homo sapiens (human)
negative regulation of phosphorylationRho-associated protein kinase 1Homo sapiens (human)
positive regulation of MAPK cascadeRho-associated protein kinase 1Homo sapiens (human)
regulation of keratinocyte differentiationRho-associated protein kinase 1Homo sapiens (human)
regulation of neuron differentiationRho-associated protein kinase 1Homo sapiens (human)
leukocyte migrationRho-associated protein kinase 1Homo sapiens (human)
leukocyte tethering or rollingRho-associated protein kinase 1Homo sapiens (human)
negative regulation of membrane protein ectodomain proteolysisRho-associated protein kinase 1Homo sapiens (human)
myoblast migrationRho-associated protein kinase 1Homo sapiens (human)
regulation of stress fiber assemblyRho-associated protein kinase 1Homo sapiens (human)
regulation of focal adhesion assemblyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of focal adhesion assemblyRho-associated protein kinase 1Homo sapiens (human)
mRNA destabilizationRho-associated protein kinase 1Homo sapiens (human)
negative regulation of biomineral tissue developmentRho-associated protein kinase 1Homo sapiens (human)
regulation of microtubule cytoskeleton organizationRho-associated protein kinase 1Homo sapiens (human)
response to transforming growth factor betaRho-associated protein kinase 1Homo sapiens (human)
protein localization to plasma membraneRho-associated protein kinase 1Homo sapiens (human)
regulation of synapse maturationRho-associated protein kinase 1Homo sapiens (human)
podocyte cell migrationRho-associated protein kinase 1Homo sapiens (human)
motor neuron apoptotic processRho-associated protein kinase 1Homo sapiens (human)
blood vessel diameter maintenanceRho-associated protein kinase 1Homo sapiens (human)
regulation of angiotensin-activated signaling pathwayRho-associated protein kinase 1Homo sapiens (human)
neuron projection arborizationRho-associated protein kinase 1Homo sapiens (human)
positive regulation of amyloid-beta clearanceRho-associated protein kinase 1Homo sapiens (human)
regulation of synaptic vesicle endocytosisRho-associated protein kinase 1Homo sapiens (human)
negative regulation of amyloid-beta formationRho-associated protein kinase 1Homo sapiens (human)
negative regulation of amyloid precursor protein catabolic processRho-associated protein kinase 1Homo sapiens (human)
regulation of establishment of endothelial barrierRho-associated protein kinase 1Homo sapiens (human)
negative regulation of bicellular tight junction assemblyRho-associated protein kinase 1Homo sapiens (human)
positive regulation of connective tissue replacementRho-associated protein kinase 1Homo sapiens (human)
response to angiotensinRho-associated protein kinase 1Homo sapiens (human)
regulation of establishment of cell polarityRho-associated protein kinase 1Homo sapiens (human)
regulation of cell motilityRho-associated protein kinase 1Homo sapiens (human)
negative regulation of motor neuron apoptotic processRho-associated protein kinase 1Homo sapiens (human)
regulation of cell junction assemblyRho-associated protein kinase 1Homo sapiens (human)
mitotic cytokinesisRho-associated protein kinase 1Homo sapiens (human)
embryonic morphogenesisRho-associated protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationRho-associated protein kinase 1Homo sapiens (human)
actomyosin structure organizationRho-associated protein kinase 1Homo sapiens (human)
protein phosphorylationNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
protein autophosphorylationNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
spliceosomal tri-snRNP complex assemblySerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
spliceosomal snRNP assemblySerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
mRNA splicing, via spliceosomeSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
positive regulation of hippo signalingSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
mRNA cis splicing, via spliceosomeSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
positive regulation of protein export from nucleusSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
regulation of mitotic cell cycle spindle assembly checkpointSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
nuclear membrane disassemblySerine/threonine-protein kinase ATRHomo sapiens (human)
DNA damage checkpoint signalingSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleobase-containing compound metabolic processSerine/threonine-protein kinase ATRHomo sapiens (human)
DNA replicationSerine/threonine-protein kinase ATRHomo sapiens (human)
double-strand break repairSerine/threonine-protein kinase ATRHomo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase ATRHomo sapiens (human)
DNA damage responseSerine/threonine-protein kinase ATRHomo sapiens (human)
negative regulation of DNA replicationSerine/threonine-protein kinase ATRHomo sapiens (human)
response to xenobiotic stimulusSerine/threonine-protein kinase ATRHomo sapiens (human)
response to mechanical stimulusSerine/threonine-protein kinase ATRHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ATRHomo sapiens (human)
replication fork processingSerine/threonine-protein kinase ATRHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseSerine/threonine-protein kinase ATRHomo sapiens (human)
cellular response to UVSerine/threonine-protein kinase ATRHomo sapiens (human)
interstrand cross-link repairSerine/threonine-protein kinase ATRHomo sapiens (human)
positive regulation of DNA damage response, signal transduction by p53 class mediatorSerine/threonine-protein kinase ATRHomo sapiens (human)
mitotic G2/M transition checkpointSerine/threonine-protein kinase ATRHomo sapiens (human)
response to arsenic-containing substanceSerine/threonine-protein kinase ATRHomo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ATRHomo sapiens (human)
protein localization to chromosome, telomeric regionSerine/threonine-protein kinase ATRHomo sapiens (human)
cellular response to gamma radiationSerine/threonine-protein kinase ATRHomo sapiens (human)
replicative senescenceSerine/threonine-protein kinase ATRHomo sapiens (human)
establishment of RNA localization to telomereSerine/threonine-protein kinase ATRHomo sapiens (human)
establishment of protein-containing complex localization to telomereSerine/threonine-protein kinase ATRHomo sapiens (human)
regulation of cellular response to heatSerine/threonine-protein kinase ATRHomo sapiens (human)
positive regulation of telomerase catalytic core complex assemblySerine/threonine-protein kinase ATRHomo sapiens (human)
regulation of double-strand break repairSerine/threonine-protein kinase ATRHomo sapiens (human)
DNA repairSerine/threonine-protein kinase ATRHomo sapiens (human)
telomere maintenanceSerine/threonine-protein kinase ATRHomo sapiens (human)
positive regulation of miRNA processingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
MAPK cascadeReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of protein phosphorylationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
inflammatory responseReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
response to oxidative stressReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of gene expressionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein catabolic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of interleukin-8 productionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of tumor necrosis factor productionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
response to tumor necrosis factorReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
intracellular signal transductionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
peptidyl-serine autophosphorylationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of programmed cell deathReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of neuron apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of macrophage differentiationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of JNK cascadeReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein autophosphorylationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of inflammatory responseReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of necroptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of necroptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of programmed necrotic cell deathReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of interleukin-6-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
T cell apoptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
necroptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cellular response to hydrogen peroxideReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
regulation of ATP:ADP antiporter activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cellular response to tumor necrosis factorReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cellular response to growth factor stimulusReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
programmed necrotic cell deathReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ripoptosome assemblyReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
necroptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of execution phase of apoptosisReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ripoptosome assembly involved in necroptotic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
amyloid fibril formationReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
signal transductionCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
positive regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of skeletal muscle adaptationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
cell differentiationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of synapse structural plasticityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of calcium ion transportCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of dendritic spine developmentCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
positive regulation of dendritic spine morphogenesisCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
positive regulation of synapse maturationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
regulation of neuron migrationCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
regulation of skeletal muscle adaptationCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
insulin secretionCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
cell differentiationCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
regulation of calcium ion transportCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
regulation of cell growthCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of the force of heart contractionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of membrane depolarizationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of transcription by RNA polymerase IICalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of heart contractionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cell communication by electrical couplingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
peptidyl-threonine phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
endoplasmic reticulum calcium ion homeostasisCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
relaxation of cardiac muscleCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cellular localizationCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cellular response to calcium ionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cardiac muscle cell contractionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of heart rate by cardiac conductionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cardiac muscle cell action potentialCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cardiac muscle cell action potential involved in regulation of contractionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of relaxation of cardiac muscleCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
negative regulation of sodium ion transmembrane transportCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
negative regulation of sodium ion transmembrane transporter activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
chromatin remodelingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
regulation of transcription by RNA polymerase IIDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nervous system developmentDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
circadian rhythmDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-serine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-threonine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of microtubule polymerizationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
positive regulation of RNA splicingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
amyloid-beta formationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-serine autophosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
peptidyl-tyrosine autophosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein autophosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of mRNA splicing, via spliceosomeDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of DNA methylation-dependent heterochromatin formationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
positive regulation of protein deacetylationDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIActivin receptor type-2BHomo sapiens (human)
gastrulation with mouth forming secondActivin receptor type-2BHomo sapiens (human)
kidney developmentActivin receptor type-2BHomo sapiens (human)
lymphangiogenesisActivin receptor type-2BHomo sapiens (human)
blood vessel remodelingActivin receptor type-2BHomo sapiens (human)
regulation of DNA-templated transcriptionActivin receptor type-2BHomo sapiens (human)
signal transductionActivin receptor type-2BHomo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayActivin receptor type-2BHomo sapiens (human)
determination of left/right symmetryActivin receptor type-2BHomo sapiens (human)
mesoderm developmentActivin receptor type-2BHomo sapiens (human)
heart developmentActivin receptor type-2BHomo sapiens (human)
response to glucoseActivin receptor type-2BHomo sapiens (human)
post-embryonic developmentActivin receptor type-2BHomo sapiens (human)
anterior/posterior pattern specificationActivin receptor type-2BHomo sapiens (human)
insulin secretionActivin receptor type-2BHomo sapiens (human)
lung developmentActivin receptor type-2BHomo sapiens (human)
positive regulation of bone mineralizationActivin receptor type-2BHomo sapiens (human)
BMP signaling pathwayActivin receptor type-2BHomo sapiens (human)
pancreas developmentActivin receptor type-2BHomo sapiens (human)
activin receptor signaling pathwayActivin receptor type-2BHomo sapiens (human)
positive regulation of activin receptor signaling pathwayActivin receptor type-2BHomo sapiens (human)
organ growthActivin receptor type-2BHomo sapiens (human)
odontogenesis of dentin-containing toothActivin receptor type-2BHomo sapiens (human)
positive regulation of osteoblast differentiationActivin receptor type-2BHomo sapiens (human)
embryonic foregut morphogenesisActivin receptor type-2BHomo sapiens (human)
skeletal system morphogenesisActivin receptor type-2BHomo sapiens (human)
roof of mouth developmentActivin receptor type-2BHomo sapiens (human)
lymphatic endothelial cell differentiationActivin receptor type-2BHomo sapiens (human)
artery developmentActivin receptor type-2BHomo sapiens (human)
venous blood vessel developmentActivin receptor type-2BHomo sapiens (human)
retina vasculature development in camera-type eyeActivin receptor type-2BHomo sapiens (human)
negative regulation of cold-induced thermogenesisActivin receptor type-2BHomo sapiens (human)
cellular response to growth factor stimulusActivin receptor type-2BHomo sapiens (human)
protein phosphorylationActivin receptor type-2BHomo sapiens (human)
outflow tract septum morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
atrioventricular valve morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
cardiac muscle tissue developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
pharyngeal arch artery morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of gene expressionBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of SMAD protein signal transductionBone morphogenetic protein receptor type-2Homo sapiens (human)
osteoblast differentiationBone morphogenetic protein receptor type-2Homo sapiens (human)
mesoderm formationBone morphogenetic protein receptor type-2Homo sapiens (human)
maternal placenta developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
endothelial cell proliferationBone morphogenetic protein receptor type-2Homo sapiens (human)
lymphangiogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
blood vessel remodelingBone morphogenetic protein receptor type-2Homo sapiens (human)
chondrocyte developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of systemic arterial blood pressureBone morphogenetic protein receptor type-2Homo sapiens (human)
outflow tract morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
aortic valve developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
pulmonary valve developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
mitral valve morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
tricuspid valve morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
endocardial cushion developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of cell proliferation involved in heart valve morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayBone morphogenetic protein receptor type-2Homo sapiens (human)
cellular response to starvationBone morphogenetic protein receptor type-2Homo sapiens (human)
anterior/posterior pattern specificationBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of epithelial cell migrationBone morphogenetic protein receptor type-2Homo sapiens (human)
regulation of lung blood pressureBone morphogenetic protein receptor type-2Homo sapiens (human)
proteoglycan biosynthetic processBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of cell growthBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of bone mineralizationBone morphogenetic protein receptor type-2Homo sapiens (human)
BMP signaling pathwayBone morphogenetic protein receptor type-2Homo sapiens (human)
activin receptor signaling pathwayBone morphogenetic protein receptor type-2Homo sapiens (human)
regulation of cell population proliferationBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of osteoblast differentiationBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of ossificationBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of vasoconstrictionBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBone morphogenetic protein receptor type-2Homo sapiens (human)
lung alveolus developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of smooth muscle cell proliferationBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of axon extension involved in axon guidanceBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of muscle cell differentiationBone morphogenetic protein receptor type-2Homo sapiens (human)
limb developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
endochondral bone morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of SMAD protein signal transductionBone morphogenetic protein receptor type-2Homo sapiens (human)
ventricular septum morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
atrial septum morphogenesisBone morphogenetic protein receptor type-2Homo sapiens (human)
lung vasculature developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
lymphatic endothelial cell differentiationBone morphogenetic protein receptor type-2Homo sapiens (human)
artery developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
venous blood vessel developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
positive regulation of cartilage developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
retina vasculature development in camera-type eyeBone morphogenetic protein receptor type-2Homo sapiens (human)
cellular response to BMP stimulusBone morphogenetic protein receptor type-2Homo sapiens (human)
endothelial cell apoptotic processBone morphogenetic protein receptor type-2Homo sapiens (human)
negative regulation of chondrocyte proliferationBone morphogenetic protein receptor type-2Homo sapiens (human)
semi-lunar valve developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
cellular response to growth factor stimulusBone morphogenetic protein receptor type-2Homo sapiens (human)
blood vessel developmentBone morphogenetic protein receptor type-2Homo sapiens (human)
protein phosphorylationBone morphogenetic protein receptor type-2Homo sapiens (human)
protein phosphorylationProtein-tyrosine kinase 6Homo sapiens (human)
tyrosine phosphorylation of STAT proteinProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of neuron projection developmentProtein-tyrosine kinase 6Homo sapiens (human)
cell migrationProtein-tyrosine kinase 6Homo sapiens (human)
ERBB2 signaling pathwayProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of DNA replicationProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of cell cycleProtein-tyrosine kinase 6Homo sapiens (human)
negative regulation of growthProtein-tyrosine kinase 6Homo sapiens (human)
protein autophosphorylationProtein-tyrosine kinase 6Homo sapiens (human)
intestinal epithelial cell differentiationProtein-tyrosine kinase 6Homo sapiens (human)
negative regulation of protein tyrosine kinase activityProtein-tyrosine kinase 6Homo sapiens (human)
cellular response to retinoic acidProtein-tyrosine kinase 6Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayProtein-tyrosine kinase 6Homo sapiens (human)
innate immune responseProtein-tyrosine kinase 6Homo sapiens (human)
cell differentiationProtein-tyrosine kinase 6Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProtein-tyrosine kinase 6Homo sapiens (human)
protein phosphorylationcGMP-dependent protein kinase 1 Homo sapiens (human)
neuron migrationcGMP-dependent protein kinase 1 Homo sapiens (human)
signal transductioncGMP-dependent protein kinase 1 Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationcGMP-dependent protein kinase 1 Homo sapiens (human)
spermatid developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of inositol phosphate biosynthetic processcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of glutamate secretioncGMP-dependent protein kinase 1 Homo sapiens (human)
dendrite developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
cGMP-mediated signalingcGMP-dependent protein kinase 1 Homo sapiens (human)
cerebellum developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
actin cytoskeleton organizationcGMP-dependent protein kinase 1 Homo sapiens (human)
forebrain developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
positive regulation of circadian rhythmcGMP-dependent protein kinase 1 Homo sapiens (human)
regulation of GTPase activitycGMP-dependent protein kinase 1 Homo sapiens (human)
collateral sproutingcGMP-dependent protein kinase 1 Homo sapiens (human)
relaxation of vascular associated smooth musclecGMP-dependent protein kinase 1 Homo sapiens (human)
cell growth involved in cardiac muscle cell developmentcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of platelet aggregationcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationcGMP-dependent protein kinase 1 Homo sapiens (human)
negative regulation of vascular associated smooth muscle cell migrationcGMP-dependent protein kinase 1 Homo sapiens (human)
regulation of testosterone biosynthetic processcGMP-dependent protein kinase 1 Homo sapiens (human)
protein kinase A signalingcGMP-dependent protein kinase 1 Homo sapiens (human)
alternative mRNA splicing, via spliceosomeCyclin-dependent kinase 13Homo sapiens (human)
regulation of signal transductionCyclin-dependent kinase 13Homo sapiens (human)
hemopoiesisCyclin-dependent kinase 13Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IICyclin-dependent kinase 13Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 13Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 13Homo sapiens (human)
negative regulation of stem cell differentiationCyclin-dependent kinase 13Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 13Homo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
nucleocytoplasmic transportCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
signal transductionCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
cell differentiationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
negative regulation of protein bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
regulation of protein localizationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
intracellular signal transductionCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
regulation of protein bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of protein export from nucleusCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
regulation of muscle cell differentiationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of muscle cell differentiationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of synapse structural plasticityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of dendritic spine developmentCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
positive regulation of protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
immune responseInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
gene expressionInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of lipid storageInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of type I interferon productionInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
response to interferon-betaInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
regulation of protein-containing complex assemblyInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
mRNA stabilizationInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
defense response to virusInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
type I interferon-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of type I interferon-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
interleukin-17-mediated signaling pathwayInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
cellular response to virusInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
peptidyl-serine phosphorylationInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProtein-tyrosine kinase 2-betaHomo sapiens (human)
MAPK cascadeProtein-tyrosine kinase 2-betaHomo sapiens (human)
oocyte maturationProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to hypoxiaProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell-matrix adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
sprouting angiogenesisProtein-tyrosine kinase 2-betaHomo sapiens (human)
adaptive immune responseProtein-tyrosine kinase 2-betaHomo sapiens (human)
marginal zone B cell differentiationProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to ischemiaProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein phosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
cellular defense responseProtein-tyrosine kinase 2-betaHomo sapiens (human)
signal transductionProtein-tyrosine kinase 2-betaHomo sapiens (human)
cell surface receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
signal complex assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
integrin-mediated signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell population proliferationProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of cell population proliferationProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of cell shapeProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to xenobiotic stimulusProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to mechanical stimulusProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to hormoneProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to glucoseProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of endothelial cell migrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of muscle cell apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of macrophage chemotaxisProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of neuron projection developmentProtein-tyrosine kinase 2-betaHomo sapiens (human)
glial cell proliferationProtein-tyrosine kinase 2-betaHomo sapiens (human)
peptidyl-tyrosine phosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of cell adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell growthProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of cell migrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of bone mineralizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of actin filament polymerizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
cortical cytoskeleton organizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
neuron projection developmentProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of actin cytoskeleton organizationProtein-tyrosine kinase 2-betaHomo sapiens (human)
tumor necrosis factor-mediated signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to immobilization stressProtein-tyrosine kinase 2-betaHomo sapiens (human)
peptidyl-tyrosine autophosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to cocaineProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to hydrogen peroxideProtein-tyrosine kinase 2-betaHomo sapiens (human)
activation of Janus kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
stress fiber assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to cation stressProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of potassium ion transportProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of neuron apoptotic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
blood vessel endothelial cell migrationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of nitric oxide biosynthetic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
bone resorptionProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to ethanolProtein-tyrosine kinase 2-betaHomo sapiens (human)
negative regulation of myeloid cell differentiationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of translationProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of angiogenesisProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of protein kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of JNK cascadeProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein autophosphorylationProtein-tyrosine kinase 2-betaHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
focal adhesion assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of synaptic plasticityProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosolProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to cAMPProtein-tyrosine kinase 2-betaHomo sapiens (human)
response to calcium ionProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProtein-tyrosine kinase 2-betaHomo sapiens (human)
long-term synaptic potentiationProtein-tyrosine kinase 2-betaHomo sapiens (human)
long-term synaptic depressionProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein-containing complex assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
chemokine-mediated signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein-tyrosine kinase 2-betaHomo sapiens (human)
cellular response to retinoic acidProtein-tyrosine kinase 2-betaHomo sapiens (human)
cellular response to fluid shear stressProtein-tyrosine kinase 2-betaHomo sapiens (human)
endothelin receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of postsynaptic density assemblyProtein-tyrosine kinase 2-betaHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionProtein-tyrosine kinase 2-betaHomo sapiens (human)
regulation of ubiquitin-dependent protein catabolic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of B cell chemotaxisProtein-tyrosine kinase 2-betaHomo sapiens (human)
positive regulation of DNA biosynthetic processProtein-tyrosine kinase 2-betaHomo sapiens (human)
epidermal growth factor receptor signaling pathwayProtein-tyrosine kinase 2-betaHomo sapiens (human)
G2/M transition of mitotic cell cycleMaternal embryonic leucine zipper kinaseHomo sapiens (human)
apoptotic processMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cell population proliferationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressMaternal embryonic leucine zipper kinaseHomo sapiens (human)
hemopoiesisMaternal embryonic leucine zipper kinaseHomo sapiens (human)
positive regulation of apoptotic processMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein autophosphorylationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
neural precursor cell proliferationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein phosphorylationMaternal embryonic leucine zipper kinaseHomo sapiens (human)
mitotic sister chromatid segregationStructural maintenance of chromosomes protein 1AHomo sapiens (human)
DNA repairStructural maintenance of chromosomes protein 1AHomo sapiens (human)
sister chromatid cohesionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mitotic sister chromatid cohesionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
response to radiationStructural maintenance of chromosomes protein 1AHomo sapiens (human)
establishment of mitotic sister chromatid cohesionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
establishment of meiotic sister chromatid cohesionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
somatic stem cell population maintenanceStructural maintenance of chromosomes protein 1AHomo sapiens (human)
cell divisionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
meiotic cell cycleStructural maintenance of chromosomes protein 1AHomo sapiens (human)
response to DNA damage checkpoint signalingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mitotic spindle assemblyStructural maintenance of chromosomes protein 1AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
double-strand break repair via homologous recombinationChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
chromatin remodelingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
negative regulation of gene expressionChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
regulation of cell fate specificationChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
negative regulation of DNA-templated transcriptionChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
regulation of synapse assemblyChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
terminal button organizationChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
regulation of stem cell differentiationChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
very long-chain fatty acid metabolic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
generation of precursor metabolites and energyPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
lipid metabolic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
prostaglandin metabolic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
spermatogenesisPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
fatty acid catabolic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
fatty acid oxidationPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA oxidasePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
hydrogen peroxide biosynthetic processPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
very long-chain fatty acid beta-oxidationPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
lipid homeostasisPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
traversing start control point of mitotic cell cycleCyclin-dependent kinase 10Homo sapiens (human)
negative regulation of cell population proliferationCyclin-dependent kinase 10Homo sapiens (human)
peptidyl-threonine phosphorylationCyclin-dependent kinase 10Homo sapiens (human)
cell projection organizationCyclin-dependent kinase 10Homo sapiens (human)
regulation of actin cytoskeleton organizationCyclin-dependent kinase 10Homo sapiens (human)
positive regulation of MAPK cascadeCyclin-dependent kinase 10Homo sapiens (human)
negative regulation of cilium assemblyCyclin-dependent kinase 10Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 10Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 10Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
angiogenesisSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of endothelial cell proliferationSerine/threonine-protein kinase D1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase D1Homo sapiens (human)
inflammatory responseSerine/threonine-protein kinase D1Homo sapiens (human)
Golgi organizationSerine/threonine-protein kinase D1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
integrin-mediated signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
nervous system developmentSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of endothelial cell migrationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase D1Homo sapiens (human)
regulation of keratinocyte proliferationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of neuron projection developmentSerine/threonine-protein kinase D1Homo sapiens (human)
regulation of skeletal muscle contraction by modulation of calcium ion sensitivity of myofibrilSerine/threonine-protein kinase D1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
sphingolipid biosynthetic processSerine/threonine-protein kinase D1Homo sapiens (human)
cell differentiationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to amino acid starvationSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase D1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of protein import into nucleusSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase D1Homo sapiens (human)
innate immune responseSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of osteoblast differentiationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of cell sizeSerine/threonine-protein kinase D1Homo sapiens (human)
negative regulation of endocytosisSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase D1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of protein export from nucleusSerine/threonine-protein kinase D1Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
Golgi vesicle transportSerine/threonine-protein kinase D1Homo sapiens (human)
defense response to Gram-negative bacteriumSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySerine/threonine-protein kinase D1Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of sarcomere organizationSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to hydroperoxideSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to norepinephrine stimulusSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of peptide hormone secretionSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblySerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to angiotensinSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateSerine/threonine-protein kinase D1Homo sapiens (human)
cellular response to endothelinSerine/threonine-protein kinase D1Homo sapiens (human)
positive regulation of endothelial cell chemotaxisSerine/threonine-protein kinase D1Homo sapiens (human)
regulation of integrin-mediated signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D1Homo sapiens (human)
DNA damage checkpoint signalingSerine/threonine-protein kinase 38Homo sapiens (human)
chromatin organizationSerine/threonine-protein kinase 38Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 38Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase 38Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 38Homo sapiens (human)
protein modification processSerine/threonine-protein kinase 38Homo sapiens (human)
negative regulation of MAP kinase activitySerine/threonine-protein kinase 38Homo sapiens (human)
postsynapse organizationSerine/threonine-protein kinase 38Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 38Homo sapiens (human)
neural crest cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of protein phosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
signal transductionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nervous system developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
synapse assemblyReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
heart developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
lactationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
negative regulation of cell population proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
embryonic pattern specificationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
peptidyl-tyrosine phosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
central nervous system morphogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
olfactory bulb interneuron differentiationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
regulation of cell migrationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB2-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ERBB4-ERBB4 signaling pathwayReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrial fragmentation involved in apoptotic processReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cell fate commitmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of DNA-templated transcriptionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein autophosphorylationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mammary gland epithelial cell differentiationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mammary gland alveolus developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cardiac muscle tissue regenerationReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cellular response to epidermal growth factor stimulusReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
establishment of planar polarity involved in nephron morphogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of protein localization to cell surfaceReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
negative regulation of apoptotic processReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
positive regulation of kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
multicellular organism developmentReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neurogenesisReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-2Homo sapiens (human)
chemical synaptic transmissionRibosomal protein S6 kinase alpha-2Homo sapiens (human)
negative regulation of cell population proliferationRibosomal protein S6 kinase alpha-2Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-2Homo sapiens (human)
positive regulation of apoptotic processRibosomal protein S6 kinase alpha-2Homo sapiens (human)
negative regulation of cell cycleRibosomal protein S6 kinase alpha-2Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-2Homo sapiens (human)
positive regulation of protein phosphorylationEphrin type-A receptor 7Homo sapiens (human)
brain developmentEphrin type-A receptor 7Homo sapiens (human)
phosphorylationEphrin type-A receptor 7Homo sapiens (human)
regulation of cell-cell adhesionEphrin type-A receptor 7Homo sapiens (human)
retinal ganglion cell axon guidanceEphrin type-A receptor 7Homo sapiens (human)
regulation of protein autophosphorylationEphrin type-A receptor 7Homo sapiens (human)
regulation of cysteine-type endopeptidase activity involved in apoptotic processEphrin type-A receptor 7Homo sapiens (human)
positive regulation of neuron apoptotic processEphrin type-A receptor 7Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 7Homo sapiens (human)
negative regulation of collateral sproutingEphrin type-A receptor 7Homo sapiens (human)
branching morphogenesis of a nerveEphrin type-A receptor 7Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEphrin type-A receptor 7Homo sapiens (human)
modulation of chemical synaptic transmissionEphrin type-A receptor 7Homo sapiens (human)
negative chemotaxisEphrin type-A receptor 7Homo sapiens (human)
neuron apoptotic processEphrin type-A receptor 7Homo sapiens (human)
negative regulation of synapse assemblyEphrin type-A receptor 7Homo sapiens (human)
regulation of ERK1 and ERK2 cascadeEphrin type-A receptor 7Homo sapiens (human)
nephric duct morphogenesisEphrin type-A receptor 7Homo sapiens (human)
regulation of postsynapse organizationEphrin type-A receptor 7Homo sapiens (human)
axon guidanceEphrin type-A receptor 7Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 7Homo sapiens (human)
cholesterol biosynthetic processDelta(24)-sterol reductaseHomo sapiens (human)
cholesterol biosynthetic processDelta(24)-sterol reductaseHomo sapiens (human)
Ras protein signal transductionDelta(24)-sterol reductaseHomo sapiens (human)
protein localizationDelta(24)-sterol reductaseHomo sapiens (human)
negative regulation of cell population proliferationDelta(24)-sterol reductaseHomo sapiens (human)
response to hormoneDelta(24)-sterol reductaseHomo sapiens (human)
tissue developmentDelta(24)-sterol reductaseHomo sapiens (human)
male genitalia developmentDelta(24)-sterol reductaseHomo sapiens (human)
plasminogen activationDelta(24)-sterol reductaseHomo sapiens (human)
cholesterol biosynthetic process via desmosterolDelta(24)-sterol reductaseHomo sapiens (human)
cholesterol biosynthetic process via lathosterolDelta(24)-sterol reductaseHomo sapiens (human)
amyloid precursor protein catabolic processDelta(24)-sterol reductaseHomo sapiens (human)
skin developmentDelta(24)-sterol reductaseHomo sapiens (human)
membrane organizationDelta(24)-sterol reductaseHomo sapiens (human)
steroid metabolic processDelta(24)-sterol reductaseHomo sapiens (human)
protein phosphorylationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-1Homo sapiens (human)
chemical synaptic transmissionRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of cell growthRibosomal protein S6 kinase alpha-1Homo sapiens (human)
negative regulation of TOR signalingRibosomal protein S6 kinase alpha-1Homo sapiens (human)
intracellular signal transductionRibosomal protein S6 kinase alpha-1Homo sapiens (human)
negative regulation of apoptotic processRibosomal protein S6 kinase alpha-1Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processRibosomal protein S6 kinase alpha-1Homo sapiens (human)
regulation of translation in response to stressRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of cell differentiationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIRibosomal protein S6 kinase alpha-1Homo sapiens (human)
hepatocyte proliferationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of hepatic stellate cell activationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionRibosomal protein S6 kinase alpha-1Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-1Homo sapiens (human)
positive regulation of protein phosphorylationDual specificity testis-specific protein kinase 1Homo sapiens (human)
spermatogenesisDual specificity testis-specific protein kinase 1Homo sapiens (human)
negative regulation of protein autophosphorylationDual specificity testis-specific protein kinase 1Homo sapiens (human)
regulation of protein localizationDual specificity testis-specific protein kinase 1Homo sapiens (human)
regulation of actin cytoskeleton organizationDual specificity testis-specific protein kinase 1Homo sapiens (human)
negative regulation of phosphorylationDual specificity testis-specific protein kinase 1Homo sapiens (human)
positive regulation of stress fiber assemblyDual specificity testis-specific protein kinase 1Homo sapiens (human)
establishment of vesicle localizationDual specificity testis-specific protein kinase 1Homo sapiens (human)
negative regulation of protein serine/threonine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
podocyte cell migrationDual specificity testis-specific protein kinase 1Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingDual specificity testis-specific protein kinase 1Homo sapiens (human)
positive regulation of protein localization to nucleusDual specificity testis-specific protein kinase 1Homo sapiens (human)
negative regulation of cilium assemblyDual specificity testis-specific protein kinase 1Homo sapiens (human)
actin cytoskeleton organizationDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein phosphorylationMyosin light chain kinase, smooth muscleHomo sapiens (human)
smooth muscle contractionMyosin light chain kinase, smooth muscleHomo sapiens (human)
tonic smooth muscle contractionMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of cell migrationMyosin light chain kinase, smooth muscleHomo sapiens (human)
bleb assemblyMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of calcium ion transportMyosin light chain kinase, smooth muscleHomo sapiens (human)
aorta smooth muscle tissue morphogenesisMyosin light chain kinase, smooth muscleHomo sapiens (human)
cellular hypotonic responseMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of wound healingMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 11Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 11Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 11Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 11Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 11Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 11Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 11Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 11Homo sapiens (human)
cardiac muscle cell proliferationMitogen-activated protein kinase 11Homo sapiens (human)
negative regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 11Homo sapiens (human)
bone developmentMitogen-activated protein kinase 11Homo sapiens (human)
cellular response to interleukin-1Mitogen-activated protein kinase 11Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 11Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 11Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 11Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 11Homo sapiens (human)
G1 to G0 transitionSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase STK11Homo sapiens (human)
tissue homeostasisSerine/threonine-protein kinase STK11Homo sapiens (human)
vasculature developmentSerine/threonine-protein kinase STK11Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase STK11Homo sapiens (human)
protein dephosphorylationSerine/threonine-protein kinase STK11Homo sapiens (human)
autophagySerine/threonine-protein kinase STK11Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase STK11Homo sapiens (human)
spermatogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase STK11Homo sapiens (human)
response to ionizing radiationSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase STK11Homo sapiens (human)
response to activitySerine/threonine-protein kinase STK11Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase STK11Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of cell growthSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase STK11Homo sapiens (human)
activation of protein kinase activitySerine/threonine-protein kinase STK11Homo sapiens (human)
response to glucagonSerine/threonine-protein kinase STK11Homo sapiens (human)
response to lipidSerine/threonine-protein kinase STK11Homo sapiens (human)
protein localization to nucleusSerine/threonine-protein kinase STK11Homo sapiens (human)
glucose homeostasisSerine/threonine-protein kinase STK11Homo sapiens (human)
anoikisSerine/threonine-protein kinase STK11Homo sapiens (human)
positive thymic T cell selectionSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of gluconeogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of dendrite morphogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of axonogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
T cell receptor signaling pathwaySerine/threonine-protein kinase STK11Homo sapiens (human)
Golgi localizationSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of cell cycleSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase STK11Homo sapiens (human)
epithelial cell proliferation involved in prostate gland developmentSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of epithelial cell proliferation involved in prostate gland developmentSerine/threonine-protein kinase STK11Homo sapiens (human)
cellular response to UV-BSerine/threonine-protein kinase STK11Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase STK11Homo sapiens (human)
response to thyroid hormoneSerine/threonine-protein kinase STK11Homo sapiens (human)
dendrite extensionSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of cold-induced thermogenesisSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of protein localization to nucleusSerine/threonine-protein kinase STK11Homo sapiens (human)
positive regulation of vesicle transport along microtubuleSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase STK11Homo sapiens (human)
negative regulation of TORC1 signalingSerine/threonine-protein kinase STK11Homo sapiens (human)
signal transductionSerine/threonine-protein kinase STK11Homo sapiens (human)
regulation of Wnt signaling pathwaySerine/threonine-protein kinase STK11Homo sapiens (human)
visual perceptionRhodopsin kinase GRK1Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathwayRhodopsin kinase GRK1Homo sapiens (human)
rhodopsin mediated signaling pathwayRhodopsin kinase GRK1Homo sapiens (human)
regulation of opsin-mediated signaling pathwayRhodopsin kinase GRK1Homo sapiens (human)
protein autophosphorylationRhodopsin kinase GRK1Homo sapiens (human)
protein phosphorylationRhodopsin kinase GRK1Homo sapiens (human)
regulation of signal transductionRhodopsin kinase GRK1Homo sapiens (human)
activation of protein kinase B activityNT-3 growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityNT-3 growth factor receptorHomo sapiens (human)
negative regulation of protein phosphorylationNT-3 growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationNT-3 growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayNT-3 growth factor receptorHomo sapiens (human)
nervous system developmentNT-3 growth factor receptorHomo sapiens (human)
heart developmentNT-3 growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationNT-3 growth factor receptorHomo sapiens (human)
positive regulation of gene expressionNT-3 growth factor receptorHomo sapiens (human)
cell differentiationNT-3 growth factor receptorHomo sapiens (human)
positive regulation of cell migrationNT-3 growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationNT-3 growth factor receptorHomo sapiens (human)
neurotrophin signaling pathwayNT-3 growth factor receptorHomo sapiens (human)
positive regulation of positive chemotaxisNT-3 growth factor receptorHomo sapiens (human)
activation of GTPase activityNT-3 growth factor receptorHomo sapiens (human)
positive regulation of neuron projection developmentNT-3 growth factor receptorHomo sapiens (human)
positive regulation of kinase activityNT-3 growth factor receptorHomo sapiens (human)
cellular response to nerve growth factor stimulusNT-3 growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNT-3 growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionNT-3 growth factor receptorHomo sapiens (human)
multicellular organism developmentNT-3 growth factor receptorHomo sapiens (human)
B cell homeostasisSerine/threonine-protein kinase N1Homo sapiens (human)
B cell apoptotic processSerine/threonine-protein kinase N1Homo sapiens (human)
negative regulation of protein phosphorylationSerine/threonine-protein kinase N1Homo sapiens (human)
regulation of germinal center formationSerine/threonine-protein kinase N1Homo sapiens (human)
regulation of immunoglobulin productionSerine/threonine-protein kinase N1Homo sapiens (human)
renal system processSerine/threonine-protein kinase N1Homo sapiens (human)
chromatin remodelingSerine/threonine-protein kinase N1Homo sapiens (human)
regulation of transcription by RNA polymerase IISerine/threonine-protein kinase N1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase N1Homo sapiens (human)
hyperosmotic responseSerine/threonine-protein kinase N1Homo sapiens (human)
signal transductionSerine/threonine-protein kinase N1Homo sapiens (human)
epithelial cell migrationSerine/threonine-protein kinase N1Homo sapiens (human)
negative regulation of B cell proliferationSerine/threonine-protein kinase N1Homo sapiens (human)
post-translational protein modificationSerine/threonine-protein kinase N1Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase N1Homo sapiens (human)
spleen developmentSerine/threonine-protein kinase N1Homo sapiens (human)
regulation of androgen receptor signaling pathwaySerine/threonine-protein kinase N1Homo sapiens (human)
regulation of cell motilitySerine/threonine-protein kinase N1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase N1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase N1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase N2Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase N2Homo sapiens (human)
cell adhesionSerine/threonine-protein kinase N2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase N2Homo sapiens (human)
epithelial cell migrationSerine/threonine-protein kinase N2Homo sapiens (human)
cell projection organizationSerine/threonine-protein kinase N2Homo sapiens (human)
positive regulation of cytokinesisSerine/threonine-protein kinase N2Homo sapiens (human)
apical junction assemblySerine/threonine-protein kinase N2Homo sapiens (human)
positive regulation of viral genome replicationSerine/threonine-protein kinase N2Homo sapiens (human)
positive regulation of mitotic cell cycleSerine/threonine-protein kinase N2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase N2Homo sapiens (human)
regulation of cell motilitySerine/threonine-protein kinase N2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase N2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase N2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myeloid dendritic cell cytokine productionCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
adaptive immune responseCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
inflammatory responseCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
signal transductionCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
long-term memoryCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
regulation of T cell differentiation in thymusCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
myeloid dendritic cell differentiationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
regulation of osteoclast differentiationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
positive regulation of DNA-templated transcriptionCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
intracellular signal transductionCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
microtubule-based processMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
positive regulation of neuron apoptotic processMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
cell cycle G1/S phase transitionMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
positive regulation of JNK cascadeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
negative regulation of amyloid-beta formationBDNF/NT-3 growth factors receptorHomo sapiens (human)
vasculogenesisBDNF/NT-3 growth factors receptorHomo sapiens (human)
neuron migrationBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of protein phosphorylationBDNF/NT-3 growth factors receptorHomo sapiens (human)
learningBDNF/NT-3 growth factors receptorHomo sapiens (human)
circadian rhythmBDNF/NT-3 growth factors receptorHomo sapiens (human)
feeding behaviorBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of cell population proliferationBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of gene expressionBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of neuron projection developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
glutamate secretionBDNF/NT-3 growth factors receptorHomo sapiens (human)
neuronal action potential propagationBDNF/NT-3 growth factors receptorHomo sapiens (human)
central nervous system neuron developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
cerebral cortex developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
myelination in peripheral nervous systemBDNF/NT-3 growth factors receptorHomo sapiens (human)
neuron differentiationBDNF/NT-3 growth factors receptorHomo sapiens (human)
brain-derived neurotrophic factor receptor signaling pathwayBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationBDNF/NT-3 growth factors receptorHomo sapiens (human)
neurotrophin signaling pathwayBDNF/NT-3 growth factors receptorHomo sapiens (human)
mechanoreceptor differentiationBDNF/NT-3 growth factors receptorHomo sapiens (human)
regulation of GTPase activityBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of MAPK cascadeBDNF/NT-3 growth factors receptorHomo sapiens (human)
negative regulation of neuron apoptotic processBDNF/NT-3 growth factors receptorHomo sapiens (human)
retinal rod cell developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
protein autophosphorylationBDNF/NT-3 growth factors receptorHomo sapiens (human)
oligodendrocyte differentiationBDNF/NT-3 growth factors receptorHomo sapiens (human)
peripheral nervous system neuron developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of axonogenesisBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of synapse assemblyBDNF/NT-3 growth factors receptorHomo sapiens (human)
long-term synaptic potentiationBDNF/NT-3 growth factors receptorHomo sapiens (human)
cellular response to amino acid stimulusBDNF/NT-3 growth factors receptorHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionBDNF/NT-3 growth factors receptorHomo sapiens (human)
negative regulation of anoikisBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of kinase activityBDNF/NT-3 growth factors receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeBDNF/NT-3 growth factors receptorHomo sapiens (human)
multicellular organism developmentBDNF/NT-3 growth factors receptorHomo sapiens (human)
cellular response to brain-derived neurotrophic factor stimulusBDNF/NT-3 growth factors receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayBDNF/NT-3 growth factors receptorHomo sapiens (human)
trans-synaptic signaling by neuropeptide, modulating synaptic transmissionBDNF/NT-3 growth factors receptorHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 6Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase 6Homo sapiens (human)
signal transductionMitogen-activated protein kinase 6Homo sapiens (human)
positive regulation of dendritic spine developmentMitogen-activated protein kinase 6Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 6Homo sapiens (human)
carbohydrate metabolic processPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
glycogen biosynthetic processPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
ossificationDiscoidin domain-containing receptor 2Homo sapiens (human)
endochondral bone growthDiscoidin domain-containing receptor 2Homo sapiens (human)
cell adhesionDiscoidin domain-containing receptor 2Homo sapiens (human)
signal transductionDiscoidin domain-containing receptor 2Homo sapiens (human)
regulation of extracellular matrix disassemblyDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of fibroblast migrationDiscoidin domain-containing receptor 2Homo sapiens (human)
peptidyl-tyrosine phosphorylationDiscoidin domain-containing receptor 2Homo sapiens (human)
collagen fibril organizationDiscoidin domain-containing receptor 2Homo sapiens (human)
regulation of bone mineralizationDiscoidin domain-containing receptor 2Homo sapiens (human)
biomineral tissue developmentDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of collagen biosynthetic processDiscoidin domain-containing receptor 2Homo sapiens (human)
regulation of tissue remodelingDiscoidin domain-containing receptor 2Homo sapiens (human)
chondrocyte proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
response to muscle stretchDiscoidin domain-containing receptor 2Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayDiscoidin domain-containing receptor 2Homo sapiens (human)
negative regulation of apoptotic processDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of osteoblast differentiationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of protein kinase activityDiscoidin domain-containing receptor 2Homo sapiens (human)
protein autophosphorylationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of fibroblast proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityDiscoidin domain-containing receptor 2Homo sapiens (human)
cellular response to hypoxiaDiscoidin domain-containing receptor 2Homo sapiens (human)
cellular response to transforming growth factor beta stimulusDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of extracellular matrix disassemblyDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of wound healingDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDiscoidin domain-containing receptor 2Homo sapiens (human)
negative regulation of hydrogen peroxide-mediated programmed cell deathDiscoidin domain-containing receptor 2Homo sapiens (human)
cellular response to angiotensinDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell migrationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of hepatic stellate cell proliferationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of hepatic stellate cell activationDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of neuron projection developmentDiscoidin domain-containing receptor 2Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionDiscoidin domain-containing receptor 2Homo sapiens (human)
multicellular organism developmentDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of kinase activityDiscoidin domain-containing receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDiscoidin domain-containing receptor 2Homo sapiens (human)
protein phosphorylationAP2-associated protein kinase 1Homo sapiens (human)
regulation of protein localizationAP2-associated protein kinase 1Homo sapiens (human)
positive regulation of Notch signaling pathwayAP2-associated protein kinase 1Homo sapiens (human)
protein stabilizationAP2-associated protein kinase 1Homo sapiens (human)
membrane organizationAP2-associated protein kinase 1Homo sapiens (human)
presynaptic endocytosisAP2-associated protein kinase 1Homo sapiens (human)
regulation of clathrin-dependent endocytosisAP2-associated protein kinase 1Homo sapiens (human)
regulation of vascular permeability involved in acute inflammatory responseMyosin light chain kinase 3Homo sapiens (human)
protein phosphorylationMyosin light chain kinase 3Homo sapiens (human)
sarcomere organizationMyosin light chain kinase 3Homo sapiens (human)
sarcomerogenesisMyosin light chain kinase 3Homo sapiens (human)
cardiac myofibril assemblyMyosin light chain kinase 3Homo sapiens (human)
positive regulation of sarcomere organizationMyosin light chain kinase 3Homo sapiens (human)
cellular response to interleukin-1Myosin light chain kinase 3Homo sapiens (human)
biological_processPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
cellular response to heatPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
protein stabilizationPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
protein foldingPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
regulation of heart rateSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
regulation of cardiac muscle contractionSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
bundle of His cell to Purkinje myocyte communicationSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
regulation of cardiac conductionSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
natural killer cell differentiationRab-like protein 3Homo sapiens (human)
B cell differentiationRab-like protein 3Homo sapiens (human)
T cell differentiation in thymusRab-like protein 3Homo sapiens (human)
regulation of Ras protein signal transductionRab-like protein 3Homo sapiens (human)
protein stabilizationRab-like protein 3Homo sapiens (human)
regulation of protein lipidationRab-like protein 3Homo sapiens (human)
intracellular protein transportRab-like protein 3Homo sapiens (human)
negative regulation of GTPase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
MAPK cascadeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein import into nucleusLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endocytosisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
autophagyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
response to oxidative stressLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrion organizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulum organizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Golgi organizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
lysosome organizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
JNK cascadeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Rho protein signal transductionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
spermatogenesisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuromuscular junction developmentLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein localizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
determination of adult lifespanLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to starvationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of autophagyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of autophagyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of protein kinase A signalingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein processingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of neuron projection developmentLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of neuron maturationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of macroautophagyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
calcium-mediated signalingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
striatum developmentLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
olfactory bulb developmentLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
tangential migration from the subventricular zone to the olfactory bulbLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein ubiquitinationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of protein stabilityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to oxidative stressLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to reactive oxygen speciesLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
intracellular signal transductionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of kidney sizeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
exploration behaviorLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
locomotory exploration behaviorLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of lysosomal lumen pHLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of locomotionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of membrane potentialLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of programmed cell deathLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of MAP kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTP metabolic processLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein autophosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
intracellular distribution of mitochondriaLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuron projection morphogenesisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrion localizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of mitochondrial depolarizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of synaptic transmission, glutamatergicLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
canonical Wnt signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
excitatory postsynaptic potentialLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of dopamine receptor signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of dopamine receptor signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of ER to Golgi vesicle-mediated transportLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of canonical Wnt signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of dendritic spine morphogenesisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein localization to mitochondrionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein localization to endoplasmic reticulum exit siteLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to manganese ionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of mitochondrial fissionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of excitatory postsynaptic potentialLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuron projection arborizationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of synaptic vesicle endocytosisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of protein autoubiquitinationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of neuroblast proliferationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of synaptic vesicle transportLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of late endosome to lysosome transportLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of autophagosome assemblyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of thioredoxin peroxidase activity by peptidyl-threonine phosphorylationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein targeting to mitochondrionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
negative regulation of protein processing involved in protein targeting to mitochondrionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to dopamineLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
positive regulation of microglial cell activationLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Wnt signalosome assemblyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of retrograde transport, endosome to GolgiLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of CAMKK-AMPK signaling cascadeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of branching morphogenesis of a nerveLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of synaptic vesicle exocytosisLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
regulation of reactive oxygen species metabolic processLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
signal transductionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cell migrationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
actomyosin structure organizationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
actomyosin structure organizationSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
fatty acid beta-oxidationAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenaseAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase N3Homo sapiens (human)
signal transductionSerine/threonine-protein kinase N3Homo sapiens (human)
epithelial cell migrationSerine/threonine-protein kinase N3Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase N3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase N3Homo sapiens (human)
autophagySerine/threonine-protein kinase ULK3Homo sapiens (human)
smoothened signaling pathwaySerine/threonine-protein kinase ULK3Homo sapiens (human)
negative regulation of smoothened signaling pathwaySerine/threonine-protein kinase ULK3Homo sapiens (human)
positive regulation of smoothened signaling pathwaySerine/threonine-protein kinase ULK3Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ULK3Homo sapiens (human)
fibroblast activationSerine/threonine-protein kinase ULK3Homo sapiens (human)
cellular senescenceSerine/threonine-protein kinase ULK3Homo sapiens (human)
reticulophagySerine/threonine-protein kinase ULK3Homo sapiens (human)
piecemeal microautophagy of the nucleusSerine/threonine-protein kinase ULK3Homo sapiens (human)
response to starvationSerine/threonine-protein kinase ULK3Homo sapiens (human)
autophagosome assemblySerine/threonine-protein kinase ULK3Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase ULK3Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ULK3Homo sapiens (human)
regulation of autophagySerine/threonine-protein kinase ULK3Homo sapiens (human)
positive regulation of kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
negative regulation of apoptotic processDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
cellular response to fibroblast growth factor stimulusDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
positive regulation of fibroblast growth factor receptor signaling pathwayDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
cellular response to stressMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
fatty acid beta-oxidationAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
fatty acid beta-oxidation using acyl-CoA dehydrogenaseAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
mRNA processingSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
rRNA catabolic processSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
apoptotic chromosome condensationSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
negative regulation of DNA-templated transcriptionSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
IRE1-mediated unfolded protein responseSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase MARK2Homo sapiens (human)
neuron migrationSerine/threonine-protein kinase MARK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
positive regulation of neuron projection developmentSerine/threonine-protein kinase MARK2Homo sapiens (human)
Wnt signaling pathwaySerine/threonine-protein kinase MARK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase MARK2Homo sapiens (human)
activation of protein kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase MARK2Homo sapiens (human)
establishment or maintenance of epithelial cell apical/basal polaritySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of cytoskeleton organizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
mitochondrion localizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
axon developmentSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of microtubule cytoskeleton organizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
establishment or maintenance of cell polarity regulating cell shapeSerine/threonine-protein kinase MARK2Homo sapiens (human)
regulation of microtubule bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase MARK2Homo sapiens (human)
central nervous system developmentATP-dependent RNA helicase DHX30Homo sapiens (human)
DNA duplex unwindingATP-dependent RNA helicase DHX30Homo sapiens (human)
mitochondrial large ribosomal subunit assemblyATP-dependent RNA helicase DHX30Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
DNA repairSerine/threonine-protein kinase TAO1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TAO1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase TAO1Homo sapiens (human)
negative regulation of microtubule depolymerizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase TAO1Homo sapiens (human)
phosphorylationSerine/threonine-protein kinase TAO1Homo sapiens (human)
central nervous system neuron developmentSerine/threonine-protein kinase TAO1Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeSerine/threonine-protein kinase TAO1Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
positive regulation of JNK cascadeSerine/threonine-protein kinase TAO1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase TAO1Homo sapiens (human)
regulation of cytoskeleton organizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
neuron cellular homeostasisSerine/threonine-protein kinase TAO1Homo sapiens (human)
regulation of microtubule cytoskeleton organizationSerine/threonine-protein kinase TAO1Homo sapiens (human)
execution phase of apoptosisSerine/threonine-protein kinase TAO1Homo sapiens (human)
positive regulation of protein acetylationSerine/threonine-protein kinase TAO1Homo sapiens (human)
protein phosphorylationSTE20-related kinase adapter protein alphaHomo sapiens (human)
G1 to G0 transitionSTE20-related kinase adapter protein alphaHomo sapiens (human)
protein export from nucleusSTE20-related kinase adapter protein alphaHomo sapiens (human)
activation of protein kinase activitySTE20-related kinase adapter protein alphaHomo sapiens (human)
skeletal muscle contractionMyosin-14Homo sapiens (human)
mitochondrion organizationMyosin-14Homo sapiens (human)
skeletal muscle tissue developmentMyosin-14Homo sapiens (human)
sensory perception of soundMyosin-14Homo sapiens (human)
regulation of cell shapeMyosin-14Homo sapiens (human)
neuronal action potentialMyosin-14Homo sapiens (human)
actin filament-based movementMyosin-14Homo sapiens (human)
actomyosin structure organizationMyosin-14Homo sapiens (human)
vocalization behaviorMyosin-14Homo sapiens (human)
negative regulation of mitochondrial fusionAarF domain-containing protein kinase 1Homo sapiens (human)
positive regulation of cristae formationAarF domain-containing protein kinase 1Homo sapiens (human)
mitochondrion organizationAarF domain-containing protein kinase 1Homo sapiens (human)
lipid homeostasisAarF domain-containing protein kinase 1Homo sapiens (human)
chromatin organizationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
chromosome segregationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
negative regulation of autophagySerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
nucleus localizationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
cellular response to gamma radiationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
regulation of chromatin organizationSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 32CHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 32CHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-3Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase pim-3Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase pim-3Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-3Homo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusSerine/threonine-protein kinase pim-3Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-3Homo sapiens (human)
protein localizationATP-dependent RNA helicase DDX42Homo sapiens (human)
regulation of apoptotic processATP-dependent RNA helicase DDX42Homo sapiens (human)
U2-type prespliceosome assemblyATP-dependent RNA helicase DDX42Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase VRK2Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase VRK2Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase VRK2Homo sapiens (human)
regulation of interleukin-1-mediated signaling pathwaySerine/threonine-protein kinase VRK2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase VRK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase VRK2Homo sapiens (human)
eye developmentHomeodomain-interacting protein kinase 1Homo sapiens (human)
protein phosphorylationHomeodomain-interacting protein kinase 1Homo sapiens (human)
cell population proliferationHomeodomain-interacting protein kinase 1Homo sapiens (human)
positive regulation of cell population proliferationHomeodomain-interacting protein kinase 1Homo sapiens (human)
anterior/posterior pattern specificationHomeodomain-interacting protein kinase 1Homo sapiens (human)
regulation of tumor necrosis factor-mediated signaling pathwayHomeodomain-interacting protein kinase 1Homo sapiens (human)
retina layer formationHomeodomain-interacting protein kinase 1Homo sapiens (human)
neuron differentiationHomeodomain-interacting protein kinase 1Homo sapiens (human)
adherens junction assemblyHomeodomain-interacting protein kinase 1Homo sapiens (human)
positive regulation of angiogenesisHomeodomain-interacting protein kinase 1Homo sapiens (human)
embryonic camera-type eye morphogenesisHomeodomain-interacting protein kinase 1Homo sapiens (human)
embryonic retina morphogenesis in camera-type eyeHomeodomain-interacting protein kinase 1Homo sapiens (human)
definitive hemopoiesisHomeodomain-interacting protein kinase 1Homo sapiens (human)
lens induction in camera-type eyeHomeodomain-interacting protein kinase 1Homo sapiens (human)
iris morphogenesisHomeodomain-interacting protein kinase 1Homo sapiens (human)
endothelial cell apoptotic processHomeodomain-interacting protein kinase 1Homo sapiens (human)
extrinsic apoptotic signaling pathwayHomeodomain-interacting protein kinase 1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorHomeodomain-interacting protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationHomeodomain-interacting protein kinase 1Homo sapiens (human)
peptidyl-threonine phosphorylationHomeodomain-interacting protein kinase 1Homo sapiens (human)
smoothened signaling pathwayHomeodomain-interacting protein kinase 1Homo sapiens (human)
inflammatory responseCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
nervous system developmentCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of neuron projection developmentCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of CREB transcription factor activityCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of apoptotic processCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
negative regulation of apoptotic processCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of phagocytosisCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
regulation of dendrite developmentCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of respiratory burstCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
regulation of granulocyte chemotaxisCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
positive regulation of neutrophil chemotaxisCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
response to UVMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
response to tumor necrosis factorMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein modification processCyclin-dependent kinase-like 3Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase-like 3Homo sapiens (human)
negative regulation of axon extensionCyclin-dependent kinase-like 3Homo sapiens (human)
positive regulation of dendrite morphogenesisCyclin-dependent kinase-like 3Homo sapiens (human)
dendrite extensionCyclin-dependent kinase-like 3Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase-like 3Homo sapiens (human)
MAPK cascadeMAP kinase-activated protein kinase 5Homo sapiens (human)
regulation of translationMAP kinase-activated protein kinase 5Homo sapiens (human)
signal transductionMAP kinase-activated protein kinase 5Homo sapiens (human)
Ras protein signal transductionMAP kinase-activated protein kinase 5Homo sapiens (human)
negative regulation of TOR signalingMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMAP kinase-activated protein kinase 5Homo sapiens (human)
protein autophosphorylationMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of telomerase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of dendritic spine developmentMAP kinase-activated protein kinase 5Homo sapiens (human)
cellular senescenceMAP kinase-activated protein kinase 5Homo sapiens (human)
stress-induced premature senescenceMAP kinase-activated protein kinase 5Homo sapiens (human)
regulation of signal transduction by p53 class mediatorMAP kinase-activated protein kinase 5Homo sapiens (human)
positive regulation of telomere cappingMAP kinase-activated protein kinase 5Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-activated protein kinase 5Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
exocytosisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of neuron projection developmentSerine/threonine-protein kinase BRSK2Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase BRSK2Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
neuron differentiationSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ERAD pathwaySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of ATP-dependent activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase BRSK2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusSerine/threonine-protein kinase BRSK2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressSerine/threonine-protein kinase BRSK2Homo sapiens (human)
microtubule cytoskeleton organization involved in establishment of planar polaritySerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of retrograde protein transport, ER to cytosolSerine/threonine-protein kinase BRSK2Homo sapiens (human)
regulation of synaptic vesicle clusteringSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase NIM1Homo sapiens (human)
autophagySerine/threonine-protein kinase ULK2Homo sapiens (human)
signal transductionSerine/threonine-protein kinase ULK2Homo sapiens (human)
response to starvationSerine/threonine-protein kinase ULK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase ULK2Homo sapiens (human)
collateral sproutingSerine/threonine-protein kinase ULK2Homo sapiens (human)
autophagy of mitochondrionSerine/threonine-protein kinase ULK2Homo sapiens (human)
axon extensionSerine/threonine-protein kinase ULK2Homo sapiens (human)
reticulophagySerine/threonine-protein kinase ULK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase ULK2Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase ULK2Homo sapiens (human)
piecemeal microautophagy of the nucleusSerine/threonine-protein kinase ULK2Homo sapiens (human)
negative regulation of collateral sproutingSerine/threonine-protein kinase ULK2Homo sapiens (human)
autophagosome assemblySerine/threonine-protein kinase ULK2Homo sapiens (human)
microvillus assemblyMisshapen-like kinase 1Homo sapiens (human)
regulation of cell-matrix adhesionMisshapen-like kinase 1Homo sapiens (human)
protein phosphorylationMisshapen-like kinase 1Homo sapiens (human)
JNK cascadeMisshapen-like kinase 1Homo sapiens (human)
chemical synaptic transmissionMisshapen-like kinase 1Homo sapiens (human)
brain developmentMisshapen-like kinase 1Homo sapiens (human)
regulation of cell-cell adhesionMisshapen-like kinase 1Homo sapiens (human)
actin cytoskeleton organizationMisshapen-like kinase 1Homo sapiens (human)
regulation of cell migrationMisshapen-like kinase 1Homo sapiens (human)
positive regulation of JNK cascadeMisshapen-like kinase 1Homo sapiens (human)
protein autophosphorylationMisshapen-like kinase 1Homo sapiens (human)
dendrite morphogenesisMisshapen-like kinase 1Homo sapiens (human)
positive regulation of p38MAPK cascadeMisshapen-like kinase 1Homo sapiens (human)
regulation of AMPA receptor activityMisshapen-like kinase 1Homo sapiens (human)
MAPK cascadeMisshapen-like kinase 1Homo sapiens (human)
neuron projection morphogenesisMisshapen-like kinase 1Homo sapiens (human)
regulation of MAPK cascadeMisshapen-like kinase 1Homo sapiens (human)
hippocampus developmentSerine/threonine-protein kinase DCLK2Homo sapiens (human)
pyramidal neuron developmentSerine/threonine-protein kinase DCLK2Homo sapiens (human)
protein localization to nucleusSerine/threonine-protein kinase DCLK2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase DCLK2Homo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase DCLK2Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase DCLK2Homo sapiens (human)
intracellular signal transductionCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform alpha-likeHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform alpha-likeHomo sapiens (human)
signal transductionCasein kinase I isoform alpha-likeHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayCasein kinase I isoform alpha-likeHomo sapiens (human)
chromatin remodelingHomeodomain-interacting protein kinase 4Homo sapiens (human)
regulation of signal transduction by p53 class mediatorHomeodomain-interacting protein kinase 4Homo sapiens (human)
peptidyl-threonine phosphorylationHomeodomain-interacting protein kinase 4Homo sapiens (human)
peptidyl-serine phosphorylationHomeodomain-interacting protein kinase 4Homo sapiens (human)
visual perceptionMyosin-IIIaHomo sapiens (human)
sensory perception of soundMyosin-IIIaHomo sapiens (human)
protein autophosphorylationMyosin-IIIaHomo sapiens (human)
cochlea morphogenesisMyosin-IIIaHomo sapiens (human)
regulation of actin filament lengthMyosin-IIIaHomo sapiens (human)
positive regulation of filopodium assemblyMyosin-IIIaHomo sapiens (human)
peptidyl-serine phosphorylationMyosin-IIIaHomo sapiens (human)
regulation of cell cycle processAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
regulation of cell cycle processAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek11Homo sapiens (human)
mitotic intra-S DNA damage checkpoint signalingSerine/threonine-protein kinase Nek11Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase Nek11Homo sapiens (human)
regulation of mitotic cell cycle phase transitionSerine/threonine-protein kinase Nek11Homo sapiens (human)
protein phosphorylationAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
ubiquinone biosynthetic processAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
phosphorylationAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
regulation of autophagyPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
positive regulation of autophagosome assemblyPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase 15Homo sapiens (human)
regulation of COPII vesicle coatingMitogen-activated protein kinase 15Homo sapiens (human)
DNA damage responseMitogen-activated protein kinase 15Homo sapiens (human)
endoplasmic reticulum organizationMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of cell population proliferationMitogen-activated protein kinase 15Homo sapiens (human)
regulation of autophagyMitogen-activated protein kinase 15Homo sapiens (human)
negative regulation of cell migrationMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase 15Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase 15Homo sapiens (human)
dopamine uptakeMitogen-activated protein kinase 15Homo sapiens (human)
regulation of cilium assemblyMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase 15Homo sapiens (human)
protein localization to ciliary transition zoneMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of metaphase/anaphase transition of meiosis IMitogen-activated protein kinase 15Homo sapiens (human)
positive regulation of spindle assemblyMitogen-activated protein kinase 15Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 15Homo sapiens (human)
mitotic cell cycleSerine/threonine-protein kinase Nek9Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase Nek9Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek9Homo sapiens (human)
response to ionizing radiationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase BRSK1Homo sapiens (human)
response to UVSerine/threonine-protein kinase BRSK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase BRSK1Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
neurotransmitter secretionSerine/threonine-protein kinase BRSK1Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase BRSK1Homo sapiens (human)
associative learningSerine/threonine-protein kinase BRSK1Homo sapiens (human)
response to UVSerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of neuron projection developmentSerine/threonine-protein kinase BRSK1Homo sapiens (human)
establishment of cell polaritySerine/threonine-protein kinase BRSK1Homo sapiens (human)
neuron differentiationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of synaptic plasticitySerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of axonogenesisSerine/threonine-protein kinase BRSK1Homo sapiens (human)
centrosome duplicationSerine/threonine-protein kinase BRSK1Homo sapiens (human)
microtubule cytoskeleton organization involved in establishment of planar polaritySerine/threonine-protein kinase BRSK1Homo sapiens (human)
synaptic vesicle cycleSerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of synaptic vesicle clusteringSerine/threonine-protein kinase BRSK1Homo sapiens (human)
regulation of translational initiation by eIF2 alpha phosphorylationSerine/threonine-protein kinase 35Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek7Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase Nek7Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseSerine/threonine-protein kinase Nek7Homo sapiens (human)
cellular response to potassium ionSerine/threonine-protein kinase Nek7Homo sapiens (human)
spindle assemblySerine/threonine-protein kinase Nek7Homo sapiens (human)
positive regulation of telomerase activitySerine/threonine-protein kinase Nek7Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblySerine/threonine-protein kinase Nek7Homo sapiens (human)
positive regulation of telomere cappingSerine/threonine-protein kinase Nek7Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase Nek7Homo sapiens (human)
signal transductionRhodopsin kinase GRK7Homo sapiens (human)
visual perceptionRhodopsin kinase GRK7Homo sapiens (human)
regulation of opsin-mediated signaling pathwayRhodopsin kinase GRK7Homo sapiens (human)
protein autophosphorylationRhodopsin kinase GRK7Homo sapiens (human)
regulation of signal transductionRhodopsin kinase GRK7Homo sapiens (human)
protein phosphorylationRhodopsin kinase GRK7Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 32AHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 32AHomo sapiens (human)
visual perceptionMyosin-IIIbHomo sapiens (human)
sensory perception of soundMyosin-IIIbHomo sapiens (human)
cochlea morphogenesisMyosin-IIIbHomo sapiens (human)
regulation of actin filament lengthMyosin-IIIbHomo sapiens (human)
peptidyl-serine phosphorylationMyosin-IIIbHomo sapiens (human)
positive regulation of filopodium assemblyMyosin-IIIbHomo sapiens (human)
spliceosomal complex assemblyATP-dependent RNA helicase DDX1Homo sapiens (human)
positive regulation of myeloid dendritic cell cytokine productionATP-dependent RNA helicase DDX1Homo sapiens (human)
double-strand break repairATP-dependent RNA helicase DDX1Homo sapiens (human)
tRNA splicing, via endonucleolytic cleavage and ligationATP-dependent RNA helicase DDX1Homo sapiens (human)
regulation of translational initiationATP-dependent RNA helicase DDX1Homo sapiens (human)
DNA duplex unwindingATP-dependent RNA helicase DDX1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionATP-dependent RNA helicase DDX1Homo sapiens (human)
response to exogenous dsRNAATP-dependent RNA helicase DDX1Homo sapiens (human)
innate immune responseATP-dependent RNA helicase DDX1Homo sapiens (human)
defense response to virusATP-dependent RNA helicase DDX1Homo sapiens (human)
nucleic acid metabolic processATP-dependent RNA helicase DDX1Homo sapiens (human)
protein localization to cytoplasmic stress granuleATP-dependent RNA helicase DDX1Homo sapiens (human)
protein phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
DNA damage responseDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
smoothened signaling pathwayDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
positive regulation of glycogen biosynthetic processDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
signal transductionCyclin-dependent kinase-like 2Homo sapiens (human)
sex differentiationCyclin-dependent kinase-like 2Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase-like 2Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase-like 2Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
cell population proliferationMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
positive regulation of MAPK cascadeMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Sgk3Homo sapiens (human)
regulation of cell migrationSerine/threonine-protein kinase Sgk3Homo sapiens (human)
regulation of cell population proliferationSerine/threonine-protein kinase Sgk3Homo sapiens (human)
regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandSerine/threonine-protein kinase Sgk3Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase Sgk3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein phosphorylationAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
ubiquinone biosynthetic processAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
cerebellar Purkinje cell layer morphogenesisAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
microtubule cytoskeleton organizationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of cell cycleMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule cytoskeleton organizationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule bundle formationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
protein phosphorylationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
nervous system developmentMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of programmed cell deathMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cilium organizationMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of cilium assemblyMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
regulation of centrosome cycleMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cell divisionMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
positive regulation of protein localization to centrosomeMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
intracellular signal transductionMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek1Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek1Homo sapiens (human)
cilium assemblySerine/threonine-protein kinase Nek1Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 15Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 15Homo sapiens (human)
protein phosphorylationPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
regulation of respiratory gaseous exchangePAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of glycogen biosynthetic processPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of translationPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
protein autophosphorylationPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
regulation of glucagon secretionPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
energy homeostasisPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
MAPK cascadeCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
calcium-mediated signalingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
cellular response to reactive oxygen speciesCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
regulation of protein kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
CAMKK-AMPK signaling cascadeCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
positive regulation of autophagy of mitochondrionCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein phosphorylationEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
tRNA processingEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
regulation of signal transduction by p53 class mediatorEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
tRNA threonylcarbamoyladenosine metabolic processEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein phosphorylationSRSF protein kinase 1Homo sapiens (human)
chromosome segregationSRSF protein kinase 1Homo sapiens (human)
RNA splicingSRSF protein kinase 1Homo sapiens (human)
sperm DNA condensationSRSF protein kinase 1Homo sapiens (human)
intracellular signal transductionSRSF protein kinase 1Homo sapiens (human)
positive regulation of viral genome replicationSRSF protein kinase 1Homo sapiens (human)
negative regulation of viral genome replicationSRSF protein kinase 1Homo sapiens (human)
innate immune responseSRSF protein kinase 1Homo sapiens (human)
regulation of mRNA splicing, via spliceosomeSRSF protein kinase 1Homo sapiens (human)
regulation of mRNA processingSRSF protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationSRSF protein kinase 1Homo sapiens (human)
spliceosomal complex assemblySRSF protein kinase 1Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
G2/M transition of mitotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
mitotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
regulation of mitotic nuclear divisionMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
negative regulation of G2/M transition of mitotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
protein phosphorylationMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
negative regulation of G2/MI transition of meiotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
meiotic cell cycleMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
response to ischemiaMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to amino acid starvationMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
response to endoplasmic reticulum stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
neuron intrinsic apoptotic signaling pathway in response to oxidative stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
innate immune responseMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of protein kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of DNA-templated transcriptionMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of JNK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
neuron apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to hydrogen peroxideMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
endothelial cell apoptotic processMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
apoptotic signaling pathwayMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
programmed necrotic cell deathMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of p38MAPK cascadeMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to reactive nitrogen speciesMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cellular response to stressMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
glycerophospholipid metabolic processPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phagocytosisPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
signal transductionPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phospholipid biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
fibroblast migrationPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
cell migrationPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
actin cytoskeleton organizationPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
keratinocyte differentiationPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
focal adhesion assemblyPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
cell chemotaxisPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
protein localization to plasma membranePhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
activation of GTPase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
ruffle assemblyPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
blood vessel developmentMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
positive regulation of cell proliferation in bone marrowMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
positive regulation of p38MAPK cascadeMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
negative regulation of cellular senescenceMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
acute inflammatory responseEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
phagocytosisEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
negative regulation of cell population proliferationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
regulation of eIF2 alpha phosphorylation by hemeEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
macrophage differentiationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
negative regulation of translational initiation by ironEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protoporphyrinogen IX metabolic processEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein autophosphorylationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
negative regulation of hemoglobin biosynthetic processEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
establishment of localization in cellEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
multicellular organismal-level iron ion homeostasisEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
integrated stress response signalingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
HRI-mediated signalingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
positive regulation of mitophagyEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
response to iron ion starvationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
regulation of translational initiation by eIF2 alpha phosphorylationEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
maturation of SSU-rRNASerine/threonine-protein kinase RIO1Homo sapiens (human)
ribosomal small subunit biogenesisSerine/threonine-protein kinase RIO1Homo sapiens (human)
positive regulation of rRNA processingSerine/threonine-protein kinase RIO1Homo sapiens (human)
regulation of translationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein phosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
intracellular signal transductionMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein autophosphorylationMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionSerine/threonine-protein kinase RIO2Homo sapiens (human)
maturation of SSU-rRNASerine/threonine-protein kinase RIO2Homo sapiens (human)
ribosomal small subunit biogenesisSerine/threonine-protein kinase RIO2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase RIO2Homo sapiens (human)
positive regulation of ribosomal small subunit export from nucleusSerine/threonine-protein kinase RIO2Homo sapiens (human)
positive regulation of rRNA processingSerine/threonine-protein kinase RIO2Homo sapiens (human)
positive regulation of apoptotic processCyclin-dependent kinase 19Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 19Homo sapiens (human)
cellular response to lipopolysaccharideCyclin-dependent kinase 19Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 19Homo sapiens (human)
response to toxic substanceTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
protein tetramerizationTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
metal ion transportTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
monoatomic cation transmembrane transportTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
protein phosphorylationTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
spermatid developmentTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 33Homo sapiens (human)
mitotic DNA damage checkpoint signalingSerine/threonine-protein kinase 33Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityNucleolar GTP-binding protein 1Homo sapiens (human)
maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)Nucleolar GTP-binding protein 1Homo sapiens (human)
osteoblast differentiationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of DNA replicationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of cell population proliferationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of cell-cell adhesionNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of cell migrationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of protein ubiquitinationNucleolar GTP-binding protein 1Homo sapiens (human)
negative regulation of collagen bindingNucleolar GTP-binding protein 1Homo sapiens (human)
ribosomal large subunit biogenesisNucleolar GTP-binding protein 1Homo sapiens (human)
protein stabilizationNucleolar GTP-binding protein 1Homo sapiens (human)
angiogenesisSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of endothelial cell proliferationSerine/threonine-protein kinase D2Homo sapiens (human)
adaptive immune responseSerine/threonine-protein kinase D2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase D2Homo sapiens (human)
cell adhesionSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of endothelial cell migrationSerine/threonine-protein kinase D2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase D2Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase D2Homo sapiens (human)
sphingolipid biosynthetic processSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of interleukin-2 productionSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of interleukin-8 productionSerine/threonine-protein kinase D2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase D2Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of fibroblast growth factor receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of angiogenesisSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of cell adhesionSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase D2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase D2Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
T cell receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of T cell receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySerine/threonine-protein kinase D2Homo sapiens (human)
endothelial tube morphogenesisSerine/threonine-protein kinase D2Homo sapiens (human)
regulation of T cell apoptotic processSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of DNA biosynthetic processSerine/threonine-protein kinase D2Homo sapiens (human)
positive regulation of endothelial cell chemotaxisSerine/threonine-protein kinase D2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwaySerine/threonine-protein kinase D2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase DCLK3Homo sapiens (human)
protein phosphorylationNUAK family SNF1-like kinase 2Homo sapiens (human)
apoptotic processNUAK family SNF1-like kinase 2Homo sapiens (human)
actin cytoskeleton organizationNUAK family SNF1-like kinase 2Homo sapiens (human)
protein localization to nucleusNUAK family SNF1-like kinase 2Homo sapiens (human)
regulation of hippo signalingNUAK family SNF1-like kinase 2Homo sapiens (human)
cellular response to glucose starvationNUAK family SNF1-like kinase 2Homo sapiens (human)
negative regulation of apoptotic processNUAK family SNF1-like kinase 2Homo sapiens (human)
rRNA modificationRNA cytidine acetyltransferaseHomo sapiens (human)
regulation of translationRNA cytidine acetyltransferaseHomo sapiens (human)
protein acetylationRNA cytidine acetyltransferaseHomo sapiens (human)
regulation of centrosome duplicationRNA cytidine acetyltransferaseHomo sapiens (human)
negative regulation of telomere maintenance via telomeraseRNA cytidine acetyltransferaseHomo sapiens (human)
ribosomal small subunit biogenesisRNA cytidine acetyltransferaseHomo sapiens (human)
positive regulation of translationRNA cytidine acetyltransferaseHomo sapiens (human)
tRNA acetylationRNA cytidine acetyltransferaseHomo sapiens (human)
rRNA acetylation involved in maturation of SSU-rRNARNA cytidine acetyltransferaseHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase SIK2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase SIK2Homo sapiens (human)
regulation of insulin receptor signaling pathwaySerine/threonine-protein kinase SIK2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase SIK2Homo sapiens (human)
striated muscle contractionMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
neuromuscular synaptic transmissionMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
positive regulation of gene expressionMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
skeletal muscle satellite cell differentiationMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
peptidyl-threonine phosphorylationMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
regulation of muscle filament slidingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
skeletal muscle cell differentiationMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
protein autophosphorylationMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cardiac muscle tissue morphogenesisMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cardiac muscle contractionMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
apoptotic processSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of cell migrationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cytoplasmic microtubule organizationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of apoptotic processSTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein autophosphorylationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
regulation of focal adhesion assemblySTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein phosphorylationSTE20-like serine/threonine-protein kinase Homo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
DNA repairSerine/threonine-protein kinase TAO3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TAO3Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase TAO3Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase TAO3Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
positive regulation of JUN kinase activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
negative regulation of JNK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
positive regulation of JNK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase TAO3Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase TAO3Homo sapiens (human)
neuron projection morphogenesisSerine/threonine-protein kinase TAO3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHomeodomain-interacting protein kinase 2Homo sapiens (human)
eye developmentHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of protein phosphorylationHomeodomain-interacting protein kinase 2Homo sapiens (human)
respiratory system processHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein phosphorylationHomeodomain-interacting protein kinase 2Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
adult walking behaviorHomeodomain-interacting protein kinase 2Homo sapiens (human)
cell population proliferationHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of cell population proliferationHomeodomain-interacting protein kinase 2Homo sapiens (human)
anterior/posterior pattern specificationHomeodomain-interacting protein kinase 2Homo sapiens (human)
gene expressionHomeodomain-interacting protein kinase 2Homo sapiens (human)
retina layer formationHomeodomain-interacting protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationHomeodomain-interacting protein kinase 2Homo sapiens (human)
peptidyl-threonine phosphorylationHomeodomain-interacting protein kinase 2Homo sapiens (human)
neuron differentiationHomeodomain-interacting protein kinase 2Homo sapiens (human)
erythrocyte differentiationHomeodomain-interacting protein kinase 2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
negative regulation of BMP signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
PML body organizationHomeodomain-interacting protein kinase 2Homo sapiens (human)
thyroid gland developmentHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of protein bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
epigenetic regulation of gene expressionHomeodomain-interacting protein kinase 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorHomeodomain-interacting protein kinase 2Homo sapiens (human)
negative regulation of neuron apoptotic processHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of angiogenesisHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of JNK cascadeHomeodomain-interacting protein kinase 2Homo sapiens (human)
embryonic camera-type eye morphogenesisHomeodomain-interacting protein kinase 2Homo sapiens (human)
voluntary musculoskeletal movementHomeodomain-interacting protein kinase 2Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
neuron apoptotic processHomeodomain-interacting protein kinase 2Homo sapiens (human)
regulation of cell cycleHomeodomain-interacting protein kinase 2Homo sapiens (human)
embryonic retina morphogenesis in camera-type eyeHomeodomain-interacting protein kinase 2Homo sapiens (human)
lens induction in camera-type eyeHomeodomain-interacting protein kinase 2Homo sapiens (human)
SMAD protein signal transductionHomeodomain-interacting protein kinase 2Homo sapiens (human)
lung morphogenesisHomeodomain-interacting protein kinase 2Homo sapiens (human)
iris morphogenesisHomeodomain-interacting protein kinase 2Homo sapiens (human)
cellular response to hypoxiaHomeodomain-interacting protein kinase 2Homo sapiens (human)
intrinsic apoptotic signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
regulation of signal transduction by p53 class mediatorHomeodomain-interacting protein kinase 2Homo sapiens (human)
negative regulation of ubiquitin-dependent protein catabolic processHomeodomain-interacting protein kinase 2Homo sapiens (human)
smoothened signaling pathwayHomeodomain-interacting protein kinase 2Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein kinase SrmsHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase SrmsHomo sapiens (human)
peptidyl-tyrosine autophosphorylationTyrosine-protein kinase SrmsHomo sapiens (human)
positive regulation of TORC1 signalingTyrosine-protein kinase SrmsHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase SrmsHomo sapiens (human)
cell differentiationTyrosine-protein kinase SrmsHomo sapiens (human)
innate immune responseTyrosine-protein kinase SrmsHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase SrmsHomo sapiens (human)
protein phosphorylationHomeodomain-interacting protein kinase 3Homo sapiens (human)
apoptotic processHomeodomain-interacting protein kinase 3Homo sapiens (human)
mRNA transcriptionHomeodomain-interacting protein kinase 3Homo sapiens (human)
peptidyl-serine phosphorylationHomeodomain-interacting protein kinase 3Homo sapiens (human)
peptidyl-threonine phosphorylationHomeodomain-interacting protein kinase 3Homo sapiens (human)
negative regulation of apoptotic processHomeodomain-interacting protein kinase 3Homo sapiens (human)
negative regulation of JUN kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase PLK3Homo sapiens (human)
G2/M transition of mitotic cell cycleSerine/threonine-protein kinase PLK3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IISerine/threonine-protein kinase PLK3Homo sapiens (human)
response to reactive oxygen speciesSerine/threonine-protein kinase PLK3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK3Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PLK3Homo sapiens (human)
response to osmotic stressSerine/threonine-protein kinase PLK3Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase PLK3Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestSerine/threonine-protein kinase PLK3Homo sapiens (human)
endomitotic cell cycleSerine/threonine-protein kinase PLK3Homo sapiens (human)
response to radiationSerine/threonine-protein kinase PLK3Homo sapiens (human)
cytoplasmic microtubule organizationSerine/threonine-protein kinase PLK3Homo sapiens (human)
regulation of cytokinesisSerine/threonine-protein kinase PLK3Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PLK3Homo sapiens (human)
mitotic G1/S transition checkpoint signalingSerine/threonine-protein kinase PLK3Homo sapiens (human)
regulation of cell divisionSerine/threonine-protein kinase PLK3Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionSerine/threonine-protein kinase PLK3Homo sapiens (human)
Golgi disassemblySerine/threonine-protein kinase PLK3Homo sapiens (human)
positive regulation of intracellular protein transportSerine/threonine-protein kinase PLK3Homo sapiens (human)
regulation of signal transduction by p53 class mediatorSerine/threonine-protein kinase PLK3Homo sapiens (human)
positive regulation of chaperone-mediated autophagySerine/threonine-protein kinase PLK3Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxiaSerine/threonine-protein kinase PLK3Homo sapiens (human)
mitotic spindle organizationSerine/threonine-protein kinase PLK3Homo sapiens (human)
dTTP catabolic processdCTP pyrophosphatase 1Homo sapiens (human)
dCTP catabolic processdCTP pyrophosphatase 1Homo sapiens (human)
nucleoside triphosphate catabolic processdCTP pyrophosphatase 1Homo sapiens (human)
DNA protectiondCTP pyrophosphatase 1Homo sapiens (human)
regulation of RNA splicingDual specificity protein kinase CLK4Homo sapiens (human)
peptidyl-tyrosine phosphorylationDual specificity protein kinase CLK4Homo sapiens (human)
regulation of translationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cell surface receptor signaling pathwayMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
hemopoiesisMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
intracellular signal transductionMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cellular response to arsenic-containing substanceMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
peptidyl-serine phosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein autophosphorylationMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase Nek6Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase Nek6Homo sapiens (human)
mitotic spindle organizationSerine/threonine-protein kinase Nek6Homo sapiens (human)
chromosome segregationSerine/threonine-protein kinase Nek6Homo sapiens (human)
mitotic nuclear membrane disassemblySerine/threonine-protein kinase Nek6Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase Nek6Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase Nek6Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionSerine/threonine-protein kinase Nek6Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase Nek6Homo sapiens (human)
spindle assemblySerine/threonine-protein kinase Nek6Homo sapiens (human)
cell divisionSerine/threonine-protein kinase Nek6Homo sapiens (human)
regulation of cellular senescenceSerine/threonine-protein kinase Nek6Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform gamma-1Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform gamma-1Homo sapiens (human)
signal transductionCasein kinase I isoform gamma-1Homo sapiens (human)
endocytosisCasein kinase I isoform gamma-1Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform gamma-1Homo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase PAK 6Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 6Homo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase PAK 6Homo sapiens (human)
learningSerine/threonine-protein kinase PAK 6Homo sapiens (human)
memorySerine/threonine-protein kinase PAK 6Homo sapiens (human)
locomotory behaviorSerine/threonine-protein kinase PAK 6Homo sapiens (human)
neuron projection arborizationSerine/threonine-protein kinase PAK 6Homo sapiens (human)
neuron projection extensionSerine/threonine-protein kinase PAK 6Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 6Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 6Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 6Homo sapiens (human)
protein phosphorylationSNF-related serine/threonine-protein kinaseHomo sapiens (human)
myeloid cell differentiationSNF-related serine/threonine-protein kinaseHomo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase LATS2Homo sapiens (human)
inner cell mass cell fate commitmentSerine/threonine-protein kinase LATS2Homo sapiens (human)
inner cell mass cellular morphogenesisSerine/threonine-protein kinase LATS2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase LATS2Homo sapiens (human)
protein localizationSerine/threonine-protein kinase LATS2Homo sapiens (human)
hormone-mediated signaling pathwaySerine/threonine-protein kinase LATS2Homo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase LATS2Homo sapiens (human)
keratinocyte differentiationSerine/threonine-protein kinase LATS2Homo sapiens (human)
hippo signalingSerine/threonine-protein kinase LATS2Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase LATS2Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activitySerine/threonine-protein kinase LATS2Homo sapiens (human)
cell divisionSerine/threonine-protein kinase LATS2Homo sapiens (human)
canonical Wnt signaling pathwaySerine/threonine-protein kinase LATS2Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwaySerine/threonine-protein kinase LATS2Homo sapiens (human)
negative regulation of protein localization to nucleusSerine/threonine-protein kinase LATS2Homo sapiens (human)
regulation of organ growthSerine/threonine-protein kinase LATS2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase LATS2Homo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase LATS2Homo sapiens (human)
epithelial cilium movement involved in extracellular fluid movementSerine/threonine-protein kinase 36Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 36Homo sapiens (human)
smoothened signaling pathwaySerine/threonine-protein kinase 36Homo sapiens (human)
brain developmentSerine/threonine-protein kinase 36Homo sapiens (human)
post-embryonic developmentSerine/threonine-protein kinase 36Homo sapiens (human)
axoneme assemblySerine/threonine-protein kinase 36Homo sapiens (human)
positive regulation of smoothened signaling pathwaySerine/threonine-protein kinase 36Homo sapiens (human)
regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase 36Homo sapiens (human)
cilium assemblySerine/threonine-protein kinase 36Homo sapiens (human)
translationPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
phenylalanyl-tRNA aminoacylationPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
protein heterotetramerizationPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
positive regulation of Notch signaling pathwayBMP-2-inducible protein kinaseHomo sapiens (human)
regulation of clathrin-dependent endocytosisBMP-2-inducible protein kinaseHomo sapiens (human)
regulation of bone mineralizationBMP-2-inducible protein kinaseHomo sapiens (human)
ribosomal large subunit assemblyMidasinHomo sapiens (human)
ribosomal large subunit export from nucleusMidasinHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
neutrophil mediated immunityInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
JNK cascadeInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
toll-like receptor 4 signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
toll-like receptor 9 signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
interleukin-33-mediated signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
innate immune responseInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
positive regulation of smooth muscle cell proliferationInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
interleukin-1-mediated signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
neutrophil migrationInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
cytokine-mediated signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
Toll signaling pathwayInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
cellular response to lipopolysaccharideInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
intracellular signal transductionInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 32BHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 32BHomo sapiens (human)
positive regulation of programmed cell deathMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
GCN2-mediated signalingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
pyroptosisMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
inflammatory responseMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cytoskeleton organizationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cell deathMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cell differentiationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
embryonic digit morphogenesisMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
positive regulation of apoptotic processMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein autophosphorylationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
limb developmentMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cellular response to gamma radiationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
positive regulation of mitotic DNA damage checkpointMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
regulation of mitotic metaphase/anaphase transitionMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
chromosome segregationMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
transcription by RNA polymerase IICyclin-dependent kinase 12Homo sapiens (human)
mRNA processingCyclin-dependent kinase 12Homo sapiens (human)
RNA splicingCyclin-dependent kinase 12Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IICyclin-dependent kinase 12Homo sapiens (human)
regulation of MAP kinase activityCyclin-dependent kinase 12Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICyclin-dependent kinase 12Homo sapiens (human)
protein autophosphorylationCyclin-dependent kinase 12Homo sapiens (human)
regulation of cell cycleCyclin-dependent kinase 12Homo sapiens (human)
negative regulation of stem cell differentiationCyclin-dependent kinase 12Homo sapiens (human)
protein phosphorylationCyclin-dependent kinase 12Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusSerine/threonine-protein kinase PLK2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PLK2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestSerine/threonine-protein kinase PLK2Homo sapiens (human)
mitotic spindle organizationSerine/threonine-protein kinase PLK2Homo sapiens (human)
Ras protein signal transductionSerine/threonine-protein kinase PLK2Homo sapiens (human)
memorySerine/threonine-protein kinase PLK2Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of angiogenesisSerine/threonine-protein kinase PLK2Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase PLK2Homo sapiens (human)
Rap protein signal transductionSerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase PLK2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase PLK2Homo sapiens (human)
positive regulation of protein catabolic processSerine/threonine-protein kinase PLK2Homo sapiens (human)
regulation of centriole replicationSerine/threonine-protein kinase PLK2Homo sapiens (human)
regulation of synaptic plasticitySerine/threonine-protein kinase PLK2Homo sapiens (human)
long-term synaptic potentiationSerine/threonine-protein kinase PLK2Homo sapiens (human)
long-term synaptic depressionSerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of apoptotic process in bone marrow cellSerine/threonine-protein kinase PLK2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisSerine/threonine-protein kinase PLK2Homo sapiens (human)
negative regulation of cellular senescenceSerine/threonine-protein kinase PLK2Homo sapiens (human)
aerobic respirationNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
negative regulation of cell growthNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial respiratory chain complex I assemblyNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
cellular response to interferon-betaNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
proton motive force-driven mitochondrial ATP synthesisNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
protein insertion into mitochondrial inner membraneNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
positive regulation of protein catabolic processNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
negative regulation of DNA-templated transcriptionNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
cellular response to retinoic acidNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
reactive oxygen species metabolic processNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
apoptotic signaling pathwayNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
extrinsic apoptotic signaling pathwayNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
positive regulation of execution phase of apoptosisNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
positive regulation of gene expressionSerine/threonine-protein kinase MARK1Homo sapiens (human)
negative regulation of gene expressionSerine/threonine-protein kinase MARK1Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase MARK1Homo sapiens (human)
neuron migrationSerine/threonine-protein kinase MARK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MARK1Homo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase MARK1Homo sapiens (human)
negative regulation of epithelial to mesenchymal transitionSerine/threonine-protein kinase MARK1Homo sapiens (human)
regulation of neuron projection developmentSerine/threonine-protein kinase MARK1Homo sapiens (human)
Wnt signaling pathwaySerine/threonine-protein kinase MARK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase MARK1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase MARK1Homo sapiens (human)
regulation of dendrite developmentSerine/threonine-protein kinase MARK1Homo sapiens (human)
establishment of mitochondrion localizationSerine/threonine-protein kinase MARK1Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-2Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase pim-2Homo sapiens (human)
apoptotic mitochondrial changesSerine/threonine-protein kinase pim-2Homo sapiens (human)
response to virusSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
macroautophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of macroautophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-2Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase pim-2Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase PAK 5Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase PAK 5Homo sapiens (human)
signal transductionSerine/threonine-protein kinase PAK 5Homo sapiens (human)
learningSerine/threonine-protein kinase PAK 5Homo sapiens (human)
memorySerine/threonine-protein kinase PAK 5Homo sapiens (human)
locomotory behaviorSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cell population proliferationSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cell migrationSerine/threonine-protein kinase PAK 5Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwaySerine/threonine-protein kinase PAK 5Homo sapiens (human)
regulation of MAPK cascadeSerine/threonine-protein kinase PAK 5Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase PAK 5Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase PAK 5Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 26Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase 26Homo sapiens (human)
cellular response to starvationSerine/threonine-protein kinase 26Homo sapiens (human)
microvillus assemblySerine/threonine-protein kinase 26Homo sapiens (human)
negative regulation of cell migrationSerine/threonine-protein kinase 26Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase 26Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 26Homo sapiens (human)
regulation of apoptotic processSerine/threonine-protein kinase 26Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 26Homo sapiens (human)
DNA damage checkpoint signalingeIF-2-alpha kinase GCN2Homo sapiens (human)
positive regulation of defense response to virus by hosteIF-2-alpha kinase GCN2Homo sapiens (human)
adaptive immune responseeIF-2-alpha kinase GCN2Homo sapiens (human)
T cell activation involved in immune responseeIF-2-alpha kinase GCN2Homo sapiens (human)
positive regulation of adaptive immune responseeIF-2-alpha kinase GCN2Homo sapiens (human)
regulation of translational initiationeIF-2-alpha kinase GCN2Homo sapiens (human)
protein phosphorylationeIF-2-alpha kinase GCN2Homo sapiens (human)
learningeIF-2-alpha kinase GCN2Homo sapiens (human)
long-term memoryeIF-2-alpha kinase GCN2Homo sapiens (human)
regulation of translational initiation by eIF2 alpha phosphorylationeIF-2-alpha kinase GCN2Homo sapiens (human)
viral translationeIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of translational initiation in response to stresseIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of CREB transcription factor activityeIF-2-alpha kinase GCN2Homo sapiens (human)
cellular response to amino acid starvationeIF-2-alpha kinase GCN2Homo sapiens (human)
cellular response to UVeIF-2-alpha kinase GCN2Homo sapiens (human)
eiF2alpha phosphorylation in response to endoplasmic reticulum stresseIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation by host of viral genome replicationeIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of neuron differentiationeIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of translational initiationeIF-2-alpha kinase GCN2Homo sapiens (human)
protein autophosphorylationeIF-2-alpha kinase GCN2Homo sapiens (human)
defense response to viruseIF-2-alpha kinase GCN2Homo sapiens (human)
regulation of feeding behavioreIF-2-alpha kinase GCN2Homo sapiens (human)
cellular response to coldeIF-2-alpha kinase GCN2Homo sapiens (human)
positive regulation of translational initiation in response to starvationeIF-2-alpha kinase GCN2Homo sapiens (human)
GCN2-mediated signalingeIF-2-alpha kinase GCN2Homo sapiens (human)
positive regulation of long-term synaptic potentiationeIF-2-alpha kinase GCN2Homo sapiens (human)
neuron projection extensioneIF-2-alpha kinase GCN2Homo sapiens (human)
negative regulation of cytoplasmic translational initiation in response to stresseIF-2-alpha kinase GCN2Homo sapiens (human)
MAPK cascadeSerine/threonine-protein kinase NLKHomo sapiens (human)
regulation of DNA-templated transcriptionSerine/threonine-protein kinase NLKHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase NLKHomo sapiens (human)
transforming growth factor beta receptor signaling pathwaySerine/threonine-protein kinase NLKHomo sapiens (human)
Wnt signaling pathway, calcium modulating pathwaySerine/threonine-protein kinase NLKHomo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase NLKHomo sapiens (human)
negative regulation of Wnt signaling pathwaySerine/threonine-protein kinase NLKHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase NLKHomo sapiens (human)
protein stabilizationSerine/threonine-protein kinase NLKHomo sapiens (human)
cellular response to osmotic stressSerine/threonine-protein kinase NLKHomo sapiens (human)
negative regulation of TORC1 signalingSerine/threonine-protein kinase NLKHomo sapiens (human)
positive regulation of receptor signaling pathway via STATSerine/threonine-protein kinase NLKHomo sapiens (human)
lysosome organizationPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol biosynthetic processPhosphatidylinositol 4-kinase betaHomo sapiens (human)
receptor-mediated endocytosisPhosphatidylinositol 4-kinase betaHomo sapiens (human)
signal transductionPhosphatidylinositol 4-kinase betaHomo sapiens (human)
inner ear developmentPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol phosphate biosynthetic processPhosphatidylinositol 4-kinase betaHomo sapiens (human)
phosphatidylinositol-mediated signalingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 17AHomo sapiens (human)
apoptotic processSerine/threonine-protein kinase 17AHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 17AHomo sapiens (human)
positive regulation of apoptotic processSerine/threonine-protein kinase 17AHomo sapiens (human)
positive regulation of fibroblast apoptotic processSerine/threonine-protein kinase 17AHomo sapiens (human)
regulation of reactive oxygen species metabolic processSerine/threonine-protein kinase 17AHomo sapiens (human)
response to dietary excessSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein phosphorylationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cell volume homeostasisSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
inflammatory responseSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
signal transductionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
regulation of blood pressureSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
positive regulation of T cell chemotaxisSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
peptidyl-threonine phosphorylationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
intracellular chloride ion homeostasisSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
positive regulation of ion transmembrane transporter activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
intracellular signal transductionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
sodium ion transmembrane transportSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cellular response to potassium ionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
maintenance of lens transparencySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
chemokine (C-X-C motif) ligand 12 signaling pathwaySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
macrophage activationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
positive regulation of potassium ion transportSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein autophosphorylationSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
regulation of inflammatory responseSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
renal sodium ion absorptionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cellular hyperosmotic responseSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cellular hypotonic responseSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of pancreatic juice secretionSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
positive regulation of p38MAPK cascadeSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of potassium ion transmembrane transporter activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of potassium ion transmembrane transportSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
response to aldosteroneSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of creatine transmembrane transporter activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cellular response to chemokineSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
negative regulation of sodium ion transmembrane transporter activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
biological_processEphrin type-A receptor 6Homo sapiens (human)
axon guidanceEphrin type-A receptor 6Homo sapiens (human)
ephrin receptor signaling pathwayEphrin type-A receptor 6Homo sapiens (human)
protein phosphorylationEphrin type-A receptor 6Homo sapiens (human)
glycogen metabolic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of glycolytic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
negative regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
ATP biosynthetic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
sterol biosynthetic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of fatty acid metabolic process5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
intracellular signal transduction5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
positive regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of fatty acid oxidation5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of glucose import5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
regulation of catalytic activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
activation of innate immune responseSerine/threonine-protein kinase TBK1Homo sapiens (human)
cytoplasmic pattern recognition receptor signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TBK1Homo sapiens (human)
inflammatory responseSerine/threonine-protein kinase TBK1Homo sapiens (human)
canonical NF-kappaB signal transductionSerine/threonine-protein kinase TBK1Homo sapiens (human)
response to virusSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase TBK1Homo sapiens (human)
negative regulation of gene expressionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of macroautophagySerine/threonine-protein kinase TBK1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase TBK1Homo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase TBK1Homo sapiens (human)
regulation of type I interferon productionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of type I interferon productionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of interferon-alpha productionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of interferon-beta productionSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationSerine/threonine-protein kinase TBK1Homo sapiens (human)
toll-like receptor 4 signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase TBK1Homo sapiens (human)
dendritic cell proliferationSerine/threonine-protein kinase TBK1Homo sapiens (human)
innate immune responseSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISerine/threonine-protein kinase TBK1Homo sapiens (human)
defense response to Gram-positive bacteriumSerine/threonine-protein kinase TBK1Homo sapiens (human)
defense response to virusSerine/threonine-protein kinase TBK1Homo sapiens (human)
type I interferon-mediated signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of type I interferon-mediated signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
antiviral innate immune responseSerine/threonine-protein kinase TBK1Homo sapiens (human)
cGAS/STING signaling pathwaySerine/threonine-protein kinase TBK1Homo sapiens (human)
negative regulation of TORC1 signalingSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of xenophagySerine/threonine-protein kinase TBK1Homo sapiens (human)
macroautophagySerine/threonine-protein kinase TBK1Homo sapiens (human)
positive regulation of non-motile cilium assemblySeptin-9Homo sapiens (human)
protein localizationSeptin-9Homo sapiens (human)
cytoskeleton-dependent cytokinesisSeptin-9Homo sapiens (human)
protein phosphorylationDeath-associated protein kinase 2Homo sapiens (human)
apoptotic processDeath-associated protein kinase 2Homo sapiens (human)
regulation of autophagyDeath-associated protein kinase 2Homo sapiens (human)
intracellular signal transductionDeath-associated protein kinase 2Homo sapiens (human)
regulation of apoptotic processDeath-associated protein kinase 2Homo sapiens (human)
anoikisDeath-associated protein kinase 2Homo sapiens (human)
protein autophosphorylationDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of neutrophil chemotaxisDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of eosinophil chemotaxisDeath-associated protein kinase 2Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathwayDeath-associated protein kinase 2Homo sapiens (human)
positive regulation of apoptotic processDeath-associated protein kinase 2Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorRibosomal protein S6 kinase alpha-6Homo sapiens (human)
signal transductionRibosomal protein S6 kinase alpha-6Homo sapiens (human)
central nervous system developmentRibosomal protein S6 kinase alpha-6Homo sapiens (human)
negative regulation of embryonic developmentRibosomal protein S6 kinase alpha-6Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeRibosomal protein S6 kinase alpha-6Homo sapiens (human)
negative regulation of mesoderm developmentRibosomal protein S6 kinase alpha-6Homo sapiens (human)
peptidyl-serine phosphorylationRibosomal protein S6 kinase alpha-6Homo sapiens (human)
positive regulation of protein phosphorylationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein phosphorylationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoskeleton organizationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
response to organonitrogen compoundTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
Wnt signaling pathwayTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
microvillus assemblyTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
actin cytoskeleton organizationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
intracellular signal transductionTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
positive regulation of JNK cascadeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein autophosphorylationTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
regulation of dendrite morphogenesisTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein localization to plasma membraneTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
neuron projection morphogenesisTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
regulation of MAPK cascadeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
MAPK cascadeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
chromatin organizationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
intracellular protein transportSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
regulation of chromatin organizationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
chromosome segregationSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
regulation of cell growthSerine/threonine-protein kinase TAO2Homo sapiens (human)
protein targeting to membraneSerine/threonine-protein kinase TAO2Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase TAO2Homo sapiens (human)
DNA damage responseSerine/threonine-protein kinase TAO2Homo sapiens (human)
mitotic G2 DNA damage checkpoint signalingSerine/threonine-protein kinase TAO2Homo sapiens (human)
axonogenesisSerine/threonine-protein kinase TAO2Homo sapiens (human)
regulation of cell shapeSerine/threonine-protein kinase TAO2Homo sapiens (human)
cell migrationSerine/threonine-protein kinase TAO2Homo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase TAO2Homo sapiens (human)
positive regulation of protein autophosphorylationSerine/threonine-protein kinase TAO2Homo sapiens (human)
activation of protein kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeSerine/threonine-protein kinase TAO2Homo sapiens (human)
regulation of actin cytoskeleton organizationSerine/threonine-protein kinase TAO2Homo sapiens (human)
positive regulation of MAPK cascadeSerine/threonine-protein kinase TAO2Homo sapiens (human)
positive regulation of JNK cascadeSerine/threonine-protein kinase TAO2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase TAO2Homo sapiens (human)
focal adhesion assemblySerine/threonine-protein kinase TAO2Homo sapiens (human)
stress-activated MAPK cascadeSerine/threonine-protein kinase TAO2Homo sapiens (human)
basal dendrite morphogenesisSerine/threonine-protein kinase TAO2Homo sapiens (human)
basal dendrite arborizationSerine/threonine-protein kinase TAO2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase TAO2Homo sapiens (human)
long-chain fatty acid metabolic processLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
long-chain fatty-acyl-CoA biosynthetic processLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
positive regulation of long-chain fatty acid import across plasma membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
protein autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
signal transductionALK tyrosine kinase receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayALK tyrosine kinase receptorHomo sapiens (human)
phosphorylationALK tyrosine kinase receptorHomo sapiens (human)
hippocampus developmentALK tyrosine kinase receptorHomo sapiens (human)
adult behaviorALK tyrosine kinase receptorHomo sapiens (human)
swimming behaviorALK tyrosine kinase receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
regulation of apoptotic processALK tyrosine kinase receptorHomo sapiens (human)
protein autophosphorylationALK tyrosine kinase receptorHomo sapiens (human)
neuron developmentALK tyrosine kinase receptorHomo sapiens (human)
negative regulation of lipid catabolic processALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityALK tyrosine kinase receptorHomo sapiens (human)
regulation of dopamine receptor signaling pathwayALK tyrosine kinase receptorHomo sapiens (human)
response to environmental enrichmentALK tyrosine kinase receptorHomo sapiens (human)
energy homeostasisALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of dendrite developmentALK tyrosine kinase receptorHomo sapiens (human)
regulation of neuron differentiationALK tyrosine kinase receptorHomo sapiens (human)
regulation of cell population proliferationALK tyrosine kinase receptorHomo sapiens (human)
multicellular organism developmentALK tyrosine kinase receptorHomo sapiens (human)
positive regulation of kinase activityALK tyrosine kinase receptorHomo sapiens (human)
skeletal muscle tissue developmentSRSF protein kinase 3Homo sapiens (human)
cell differentiationSRSF protein kinase 3Homo sapiens (human)
muscle tissue developmentSRSF protein kinase 3Homo sapiens (human)
peptidyl-serine phosphorylationSRSF protein kinase 3Homo sapiens (human)
spliceosomal complex assemblySRSF protein kinase 3Homo sapiens (human)
intracellular signal transductionSRSF protein kinase 3Homo sapiens (human)
regulation of mRNA processingSRSF protein kinase 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase ICKHomo sapiens (human)
signal transductionSerine/threonine-protein kinase ICKHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase ICKHomo sapiens (human)
intraciliary anterograde transportSerine/threonine-protein kinase ICKHomo sapiens (human)
intraciliary retrograde transportSerine/threonine-protein kinase ICKHomo sapiens (human)
intraciliary transportSerine/threonine-protein kinase ICKHomo sapiens (human)
cilium assemblySerine/threonine-protein kinase ICKHomo sapiens (human)
mitotic cell cycleCyclin-dependent kinase 11AHomo sapiens (human)
regulation of cell growthCyclin-dependent kinase 11AHomo sapiens (human)
regulation of DNA-templated transcriptionCyclin-dependent kinase 11AHomo sapiens (human)
protein phosphorylationCyclin-dependent kinase 11AHomo sapiens (human)
apoptotic processCyclin-dependent kinase 11AHomo sapiens (human)
regulation of mRNA processingCyclin-dependent kinase 11AHomo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinase 11AHomo sapiens (human)
protein phosphorylationAurora kinase CHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase CHomo sapiens (human)
positive regulation of cytokinesisAurora kinase CHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase CHomo sapiens (human)
cell divisionAurora kinase CHomo sapiens (human)
meiotic cell cycleAurora kinase CHomo sapiens (human)
regulation of cytokinesisAurora kinase CHomo sapiens (human)
mitotic spindle organizationAurora kinase CHomo sapiens (human)
G1/S transition of mitotic cell cycleCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
response to ischemiaCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
calcium ion transportCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
cellular response to interferon-betaCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
angiotensin-activated signaling pathwayCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein autophosphorylationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of neurotransmitter secretionCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of neuronal synaptic plasticityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
negative regulation of hydrolase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
positive regulation of calcium ion transportCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
dendritic spine developmentCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
cellular response to type II interferonCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
peptidyl-threonine autophosphorylationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of endocannabinoid signaling pathwayCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
regulation of neuron migrationCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
mitochondrial genome maintenanceRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of endothelial cell proliferationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
signal transductionRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of TOR signalingRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of angiogenesisRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell sizeRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
brain morphogenesisRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
homeostasis of number of cells within a tissueRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of vascular endothelial cell proliferationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
positive regulation of artery morphogenesisRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
negative regulation of cellular senescenceRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
intracellular signal transductionRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
peptidyl-serine phosphorylationRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
negative regulation of autophagySerine/threonine-protein kinase 38-likeHomo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase 38-likeHomo sapiens (human)
regulation of cellular component organizationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
postsynapse organizationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
peptidyl-serine phosphorylationSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein phosphorylationMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
cytoskeleton organizationMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
brain developmentMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
intracellular signal transductionMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
peptidyl-serine phosphorylationMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase SIK3Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase SIK3Homo sapiens (human)
positive regulation of TORC2 signalingSerine/threonine-protein kinase SIK3Homo sapiens (human)
microtubule cytoskeleton organizationSerine/threonine-protein kinase SIK3Homo sapiens (human)
intracellular signal transductionSerine/threonine-protein kinase SIK3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
cellular response to mechanical stimulusMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIThyroid hormone receptor-associated protein 3Homo sapiens (human)
regulation of alternative mRNA splicing, via spliceosomeThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear-transcribed mRNA catabolic processThyroid hormone receptor-associated protein 3Homo sapiens (human)
mRNA processingThyroid hormone receptor-associated protein 3Homo sapiens (human)
circadian rhythmThyroid hormone receptor-associated protein 3Homo sapiens (human)
RNA splicingThyroid hormone receptor-associated protein 3Homo sapiens (human)
positive regulation of circadian rhythmThyroid hormone receptor-associated protein 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionThyroid hormone receptor-associated protein 3Homo sapiens (human)
positive regulation of mRNA splicing, via spliceosomeThyroid hormone receptor-associated protein 3Homo sapiens (human)
mRNA stabilizationThyroid hormone receptor-associated protein 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIThyroid hormone receptor-associated protein 3Homo sapiens (human)
DNA repairDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
myoblast fusionDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
positive regulation of DNA-templated transcriptionDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
adipose tissue developmentDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
peptidyl-serine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
peptidyl-threonine phosphorylationDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
protein phosphorylationMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
regulation of T cell mediated cytotoxicityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of adaptive immune responseReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of phosphatase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
activation of protein kinase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of type II interferon productionReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
T cell differentiation in thymusReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein modification processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
non-canonical NF-kappaB signal transductionReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of apoptotic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
T cell homeostasisReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of activated T cell proliferationReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein autophosphorylationReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
lymph node developmentReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
spleen developmentReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
thymus developmentReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
defense response to virusReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of necroptotic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of activation-induced cell death of T cellsReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
necroptotic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
cellular response to hydrogen peroxideReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
reactive oxygen species metabolic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
programmed necrotic cell deathReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
necroptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
execution phase of necroptosisReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
amyloid fibril formationReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
regulation of CD8-positive, alpha-beta cytotoxic T cell extravasationReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
signal transductionReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cytoskeleton organizationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
establishment or maintenance of cell polaritySerine/threonine-protein kinase MRCK betaHomo sapiens (human)
signal transductionSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cell migrationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
actin cytoskeleton organizationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
actomyosin structure organizationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
peptidyl-threonine phosphorylationSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
positive regulation of cytokine productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of cytokine-mediated signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein phosphorylationInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to virusInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
positive regulation of macrophage tolerance inductionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of macrophage cytokine productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
cytokine-mediated signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to peptidoglycanInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to lipopolysaccharideInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of interleukin-12 productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of interleukin-6 productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of tumor necrosis factor productionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of toll-like receptor signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of protein catabolic processInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of protein-containing complex disassemblyInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
regulation of protein-containing complex disassemblyInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to exogenous dsRNAInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of MAP kinase activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
negative regulation of innate immune responseInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
interleukin-1-mediated signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
response to interleukin-1Interleukin-1 receptor-associated kinase 3Homo sapiens (human)
Toll signaling pathwayInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
cellular response to lipopolysaccharideInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
intracellular signal transductionInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase 24Homo sapiens (human)
signal transductionSerine/threonine-protein kinase 24Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressSerine/threonine-protein kinase 24Homo sapiens (human)
cellular response to starvationSerine/threonine-protein kinase 24Homo sapiens (human)
negative regulation of cell migrationSerine/threonine-protein kinase 24Homo sapiens (human)
cellular response to oxidative stressSerine/threonine-protein kinase 24Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase 24Homo sapiens (human)
regulation of axon regenerationSerine/threonine-protein kinase 24Homo sapiens (human)
positive regulation of axon regenerationSerine/threonine-protein kinase 24Homo sapiens (human)
execution phase of apoptosisSerine/threonine-protein kinase 24Homo sapiens (human)
Wnt signaling pathwayCasein kinase I isoform gamma-3Homo sapiens (human)
protein modification processCasein kinase I isoform gamma-3Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase I isoform gamma-3Homo sapiens (human)
signal transductionCasein kinase I isoform gamma-3Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayCasein kinase I isoform gamma-3Homo sapiens (human)
endocytosisCasein kinase I isoform gamma-3Homo sapiens (human)
MAPK cascadeMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
placenta developmentMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
response to UV-CMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
regulation of gene expressionMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
male germ-line sex determinationMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of telomere maintenance via telomeraseMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of JUN kinase activityMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of telomerase activityMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
chorionic trophoblast cell differentiationMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of p38MAPK cascadeMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
positive regulation of telomere cappingMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (573)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activityBone morphogenetic protein receptor type-1BHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityBone morphogenetic protein receptor type-1BHomo sapiens (human)
transmembrane signaling receptor activityBone morphogenetic protein receptor type-1BHomo sapiens (human)
protein bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
ATP bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
BMP bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
SMAD bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
metal ion bindingBone morphogenetic protein receptor type-1BHomo sapiens (human)
BMP receptor activityBone morphogenetic protein receptor type-1BHomo sapiens (human)
transforming growth factor beta receptor activity, type IBone morphogenetic protein receptor type-1BHomo sapiens (human)
protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
ATP bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK4Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK4Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase PLK4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK4Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 25Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 25Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 25Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 25Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 25Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 25Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 25Homo sapiens (human)
DNA bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
DNA helicase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA helicase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
mRNA bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
GTPase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
protein bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
ATP bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
transcription factor bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
poly(A) bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
eukaryotic initiation factor 4E bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
ATP hydrolysis activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
ribonucleoside triphosphate phosphatase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
translation initiation factor bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA strand annealing activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
signaling adaptor activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
RNA stem-loop bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
gamma-tubulin bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
ribosomal small subunit bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
CTPase activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
protein serine/threonine kinase activator activityATP-dependent RNA helicase DDX3XHomo sapiens (human)
cadherin bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
mRNA 5'-UTR bindingATP-dependent RNA helicase DDX3XHomo sapiens (human)
protein bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
magnesium ion bindingPyridoxal kinaseHomo sapiens (human)
ATP bindingPyridoxal kinaseHomo sapiens (human)
zinc ion bindingPyridoxal kinaseHomo sapiens (human)
pyridoxal kinase activityPyridoxal kinaseHomo sapiens (human)
pyridoxal phosphate bindingPyridoxal kinaseHomo sapiens (human)
potassium ion bindingPyridoxal kinaseHomo sapiens (human)
sodium ion bindingPyridoxal kinaseHomo sapiens (human)
lithium ion bindingPyridoxal kinaseHomo sapiens (human)
protein homodimerization activityPyridoxal kinaseHomo sapiens (human)
transcription coactivator bindingCitron Rho-interacting kinaseHomo sapiens (human)
protein serine/threonine kinase activityCitron Rho-interacting kinaseHomo sapiens (human)
protein bindingCitron Rho-interacting kinaseHomo sapiens (human)
ATP bindingCitron Rho-interacting kinaseHomo sapiens (human)
SH3 domain bindingCitron Rho-interacting kinaseHomo sapiens (human)
protein kinase bindingCitron Rho-interacting kinaseHomo sapiens (human)
PDZ domain bindingCitron Rho-interacting kinaseHomo sapiens (human)
protein serine/threonine kinase inhibitor activityCitron Rho-interacting kinaseHomo sapiens (human)
metal ion bindingCitron Rho-interacting kinaseHomo sapiens (human)
scaffold protein bindingCitron Rho-interacting kinaseHomo sapiens (human)
protein serine kinase activityCitron Rho-interacting kinaseHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase RIO3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase RIO3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase RIO3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase RIO3Homo sapiens (human)
caspase bindingSerine/threonine-protein kinase RIO3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase RIO3Homo sapiens (human)
magnesium ion bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
MAP kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
JUN kinase kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
enzyme bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein kinase bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein phosphatase bindingDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
molecular function activator activityDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Chk1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Chk1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Chk1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Chk1Homo sapiens (human)
protein domain specific bindingSerine/threonine-protein kinase Chk1Homo sapiens (human)
histone H3T11 kinase activitySerine/threonine-protein kinase Chk1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Chk1Homo sapiens (human)
protein kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein kinase bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
identical protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein homodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein heterodimerization activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
scaffold protein bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
protein serine kinase activityInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
transferrin receptor bindingInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
guanylate kinase activityPeripheral plasma membrane protein CASKHomo sapiens (human)
protein serine/threonine kinase activityPeripheral plasma membrane protein CASKHomo sapiens (human)
protein bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
calmodulin bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
ATP bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
neurexin family protein bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
protein serine kinase activityPeripheral plasma membrane protein CASKHomo sapiens (human)
signaling receptor bindingPeripheral plasma membrane protein CASKHomo sapiens (human)
protein kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase AHomo sapiens (human)
protein bindingAurora kinase AHomo sapiens (human)
ATP bindingAurora kinase AHomo sapiens (human)
protein kinase bindingAurora kinase AHomo sapiens (human)
ubiquitin protein ligase bindingAurora kinase AHomo sapiens (human)
histone H3S10 kinase activityAurora kinase AHomo sapiens (human)
protein heterodimerization activityAurora kinase AHomo sapiens (human)
protein serine kinase activityAurora kinase AHomo sapiens (human)
molecular function activator activityAurora kinase AHomo sapiens (human)
protein serine/threonine kinase activityCyclin-G-associated kinaseHomo sapiens (human)
protein bindingCyclin-G-associated kinaseHomo sapiens (human)
ATP bindingCyclin-G-associated kinaseHomo sapiens (human)
cyclin bindingCyclin-G-associated kinaseHomo sapiens (human)
protein-folding chaperone bindingCyclin-G-associated kinaseHomo sapiens (human)
protein serine kinase activityCyclin-G-associated kinaseHomo sapiens (human)
clathrin bindingCyclin-G-associated kinaseHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase DCLK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase DCLK1Homo sapiens (human)
protein kinase activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein homodimerization activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein-containing complex bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein heterodimerization activityInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
scaffold protein bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
transferrin receptor bindingInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
protein tyrosine kinase activityMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
protein bindingMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
ATP bindingMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
metal ion bindingMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
Wnt-protein bindingMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
ephrin receptor activityEphrin type-B receptor 6Homo sapiens (human)
protein bindingEphrin type-B receptor 6Homo sapiens (human)
ATP bindingEphrin type-B receptor 6Homo sapiens (human)
signaling receptor activityEphrin type-B receptor 6Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-B receptor 6Homo sapiens (human)
FAD bindingPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
flavin adenine dinucleotide bindingPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
pristanoyl-CoA oxidase activityPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
fatty acid bindingPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 13Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 13Homo sapiens (human)
protein bindingMitogen-activated protein kinase 13Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 13Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 13Homo sapiens (human)
protein serine/threonine kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
3-phosphoinositide-dependent protein kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
ATP binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
phospholipase activator activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
phospholipase binding3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein serine kinase activity3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein serine/threonine kinase activator activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
IkappaB kinase complex bindingMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
protein serine/threonine kinase activityDeath-associated protein kinase 3Homo sapiens (human)
protein bindingDeath-associated protein kinase 3Homo sapiens (human)
ATP bindingDeath-associated protein kinase 3Homo sapiens (human)
cAMP response element binding protein bindingDeath-associated protein kinase 3Homo sapiens (human)
small GTPase bindingDeath-associated protein kinase 3Homo sapiens (human)
identical protein bindingDeath-associated protein kinase 3Homo sapiens (human)
protein homodimerization activityDeath-associated protein kinase 3Homo sapiens (human)
leucine zipper domain bindingDeath-associated protein kinase 3Homo sapiens (human)
protein serine kinase activityDeath-associated protein kinase 3Homo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
transcription coactivator bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
type II transforming growth factor beta receptor bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
receptor tyrosine kinase bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
ubiquitin protein ligase bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
histone kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
scaffold protein bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein serine/threonine kinase bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
DNA-binding transcription factor bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
linear polyubiquitin bindingMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
protein serine/threonine kinase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
signaling receptor bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
ATP bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
LIM domain bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
signaling adaptor activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
identical protein bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein homodimerization activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
CARD domain bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
caspase bindingReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein serine kinase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
JUN kinase kinase kinase activityReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein kinase activityMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
protein serine/threonine kinase activityMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
protein bindingMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
ATP bindingMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
protein serine kinase activityMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
histone H2A kinase activityMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
p53 bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
protein serine/threonine kinase activityNUAK family SNF1-like kinase 1Homo sapiens (human)
protein bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
ATP bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
metal ion bindingNUAK family SNF1-like kinase 1Homo sapiens (human)
protein serine kinase activityNUAK family SNF1-like kinase 1Homo sapiens (human)
magnesium ion bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
GTPase activityDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
protein bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
GTP bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
phosphatidic acid bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
GTPase-dependent fusogenic activityDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
membrane bending activityDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cardiolipin bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
microtubule bindingDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
protein bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
phosphatidylinositol kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
protein kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
signaling receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-12 receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK2Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK2Homo sapiens (human)
protein kinase bindingTyrosine-protein kinase JAK2Homo sapiens (human)
heme bindingTyrosine-protein kinase JAK2Homo sapiens (human)
type 1 angiotensin receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
acetylcholine receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
histone H3Y41 kinase activityTyrosine-protein kinase JAK2Homo sapiens (human)
SH2 domain bindingTyrosine-protein kinase JAK2Homo sapiens (human)
histone bindingTyrosine-protein kinase JAK2Homo sapiens (human)
identical protein bindingTyrosine-protein kinase JAK2Homo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase JAK2Homo sapiens (human)
insulin receptor substrate bindingTyrosine-protein kinase JAK2Homo sapiens (human)
metal ion bindingTyrosine-protein kinase JAK2Homo sapiens (human)
peptide hormone receptor bindingTyrosine-protein kinase JAK2Homo sapiens (human)
protease bindingRho-associated protein kinase 2Homo sapiens (human)
RNA bindingRho-associated protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityRho-associated protein kinase 2Homo sapiens (human)
structural molecule activityRho-associated protein kinase 2Homo sapiens (human)
protein bindingRho-associated protein kinase 2Homo sapiens (human)
ATP bindingRho-associated protein kinase 2Homo sapiens (human)
small GTPase bindingRho-associated protein kinase 2Homo sapiens (human)
metal ion bindingRho-associated protein kinase 2Homo sapiens (human)
tau protein bindingRho-associated protein kinase 2Homo sapiens (human)
tau-protein kinase activityRho-associated protein kinase 2Homo sapiens (human)
endopeptidase activator activityRho-associated protein kinase 2Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activityRho-associated protein kinase 2Homo sapiens (human)
protein serine kinase activityRho-associated protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ULK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
GTPase bindingSerine/threonine-protein kinase ULK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ULK1Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
RNA endonuclease activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
platelet-derived growth factor receptor bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
enzyme bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Hsp70 protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
ADP bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Hsp90 protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
unfolded protein bindingSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein tyrosine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H3S10 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H3S28 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
histone H2AS1 kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-5Homo sapiens (human)
RNA bindingU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
RNA helicase activityU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
helicase activityU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
protein bindingU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
ATP bindingU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
ATP hydrolysis activityU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
identical protein bindingU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-4Homo sapiens (human)
histone H3S10 kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
histone H3S28 kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-4Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingSerine/threonine-protein kinase 16Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activitySerine/threonine-protein kinase 16Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 16Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 16Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 16Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 16Homo sapiens (human)
ATP bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol bindingPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol kinase activityPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 3Homo sapiens (human)
MAP kinase kinase activitySerine/threonine-protein kinase PAK 3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
SH3 domain bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase PAK 3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 3Homo sapiens (human)
protein kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
protein bindingCyclin-dependent kinase-like 5Homo sapiens (human)
ATP bindingCyclin-dependent kinase-like 5Homo sapiens (human)
kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
small GTPase bindingCyclin-dependent kinase-like 5Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase-like 5Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 17BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 17BHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 17BHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 17BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 10Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 10Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 10Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 10Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 10Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 10Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase D3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase D3Homo sapiens (human)
kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase D3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase D3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 14Homo sapiens (human)
protein bindingCyclin-dependent kinase 14Homo sapiens (human)
ATP bindingCyclin-dependent kinase 14Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 14Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 14Homo sapiens (human)
single-stranded DNA bindingStructural maintenance of chromosomes protein 2Homo sapiens (human)
protein bindingStructural maintenance of chromosomes protein 2Homo sapiens (human)
ATP bindingStructural maintenance of chromosomes protein 2Homo sapiens (human)
ATP hydrolysis activityStructural maintenance of chromosomes protein 2Homo sapiens (human)
chromatin bindingStructural maintenance of chromosomes protein 2Homo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 6Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase OSR1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase OSR1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase OSR1Homo sapiens (human)
creatine kinase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
microtubule bindingMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase LATS1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
nuclear estrogen receptor bindingSerine/threonine-protein kinase LATS1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase LATS1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cadherin binding involved in cell-cell adhesionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 4Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Chk2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
ubiquitin protein ligase bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase Chk2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Chk2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Chk2Homo sapiens (human)
supercoiled DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
magnesium ion bindingTyrosine-protein kinase ABL1Homo sapiens (human)
four-way junction DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
bubble DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase ABL1Homo sapiens (human)
DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
transcription coactivator activityTyrosine-protein kinase ABL1Homo sapiens (human)
actin monomer bindingTyrosine-protein kinase ABL1Homo sapiens (human)
nicotinate-nucleotide adenylyltransferase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
protein kinase C bindingTyrosine-protein kinase ABL1Homo sapiens (human)
protein bindingTyrosine-protein kinase ABL1Homo sapiens (human)
ATP bindingTyrosine-protein kinase ABL1Homo sapiens (human)
kinase activityTyrosine-protein kinase ABL1Homo sapiens (human)
SH3 domain bindingTyrosine-protein kinase ABL1Homo sapiens (human)
syntaxin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
manganese ion bindingTyrosine-protein kinase ABL1Homo sapiens (human)
neuropilin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
SH2 domain bindingTyrosine-protein kinase ABL1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase ABL1Homo sapiens (human)
actin filament bindingTyrosine-protein kinase ABL1Homo sapiens (human)
mitogen-activated protein kinase bindingTyrosine-protein kinase ABL1Homo sapiens (human)
proline-rich region bindingTyrosine-protein kinase ABL1Homo sapiens (human)
delta-catenin bindingTyrosine-protein kinase ABL1Homo sapiens (human)
sequence-specific double-stranded DNA bindingTyrosine-protein kinase ABL1Homo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
small GTPase bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
enzyme bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
identical protein bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
metal ion bindingRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
MAP kinase kinase kinase activityRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
growth factor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
RNA polymerase I core bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
transmembrane signaling receptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
signaling receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
coreceptor activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor tyrosine kinase bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
identical protein bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ErbB-3 class receptor bindingReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein heterodimerization activityReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
protein tyrosine kinase activityHigh affinity nerve growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityHigh affinity nerve growth factor receptorHomo sapiens (human)
GPI-linked ephrin receptor activityHigh affinity nerve growth factor receptorHomo sapiens (human)
neurotrophin p75 receptor bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
protein bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
ATP bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
nerve growth factor receptor activityHigh affinity nerve growth factor receptorHomo sapiens (human)
kinase bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
identical protein bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
protein homodimerization activityHigh affinity nerve growth factor receptorHomo sapiens (human)
nerve growth factor bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
neurotrophin bindingHigh affinity nerve growth factor receptorHomo sapiens (human)
neurotrophin receptor activityHigh affinity nerve growth factor receptorHomo sapiens (human)
protein bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
GTP bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
metal ion bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
G protein-coupled receptor bindingGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
GTPase activityGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
adenine nucleotide transmembrane transporter activityADP/ATP translocase 2Homo sapiens (human)
RNA bindingADP/ATP translocase 2Homo sapiens (human)
ATP:ADP antiporter activityADP/ATP translocase 2Homo sapiens (human)
protein bindingADP/ATP translocase 2Homo sapiens (human)
proton transmembrane transporter activityADP/ATP translocase 2Homo sapiens (human)
adenine transmembrane transporter activityADP/ATP translocase 2Homo sapiens (human)
oxidative phosphorylation uncoupler activityADP/ATP translocase 2Homo sapiens (human)
ubiquitin protein ligase bindingADP/ATP translocase 2Homo sapiens (human)
chromatin bindingProtein kinase C beta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C beta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C beta typeHomo sapiens (human)
protein kinase C bindingProtein kinase C beta typeHomo sapiens (human)
calcium channel regulator activityProtein kinase C beta typeHomo sapiens (human)
protein bindingProtein kinase C beta typeHomo sapiens (human)
ATP bindingProtein kinase C beta typeHomo sapiens (human)
zinc ion bindingProtein kinase C beta typeHomo sapiens (human)
nuclear receptor coactivator activityProtein kinase C beta typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C beta typeHomo sapiens (human)
histone bindingProtein kinase C beta typeHomo sapiens (human)
nuclear androgen receptor bindingProtein kinase C beta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C beta typeHomo sapiens (human)
amyloid-beta bindingInsulin receptorHomo sapiens (human)
protein tyrosine kinase activityInsulin receptorHomo sapiens (human)
insulin receptor activityInsulin receptorHomo sapiens (human)
insulin-like growth factor receptor bindingInsulin receptorHomo sapiens (human)
protein bindingInsulin receptorHomo sapiens (human)
ATP bindingInsulin receptorHomo sapiens (human)
GTP bindingInsulin receptorHomo sapiens (human)
protein domain specific bindingInsulin receptorHomo sapiens (human)
insulin-like growth factor I bindingInsulin receptorHomo sapiens (human)
insulin-like growth factor II bindingInsulin receptorHomo sapiens (human)
cargo receptor activityInsulin receptorHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin receptorHomo sapiens (human)
insulin bindingInsulin receptorHomo sapiens (human)
insulin receptor substrate bindingInsulin receptorHomo sapiens (human)
protein-containing complex bindingInsulin receptorHomo sapiens (human)
PTB domain bindingInsulin receptorHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase LckHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase LckHomo sapiens (human)
protein serine/threonine phosphatase activityTyrosine-protein kinase LckHomo sapiens (human)
protein bindingTyrosine-protein kinase LckHomo sapiens (human)
ATP bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase LckHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase LckHomo sapiens (human)
SH2 domain bindingTyrosine-protein kinase LckHomo sapiens (human)
T cell receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD4 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
CD8 receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
identical protein bindingTyrosine-protein kinase LckHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase LckHomo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase LckHomo sapiens (human)
ATPase bindingTyrosine-protein kinase LckHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase LckHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
protein bindingTyrosine-protein kinase FynHomo sapiens (human)
ATP bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase FynHomo sapiens (human)
enzyme bindingTyrosine-protein kinase FynHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
identical protein bindingTyrosine-protein kinase FynHomo sapiens (human)
alpha-tubulin bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase FynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase FynHomo sapiens (human)
metal ion bindingTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
tau protein bindingTyrosine-protein kinase FynHomo sapiens (human)
tau-protein kinase activityTyrosine-protein kinase FynHomo sapiens (human)
growth factor receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase FynHomo sapiens (human)
disordered domain specific bindingTyrosine-protein kinase FynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
virus receptor activityCyclin-dependent kinase 1Homo sapiens (human)
chromatin bindingCyclin-dependent kinase 1Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein bindingCyclin-dependent kinase 1Homo sapiens (human)
ATP bindingCyclin-dependent kinase 1Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 1Homo sapiens (human)
kinase activityCyclin-dependent kinase 1Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 1Homo sapiens (human)
Hsp70 protein bindingCyclin-dependent kinase 1Homo sapiens (human)
histone kinase activityCyclin-dependent kinase 1Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 1Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 1Homo sapiens (human)
purine nucleobase bindingGlycogen phosphorylase, liver formHomo sapiens (human)
protein bindingGlycogen phosphorylase, liver formHomo sapiens (human)
ATP bindingGlycogen phosphorylase, liver formHomo sapiens (human)
glucose bindingGlycogen phosphorylase, liver formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
AMP bindingGlycogen phosphorylase, liver formHomo sapiens (human)
vitamin bindingGlycogen phosphorylase, liver formHomo sapiens (human)
bile acid bindingGlycogen phosphorylase, liver formHomo sapiens (human)
identical protein bindingGlycogen phosphorylase, liver formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, liver formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, liver formHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase Fes/FpsHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
ATP bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
microtubule bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
immunoglobulin receptor bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
phosphatidylinositol bindingTyrosine-protein kinase Fes/FpsHomo sapiens (human)
protein tyrosine kinase activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
macrophage colony-stimulating factor receptor activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
protein bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
ATP bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
protein phosphatase bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cytokine bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
protein homodimerization activityMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
growth factor bindingMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase YesHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase YesHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase YesHomo sapiens (human)
protein bindingTyrosine-protein kinase YesHomo sapiens (human)
ATP bindingTyrosine-protein kinase YesHomo sapiens (human)
enzyme bindingTyrosine-protein kinase YesHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase YesHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase YesHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase LynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase LynHomo sapiens (human)
platelet-derived growth factor receptor bindingTyrosine-protein kinase LynHomo sapiens (human)
integrin bindingTyrosine-protein kinase LynHomo sapiens (human)
protein bindingTyrosine-protein kinase LynHomo sapiens (human)
ATP bindingTyrosine-protein kinase LynHomo sapiens (human)
kinase activityTyrosine-protein kinase LynHomo sapiens (human)
SH3 domain bindingTyrosine-protein kinase LynHomo sapiens (human)
ubiquitin protein ligase bindingTyrosine-protein kinase LynHomo sapiens (human)
gamma-tubulin bindingTyrosine-protein kinase LynHomo sapiens (human)
glycosphingolipid bindingTyrosine-protein kinase LynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase LynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase LynHomo sapiens (human)
phosphoprotein bindingTyrosine-protein kinase LynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase LynHomo sapiens (human)
phosphorylation-dependent protein bindingTyrosine-protein kinase LynHomo sapiens (human)
phosphatidylinositol 3-kinase activator activityTyrosine-protein kinase LynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase LynHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
calcium ion bindingProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
signaling receptor activityProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
G-protein alpha-subunit bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein tyrosine kinase activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor receptor activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
ATP bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor I bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
identical protein bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor substrate bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein-containing complex bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein transporter activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor activityInsulin-like growth factor 1 receptorHomo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
RNA bindingSignal recognition particle receptor subunit alphaHomo sapiens (human)
GTP bindingSignal recognition particle receptor subunit alphaHomo sapiens (human)
ATP hydrolysis activitySignal recognition particle receptor subunit alphaHomo sapiens (human)
signal recognition particle bindingSignal recognition particle receptor subunit alphaHomo sapiens (human)
GTPase activitySignal recognition particle receptor subunit alphaHomo sapiens (human)
protein bindingCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
ubiquinol-cytochrome-c reductase activityCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
heme bindingCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
metal ion bindingCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
protein tyrosine kinase activityHepatocyte growth factor receptorHomo sapiens (human)
protein bindingHepatocyte growth factor receptorHomo sapiens (human)
ATP bindingHepatocyte growth factor receptorHomo sapiens (human)
semaphorin receptor activityHepatocyte growth factor receptorHomo sapiens (human)
protein phosphatase bindingHepatocyte growth factor receptorHomo sapiens (human)
identical protein bindingHepatocyte growth factor receptorHomo sapiens (human)
molecular function activator activityHepatocyte growth factor receptorHomo sapiens (human)
hepatocyte growth factor receptor activityHepatocyte growth factor receptorHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase HCKHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase HCKHomo sapiens (human)
protein bindingTyrosine-protein kinase HCKHomo sapiens (human)
ATP bindingTyrosine-protein kinase HCKHomo sapiens (human)
lipid bindingTyrosine-protein kinase HCKHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase HCKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase HCKHomo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein phosphatase bindingProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
protein kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein tyrosine kinase activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet activating factor receptor activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor beta-receptor activityPlatelet-derived growth factor receptor betaHomo sapiens (human)
signaling receptor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor receptor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
ATP bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
enzyme bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
protein kinase bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
vascular endothelial growth factor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
platelet-derived growth factor bindingPlatelet-derived growth factor receptor betaHomo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase FgrHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FgrHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FgrHomo sapiens (human)
protein bindingTyrosine-protein kinase FgrHomo sapiens (human)
ATP bindingTyrosine-protein kinase FgrHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase FgrHomo sapiens (human)
immunoglobulin receptor bindingTyrosine-protein kinase FgrHomo sapiens (human)
Fc-gamma receptor I complex bindingTyrosine-protein kinase FgrHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FgrHomo sapiens (human)
magnesium ion bindingWee1-like protein kinase 2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityWee1-like protein kinase 2Homo sapiens (human)
ATP bindingWee1-like protein kinase 2Homo sapiens (human)
protein tyrosine kinase activityWee1-like protein kinase 2Homo sapiens (human)
protein bindingUncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)
ATP bindingUncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)
protein serine kinase activityUncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)
protein serine/threonine kinase activityUncharacterized serine/threonine-protein kinase SBK3Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase A-RafHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase A-RafHomo sapiens (human)
protein bindingSerine/threonine-protein kinase A-RafHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase A-RafHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase A-RafHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase A-RafHomo sapiens (human)
MAP kinase kinase kinase activitySerine/threonine-protein kinase A-RafHomo sapiens (human)
protease bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
protein tyrosine kinase activityMast/stem cell growth factor receptor KitHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityMast/stem cell growth factor receptor KitHomo sapiens (human)
stem cell factor receptor activityMast/stem cell growth factor receptor KitHomo sapiens (human)
protein bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
ATP bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
cytokine bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
SH2 domain bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
protein homodimerization activityMast/stem cell growth factor receptor KitHomo sapiens (human)
metal ion bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
growth factor bindingMast/stem cell growth factor receptor KitHomo sapiens (human)
protein bindingGlycogen phosphorylase, brain formHomo sapiens (human)
glycogen phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
linear malto-oligosaccharide phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
SHG alpha-glucan phosphorylase activityGlycogen phosphorylase, brain formHomo sapiens (human)
pyridoxal phosphate bindingGlycogen phosphorylase, brain formHomo sapiens (human)
protein serine/threonine kinase activityBreakpoint cluster region proteinHomo sapiens (human)
protein tyrosine kinase activityBreakpoint cluster region proteinHomo sapiens (human)
guanyl-nucleotide exchange factor activityBreakpoint cluster region proteinHomo sapiens (human)
GTPase activator activityBreakpoint cluster region proteinHomo sapiens (human)
protein bindingBreakpoint cluster region proteinHomo sapiens (human)
ATP bindingBreakpoint cluster region proteinHomo sapiens (human)
protein serine kinase activityBreakpoint cluster region proteinHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
transcription factor bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
manganese ion bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ribosomal small subunit bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 1Homo sapiens (human)
protein bindingFibroblast growth factor receptor 1Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 1Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 1Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 1Homo sapiens (human)
SH2 domain bindingFibroblast growth factor receptor 1Homo sapiens (human)
identical protein bindingFibroblast growth factor receptor 1Homo sapiens (human)
protein homodimerization activityFibroblast growth factor receptor 1Homo sapiens (human)
receptor-receptor interactionFibroblast growth factor receptor 1Homo sapiens (human)
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 4Homo sapiens (human)
protein bindingCyclin-dependent kinase 4Homo sapiens (human)
ATP bindingCyclin-dependent kinase 4Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase regulator activityCyclin-dependent kinase 4Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 4Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 4Homo sapiens (human)
ATP:ADP antiporter activityADP/ATP translocase 3Homo sapiens (human)
protein bindingADP/ATP translocase 3Homo sapiens (human)
nucleotide bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
DNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
RNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
IMP dehydrogenase activityInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
protein bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
metal ion bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
protein kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein kinase C bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signaling receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
insulin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase activator activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
enzyme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
heme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nuclear estrogen receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
SH2 domain bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transmembrane transporter bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cadherin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATPase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phosphoprotein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
BMP receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
connexin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
scaffold protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cAMP-dependent protein kinase inhibitor activitycAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
protein bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cAMP-dependent protein kinase regulator activitycAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
protein domain specific bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
ubiquitin protein ligase bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
protein kinase A catalytic subunit bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cAMP bindingcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityInsulin receptor-related proteinHomo sapiens (human)
protein bindingInsulin receptor-related proteinHomo sapiens (human)
ATP bindingInsulin receptor-related proteinHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin receptor-related proteinHomo sapiens (human)
insulin receptor substrate bindingInsulin receptor-related proteinHomo sapiens (human)
insulin receptor activityInsulin receptor-related proteinHomo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
MAP kinase kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
calcium ion bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
mitogen-activated protein kinase kinase bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
identical protein bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
scaffold protein bindingSerine/threonine-protein kinase B-rafHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
MAP kinase kinase kinase activitySerine/threonine-protein kinase B-rafHomo sapiens (human)
protein serine/threonine kinase activityPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
phosphorylase kinase activityPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
protein bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
calmodulin bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
ATP bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
enzyme bindingPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
tau-protein kinase activityPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
dihydronicotinamide riboside quinone reductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
zinc ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
electron transfer activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
oxidoreductase activity, acting on other nitrogenous compounds as donorsRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
chloride ion bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein homodimerization activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
FAD bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
melatonin bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
resveratrol bindingRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
NAD(P)H dehydrogenase (quinone) activityRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
protein kinase activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor alpha-receptor activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
vascular endothelial growth factor receptor activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor receptor bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
ATP bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
vascular endothelial growth factor bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein homodimerization activityPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein-containing complex bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
platelet-derived growth factor bindingPlatelet-derived growth factor receptor alphaHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FerHomo sapiens (human)
epidermal growth factor receptor bindingTyrosine-protein kinase FerHomo sapiens (human)
protein bindingTyrosine-protein kinase FerHomo sapiens (human)
ATP bindingTyrosine-protein kinase FerHomo sapiens (human)
protein phosphatase 1 bindingTyrosine-protein kinase FerHomo sapiens (human)
lipid bindingTyrosine-protein kinase FerHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FerHomo sapiens (human)
protein kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
integrin bindingProtein kinase C alpha typeHomo sapiens (human)
protein bindingProtein kinase C alpha typeHomo sapiens (human)
ATP bindingProtein kinase C alpha typeHomo sapiens (human)
zinc ion bindingProtein kinase C alpha typeHomo sapiens (human)
enzyme bindingProtein kinase C alpha typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol bindingProtein kinase C alpha typeHomo sapiens (human)
magnesium ion bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein serine/threonine kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
AMP-activated protein kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cAMP-dependent protein kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein serine/threonine/tyrosine kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
ATP bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein kinase bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein domain specific bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
manganese ion bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein kinase A regulatory subunit bindingcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
channel activator activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
protein serine kinase activitycAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 1 Homo sapiens (human)
placental growth factor receptor activityVascular endothelial growth factor receptor 1 Homo sapiens (human)
protein bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
ATP bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
ATP hydrolysis activityGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
protein-macromolecule adaptor activityGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
5'-3' DNA helicase activityGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
metal ion bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
4 iron, 4 sulfur cluster bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
DNA helicase activityGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
damaged DNA bindingGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
RNA bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
double-stranded RNA bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
ATP bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein phosphatase regulator activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
identical protein bindingInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine kinase activityInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
protein bindingCasein kinase II subunit alpha'Homo sapiens (human)
ATP bindingCasein kinase II subunit alpha'Homo sapiens (human)
protein serine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
GTPase activityRas-related protein Rab-6AHomo sapiens (human)
protein bindingRas-related protein Rab-6AHomo sapiens (human)
GTP bindingRas-related protein Rab-6AHomo sapiens (human)
protein domain specific bindingRas-related protein Rab-6AHomo sapiens (human)
myosin V bindingRas-related protein Rab-6AHomo sapiens (human)
transcription coactivator activitySerine/threonine-protein kinase MAKHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase MAKHomo sapiens (human)
protein bindingSerine/threonine-protein kinase MAKHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase MAKHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase MAKHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MAKHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MAKHomo sapiens (human)
RNA bindingCyclin-dependent kinase 11BHomo sapiens (human)
protein kinase activityCyclin-dependent kinase 11BHomo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 11BHomo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 11BHomo sapiens (human)
protein bindingCyclin-dependent kinase 11BHomo sapiens (human)
ATP bindingCyclin-dependent kinase 11BHomo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 11BHomo sapiens (human)
fibronectin bindingEphrin type-A receptor 1Homo sapiens (human)
protein kinase activityEphrin type-A receptor 1Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 1Homo sapiens (human)
ATP bindingEphrin type-A receptor 1Homo sapiens (human)
protein kinase bindingEphrin type-A receptor 1Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEphrin type-A receptor 1Homo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 2Homo sapiens (human)
protein bindingFibroblast growth factor receptor 2Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 2Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 2Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 2Homo sapiens (human)
protein homodimerization activityFibroblast growth factor receptor 2Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
transmembrane signaling receptor activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
growth factor bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein tyrosine kinase activator activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ubiquitin protein ligase bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neuregulin bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
identical protein bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ErbB-3 class receptor bindingReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
protein heterodimerization activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
neuregulin receptor activityReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
phosphoribosylaminoimidazole carboxylase activityMultifunctional protein ADE2Homo sapiens (human)
phosphoribosylaminoimidazolesuccinocarboxamide synthase activityMultifunctional protein ADE2Homo sapiens (human)
protein bindingMultifunctional protein ADE2Homo sapiens (human)
ATP bindingMultifunctional protein ADE2Homo sapiens (human)
identical protein bindingMultifunctional protein ADE2Homo sapiens (human)
5-amino-4-imidazole carboxylate lyase activityMultifunctional protein ADE2Homo sapiens (human)
cadherin bindingMultifunctional protein ADE2Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 4Homo sapiens (human)
protein bindingFibroblast growth factor receptor 4Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 4Homo sapiens (human)
heparin bindingFibroblast growth factor receptor 4Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 4Homo sapiens (human)
protein tyrosine kinase activityFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor receptor activityFibroblast growth factor receptor 3Homo sapiens (human)
protein bindingFibroblast growth factor receptor 3Homo sapiens (human)
ATP bindingFibroblast growth factor receptor 3Homo sapiens (human)
fibroblast growth factor bindingFibroblast growth factor receptor 3Homo sapiens (human)
identical protein bindingFibroblast growth factor receptor 3Homo sapiens (human)
protein serine/threonine kinase activitycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
AMP-activated protein kinase activitycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
cAMP-dependent protein kinase activitycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
protein bindingcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
ATP bindingcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
protein serine kinase activitycAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
protein kinase A regulatory subunit bindingcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
magnesium ion bindingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein serine/threonine kinase activitycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
AMP-activated protein kinase activitycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
cAMP-dependent protein kinase activitycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein bindingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
ATP bindingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
ubiquitin protein ligase bindingcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
protein serine kinase activitycAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
ferrochelatase activityFerrochelatase, mitochondrialHomo sapiens (human)
protein bindingFerrochelatase, mitochondrialHomo sapiens (human)
ferrous iron bindingFerrochelatase, mitochondrialHomo sapiens (human)
heme bindingFerrochelatase, mitochondrialHomo sapiens (human)
iron-responsive element bindingFerrochelatase, mitochondrialHomo sapiens (human)
identical protein bindingFerrochelatase, mitochondrialHomo sapiens (human)
protein homodimerization activityFerrochelatase, mitochondrialHomo sapiens (human)
2 iron, 2 sulfur cluster bindingFerrochelatase, mitochondrialHomo sapiens (human)
protein kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
PDZ domain bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
peptide bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
identical protein bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein phosphatase 2A bindingRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase beta-1Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK1Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK1Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK1Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK1Homo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase JAK1Homo sapiens (human)
ubiquitin protein ligase bindingTyrosine-protein kinase JAK1Homo sapiens (human)
CCR5 chemokine receptor bindingTyrosine-protein kinase JAK1Homo sapiens (human)
metal ion bindingTyrosine-protein kinase JAK1Homo sapiens (human)
protein kinase activityProtein kinase C eta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
protein bindingProtein kinase C eta typeHomo sapiens (human)
ATP bindingProtein kinase C eta typeHomo sapiens (human)
enzyme bindingProtein kinase C eta typeHomo sapiens (human)
small GTPase bindingProtein kinase C eta typeHomo sapiens (human)
metal ion bindingProtein kinase C eta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C eta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C eta typeHomo sapiens (human)
histone kinase activityCyclin-dependent kinase 2Homo sapiens (human)
magnesium ion bindingCyclin-dependent kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein bindingCyclin-dependent kinase 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase 2Homo sapiens (human)
protein domain specific bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 2Homo sapiens (human)
protein kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
protein bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
ATP bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
Edg-2 lysophosphatidic acid receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
beta-adrenergic receptor kinase activityBeta-adrenergic receptor kinase 1Homo sapiens (human)
G protein-coupled receptor bindingBeta-adrenergic receptor kinase 1Homo sapiens (human)
RNA bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
RNA helicase activityProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
helicase activityProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
protein bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
ATP bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
ATP hydrolysis activityProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
protein domain specific bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cadherin bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
mRNA bindingProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
protein bindingActivin receptor type-2AHomo sapiens (human)
activin receptor activityActivin receptor type-2AHomo sapiens (human)
activin bindingActivin receptor type-2AHomo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-2AHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityActivin receptor type-2AHomo sapiens (human)
protein bindingActivin receptor type-2AHomo sapiens (human)
ATP bindingActivin receptor type-2AHomo sapiens (human)
coreceptor activityActivin receptor type-2AHomo sapiens (human)
activin receptor activityActivin receptor type-2AHomo sapiens (human)
growth factor bindingActivin receptor type-2AHomo sapiens (human)
PDZ domain bindingActivin receptor type-2AHomo sapiens (human)
inhibin bindingActivin receptor type-2AHomo sapiens (human)
metal ion bindingActivin receptor type-2AHomo sapiens (human)
BMP receptor activityActivin receptor type-2AHomo sapiens (human)
phosphotyrosine residue bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
protein bindingMitogen-activated protein kinase 3 Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 3 Homo sapiens (human)
phosphatase bindingMitogen-activated protein kinase 3 Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 3 Homo sapiens (human)
DNA-binding transcription factor bindingMitogen-activated protein kinase 3 Homo sapiens (human)
protein serine/threonine kinase activityMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
protein bindingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
ATP bindingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
tau protein bindingMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
tau-protein kinase activityMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
protein serine kinase activityMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
deoxyadenosine kinase activityDeoxycytidine kinaseHomo sapiens (human)
deoxycytidine kinase activityDeoxycytidine kinaseHomo sapiens (human)
deoxyguanosine kinase activityDeoxycytidine kinaseHomo sapiens (human)
ATP bindingDeoxycytidine kinaseHomo sapiens (human)
protein homodimerization activityDeoxycytidine kinaseHomo sapiens (human)
cytidine kinase activityDeoxycytidine kinaseHomo sapiens (human)
phosphotyrosine residue bindingMitogen-activated protein kinase 1Homo sapiens (human)
DNA bindingMitogen-activated protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
protein bindingMitogen-activated protein kinase 1Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 1Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
phosphatase bindingMitogen-activated protein kinase 1Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase 1Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 1Homo sapiens (human)
virus receptor activityEphrin type-A receptor 2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEphrin type-A receptor 2Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 2Homo sapiens (human)
protein bindingEphrin type-A receptor 2Homo sapiens (human)
ATP bindingEphrin type-A receptor 2Homo sapiens (human)
growth factor bindingEphrin type-A receptor 2Homo sapiens (human)
cadherin bindingEphrin type-A receptor 2Homo sapiens (human)
molecular function activator activityEphrin type-A receptor 2Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 3Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 3Homo sapiens (human)
protein bindingEphrin type-A receptor 3Homo sapiens (human)
ATP bindingEphrin type-A receptor 3Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 3Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 8Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 8Homo sapiens (human)
ATP bindingEphrin type-A receptor 8Homo sapiens (human)
growth factor bindingEphrin type-A receptor 8Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 8Homo sapiens (human)
amyloid-beta bindingEphrin type-B receptor 2Homo sapiens (human)
protein tyrosine kinase activityEphrin type-B receptor 2Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-B receptor 2Homo sapiens (human)
signaling receptor bindingEphrin type-B receptor 2Homo sapiens (human)
protein bindingEphrin type-B receptor 2Homo sapiens (human)
ATP bindingEphrin type-B receptor 2Homo sapiens (human)
axon guidance receptor activityEphrin type-B receptor 2Homo sapiens (human)
identical protein bindingEphrin type-B receptor 2Homo sapiens (human)
protein-containing complex bindingEphrin type-B receptor 2Homo sapiens (human)
protein kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein tyrosine kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein bindingLeukocyte tyrosine kinase receptorHomo sapiens (human)
ATP bindingLeukocyte tyrosine kinase receptorHomo sapiens (human)
receptor signaling protein tyrosine kinase activator activityLeukocyte tyrosine kinase receptorHomo sapiens (human)
protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
growth hormone receptor bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
protein bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
ATP bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
type 1 angiotensin receptor bindingNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
magnesium ion bindingWee1-like protein kinaseHomo sapiens (human)
protein tyrosine kinase activityWee1-like protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityWee1-like protein kinaseHomo sapiens (human)
protein bindingWee1-like protein kinaseHomo sapiens (human)
ATP bindingWee1-like protein kinaseHomo sapiens (human)
heme oxygenase (decyclizing) activityHeme oxygenase 2Homo sapiens (human)
protein bindingHeme oxygenase 2Homo sapiens (human)
metal ion bindingHeme oxygenase 2Homo sapiens (human)
heme bindingHeme oxygenase 2Homo sapiens (human)
virus receptor activityTyrosine-protein kinase receptor UFOHomo sapiens (human)
phosphatidylserine bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase receptor UFOHomo sapiens (human)
protein bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
ATP bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
myosin heavy chain bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase receptor UFOHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityTyrosine-protein kinase receptor UFOHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 4Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 4Homo sapiens (human)
protein bindingMitogen-activated protein kinase 4Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 4Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase 4Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase 4Homo sapiens (human)
protein heterodimerization activityMitogen-activated protein kinase 4Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 4Homo sapiens (human)
methionine adenosyltransferase activityS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
protein bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
ATP bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
small molecule bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
identical protein bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
metal ion bindingS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
G protein-coupled receptor bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
ATPase activator activityDnaJ homolog subfamily A member 1Homo sapiens (human)
protein bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
ATP bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
Hsp70 protein bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
Tat protein bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
ubiquitin protein ligase bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
metal ion bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
low-density lipoprotein particle receptor bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
unfolded protein bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
protein-folding chaperone bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
C3HC4-type RING finger domain bindingDnaJ homolog subfamily A member 1Homo sapiens (human)
protein kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
calmodulin bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
enzyme bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein kinase bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nitric-oxide synthase regulator activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase inhibitor activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
identical protein bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein homodimerization activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
phosphatidylinositol-3,4-bisphosphate bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
14-3-3 protein bindingRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
potassium channel activator activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
metal ion bindingRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
molecular function activator activityRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingG protein-coupled receptor kinase 4Homo sapiens (human)
rhodopsin kinase activityG protein-coupled receptor kinase 4Homo sapiens (human)
protein kinase activityG protein-coupled receptor kinase 4Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein bindingDual specificity protein kinase TTKHomo sapiens (human)
ATP bindingDual specificity protein kinase TTKHomo sapiens (human)
identical protein bindingDual specificity protein kinase TTKHomo sapiens (human)
kinetochore bindingDual specificity protein kinase TTKHomo sapiens (human)
protein serine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
DNA helicase activityDNA replication licensing factor MCM4Homo sapiens (human)
single-stranded DNA bindingDNA replication licensing factor MCM4Homo sapiens (human)
protein bindingDNA replication licensing factor MCM4Homo sapiens (human)
ATP bindingDNA replication licensing factor MCM4Homo sapiens (human)
ATP hydrolysis activityDNA replication licensing factor MCM4Homo sapiens (human)
single-stranded DNA helicase activityDNA replication licensing factor MCM4Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
microfilament motor activityMyosin-10Homo sapiens (human)
actin filament bindingMyosin-10Homo sapiens (human)
microfilament motor activityMyosin-10Homo sapiens (human)
actin bindingMyosin-10Homo sapiens (human)
protein bindingMyosin-10Homo sapiens (human)
calmodulin bindingMyosin-10Homo sapiens (human)
ATP bindingMyosin-10Homo sapiens (human)
RNA stem-loop bindingMyosin-10Homo sapiens (human)
ADP bindingMyosin-10Homo sapiens (human)
mRNA 5'-UTR bindingMyosin-10Homo sapiens (human)
actin filament bindingMyosin-10Homo sapiens (human)
protein bindingTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
ATP bindingTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 3Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 3Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
protein phosphatase bindingVascular endothelial growth factor receptor 3Homo sapiens (human)
protein homodimerization activityVascular endothelial growth factor receptor 3Homo sapiens (human)
protein tyrosine kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor receptor activityVascular endothelial growth factor receptor 2Homo sapiens (human)
integrin bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
ATP bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
coreceptor activityVascular endothelial growth factor receptor 2Homo sapiens (human)
growth factor bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
vascular endothelial growth factor bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
identical protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
cadherin bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
Hsp90 protein bindingVascular endothelial growth factor receptor 2Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
MAP-kinase scaffold activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
PDZ domain bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein serine/threonine kinase activator activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
metal ion bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
scaffold protein bindingDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
protein tyrosine kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
cytokine receptor activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
vascular endothelial growth factor receptor activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
ATP bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
nuclear glucocorticoid receptor bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein-containing complex bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
phosphatidylinositol 3-kinase activator activityReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
growth factor bindingReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
protein serine/threonine kinase activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
transforming growth factor beta receptor activity, type IBone morphogenetic protein receptor type-1AHomo sapiens (human)
protein bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
ATP bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
BMP bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
protein homodimerization activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
SMAD bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
metal ion bindingBone morphogenetic protein receptor type-1AHomo sapiens (human)
BMP receptor activityBone morphogenetic protein receptor type-1AHomo sapiens (human)
activin receptor activityActivin receptor type-1BHomo sapiens (human)
growth factor bindingActivin receptor type-1BHomo sapiens (human)
activin bindingActivin receptor type-1BHomo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-1BHomo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityActivin receptor type-1BHomo sapiens (human)
protein bindingActivin receptor type-1BHomo sapiens (human)
ATP bindingActivin receptor type-1BHomo sapiens (human)
activin receptor activity, type IActivin receptor type-1BHomo sapiens (human)
activin receptor activityActivin receptor type-1BHomo sapiens (human)
ubiquitin protein ligase bindingActivin receptor type-1BHomo sapiens (human)
inhibin bindingActivin receptor type-1BHomo sapiens (human)
SMAD bindingActivin receptor type-1BHomo sapiens (human)
metal ion bindingActivin receptor type-1BHomo sapiens (human)
I-SMAD bindingActivin receptor type-1BHomo sapiens (human)
transforming growth factor beta receptor activityTGF-beta receptor type-1Homo sapiens (human)
growth factor bindingTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-1Homo sapiens (human)
protein kinase activityTGF-beta receptor type-1Homo sapiens (human)
protein serine/threonine kinase activityTGF-beta receptor type-1Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta receptor activityTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta receptor activity, type ITGF-beta receptor type-1Homo sapiens (human)
type II transforming growth factor beta receptor bindingTGF-beta receptor type-1Homo sapiens (human)
protein bindingTGF-beta receptor type-1Homo sapiens (human)
ATP bindingTGF-beta receptor type-1Homo sapiens (human)
ubiquitin protein ligase bindingTGF-beta receptor type-1Homo sapiens (human)
SMAD bindingTGF-beta receptor type-1Homo sapiens (human)
metal ion bindingTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-1Homo sapiens (human)
I-SMAD bindingTGF-beta receptor type-1Homo sapiens (human)
activin receptor activity, type ITGF-beta receptor type-1Homo sapiens (human)
activin bindingTGF-beta receptor type-1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta receptor activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta receptor activity, type ISerine/threonine-protein kinase receptor R3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin receptor activity, type ISerine/threonine-protein kinase receptor R3Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
SMAD bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
activin bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta bindingSerine/threonine-protein kinase receptor R3Homo sapiens (human)
BMP receptor activitySerine/threonine-protein kinase receptor R3Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-2Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta receptor activityTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta receptor activity, type IITGF-beta receptor type-2Homo sapiens (human)
protein bindingTGF-beta receptor type-2Homo sapiens (human)
ATP bindingTGF-beta receptor type-2Homo sapiens (human)
glycosaminoglycan bindingTGF-beta receptor type-2Homo sapiens (human)
kinase activator activityTGF-beta receptor type-2Homo sapiens (human)
type I transforming growth factor beta receptor bindingTGF-beta receptor type-2Homo sapiens (human)
SMAD bindingTGF-beta receptor type-2Homo sapiens (human)
metal ion bindingTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta bindingTGF-beta receptor type-2Homo sapiens (human)
molecular adaptor activityTGF-beta receptor type-2Homo sapiens (human)
activin receptor activityTGF-beta receptor type-2Homo sapiens (human)
activin bindingTGF-beta receptor type-2Homo sapiens (human)
protein serine/threonine kinase activityTGF-beta receptor type-2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase CSKHomo sapiens (human)
protein bindingTyrosine-protein kinase CSKHomo sapiens (human)
ATP bindingTyrosine-protein kinase CSKHomo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase CSKHomo sapiens (human)
protein kinase A catalytic subunit bindingTyrosine-protein kinase CSKHomo sapiens (human)
identical protein bindingTyrosine-protein kinase CSKHomo sapiens (human)
metal ion bindingTyrosine-protein kinase CSKHomo sapiens (human)
proline-rich region bindingTyrosine-protein kinase CSKHomo sapiens (human)
protein tyrosine kinase bindingTyrosine-protein kinase CSKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase CSKHomo sapiens (human)
bis(5'-nucleosyl)-tetraphosphatase (asymmetrical) activityGlycine--tRNA ligaseHomo sapiens (human)
glycine-tRNA ligase activityGlycine--tRNA ligaseHomo sapiens (human)
protein bindingGlycine--tRNA ligaseHomo sapiens (human)
ATP bindingGlycine--tRNA ligaseHomo sapiens (human)
transferase activityGlycine--tRNA ligaseHomo sapiens (human)
identical protein bindingGlycine--tRNA ligaseHomo sapiens (human)
protein dimerization activityGlycine--tRNA ligaseHomo sapiens (human)
protein kinase activityProtein kinase C iota typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C iota typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C iota typeHomo sapiens (human)
protein bindingProtein kinase C iota typeHomo sapiens (human)
ATP bindingProtein kinase C iota typeHomo sapiens (human)
phospholipid bindingProtein kinase C iota typeHomo sapiens (human)
metal ion bindingProtein kinase C iota typeHomo sapiens (human)
protein serine kinase activityProtein kinase C iota typeHomo sapiens (human)
RNA bindingExosome RNA helicase MTR4Homo sapiens (human)
RNA helicase activityExosome RNA helicase MTR4Homo sapiens (human)
protein bindingExosome RNA helicase MTR4Homo sapiens (human)
ATP bindingExosome RNA helicase MTR4Homo sapiens (human)
ATP hydrolysis activityExosome RNA helicase MTR4Homo sapiens (human)
protein serine/threonine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
ATP bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
protein kinase activator activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
insulin receptor substrate bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
protein serine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
ATP bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
insulin receptor substrate bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
protein serine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
RNA polymerase III type 1 promoter sequence-specific DNA bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
RNA polymerase III type 2 promoter sequence-specific DNA bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
RNA polymerase III type 3 promoter sequence-specific DNA bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
TFIIIC-class transcription factor complex bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
protein bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
kinase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
identical protein bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
ribosome bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
phosphoprotein bindingSerine/threonine-protein kinase mTORHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase mTORHomo sapiens (human)
protein tyrosine kinase activityMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
protein bindingMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
ATP bindingMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase TecHomo sapiens (human)
protein bindingTyrosine-protein kinase TecHomo sapiens (human)
ATP bindingTyrosine-protein kinase TecHomo sapiens (human)
phospholipid bindingTyrosine-protein kinase TecHomo sapiens (human)
metal ion bindingTyrosine-protein kinase TecHomo sapiens (human)
protein bindingTyrosine-protein kinase TXKHomo sapiens (human)
ATP bindingTyrosine-protein kinase TXKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase TXKHomo sapiens (human)
magnesium ion bindingTyrosine-protein kinase ABL2Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase ABL2Homo sapiens (human)
actin monomer bindingTyrosine-protein kinase ABL2Homo sapiens (human)
protein kinase activityTyrosine-protein kinase ABL2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase ABL2Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ABL2Homo sapiens (human)
protein bindingTyrosine-protein kinase ABL2Homo sapiens (human)
ATP bindingTyrosine-protein kinase ABL2Homo sapiens (human)
manganese ion bindingTyrosine-protein kinase ABL2Homo sapiens (human)
actin filament bindingTyrosine-protein kinase ABL2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FRKHomo sapiens (human)
protein bindingTyrosine-protein kinase FRKHomo sapiens (human)
ATP bindingTyrosine-protein kinase FRKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FRKHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FRKHomo sapiens (human)
protein bindingG protein-coupled receptor kinase 6Homo sapiens (human)
ATP bindingG protein-coupled receptor kinase 6Homo sapiens (human)
beta-adrenergic receptor kinase activityG protein-coupled receptor kinase 6Homo sapiens (human)
G protein-coupled receptor kinase activityG protein-coupled receptor kinase 6Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase ZAP-70Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase ZAP-70Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ZAP-70Homo sapiens (human)
protein bindingTyrosine-protein kinase ZAP-70Homo sapiens (human)
ATP bindingTyrosine-protein kinase ZAP-70Homo sapiens (human)
signaling receptor bindingTyrosine-protein kinase ZAP-70Homo sapiens (human)
phosphotyrosine residue bindingTyrosine-protein kinase SYKHomo sapiens (human)
protein kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
protein serine/threonine kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase SYKHomo sapiens (human)
integrin bindingTyrosine-protein kinase SYKHomo sapiens (human)
protein bindingTyrosine-protein kinase SYKHomo sapiens (human)
ATP bindingTyrosine-protein kinase SYKHomo sapiens (human)
interleukin-15 receptor bindingTyrosine-protein kinase SYKHomo sapiens (human)
kinase activityTyrosine-protein kinase SYKHomo sapiens (human)
protein kinase bindingTyrosine-protein kinase SYKHomo sapiens (human)
phosphatase bindingTyrosine-protein kinase SYKHomo sapiens (human)
Toll-like receptor bindingTyrosine-protein kinase SYKHomo sapiens (human)
SH2 domain bindingTyrosine-protein kinase SYKHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase SYKHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase SYKHomo sapiens (human)
protein binding26S proteasome regulatory subunit 6BHomo sapiens (human)
ATP binding26S proteasome regulatory subunit 6BHomo sapiens (human)
ATP hydrolysis activity26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome-activating activity26S proteasome regulatory subunit 6BHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 8Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 8Homo sapiens (human)
protein bindingMitogen-activated protein kinase 8Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 8Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 8Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 8Homo sapiens (human)
histone deacetylase regulator activityMitogen-activated protein kinase 8Homo sapiens (human)
histone deacetylase bindingMitogen-activated protein kinase 8Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 8Homo sapiens (human)
protein serine/threonine kinase bindingMitogen-activated protein kinase 8Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein bindingMitogen-activated protein kinase 9Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 9Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 9Homo sapiens (human)
protein kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
JUN kinase kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
molecular adaptor activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein kinase bindingDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
protein bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
ATP bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
1-phosphatidylinositol-5-phosphate 4-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
protein homodimerization activityPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
protein kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein bindingCasein kinase I isoform alphaHomo sapiens (human)
ATP bindingCasein kinase I isoform alphaHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform alphaHomo sapiens (human)
protein kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein bindingCasein kinase I isoform deltaHomo sapiens (human)
ATP bindingCasein kinase I isoform deltaHomo sapiens (human)
cadherin bindingCasein kinase I isoform deltaHomo sapiens (human)
tau-protein kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform deltaHomo sapiens (human)
protein kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
protein serine/threonine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
ATP bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
1-phosphatidylinositol-3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
identical protein bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
ephrin receptor bindingPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
protein serine kinase activityPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
protein kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
protein bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
ATP bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
protein serine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
calmodulin bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-activated protein kinase 2Homo sapiens (human)
mitogen-activated protein kinase bindingMAP kinase-activated protein kinase 2Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 8Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 8Homo sapiens (human)
protein bindingCyclin-dependent kinase 8Homo sapiens (human)
ATP bindingCyclin-dependent kinase 8Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 8Homo sapiens (human)
ubiquitin protein ligase activityCyclin-dependent kinase 8Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 8Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 8Homo sapiens (human)
RNA bindingElongation factor Tu, mitochondrialHomo sapiens (human)
translation elongation factor activityElongation factor Tu, mitochondrialHomo sapiens (human)
GTPase activityElongation factor Tu, mitochondrialHomo sapiens (human)
protein bindingElongation factor Tu, mitochondrialHomo sapiens (human)
GTP bindingElongation factor Tu, mitochondrialHomo sapiens (human)
choline-phosphate cytidylyltransferase activityCholine-phosphate cytidylyltransferase AHomo sapiens (human)
protein bindingCholine-phosphate cytidylyltransferase AHomo sapiens (human)
calmodulin bindingCholine-phosphate cytidylyltransferase AHomo sapiens (human)
identical protein bindingCholine-phosphate cytidylyltransferase AHomo sapiens (human)
protein homodimerization activityCholine-phosphate cytidylyltransferase AHomo sapiens (human)
molecular function inhibitor activityCholine-phosphate cytidylyltransferase AHomo sapiens (human)
phosphatidylcholine bindingCholine-phosphate cytidylyltransferase AHomo sapiens (human)
RNA bindingCasein kinase I isoform epsilonHomo sapiens (human)
protein kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
protein bindingCasein kinase I isoform epsilonHomo sapiens (human)
ATP bindingCasein kinase I isoform epsilonHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform epsilonHomo sapiens (human)
acyl-CoA dehydrogenase activityVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
long-chain fatty acyl-CoA dehydrogenase activityVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
protein bindingVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
very-long-chain fatty acyl-CoA dehydrogenase activityVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
identical protein bindingVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
flavin adenine dinucleotide bindingVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
fatty-acyl-CoA bindingVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
protein bindingDual specificity protein kinase CLK1Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK1Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein bindingDual specificity protein kinase CLK2Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK2Homo sapiens (human)
identical protein bindingDual specificity protein kinase CLK2Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK2Homo sapiens (human)
RNA bindingDual specificity protein kinase CLK3Homo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK3Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK3Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK3Homo sapiens (human)
protein bindingDual specificity protein kinase CLK3Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK3Homo sapiens (human)
identical protein bindingDual specificity protein kinase CLK3Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK3Homo sapiens (human)
protein serine/threonine kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
signaling receptor bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
protease bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
p53 bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine/threonine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ubiquitin protein ligase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
dynactin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
NF-kappaB bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase activityCyclin-dependent kinase 7Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 7Homo sapiens (human)
protein bindingCyclin-dependent kinase 7Homo sapiens (human)
ATP bindingCyclin-dependent kinase 7Homo sapiens (human)
ATP-dependent activity, acting on DNACyclin-dependent kinase 7Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 7Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 7Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 7Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCyclin-dependent kinase 9Homo sapiens (human)
transcription coactivator bindingCyclin-dependent kinase 9Homo sapiens (human)
DNA bindingCyclin-dependent kinase 9Homo sapiens (human)
chromatin bindingCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation factor activityCyclin-dependent kinase 9Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 9Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein bindingCyclin-dependent kinase 9Homo sapiens (human)
ATP bindingCyclin-dependent kinase 9Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 9Homo sapiens (human)
kinase activityCyclin-dependent kinase 9Homo sapiens (human)
protein kinase bindingCyclin-dependent kinase 9Homo sapiens (human)
7SK snRNA bindingCyclin-dependent kinase 9Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 9Homo sapiens (human)
GTPase activityRas-related protein Rab-27AHomo sapiens (human)
G protein activityRas-related protein Rab-27AHomo sapiens (human)
protein bindingRas-related protein Rab-27AHomo sapiens (human)
GTP bindingRas-related protein Rab-27AHomo sapiens (human)
GDP bindingRas-related protein Rab-27AHomo sapiens (human)
protein domain specific bindingRas-related protein Rab-27AHomo sapiens (human)
myosin V bindingRas-related protein Rab-27AHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase BlkHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase BlkHomo sapiens (human)
protein bindingTyrosine-protein kinase BlkHomo sapiens (human)
ATP bindingTyrosine-protein kinase BlkHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase BlkHomo sapiens (human)
protein kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein serine/threonine kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
ATP bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein kinase bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
heat shock protein bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
identical protein bindingInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein homodimerization activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein heterodimerization activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein serine kinase activityInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein kinase activityRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-3Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein kinase bindingRibosomal protein S6 kinase alpha-3Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-3Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-3Homo sapiens (human)
protein tyrosine kinase activityCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
protein bindingCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
ATP bindingCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
metal ion bindingCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
cAMP-dependent protein kinase activitycAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein bindingcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
ATP bindingcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein serine kinase activitycAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Nek2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek2Homo sapiens (human)
protein phosphatase bindingSerine/threonine-protein kinase Nek2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek3Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek4Homo sapiens (human)
manganese ion bindingSerine/threonine-protein kinase Nek4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek4Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein bindingTyrosine-protein kinase JAK3Homo sapiens (human)
ATP bindingTyrosine-protein kinase JAK3Homo sapiens (human)
protein phosphatase bindingTyrosine-protein kinase JAK3Homo sapiens (human)
growth hormone receptor bindingTyrosine-protein kinase JAK3Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase JAK3Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein kinase bindingDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
microtubule bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
anaphase-promoting complex bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase PLK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK1Homo sapiens (human)
protein kinase activityDeath-associated protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityDeath-associated protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityDeath-associated protein kinase 1Homo sapiens (human)
protein bindingDeath-associated protein kinase 1Homo sapiens (human)
calmodulin bindingDeath-associated protein kinase 1Homo sapiens (human)
ATP bindingDeath-associated protein kinase 1Homo sapiens (human)
GTP bindingDeath-associated protein kinase 1Homo sapiens (human)
syntaxin-1 bindingDeath-associated protein kinase 1Homo sapiens (human)
identical protein bindingDeath-associated protein kinase 1Homo sapiens (human)
protein serine kinase activityDeath-associated protein kinase 1Homo sapiens (human)
protein kinase activityLIM domain kinase 1Homo sapiens (human)
protein serine/threonine kinase activityLIM domain kinase 1Homo sapiens (human)
protein bindingLIM domain kinase 1Homo sapiens (human)
ATP bindingLIM domain kinase 1Homo sapiens (human)
heat shock protein bindingLIM domain kinase 1Homo sapiens (human)
metal ion bindingLIM domain kinase 1Homo sapiens (human)
protein serine kinase activityLIM domain kinase 1Homo sapiens (human)
protein serine/threonine kinase activityLIM domain kinase 2Homo sapiens (human)
protein bindingLIM domain kinase 2Homo sapiens (human)
ATP bindingLIM domain kinase 2Homo sapiens (human)
metal ion bindingLIM domain kinase 2Homo sapiens (human)
protein serine kinase activityLIM domain kinase 2Homo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase 12Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
protein bindingMitogen-activated protein kinase 12Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 12Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 12Homo sapiens (human)
JUN kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
protein bindingMitogen-activated protein kinase 10Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 10Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cAMP-dependent protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cAMP-dependent protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
AMP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
ADP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
chromatin binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine/threonine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
metal ion binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
histone H2BS36 kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
ephrin receptor activityEphrin type-B receptor 3Homo sapiens (human)
protein bindingEphrin type-B receptor 3Homo sapiens (human)
ATP bindingEphrin type-B receptor 3Homo sapiens (human)
axon guidance receptor activityEphrin type-B receptor 3Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-B receptor 3Homo sapiens (human)
ephrin receptor activityEphrin type-A receptor 5Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 5Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 5Homo sapiens (human)
protein bindingEphrin type-A receptor 5Homo sapiens (human)
ATP bindingEphrin type-A receptor 5Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEphrin type-B receptor 4Homo sapiens (human)
ephrin receptor activityEphrin type-B receptor 4Homo sapiens (human)
protein bindingEphrin type-B receptor 4Homo sapiens (human)
ATP bindingEphrin type-B receptor 4Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-B receptor 1Homo sapiens (human)
protein bindingEphrin type-B receptor 1Homo sapiens (human)
ATP bindingEphrin type-B receptor 1Homo sapiens (human)
axon guidance receptor activityEphrin type-B receptor 1Homo sapiens (human)
protein-containing complex bindingEphrin type-B receptor 1Homo sapiens (human)
amyloid-beta bindingEphrin type-A receptor 4Homo sapiens (human)
protein kinase activityEphrin type-A receptor 4Homo sapiens (human)
protein tyrosine kinase activityEphrin type-A receptor 4Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 4Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 4Homo sapiens (human)
protein bindingEphrin type-A receptor 4Homo sapiens (human)
ATP bindingEphrin type-A receptor 4Homo sapiens (human)
kinase activityEphrin type-A receptor 4Homo sapiens (human)
PH domain bindingEphrin type-A receptor 4Homo sapiens (human)
identical protein bindingEphrin type-A receptor 4Homo sapiens (human)
ephrin receptor bindingEphrin type-A receptor 4Homo sapiens (human)
DH domain bindingEphrin type-A receptor 4Homo sapiens (human)
protein tyrosine kinase bindingEphrin type-A receptor 4Homo sapiens (human)
adenylate kinase activityAdenylate kinase 2, mitochondrialHomo sapiens (human)
protein bindingAdenylate kinase 2, mitochondrialHomo sapiens (human)
ATP bindingAdenylate kinase 2, mitochondrialHomo sapiens (human)
RNA bindingAdenosine kinaseHomo sapiens (human)
deoxyadenosine kinase activityAdenosine kinaseHomo sapiens (human)
ATP bindingAdenosine kinaseHomo sapiens (human)
metal ion bindingAdenosine kinaseHomo sapiens (human)
adenosine kinase activityAdenosine kinaseHomo sapiens (human)
protein bindingHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
ATP bindingHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
protein serine kinase activityHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
protein serine/threonine kinase activityHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase SIK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
cAMP response element binding protein bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
histone deacetylase bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
14-3-3 protein bindingSerine/threonine-protein kinase SIK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase SIK1Homo sapiens (human)
protein serine/threonine kinase activityReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
protein bindingReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
ATP bindingReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
protein serine kinase activityReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
G protein activityRas-related protein Rab-10Homo sapiens (human)
protein bindingRas-related protein Rab-10Homo sapiens (human)
GTP bindingRas-related protein Rab-10Homo sapiens (human)
GDP bindingRas-related protein Rab-10Homo sapiens (human)
myosin V bindingRas-related protein Rab-10Homo sapiens (human)
cadherin binding involved in cell-cell adhesionRas-related protein Rab-10Homo sapiens (human)
actin filament bindingActin-related protein 3Homo sapiens (human)
structural constituent of cytoskeletonActin-related protein 3Homo sapiens (human)
protein bindingActin-related protein 3Homo sapiens (human)
ATP bindingActin-related protein 3Homo sapiens (human)
actin filament bindingActin-related protein 2Homo sapiens (human)
structural constituent of cytoskeletonActin-related protein 2Homo sapiens (human)
protein bindingActin-related protein 2Homo sapiens (human)
ATP bindingActin-related protein 2Homo sapiens (human)
nuclear export signal receptor activityGTP-binding nuclear protein RanHomo sapiens (human)
pre-miRNA bindingGTP-binding nuclear protein RanHomo sapiens (human)
magnesium ion bindingGTP-binding nuclear protein RanHomo sapiens (human)
chromatin bindingGTP-binding nuclear protein RanHomo sapiens (human)
RNA bindingGTP-binding nuclear protein RanHomo sapiens (human)
GTPase activityGTP-binding nuclear protein RanHomo sapiens (human)
G protein activityGTP-binding nuclear protein RanHomo sapiens (human)
protein bindingGTP-binding nuclear protein RanHomo sapiens (human)
GTP bindingGTP-binding nuclear protein RanHomo sapiens (human)
GDP bindingGTP-binding nuclear protein RanHomo sapiens (human)
protein domain specific bindingGTP-binding nuclear protein RanHomo sapiens (human)
cadherin bindingGTP-binding nuclear protein RanHomo sapiens (human)
dynein intermediate chain bindingGTP-binding nuclear protein RanHomo sapiens (human)
protein heterodimerization activityGTP-binding nuclear protein RanHomo sapiens (human)
importin-alpha family protein bindingGTP-binding nuclear protein RanHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein bindingCasein kinase II subunit alphaHomo sapiens (human)
ATP bindingCasein kinase II subunit alphaHomo sapiens (human)
kinase activityCasein kinase II subunit alphaHomo sapiens (human)
identical protein bindingCasein kinase II subunit alphaHomo sapiens (human)
Hsp90 protein bindingCasein kinase II subunit alphaHomo sapiens (human)
protein serine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
GTP bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
protein homodimerization activityPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
1-phosphatidylinositol-5-phosphate 4-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
magnesium ion bindingSRSF protein kinase 2Homo sapiens (human)
RNA bindingSRSF protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activitySRSF protein kinase 2Homo sapiens (human)
protein bindingSRSF protein kinase 2Homo sapiens (human)
ATP bindingSRSF protein kinase 2Homo sapiens (human)
14-3-3 protein bindingSRSF protein kinase 2Homo sapiens (human)
protein serine kinase activitySRSF protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform gamma-2Homo sapiens (human)
protein bindingCasein kinase I isoform gamma-2Homo sapiens (human)
ATP bindingCasein kinase I isoform gamma-2Homo sapiens (human)
protein serine kinase activityCasein kinase I isoform gamma-2Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
molecular function activator activityMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
protein bindingCyclin-dependent kinase 3Homo sapiens (human)
ATP bindingCyclin-dependent kinase 3Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 3Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase-like 1Homo sapiens (human)
ATP bindingCyclin-dependent kinase-like 1Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase-like 1Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase-like 1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 6Homo sapiens (human)
protein bindingCyclin-dependent kinase 6Homo sapiens (human)
ATP bindingCyclin-dependent kinase 6Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 6Homo sapiens (human)
FBXO family protein bindingCyclin-dependent kinase 6Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 6Homo sapiens (human)
microtubule bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
p53 bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
ErbB-2 class receptor bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
ATP bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
acetylcholine receptor activator activityCyclin-dependent-like kinase 5 Homo sapiens (human)
ErbB-3 class receptor bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
tau protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
tau-protein kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
Hsp90 protein bindingCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine kinase activityCyclin-dependent-like kinase 5 Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 16Homo sapiens (human)
protein bindingCyclin-dependent kinase 16Homo sapiens (human)
ATP bindingCyclin-dependent kinase 16Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 16Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 16Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 17Homo sapiens (human)
protein bindingCyclin-dependent kinase 17Homo sapiens (human)
ATP bindingCyclin-dependent kinase 17Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 17Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 17Homo sapiens (human)
6-phosphofructokinase activityATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
protein bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
protein-containing complex bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
cadherin bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
metal ion bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
ATP bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
monosaccharide bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
AMP bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
identical protein bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
fructose-6-phosphate bindingATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
actin monomer bindingProtein kinase C epsilon typeHomo sapiens (human)
protein kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein bindingProtein kinase C epsilon typeHomo sapiens (human)
ATP bindingProtein kinase C epsilon typeHomo sapiens (human)
enzyme activator activityProtein kinase C epsilon typeHomo sapiens (human)
enzyme bindingProtein kinase C epsilon typeHomo sapiens (human)
signaling receptor activator activityProtein kinase C epsilon typeHomo sapiens (human)
ethanol bindingProtein kinase C epsilon typeHomo sapiens (human)
metal ion bindingProtein kinase C epsilon typeHomo sapiens (human)
14-3-3 protein bindingProtein kinase C epsilon typeHomo sapiens (human)
protein serine kinase activityProtein kinase C epsilon typeHomo sapiens (human)
protein kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
MAP-kinase scaffold activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein kinase activator activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activator activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
scaffold protein bindingDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
protein kinase activityAngiopoietin-1 receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityAngiopoietin-1 receptorHomo sapiens (human)
protein bindingAngiopoietin-1 receptorHomo sapiens (human)
ATP bindingAngiopoietin-1 receptorHomo sapiens (human)
growth factor bindingAngiopoietin-1 receptorHomo sapiens (human)
signaling receptor activityAngiopoietin-1 receptorHomo sapiens (human)
identical protein bindingAngiopoietin-1 receptorHomo sapiens (human)
transcription corepressor activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
bHLH transcription factor bindingMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
DNA bindingDNA topoisomerase 2-betaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-betaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-betaHomo sapiens (human)
protein bindingDNA topoisomerase 2-betaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complex bindingDNA topoisomerase 2-betaHomo sapiens (human)
metal ion bindingDNA topoisomerase 2-betaHomo sapiens (human)
protein kinase activityProtein kinase C theta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C theta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C theta typeHomo sapiens (human)
protein bindingProtein kinase C theta typeHomo sapiens (human)
ATP bindingProtein kinase C theta typeHomo sapiens (human)
metal ion bindingProtein kinase C theta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C theta typeHomo sapiens (human)
activin receptor activity, type IActivin receptor type-1Homo sapiens (human)
protein kinase activityActivin receptor type-1Homo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-1Homo sapiens (human)
transmembrane receptor protein serine/threonine kinase activityActivin receptor type-1Homo sapiens (human)
protein bindingActivin receptor type-1Homo sapiens (human)
ATP bindingActivin receptor type-1Homo sapiens (human)
peptide hormone bindingActivin receptor type-1Homo sapiens (human)
protein homodimerization activityActivin receptor type-1Homo sapiens (human)
cadherin bindingActivin receptor type-1Homo sapiens (human)
SMAD bindingActivin receptor type-1Homo sapiens (human)
metal ion bindingActivin receptor type-1Homo sapiens (human)
activin bindingActivin receptor type-1Homo sapiens (human)
transforming growth factor beta bindingActivin receptor type-1Homo sapiens (human)
BMP receptor activityActivin receptor type-1Homo sapiens (human)
protein tyrosine kinase bindingActivin receptor type-1Homo sapiens (human)
transforming growth factor beta receptor activity, type IActivin receptor type-1Homo sapiens (human)
macrophage colony-stimulating factor receptor activityMacrophage-stimulating protein receptorHomo sapiens (human)
protein bindingMacrophage-stimulating protein receptorHomo sapiens (human)
ATP bindingMacrophage-stimulating protein receptorHomo sapiens (human)
enzyme bindingMacrophage-stimulating protein receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityMacrophage-stimulating protein receptorHomo sapiens (human)
actin bindingFocal adhesion kinase 1Homo sapiens (human)
protein tyrosine kinase activityFocal adhesion kinase 1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityFocal adhesion kinase 1Homo sapiens (human)
protein tyrosine phosphatase activityFocal adhesion kinase 1Homo sapiens (human)
integrin bindingFocal adhesion kinase 1Homo sapiens (human)
protein bindingFocal adhesion kinase 1Homo sapiens (human)
ATP bindingFocal adhesion kinase 1Homo sapiens (human)
JUN kinase bindingFocal adhesion kinase 1Homo sapiens (human)
protein kinase bindingFocal adhesion kinase 1Homo sapiens (human)
protein phosphatase bindingFocal adhesion kinase 1Homo sapiens (human)
SH2 domain bindingFocal adhesion kinase 1Homo sapiens (human)
molecular function activator activityFocal adhesion kinase 1Homo sapiens (human)
protein kinase activityProtein kinase C zeta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C zeta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C zeta typeHomo sapiens (human)
protein bindingProtein kinase C zeta typeHomo sapiens (human)
ATP bindingProtein kinase C zeta typeHomo sapiens (human)
potassium channel regulator activityProtein kinase C zeta typeHomo sapiens (human)
protein kinase bindingProtein kinase C zeta typeHomo sapiens (human)
phospholipase bindingProtein kinase C zeta typeHomo sapiens (human)
insulin receptor substrate bindingProtein kinase C zeta typeHomo sapiens (human)
protein-containing complex bindingProtein kinase C zeta typeHomo sapiens (human)
metal ion bindingProtein kinase C zeta typeHomo sapiens (human)
14-3-3 protein bindingProtein kinase C zeta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C zeta typeHomo sapiens (human)
protein kinase activityProtein kinase C delta typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
diacylglycerol-dependent, calcium-independent serine/threonine kinase activityProtein kinase C delta typeHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein kinase C delta typeHomo sapiens (human)
protein bindingProtein kinase C delta typeHomo sapiens (human)
ATP bindingProtein kinase C delta typeHomo sapiens (human)
enzyme activator activityProtein kinase C delta typeHomo sapiens (human)
enzyme bindingProtein kinase C delta typeHomo sapiens (human)
protein kinase bindingProtein kinase C delta typeHomo sapiens (human)
insulin receptor substrate bindingProtein kinase C delta typeHomo sapiens (human)
metal ion bindingProtein kinase C delta typeHomo sapiens (human)
protein serine kinase activityProtein kinase C delta typeHomo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase BTKHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase BTKHomo sapiens (human)
protein bindingTyrosine-protein kinase BTKHomo sapiens (human)
ATP bindingTyrosine-protein kinase BTKHomo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate bindingTyrosine-protein kinase BTKHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase BTKHomo sapiens (human)
identical protein bindingTyrosine-protein kinase BTKHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase BTKHomo sapiens (human)
metal ion bindingTyrosine-protein kinase BTKHomo sapiens (human)
virus receptor activityTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
protein bindingTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
ATP bindingTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
phosphatidylinositol 3-kinase bindingTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
protein bindingCyclin-dependent kinase 18Homo sapiens (human)
ATP bindingCyclin-dependent kinase 18Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 18Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 18Homo sapiens (human)
protein serine/threonine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
protein tyrosine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
GTPase inhibitor activityActivated CDC42 kinase 1Homo sapiens (human)
epidermal growth factor receptor bindingActivated CDC42 kinase 1Homo sapiens (human)
protein bindingActivated CDC42 kinase 1Homo sapiens (human)
ATP bindingActivated CDC42 kinase 1Homo sapiens (human)
ubiquitin protein ligase bindingActivated CDC42 kinase 1Homo sapiens (human)
identical protein bindingActivated CDC42 kinase 1Homo sapiens (human)
metal ion bindingActivated CDC42 kinase 1Homo sapiens (human)
WW domain bindingActivated CDC42 kinase 1Homo sapiens (human)
protein serine kinase activityActivated CDC42 kinase 1Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
protein bindingEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
collagen bindingEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
ATP bindingEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
protein tyrosine kinase collagen receptor activityEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
metal ion bindingEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase ITK/TSKHomo sapiens (human)
protein bindingTyrosine-protein kinase ITK/TSKHomo sapiens (human)
ATP bindingTyrosine-protein kinase ITK/TSKHomo sapiens (human)
metal ion bindingTyrosine-protein kinase ITK/TSKHomo sapiens (human)
protein serine/threonine kinase activityMyotonin-protein kinaseHomo sapiens (human)
protein bindingMyotonin-protein kinaseHomo sapiens (human)
ATP bindingMyotonin-protein kinaseHomo sapiens (human)
myosin phosphatase regulator activityMyotonin-protein kinaseHomo sapiens (human)
metal ion bindingMyotonin-protein kinaseHomo sapiens (human)
protein serine kinase activityMyotonin-protein kinaseHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein serine/threonine kinase activator activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
protein bindingTyrosine-protein kinase MerHomo sapiens (human)
ATP bindingTyrosine-protein kinase MerHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityTyrosine-protein kinase MerHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 4Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 4Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 4Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 4Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 4Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 4Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase 4Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingSerine/threonine-protein kinase 4Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 4Homo sapiens (human)
chromatin binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein serine/threonine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cAMP-dependent protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
metal ion binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
tau protein binding5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
tau-protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
protein serine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
histone H2BS36 kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
collagen bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
gamma-tubulin bindingSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
protein serine/threonine kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
protein tyrosine kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
protein bindingDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
ATP bindingDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
metal ion bindingDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
protein serine kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
MAP kinase kinase activityDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 7Homo sapiens (human)
enzyme inhibitor activityMitogen-activated protein kinase 7Homo sapiens (human)
protein bindingMitogen-activated protein kinase 7Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 7Homo sapiens (human)
mitogen-activated protein kinase bindingMitogen-activated protein kinase 7Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 7Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 7Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein tyrosine kinase activator activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase PAK 2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 3Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 3Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase 3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 3Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
zinc ion bindingMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
protein kinase activitycGMP-dependent protein kinase 2Homo sapiens (human)
cGMP-dependent protein kinase activitycGMP-dependent protein kinase 2Homo sapiens (human)
ATP bindingcGMP-dependent protein kinase 2Homo sapiens (human)
cGMP bindingcGMP-dependent protein kinase 2Homo sapiens (human)
identical protein bindingcGMP-dependent protein kinase 2Homo sapiens (human)
mitogen-activated protein kinase bindingcGMP-dependent protein kinase 2Homo sapiens (human)
protein serine kinase activitycGMP-dependent protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityIntegrin-linked protein kinaseHomo sapiens (human)
protein bindingIntegrin-linked protein kinaseHomo sapiens (human)
ATP bindingIntegrin-linked protein kinaseHomo sapiens (human)
protein kinase bindingIntegrin-linked protein kinaseHomo sapiens (human)
protein serine kinase activityIntegrin-linked protein kinaseHomo sapiens (human)
protein kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein bindingRho-associated protein kinase 1Homo sapiens (human)
ATP bindingRho-associated protein kinase 1Homo sapiens (human)
small GTPase bindingRho-associated protein kinase 1Homo sapiens (human)
metal ion bindingRho-associated protein kinase 1Homo sapiens (human)
tau protein bindingRho-associated protein kinase 1Homo sapiens (human)
tau-protein kinase activityRho-associated protein kinase 1Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein serine kinase activityRho-associated protein kinase 1Homo sapiens (human)
protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
protein bindingNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
ATP bindingNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
RNA bindingSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein bindingSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
DNA bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase ATRHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ATRHomo sapiens (human)
protein bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
MutLalpha complex bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
MutSalpha complex bindingSerine/threonine-protein kinase ATRHomo sapiens (human)
histone H2AXS139 kinase activitySerine/threonine-protein kinase ATRHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ATRHomo sapiens (human)
protein kinase activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
death receptor bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ubiquitin protein ligase bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
signaling adaptor activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
identical protein bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein homodimerization activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein-containing complex bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
death domain bindingReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
JUN kinase kinase kinase activityReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
actin bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calcium-dependent protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
identical protein bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
protein homodimerization activityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calcium-dependent protein serine/threonine phosphatase activityCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
identical protein bindingCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
protein homodimerization activityCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
sodium channel inhibitor activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
titin bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
identical protein bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein homodimerization activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
transmembrane transporter bindingCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
protein kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein serine/threonine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
ATP bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
identical protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
tau protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
tau-protein kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
protein serine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
histone H3T45 kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
transcription coactivator activityDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
activin receptor activity, type IIActivin receptor type-2BHomo sapiens (human)
protein serine/threonine kinase activityActivin receptor type-2BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityActivin receptor type-2BHomo sapiens (human)
protein bindingActivin receptor type-2BHomo sapiens (human)
ATP bindingActivin receptor type-2BHomo sapiens (human)
activin receptor activity, type IIActivin receptor type-2BHomo sapiens (human)
kinase activator activityActivin receptor type-2BHomo sapiens (human)
growth factor bindingActivin receptor type-2BHomo sapiens (human)
metal ion bindingActivin receptor type-2BHomo sapiens (human)
activin bindingActivin receptor type-2BHomo sapiens (human)
activin receptor activityActivin receptor type-2BHomo sapiens (human)
protein bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
ATP bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
activin receptor activity, type IIBone morphogenetic protein receptor type-2Homo sapiens (human)
growth factor bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
BMP bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
cadherin bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
metal ion bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
BMP receptor activityBone morphogenetic protein receptor type-2Homo sapiens (human)
protein tyrosine kinase bindingBone morphogenetic protein receptor type-2Homo sapiens (human)
transforming growth factor beta receptor activityBone morphogenetic protein receptor type-2Homo sapiens (human)
protein tyrosine kinase activityProtein-tyrosine kinase 6Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein-tyrosine kinase 6Homo sapiens (human)
protein bindingProtein-tyrosine kinase 6Homo sapiens (human)
ATP bindingProtein-tyrosine kinase 6Homo sapiens (human)
identical protein bindingProtein-tyrosine kinase 6Homo sapiens (human)
signaling receptor bindingProtein-tyrosine kinase 6Homo sapiens (human)
protein kinase activitycGMP-dependent protein kinase 1 Homo sapiens (human)
cGMP-dependent protein kinase activitycGMP-dependent protein kinase 1 Homo sapiens (human)
calcium channel regulator activitycGMP-dependent protein kinase 1 Homo sapiens (human)
protein bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
ATP bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
cGMP bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
identical protein bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
mitogen-activated protein kinase p38 bindingcGMP-dependent protein kinase 1 Homo sapiens (human)
protein serine kinase activitycGMP-dependent protein kinase 1 Homo sapiens (human)
RNA bindingCyclin-dependent kinase 13Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 13Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 13Homo sapiens (human)
protein bindingCyclin-dependent kinase 13Homo sapiens (human)
ATP bindingCyclin-dependent kinase 13Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 13Homo sapiens (human)
protein kinase bindingCyclin-dependent kinase 13Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 13Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 13Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
K63-linked polyubiquitin modification-dependent protein bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
protein serine/threonine kinase activityInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
protein bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
ATP bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
IkappaB kinase activityInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
protein phosphatase bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
ubiquitin protein ligase bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
K48-linked polyubiquitin modification-dependent protein bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
identical protein bindingInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
calmodulin-dependent protein kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein tyrosine kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
ATP bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
ubiquitin protein ligase bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
glutamate receptor bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
3-phosphoinositide-dependent protein kinase bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein-containing complex bindingProtein-tyrosine kinase 2-betaHomo sapiens (human)
neurotransmitter receptor regulator activityProtein-tyrosine kinase 2-betaHomo sapiens (human)
protein serine/threonine kinase activityMaternal embryonic leucine zipper kinaseHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityMaternal embryonic leucine zipper kinaseHomo sapiens (human)
calcium ion bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
ATP bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
lipid bindingMaternal embryonic leucine zipper kinaseHomo sapiens (human)
protein serine kinase activityMaternal embryonic leucine zipper kinaseHomo sapiens (human)
chromatin bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
RNA bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
protein bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
ATP bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
ATP hydrolysis activityStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mediator complex bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
protein heterodimerization activityStructural maintenance of chromosomes protein 1AHomo sapiens (human)
DNA bindingStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nucleosomal DNA bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
transcription coregulator bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
transcription corepressor activityChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
helicase activityChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
protein bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
ATP bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
zinc ion bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
ATP hydrolysis activityChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
histone deacetylase bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
ATP-dependent chromatin remodeler activityChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
chromatin bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
DNA bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
histone bindingChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
acyl-CoA oxidase activityPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
protein bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
PDZ domain bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
protein homodimerization activityPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
FAD bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
fatty acid bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
flavin adenine dinucleotide bindingPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
palmitoyl-CoA oxidase activityPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 10Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 10Homo sapiens (human)
protein bindingCyclin-dependent kinase 10Homo sapiens (human)
ATP bindingCyclin-dependent kinase 10Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 10Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
protein kinase C bindingSerine/threonine-protein kinase D1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase D1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase D1Homo sapiens (human)
kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
heat shock protein bindingSerine/threonine-protein kinase D1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase D1Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase D1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase D1Homo sapiens (human)
phosphatidylinositol 3-kinase activator activitySerine/threonine-protein kinase D1Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 38Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 38Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 38Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 38Homo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingSerine/threonine-protein kinase 38Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase 38Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 38Homo sapiens (human)
histone reader activitySerine/threonine-protein kinase 38Homo sapiens (human)
UFM1-modified protein reader activitySerine/threonine-protein kinase 38Homo sapiens (human)
transcription cis-regulatory region bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
epidermal growth factor receptor bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
ATP bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neuregulin receptor activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
protein homodimerization activityReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
GABA receptor bindingReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-2Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-2Homo sapiens (human)
protein tyrosine kinase activityEphrin type-A receptor 7Homo sapiens (human)
GPI-linked ephrin receptor activityEphrin type-A receptor 7Homo sapiens (human)
protein bindingEphrin type-A receptor 7Homo sapiens (human)
ATP bindingEphrin type-A receptor 7Homo sapiens (human)
axon guidance receptor activityEphrin type-A receptor 7Homo sapiens (human)
growth factor bindingEphrin type-A receptor 7Homo sapiens (human)
chemorepellent activityEphrin type-A receptor 7Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 7Homo sapiens (human)
delta24(24-1) sterol reductase activityDelta(24)-sterol reductaseHomo sapiens (human)
protein bindingDelta(24)-sterol reductaseHomo sapiens (human)
oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptorDelta(24)-sterol reductaseHomo sapiens (human)
enzyme bindingDelta(24)-sterol reductaseHomo sapiens (human)
peptide antigen bindingDelta(24)-sterol reductaseHomo sapiens (human)
delta24-sterol reductase activityDelta(24)-sterol reductaseHomo sapiens (human)
FAD bindingDelta(24)-sterol reductaseHomo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein serine/threonine kinase activityRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-1Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-1Homo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-1Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-1Homo sapiens (human)
protein kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein tyrosine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein bindingDual specificity testis-specific protein kinase 1Homo sapiens (human)
ATP bindingDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein kinase bindingDual specificity testis-specific protein kinase 1Homo sapiens (human)
metal ion bindingDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein serine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity testis-specific protein kinase 1Homo sapiens (human)
actin bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase, smooth muscleHomo sapiens (human)
protein bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
calmodulin bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
ATP bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
metal ion bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 11Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 11Homo sapiens (human)
protein bindingMitogen-activated protein kinase 11Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 11Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 11Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
p53 bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase STK11Homo sapiens (human)
protein bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
LRR domain bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
protein kinase activator activitySerine/threonine-protein kinase STK11Homo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase STK11Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase STK11Homo sapiens (human)
protein kinase activityRhodopsin kinase GRK1Homo sapiens (human)
ATP bindingRhodopsin kinase GRK1Homo sapiens (human)
rhodopsin kinase activityRhodopsin kinase GRK1Homo sapiens (human)
p53 bindingNT-3 growth factor receptorHomo sapiens (human)
neurotrophin receptor activityNT-3 growth factor receptorHomo sapiens (human)
protein bindingNT-3 growth factor receptorHomo sapiens (human)
ATP bindingNT-3 growth factor receptorHomo sapiens (human)
neurotrophin bindingNT-3 growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityNT-3 growth factor receptorHomo sapiens (human)
chromatin bindingSerine/threonine-protein kinase N1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
protein kinase C bindingSerine/threonine-protein kinase N1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase N1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase N1Homo sapiens (human)
nuclear receptor coactivator activitySerine/threonine-protein kinase N1Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase N1Homo sapiens (human)
histone H3T11 kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
histone bindingSerine/threonine-protein kinase N1Homo sapiens (human)
histone deacetylase bindingSerine/threonine-protein kinase N1Homo sapiens (human)
nuclear androgen receptor bindingSerine/threonine-protein kinase N1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase N1Homo sapiens (human)
RNA bindingSerine/threonine-protein kinase N2Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase N2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase N2Homo sapiens (human)
kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase N2Homo sapiens (human)
histone deacetylase bindingSerine/threonine-protein kinase N2Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase N2Homo sapiens (human)
RNA polymerase bindingSerine/threonine-protein kinase N2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase N2Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
calcium-dependent protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
small GTPase bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
mitogen-activated protein kinase kinase bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
protease bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
protein bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
ATP bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
protein homodimerization activityBDNF/NT-3 growth factors receptorHomo sapiens (human)
neurotrophin bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
brain-derived neurotrophic factor bindingBDNF/NT-3 growth factors receptorHomo sapiens (human)
brain-derived neurotrophic factor receptor activityBDNF/NT-3 growth factors receptorHomo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 6Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 6Homo sapiens (human)
protein bindingMitogen-activated protein kinase 6Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 6Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase 6Homo sapiens (human)
protein heterodimerization activityMitogen-activated protein kinase 6Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 6Homo sapiens (human)
phosphorylase kinase activityPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
calmodulin bindingPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
ATP bindingPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
enzyme bindingPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
tau-protein kinase activityPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
protein serine kinase activityPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityDiscoidin domain-containing receptor 2Homo sapiens (human)
protein bindingDiscoidin domain-containing receptor 2Homo sapiens (human)
collagen bindingDiscoidin domain-containing receptor 2Homo sapiens (human)
ATP bindingDiscoidin domain-containing receptor 2Homo sapiens (human)
protein tyrosine kinase collagen receptor activityDiscoidin domain-containing receptor 2Homo sapiens (human)
protein serine/threonine kinase activityAP2-associated protein kinase 1Homo sapiens (human)
Notch bindingAP2-associated protein kinase 1Homo sapiens (human)
protein bindingAP2-associated protein kinase 1Homo sapiens (human)
ATP bindingAP2-associated protein kinase 1Homo sapiens (human)
AP-2 adaptor complex bindingAP2-associated protein kinase 1Homo sapiens (human)
protein serine kinase activityAP2-associated protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityMyosin light chain kinase 3Homo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase 3Homo sapiens (human)
protein bindingMyosin light chain kinase 3Homo sapiens (human)
ATP bindingMyosin light chain kinase 3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase SBK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase SBK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase SBK1Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 19Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 19Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 19Homo sapiens (human)
molecular_functionPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
ATP hydrolysis activityPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
ATP-dependent protein folding chaperonePutative heat shock protein HSP 90-beta 2Homo sapiens (human)
disordered domain specific bindingPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
ATP bindingPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
unfolded protein bindingPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein bindingSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TNNI3KHomo sapiens (human)
protein bindingRab-like protein 3Homo sapiens (human)
GTP bindingRab-like protein 3Homo sapiens (human)
protein homodimerization activityRab-like protein 3Homo sapiens (human)
GTPase activityRab-like protein 3Homo sapiens (human)
SNARE bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
magnesium ion bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
actin bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTPase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
JUN kinase kinase kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
MAP kinase kinase kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTPase activator activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
ATP bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTP bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
microtubule bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
tubulin bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
syntaxin-1 bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
signaling receptor complex adaptor activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
clathrin bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
small GTPase bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
GTP-dependent protein kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
peroxidase inhibitor activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
co-receptor bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
identical protein bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein homodimerization activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
transmembrane transporter bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein kinase A bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
protein serine kinase activityLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
beta-catenin destruction complex bindingLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
protein bindingSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
identical protein bindingSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
protein bindingSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
flavin adenine dinucleotide bindingAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek5Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek5Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek5Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek5Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Nek5Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase N3Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase N3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase N3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase N3Homo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase N3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase N3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase N3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ULK3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase ULK3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase ULK3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ULK3Homo sapiens (human)
protein serine/threonine kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
protein tyrosine kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
protein bindingDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
ATP bindingDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
protein serine kinase activityDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 15Homo sapiens (human)
acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
long-chain fatty acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
protein bindingAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
very-long-chain fatty acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
flavin adenine dinucleotide bindingAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
medium-chain fatty acyl-CoA dehydrogenase activityAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
endonuclease activitySerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
RNA endonuclease activitySerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
unfolded protein bindingSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
RNA bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
lipid bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
protein kinase activator activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase MARK2Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MARK2Homo sapiens (human)
chromatin bindingATP-dependent RNA helicase DHX30Homo sapiens (human)
RNA bindingATP-dependent RNA helicase DHX30Homo sapiens (human)
RNA helicase activityATP-dependent RNA helicase DHX30Homo sapiens (human)
double-stranded RNA bindingATP-dependent RNA helicase DHX30Homo sapiens (human)
protein bindingATP-dependent RNA helicase DHX30Homo sapiens (human)
ATP bindingATP-dependent RNA helicase DHX30Homo sapiens (human)
ATP hydrolysis activityATP-dependent RNA helicase DHX30Homo sapiens (human)
G-quadruplex RNA bindingATP-dependent RNA helicase DHX30Homo sapiens (human)
DNA helicase activityATP-dependent RNA helicase DHX30Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
transferase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
alpha-tubulin bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
beta-tubulin bindingSerine/threonine-protein kinase TAO1Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TAO1Homo sapiens (human)
protein kinase activitySTE20-related kinase adapter protein alphaHomo sapiens (human)
protein bindingSTE20-related kinase adapter protein alphaHomo sapiens (human)
ATP bindingSTE20-related kinase adapter protein alphaHomo sapiens (human)
kinase bindingSTE20-related kinase adapter protein alphaHomo sapiens (human)
protein kinase activator activitySTE20-related kinase adapter protein alphaHomo sapiens (human)
protein serine/threonine kinase activator activitySTE20-related kinase adapter protein alphaHomo sapiens (human)
microfilament motor activityMyosin-14Homo sapiens (human)
actin filament bindingMyosin-14Homo sapiens (human)
calmodulin bindingMyosin-14Homo sapiens (human)
ATP bindingMyosin-14Homo sapiens (human)
protein serine/threonine kinase activityAarF domain-containing protein kinase 1Homo sapiens (human)
ATP bindingAarF domain-containing protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 32CHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 32CHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 32CHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 32CHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 32CHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-3Homo sapiens (human)
RNA bindingATP-dependent RNA helicase DDX42Homo sapiens (human)
RNA helicase activityATP-dependent RNA helicase DDX42Homo sapiens (human)
protein bindingATP-dependent RNA helicase DDX42Homo sapiens (human)
ATP bindingATP-dependent RNA helicase DDX42Homo sapiens (human)
ATP hydrolysis activityATP-dependent RNA helicase DDX42Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase VRK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase VRK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein domain specific bindingSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase VRK2Homo sapiens (human)
protein bindingMyosin light chain kinase family member 4Homo sapiens (human)
ATP bindingMyosin light chain kinase family member 4Homo sapiens (human)
protein serine kinase activityMyosin light chain kinase family member 4Homo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase family member 4Homo sapiens (human)
protein bindingHomeodomain-interacting protein kinase 1Homo sapiens (human)
ATP bindingHomeodomain-interacting protein kinase 1Homo sapiens (human)
protein serine kinase activityHomeodomain-interacting protein kinase 1Homo sapiens (human)
protein tyrosine kinase activityHomeodomain-interacting protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityHomeodomain-interacting protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
protein kinase activityCyclin-dependent kinase-like 3Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase-like 3Homo sapiens (human)
protein bindingCyclin-dependent kinase-like 3Homo sapiens (human)
ATP bindingCyclin-dependent kinase-like 3Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase-like 3Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase-like 3Homo sapiens (human)
p53 bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
MAP kinase kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
protein bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
ATP bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
protein serine kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
mitogen-activated protein kinase bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-activated protein kinase 5Homo sapiens (human)
calmodulin bindingMAP kinase-activated protein kinase 5Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATPase bindingSerine/threonine-protein kinase BRSK2Homo sapiens (human)
ATPase regulator activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase BRSK2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase NIM1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase NIM1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase NIM1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase NIM1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ULK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase ULK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase ULK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ULK2Homo sapiens (human)
protein kinase activityMisshapen-like kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMisshapen-like kinase 1Homo sapiens (human)
protein bindingMisshapen-like kinase 1Homo sapiens (human)
ATP bindingMisshapen-like kinase 1Homo sapiens (human)
protein serine kinase activityMisshapen-like kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase DCLK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase DCLK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase DCLK2Homo sapiens (human)
microtubule bindingSerine/threonine-protein kinase DCLK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase DCLK2Homo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
ATP bindingCasein kinase I isoform alpha-likeHomo sapiens (human)
protein serine kinase activityCasein kinase I isoform alpha-likeHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform alpha-likeHomo sapiens (human)
protein bindingHomeodomain-interacting protein kinase 4Homo sapiens (human)
ATP bindingHomeodomain-interacting protein kinase 4Homo sapiens (human)
histone kinase activityHomeodomain-interacting protein kinase 4Homo sapiens (human)
protein serine kinase activityHomeodomain-interacting protein kinase 4Homo sapiens (human)
protein tyrosine kinase activityHomeodomain-interacting protein kinase 4Homo sapiens (human)
protein serine/threonine kinase activityHomeodomain-interacting protein kinase 4Homo sapiens (human)
microfilament motor activityMyosin-IIIaHomo sapiens (human)
actin bindingMyosin-IIIaHomo sapiens (human)
protein kinase activityMyosin-IIIaHomo sapiens (human)
protein bindingMyosin-IIIaHomo sapiens (human)
calmodulin bindingMyosin-IIIaHomo sapiens (human)
ATP bindingMyosin-IIIaHomo sapiens (human)
ADP bindingMyosin-IIIaHomo sapiens (human)
plus-end directed microfilament motor activityMyosin-IIIaHomo sapiens (human)
protein serine kinase activityMyosin-IIIaHomo sapiens (human)
protein serine/threonine kinase activityMyosin-IIIaHomo sapiens (human)
protein serine/threonine kinase activityAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
protein bindingAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
ATP bindingAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
protein serine kinase activityAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek11Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek11Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek11Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek11Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek11Homo sapiens (human)
protein kinase activityAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
protein bindingAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
ATP bindingAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
kinase activityAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
ADP bindingAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
protein bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
ATP bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
identical protein bindingPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
1-phosphatidylinositol-5-phosphate 4-kinase activityPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
chromatin bindingMitogen-activated protein kinase 15Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
protein bindingMitogen-activated protein kinase 15Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 15Homo sapiens (human)
kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
SH3 domain bindingMitogen-activated protein kinase 15Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 15Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek9Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek9Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek9Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase Nek9Homo sapiens (human)
protein kinase activator activitySerine/threonine-protein kinase Nek9Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek9Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek9Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase BRSK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
gamma-tubulin bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase BRSK1Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase BRSK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 35Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 35Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 35Homo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activitySerine/threonine-protein kinase 35Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek7Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek7Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek7Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek7Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek7Homo sapiens (human)
molecular function activator activitySerine/threonine-protein kinase Nek7Homo sapiens (human)
protein bindingRhodopsin kinase GRK7Homo sapiens (human)
ATP bindingRhodopsin kinase GRK7Homo sapiens (human)
rhodopsin kinase activityRhodopsin kinase GRK7Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 32AHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 32AHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 32AHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 32AHomo sapiens (human)
actin bindingMyosin-IIIbHomo sapiens (human)
protein bindingMyosin-IIIbHomo sapiens (human)
ATP bindingMyosin-IIIbHomo sapiens (human)
protein serine kinase activityMyosin-IIIbHomo sapiens (human)
protein serine/threonine kinase activityMyosin-IIIbHomo sapiens (human)
microfilament motor activityMyosin-IIIbHomo sapiens (human)
DNA bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
chromatin bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
transcription coregulator activityATP-dependent RNA helicase DDX1Homo sapiens (human)
RNA bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
RNA helicase activityATP-dependent RNA helicase DDX1Homo sapiens (human)
double-stranded RNA bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
nuclease activityATP-dependent RNA helicase DDX1Homo sapiens (human)
exonuclease activityATP-dependent RNA helicase DDX1Homo sapiens (human)
protein bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
ATP bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
poly(A) bindingATP-dependent RNA helicase DDX1Homo sapiens (human)
ATP hydrolysis activityATP-dependent RNA helicase DDX1Homo sapiens (human)
DNA/RNA helicase activityATP-dependent RNA helicase DDX1Homo sapiens (human)
magnesium ion bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein serine/threonine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
ATP bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
manganese ion bindingDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein serine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
protein kinase activityCyclin-dependent kinase-like 2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase-like 2Homo sapiens (human)
ATP bindingCyclin-dependent kinase-like 2Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase-like 2Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase-like 2Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
calcium channel regulator activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Sgk3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Sgk3Homo sapiens (human)
potassium channel regulator activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
sodium channel regulator activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
chloride channel regulator activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
phosphatidylinositol bindingSerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Sgk3Homo sapiens (human)
protein kinase activityAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
ATP bindingAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
lipid bindingAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
ATP hydrolysis activityAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
protein bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
ATP bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cytoskeletal anchor activityMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
gamma-tubulin bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
ubiquitin bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
tau protein bindingMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
tau-protein kinase activityMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
protein serine kinase activityMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
protein tyrosine kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek1Homo sapiens (human)
kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase Nek1Homo sapiens (human)
14-3-3 protein bindingSerine/threonine-protein kinase Nek1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek1Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 15Homo sapiens (human)
protein bindingCyclin-dependent kinase 15Homo sapiens (human)
ATP bindingCyclin-dependent kinase 15Homo sapiens (human)
metal ion bindingCyclin-dependent kinase 15Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 15Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 15Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 15Homo sapiens (human)
protein serine/threonine kinase activityPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
protein bindingPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
phosphatidylinositol bindingPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein tyrosine kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
calcium ion bindingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
p53 bindingEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein serine/threonine kinase activityEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein bindingEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
ATP bindingEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
hydrolase activityEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
protein serine kinase activityEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
magnesium ion bindingSRSF protein kinase 1Homo sapiens (human)
RNA bindingSRSF protein kinase 1Homo sapiens (human)
protein kinase activitySRSF protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySRSF protein kinase 1Homo sapiens (human)
protein bindingSRSF protein kinase 1Homo sapiens (human)
ATP bindingSRSF protein kinase 1Homo sapiens (human)
protein serine kinase activitySRSF protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
protein bindingMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
ATP bindingMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
metal ion bindingMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
protein serine kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
protein kinase activityMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein domain specific bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
identical protein bindingMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein homodimerization activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
1-phosphatidylinositol-3-phosphate 5-kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
protein bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
1-phosphatidylinositol-4-phosphate 5-kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
kinase bindingPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
phosphatidylinositol kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
1-phosphatidylinositol-5-kinase activityPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activityEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein bindingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
ATP bindingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
heme bindingEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein homodimerization activityEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein serine kinase activityEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase RIO1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase RIO1Homo sapiens (human)
hydrolase activitySerine/threonine-protein kinase RIO1Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase RIO1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase RIO1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase RIO1Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
metal ion bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
calmodulin bindingMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase RIO2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase RIO2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase RIO2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase RIO2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase RIO2Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase RIO2Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 19Homo sapiens (human)
ATP bindingCyclin-dependent kinase 19Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 19Homo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 19Homo sapiens (human)
protein serine/threonine kinase activityTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
protein bindingTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
ATP bindingTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
metal ion bindingTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
protein serine kinase activityTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
monoatomic cation channel activityTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
magnesium ion bindingTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein-containing complex bindingTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 33Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 33Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 33Homo sapiens (human)
RNA bindingNucleolar GTP-binding protein 1Homo sapiens (human)
GTPase activityNucleolar GTP-binding protein 1Homo sapiens (human)
protein bindingNucleolar GTP-binding protein 1Homo sapiens (human)
GTP bindingNucleolar GTP-binding protein 1Homo sapiens (human)
preribosome bindingNucleolar GTP-binding protein 1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase D2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase D2Homo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activitySerine/threonine-protein kinase D2Homo sapiens (human)
protein kinase C bindingSerine/threonine-protein kinase D2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase D2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase D2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase D2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase D2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase DCLK3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase DCLK3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase DCLK3Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase DCLK3Homo sapiens (human)
magnesium ion bindingNUAK family SNF1-like kinase 2Homo sapiens (human)
protein serine/threonine kinase activityNUAK family SNF1-like kinase 2Homo sapiens (human)
protein bindingNUAK family SNF1-like kinase 2Homo sapiens (human)
ATP bindingNUAK family SNF1-like kinase 2Homo sapiens (human)
protein serine kinase activityNUAK family SNF1-like kinase 2Homo sapiens (human)
RNA bindingRNA cytidine acetyltransferaseHomo sapiens (human)
protein bindingRNA cytidine acetyltransferaseHomo sapiens (human)
ATP bindingRNA cytidine acetyltransferaseHomo sapiens (human)
N-acetyltransferase activityRNA cytidine acetyltransferaseHomo sapiens (human)
tRNA N-acetyltransferase activityRNA cytidine acetyltransferaseHomo sapiens (human)
DNA polymerase bindingRNA cytidine acetyltransferaseHomo sapiens (human)
mRNA N-acetyltransferase activityRNA cytidine acetyltransferaseHomo sapiens (human)
tRNA bindingRNA cytidine acetyltransferaseHomo sapiens (human)
rRNA cytidine N-acetyltransferase activityRNA cytidine acetyltransferaseHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase SIK2Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase SIK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase SIK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase SIK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase SIK2Homo sapiens (human)
calmodulin-dependent protein kinase activityMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
protein bindingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
calmodulin bindingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
ATP bindingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
myosin light chain bindingMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
protein serine/threonine kinase activitySTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
ATP bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
identical protein bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein homodimerization activitySTE20-like serine/threonine-protein kinase Homo sapiens (human)
cadherin bindingSTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein serine kinase activitySTE20-like serine/threonine-protein kinase Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
protein kinase inhibitor activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase TAO3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase TAO3Homo sapiens (human)
transferase activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TAO3Homo sapiens (human)
transcription coactivator activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
transcription corepressor activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein kinase activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein serine/threonine kinase activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
ATP bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
SMAD bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
virion bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein serine kinase activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein tyrosine kinase activityHomeodomain-interacting protein kinase 2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase SrmsHomo sapiens (human)
protein bindingTyrosine-protein kinase SrmsHomo sapiens (human)
ATP bindingTyrosine-protein kinase SrmsHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase SrmsHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase SrmsHomo sapiens (human)
protein kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
ATP bindingHomeodomain-interacting protein kinase 3Homo sapiens (human)
protein serine kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
protein tyrosine kinase activityHomeodomain-interacting protein kinase 3Homo sapiens (human)
p53 bindingSerine/threonine-protein kinase PLK3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK3Homo sapiens (human)
magnesium ion bindingdCTP pyrophosphatase 1Homo sapiens (human)
protein bindingdCTP pyrophosphatase 1Homo sapiens (human)
pyrimidine deoxyribonucleotide bindingdCTP pyrophosphatase 1Homo sapiens (human)
identical protein bindingdCTP pyrophosphatase 1Homo sapiens (human)
nucleoside triphosphate diphosphatase activitydCTP pyrophosphatase 1Homo sapiens (human)
dCTP diphosphatase activitydCTP pyrophosphatase 1Homo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein bindingDual specificity protein kinase CLK4Homo sapiens (human)
ATP bindingDual specificity protein kinase CLK4Homo sapiens (human)
protein serine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase CLK4Homo sapiens (human)
protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
ATP bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
metal ion bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein serine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calcium-dependent protein serine/threonine kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calmodulin-dependent protein kinase activityMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
calmodulin bindingMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
transcription corepressor bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase Nek6Homo sapiens (human)
protein bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
kinesin bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein kinase bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
ubiquitin protein ligase bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase Nek6Homo sapiens (human)
DNA-binding transcription factor bindingSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform gamma-1Homo sapiens (human)
protein bindingCasein kinase I isoform gamma-1Homo sapiens (human)
ATP bindingCasein kinase I isoform gamma-1Homo sapiens (human)
protein serine kinase activityCasein kinase I isoform gamma-1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 6Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 6Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase PAK 6Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 6Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 6Homo sapiens (human)
magnesium ion bindingSNF-related serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activitySNF-related serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingSNF-related serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activitySNF-related serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase LATS2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase LATS2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase LATS2Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase LATS2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase LATS2Homo sapiens (human)
transcription corepressor bindingSerine/threonine-protein kinase 36Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 36Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 36Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 36Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 36Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 36Homo sapiens (human)
magnesium ion bindingPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
RNA bindingPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
phenylalanine-tRNA ligase activityPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
protein bindingPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
ATP bindingPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
protein bindingBMP-2-inducible protein kinaseHomo sapiens (human)
ATP bindingBMP-2-inducible protein kinaseHomo sapiens (human)
protein serine kinase activityBMP-2-inducible protein kinaseHomo sapiens (human)
phosphatase regulator activityBMP-2-inducible protein kinaseHomo sapiens (human)
AP-2 adaptor complex bindingBMP-2-inducible protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityBMP-2-inducible protein kinaseHomo sapiens (human)
protein bindingMidasinHomo sapiens (human)
ATP bindingMidasinHomo sapiens (human)
ATP hydrolysis activityMidasinHomo sapiens (human)
magnesium ion bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
protein serine/threonine kinase activityInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
interleukin-1 receptor bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
protein bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
ATP bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
kinase activityInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
protein kinase bindingInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
protein serine kinase activityInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 32BHomo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 32BHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 32BHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 32BHomo sapiens (human)
magnesium ion bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
RNA bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
JUN kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein kinase activator activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
ribosome bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
small ribosomal subunit rRNA bindingMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
protein kinase activityCyclin-dependent kinase 12Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 12Homo sapiens (human)
protein bindingCyclin-dependent kinase 12Homo sapiens (human)
ATP bindingCyclin-dependent kinase 12Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityCyclin-dependent kinase 12Homo sapiens (human)
protein kinase bindingCyclin-dependent kinase 12Homo sapiens (human)
cyclin bindingCyclin-dependent kinase 12Homo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 12Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PLK2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PLK2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PLK2Homo sapiens (human)
ATP-dependent protein bindingSerine/threonine-protein kinase PLK2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PLK2Homo sapiens (human)
protein bindingNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
ATP bindingNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
endopeptidase activator activityNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
phosphatidylserine bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MARK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase MARK1Homo sapiens (human)
phosphatidic acid bindingSerine/threonine-protein kinase MARK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MARK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase PAK 5Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase PAK 5Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase PAK 5Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase PAK 5Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 26Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 26Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 26Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 26Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase 26Homo sapiens (human)
protein homodimerization activitySerine/threonine-protein kinase 26Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 26Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 26Homo sapiens (human)
tRNA bindingeIF-2-alpha kinase GCN2Homo sapiens (human)
protein serine/threonine kinase activityeIF-2-alpha kinase GCN2Homo sapiens (human)
eukaryotic translation initiation factor 2alpha kinase activityeIF-2-alpha kinase GCN2Homo sapiens (human)
ATP bindingeIF-2-alpha kinase GCN2Homo sapiens (human)
protein serine kinase activityeIF-2-alpha kinase GCN2Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase NLKHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase NLKHomo sapiens (human)
MAP kinase activitySerine/threonine-protein kinase NLKHomo sapiens (human)
protein bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
ubiquitin protein ligase bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
SH2 domain bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase NLKHomo sapiens (human)
DNA-binding transcription factor bindingSerine/threonine-protein kinase NLKHomo sapiens (human)
1-phosphatidylinositol 4-kinase activityPhosphatidylinositol 4-kinase betaHomo sapiens (human)
protein bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
ATP bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
14-3-3 protein bindingPhosphatidylinositol 4-kinase betaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 17AHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 17AHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 17AHomo sapiens (human)
protein serine/threonine kinase activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein bindingSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
ATP bindingSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
kinase activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein kinase bindingSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
protein serine kinase activitySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
molecular_functionEphrin type-A receptor 6Homo sapiens (human)
protein bindingEphrin type-A receptor 6Homo sapiens (human)
ATP bindingEphrin type-A receptor 6Homo sapiens (human)
transmembrane-ephrin receptor activityEphrin type-A receptor 6Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cAMP-dependent protein kinase inhibitor activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cAMP-dependent protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
phosphorylase kinase regulator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
protein kinase activator activity5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
ADP binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
AMP binding5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleic acid bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase TBK1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TBK1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
protein phosphatase bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
identical protein bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
phosphoprotein bindingSerine/threonine-protein kinase TBK1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TBK1Homo sapiens (human)
protein bindingSeptin-9Homo sapiens (human)
GTP bindingSeptin-9Homo sapiens (human)
cadherin bindingSeptin-9Homo sapiens (human)
GTPase activitySeptin-9Homo sapiens (human)
molecular adaptor activitySeptin-9Homo sapiens (human)
protein serine/threonine kinase activityDeath-associated protein kinase 2Homo sapiens (human)
protein bindingDeath-associated protein kinase 2Homo sapiens (human)
calmodulin bindingDeath-associated protein kinase 2Homo sapiens (human)
ATP bindingDeath-associated protein kinase 2Homo sapiens (human)
identical protein bindingDeath-associated protein kinase 2Homo sapiens (human)
protein serine kinase activityDeath-associated protein kinase 2Homo sapiens (human)
magnesium ion bindingRibosomal protein S6 kinase alpha-6Homo sapiens (human)
protein kinase activityRibosomal protein S6 kinase alpha-6Homo sapiens (human)
protein bindingRibosomal protein S6 kinase alpha-6Homo sapiens (human)
ATP bindingRibosomal protein S6 kinase alpha-6Homo sapiens (human)
protein serine kinase activityRibosomal protein S6 kinase alpha-6Homo sapiens (human)
ribosomal protein S6 kinase activityRibosomal protein S6 kinase alpha-6Homo sapiens (human)
protein kinase activityTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein bindingTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
ATP bindingTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein serine kinase activityTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
MAP kinase kinase kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
mitogen-activated protein kinase kinase bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
neuropilin bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
protein serine/threonine kinase activator activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
tau protein bindingSerine/threonine-protein kinase TAO2Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase TAO2Homo sapiens (human)
long-chain fatty acid-CoA ligase activityLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
protein bindingLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
ATP bindingLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
arachidonate-CoA ligase activityLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
oleoyl-CoA ligase activityLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
protein tyrosine kinase activityALK tyrosine kinase receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityALK tyrosine kinase receptorHomo sapiens (human)
protein bindingALK tyrosine kinase receptorHomo sapiens (human)
ATP bindingALK tyrosine kinase receptorHomo sapiens (human)
heparin bindingALK tyrosine kinase receptorHomo sapiens (human)
receptor signaling protein tyrosine kinase activator activityALK tyrosine kinase receptorHomo sapiens (human)
identical protein bindingALK tyrosine kinase receptorHomo sapiens (human)
protein bindingSRSF protein kinase 3Homo sapiens (human)
ATP bindingSRSF protein kinase 3Homo sapiens (human)
protein serine kinase activitySRSF protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activitySRSF protein kinase 3Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase ICKHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase ICKHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase ICKHomo sapiens (human)
protein bindingSerine/threonine-protein kinase ICKHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase ICKHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase ICKHomo sapiens (human)
protein kinase activityCyclin-dependent kinase 11AHomo sapiens (human)
protein serine/threonine kinase activityCyclin-dependent kinase 11AHomo sapiens (human)
cyclin-dependent protein serine/threonine kinase activityCyclin-dependent kinase 11AHomo sapiens (human)
ATP bindingCyclin-dependent kinase 11AHomo sapiens (human)
protein serine kinase activityCyclin-dependent kinase 11AHomo sapiens (human)
protein kinase activityAurora kinase CHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase CHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase CHomo sapiens (human)
protein bindingAurora kinase CHomo sapiens (human)
ATP bindingAurora kinase CHomo sapiens (human)
protein serine kinase activityAurora kinase CHomo sapiens (human)
protein serine/threonine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
calmodulin-dependent protein kinase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
ATP bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
kinase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
glutamate receptor bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
identical protein bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein homodimerization activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein serine kinase activityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
protein kinase activityRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein serine/threonine kinase activityRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein bindingRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
ATP bindingRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
protein serine kinase activityRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
actin bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase 38-likeHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 38-likeHomo sapiens (human)
magnesium ion bindingMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
protein serine/threonine kinase activityMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
protein bindingMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
ATP bindingMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
microtubule bindingMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
protein serine kinase activityMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase SIK3Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase SIK3Homo sapiens (human)
protein bindingSerine/threonine-protein kinase SIK3Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase SIK3Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase SIK3Homo sapiens (human)
tau-protein kinase activitySerine/threonine-protein kinase SIK3Homo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
protein kinase bindingMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
transcription coregulator activityThyroid hormone receptor-associated protein 3Homo sapiens (human)
transcription coactivator activityThyroid hormone receptor-associated protein 3Homo sapiens (human)
RNA bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
protein bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
ATP bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear receptor coactivator activityThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear vitamin D receptor bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear thyroid hormone receptor bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
phosphoprotein bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
DNA bindingThyroid hormone receptor-associated protein 3Homo sapiens (human)
transcription coactivator activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein tyrosine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein bindingDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
ATP bindingDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein serine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein serine/threonine kinase activityDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
protein kinase activityMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
MAP kinase kinase kinase kinase activityMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
transcription coactivator activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein kinase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein serine/threonine kinase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein bindingReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
ATP bindingReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
identical protein bindingReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein-containing complex bindingReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein serine kinase activityReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
magnesium ion bindingSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
protein kinase activitySerine/threonine-protein kinase MRCK betaHomo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase MRCK betaHomo sapiens (human)
ATP bindingSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
small GTPase bindingSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
protein-containing complex bindingSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase MRCK betaHomo sapiens (human)
magnesium ion bindingInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein serine/threonine kinase activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein bindingInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
ATP bindingInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein kinase bindingInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein homodimerization activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein heterodimerization activityInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
protein kinase activitySerine/threonine-protein kinase 24Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase 24Homo sapiens (human)
protein bindingSerine/threonine-protein kinase 24Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase 24Homo sapiens (human)
cadherin bindingSerine/threonine-protein kinase 24Homo sapiens (human)
metal ion bindingSerine/threonine-protein kinase 24Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase 24Homo sapiens (human)
protein kinase activityCasein kinase I isoform gamma-3Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase I isoform gamma-3Homo sapiens (human)
ATP bindingCasein kinase I isoform gamma-3Homo sapiens (human)
protein serine kinase activityCasein kinase I isoform gamma-3Homo sapiens (human)
MAP kinase kinase kinase activityMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
protein bindingMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
ATP bindingMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
metal ion bindingMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (459)

Processvia Protein(s)Taxonomy
plasma membraneBone morphogenetic protein receptor type-1BHomo sapiens (human)
dendriteBone morphogenetic protein receptor type-1BHomo sapiens (human)
neuronal cell bodyBone morphogenetic protein receptor type-1BHomo sapiens (human)
receptor complexBone morphogenetic protein receptor type-1BHomo sapiens (human)
HFE-transferrin receptor complexBone morphogenetic protein receptor type-1BHomo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-1BHomo sapiens (human)
cytosolPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complex, class IAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)
XY bodySerine/threonine-protein kinase PLK4Homo sapiens (human)
nucleolusSerine/threonine-protein kinase PLK4Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK4Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK4Homo sapiens (human)
cytosolSerine/threonine-protein kinase PLK4Homo sapiens (human)
cleavage furrowSerine/threonine-protein kinase PLK4Homo sapiens (human)
deuterosomeSerine/threonine-protein kinase PLK4Homo sapiens (human)
procentrioleSerine/threonine-protein kinase PLK4Homo sapiens (human)
procentriole replication complexSerine/threonine-protein kinase PLK4Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK4Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 25Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 25Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase 25Homo sapiens (human)
FAR/SIN/STRIPAK complexSerine/threonine-protein kinase 25Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 25Homo sapiens (human)
eukaryotic translation initiation factor 3 complexATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytosolic small ribosomal subunitATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytoplasmATP-dependent RNA helicase DDX3XHomo sapiens (human)
extracellular regionATP-dependent RNA helicase DDX3XHomo sapiens (human)
nucleusATP-dependent RNA helicase DDX3XHomo sapiens (human)
nucleoplasmATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytoplasmATP-dependent RNA helicase DDX3XHomo sapiens (human)
centrosomeATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytosolATP-dependent RNA helicase DDX3XHomo sapiens (human)
plasma membraneATP-dependent RNA helicase DDX3XHomo sapiens (human)
cytoplasmic stress granuleATP-dependent RNA helicase DDX3XHomo sapiens (human)
lamellipodiumATP-dependent RNA helicase DDX3XHomo sapiens (human)
cell leading edgeATP-dependent RNA helicase DDX3XHomo sapiens (human)
secretory granule lumenATP-dependent RNA helicase DDX3XHomo sapiens (human)
extracellular exosomeATP-dependent RNA helicase DDX3XHomo sapiens (human)
ficolin-1-rich granule lumenATP-dependent RNA helicase DDX3XHomo sapiens (human)
NLRP3 inflammasome complexATP-dependent RNA helicase DDX3XHomo sapiens (human)
nucleusATP-dependent RNA helicase DDX3XHomo sapiens (human)
P granuleATP-dependent RNA helicase DDX3XHomo sapiens (human)
nucleoplasmPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
endoplasmic reticulumPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
cytosolPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
endocytic vesiclePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
intracellular membrane-bounded organellePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betaHomo sapiens (human)
extracellular regionPyridoxal kinaseHomo sapiens (human)
nucleusPyridoxal kinaseHomo sapiens (human)
nucleoplasmPyridoxal kinaseHomo sapiens (human)
cytosolPyridoxal kinaseHomo sapiens (human)
secretory granule lumenPyridoxal kinaseHomo sapiens (human)
specific granule lumenPyridoxal kinaseHomo sapiens (human)
extracellular exosomePyridoxal kinaseHomo sapiens (human)
cytosolPyridoxal kinaseHomo sapiens (human)
cytosolCitron Rho-interacting kinaseHomo sapiens (human)
membraneCitron Rho-interacting kinaseHomo sapiens (human)
cytosolSerine/threonine-protein kinase RIO3Homo sapiens (human)
preribosome, small subunit precursorSerine/threonine-protein kinase RIO3Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO3Homo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cytoplasmDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 7Homo sapiens (human)
chromosome, telomeric regionSerine/threonine-protein kinase Chk1Homo sapiens (human)
condensed nuclear chromosomeSerine/threonine-protein kinase Chk1Homo sapiens (human)
extracellular spaceSerine/threonine-protein kinase Chk1Homo sapiens (human)
nucleusSerine/threonine-protein kinase Chk1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Chk1Homo sapiens (human)
replication forkSerine/threonine-protein kinase Chk1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Chk1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Chk1Homo sapiens (human)
cytosolSerine/threonine-protein kinase Chk1Homo sapiens (human)
intracellular membrane-bounded organelleSerine/threonine-protein kinase Chk1Homo sapiens (human)
chromatinSerine/threonine-protein kinase Chk1Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase Chk1Homo sapiens (human)
nucleusSerine/threonine-protein kinase Chk1Homo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
nucleusInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
IkappaB kinase complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
cytoplasmic side of plasma membraneInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
membrane raftInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
CD40 receptor complexInhibitor of nuclear factor kappa-B kinase subunit betaHomo sapiens (human)
basement membranePeripheral plasma membrane protein CASKHomo sapiens (human)
nuclear laminaPeripheral plasma membrane protein CASKHomo sapiens (human)
nucleolusPeripheral plasma membrane protein CASKHomo sapiens (human)
cytoplasmPeripheral plasma membrane protein CASKHomo sapiens (human)
cytosolPeripheral plasma membrane protein CASKHomo sapiens (human)
cell-cell junctionPeripheral plasma membrane protein CASKHomo sapiens (human)
focal adhesionPeripheral plasma membrane protein CASKHomo sapiens (human)
actin cytoskeletonPeripheral plasma membrane protein CASKHomo sapiens (human)
nuclear matrixPeripheral plasma membrane protein CASKHomo sapiens (human)
vesiclePeripheral plasma membrane protein CASKHomo sapiens (human)
presynaptic membranePeripheral plasma membrane protein CASKHomo sapiens (human)
ciliary membranePeripheral plasma membrane protein CASKHomo sapiens (human)
Schaffer collateral - CA1 synapsePeripheral plasma membrane protein CASKHomo sapiens (human)
basement membranePeripheral plasma membrane protein CASKHomo sapiens (human)
cell-cell junctionPeripheral plasma membrane protein CASKHomo sapiens (human)
basolateral plasma membranePeripheral plasma membrane protein CASKHomo sapiens (human)
plasma membranePeripheral plasma membrane protein CASKHomo sapiens (human)
spindle microtubuleAurora kinase AHomo sapiens (human)
nucleusAurora kinase AHomo sapiens (human)
nucleoplasmAurora kinase AHomo sapiens (human)
centrosomeAurora kinase AHomo sapiens (human)
centrioleAurora kinase AHomo sapiens (human)
spindleAurora kinase AHomo sapiens (human)
cytosolAurora kinase AHomo sapiens (human)
postsynaptic densityAurora kinase AHomo sapiens (human)
microtubule cytoskeletonAurora kinase AHomo sapiens (human)
basolateral plasma membraneAurora kinase AHomo sapiens (human)
midbodyAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
ciliary basal bodyAurora kinase AHomo sapiens (human)
germinal vesicleAurora kinase AHomo sapiens (human)
axon hillockAurora kinase AHomo sapiens (human)
pronucleusAurora kinase AHomo sapiens (human)
perinuclear region of cytoplasmAurora kinase AHomo sapiens (human)
mitotic spindleAurora kinase AHomo sapiens (human)
meiotic spindleAurora kinase AHomo sapiens (human)
mitotic spindle poleAurora kinase AHomo sapiens (human)
glutamatergic synapseAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
chromosome passenger complexAurora kinase AHomo sapiens (human)
spindle midzoneAurora kinase AHomo sapiens (human)
kinetochoreAurora kinase AHomo sapiens (human)
Golgi apparatusCyclin-G-associated kinaseHomo sapiens (human)
cytosolCyclin-G-associated kinaseHomo sapiens (human)
focal adhesionCyclin-G-associated kinaseHomo sapiens (human)
membraneCyclin-G-associated kinaseHomo sapiens (human)
clathrin-coated vesicleCyclin-G-associated kinaseHomo sapiens (human)
vesicleCyclin-G-associated kinaseHomo sapiens (human)
intracellular membrane-bounded organelleCyclin-G-associated kinaseHomo sapiens (human)
perinuclear region of cytoplasmCyclin-G-associated kinaseHomo sapiens (human)
presynapseCyclin-G-associated kinaseHomo sapiens (human)
vesicleCyclin-G-associated kinaseHomo sapiens (human)
cytoplasmCyclin-G-associated kinaseHomo sapiens (human)
intracellular membrane-bounded organelleCyclin-G-associated kinaseHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase DCLK1Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase DCLK1Homo sapiens (human)
nucleoplasmInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
IkappaB kinase complexInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytoplasmic side of plasma membraneInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
CD40 receptor complexInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit alphaHomo sapiens (human)
plasma membraneMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
neuromuscular junctionMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
postsynaptic membraneMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
receptor complexMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
plasma membraneMuscle, skeletal receptor tyrosine-protein kinaseHomo sapiens (human)
extracellular regionEphrin type-B receptor 6Homo sapiens (human)
cytosolEphrin type-B receptor 6Homo sapiens (human)
plasma membraneEphrin type-B receptor 6Homo sapiens (human)
plasma membraneEphrin type-B receptor 6Homo sapiens (human)
dendriteEphrin type-B receptor 6Homo sapiens (human)
peroxisomePeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
peroxisomal matrixPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
cytosolPeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
membranePeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
peroxisomePeroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)
cytosolMitogen-activated protein kinase 13Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 13Homo sapiens (human)
nucleusMitogen-activated protein kinase 13Homo sapiens (human)
nucleus3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasm3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytosol3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
plasma membrane3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
focal adhesion3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
postsynaptic density3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasmic vesicle3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cell projection3-phosphoinositide-dependent protein kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
membraneMitogen-activated protein kinase kinase kinase 13Homo sapiens (human)
nucleusDeath-associated protein kinase 3Homo sapiens (human)
nucleoplasmDeath-associated protein kinase 3Homo sapiens (human)
cytosolDeath-associated protein kinase 3Homo sapiens (human)
PML bodyDeath-associated protein kinase 3Homo sapiens (human)
nucleusDeath-associated protein kinase 3Homo sapiens (human)
cytoplasmDeath-associated protein kinase 3Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
nucleusMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
plasma membraneMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
endosome membraneMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
ATAC complexMitogen-activated protein kinase kinase kinase 7Homo sapiens (human)
plasma membraneReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulumReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytosolReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytoskeletonReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
vesicleReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
protein-containing complexReceptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)
kinetochoreMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
nucleoplasmMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
cytosolMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
membraneMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
intracellular membrane-bounded organelleMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
outer kinetochoreMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
kinetochoreMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
nucleusMitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)
fibrillar centerNUAK family SNF1-like kinase 1Homo sapiens (human)
nucleusNUAK family SNF1-like kinase 1Homo sapiens (human)
nucleoplasmNUAK family SNF1-like kinase 1Homo sapiens (human)
cytoplasmNUAK family SNF1-like kinase 1Homo sapiens (human)
microtubule cytoskeletonNUAK family SNF1-like kinase 1Homo sapiens (human)
nucleoplasmDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrionDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial outer membraneDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial inner membraneDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial intermembrane spaceDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cytosolDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
membraneDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial cristaDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
dendriteDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
axon cytoplasmDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial intermembrane spaceDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
cytoplasmDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
microtubuleDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
mitochondrial membraneDynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)
phagocytic cupPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
uropodPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
nucleoplasmPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
cytosolPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
adherens junctionPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
focal adhesionPhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
endosome membranePhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
ruffle membranePhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
presynapsePhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 5-kinase type-1 gammaHomo sapiens (human)
extrinsic component of plasma membraneTyrosine-protein kinase JAK2Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK2Homo sapiens (human)
nucleusTyrosine-protein kinase JAK2Homo sapiens (human)
nucleoplasmTyrosine-protein kinase JAK2Homo sapiens (human)
cytoplasmTyrosine-protein kinase JAK2Homo sapiens (human)
cytosolTyrosine-protein kinase JAK2Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK2Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK2Homo sapiens (human)
caveolaTyrosine-protein kinase JAK2Homo sapiens (human)
focal adhesionTyrosine-protein kinase JAK2Homo sapiens (human)
granulocyte macrophage colony-stimulating factor receptor complexTyrosine-protein kinase JAK2Homo sapiens (human)
endosome lumenTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-12 receptor complexTyrosine-protein kinase JAK2Homo sapiens (human)
membrane raftTyrosine-protein kinase JAK2Homo sapiens (human)
interleukin-23 receptor complexTyrosine-protein kinase JAK2Homo sapiens (human)
postsynapseTyrosine-protein kinase JAK2Homo sapiens (human)
glutamatergic synapseTyrosine-protein kinase JAK2Homo sapiens (human)
euchromatinTyrosine-protein kinase JAK2Homo sapiens (human)
cytosolTyrosine-protein kinase JAK2Homo sapiens (human)
nucleusRho-associated protein kinase 2Homo sapiens (human)
centrosomeRho-associated protein kinase 2Homo sapiens (human)
cytosolRho-associated protein kinase 2Homo sapiens (human)
plasma membraneRho-associated protein kinase 2Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleRho-associated protein kinase 2Homo sapiens (human)
centrosomeRho-associated protein kinase 2Homo sapiens (human)
cytoskeletonRho-associated protein kinase 2Homo sapiens (human)
cytoplasmRho-associated protein kinase 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagosome membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK1Homo sapiens (human)
mitochondrial outer membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK1Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK1Homo sapiens (human)
axonSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
recycling endosomeSerine/threonine-protein kinase ULK1Homo sapiens (human)
omegasome membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
Atg1/ULK1 kinase complexSerine/threonine-protein kinase ULK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK1Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK1Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK1Homo sapiens (human)
nuclear inner membraneSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
Ire1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
AIP1-IRE1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-TRAF2-ASK1 complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
IRE1-RACK1-PP2A complexSerine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-5Homo sapiens (human)
nucleusU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
nucleoplasmU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
membraneU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
U4/U6 x U5 tri-snRNP complexU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
spliceosomal complexU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
U5 snRNPU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
U2-type precatalytic spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
U2-type catalytic step 1 spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
catalytic step 2 spliceosomeU5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-4Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-4Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-4Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-4Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-4Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-4Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 16Homo sapiens (human)
Golgi-associated vesicleSerine/threonine-protein kinase 16Homo sapiens (human)
cytosolSerine/threonine-protein kinase 16Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase 16Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase 16Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 16Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 16Homo sapiens (human)
cytosolPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
membranePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammaHomo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 3Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 3Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase PAK 3Homo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase PAK 3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 3Homo sapiens (human)
ruffle membraneCyclin-dependent kinase-like 5Homo sapiens (human)
glutamatergic synapseCyclin-dependent kinase-like 5Homo sapiens (human)
nucleusCyclin-dependent kinase-like 5Homo sapiens (human)
nucleoplasmCyclin-dependent kinase-like 5Homo sapiens (human)
centrosomeCyclin-dependent kinase-like 5Homo sapiens (human)
dendrite cytoplasmCyclin-dependent kinase-like 5Homo sapiens (human)
ciliary basal bodyCyclin-dependent kinase-like 5Homo sapiens (human)
dendritic growth coneCyclin-dependent kinase-like 5Homo sapiens (human)
perinuclear region of cytoplasmCyclin-dependent kinase-like 5Homo sapiens (human)
ciliary tipCyclin-dependent kinase-like 5Homo sapiens (human)
postsynaptic density, intracellular componentCyclin-dependent kinase-like 5Homo sapiens (human)
nucleusCyclin-dependent kinase-like 5Homo sapiens (human)
dendrite cytoplasmCyclin-dependent kinase-like 5Homo sapiens (human)
nucleusSerine/threonine-protein kinase 17BHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 17BHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentSerine/threonine-protein kinase 17BHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase 17BHomo sapiens (human)
actin cytoskeletonSerine/threonine-protein kinase 17BHomo sapiens (human)
Flemming bodySerine/threonine-protein kinase 17BHomo sapiens (human)
nucleusSerine/threonine-protein kinase 17BHomo sapiens (human)
cytosolSerine/threonine-protein kinase 10Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase 10Homo sapiens (human)
specific granule membraneSerine/threonine-protein kinase 10Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase 10Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 10Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase D3Homo sapiens (human)
cytosolSerine/threonine-protein kinase D3Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase D3Homo sapiens (human)
cytosolSerine/threonine-protein kinase D3Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 14Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 14Homo sapiens (human)
cytosolCyclin-dependent kinase 14Homo sapiens (human)
plasma membraneCyclin-dependent kinase 14Homo sapiens (human)
cytoplasmic cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 14Homo sapiens (human)
cytoplasmCyclin-dependent kinase 14Homo sapiens (human)
cytosolCyclin-dependent kinase 14Homo sapiens (human)
nucleusCyclin-dependent kinase 14Homo sapiens (human)
nuclear chromosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
condensed chromosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
condensed nuclear chromosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
condensin complexStructural maintenance of chromosomes protein 2Homo sapiens (human)
nucleusStructural maintenance of chromosomes protein 2Homo sapiens (human)
nucleoplasmStructural maintenance of chromosomes protein 2Homo sapiens (human)
nucleolusStructural maintenance of chromosomes protein 2Homo sapiens (human)
cytoplasmStructural maintenance of chromosomes protein 2Homo sapiens (human)
cytosolStructural maintenance of chromosomes protein 2Homo sapiens (human)
extracellular exosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
condensed chromosomeStructural maintenance of chromosomes protein 2Homo sapiens (human)
chromatinStructural maintenance of chromosomes protein 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase OSR1Homo sapiens (human)
cytosolSerine/threonine-protein kinase OSR1Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase OSR1Homo sapiens (human)
cytosolSerine/threonine-protein kinase OSR1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
focal adhesionMitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase LATS1Homo sapiens (human)
spindle poleSerine/threonine-protein kinase LATS1Homo sapiens (human)
nucleusSerine/threonine-protein kinase LATS1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase LATS1Homo sapiens (human)
cytosolSerine/threonine-protein kinase LATS1Homo sapiens (human)
midbodySerine/threonine-protein kinase LATS1Homo sapiens (human)
spindle poleSerine/threonine-protein kinase LATS1Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 4Homo sapiens (human)
adherens junctionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
focal adhesionSerine/threonine-protein kinase PAK 4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 4Homo sapiens (human)
chromosome, telomeric regionSerine/threonine-protein kinase Chk2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Chk2Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase Chk2Homo sapiens (human)
PML bodySerine/threonine-protein kinase Chk2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Chk2Homo sapiens (human)
nucleusSerine/threonine-protein kinase Chk2Homo sapiens (human)
ruffleTyrosine-protein kinase ABL1Homo sapiens (human)
nucleusTyrosine-protein kinase ABL1Homo sapiens (human)
nucleoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
nucleolusTyrosine-protein kinase ABL1Homo sapiens (human)
cytoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
mitochondrionTyrosine-protein kinase ABL1Homo sapiens (human)
cytosolTyrosine-protein kinase ABL1Homo sapiens (human)
actin cytoskeletonTyrosine-protein kinase ABL1Homo sapiens (human)
nuclear bodyTyrosine-protein kinase ABL1Homo sapiens (human)
dendriteTyrosine-protein kinase ABL1Homo sapiens (human)
growth coneTyrosine-protein kinase ABL1Homo sapiens (human)
nuclear membraneTyrosine-protein kinase ABL1Homo sapiens (human)
neuronal cell bodyTyrosine-protein kinase ABL1Homo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase ABL1Homo sapiens (human)
postsynapseTyrosine-protein kinase ABL1Homo sapiens (human)
protein-containing complexTyrosine-protein kinase ABL1Homo sapiens (human)
plasma membraneTyrosine-protein kinase ABL1Homo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
plasma membraneRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
nucleusRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
mitochondrial outer membraneRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
Golgi apparatusRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
plasma membraneRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
pseudopodiumRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
mitochondrionRAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)
semaphorin receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
early endosomeReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
endosome membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
apical plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ruffle membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
myelin sheathReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
perinuclear region of cytoplasmReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
ERBB3:ERBB2 complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-2Homo sapiens (human)
early endosomeHigh affinity nerve growth factor receptorHomo sapiens (human)
late endosomeHigh affinity nerve growth factor receptorHomo sapiens (human)
plasma membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
cell surfaceHigh affinity nerve growth factor receptorHomo sapiens (human)
endosome membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
dendriteHigh affinity nerve growth factor receptorHomo sapiens (human)
early endosome membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
late endosome membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
neuronal cell bodyHigh affinity nerve growth factor receptorHomo sapiens (human)
recycling endosome membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
protein-containing complexHigh affinity nerve growth factor receptorHomo sapiens (human)
receptor complexHigh affinity nerve growth factor receptorHomo sapiens (human)
axonHigh affinity nerve growth factor receptorHomo sapiens (human)
plasma membraneHigh affinity nerve growth factor receptorHomo sapiens (human)
nucleoplasmGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cytoplasmGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
centrosomeGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cytosolGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
membraneGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
dendriteGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
midbodyGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cell bodyGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
synapseGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
extracellular exosomeGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
neuronal dense core vesicleGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
extracellular vesicleGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
heterotrimeric G-protein complexGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
cytoplasmGuanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)
nucleusADP/ATP translocase 2Homo sapiens (human)
mitochondrionADP/ATP translocase 2Homo sapiens (human)
mitochondrial inner membraneADP/ATP translocase 2Homo sapiens (human)
plasma membraneADP/ATP translocase 2Homo sapiens (human)
membraneADP/ATP translocase 2Homo sapiens (human)
mitochondrial nucleoidADP/ATP translocase 2Homo sapiens (human)
mitochondrial permeability transition pore complexADP/ATP translocase 2Homo sapiens (human)
MMXD complexADP/ATP translocase 2Homo sapiens (human)
nucleusProtein kinase C beta typeHomo sapiens (human)
nucleoplasmProtein kinase C beta typeHomo sapiens (human)
cytoplasmProtein kinase C beta typeHomo sapiens (human)
centrosomeProtein kinase C beta typeHomo sapiens (human)
cytosolProtein kinase C beta typeHomo sapiens (human)
plasma membraneProtein kinase C beta typeHomo sapiens (human)
brush border membraneProtein kinase C beta typeHomo sapiens (human)
calyx of HeldProtein kinase C beta typeHomo sapiens (human)
extracellular exosomeProtein kinase C beta typeHomo sapiens (human)
presynaptic cytosolProtein kinase C beta typeHomo sapiens (human)
spectrinProtein kinase C beta typeHomo sapiens (human)
nuclear envelopeInsulin receptorHomo sapiens (human)
nuclear lumenInsulin receptorHomo sapiens (human)
lysosomeInsulin receptorHomo sapiens (human)
late endosomeInsulin receptorHomo sapiens (human)
plasma membraneInsulin receptorHomo sapiens (human)
caveolaInsulin receptorHomo sapiens (human)
external side of plasma membraneInsulin receptorHomo sapiens (human)
endosome membraneInsulin receptorHomo sapiens (human)
membraneInsulin receptorHomo sapiens (human)
dendrite membraneInsulin receptorHomo sapiens (human)
neuronal cell body membraneInsulin receptorHomo sapiens (human)
extracellular exosomeInsulin receptorHomo sapiens (human)
insulin receptor complexInsulin receptorHomo sapiens (human)
receptor complexInsulin receptorHomo sapiens (human)
plasma membraneInsulin receptorHomo sapiens (human)
axonInsulin receptorHomo sapiens (human)
pericentriolar materialTyrosine-protein kinase LckHomo sapiens (human)
immunological synapseTyrosine-protein kinase LckHomo sapiens (human)
cytosolTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
membrane raftTyrosine-protein kinase LckHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase LckHomo sapiens (human)
plasma membraneTyrosine-protein kinase LckHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
nucleusTyrosine-protein kinase FynHomo sapiens (human)
mitochondrionTyrosine-protein kinase FynHomo sapiens (human)
endosomeTyrosine-protein kinase FynHomo sapiens (human)
cytosolTyrosine-protein kinase FynHomo sapiens (human)
actin filamentTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
postsynaptic densityTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
perikaryonTyrosine-protein kinase FynHomo sapiens (human)
cell bodyTyrosine-protein kinase FynHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase FynHomo sapiens (human)
perinuclear endoplasmic reticulumTyrosine-protein kinase FynHomo sapiens (human)
glial cell projectionTyrosine-protein kinase FynHomo sapiens (human)
Schaffer collateral - CA1 synapseTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
mitochondrial matrixCyclin-dependent kinase 1Homo sapiens (human)
chromosome, telomeric regionCyclin-dependent kinase 1Homo sapiens (human)
nucleusCyclin-dependent kinase 1Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 1Homo sapiens (human)
mitochondrionCyclin-dependent kinase 1Homo sapiens (human)
endoplasmic reticulum membraneCyclin-dependent kinase 1Homo sapiens (human)
centrosomeCyclin-dependent kinase 1Homo sapiens (human)
cytosolCyclin-dependent kinase 1Homo sapiens (human)
spindle microtubuleCyclin-dependent kinase 1Homo sapiens (human)
membraneCyclin-dependent kinase 1Homo sapiens (human)
midbodyCyclin-dependent kinase 1Homo sapiens (human)
extracellular exosomeCyclin-dependent kinase 1Homo sapiens (human)
mitotic spindleCyclin-dependent kinase 1Homo sapiens (human)
cyclin A1-CDK1 complexCyclin-dependent kinase 1Homo sapiens (human)
cyclin A2-CDK1 complexCyclin-dependent kinase 1Homo sapiens (human)
cyclin B1-CDK1 complexCyclin-dependent kinase 1Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 1Homo sapiens (human)
cytoplasmCyclin-dependent kinase 1Homo sapiens (human)
nucleusCyclin-dependent kinase 1Homo sapiens (human)
extracellular regionGlycogen phosphorylase, liver formHomo sapiens (human)
cytosolGlycogen phosphorylase, liver formHomo sapiens (human)
secretory granule lumenGlycogen phosphorylase, liver formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, liver formHomo sapiens (human)
ficolin-1-rich granule lumenGlycogen phosphorylase, liver formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, liver formHomo sapiens (human)
cytoplasmic vesicleTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cytoplasmTyrosine-protein kinase Fes/FpsHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cytosolTyrosine-protein kinase Fes/FpsHomo sapiens (human)
focal adhesionTyrosine-protein kinase Fes/FpsHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase Fes/FpsHomo sapiens (human)
microtubule cytoskeletonTyrosine-protein kinase Fes/FpsHomo sapiens (human)
plasma membraneTyrosine-protein kinase Fes/FpsHomo sapiens (human)
nucleoplasmMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
plasma membraneMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
cell surfaceMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
intracellular membrane-bounded organelleMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
CSF1-CSF1R complexMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
receptor complexMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
plasma membraneMacrophage colony-stimulating factor 1 receptorHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase YesHomo sapiens (human)
centrosomeTyrosine-protein kinase YesHomo sapiens (human)
cytosolTyrosine-protein kinase YesHomo sapiens (human)
actin filamentTyrosine-protein kinase YesHomo sapiens (human)
plasma membraneTyrosine-protein kinase YesHomo sapiens (human)
focal adhesionTyrosine-protein kinase YesHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase YesHomo sapiens (human)
plasma membraneTyrosine-protein kinase YesHomo sapiens (human)
plasma membraneTyrosine-protein kinase LynHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase LynHomo sapiens (human)
nucleusTyrosine-protein kinase LynHomo sapiens (human)
cytoplasmTyrosine-protein kinase LynHomo sapiens (human)
lysosomal membraneTyrosine-protein kinase LynHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase LynHomo sapiens (human)
cytosolTyrosine-protein kinase LynHomo sapiens (human)
plasma membraneTyrosine-protein kinase LynHomo sapiens (human)
adherens junctionTyrosine-protein kinase LynHomo sapiens (human)
mitochondrial cristaTyrosine-protein kinase LynHomo sapiens (human)
endocytic vesicle membraneTyrosine-protein kinase LynHomo sapiens (human)
intracellular membrane-bounded organelleTyrosine-protein kinase LynHomo sapiens (human)
membrane raftTyrosine-protein kinase LynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase LynHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase LynHomo sapiens (human)
glutamatergic synapseTyrosine-protein kinase LynHomo sapiens (human)
postsynaptic specialization, intracellular componentTyrosine-protein kinase LynHomo sapiens (human)
integrin alpha2-beta1 complexTyrosine-protein kinase LynHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
early endosomeProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
endosome membraneProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
dendriteProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
neuronal cell bodyProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
receptor complexProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
plasma membrane protein complexProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
axonProto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)
plasma membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
caveolaInsulin-like growth factor 1 receptorHomo sapiens (human)
membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
T-tubuleInsulin-like growth factor 1 receptorHomo sapiens (human)
neuronal cell bodyInsulin-like growth factor 1 receptorHomo sapiens (human)
intracellular membrane-bounded organelleInsulin-like growth factor 1 receptorHomo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexInsulin-like growth factor 1 receptorHomo sapiens (human)
receptor complexInsulin-like growth factor 1 receptorHomo sapiens (human)
protein kinase complexInsulin-like growth factor 1 receptorHomo sapiens (human)
axonInsulin-like growth factor 1 receptorHomo sapiens (human)
plasma membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor complexInsulin-like growth factor 1 receptorHomo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
signal recognition particle receptor complexSignal recognition particle receptor subunit alphaHomo sapiens (human)
endoplasmic reticulum membraneSignal recognition particle receptor subunit alphaHomo sapiens (human)
membraneSignal recognition particle receptor subunit alphaHomo sapiens (human)
extracellular exosomeSignal recognition particle receptor subunit alphaHomo sapiens (human)
endoplasmic reticulum membraneSignal recognition particle receptor subunit alphaHomo sapiens (human)
nucleusCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
mitochondrionCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
mitochondrial inner membraneCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
mitochondrial respiratory chain complex IIICytochrome c1, heme protein, mitochondrialHomo sapiens (human)
membraneCytochrome c1, heme protein, mitochondrialHomo sapiens (human)
extracellular regionHepatocyte growth factor receptorHomo sapiens (human)
plasma membraneHepatocyte growth factor receptorHomo sapiens (human)
basal plasma membraneHepatocyte growth factor receptorHomo sapiens (human)
cell surfaceHepatocyte growth factor receptorHomo sapiens (human)
membraneHepatocyte growth factor receptorHomo sapiens (human)
postsynapseHepatocyte growth factor receptorHomo sapiens (human)
basal plasma membraneHepatocyte growth factor receptorHomo sapiens (human)
plasma membraneHepatocyte growth factor receptorHomo sapiens (human)
receptor complexHepatocyte growth factor receptorHomo sapiens (human)
actin filamentTyrosine-protein kinase HCKHomo sapiens (human)
nucleusTyrosine-protein kinase HCKHomo sapiens (human)
lysosomeTyrosine-protein kinase HCKHomo sapiens (human)
Golgi apparatusTyrosine-protein kinase HCKHomo sapiens (human)
cytosolTyrosine-protein kinase HCKHomo sapiens (human)
plasma membraneTyrosine-protein kinase HCKHomo sapiens (human)
caveolaTyrosine-protein kinase HCKHomo sapiens (human)
focal adhesionTyrosine-protein kinase HCKHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase HCKHomo sapiens (human)
transport vesicleTyrosine-protein kinase HCKHomo sapiens (human)
cell projectionTyrosine-protein kinase HCKHomo sapiens (human)
intracellular membrane-bounded organelleTyrosine-protein kinase HCKHomo sapiens (human)
plasma membraneTyrosine-protein kinase HCKHomo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
membraneProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
receptor complexProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase ROSHomo sapiens (human)
nucleusPlatelet-derived growth factor receptor betaHomo sapiens (human)
cytoplasmPlatelet-derived growth factor receptor betaHomo sapiens (human)
Golgi apparatusPlatelet-derived growth factor receptor betaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
focal adhesionPlatelet-derived growth factor receptor betaHomo sapiens (human)
membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
apical plasma membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
cytoplasmic vesiclePlatelet-derived growth factor receptor betaHomo sapiens (human)
lysosomal lumenPlatelet-derived growth factor receptor betaHomo sapiens (human)
intracellular membrane-bounded organellePlatelet-derived growth factor receptor betaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor betaHomo sapiens (human)
receptor complexPlatelet-derived growth factor receptor betaHomo sapiens (human)
cytoskeletonTyrosine-protein kinase FgrHomo sapiens (human)
actin cytoskeletonTyrosine-protein kinase FgrHomo sapiens (human)
ruffle membraneTyrosine-protein kinase FgrHomo sapiens (human)
extracellular regionTyrosine-protein kinase FgrHomo sapiens (human)
mitochondrial inner membraneTyrosine-protein kinase FgrHomo sapiens (human)
mitochondrial intermembrane spaceTyrosine-protein kinase FgrHomo sapiens (human)
cytosolTyrosine-protein kinase FgrHomo sapiens (human)
plasma membraneTyrosine-protein kinase FgrHomo sapiens (human)
aggresomeTyrosine-protein kinase FgrHomo sapiens (human)
secretory granule lumenTyrosine-protein kinase FgrHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase FgrHomo sapiens (human)
plasma membraneTyrosine-protein kinase FgrHomo sapiens (human)
nucleoplasmWee1-like protein kinase 2Homo sapiens (human)
cytosolWee1-like protein kinase 2Homo sapiens (human)
plasma membraneWee1-like protein kinase 2Homo sapiens (human)
cytoplasmWee1-like protein kinase 2Homo sapiens (human)
nucleusWee1-like protein kinase 2Homo sapiens (human)
cellular_componentSerine/threonine-protein kinase A-RafHomo sapiens (human)
cytosolSerine/threonine-protein kinase A-RafHomo sapiens (human)
cytosolSerine/threonine-protein kinase A-RafHomo sapiens (human)
mitochondrionSerine/threonine-protein kinase A-RafHomo sapiens (human)
fibrillar centerMast/stem cell growth factor receptor KitHomo sapiens (human)
acrosomal vesicleMast/stem cell growth factor receptor KitHomo sapiens (human)
extracellular spaceMast/stem cell growth factor receptor KitHomo sapiens (human)
plasma membraneMast/stem cell growth factor receptor KitHomo sapiens (human)
cell-cell junctionMast/stem cell growth factor receptor KitHomo sapiens (human)
external side of plasma membraneMast/stem cell growth factor receptor KitHomo sapiens (human)
cytoplasmic side of plasma membraneMast/stem cell growth factor receptor KitHomo sapiens (human)
plasma membraneMast/stem cell growth factor receptor KitHomo sapiens (human)
receptor complexMast/stem cell growth factor receptor KitHomo sapiens (human)
extracellular regionGlycogen phosphorylase, brain formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, brain formHomo sapiens (human)
membraneGlycogen phosphorylase, brain formHomo sapiens (human)
azurophil granule lumenGlycogen phosphorylase, brain formHomo sapiens (human)
extracellular exosomeGlycogen phosphorylase, brain formHomo sapiens (human)
cytoplasmGlycogen phosphorylase, brain formHomo sapiens (human)
cytosolBreakpoint cluster region proteinHomo sapiens (human)
plasma membraneBreakpoint cluster region proteinHomo sapiens (human)
postsynaptic densityBreakpoint cluster region proteinHomo sapiens (human)
membraneBreakpoint cluster region proteinHomo sapiens (human)
axonBreakpoint cluster region proteinHomo sapiens (human)
dendritic spineBreakpoint cluster region proteinHomo sapiens (human)
extracellular exosomeBreakpoint cluster region proteinHomo sapiens (human)
protein-containing complexBreakpoint cluster region proteinHomo sapiens (human)
Schaffer collateral - CA1 synapseBreakpoint cluster region proteinHomo sapiens (human)
glutamatergic synapseBreakpoint cluster region proteinHomo sapiens (human)
membraneBreakpoint cluster region proteinHomo sapiens (human)
nucleusSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleolusSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytosolSerine/threonine-protein kinase pim-1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 1Homo sapiens (human)
nucleusFibroblast growth factor receptor 1Homo sapiens (human)
cytosolFibroblast growth factor receptor 1Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 1Homo sapiens (human)
membraneFibroblast growth factor receptor 1Homo sapiens (human)
cytoplasmic vesicleFibroblast growth factor receptor 1Homo sapiens (human)
receptor complexFibroblast growth factor receptor 1Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 1Homo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusCyclin-dependent kinase 4Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 4Homo sapiens (human)
nucleolusCyclin-dependent kinase 4Homo sapiens (human)
cytosolCyclin-dependent kinase 4Homo sapiens (human)
bicellular tight junctionCyclin-dependent kinase 4Homo sapiens (human)
nuclear membraneCyclin-dependent kinase 4Homo sapiens (human)
cyclin D1-CDK4 complexCyclin-dependent kinase 4Homo sapiens (human)
cyclin D2-CDK4 complexCyclin-dependent kinase 4Homo sapiens (human)
cyclin D3-CDK4 complexCyclin-dependent kinase 4Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 4Homo sapiens (human)
chromatinCyclin-dependent kinase 4Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 4Homo sapiens (human)
nucleusCyclin-dependent kinase 4Homo sapiens (human)
cytoplasmCyclin-dependent kinase 4Homo sapiens (human)
nucleusADP/ATP translocase 3Homo sapiens (human)
mitochondrionADP/ATP translocase 3Homo sapiens (human)
mitochondrial inner membraneADP/ATP translocase 3Homo sapiens (human)
membraneADP/ATP translocase 3Homo sapiens (human)
TIM23 mitochondrial import inner membrane translocase complexADP/ATP translocase 3Homo sapiens (human)
extracellular regionInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
nucleusInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
peroxisomal membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytosolInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
secretory granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
extracellular exosomeInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
ficolin-1-rich granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
podosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nucleoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrial inner membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
lysosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
late endosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytosolProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
actin filamentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
caveolaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell junctionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ruffle membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neuronal cell bodyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic growth coneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
membrane raftProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
perinuclear region of cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
extracellular exosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
synaptic membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
glutamatergic synapseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
postsynaptic specialization, intracellular componentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic filopodiumProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
axonemecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cytoplasmcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
centrosomecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cytosolcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
plasma membranecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
focal adhesioncAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
membranecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
plasma membrane raftcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
extracellular exosomecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
ciliary basecAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cAMP-dependent protein kinase complexcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
nucleotide-activated protein kinase complexcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
protein-containing complexcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
cytosolcAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)
plasma membraneInsulin receptor-related proteinHomo sapiens (human)
receptor complexInsulin receptor-related proteinHomo sapiens (human)
insulin receptor complexInsulin receptor-related proteinHomo sapiens (human)
plasma membraneInsulin receptor-related proteinHomo sapiens (human)
axonInsulin receptor-related proteinHomo sapiens (human)
nucleusSerine/threonine-protein kinase B-rafHomo sapiens (human)
cytosolSerine/threonine-protein kinase B-rafHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase B-rafHomo sapiens (human)
neuron projectionSerine/threonine-protein kinase B-rafHomo sapiens (human)
intracellular membrane-bounded organelleSerine/threonine-protein kinase B-rafHomo sapiens (human)
cell bodySerine/threonine-protein kinase B-rafHomo sapiens (human)
presynapseSerine/threonine-protein kinase B-rafHomo sapiens (human)
cytosolSerine/threonine-protein kinase B-rafHomo sapiens (human)
mitochondrionSerine/threonine-protein kinase B-rafHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase B-rafHomo sapiens (human)
cytosolPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
phosphorylase kinase complexPhosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)
nucleoplasmRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
extracellular exosomeRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
cytosolRibosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)
nucleusPlatelet-derived growth factor receptor alphaHomo sapiens (human)
nucleoplasmPlatelet-derived growth factor receptor alphaHomo sapiens (human)
cytoplasmPlatelet-derived growth factor receptor alphaHomo sapiens (human)
endoplasmic reticulum membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
Golgi apparatusPlatelet-derived growth factor receptor alphaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
microvillusPlatelet-derived growth factor receptor alphaHomo sapiens (human)
ciliumPlatelet-derived growth factor receptor alphaHomo sapiens (human)
external side of plasma membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
cell junctionPlatelet-derived growth factor receptor alphaHomo sapiens (human)
protein-containing complexPlatelet-derived growth factor receptor alphaHomo sapiens (human)
receptor complexPlatelet-derived growth factor receptor alphaHomo sapiens (human)
plasma membranePlatelet-derived growth factor receptor alphaHomo sapiens (human)
actin cytoskeletonTyrosine-protein kinase FerHomo sapiens (human)
microtubule cytoskeletonTyrosine-protein kinase FerHomo sapiens (human)
lamellipodiumTyrosine-protein kinase FerHomo sapiens (human)
cell junctionTyrosine-protein kinase FerHomo sapiens (human)
nucleusTyrosine-protein kinase FerHomo sapiens (human)
cytoplasmTyrosine-protein kinase FerHomo sapiens (human)
cytosolTyrosine-protein kinase FerHomo sapiens (human)
adherens junctionTyrosine-protein kinase FerHomo sapiens (human)
cell cortexTyrosine-protein kinase FerHomo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase FerHomo sapiens (human)
chromatinTyrosine-protein kinase FerHomo sapiens (human)
plasma membraneTyrosine-protein kinase FerHomo sapiens (human)
ciliary basal bodyProtein kinase C alpha typeHomo sapiens (human)
nucleoplasmProtein kinase C alpha typeHomo sapiens (human)
cytoplasmProtein kinase C alpha typeHomo sapiens (human)
mitochondrionProtein kinase C alpha typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C alpha typeHomo sapiens (human)
cytosolProtein kinase C alpha typeHomo sapiens (human)
plasma membraneProtein kinase C alpha typeHomo sapiens (human)
mitochondrial membraneProtein kinase C alpha typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C alpha typeHomo sapiens (human)
extracellular exosomeProtein kinase C alpha typeHomo sapiens (human)
alphav-beta3 integrin-PKCalpha complexProtein kinase C alpha typeHomo sapiens (human)
axonemecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytoplasmcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
acrosomal vesiclecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
nucleoplasmcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytoplasmcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
mitochondrial matrixcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
centrosomecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
plasma membranecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
nuclear speckcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
neuromuscular junctioncAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
sperm flagellumcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
dendritic spinecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
plasma membrane raftcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
extracellular exosomecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
ciliary basecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
glutamatergic synapsecAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cAMP-dependent protein kinase complexcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
calcium channel complexcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)
extracellular spaceVascular endothelial growth factor receptor 1 Homo sapiens (human)
endosomeVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 1 Homo sapiens (human)
focal adhesionVascular endothelial growth factor receptor 1 Homo sapiens (human)
actin cytoskeletonVascular endothelial growth factor receptor 1 Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 1 Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 1 Homo sapiens (human)
nucleusGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
nucleoplasmGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
cytoplasmGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
spindleGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
cytosolGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription factor TFIIH core complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription factor TFIID complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
transcription factor TFIIH holo complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
CAK-ERCC2 complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
MMXD complexGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
nucleusGeneral transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)
cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
nucleoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
cytosolInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
ribosomeInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
membraneInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
perinuclear region of cytoplasmInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
nucleusInterferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)
PcG protein complexCasein kinase II subunit alpha'Homo sapiens (human)
acrosomal vesicleCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
nucleoplasmCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alpha'Homo sapiens (human)
chromatinCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
Golgi membraneRas-related protein Rab-6AHomo sapiens (human)
acrosomal membraneRas-related protein Rab-6AHomo sapiens (human)
endoplasmic reticulum membraneRas-related protein Rab-6AHomo sapiens (human)
Golgi apparatusRas-related protein Rab-6AHomo sapiens (human)
trans-Golgi networkRas-related protein Rab-6AHomo sapiens (human)
cytosolRas-related protein Rab-6AHomo sapiens (human)
plasma membraneRas-related protein Rab-6AHomo sapiens (human)
membraneRas-related protein Rab-6AHomo sapiens (human)
secretory granule membraneRas-related protein Rab-6AHomo sapiens (human)
cytoplasmic vesicleRas-related protein Rab-6AHomo sapiens (human)
trans-Golgi network membraneRas-related protein Rab-6AHomo sapiens (human)
extracellular exosomeRas-related protein Rab-6AHomo sapiens (human)
endosome to plasma membrane transport vesicleRas-related protein Rab-6AHomo sapiens (human)
Golgi apparatusRas-related protein Rab-6AHomo sapiens (human)
endomembrane systemRas-related protein Rab-6AHomo sapiens (human)
photoreceptor outer segmentSerine/threonine-protein kinase MAKHomo sapiens (human)
photoreceptor inner segmentSerine/threonine-protein kinase MAKHomo sapiens (human)
nucleusSerine/threonine-protein kinase MAKHomo sapiens (human)
centrosomeSerine/threonine-protein kinase MAKHomo sapiens (human)
axonemeSerine/threonine-protein kinase MAKHomo sapiens (human)
midbodySerine/threonine-protein kinase MAKHomo sapiens (human)
motile ciliumSerine/threonine-protein kinase MAKHomo sapiens (human)
photoreceptor connecting ciliumSerine/threonine-protein kinase MAKHomo sapiens (human)
mitotic spindleSerine/threonine-protein kinase MAKHomo sapiens (human)
ciliumSerine/threonine-protein kinase MAKHomo sapiens (human)
nucleusSerine/threonine-protein kinase MAKHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase MAKHomo sapiens (human)
nucleusCyclin-dependent kinase 11BHomo sapiens (human)
cytoplasmCyclin-dependent kinase 11BHomo sapiens (human)
nucleusCyclin-dependent kinase 11BHomo sapiens (human)
plasma membraneEphrin type-A receptor 1Homo sapiens (human)
receptor complexEphrin type-A receptor 1Homo sapiens (human)
plasma membraneEphrin type-A receptor 1Homo sapiens (human)
collagen-containing extracellular matrixFibroblast growth factor receptor 2Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 2Homo sapiens (human)
nucleusFibroblast growth factor receptor 2Homo sapiens (human)
cytoplasmFibroblast growth factor receptor 2Homo sapiens (human)
Golgi apparatusFibroblast growth factor receptor 2Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 2Homo sapiens (human)
cell cortexFibroblast growth factor receptor 2Homo sapiens (human)
cell surfaceFibroblast growth factor receptor 2Homo sapiens (human)
membraneFibroblast growth factor receptor 2Homo sapiens (human)
cytoplasmic vesicleFibroblast growth factor receptor 2Homo sapiens (human)
excitatory synapseFibroblast growth factor receptor 2Homo sapiens (human)
receptor complexFibroblast growth factor receptor 2Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 2Homo sapiens (human)
extracellular spaceReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
apical plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
lateral plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
ERBB3:ERBB2 complexReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-3Homo sapiens (human)
cytoplasmMultifunctional protein ADE2Homo sapiens (human)
cytosolMultifunctional protein ADE2Homo sapiens (human)
membraneMultifunctional protein ADE2Homo sapiens (human)
extracellular exosomeMultifunctional protein ADE2Homo sapiens (human)
cell-cell junctionFibroblast growth factor receptor 4Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 4Homo sapiens (human)
endosomeFibroblast growth factor receptor 4Homo sapiens (human)
endoplasmic reticulumFibroblast growth factor receptor 4Homo sapiens (human)
Golgi apparatusFibroblast growth factor receptor 4Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 4Homo sapiens (human)
transport vesicleFibroblast growth factor receptor 4Homo sapiens (human)
receptor complexFibroblast growth factor receptor 4Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 4Homo sapiens (human)
focal adhesionFibroblast growth factor receptor 3Homo sapiens (human)
extracellular regionFibroblast growth factor receptor 3Homo sapiens (human)
endoplasmic reticulumFibroblast growth factor receptor 3Homo sapiens (human)
Golgi apparatusFibroblast growth factor receptor 3Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 3Homo sapiens (human)
cell surfaceFibroblast growth factor receptor 3Homo sapiens (human)
transport vesicleFibroblast growth factor receptor 3Homo sapiens (human)
receptor complexFibroblast growth factor receptor 3Homo sapiens (human)
plasma membraneFibroblast growth factor receptor 3Homo sapiens (human)
nucleoplasmcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
ciliary basecAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
cAMP-dependent protein kinase complexcAMP-dependent protein kinase catalytic subunit gammaHomo sapiens (human)
nucleoplasmcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
centrosomecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
plasma membranecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
extracellular exosomecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
ciliary basecAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
cAMP-dependent protein kinase complexcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
cytosolcAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)
mitochondrial inner membraneFerrochelatase, mitochondrialHomo sapiens (human)
mitochondrial matrixFerrochelatase, mitochondrialHomo sapiens (human)
mitochondrionFerrochelatase, mitochondrialHomo sapiens (human)
nucleoplasmRibosomal protein S6 kinase beta-1Homo sapiens (human)
mitochondrionRibosomal protein S6 kinase beta-1Homo sapiens (human)
mitochondrial outer membraneRibosomal protein S6 kinase beta-1Homo sapiens (human)
cytosolRibosomal protein S6 kinase beta-1Homo sapiens (human)
cell surfaceRibosomal protein S6 kinase beta-1Homo sapiens (human)
neuron projectionRibosomal protein S6 kinase beta-1Homo sapiens (human)
perinuclear region of cytoplasmRibosomal protein S6 kinase beta-1Homo sapiens (human)
postsynapseRibosomal protein S6 kinase beta-1Homo sapiens (human)
glutamatergic synapseRibosomal protein S6 kinase beta-1Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase beta-1Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase beta-1Homo sapiens (human)
cytoplasmTyrosine-protein kinase JAK1Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK1Homo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein kinase JAK1Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK1Homo sapiens (human)
nucleusTyrosine-protein kinase JAK1Homo sapiens (human)
cytoplasmTyrosine-protein kinase JAK1Homo sapiens (human)
endosomeTyrosine-protein kinase JAK1Homo sapiens (human)
cytosolTyrosine-protein kinase JAK1Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK1Homo sapiens (human)
focal adhesionTyrosine-protein kinase JAK1Homo sapiens (human)
cytosolTyrosine-protein kinase JAK1Homo sapiens (human)
cytoplasmProtein kinase C eta typeHomo sapiens (human)
cytosolProtein kinase C eta typeHomo sapiens (human)
plasma membraneProtein kinase C eta typeHomo sapiens (human)
cell-cell junctionProtein kinase C eta typeHomo sapiens (human)
extracellular exosomeProtein kinase C eta typeHomo sapiens (human)
chromosome, telomeric regionCyclin-dependent kinase 2Homo sapiens (human)
condensed chromosomeCyclin-dependent kinase 2Homo sapiens (human)
X chromosomeCyclin-dependent kinase 2Homo sapiens (human)
Y chromosomeCyclin-dependent kinase 2Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
nuclear envelopeCyclin-dependent kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
endosomeCyclin-dependent kinase 2Homo sapiens (human)
centrosomeCyclin-dependent kinase 2Homo sapiens (human)
cytosolCyclin-dependent kinase 2Homo sapiens (human)
Cajal bodyCyclin-dependent kinase 2Homo sapiens (human)
cyclin A1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin A2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E1-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin E2-CDK2 complexCyclin-dependent kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 2Homo sapiens (human)
transcription regulator complexCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase 2Homo sapiens (human)
nucleusCyclin-dependent kinase 2Homo sapiens (human)
cytoplasmBeta-adrenergic receptor kinase 1Homo sapiens (human)
cytosolBeta-adrenergic receptor kinase 1Homo sapiens (human)
plasma membraneBeta-adrenergic receptor kinase 1Homo sapiens (human)
ciliumBeta-adrenergic receptor kinase 1Homo sapiens (human)
membraneBeta-adrenergic receptor kinase 1Homo sapiens (human)
presynapseBeta-adrenergic receptor kinase 1Homo sapiens (human)
postsynapseBeta-adrenergic receptor kinase 1Homo sapiens (human)
P-bodyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
nucleusProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytosolProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmic stress granuleProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
membraneProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
RISC complexProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmic stress granuleProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
P-bodyProbable ATP-dependent RNA helicase DDX6Homo sapiens (human)
cytoplasmActivin receptor type-2AHomo sapiens (human)
plasma membraneActivin receptor type-2AHomo sapiens (human)
cell surfaceActivin receptor type-2AHomo sapiens (human)
inhibin-betaglycan-ActRII complexActivin receptor type-2AHomo sapiens (human)
receptor complexActivin receptor type-2AHomo sapiens (human)
plasma membraneActivin receptor type-2AHomo sapiens (human)
activin receptor complexActivin receptor type-2AHomo sapiens (human)
nucleusMitogen-activated protein kinase 3 Homo sapiens (human)
nuclear envelopeMitogen-activated protein kinase 3 Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 3 Homo sapiens (human)
early endosomeMitogen-activated protein kinase 3 Homo sapiens (human)
late endosomeMitogen-activated protein kinase 3 Homo sapiens (human)
endoplasmic reticulum lumenMitogen-activated protein kinase 3 Homo sapiens (human)
Golgi apparatusMitogen-activated protein kinase 3 Homo sapiens (human)
cytosolMitogen-activated protein kinase 3 Homo sapiens (human)
cytoskeletonMitogen-activated protein kinase 3 Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 3 Homo sapiens (human)
caveolaMitogen-activated protein kinase 3 Homo sapiens (human)
focal adhesionMitogen-activated protein kinase 3 Homo sapiens (human)
pseudopodiumMitogen-activated protein kinase 3 Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 3 Homo sapiens (human)
nucleusMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 3 Homo sapiens (human)
cytoplasmMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
cytosolMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
plasma membraneMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
dendriteMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
extracellular exosomeMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
plasma membraneMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
cytoplasmMAP/microtubule affinity-regulating kinase 3Homo sapiens (human)
nucleoplasmDeoxycytidine kinaseHomo sapiens (human)
cytosolDeoxycytidine kinaseHomo sapiens (human)
mitochondrionDeoxycytidine kinaseHomo sapiens (human)
cytoplasmDeoxycytidine kinaseHomo sapiens (human)
extracellular regionMitogen-activated protein kinase 1Homo sapiens (human)
nucleusMitogen-activated protein kinase 1Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 1Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 1Homo sapiens (human)
early endosomeMitogen-activated protein kinase 1Homo sapiens (human)
late endosomeMitogen-activated protein kinase 1Homo sapiens (human)
endoplasmic reticulum lumenMitogen-activated protein kinase 1Homo sapiens (human)
Golgi apparatusMitogen-activated protein kinase 1Homo sapiens (human)
centrosomeMitogen-activated protein kinase 1Homo sapiens (human)
cytosolMitogen-activated protein kinase 1Homo sapiens (human)
cytoskeletonMitogen-activated protein kinase 1Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 1Homo sapiens (human)
caveolaMitogen-activated protein kinase 1Homo sapiens (human)
focal adhesionMitogen-activated protein kinase 1Homo sapiens (human)
pseudopodiumMitogen-activated protein kinase 1Homo sapiens (human)
azurophil granule lumenMitogen-activated protein kinase 1Homo sapiens (human)
synapseMitogen-activated protein kinase 1Homo sapiens (human)
mitotic spindleMitogen-activated protein kinase 1Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 1Homo sapiens (human)
nucleusMitogen-activated protein kinase 1Homo sapiens (human)
plasma membraneEphrin type-A receptor 2Homo sapiens (human)
focal adhesionEphrin type-A receptor 2Homo sapiens (human)
cell surfaceEphrin type-A receptor 2Homo sapiens (human)
lamellipodiumEphrin type-A receptor 2Homo sapiens (human)
leading edge membraneEphrin type-A receptor 2Homo sapiens (human)
lamellipodium membraneEphrin type-A receptor 2Homo sapiens (human)
ruffle membraneEphrin type-A receptor 2Homo sapiens (human)
tight junctionEphrin type-A receptor 2Homo sapiens (human)
receptor complexEphrin type-A receptor 2Homo sapiens (human)
plasma membraneEphrin type-A receptor 2Homo sapiens (human)
extracellular regionEphrin type-A receptor 3Homo sapiens (human)
nucleoplasmEphrin type-A receptor 3Homo sapiens (human)
early endosomeEphrin type-A receptor 3Homo sapiens (human)
cytosolEphrin type-A receptor 3Homo sapiens (human)
plasma membraneEphrin type-A receptor 3Homo sapiens (human)
actin cytoskeletonEphrin type-A receptor 3Homo sapiens (human)
nuclear membraneEphrin type-A receptor 3Homo sapiens (human)
dendriteEphrin type-A receptor 3Homo sapiens (human)
plasma membraneEphrin type-A receptor 3Homo sapiens (human)
plasma membraneEphrin type-A receptor 8Homo sapiens (human)
early endosome membraneEphrin type-A receptor 8Homo sapiens (human)
neuron projectionEphrin type-A receptor 8Homo sapiens (human)
dendriteEphrin type-A receptor 8Homo sapiens (human)
plasma membraneEphrin type-A receptor 8Homo sapiens (human)
extracellular regionEphrin type-B receptor 2Homo sapiens (human)
nucleoplasmEphrin type-B receptor 2Homo sapiens (human)
cytosolEphrin type-B receptor 2Homo sapiens (human)
plasma membraneEphrin type-B receptor 2Homo sapiens (human)
cell surfaceEphrin type-B receptor 2Homo sapiens (human)
axonEphrin type-B receptor 2Homo sapiens (human)
dendriteEphrin type-B receptor 2Homo sapiens (human)
presynaptic membraneEphrin type-B receptor 2Homo sapiens (human)
neuronal cell bodyEphrin type-B receptor 2Homo sapiens (human)
dendritic spineEphrin type-B receptor 2Homo sapiens (human)
postsynaptic membraneEphrin type-B receptor 2Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseEphrin type-B receptor 2Homo sapiens (human)
postsynapseEphrin type-B receptor 2Homo sapiens (human)
glutamatergic synapseEphrin type-B receptor 2Homo sapiens (human)
plasma membraneEphrin type-B receptor 2Homo sapiens (human)
dendriteEphrin type-B receptor 2Homo sapiens (human)
plasma membraneLeukocyte tyrosine kinase receptorHomo sapiens (human)
membraneLeukocyte tyrosine kinase receptorHomo sapiens (human)
receptor complexLeukocyte tyrosine kinase receptorHomo sapiens (human)
plasma membraneLeukocyte tyrosine kinase receptorHomo sapiens (human)
plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytoplasmic side of plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
extrinsic component of plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
nucleusNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytoplasmNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytosolNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytoskeletonNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
plasma membraneNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-12 receptor complexNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
extracellular exosomeNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
interleukin-23 receptor complexNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
cytosolNon-receptor tyrosine-protein kinase TYK2Homo sapiens (human)
nucleusWee1-like protein kinaseHomo sapiens (human)
nucleoplasmWee1-like protein kinaseHomo sapiens (human)
nucleolusWee1-like protein kinaseHomo sapiens (human)
cytoplasmWee1-like protein kinaseHomo sapiens (human)
endoplasmic reticulum membraneHeme oxygenase 2Homo sapiens (human)
plasma membraneHeme oxygenase 2Homo sapiens (human)
membraneHeme oxygenase 2Homo sapiens (human)
specific granule membraneHeme oxygenase 2Homo sapiens (human)
extracellular spaceTyrosine-protein kinase receptor UFOHomo sapiens (human)
plasma membraneTyrosine-protein kinase receptor UFOHomo sapiens (human)
cell surfaceTyrosine-protein kinase receptor UFOHomo sapiens (human)
actin cytoskeletonTyrosine-protein kinase receptor UFOHomo sapiens (human)
intracellular membrane-bounded organelleTyrosine-protein kinase receptor UFOHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase receptor UFOHomo sapiens (human)
plasma membraneTyrosine-protein kinase receptor UFOHomo sapiens (human)
receptor complexTyrosine-protein kinase receptor UFOHomo sapiens (human)
nucleusMitogen-activated protein kinase 4Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 4Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 4Homo sapiens (human)
cytosolMitogen-activated protein kinase 4Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 4Homo sapiens (human)
nucleusMitogen-activated protein kinase 4Homo sapiens (human)
cytosolS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
methionine adenosyltransferase complexS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
cytosolS-adenosylmethionine synthase isoform type-2Homo sapiens (human)
nucleusDnaJ homolog subfamily A member 1Homo sapiens (human)
mitochondrionDnaJ homolog subfamily A member 1Homo sapiens (human)
cytosolDnaJ homolog subfamily A member 1Homo sapiens (human)
microtubule cytoskeletonDnaJ homolog subfamily A member 1Homo sapiens (human)
membraneDnaJ homolog subfamily A member 1Homo sapiens (human)
perinuclear region of cytoplasmDnaJ homolog subfamily A member 1Homo sapiens (human)
extracellular exosomeDnaJ homolog subfamily A member 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneDnaJ homolog subfamily A member 1Homo sapiens (human)
cytoplasmDnaJ homolog subfamily A member 1Homo sapiens (human)
cytosolDnaJ homolog subfamily A member 1Homo sapiens (human)
cytoplasmRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
mitochondrial intermembrane spaceRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
membraneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nucleusRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nucleoplasmRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
spindleRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
plasma membraneRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell-cell junctionRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
cell cortexRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
microtubule cytoskeletonRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
lamellipodiumRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
vesicleRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
ciliary basal bodyRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
postsynapseRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
glutamatergic synapseRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
protein-containing complexRAC-alpha serine/threonine-protein kinaseHomo sapiens (human)
nucleusRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
nucleoplasmRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
early endosomeRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cytosolRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
plasma membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cell cortexRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
ruffle membraneRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
intracellular membrane-bounded organelleRAC-beta serine/threonine-protein kinaseHomo sapiens (human)
cytosolG protein-coupled receptor kinase 4Homo sapiens (human)
plasma membraneG protein-coupled receptor kinase 4Homo sapiens (human)
cell cortexG protein-coupled receptor kinase 4Homo sapiens (human)
photoreceptor disc membraneG protein-coupled receptor kinase 4Homo sapiens (human)
cytoplasmG protein-coupled receptor kinase 4Homo sapiens (human)
cytoplasmDual specificity protein kinase TTKHomo sapiens (human)
spindleDual specificity protein kinase TTKHomo sapiens (human)
membraneDual specificity protein kinase TTKHomo sapiens (human)
kinetochoreDual specificity protein kinase TTKHomo sapiens (human)
nucleusDual specificity protein kinase TTKHomo sapiens (human)
chromosome, telomeric regionDNA replication licensing factor MCM4Homo sapiens (human)
nucleusDNA replication licensing factor MCM4Homo sapiens (human)
nucleoplasmDNA replication licensing factor MCM4Homo sapiens (human)
membraneDNA replication licensing factor MCM4Homo sapiens (human)
MCM complexDNA replication licensing factor MCM4Homo sapiens (human)
CMG complexDNA replication licensing factor MCM4Homo sapiens (human)
nucleusDNA replication licensing factor MCM4Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
postsynaptic actin cytoskeletonMyosin-10Homo sapiens (human)
stress fiberMyosin-10Homo sapiens (human)
nucleusMyosin-10Homo sapiens (human)
cytoplasmMyosin-10Homo sapiens (human)
cytosolMyosin-10Homo sapiens (human)
cell cortexMyosin-10Homo sapiens (human)
lamellipodiumMyosin-10Homo sapiens (human)
midbodyMyosin-10Homo sapiens (human)
cleavage furrowMyosin-10Homo sapiens (human)
actomyosinMyosin-10Homo sapiens (human)
extracellular exosomeMyosin-10Homo sapiens (human)
myosin II filamentMyosin-10Homo sapiens (human)
myosin complexMyosin-10Homo sapiens (human)
myosin II complexMyosin-10Homo sapiens (human)
myosin filamentMyosin-10Homo sapiens (human)
cytoplasmMyosin-10Homo sapiens (human)
plasma membraneTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
receptor complexTyrosine-protein kinase receptor Tie-1Homo sapiens (human)
extracellular regionVascular endothelial growth factor receptor 3Homo sapiens (human)
nucleoplasmVascular endothelial growth factor receptor 3Homo sapiens (human)
cytosolVascular endothelial growth factor receptor 3Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 3Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 3Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 3Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Mus musculus (house mouse)
extracellular regionVascular endothelial growth factor receptor 2Homo sapiens (human)
nucleusVascular endothelial growth factor receptor 2Homo sapiens (human)
endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
early endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
endoplasmic reticulumVascular endothelial growth factor receptor 2Homo sapiens (human)
Golgi apparatusVascular endothelial growth factor receptor 2Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
external side of plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
cell junctionVascular endothelial growth factor receptor 2Homo sapiens (human)
membrane raftVascular endothelial growth factor receptor 2Homo sapiens (human)
anchoring junctionVascular endothelial growth factor receptor 2Homo sapiens (human)
sorting endosomeVascular endothelial growth factor receptor 2Homo sapiens (human)
plasma membraneVascular endothelial growth factor receptor 2Homo sapiens (human)
receptor complexVascular endothelial growth factor receptor 2Homo sapiens (human)
extracellular regionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
mitochondrionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
early endosomeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
late endosomeDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
peroxisomal membraneDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
endoplasmic reticulumDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
Golgi apparatusDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
microtubuleDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
cell-cell junctionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
focal adhesionDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
cytoplasmic side of plasma membraneDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
perinuclear region of cytoplasmDual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)
endoplasmic reticulumReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
endoplasmic reticulum lumenReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
plasma membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
endosome membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
receptor complexReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
plasma membraneReceptor-type tyrosine-protein kinase FLT3Homo sapiens (human)
caveolaBone morphogenetic protein receptor type-1AHomo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
external side of plasma membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
dendriteBone morphogenetic protein receptor type-1AHomo sapiens (human)
neuronal cell bodyBone morphogenetic protein receptor type-1AHomo sapiens (human)
HFE-transferrin receptor complexBone morphogenetic protein receptor type-1AHomo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-1AHomo sapiens (human)
receptor complexBone morphogenetic protein receptor type-1AHomo sapiens (human)
cytosolActivin receptor type-1BHomo sapiens (human)
plasma membraneActivin receptor type-1BHomo sapiens (human)
cell surfaceActivin receptor type-1BHomo sapiens (human)
receptor complexActivin receptor type-1BHomo sapiens (human)
activin receptor complexActivin receptor type-1BHomo sapiens (human)
plasma membraneActivin receptor type-1BHomo sapiens (human)
nucleusTGF-beta receptor type-1Homo sapiens (human)
endosomeTGF-beta receptor type-1Homo sapiens (human)
plasma membraneTGF-beta receptor type-1Homo sapiens (human)
bicellular tight junctionTGF-beta receptor type-1Homo sapiens (human)
cell surfaceTGF-beta receptor type-1Homo sapiens (human)
membrane raftTGF-beta receptor type-1Homo sapiens (human)
transforming growth factor beta ligand-receptor complexTGF-beta receptor type-1Homo sapiens (human)
receptor complexTGF-beta receptor type-1Homo sapiens (human)
plasma membraneTGF-beta receptor type-1Homo sapiens (human)
activin receptor complexTGF-beta receptor type-1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase receptor R3Homo sapiens (human)
cell surfaceSerine/threonine-protein kinase receptor R3Homo sapiens (human)
dendriteSerine/threonine-protein kinase receptor R3Homo sapiens (human)
neuronal cell bodySerine/threonine-protein kinase receptor R3Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase receptor R3Homo sapiens (human)
BMP receptor complexSerine/threonine-protein kinase receptor R3Homo sapiens (human)
extracellular regionTGF-beta receptor type-2Homo sapiens (human)
cytosolTGF-beta receptor type-2Homo sapiens (human)
plasma membraneTGF-beta receptor type-2Homo sapiens (human)
caveolaTGF-beta receptor type-2Homo sapiens (human)
external side of plasma membraneTGF-beta receptor type-2Homo sapiens (human)
membraneTGF-beta receptor type-2Homo sapiens (human)
membrane raftTGF-beta receptor type-2Homo sapiens (human)
transforming growth factor beta ligand-receptor complexTGF-beta receptor type-2Homo sapiens (human)
receptor complexTGF-beta receptor type-2Homo sapiens (human)
plasma membraneTGF-beta receptor type-2Homo sapiens (human)
cytoplasmTyrosine-protein kinase CSKHomo sapiens (human)
cytosolTyrosine-protein kinase CSKHomo sapiens (human)
plasma membraneTyrosine-protein kinase CSKHomo sapiens (human)
cell-cell junctionTyrosine-protein kinase CSKHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase CSKHomo sapiens (human)
plasma membraneTyrosine-protein kinase CSKHomo sapiens (human)
mitochondrial matrixGlycine--tRNA ligaseHomo sapiens (human)
cytosolGlycine--tRNA ligaseHomo sapiens (human)
secretory granuleGlycine--tRNA ligaseHomo sapiens (human)
axonGlycine--tRNA ligaseHomo sapiens (human)
extracellular exosomeGlycine--tRNA ligaseHomo sapiens (human)
cytoplasmGlycine--tRNA ligaseHomo sapiens (human)
mitochondrionGlycine--tRNA ligaseHomo sapiens (human)
Golgi membraneProtein kinase C iota typeHomo sapiens (human)
nucleusProtein kinase C iota typeHomo sapiens (human)
nucleoplasmProtein kinase C iota typeHomo sapiens (human)
endosomeProtein kinase C iota typeHomo sapiens (human)
cytosolProtein kinase C iota typeHomo sapiens (human)
plasma membraneProtein kinase C iota typeHomo sapiens (human)
brush borderProtein kinase C iota typeHomo sapiens (human)
bicellular tight junctionProtein kinase C iota typeHomo sapiens (human)
microtubule cytoskeletonProtein kinase C iota typeHomo sapiens (human)
apical plasma membraneProtein kinase C iota typeHomo sapiens (human)
cell leading edgeProtein kinase C iota typeHomo sapiens (human)
Schmidt-Lanterman incisureProtein kinase C iota typeHomo sapiens (human)
intercellular bridgeProtein kinase C iota typeHomo sapiens (human)
extracellular exosomeProtein kinase C iota typeHomo sapiens (human)
tight junctionProtein kinase C iota typeHomo sapiens (human)
Schaffer collateral - CA1 synapseProtein kinase C iota typeHomo sapiens (human)
glutamatergic synapseProtein kinase C iota typeHomo sapiens (human)
PAR polarity complexProtein kinase C iota typeHomo sapiens (human)
nuclear exosome (RNase complex)Exosome RNA helicase MTR4Homo sapiens (human)
exosome (RNase complex)Exosome RNA helicase MTR4Homo sapiens (human)
nucleusExosome RNA helicase MTR4Homo sapiens (human)
nucleoplasmExosome RNA helicase MTR4Homo sapiens (human)
nucleolusExosome RNA helicase MTR4Homo sapiens (human)
nuclear speckExosome RNA helicase MTR4Homo sapiens (human)
TRAMP complexExosome RNA helicase MTR4Homo sapiens (human)
catalytic step 2 spliceosomeExosome RNA helicase MTR4Homo sapiens (human)
nucleusExosome RNA helicase MTR4Homo sapiens (human)
cytosolPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complex, class IAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
intercalated discPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
lamellipodiumPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
perinuclear region of cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complex, class IBPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)
nucleusPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
nucleoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
nucleolusPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
cytosolPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complex, class IAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
midbodyPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
intracellular membrane-bounded organellePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
phosphatidylinositol 3-kinase complexPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)
PML bodySerine/threonine-protein kinase mTORHomo sapiens (human)
lysosomal membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
cytosolSerine/threonine-protein kinase mTORHomo sapiens (human)
Golgi membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase mTORHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase mTORHomo sapiens (human)
mitochondrial outer membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
lysosomeSerine/threonine-protein kinase mTORHomo sapiens (human)
lysosomal membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
cytosolSerine/threonine-protein kinase mTORHomo sapiens (human)
endomembrane systemSerine/threonine-protein kinase mTORHomo sapiens (human)
membraneSerine/threonine-protein kinase mTORHomo sapiens (human)
dendriteSerine/threonine-protein kinase mTORHomo sapiens (human)
TORC1 complexSerine/threonine-protein kinase mTORHomo sapiens (human)
TORC2 complexSerine/threonine-protein kinase mTORHomo sapiens (human)
phagocytic vesicleSerine/threonine-protein kinase mTORHomo sapiens (human)
nuclear envelopeSerine/threonine-protein kinase mTORHomo sapiens (human)
nucleusSerine/threonine-protein kinase mTORHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase mTORHomo sapiens (human)
cytosolMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
plasma membraneMegakaryocyte-associated tyrosine-protein kinaseHomo sapiens (human)
cytosolTyrosine-protein kinase TecHomo sapiens (human)
cytoskeletonTyrosine-protein kinase TecHomo sapiens (human)
plasma membraneTyrosine-protein kinase TecHomo sapiens (human)
plasma membraneTyrosine-protein kinase TecHomo sapiens (human)
nucleusTyrosine-protein kinase TXKHomo sapiens (human)
nucleoplasmTyrosine-protein kinase TXKHomo sapiens (human)
nucleolusTyrosine-protein kinase TXKHomo sapiens (human)
cytoplasmTyrosine-protein kinase TXKHomo sapiens (human)
cytosolTyrosine-protein kinase TXKHomo sapiens (human)
plasma membraneTyrosine-protein kinase TXKHomo sapiens (human)
plasma membraneTyrosine-protein kinase TXKHomo sapiens (human)
cytosolTyrosine-protein kinase ABL2Homo sapiens (human)
actin cytoskeletonTyrosine-protein kinase ABL2Homo sapiens (human)
plasma membraneTyrosine-protein kinase ABL2Homo sapiens (human)
extracellular regionTyrosine-protein kinase FRKHomo sapiens (human)
nucleusTyrosine-protein kinase FRKHomo sapiens (human)
nucleoplasmTyrosine-protein kinase FRKHomo sapiens (human)
cytosolTyrosine-protein kinase FRKHomo sapiens (human)
azurophil granule lumenTyrosine-protein kinase FRKHomo sapiens (human)
specific granule lumenTyrosine-protein kinase FRKHomo sapiens (human)
extracellular exosomeTyrosine-protein kinase FRKHomo sapiens (human)
plasma membraneTyrosine-protein kinase FRKHomo sapiens (human)
plasma membraneG protein-coupled receptor kinase 6Homo sapiens (human)
membraneG protein-coupled receptor kinase 6Homo sapiens (human)
cytoplasmG protein-coupled receptor kinase 6Homo sapiens (human)
membrane raftTyrosine-protein kinase ZAP-70Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase ZAP-70Homo sapiens (human)
immunological synapseTyrosine-protein kinase ZAP-70Homo sapiens (human)
cytoplasmTyrosine-protein kinase ZAP-70Homo sapiens (human)
cytosolTyrosine-protein kinase ZAP-70Homo sapiens (human)
plasma membraneTyrosine-protein kinase ZAP-70Homo sapiens (human)
cell-cell junctionTyrosine-protein kinase ZAP-70Homo sapiens (human)
T cell receptor complexTyrosine-protein kinase ZAP-70Homo sapiens (human)
plasma membraneTyrosine-protein kinase ZAP-70Homo sapiens (human)
cytoplasmTyrosine-protein kinase SYKHomo sapiens (human)
nucleusTyrosine-protein kinase SYKHomo sapiens (human)
cytoplasmTyrosine-protein kinase SYKHomo sapiens (human)
cytosolTyrosine-protein kinase SYKHomo sapiens (human)
plasma membraneTyrosine-protein kinase SYKHomo sapiens (human)
early phagosomeTyrosine-protein kinase SYKHomo sapiens (human)
B cell receptor complexTyrosine-protein kinase SYKHomo sapiens (human)
protein-containing complexTyrosine-protein kinase SYKHomo sapiens (human)
T cell receptor complexTyrosine-protein kinase SYKHomo sapiens (human)
plasma membraneTyrosine-protein kinase SYKHomo sapiens (human)
proteasome complex26S proteasome regulatory subunit 6BHomo sapiens (human)
nucleus26S proteasome regulatory subunit 6BHomo sapiens (human)
nucleoplasm26S proteasome regulatory subunit 6BHomo sapiens (human)
cytosol26S proteasome regulatory subunit 6BHomo sapiens (human)
membrane26S proteasome regulatory subunit 6BHomo sapiens (human)
inclusion body26S proteasome regulatory subunit 6BHomo sapiens (human)
synapse26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome accessory complex26S proteasome regulatory subunit 6BHomo sapiens (human)
cytosolic proteasome complex26S proteasome regulatory subunit 6BHomo sapiens (human)
proteasome regulatory particle, base subcomplex26S proteasome regulatory subunit 6BHomo sapiens (human)
cytoplasmMitogen-activated protein kinase 8Homo sapiens (human)
nucleusMitogen-activated protein kinase 8Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 8Homo sapiens (human)
cytosolMitogen-activated protein kinase 8Homo sapiens (human)
axonMitogen-activated protein kinase 8Homo sapiens (human)
synapseMitogen-activated protein kinase 8Homo sapiens (human)
basal dendriteMitogen-activated protein kinase 8Homo sapiens (human)
nucleusMitogen-activated protein kinase 8Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 9Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 9Homo sapiens (human)
cytosolMitogen-activated protein kinase 9Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 9Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 9Homo sapiens (human)
Schaffer collateral - CA1 synapseMitogen-activated protein kinase 9Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 9Homo sapiens (human)
nucleusMitogen-activated protein kinase 9Homo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
axonDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
dendrite cytoplasmDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
perikaryonDual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)
cytoplasmDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
nucleoplasmDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
membraneDual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)
photoreceptor outer segmentPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
photoreceptor inner segmentPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
nucleoplasmPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
lysosomePhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
autophagosomePhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
cytosolPhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)
mRNA cleavage and polyadenylation specificity factor complexCasein kinase I isoform alphaHomo sapiens (human)
keratin filamentCasein kinase I isoform alphaHomo sapiens (human)
kinetochoreCasein kinase I isoform alphaHomo sapiens (human)
centrosomeCasein kinase I isoform alphaHomo sapiens (human)
spindleCasein kinase I isoform alphaHomo sapiens (human)
cytosolCasein kinase I isoform alphaHomo sapiens (human)
ciliumCasein kinase I isoform alphaHomo sapiens (human)
membraneCasein kinase I isoform alphaHomo sapiens (human)
nuclear speckCasein kinase I isoform alphaHomo sapiens (human)
beta-catenin destruction complexCasein kinase I isoform alphaHomo sapiens (human)
ciliary basal bodyCasein kinase I isoform alphaHomo sapiens (human)
cytoplasmCasein kinase I isoform alphaHomo sapiens (human)
nucleusCasein kinase I isoform alphaHomo sapiens (human)
nucleusCasein kinase I isoform deltaHomo sapiens (human)
nucleoplasmCasein kinase I isoform deltaHomo sapiens (human)
Golgi apparatusCasein kinase I isoform deltaHomo sapiens (human)
centrosomeCasein kinase I isoform deltaHomo sapiens (human)
spindleCasein kinase I isoform deltaHomo sapiens (human)
cytosolCasein kinase I isoform deltaHomo sapiens (human)
spindle microtubuleCasein kinase I isoform deltaHomo sapiens (human)
plasma membraneCasein kinase I isoform deltaHomo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membraneCasein kinase I isoform deltaHomo sapiens (human)
ciliary basal bodyCasein kinase I isoform deltaHomo sapiens (human)
perinuclear region of cytoplasmCasein kinase I isoform deltaHomo sapiens (human)
nucleusCasein kinase I isoform deltaHomo sapiens (human)
cytoplasmCasein kinase I isoform deltaHomo sapiens (human)
spindle microtubuleCasein kinase I isoform deltaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
cytosolPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IBPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
plasma membranePhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
cytoplasmPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 2Homo sapiens (human)
nucleoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
centrosomeMAP kinase-activated protein kinase 2Homo sapiens (human)
cytosolMAP kinase-activated protein kinase 2Homo sapiens (human)
extracellular exosomeMAP kinase-activated protein kinase 2Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 2Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 8Homo sapiens (human)
nucleusCyclin-dependent kinase 8Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 8Homo sapiens (human)
nucleolusCyclin-dependent kinase 8Homo sapiens (human)
CKM complexCyclin-dependent kinase 8Homo sapiens (human)
ubiquitin ligase complexCyclin-dependent kinase 8Homo sapiens (human)
mediator complexCyclin-dependent kinase 8Homo sapiens (human)
protein-containing complexCyclin-dependent kinase 8Homo sapiens (human)
nucleusCyclin-dependent kinase 8Homo sapiens (human)
mitochondrionElongation factor Tu, mitochondrialHomo sapiens (human)
mitochondrial outer membraneElongation factor Tu, mitochondrialHomo sapiens (human)
membraneElongation factor Tu, mitochondrialHomo sapiens (human)
mitochondrial nucleoidElongation factor Tu, mitochondrialHomo sapiens (human)
synapseElongation factor Tu, mitochondrialHomo sapiens (human)
extracellular exosomeElongation factor Tu, mitochondrialHomo sapiens (human)
mitochondrionElongation factor Tu, mitochondrialHomo sapiens (human)
nucleusCholine-phosphate cytidylyltransferase AHomo sapiens (human)
nuclear envelopeCholine-phosphate cytidylyltransferase AHomo sapiens (human)
endoplasmic reticulumCholine-phosphate cytidylyltransferase AHomo sapiens (human)
endoplasmic reticulum membraneCholine-phosphate cytidylyltransferase AHomo sapiens (human)
cytosolCholine-phosphate cytidylyltransferase AHomo sapiens (human)
glycogen granuleCholine-phosphate cytidylyltransferase AHomo sapiens (human)
endoplasmic reticulumCholine-phosphate cytidylyltransferase AHomo sapiens (human)
nucleusCasein kinase I isoform epsilonHomo sapiens (human)
nucleoplasmCasein kinase I isoform epsilonHomo sapiens (human)
cytoplasmCasein kinase I isoform epsilonHomo sapiens (human)
cytosolCasein kinase I isoform epsilonHomo sapiens (human)
growth coneCasein kinase I isoform epsilonHomo sapiens (human)
neuronal cell bodyCasein kinase I isoform epsilonHomo sapiens (human)
ribonucleoprotein complexCasein kinase I isoform epsilonHomo sapiens (human)
cytoplasmCasein kinase I isoform epsilonHomo sapiens (human)
nucleusCasein kinase I isoform epsilonHomo sapiens (human)
nucleoplasmVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
nucleolusVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrionVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial inner membraneVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial matrixVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial membraneVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
mitochondrial nucleoidVery long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)
nucleusDual specificity protein kinase CLK1Homo sapiens (human)
nucleusDual specificity protein kinase CLK2Homo sapiens (human)
nucleoplasmDual specificity protein kinase CLK2Homo sapiens (human)
nuclear bodyDual specificity protein kinase CLK2Homo sapiens (human)
nuclear speckDual specificity protein kinase CLK2Homo sapiens (human)
nucleusDual specificity protein kinase CLK2Homo sapiens (human)
acrosomal vesicleDual specificity protein kinase CLK3Homo sapiens (human)
nucleusDual specificity protein kinase CLK3Homo sapiens (human)
nucleoplasmDual specificity protein kinase CLK3Homo sapiens (human)
membraneDual specificity protein kinase CLK3Homo sapiens (human)
nuclear speckDual specificity protein kinase CLK3Homo sapiens (human)
intermediate filament cytoskeletonDual specificity protein kinase CLK3Homo sapiens (human)
mitochondrionGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 alphaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 alphaHomo sapiens (human)
neuronal cell bodyGlycogen synthase kinase-3 alphaHomo sapiens (human)
apical dendriteGlycogen synthase kinase-3 alphaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 alphaHomo sapiens (human)
proximal dendriteGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 alphaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 alphaHomo sapiens (human)
axonGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 alphaHomo sapiens (human)
glutamatergic synapseGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrionGlycogen synthase kinase-3 betaHomo sapiens (human)
centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
plasma membraneGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
dendriteGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 betaHomo sapiens (human)
presynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
Wnt signalosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 7Homo sapiens (human)
fibrillar centerCyclin-dependent kinase 7Homo sapiens (human)
male germ cell nucleusCyclin-dependent kinase 7Homo sapiens (human)
nucleusCyclin-dependent kinase 7Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 7Homo sapiens (human)
cytosolCyclin-dependent kinase 7Homo sapiens (human)
plasma membraneCyclin-dependent kinase 7Homo sapiens (human)
perinuclear region of cytoplasmCyclin-dependent kinase 7Homo sapiens (human)
transcription factor TFIIH core complexCyclin-dependent kinase 7Homo sapiens (human)
transcription factor TFIIH holo complexCyclin-dependent kinase 7Homo sapiens (human)
CAK-ERCC2 complexCyclin-dependent kinase 7Homo sapiens (human)
transcription factor TFIIK complexCyclin-dependent kinase 7Homo sapiens (human)
cytoplasmCyclin-dependent kinase 7Homo sapiens (human)
nucleusCyclin-dependent kinase 7Homo sapiens (human)
nucleusCyclin-dependent kinase 9Homo sapiens (human)
nucleusCyclin-dependent kinase 9Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 9Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complexCyclin-dependent kinase 9Homo sapiens (human)
membraneCyclin-dependent kinase 9Homo sapiens (human)
PML bodyCyclin-dependent kinase 9Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleCyclin-dependent kinase 9Homo sapiens (human)
transcription elongation factor complexCyclin-dependent kinase 9Homo sapiens (human)
P-TEFb complexCyclin-dependent kinase 9Homo sapiens (human)
photoreceptor outer segmentRas-related protein Rab-27AHomo sapiens (human)
extracellular regionRas-related protein Rab-27AHomo sapiens (human)
lysosomeRas-related protein Rab-27AHomo sapiens (human)
late endosomeRas-related protein Rab-27AHomo sapiens (human)
cytosolRas-related protein Rab-27AHomo sapiens (human)
dendriteRas-related protein Rab-27AHomo sapiens (human)
multivesicular body membraneRas-related protein Rab-27AHomo sapiens (human)
Weibel-Palade bodyRas-related protein Rab-27AHomo sapiens (human)
melanosome membraneRas-related protein Rab-27AHomo sapiens (human)
specific granule lumenRas-related protein Rab-27AHomo sapiens (human)
melanosomeRas-related protein Rab-27AHomo sapiens (human)
extracellular exosomeRas-related protein Rab-27AHomo sapiens (human)
exocytic vesicleRas-related protein Rab-27AHomo sapiens (human)
exocytic vesicleRas-related protein Rab-27AHomo sapiens (human)
apical plasma membraneRas-related protein Rab-27AHomo sapiens (human)
Golgi apparatusRas-related protein Rab-27AHomo sapiens (human)
secretory granuleRas-related protein Rab-27AHomo sapiens (human)
melanosomeRas-related protein Rab-27AHomo sapiens (human)
cytosolTyrosine-protein kinase BlkHomo sapiens (human)
plasma membraneTyrosine-protein kinase BlkHomo sapiens (human)
cytoplasmInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
cell surfaceInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
nucleoplasmInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
lipid dropletInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
cytosolInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
endosome membraneInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
protein-containing complexInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
nucleusInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 1Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-3Homo sapiens (human)
nucleolusRibosomal protein S6 kinase alpha-3Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-3Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-3Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-3Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-3Homo sapiens (human)
nucleoplasmCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
cytosolCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
plasma membraneCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
ruffle membraneCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
plasma membraneCytoplasmic tyrosine-protein kinase BMXHomo sapiens (human)
nucleuscAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
nucleoplasmcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
cytoplasmcAMP-dependent protein kinase catalytic subunit PRKXHomo sapiens (human)
kinetochoreSerine/threonine-protein kinase Nek2Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase Nek2Homo sapiens (human)
condensed nuclear chromosomeSerine/threonine-protein kinase Nek2Homo sapiens (human)
spindle poleSerine/threonine-protein kinase Nek2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek2Homo sapiens (human)
nucleolusSerine/threonine-protein kinase Nek2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek2Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek2Homo sapiens (human)
microtubuleSerine/threonine-protein kinase Nek2Homo sapiens (human)
midbodySerine/threonine-protein kinase Nek2Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase Nek2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek2Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek2Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek3Homo sapiens (human)
axonSerine/threonine-protein kinase Nek3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek4Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek4Homo sapiens (human)
ciliary rootletSerine/threonine-protein kinase Nek4Homo sapiens (human)
ciliary transition zoneSerine/threonine-protein kinase Nek4Homo sapiens (human)
ciliary basal bodySerine/threonine-protein kinase Nek4Homo sapiens (human)
ciliary plasmSerine/threonine-protein kinase Nek4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek4Homo sapiens (human)
extrinsic component of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
endosomeTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
cytoskeletonTyrosine-protein kinase JAK3Homo sapiens (human)
plasma membraneTyrosine-protein kinase JAK3Homo sapiens (human)
cytosolTyrosine-protein kinase JAK3Homo sapiens (human)
cytoplasmDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
nucleoplasmDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
cytoskeletonDual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)
spindle microtubuleSerine/threonine-protein kinase PLK1Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase PLK1Homo sapiens (human)
synaptonemal complexSerine/threonine-protein kinase PLK1Homo sapiens (human)
spindle poleSerine/threonine-protein kinase PLK1Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PLK1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK1Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK1Homo sapiens (human)
spindleSerine/threonine-protein kinase PLK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase PLK1Homo sapiens (human)
microtubule cytoskeletonSerine/threonine-protein kinase PLK1Homo sapiens (human)
midbodySerine/threonine-protein kinase PLK1Homo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase PLK1Homo sapiens (human)
spindle midzoneSerine/threonine-protein kinase PLK1Homo sapiens (human)
mitotic spindle poleSerine/threonine-protein kinase PLK1Homo sapiens (human)
chromatinSerine/threonine-protein kinase PLK1Homo sapiens (human)
outer kinetochoreSerine/threonine-protein kinase PLK1Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK1Homo sapiens (human)
spindle poleSerine/threonine-protein kinase PLK1Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase PLK1Homo sapiens (human)
cytoplasmDeath-associated protein kinase 1Homo sapiens (human)
plasma membraneDeath-associated protein kinase 1Homo sapiens (human)
postsynaptic densityDeath-associated protein kinase 1Homo sapiens (human)
actin cytoskeletonDeath-associated protein kinase 1Homo sapiens (human)
glutamatergic synapseDeath-associated protein kinase 1Homo sapiens (human)
DAPK1-calmodulin complexDeath-associated protein kinase 1Homo sapiens (human)
cytoplasmDeath-associated protein kinase 1Homo sapiens (human)
nucleusDeath-associated protein kinase 1Homo sapiens (human)
postsynapseLIM domain kinase 1Homo sapiens (human)
glutamatergic synapseLIM domain kinase 1Homo sapiens (human)
male germ cell nucleusLIM domain kinase 1Homo sapiens (human)
cytoplasmLIM domain kinase 1Homo sapiens (human)
cytosolLIM domain kinase 1Homo sapiens (human)
cytoskeletonLIM domain kinase 1Homo sapiens (human)
focal adhesionLIM domain kinase 1Homo sapiens (human)
membraneLIM domain kinase 1Homo sapiens (human)
nuclear speckLIM domain kinase 1Homo sapiens (human)
lamellipodiumLIM domain kinase 1Homo sapiens (human)
neuron projectionLIM domain kinase 1Homo sapiens (human)
nucleusLIM domain kinase 1Homo sapiens (human)
neuron projectionLIM domain kinase 1Homo sapiens (human)
cytoplasmLIM domain kinase 1Homo sapiens (human)
nucleusLIM domain kinase 2Homo sapiens (human)
cytoplasmLIM domain kinase 2Homo sapiens (human)
cis-Golgi networkLIM domain kinase 2Homo sapiens (human)
centrosomeLIM domain kinase 2Homo sapiens (human)
perinuclear region of cytoplasmLIM domain kinase 2Homo sapiens (human)
mitotic spindleLIM domain kinase 2Homo sapiens (human)
nucleusLIM domain kinase 2Homo sapiens (human)
cytoplasmLIM domain kinase 2Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 12Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 12Homo sapiens (human)
cytosolMitogen-activated protein kinase 12Homo sapiens (human)
nucleusMitogen-activated protein kinase 12Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 12Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 10Homo sapiens (human)
cytosolMitogen-activated protein kinase 10Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 10Homo sapiens (human)
nucleusMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
membrane5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
Golgi apparatus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytosol5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytoplasmic stress granule5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nuclear speck5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
axon5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
dendrite5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
neuronal cell body5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
extracellular regionEphrin type-B receptor 3Homo sapiens (human)
cytosolEphrin type-B receptor 3Homo sapiens (human)
plasma membraneEphrin type-B receptor 3Homo sapiens (human)
dendriteEphrin type-B receptor 3Homo sapiens (human)
plasma membraneEphrin type-B receptor 3Homo sapiens (human)
rough endoplasmic reticulumEphrin type-A receptor 5Homo sapiens (human)
plasma membraneEphrin type-A receptor 5Homo sapiens (human)
external side of plasma membraneEphrin type-A receptor 5Homo sapiens (human)
axonEphrin type-A receptor 5Homo sapiens (human)
dendriteEphrin type-A receptor 5Homo sapiens (human)
neuronal cell bodyEphrin type-A receptor 5Homo sapiens (human)
perinuclear region of cytoplasmEphrin type-A receptor 5Homo sapiens (human)
plasma membraneEphrin type-A receptor 5Homo sapiens (human)
dendriteEphrin type-A receptor 5Homo sapiens (human)
extracellular regionEphrin type-B receptor 4Homo sapiens (human)
cytosolEphrin type-B receptor 4Homo sapiens (human)
plasma membraneEphrin type-B receptor 4Homo sapiens (human)
extracellular exosomeEphrin type-B receptor 4Homo sapiens (human)
receptor complexEphrin type-B receptor 4Homo sapiens (human)
plasma membraneEphrin type-B receptor 4Homo sapiens (human)
extracellular regionEphrin type-B receptor 1Homo sapiens (human)
endoplasmic reticulumEphrin type-B receptor 1Homo sapiens (human)
cytosolEphrin type-B receptor 1Homo sapiens (human)
plasma membraneEphrin type-B receptor 1Homo sapiens (human)
axonEphrin type-B receptor 1Homo sapiens (human)
early endosome membraneEphrin type-B receptor 1Homo sapiens (human)
filopodium tipEphrin type-B receptor 1Homo sapiens (human)
membrane raftEphrin type-B receptor 1Homo sapiens (human)
extracellular exosomeEphrin type-B receptor 1Homo sapiens (human)
glutamatergic synapseEphrin type-B receptor 1Homo sapiens (human)
plasma membraneEphrin type-B receptor 1Homo sapiens (human)
dendriteEphrin type-B receptor 1Homo sapiens (human)
cytoplasmEphrin type-A receptor 4Homo sapiens (human)
mitochondrial outer membraneEphrin type-A receptor 4Homo sapiens (human)
plasma membraneEphrin type-A receptor 4Homo sapiens (human)
adherens junctionEphrin type-A receptor 4Homo sapiens (human)
cell surfaceEphrin type-A receptor 4Homo sapiens (human)
filopodiumEphrin type-A receptor 4Homo sapiens (human)
axonEphrin type-A receptor 4Homo sapiens (human)
dendriteEphrin type-A receptor 4Homo sapiens (human)
neuromuscular junctionEphrin type-A receptor 4Homo sapiens (human)
early endosome membraneEphrin type-A receptor 4Homo sapiens (human)
presynaptic membraneEphrin type-A receptor 4Homo sapiens (human)
dendritic spineEphrin type-A receptor 4Homo sapiens (human)
dendritic shaftEphrin type-A receptor 4Homo sapiens (human)
perikaryonEphrin type-A receptor 4Homo sapiens (human)
axon terminusEphrin type-A receptor 4Homo sapiens (human)
axonal growth coneEphrin type-A receptor 4Homo sapiens (human)
Schaffer collateral - CA1 synapseEphrin type-A receptor 4Homo sapiens (human)
postsynaptic density membraneEphrin type-A receptor 4Homo sapiens (human)
glutamatergic synapseEphrin type-A receptor 4Homo sapiens (human)
plasma membraneEphrin type-A receptor 4Homo sapiens (human)
dendriteEphrin type-A receptor 4Homo sapiens (human)
mitochondrial intermembrane spaceAdenylate kinase 2, mitochondrialHomo sapiens (human)
extracellular exosomeAdenylate kinase 2, mitochondrialHomo sapiens (human)
sperm mitochondrial sheathAdenylate kinase 2, mitochondrialHomo sapiens (human)
cytoplasmAdenylate kinase 2, mitochondrialHomo sapiens (human)
mitochondrionAdenylate kinase 2, mitochondrialHomo sapiens (human)
nucleoplasmAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
plasma membraneAdenosine kinaseHomo sapiens (human)
nucleusAdenosine kinaseHomo sapiens (human)
cytosolAdenosine kinaseHomo sapiens (human)
cytoplasmHormonally up-regulated neu tumor-associated kinaseHomo sapiens (human)
nucleusSerine/threonine-protein kinase SIK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK1Homo sapiens (human)
nucleusSerine/threonine-protein kinase SIK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK1Homo sapiens (human)
cytoplasmReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
membraneReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
cytoplasmReceptor-interacting serine/threonine-protein kinase 4Homo sapiens (human)
exocystRas-related protein Rab-10Homo sapiens (human)
plasma membraneRas-related protein Rab-10Homo sapiens (human)
Golgi membraneRas-related protein Rab-10Homo sapiens (human)
endosomeRas-related protein Rab-10Homo sapiens (human)
endoplasmic reticulum membraneRas-related protein Rab-10Homo sapiens (human)
Golgi apparatusRas-related protein Rab-10Homo sapiens (human)
trans-Golgi networkRas-related protein Rab-10Homo sapiens (human)
cytosolRas-related protein Rab-10Homo sapiens (human)
cytoskeletonRas-related protein Rab-10Homo sapiens (human)
plasma membraneRas-related protein Rab-10Homo sapiens (human)
adherens junctionRas-related protein Rab-10Homo sapiens (human)
focal adhesionRas-related protein Rab-10Homo sapiens (human)
ciliumRas-related protein Rab-10Homo sapiens (human)
endosome membraneRas-related protein Rab-10Homo sapiens (human)
cytoplasmic vesicle membraneRas-related protein Rab-10Homo sapiens (human)
secretory granule membraneRas-related protein Rab-10Homo sapiens (human)
phagocytic vesicle membraneRas-related protein Rab-10Homo sapiens (human)
insulin-responsive compartmentRas-related protein Rab-10Homo sapiens (human)
perinuclear region of cytoplasmRas-related protein Rab-10Homo sapiens (human)
recycling endosomeRas-related protein Rab-10Homo sapiens (human)
recycling endosome membraneRas-related protein Rab-10Homo sapiens (human)
extracellular exosomeRas-related protein Rab-10Homo sapiens (human)
exocytic vesicleRas-related protein Rab-10Homo sapiens (human)
endoplasmic reticulum tubular networkRas-related protein Rab-10Homo sapiens (human)
recycling endosomeRas-related protein Rab-10Homo sapiens (human)
secretory vesicleRas-related protein Rab-10Homo sapiens (human)
membraneRas-related protein Rab-10Homo sapiens (human)
Golgi apparatusRas-related protein Rab-10Homo sapiens (human)
nucleusActin-related protein 3Homo sapiens (human)
cytoplasmActin-related protein 3Homo sapiens (human)
cytosolActin-related protein 3Homo sapiens (human)
brush borderActin-related protein 3Homo sapiens (human)
cell-cell junctionActin-related protein 3Homo sapiens (human)
focal adhesionActin-related protein 3Homo sapiens (human)
actin cytoskeletonActin-related protein 3Homo sapiens (human)
membraneActin-related protein 3Homo sapiens (human)
lamellipodiumActin-related protein 3Homo sapiens (human)
site of double-strand breakActin-related protein 3Homo sapiens (human)
extracellular exosomeActin-related protein 3Homo sapiens (human)
Arp2/3 protein complexActin-related protein 3Homo sapiens (human)
extracellular regionActin-related protein 2Homo sapiens (human)
nucleusActin-related protein 2Homo sapiens (human)
cytoplasmActin-related protein 2Homo sapiens (human)
cytosolActin-related protein 2Homo sapiens (human)
focal adhesionActin-related protein 2Homo sapiens (human)
actin cytoskeletonActin-related protein 2Homo sapiens (human)
membraneActin-related protein 2Homo sapiens (human)
actin capActin-related protein 2Homo sapiens (human)
azurophil granule lumenActin-related protein 2Homo sapiens (human)
site of double-strand breakActin-related protein 2Homo sapiens (human)
cell projectionActin-related protein 2Homo sapiens (human)
extracellular exosomeActin-related protein 2Homo sapiens (human)
ficolin-1-rich granule lumenActin-related protein 2Homo sapiens (human)
Arp2/3 protein complexActin-related protein 2Homo sapiens (human)
cell cortexActin-related protein 2Homo sapiens (human)
Flemming bodyGTP-binding nuclear protein RanHomo sapiens (human)
male germ cell nucleusGTP-binding nuclear protein RanHomo sapiens (human)
manchetteGTP-binding nuclear protein RanHomo sapiens (human)
nucleusGTP-binding nuclear protein RanHomo sapiens (human)
nuclear envelopeGTP-binding nuclear protein RanHomo sapiens (human)
nucleoplasmGTP-binding nuclear protein RanHomo sapiens (human)
nucleolusGTP-binding nuclear protein RanHomo sapiens (human)
cytoplasmGTP-binding nuclear protein RanHomo sapiens (human)
centrioleGTP-binding nuclear protein RanHomo sapiens (human)
cytosolGTP-binding nuclear protein RanHomo sapiens (human)
membraneGTP-binding nuclear protein RanHomo sapiens (human)
midbodyGTP-binding nuclear protein RanHomo sapiens (human)
sperm flagellumGTP-binding nuclear protein RanHomo sapiens (human)
melanosomeGTP-binding nuclear protein RanHomo sapiens (human)
recycling endosomeGTP-binding nuclear protein RanHomo sapiens (human)
extracellular exosomeGTP-binding nuclear protein RanHomo sapiens (human)
chromatinGTP-binding nuclear protein RanHomo sapiens (human)
nuclear poreGTP-binding nuclear protein RanHomo sapiens (human)
protein-containing complexGTP-binding nuclear protein RanHomo sapiens (human)
RNA nuclear export complexGTP-binding nuclear protein RanHomo sapiens (human)
nucleusGTP-binding nuclear protein RanHomo sapiens (human)
cytoplasmGTP-binding nuclear protein RanHomo sapiens (human)
PcG protein complexCasein kinase II subunit alphaHomo sapiens (human)
PML bodyCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleoplasmCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
plasma membraneCasein kinase II subunit alphaHomo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alphaHomo sapiens (human)
Sin3-type complexCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleusPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
nucleoplasmPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
autophagosomePhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
endoplasmic reticulum membranePhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
cytosolPhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 betaHomo sapiens (human)
nucleusSRSF protein kinase 2Homo sapiens (human)
nucleoplasmSRSF protein kinase 2Homo sapiens (human)
nucleolusSRSF protein kinase 2Homo sapiens (human)
cytoplasmSRSF protein kinase 2Homo sapiens (human)
cytosolSRSF protein kinase 2Homo sapiens (human)
nuclear speckSRSF protein kinase 2Homo sapiens (human)
chromatinSRSF protein kinase 2Homo sapiens (human)
nucleusSRSF protein kinase 2Homo sapiens (human)
cytoplasmSRSF protein kinase 2Homo sapiens (human)
cytosolCasein kinase I isoform gamma-2Homo sapiens (human)
cell cortexCasein kinase I isoform gamma-2Homo sapiens (human)
membraneCasein kinase I isoform gamma-2Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-2Homo sapiens (human)
plasma membraneCasein kinase I isoform gamma-2Homo sapiens (human)
nucleusCasein kinase I isoform gamma-2Homo sapiens (human)
cellular_componentMitogen-activated protein kinase kinase kinase 9Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 3Homo sapiens (human)
nucleusCyclin-dependent kinase 3Homo sapiens (human)
cytoplasmCyclin-dependent kinase 3Homo sapiens (human)
nucleoplasmCyclin-dependent kinase-like 1Homo sapiens (human)
cytoplasmCyclin-dependent kinase-like 1Homo sapiens (human)
ciliary transition zoneCyclin-dependent kinase-like 1Homo sapiens (human)
intracellular membrane-bounded organelleCyclin-dependent kinase-like 1Homo sapiens (human)
extracellular exosomeCyclin-dependent kinase-like 1Homo sapiens (human)
nucleusCyclin-dependent kinase-like 1Homo sapiens (human)
ruffleCyclin-dependent kinase 6Homo sapiens (human)
nucleusCyclin-dependent kinase 6Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 6Homo sapiens (human)
cytoplasmCyclin-dependent kinase 6Homo sapiens (human)
centrosomeCyclin-dependent kinase 6Homo sapiens (human)
cytosolCyclin-dependent kinase 6Homo sapiens (human)
cyclin D1-CDK6 complexCyclin-dependent kinase 6Homo sapiens (human)
cyclin D3-CDK6 complexCyclin-dependent kinase 6Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 6Homo sapiens (human)
cyclin D2-CDK6 complexCyclin-dependent kinase 6Homo sapiens (human)
cytoplasmCyclin-dependent kinase 6Homo sapiens (human)
nucleusCyclin-dependent kinase 6Homo sapiens (human)
microtubuleCyclin-dependent-like kinase 5 Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
cytoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
cytosolCyclin-dependent-like kinase 5 Homo sapiens (human)
plasma membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
postsynaptic densityCyclin-dependent-like kinase 5 Homo sapiens (human)
membraneCyclin-dependent-like kinase 5 Homo sapiens (human)
protein kinase 5 complexCyclin-dependent-like kinase 5 Homo sapiens (human)
lamellipodiumCyclin-dependent-like kinase 5 Homo sapiens (human)
cell junctionCyclin-dependent-like kinase 5 Homo sapiens (human)
filopodiumCyclin-dependent-like kinase 5 Homo sapiens (human)
axonCyclin-dependent-like kinase 5 Homo sapiens (human)
dendriteCyclin-dependent-like kinase 5 Homo sapiens (human)
growth coneCyclin-dependent-like kinase 5 Homo sapiens (human)
neuromuscular junctionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuron projectionCyclin-dependent-like kinase 5 Homo sapiens (human)
neuronal cell bodyCyclin-dependent-like kinase 5 Homo sapiens (human)
perikaryonCyclin-dependent-like kinase 5 Homo sapiens (human)
presynapseCyclin-dependent-like kinase 5 Homo sapiens (human)
nucleusCyclin-dependent-like kinase 5 Homo sapiens (human)
cytoplasmCyclin-dependent-like kinase 5 Homo sapiens (human)
synaptic vesicleCyclin-dependent kinase 16Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmCyclin-dependent kinase 16Homo sapiens (human)
cytosolCyclin-dependent kinase 16Homo sapiens (human)
plasma membraneCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmic side of plasma membraneCyclin-dependent kinase 16Homo sapiens (human)
microtubule cytoskeletonCyclin-dependent kinase 16Homo sapiens (human)
neuron projectionCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmCyclin-dependent kinase 16Homo sapiens (human)
nucleusCyclin-dependent kinase 16Homo sapiens (human)
cytoplasmCyclin-dependent kinase 17Homo sapiens (human)
nucleusCyclin-dependent kinase 17Homo sapiens (human)
nucleusATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
cytoplasmATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
cytosolATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
membraneATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
extracellular exosomeATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
membraneATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
6-phosphofructokinase complexATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)
Golgi apparatusProtein kinase C epsilon typeHomo sapiens (human)
nucleusProtein kinase C epsilon typeHomo sapiens (human)
cytoplasmProtein kinase C epsilon typeHomo sapiens (human)
mitochondrionProtein kinase C epsilon typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C epsilon typeHomo sapiens (human)
cytosolProtein kinase C epsilon typeHomo sapiens (human)
plasma membraneProtein kinase C epsilon typeHomo sapiens (human)
intracellular membrane-bounded organelleProtein kinase C epsilon typeHomo sapiens (human)
intermediate filament cytoskeletonProtein kinase C epsilon typeHomo sapiens (human)
synapseProtein kinase C epsilon typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C epsilon typeHomo sapiens (human)
cell peripheryProtein kinase C epsilon typeHomo sapiens (human)
nucleusDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
mitochondrionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
early endosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
late endosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
endoplasmic reticulumDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
Golgi apparatusDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
centrosomeDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
cytosolDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
plasma membraneDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
focal adhesionDual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)
stress fiberAngiopoietin-1 receptorHomo sapiens (human)
actin filamentAngiopoietin-1 receptorHomo sapiens (human)
extracellular regionAngiopoietin-1 receptorHomo sapiens (human)
cytoplasmAngiopoietin-1 receptorHomo sapiens (human)
plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
microvillusAngiopoietin-1 receptorHomo sapiens (human)
cell-cell junctionAngiopoietin-1 receptorHomo sapiens (human)
focal adhesionAngiopoietin-1 receptorHomo sapiens (human)
basal plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
cell surfaceAngiopoietin-1 receptorHomo sapiens (human)
basolateral plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
apical plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
centriolar satelliteAngiopoietin-1 receptorHomo sapiens (human)
membrane raftAngiopoietin-1 receptorHomo sapiens (human)
plasma membraneAngiopoietin-1 receptorHomo sapiens (human)
receptor complexAngiopoietin-1 receptorHomo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 10Homo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
heterochromatinDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-betaHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
cytosolDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
immunological synapseProtein kinase C theta typeHomo sapiens (human)
cytosolProtein kinase C theta typeHomo sapiens (human)
plasma membraneProtein kinase C theta typeHomo sapiens (human)
aggresomeProtein kinase C theta typeHomo sapiens (human)
centriolar satelliteProtein kinase C theta typeHomo sapiens (human)
plasma membraneActivin receptor type-1Homo sapiens (human)
apical part of cellActivin receptor type-1Homo sapiens (human)
activin receptor complexActivin receptor type-1Homo sapiens (human)
BMP receptor complexActivin receptor type-1Homo sapiens (human)
plasma membraneActivin receptor type-1Homo sapiens (human)
stress fiberMacrophage-stimulating protein receptorHomo sapiens (human)
vacuoleMacrophage-stimulating protein receptorHomo sapiens (human)
plasma membraneMacrophage-stimulating protein receptorHomo sapiens (human)
cell surfaceMacrophage-stimulating protein receptorHomo sapiens (human)
receptor complexMacrophage-stimulating protein receptorHomo sapiens (human)
plasma membraneMacrophage-stimulating protein receptorHomo sapiens (human)
stress fiberFocal adhesion kinase 1Homo sapiens (human)
nucleusFocal adhesion kinase 1Homo sapiens (human)
cytoplasmFocal adhesion kinase 1Homo sapiens (human)
centrosomeFocal adhesion kinase 1Homo sapiens (human)
cytosolFocal adhesion kinase 1Homo sapiens (human)
cytoskeletonFocal adhesion kinase 1Homo sapiens (human)
plasma membraneFocal adhesion kinase 1Homo sapiens (human)
focal adhesionFocal adhesion kinase 1Homo sapiens (human)
cell cortexFocal adhesion kinase 1Homo sapiens (human)
ciliary basal bodyFocal adhesion kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleFocal adhesion kinase 1Homo sapiens (human)
perinuclear region of cytoplasmFocal adhesion kinase 1Homo sapiens (human)
plasma membraneFocal adhesion kinase 1Homo sapiens (human)
focal adhesionFocal adhesion kinase 1Homo sapiens (human)
dendritic spineFocal adhesion kinase 1Homo sapiens (human)
stress fiberProtein kinase C zeta typeHomo sapiens (human)
nuclear envelopeProtein kinase C zeta typeHomo sapiens (human)
cytoplasmProtein kinase C zeta typeHomo sapiens (human)
endosomeProtein kinase C zeta typeHomo sapiens (human)
microtubule organizing centerProtein kinase C zeta typeHomo sapiens (human)
cytosolProtein kinase C zeta typeHomo sapiens (human)
plasma membraneProtein kinase C zeta typeHomo sapiens (human)
cell-cell junctionProtein kinase C zeta typeHomo sapiens (human)
bicellular tight junctionProtein kinase C zeta typeHomo sapiens (human)
postsynaptic densityProtein kinase C zeta typeHomo sapiens (human)
membraneProtein kinase C zeta typeHomo sapiens (human)
apical plasma membraneProtein kinase C zeta typeHomo sapiens (human)
nuclear matrixProtein kinase C zeta typeHomo sapiens (human)
cell junctionProtein kinase C zeta typeHomo sapiens (human)
cell leading edgeProtein kinase C zeta typeHomo sapiens (human)
vesicleProtein kinase C zeta typeHomo sapiens (human)
myelin sheath abaxonal regionProtein kinase C zeta typeHomo sapiens (human)
axon hillockProtein kinase C zeta typeHomo sapiens (human)
apical cortexProtein kinase C zeta typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C zeta typeHomo sapiens (human)
extracellular exosomeProtein kinase C zeta typeHomo sapiens (human)
tight junctionProtein kinase C zeta typeHomo sapiens (human)
Schaffer collateral - CA1 synapseProtein kinase C zeta typeHomo sapiens (human)
glutamatergic synapseProtein kinase C zeta typeHomo sapiens (human)
PAR polarity complexProtein kinase C zeta typeHomo sapiens (human)
extracellular regionProtein kinase C delta typeHomo sapiens (human)
nucleusProtein kinase C delta typeHomo sapiens (human)
nucleoplasmProtein kinase C delta typeHomo sapiens (human)
cytoplasmProtein kinase C delta typeHomo sapiens (human)
mitochondrionProtein kinase C delta typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C delta typeHomo sapiens (human)
cytosolProtein kinase C delta typeHomo sapiens (human)
plasma membraneProtein kinase C delta typeHomo sapiens (human)
cell-cell junctionProtein kinase C delta typeHomo sapiens (human)
nuclear matrixProtein kinase C delta typeHomo sapiens (human)
azurophil granule lumenProtein kinase C delta typeHomo sapiens (human)
endolysosomeProtein kinase C delta typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C delta typeHomo sapiens (human)
extracellular exosomeProtein kinase C delta typeHomo sapiens (human)
nucleusTyrosine-protein kinase BTKHomo sapiens (human)
cytoplasmTyrosine-protein kinase BTKHomo sapiens (human)
cytosolTyrosine-protein kinase BTKHomo sapiens (human)
plasma membraneTyrosine-protein kinase BTKHomo sapiens (human)
cytoplasmic vesicleTyrosine-protein kinase BTKHomo sapiens (human)
membrane raftTyrosine-protein kinase BTKHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase BTKHomo sapiens (human)
plasma membraneTyrosine-protein kinase BTKHomo sapiens (human)
nucleusTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
nuclear envelopeTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
endoplasmic reticulum membraneTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
plasma membraneTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cell surfaceTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
plasma membraneTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
receptor complexTyrosine-protein kinase receptor TYRO3Homo sapiens (human)
cellular_componentCyclin-dependent kinase 18Homo sapiens (human)
nucleusCyclin-dependent kinase 18Homo sapiens (human)
cytoplasmCyclin-dependent kinase 18Homo sapiens (human)
nucleusActivated CDC42 kinase 1Homo sapiens (human)
cytoplasmActivated CDC42 kinase 1Homo sapiens (human)
endosomeActivated CDC42 kinase 1Homo sapiens (human)
cytosolActivated CDC42 kinase 1Homo sapiens (human)
plasma membraneActivated CDC42 kinase 1Homo sapiens (human)
clathrin-coated pitActivated CDC42 kinase 1Homo sapiens (human)
adherens junctionActivated CDC42 kinase 1Homo sapiens (human)
membraneActivated CDC42 kinase 1Homo sapiens (human)
clathrin-coated vesicleActivated CDC42 kinase 1Homo sapiens (human)
cytoplasmic vesicle membraneActivated CDC42 kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleActivated CDC42 kinase 1Homo sapiens (human)
perinuclear region of cytoplasmActivated CDC42 kinase 1Homo sapiens (human)
cytoophidiumActivated CDC42 kinase 1Homo sapiens (human)
Grb2-EGFR complexActivated CDC42 kinase 1Homo sapiens (human)
plasma membraneActivated CDC42 kinase 1Homo sapiens (human)
extracellular spaceEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
plasma membraneEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
extracellular exosomeEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
receptor complexEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
plasma membraneEpithelial discoidin domain-containing receptor 1Homo sapiens (human)
nucleusTyrosine-protein kinase ITK/TSKHomo sapiens (human)
cytosolTyrosine-protein kinase ITK/TSKHomo sapiens (human)
cell-cell junctionTyrosine-protein kinase ITK/TSKHomo sapiens (human)
plasma membraneTyrosine-protein kinase ITK/TSKHomo sapiens (human)
nuclear outer membraneMyotonin-protein kinaseHomo sapiens (human)
mitochondrial outer membraneMyotonin-protein kinaseHomo sapiens (human)
endoplasmic reticulum membraneMyotonin-protein kinaseHomo sapiens (human)
cytosolMyotonin-protein kinaseHomo sapiens (human)
plasma membraneMyotonin-protein kinaseHomo sapiens (human)
nuclear membraneMyotonin-protein kinaseHomo sapiens (human)
sarcoplasmic reticulum membraneMyotonin-protein kinaseHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
Golgi membraneMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
basolateral plasma membraneMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
plasma membraneMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
membraneMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
growth coneMitogen-activated protein kinase kinase kinase 12Homo sapiens (human)
photoreceptor outer segmentTyrosine-protein kinase MerHomo sapiens (human)
extracellular spaceTyrosine-protein kinase MerHomo sapiens (human)
cytoplasmTyrosine-protein kinase MerHomo sapiens (human)
plasma membraneTyrosine-protein kinase MerHomo sapiens (human)
plasma membraneTyrosine-protein kinase MerHomo sapiens (human)
receptor complexTyrosine-protein kinase MerHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase 4Homo sapiens (human)
nucleusSerine/threonine-protein kinase 4Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 4Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 4Homo sapiens (human)
cytosolSerine/threonine-protein kinase 4Homo sapiens (human)
nuclear bodySerine/threonine-protein kinase 4Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase 4Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
cytosol5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
apical plasma membrane5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nuclear speck5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
axon5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
dendrite5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
neuronal cell body5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
chromatin5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)
ruffleSerine/threonine-protein kinase PAK 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PAK 1Homo sapiens (human)
chromosomeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 1Homo sapiens (human)
actin filamentSerine/threonine-protein kinase PAK 1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
focal adhesionSerine/threonine-protein kinase PAK 1Homo sapiens (human)
intercalated discSerine/threonine-protein kinase PAK 1Homo sapiens (human)
Z discSerine/threonine-protein kinase PAK 1Homo sapiens (human)
lamellipodiumSerine/threonine-protein kinase PAK 1Homo sapiens (human)
axonSerine/threonine-protein kinase PAK 1Homo sapiens (human)
dendriteSerine/threonine-protein kinase PAK 1Homo sapiens (human)
nuclear membraneSerine/threonine-protein kinase PAK 1Homo sapiens (human)
ruffle membraneSerine/threonine-protein kinase PAK 1Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase PAK 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 1Homo sapiens (human)
spindleDual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)
nucleusMitogen-activated protein kinase 7Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 7Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 7Homo sapiens (human)
cytosolMitogen-activated protein kinase 7Homo sapiens (human)
PML bodyMitogen-activated protein kinase 7Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 7Homo sapiens (human)
nucleusMitogen-activated protein kinase 7Homo sapiens (human)
nucleusSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase PAK 2Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase PAK 2Homo sapiens (human)
secretory granuleSerine/threonine-protein kinase PAK 2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase PAK 2Homo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase PAK 2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 3Homo sapiens (human)
centrosomeSerine/threonine-protein kinase 3Homo sapiens (human)
nucleusSerine/threonine-protein kinase 3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 3Homo sapiens (human)
cytosolSerine/threonine-protein kinase 3Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase 3Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 1Homo sapiens (human)
cytosolcGMP-dependent protein kinase 2Homo sapiens (human)
apical plasma membranecGMP-dependent protein kinase 2Homo sapiens (human)
nuclear membranecGMP-dependent protein kinase 2Homo sapiens (human)
cytosolIntegrin-linked protein kinaseHomo sapiens (human)
plasma membraneIntegrin-linked protein kinaseHomo sapiens (human)
focal adhesionIntegrin-linked protein kinaseHomo sapiens (human)
membraneIntegrin-linked protein kinaseHomo sapiens (human)
sarcomereIntegrin-linked protein kinaseHomo sapiens (human)
lamellipodiumIntegrin-linked protein kinaseHomo sapiens (human)
focal adhesionIntegrin-linked protein kinaseHomo sapiens (human)
stress fiberIntegrin-linked protein kinaseHomo sapiens (human)
Golgi membraneRho-associated protein kinase 1Homo sapiens (human)
ruffleRho-associated protein kinase 1Homo sapiens (human)
extracellular regionRho-associated protein kinase 1Homo sapiens (human)
centrioleRho-associated protein kinase 1Homo sapiens (human)
cytosolRho-associated protein kinase 1Homo sapiens (human)
cytoskeletonRho-associated protein kinase 1Homo sapiens (human)
plasma membraneRho-associated protein kinase 1Homo sapiens (human)
cytoplasmic stress granuleRho-associated protein kinase 1Homo sapiens (human)
lamellipodiumRho-associated protein kinase 1Homo sapiens (human)
blebRho-associated protein kinase 1Homo sapiens (human)
secretory granule lumenRho-associated protein kinase 1Homo sapiens (human)
Schaffer collateral - CA1 synapseRho-associated protein kinase 1Homo sapiens (human)
cytoskeletonRho-associated protein kinase 1Homo sapiens (human)
cytoplasmRho-associated protein kinase 1Homo sapiens (human)
cytoplasmic stress granuleRho-associated protein kinase 1Homo sapiens (human)
cytoplasmNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
membraneNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
plasma membraneNon-receptor tyrosine-protein kinase TNK1Homo sapiens (human)
nucleusSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
kinetochoreSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
nucleusSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
nuclear speckSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
catalytic step 2 spliceosomeSerine/threonine-protein kinase PRP4 homologHomo sapiens (human)
chromosome, telomeric regionSerine/threonine-protein kinase ATRHomo sapiens (human)
nuclear envelopeSerine/threonine-protein kinase ATRHomo sapiens (human)
site of DNA damageSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleusSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase ATRHomo sapiens (human)
chromosomeSerine/threonine-protein kinase ATRHomo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase ATRHomo sapiens (human)
PML bodySerine/threonine-protein kinase ATRHomo sapiens (human)
ATR-ATRIP complexSerine/threonine-protein kinase ATRHomo sapiens (human)
nucleusSerine/threonine-protein kinase ATRHomo sapiens (human)
chromosomeSerine/threonine-protein kinase ATRHomo sapiens (human)
mitochondrionReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytosolReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
plasma membraneReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
endosome membraneReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
death-inducing signaling complexReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
protein-containing complexReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
receptor complexReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
ripoptosomeReceptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
centrosomeCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
endocytic vesicle membraneCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
sarcoplasmic reticulum membraneCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
synapseCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit betaHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
membraneCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
endocytic vesicle membraneCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
sarcoplasmic reticulum membraneCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
membraneCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
endocytic vesicle membraneCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
sarcoplasmic reticulum membraneCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
sarcolemmaCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)
cytoskeletonDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nucleoplasmDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
nuclear speckDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
axonDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
dendriteDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
ribonucleoprotein complexDual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)
cytoplasmActivin receptor type-2BHomo sapiens (human)
plasma membraneActivin receptor type-2BHomo sapiens (human)
protein-containing complexActivin receptor type-2BHomo sapiens (human)
receptor complexActivin receptor type-2BHomo sapiens (human)
activin receptor complexActivin receptor type-2BHomo sapiens (human)
plasma membraneActivin receptor type-2BHomo sapiens (human)
caveolaBone morphogenetic protein receptor type-2Homo sapiens (human)
extracellular spaceBone morphogenetic protein receptor type-2Homo sapiens (human)
nucleoplasmBone morphogenetic protein receptor type-2Homo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-2Homo sapiens (human)
clathrin-coated pitBone morphogenetic protein receptor type-2Homo sapiens (human)
adherens junctionBone morphogenetic protein receptor type-2Homo sapiens (human)
basal plasma membraneBone morphogenetic protein receptor type-2Homo sapiens (human)
cell surfaceBone morphogenetic protein receptor type-2Homo sapiens (human)
postsynaptic densityBone morphogenetic protein receptor type-2Homo sapiens (human)
apical plasma membraneBone morphogenetic protein receptor type-2Homo sapiens (human)
axonBone morphogenetic protein receptor type-2Homo sapiens (human)
dendriteBone morphogenetic protein receptor type-2Homo sapiens (human)
neuronal cell bodyBone morphogenetic protein receptor type-2Homo sapiens (human)
plasma membraneBone morphogenetic protein receptor type-2Homo sapiens (human)
receptor complexBone morphogenetic protein receptor type-2Homo sapiens (human)
ruffleProtein-tyrosine kinase 6Homo sapiens (human)
nucleusProtein-tyrosine kinase 6Homo sapiens (human)
nucleoplasmProtein-tyrosine kinase 6Homo sapiens (human)
cytoplasmProtein-tyrosine kinase 6Homo sapiens (human)
cytosolProtein-tyrosine kinase 6Homo sapiens (human)
plasma membraneProtein-tyrosine kinase 6Homo sapiens (human)
nuclear bodyProtein-tyrosine kinase 6Homo sapiens (human)
plasma membraneProtein-tyrosine kinase 6Homo sapiens (human)
acrosomal vesiclecGMP-dependent protein kinase 1 Homo sapiens (human)
nucleoplasmcGMP-dependent protein kinase 1 Homo sapiens (human)
cytoplasmcGMP-dependent protein kinase 1 Homo sapiens (human)
Golgi apparatuscGMP-dependent protein kinase 1 Homo sapiens (human)
cytosolcGMP-dependent protein kinase 1 Homo sapiens (human)
plasma membranecGMP-dependent protein kinase 1 Homo sapiens (human)
sarcolemmacGMP-dependent protein kinase 1 Homo sapiens (human)
cyclin K-CDK13 complexCyclin-dependent kinase 13Homo sapiens (human)
extracellular regionCyclin-dependent kinase 13Homo sapiens (human)
extracellular spaceCyclin-dependent kinase 13Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 13Homo sapiens (human)
Golgi apparatusCyclin-dependent kinase 13Homo sapiens (human)
cytosolCyclin-dependent kinase 13Homo sapiens (human)
nuclear speckCyclin-dependent kinase 13Homo sapiens (human)
ficolin-1-rich granule lumenCyclin-dependent kinase 13Homo sapiens (human)
nuclear cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 13Homo sapiens (human)
nucleusCyclin-dependent kinase 13Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complexCyclin-dependent kinase 13Homo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
intracellular anatomical structureCalcium/calmodulin-dependent protein kinase type 1Homo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
nucleusInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
nucleoplasmInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
cytoplasmInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
cytosolInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
PML bodyInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
mitochondrial membraneInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
serine/threonine protein kinase complexInhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)
NMDA selective glutamate receptor complexProtein-tyrosine kinase 2-betaHomo sapiens (human)
nucleusProtein-tyrosine kinase 2-betaHomo sapiens (human)
cytoplasmProtein-tyrosine kinase 2-betaHomo sapiens (human)
cytosolProtein-tyrosine kinase 2-betaHomo sapiens (human)
cytoskeletonProtein-tyrosine kinase 2-betaHomo sapiens (human)
focal adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
cell cortexProtein-tyrosine kinase 2-betaHomo sapiens (human)
postsynaptic densityProtein-tyrosine kinase 2-betaHomo sapiens (human)
lamellipodiumProtein-tyrosine kinase 2-betaHomo sapiens (human)
dendriteProtein-tyrosine kinase 2-betaHomo sapiens (human)
growth coneProtein-tyrosine kinase 2-betaHomo sapiens (human)
neuronal cell bodyProtein-tyrosine kinase 2-betaHomo sapiens (human)
cell bodyProtein-tyrosine kinase 2-betaHomo sapiens (human)
perinuclear region of cytoplasmProtein-tyrosine kinase 2-betaHomo sapiens (human)
apical dendriteProtein-tyrosine kinase 2-betaHomo sapiens (human)
Schaffer collateral - CA1 synapseProtein-tyrosine kinase 2-betaHomo sapiens (human)
presynapseProtein-tyrosine kinase 2-betaHomo sapiens (human)
glutamatergic synapseProtein-tyrosine kinase 2-betaHomo sapiens (human)
postsynaptic density, intracellular componentProtein-tyrosine kinase 2-betaHomo sapiens (human)
dendritic spineProtein-tyrosine kinase 2-betaHomo sapiens (human)
focal adhesionProtein-tyrosine kinase 2-betaHomo sapiens (human)
plasma membraneProtein-tyrosine kinase 2-betaHomo sapiens (human)
plasma membraneMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cell cortexMaternal embryonic leucine zipper kinaseHomo sapiens (human)
membraneMaternal embryonic leucine zipper kinaseHomo sapiens (human)
cytoplasmMaternal embryonic leucine zipper kinaseHomo sapiens (human)
chromosome, centromeric regionStructural maintenance of chromosomes protein 1AHomo sapiens (human)
kinetochoreStructural maintenance of chromosomes protein 1AHomo sapiens (human)
condensed nuclear chromosomeStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nucleusStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nucleoplasmStructural maintenance of chromosomes protein 1AHomo sapiens (human)
chromosomeStructural maintenance of chromosomes protein 1AHomo sapiens (human)
cytosolStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nuclear matrixStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mitotic cohesin complexStructural maintenance of chromosomes protein 1AHomo sapiens (human)
meiotic cohesin complexStructural maintenance of chromosomes protein 1AHomo sapiens (human)
mitotic spindle poleStructural maintenance of chromosomes protein 1AHomo sapiens (human)
cohesin complexStructural maintenance of chromosomes protein 1AHomo sapiens (human)
nucleusStructural maintenance of chromosomes protein 1AHomo sapiens (human)
chromosome, telomeric regionChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
nucleusChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
nucleoplasmChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
cytoplasmChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
centrosomeChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
membraneChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
NuRD complexChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
site of DNA damageChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
cerebellar granule cell to Purkinje cell synapseChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
chromatinChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
protein-containing complexChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
RNA polymerase II transcription regulator complexChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
nucleusChromodomain-helicase-DNA-binding protein 4Homo sapiens (human)
peroxisomePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
peroxisomePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
peroxisomal membranePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
peroxisomal matrixPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
cytosolPeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
membranePeroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)
nucleusCyclin-dependent kinase 10Homo sapiens (human)
cytoplasmCyclin-dependent kinase 10Homo sapiens (human)
ciliary basal bodyCyclin-dependent kinase 10Homo sapiens (human)
nucleusCyclin-dependent kinase 10Homo sapiens (human)
autophagosome membraneSerine/threonine-protein kinase D1Homo sapiens (human)
nucleusSerine/threonine-protein kinase D1Homo sapiens (human)
trans-Golgi networkSerine/threonine-protein kinase D1Homo sapiens (human)
cytosolSerine/threonine-protein kinase D1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase D1Homo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase D1Homo sapiens (human)
cell cortexSerine/threonine-protein kinase D1Homo sapiens (human)
Z discSerine/threonine-protein kinase D1Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase D1Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase D1Homo sapiens (human)
cytosolSerine/threonine-protein kinase D1Homo sapiens (human)
site of double-strand breakSerine/threonine-protein kinase 38Homo sapiens (human)
nucleusSerine/threonine-protein kinase 38Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 38Homo sapiens (human)
cytosolSerine/threonine-protein kinase 38Homo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase 38Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
extracellular regionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleusReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleoplasmReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
mitochondrial matrixReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
cytosolReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
basolateral plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
neuromuscular junctionReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
presynaptic membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
postsynaptic membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
postsynaptic density membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
glutamatergic synapseReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
GABA-ergic synapseReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
receptor complexReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
basal plasma membraneReceptor tyrosine-protein kinase erbB-4Homo sapiens (human)
nucleusRibosomal protein S6 kinase alpha-2Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-2Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-2Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-2Homo sapiens (human)
plasma membraneEphrin type-A receptor 7Homo sapiens (human)
glutamatergic synapseEphrin type-A receptor 7Homo sapiens (human)
plasma membraneEphrin type-A receptor 7Homo sapiens (human)
dendriteEphrin type-A receptor 7Homo sapiens (human)
Golgi membraneDelta(24)-sterol reductaseHomo sapiens (human)
nucleusDelta(24)-sterol reductaseHomo sapiens (human)
endoplasmic reticulumDelta(24)-sterol reductaseHomo sapiens (human)
endoplasmic reticulum membraneDelta(24)-sterol reductaseHomo sapiens (human)
membraneDelta(24)-sterol reductaseHomo sapiens (human)
cytoplasmDelta(24)-sterol reductaseHomo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-1Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-1Homo sapiens (human)
synapseRibosomal protein S6 kinase alpha-1Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-1Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-1Homo sapiens (human)
cytoplasmic vesicleDual specificity testis-specific protein kinase 1Homo sapiens (human)
cytoplasmDual specificity testis-specific protein kinase 1Homo sapiens (human)
centrosomeDual specificity testis-specific protein kinase 1Homo sapiens (human)
cytosolDual specificity testis-specific protein kinase 1Homo sapiens (human)
lamellipodiumDual specificity testis-specific protein kinase 1Homo sapiens (human)
perinuclear region of cytoplasmDual specificity testis-specific protein kinase 1Homo sapiens (human)
cytoplasmDual specificity testis-specific protein kinase 1Homo sapiens (human)
nucleusDual specificity testis-specific protein kinase 1Homo sapiens (human)
stress fiberMyosin light chain kinase, smooth muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase, smooth muscleHomo sapiens (human)
cytosolMyosin light chain kinase, smooth muscleHomo sapiens (human)
plasma membraneMyosin light chain kinase, smooth muscleHomo sapiens (human)
actin cytoskeletonMyosin light chain kinase, smooth muscleHomo sapiens (human)
lamellipodiumMyosin light chain kinase, smooth muscleHomo sapiens (human)
cleavage furrowMyosin light chain kinase, smooth muscleHomo sapiens (human)
cleavage furrowMyosin light chain kinase, smooth muscleHomo sapiens (human)
stress fiberMyosin light chain kinase, smooth muscleHomo sapiens (human)
lamellipodiumMyosin light chain kinase, smooth muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase, smooth muscleHomo sapiens (human)
nucleoplasmMitogen-activated protein kinase 11Homo sapiens (human)
cytosolMitogen-activated protein kinase 11Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 11Homo sapiens (human)
nucleusMitogen-activated protein kinase 11Homo sapiens (human)
nucleusSerine/threonine-protein kinase STK11Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase STK11Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase STK11Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase STK11Homo sapiens (human)
cytosolSerine/threonine-protein kinase STK11Homo sapiens (human)
membraneSerine/threonine-protein kinase STK11Homo sapiens (human)
Z discSerine/threonine-protein kinase STK11Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase STK11Homo sapiens (human)
serine/threonine protein kinase complexSerine/threonine-protein kinase STK11Homo sapiens (human)
intracellular protein-containing complexSerine/threonine-protein kinase STK11Homo sapiens (human)
nucleusSerine/threonine-protein kinase STK11Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase STK11Homo sapiens (human)
photoreceptor disc membraneRhodopsin kinase GRK1Homo sapiens (human)
cytoplasmRhodopsin kinase GRK1Homo sapiens (human)
plasma membraneNT-3 growth factor receptorHomo sapiens (human)
receptor complexNT-3 growth factor receptorHomo sapiens (human)
plasma membraneNT-3 growth factor receptorHomo sapiens (human)
axonNT-3 growth factor receptorHomo sapiens (human)
nucleusSerine/threonine-protein kinase N1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase N1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase N1Homo sapiens (human)
endosomeSerine/threonine-protein kinase N1Homo sapiens (human)
cytosolSerine/threonine-protein kinase N1Homo sapiens (human)
midbodySerine/threonine-protein kinase N1Homo sapiens (human)
cleavage furrowSerine/threonine-protein kinase N1Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase N1Homo sapiens (human)
nucleusSerine/threonine-protein kinase N2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase N2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase N2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase N2Homo sapiens (human)
cytosolSerine/threonine-protein kinase N2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase N2Homo sapiens (human)
nuclear bodySerine/threonine-protein kinase N2Homo sapiens (human)
lamellipodiumSerine/threonine-protein kinase N2Homo sapiens (human)
midbodySerine/threonine-protein kinase N2Homo sapiens (human)
cleavage furrowSerine/threonine-protein kinase N2Homo sapiens (human)
apical junction complexSerine/threonine-protein kinase N2Homo sapiens (human)
intermediate filament cytoskeletonSerine/threonine-protein kinase N2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase N2Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase N2Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
fibrillar centerCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
extracellular exosomeCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)
centrosomeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
microtubuleMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
membraneMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
centrosomeMitogen-activated protein kinase kinase kinase 11Homo sapiens (human)
early endosomeBDNF/NT-3 growth factors receptorHomo sapiens (human)
cytosolBDNF/NT-3 growth factors receptorHomo sapiens (human)
plasma membraneBDNF/NT-3 growth factors receptorHomo sapiens (human)
postsynaptic densityBDNF/NT-3 growth factors receptorHomo sapiens (human)
axonBDNF/NT-3 growth factors receptorHomo sapiens (human)
dendriteBDNF/NT-3 growth factors receptorHomo sapiens (human)
early endosome membraneBDNF/NT-3 growth factors receptorHomo sapiens (human)
terminal boutonBDNF/NT-3 growth factors receptorHomo sapiens (human)
perinuclear region of cytoplasmBDNF/NT-3 growth factors receptorHomo sapiens (human)
receptor complexBDNF/NT-3 growth factors receptorHomo sapiens (human)
axon terminusBDNF/NT-3 growth factors receptorHomo sapiens (human)
plasma membraneBDNF/NT-3 growth factors receptorHomo sapiens (human)
postsynaptic densityBDNF/NT-3 growth factors receptorHomo sapiens (human)
axonBDNF/NT-3 growth factors receptorHomo sapiens (human)
dendritic spineBDNF/NT-3 growth factors receptorHomo sapiens (human)
nucleusMitogen-activated protein kinase 6Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 6Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 6Homo sapiens (human)
cytosolMitogen-activated protein kinase 6Homo sapiens (human)
septin cytoskeletonMitogen-activated protein kinase 6Homo sapiens (human)
protein-containing complexMitogen-activated protein kinase 6Homo sapiens (human)
nucleusMitogen-activated protein kinase 6Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 6Homo sapiens (human)
cytosolPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
phosphorylase kinase complexPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformHomo sapiens (human)
plasma membraneDiscoidin domain-containing receptor 2Homo sapiens (human)
focal adhesionDiscoidin domain-containing receptor 2Homo sapiens (human)
actin cytoskeletonDiscoidin domain-containing receptor 2Homo sapiens (human)
apical plasma membraneDiscoidin domain-containing receptor 2Homo sapiens (human)
receptor complexDiscoidin domain-containing receptor 2Homo sapiens (human)
plasma membraneDiscoidin domain-containing receptor 2Homo sapiens (human)
cytosolAP2-associated protein kinase 1Homo sapiens (human)
plasma membraneAP2-associated protein kinase 1Homo sapiens (human)
clathrin-coated pitAP2-associated protein kinase 1Homo sapiens (human)
clathrin-coated vesicleAP2-associated protein kinase 1Homo sapiens (human)
cell leading edgeAP2-associated protein kinase 1Homo sapiens (human)
terminal boutonAP2-associated protein kinase 1Homo sapiens (human)
intracellular membrane-bounded organelleAP2-associated protein kinase 1Homo sapiens (human)
presynapseAP2-associated protein kinase 1Homo sapiens (human)
cytoplasmMyosin light chain kinase 3Homo sapiens (human)
cytosolMyosin light chain kinase 3Homo sapiens (human)
cytoplasmMyosin light chain kinase 3Homo sapiens (human)
actin cytoskeletonMyosin light chain kinase 3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SBK1Homo sapiens (human)
extracellular exosomePutative heat shock protein HSP 90-beta 2Homo sapiens (human)
perinuclear region of cytoplasmPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
protein-containing complexPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
plasma membranePutative heat shock protein HSP 90-beta 2Homo sapiens (human)
cytosolPutative heat shock protein HSP 90-beta 2Homo sapiens (human)
nucleusSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase TNNI3KHomo sapiens (human)
endomembrane systemRab-like protein 3Homo sapiens (human)
Golgi membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
extracellular spaceLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrial outer membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrial inner membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrial matrixLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
lysosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulumLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulum membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Golgi apparatusLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Golgi-associated vesicleLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
trans-Golgi networkLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytosolLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytoskeletonLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
plasma membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
microvillusLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
axonLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
dendriteLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
growth coneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
synaptic vesicle membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmic vesicleLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
mitochondrial membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmic side of mitochondrial outer membraneLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
dendrite cytoplasmLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuron projectionLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
neuronal cell bodyLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
terminal boutonLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
perikaryonLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
intracellular membrane-bounded organelleLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
amphisomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
autolysosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
extracellular exosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
endoplasmic reticulum exit siteLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
multivesicular body, internal vesicleLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
postsynapseLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
glutamatergic synapseLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
caveola neckLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
presynaptic cytosolLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
ribonucleoprotein complexLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
Wnt signalosomeLeucine-rich repeat serine/threonine-protein kinase 2Homo sapiens (human)
cytosolSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
lamellipodiumSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cell leading edgeSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
actomyosinSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
actomyosinSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cytoskeletonSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase MRCK alphaHomo sapiens (human)
cytosolSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
cell leading edgeSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
cytoskeletonSerine/threonine-protein kinase MRCK gammaHomo sapiens (human)
mitochondrionAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
mitochondrial matrixAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
cytoplasmAcyl-CoA dehydrogenase family member 10Homo sapiens (human)
nucleusSerine/threonine-protein kinase N3Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase N3Homo sapiens (human)
cytosolSerine/threonine-protein kinase N3Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase N3Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK3Homo sapiens (human)
ciliary tipSerine/threonine-protein kinase ULK3Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK3Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK3Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK3Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK3Homo sapiens (human)
cytoplasmDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
basolateral plasma membraneDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
apical plasma membraneDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
anchoring junctionDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
cytoplasmDual serine/threonine and tyrosine protein kinaseHomo sapiens (human)
nucleusAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
mitochondrial inner membraneAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
peroxisomeAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
mitochondrial membraneAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
mitochondrionAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
cytoplasmAcyl-CoA dehydrogenase family member 11Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
cytosolSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
endoplasmic reticulum quality control compartmentSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
IRE1-TRAF2-ASK1 complexSerine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase MARK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK2Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase MARK2Homo sapiens (human)
actin filamentSerine/threonine-protein kinase MARK2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase MARK2Homo sapiens (human)
membraneSerine/threonine-protein kinase MARK2Homo sapiens (human)
lateral plasma membraneSerine/threonine-protein kinase MARK2Homo sapiens (human)
dendriteSerine/threonine-protein kinase MARK2Homo sapiens (human)
microtubule bundleSerine/threonine-protein kinase MARK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK2Homo sapiens (human)
cytoplasmATP-dependent RNA helicase DHX30Homo sapiens (human)
mitochondrionATP-dependent RNA helicase DHX30Homo sapiens (human)
cytosolATP-dependent RNA helicase DHX30Homo sapiens (human)
ribonucleoprotein granuleATP-dependent RNA helicase DHX30Homo sapiens (human)
mitochondrial nucleoidATP-dependent RNA helicase DHX30Homo sapiens (human)
cytoplasmATP-dependent RNA helicase DHX30Homo sapiens (human)
nucleusATP-dependent RNA helicase DHX30Homo sapiens (human)
intracellular anatomical structureATP-dependent RNA helicase DHX30Homo sapiens (human)
cytosolSerine/threonine-protein kinase TAO1Homo sapiens (human)
microtubule cytoskeletonSerine/threonine-protein kinase TAO1Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase TAO1Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase TAO1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TAO1Homo sapiens (human)
nucleusSTE20-related kinase adapter protein alphaHomo sapiens (human)
nucleoplasmSTE20-related kinase adapter protein alphaHomo sapiens (human)
cytoplasmSTE20-related kinase adapter protein alphaHomo sapiens (human)
cytosolSTE20-related kinase adapter protein alphaHomo sapiens (human)
serine/threonine protein kinase complexSTE20-related kinase adapter protein alphaHomo sapiens (human)
intracellular protein-containing complexSTE20-related kinase adapter protein alphaHomo sapiens (human)
stress fiberMyosin-14Homo sapiens (human)
cytosolMyosin-14Homo sapiens (human)
brush borderMyosin-14Homo sapiens (human)
membraneMyosin-14Homo sapiens (human)
growth coneMyosin-14Homo sapiens (human)
actomyosinMyosin-14Homo sapiens (human)
extracellular exosomeMyosin-14Homo sapiens (human)
myosin II filamentMyosin-14Homo sapiens (human)
myosin II complexMyosin-14Homo sapiens (human)
cytoplasmMyosin-14Homo sapiens (human)
myosin filamentMyosin-14Homo sapiens (human)
mitochondrionAarF domain-containing protein kinase 1Homo sapiens (human)
mitochondrial inner membraneAarF domain-containing protein kinase 1Homo sapiens (human)
nucleusSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
intermediate filamentSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
nucleusSerine/threonine-protein kinase tousled-like 2Homo sapiens (human)
cytosolSerine/threonine-protein kinase pim-3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-3Homo sapiens (human)
nucleusATP-dependent RNA helicase DDX42Homo sapiens (human)
nucleoplasmATP-dependent RNA helicase DDX42Homo sapiens (human)
cytoplasmATP-dependent RNA helicase DDX42Homo sapiens (human)
cytosolATP-dependent RNA helicase DDX42Homo sapiens (human)
Cajal bodyATP-dependent RNA helicase DDX42Homo sapiens (human)
membraneATP-dependent RNA helicase DDX42Homo sapiens (human)
nuclear speckATP-dependent RNA helicase DDX42Homo sapiens (human)
U2-type prespliceosomeATP-dependent RNA helicase DDX42Homo sapiens (human)
nucleusATP-dependent RNA helicase DDX42Homo sapiens (human)
nucleusSerine/threonine-protein kinase VRK2Homo sapiens (human)
nuclear envelopeSerine/threonine-protein kinase VRK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase VRK2Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase VRK2Homo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase VRK2Homo sapiens (human)
mitochondrial membraneSerine/threonine-protein kinase VRK2Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase VRK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase VRK2Homo sapiens (human)
nucleusSerine/threonine-protein kinase VRK2Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 1Homo sapiens (human)
nucleoplasmHomeodomain-interacting protein kinase 1Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 1Homo sapiens (human)
centrosomeHomeodomain-interacting protein kinase 1Homo sapiens (human)
cytosolHomeodomain-interacting protein kinase 1Homo sapiens (human)
nuclear speckHomeodomain-interacting protein kinase 1Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 1Homo sapiens (human)
PML bodyHomeodomain-interacting protein kinase 1Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 1Homo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
intracellular anatomical structureCalcium/calmodulin-dependent protein kinase type 1DHomo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)
cytoplasmCyclin-dependent kinase-like 3Homo sapiens (human)
nucleusCyclin-dependent kinase-like 3Homo sapiens (human)
nucleoplasmMAP kinase-activated protein kinase 5Homo sapiens (human)
cytosolMAP kinase-activated protein kinase 5Homo sapiens (human)
septin cytoskeletonMAP kinase-activated protein kinase 5Homo sapiens (human)
protein-containing complexMAP kinase-activated protein kinase 5Homo sapiens (human)
cytoplasmMAP kinase-activated protein kinase 5Homo sapiens (human)
nucleusMAP kinase-activated protein kinase 5Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase BRSK2Homo sapiens (human)
endoplasmic reticulumSerine/threonine-protein kinase BRSK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK2Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase BRSK2Homo sapiens (human)
distal axonSerine/threonine-protein kinase BRSK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK2Homo sapiens (human)
cytoplasmic vesicle membraneSerine/threonine-protein kinase ULK2Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK2Homo sapiens (human)
phagophore assembly site membraneSerine/threonine-protein kinase ULK2Homo sapiens (human)
cytosolSerine/threonine-protein kinase ULK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase ULK2Homo sapiens (human)
phagophore assembly siteSerine/threonine-protein kinase ULK2Homo sapiens (human)
autophagosomeSerine/threonine-protein kinase ULK2Homo sapiens (human)
cytoplasmMisshapen-like kinase 1Homo sapiens (human)
Golgi apparatusMisshapen-like kinase 1Homo sapiens (human)
cytosolMisshapen-like kinase 1Homo sapiens (human)
postsynaptic densityMisshapen-like kinase 1Homo sapiens (human)
axonMisshapen-like kinase 1Homo sapiens (human)
dendriteMisshapen-like kinase 1Homo sapiens (human)
extracellular exosomeMisshapen-like kinase 1Homo sapiens (human)
cytoplasmMisshapen-like kinase 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase DCLK2Homo sapiens (human)
cytoskeletonSerine/threonine-protein kinase DCLK2Homo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase kinase 1Homo sapiens (human)
cytosolCasein kinase I isoform alpha-likeHomo sapiens (human)
nucleusCasein kinase I isoform alpha-likeHomo sapiens (human)
cytoplasmCasein kinase I isoform alpha-likeHomo sapiens (human)
nucleusHomeodomain-interacting protein kinase 4Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 4Homo sapiens (human)
cytoplasmMyosin-IIIaHomo sapiens (human)
filopodiumMyosin-IIIaHomo sapiens (human)
stereocilium tipMyosin-IIIaHomo sapiens (human)
filopodium tipMyosin-IIIaHomo sapiens (human)
myosin complexMyosin-IIIaHomo sapiens (human)
filamentous actinMyosin-IIIaHomo sapiens (human)
photoreceptor inner segmentMyosin-IIIaHomo sapiens (human)
stereocilium tipMyosin-IIIaHomo sapiens (human)
filopodium tipMyosin-IIIaHomo sapiens (human)
nucleusAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
cell projectionAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
cytoplasmAnkyrin repeat and protein kinase domain-containing protein 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek11Homo sapiens (human)
nucleolusSerine/threonine-protein kinase Nek11Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek11Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek11Homo sapiens (human)
mitochondrionAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
membraneAtypical kinase COQ8A, mitochondrialHomo sapiens (human)
nucleoplasmPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
autophagosomePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
endoplasmic reticulumPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
cytosolPhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
intracellular organellePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
extracellular exosomePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
plasma membranePhosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)
axonemeMitogen-activated protein kinase 15Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 15Homo sapiens (human)
nucleusMitogen-activated protein kinase 15Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 15Homo sapiens (human)
autophagosomeMitogen-activated protein kinase 15Homo sapiens (human)
Golgi apparatusMitogen-activated protein kinase 15Homo sapiens (human)
centrioleMitogen-activated protein kinase 15Homo sapiens (human)
cell-cell junctionMitogen-activated protein kinase 15Homo sapiens (human)
bicellular tight junctionMitogen-activated protein kinase 15Homo sapiens (human)
cytoplasmic vesicleMitogen-activated protein kinase 15Homo sapiens (human)
ciliary basal bodyMitogen-activated protein kinase 15Homo sapiens (human)
meiotic spindleMitogen-activated protein kinase 15Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 15Homo sapiens (human)
nucleusMitogen-activated protein kinase 15Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek9Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek9Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek9Homo sapiens (human)
nucleusSerine/threonine-protein kinase BRSK1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase BRSK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase BRSK1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK1Homo sapiens (human)
synaptic vesicleSerine/threonine-protein kinase BRSK1Homo sapiens (human)
cell junctionSerine/threonine-protein kinase BRSK1Homo sapiens (human)
presynaptic active zoneSerine/threonine-protein kinase BRSK1Homo sapiens (human)
distal axonSerine/threonine-protein kinase BRSK1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase BRSK1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 35Homo sapiens (human)
nucleolusSerine/threonine-protein kinase 35Homo sapiens (human)
nuclear bodySerine/threonine-protein kinase 35Homo sapiens (human)
nucleusSerine/threonine-protein kinase 35Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 35Homo sapiens (human)
microtubule organizing centerSerine/threonine-protein kinase Nek7Homo sapiens (human)
spindle poleSerine/threonine-protein kinase Nek7Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek7Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek7Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek7Homo sapiens (human)
microtubuleSerine/threonine-protein kinase Nek7Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek7Homo sapiens (human)
photoreceptor disc membraneRhodopsin kinase GRK7Homo sapiens (human)
cytoplasmRhodopsin kinase GRK7Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase 32AHomo sapiens (human)
cytoplasmMyosin-IIIbHomo sapiens (human)
stereocilium tipMyosin-IIIbHomo sapiens (human)
myosin complexMyosin-IIIbHomo sapiens (human)
stereocilium tipMyosin-IIIbHomo sapiens (human)
filopodium tipMyosin-IIIbHomo sapiens (human)
photoreceptor inner segmentMyosin-IIIbHomo sapiens (human)
nucleusATP-dependent RNA helicase DDX1Homo sapiens (human)
nucleoplasmATP-dependent RNA helicase DDX1Homo sapiens (human)
cytoplasmATP-dependent RNA helicase DDX1Homo sapiens (human)
mitochondrionATP-dependent RNA helicase DDX1Homo sapiens (human)
cytosolATP-dependent RNA helicase DDX1Homo sapiens (human)
cytoplasmic stress granuleATP-dependent RNA helicase DDX1Homo sapiens (human)
membraneATP-dependent RNA helicase DDX1Homo sapiens (human)
cleavage bodyATP-dependent RNA helicase DDX1Homo sapiens (human)
tRNA-splicing ligase complexATP-dependent RNA helicase DDX1Homo sapiens (human)
ribonucleoprotein complexATP-dependent RNA helicase DDX1Homo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
nucleoplasmDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytosolDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
ubiquitin ligase complexDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
ribonucleoprotein complexDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytoplasmDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
cytoskeletonDual specificity tyrosine-phosphorylation-regulated kinase 2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase-like 2Homo sapiens (human)
cytoplasmCyclin-dependent kinase-like 2Homo sapiens (human)
centrosomeCyclin-dependent kinase-like 2Homo sapiens (human)
nucleusCyclin-dependent kinase-like 2Homo sapiens (human)
membraneMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 1Homo sapiens (human)
early endosomeSerine/threonine-protein kinase Sgk3Homo sapiens (human)
cytosolSerine/threonine-protein kinase Sgk3Homo sapiens (human)
recycling endosomeSerine/threonine-protein kinase Sgk3Homo sapiens (human)
mitochondrionAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
cytosolAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
plasma membraneAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
mitochondrial membraneAtypical kinase COQ8B, mitochondrialHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
microtubule organizing centerMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cytoplasmMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
centrosomeMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule organizing centerMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cytosolMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
microtubule cytoskeletonMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
dendriteMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
midbodyMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
neuron projectionMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
gamma-tubulin complexMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
ciliary basal bodyMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
cytoplasmMAP/microtubule affinity-regulating kinase 4Homo sapiens (human)
Golgi membraneCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
plasma membraneCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
intracellular anatomical structureCalcium/calmodulin-dependent protein kinase type 1GHomo sapiens (human)
pericentriolar materialSerine/threonine-protein kinase Nek1Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek1Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek1Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek1Homo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase Nek1Homo sapiens (human)
cytoplasmCyclin-dependent kinase 15Homo sapiens (human)
nucleusCyclin-dependent kinase 15Homo sapiens (human)
cytosolCyclin-dependent kinase 15Homo sapiens (human)
nucleusPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
cytosolPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
cytosolPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
nucleusPAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)
nucleusEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
nucleoplasmEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
cytoplasmEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
EKC/KEOPS complexEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
cytosolEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
nucleusEKC/KEOPS complex subunit TP53RKHomo sapiens (human)
nucleusSRSF protein kinase 1Homo sapiens (human)
nucleoplasmSRSF protein kinase 1Homo sapiens (human)
cytoplasmSRSF protein kinase 1Homo sapiens (human)
endoplasmic reticulumSRSF protein kinase 1Homo sapiens (human)
cytosolSRSF protein kinase 1Homo sapiens (human)
plasma membraneSRSF protein kinase 1Homo sapiens (human)
nuclear matrixSRSF protein kinase 1Homo sapiens (human)
nuclear speckSRSF protein kinase 1Homo sapiens (human)
chromatinSRSF protein kinase 1Homo sapiens (human)
nucleusSRSF protein kinase 1Homo sapiens (human)
cytoplasmSRSF protein kinase 1Homo sapiens (human)
Golgi membraneMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
nucleoplasmMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
nucleolusMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
endoplasmic reticulumMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
endoplasmic reticulum membraneMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
Golgi apparatusMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
cytosolMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
membraneMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
cytoplasmMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
nucleusMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
external side of plasma membraneMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein-containing complexMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
protein kinase complexMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
IRE1-TRAF2-ASK1 complexMitogen-activated protein kinase kinase kinase 5Homo sapiens (human)
mRNA cleavage and polyadenylation specificity factor complexPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
nucleusPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
nucleoplasmPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
cytosolPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
focal adhesionPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
nuclear speckPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
lamellipodiumPhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
ruffle membranePhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
plasma membranePhosphatidylinositol 4-phosphate 5-kinase type-1 alphaHomo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 3Homo sapiens (human)
cytosolEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
cytosolEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
nucleusEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
cytoplasmEukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase RIO1Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO1Homo sapiens (human)
preribosome, small subunit precursorSerine/threonine-protein kinase RIO1Homo sapiens (human)
methyltransferase complexSerine/threonine-protein kinase RIO1Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO1Homo sapiens (human)
nucleoplasmMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytosolMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
cytoplasmMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleusMAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase RIO2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase RIO2Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO2Homo sapiens (human)
preribosome, small subunit precursorSerine/threonine-protein kinase RIO2Homo sapiens (human)
cytosolSerine/threonine-protein kinase RIO2Homo sapiens (human)
nucleusSerine/threonine-protein kinase RIO2Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 19Homo sapiens (human)
cytosolCyclin-dependent kinase 19Homo sapiens (human)
perinuclear region of cytoplasmCyclin-dependent kinase 19Homo sapiens (human)
CKM complexCyclin-dependent kinase 19Homo sapiens (human)
nucleusCyclin-dependent kinase 19Homo sapiens (human)
cytosolCyclin-dependent kinase 19Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
brush border membraneTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
apical plasma membraneTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 6Homo sapiens (human)
acrosomal vesicleTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
motile ciliumTestis-specific serine/threonine-protein kinase 1Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase 33Homo sapiens (human)
nucleusSerine/threonine-protein kinase 33Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 33Homo sapiens (human)
nucleusNucleolar GTP-binding protein 1Homo sapiens (human)
nucleoplasmNucleolar GTP-binding protein 1Homo sapiens (human)
nucleolusNucleolar GTP-binding protein 1Homo sapiens (human)
cytoplasmNucleolar GTP-binding protein 1Homo sapiens (human)
cytosolNucleolar GTP-binding protein 1Homo sapiens (human)
membraneNucleolar GTP-binding protein 1Homo sapiens (human)
nuclear membraneNucleolar GTP-binding protein 1Homo sapiens (human)
perinuclear region of cytoplasmNucleolar GTP-binding protein 1Homo sapiens (human)
nucleolusNucleolar GTP-binding protein 1Homo sapiens (human)
nucleusSerine/threonine-protein kinase D2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase D2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase D2Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase D2Homo sapiens (human)
cytosolSerine/threonine-protein kinase D2Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase D2Homo sapiens (human)
cytosolSerine/threonine-protein kinase D2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase DCLK3Homo sapiens (human)
nucleusSerine/threonine-protein kinase DCLK3Homo sapiens (human)
chromosome, telomeric regionRNA cytidine acetyltransferaseHomo sapiens (human)
nucleusRNA cytidine acetyltransferaseHomo sapiens (human)
nucleoplasmRNA cytidine acetyltransferaseHomo sapiens (human)
nucleolusRNA cytidine acetyltransferaseHomo sapiens (human)
membraneRNA cytidine acetyltransferaseHomo sapiens (human)
midbodyRNA cytidine acetyltransferaseHomo sapiens (human)
telomerase holoenzyme complexRNA cytidine acetyltransferaseHomo sapiens (human)
small-subunit processomeRNA cytidine acetyltransferaseHomo sapiens (human)
nucleolusRNA cytidine acetyltransferaseHomo sapiens (human)
endoplasmic reticulum membraneSerine/threonine-protein kinase SIK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK2Homo sapiens (human)
nucleusSerine/threonine-protein kinase SIK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK2Homo sapiens (human)
nucleusMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
sarcomereMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
synapseMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase 2, skeletal/cardiac muscleHomo sapiens (human)
cytoplasmSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cytosolSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cell leading edgeSTE20-like serine/threonine-protein kinase Homo sapiens (human)
perinuclear region of cytoplasmSTE20-like serine/threonine-protein kinase Homo sapiens (human)
extracellular exosomeSTE20-like serine/threonine-protein kinase Homo sapiens (human)
cytoplasmSTE20-like serine/threonine-protein kinase Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase TAO3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TAO3Homo sapiens (human)
PML bodyHomeodomain-interacting protein kinase 2Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 2Homo sapiens (human)
nucleoplasmHomeodomain-interacting protein kinase 2Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 2Homo sapiens (human)
cytoplasmic stress granuleHomeodomain-interacting protein kinase 2Homo sapiens (human)
nuclear bodyHomeodomain-interacting protein kinase 2Homo sapiens (human)
RNA polymerase II transcription regulator complexHomeodomain-interacting protein kinase 2Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 2Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 2Homo sapiens (human)
cytoplasmTyrosine-protein kinase SrmsHomo sapiens (human)
cytosolTyrosine-protein kinase SrmsHomo sapiens (human)
plasma membraneTyrosine-protein kinase SrmsHomo sapiens (human)
cytosolHomeodomain-interacting protein kinase 3Homo sapiens (human)
plasma membraneHomeodomain-interacting protein kinase 3Homo sapiens (human)
nuclear bodyHomeodomain-interacting protein kinase 3Homo sapiens (human)
cytoplasmHomeodomain-interacting protein kinase 3Homo sapiens (human)
nucleusHomeodomain-interacting protein kinase 3Homo sapiens (human)
PML bodyHomeodomain-interacting protein kinase 3Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK3Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PLK3Homo sapiens (human)
nucleolusSerine/threonine-protein kinase PLK3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK3Homo sapiens (human)
Golgi stackSerine/threonine-protein kinase PLK3Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK3Homo sapiens (human)
dendriteSerine/threonine-protein kinase PLK3Homo sapiens (human)
neuronal cell bodySerine/threonine-protein kinase PLK3Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase PLK3Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK3Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK3Homo sapiens (human)
spindle poleSerine/threonine-protein kinase PLK3Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK3Homo sapiens (human)
nucleusdCTP pyrophosphatase 1Homo sapiens (human)
nucleoplasmdCTP pyrophosphatase 1Homo sapiens (human)
mitochondriondCTP pyrophosphatase 1Homo sapiens (human)
cytosoldCTP pyrophosphatase 1Homo sapiens (human)
cytosoldCTP pyrophosphatase 1Homo sapiens (human)
nucleusDual specificity protein kinase CLK4Homo sapiens (human)
nucleoplasmMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nuclear bodyMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
PML bodyMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
nucleusMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
cytoplasmMAP kinase-interacting serine/threonine-protein kinase 2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase Nek6Homo sapiens (human)
spindle poleSerine/threonine-protein kinase Nek6Homo sapiens (human)
nucleusSerine/threonine-protein kinase Nek6Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase Nek6Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase Nek6Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek6Homo sapiens (human)
microtubuleSerine/threonine-protein kinase Nek6Homo sapiens (human)
nuclear speckSerine/threonine-protein kinase Nek6Homo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase Nek6Homo sapiens (human)
protein-containing complexSerine/threonine-protein kinase Nek6Homo sapiens (human)
cytosolSerine/threonine-protein kinase Nek6Homo sapiens (human)
cytosolCasein kinase I isoform gamma-1Homo sapiens (human)
nucleusCasein kinase I isoform gamma-1Homo sapiens (human)
plasma membraneCasein kinase I isoform gamma-1Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-1Homo sapiens (human)
fibrillar centerSerine/threonine-protein kinase PAK 6Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PAK 6Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 6Homo sapiens (human)
postsynaptic densitySerine/threonine-protein kinase PAK 6Homo sapiens (human)
cell junctionSerine/threonine-protein kinase PAK 6Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 6Homo sapiens (human)
nucleusSNF-related serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase LATS2Homo sapiens (human)
spindle poleSerine/threonine-protein kinase LATS2Homo sapiens (human)
nucleusSerine/threonine-protein kinase LATS2Homo sapiens (human)
cytosolSerine/threonine-protein kinase LATS2Homo sapiens (human)
centriolar satelliteSerine/threonine-protein kinase LATS2Homo sapiens (human)
nucleusSerine/threonine-protein kinase LATS2Homo sapiens (human)
spindle poleSerine/threonine-protein kinase LATS2Homo sapiens (human)
extracellular regionSerine/threonine-protein kinase 36Homo sapiens (human)
nucleusSerine/threonine-protein kinase 36Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 36Homo sapiens (human)
cytosolSerine/threonine-protein kinase 36Homo sapiens (human)
cytoskeletonSerine/threonine-protein kinase 36Homo sapiens (human)
cell projectionSerine/threonine-protein kinase 36Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 36Homo sapiens (human)
cytoplasmPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
cytosolPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
phenylalanine-tRNA ligase complexPhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
membranePhenylalanine--tRNA ligase beta subunitHomo sapiens (human)
nuclear speckBMP-2-inducible protein kinaseHomo sapiens (human)
cytoplasmBMP-2-inducible protein kinaseHomo sapiens (human)
nucleusBMP-2-inducible protein kinaseHomo sapiens (human)
nucleusMidasinHomo sapiens (human)
nucleoplasmMidasinHomo sapiens (human)
nucleolusMidasinHomo sapiens (human)
cytosolMidasinHomo sapiens (human)
membraneMidasinHomo sapiens (human)
intermediate filament cytoskeletonMidasinHomo sapiens (human)
nucleusMidasinHomo sapiens (human)
preribosome, large subunit precursorMidasinHomo sapiens (human)
cytoplasmInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
cell surfaceInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
extrinsic component of plasma membraneInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
extracellular spaceInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
cytosolInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
endosome membraneInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
nucleusInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 4Homo sapiens (human)
nucleusMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 20Homo sapiens (human)
cyclin K-CDK12 complexCyclin-dependent kinase 12Homo sapiens (human)
nucleoplasmCyclin-dependent kinase 12Homo sapiens (human)
nuclear speckCyclin-dependent kinase 12Homo sapiens (human)
nuclear cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinase 12Homo sapiens (human)
nucleusCyclin-dependent kinase 12Homo sapiens (human)
cyclin/CDK positive transcription elongation factor complexCyclin-dependent kinase 12Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK2Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK2Homo sapiens (human)
cytosolSerine/threonine-protein kinase PLK2Homo sapiens (human)
dendriteSerine/threonine-protein kinase PLK2Homo sapiens (human)
chromatinSerine/threonine-protein kinase PLK2Homo sapiens (human)
spindle poleSerine/threonine-protein kinase PLK2Homo sapiens (human)
centrioleSerine/threonine-protein kinase PLK2Homo sapiens (human)
centrosomeSerine/threonine-protein kinase PLK2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PLK2Homo sapiens (human)
kinetochoreSerine/threonine-protein kinase PLK2Homo sapiens (human)
nucleusSerine/threonine-protein kinase PLK2Homo sapiens (human)
nucleoplasmNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
cytoplasmNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrionNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial inner membraneNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial respirasomeNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial respiratory chain complex INADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
mitochondrial membraneNADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK1Homo sapiens (human)
cytoskeletonSerine/threonine-protein kinase MARK1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase MARK1Homo sapiens (human)
microtubule cytoskeletonSerine/threonine-protein kinase MARK1Homo sapiens (human)
dendriteSerine/threonine-protein kinase MARK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase MARK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase PAK 5Homo sapiens (human)
mitochondrionSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cytosolSerine/threonine-protein kinase PAK 5Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase PAK 5Homo sapiens (human)
nuclear membraneSerine/threonine-protein kinase PAK 5Homo sapiens (human)
synapseSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase PAK 5Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 26Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 26Homo sapiens (human)
Golgi-associated vesicleSerine/threonine-protein kinase 26Homo sapiens (human)
cytosolSerine/threonine-protein kinase 26Homo sapiens (human)
vesicle membraneSerine/threonine-protein kinase 26Homo sapiens (human)
membraneSerine/threonine-protein kinase 26Homo sapiens (human)
apical plasma membraneSerine/threonine-protein kinase 26Homo sapiens (human)
perinuclear region of cytoplasmSerine/threonine-protein kinase 26Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase 26Homo sapiens (human)
cell peripherySerine/threonine-protein kinase 26Homo sapiens (human)
FAR/SIN/STRIPAK complexSerine/threonine-protein kinase 26Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 26Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 26Homo sapiens (human)
cytoplasmeIF-2-alpha kinase GCN2Homo sapiens (human)
cytosolic ribosomeeIF-2-alpha kinase GCN2Homo sapiens (human)
cytosoleIF-2-alpha kinase GCN2Homo sapiens (human)
cytoplasmeIF-2-alpha kinase GCN2Homo sapiens (human)
nucleuseIF-2-alpha kinase GCN2Homo sapiens (human)
nucleusSerine/threonine-protein kinase NLKHomo sapiens (human)
nucleoplasmSerine/threonine-protein kinase NLKHomo sapiens (human)
cytosolSerine/threonine-protein kinase NLKHomo sapiens (human)
nucleusSerine/threonine-protein kinase NLKHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase NLKHomo sapiens (human)
Golgi membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
mitochondrial outer membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
endosomePhosphatidylinositol 4-kinase betaHomo sapiens (human)
Golgi apparatusPhosphatidylinositol 4-kinase betaHomo sapiens (human)
cytosolPhosphatidylinositol 4-kinase betaHomo sapiens (human)
rough endoplasmic reticulum membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
perinuclear region of cytoplasmPhosphatidylinositol 4-kinase betaHomo sapiens (human)
membranePhosphatidylinositol 4-kinase betaHomo sapiens (human)
cytoplasmPhosphatidylinositol 4-kinase betaHomo sapiens (human)
nucleusSerine/threonine-protein kinase 17AHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase 17AHomo sapiens (human)
nuclear speckSerine/threonine-protein kinase 17AHomo sapiens (human)
nucleusSerine/threonine-protein kinase 17AHomo sapiens (human)
nucleoplasmSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cytosolSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cell cortexSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
basolateral plasma membraneSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
apical plasma membraneSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
intracellular membrane-bounded organelleSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cell bodySTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cytoplasmSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
cytosolSTE20/SPS1-related proline-alanine-rich protein kinaseHomo sapiens (human)
nucleoplasmEphrin type-A receptor 6Homo sapiens (human)
plasma membraneEphrin type-A receptor 6Homo sapiens (human)
dendriteEphrin type-A receptor 6Homo sapiens (human)
plasma membraneEphrin type-A receptor 6Homo sapiens (human)
extracellular space5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TBK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase TBK1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase TBK1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TBK1Homo sapiens (human)
cytosolSerine/threonine-protein kinase TBK1Homo sapiens (human)
intracellular membrane-bounded organelleSerine/threonine-protein kinase TBK1Homo sapiens (human)
serine/threonine protein kinase complexSerine/threonine-protein kinase TBK1Homo sapiens (human)
stress fiberSeptin-9Homo sapiens (human)
cytoplasmSeptin-9Homo sapiens (human)
microtubuleSeptin-9Homo sapiens (human)
axonemeSeptin-9Homo sapiens (human)
actin cytoskeletonSeptin-9Homo sapiens (human)
perinuclear region of cytoplasmSeptin-9Homo sapiens (human)
non-motile ciliumSeptin-9Homo sapiens (human)
septin complexSeptin-9Homo sapiens (human)
septin ringSeptin-9Homo sapiens (human)
microtubule cytoskeletonSeptin-9Homo sapiens (human)
cell division siteSeptin-9Homo sapiens (human)
cytoplasmDeath-associated protein kinase 2Homo sapiens (human)
Golgi apparatusDeath-associated protein kinase 2Homo sapiens (human)
cytoplasmic vesicleDeath-associated protein kinase 2Homo sapiens (human)
autophagosome lumenDeath-associated protein kinase 2Homo sapiens (human)
intracellular membrane-bounded organelleDeath-associated protein kinase 2Homo sapiens (human)
cytoplasmDeath-associated protein kinase 2Homo sapiens (human)
nucleusDeath-associated protein kinase 2Homo sapiens (human)
fibrillar centerRibosomal protein S6 kinase alpha-6Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-6Homo sapiens (human)
nucleolusRibosomal protein S6 kinase alpha-6Homo sapiens (human)
mitochondrionRibosomal protein S6 kinase alpha-6Homo sapiens (human)
cytosolRibosomal protein S6 kinase alpha-6Homo sapiens (human)
cytoplasmRibosomal protein S6 kinase alpha-6Homo sapiens (human)
nucleoplasmRibosomal protein S6 kinase alpha-6Homo sapiens (human)
nucleusTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
nucleoplasmTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoplasmTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytosolTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoskeletonTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
apical plasma membraneTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
recycling endosomeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
extracellular exosomeTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
presynapseTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
glutamatergic synapseTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
postsynaptic density, intracellular componentTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
cytoplasmTRAF2 and NCK-interacting protein kinaseHomo sapiens (human)
nucleusSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
nucleusSerine/threonine-protein kinase tousled-like 1Homo sapiens (human)
actin cytoskeletonSerine/threonine-protein kinase TAO2Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase TAO2Homo sapiens (human)
nucleolusSerine/threonine-protein kinase TAO2Homo sapiens (human)
cytosolSerine/threonine-protein kinase TAO2Homo sapiens (human)
axonSerine/threonine-protein kinase TAO2Homo sapiens (human)
cytoplasmic vesicle membraneSerine/threonine-protein kinase TAO2Homo sapiens (human)
cytoplasmic vesicleSerine/threonine-protein kinase TAO2Homo sapiens (human)
neuron projectionSerine/threonine-protein kinase TAO2Homo sapiens (human)
dendritic growth coneSerine/threonine-protein kinase TAO2Homo sapiens (human)
axonal growth coneSerine/threonine-protein kinase TAO2Homo sapiens (human)
receptor complexSerine/threonine-protein kinase TAO2Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase TAO2Homo sapiens (human)
nucleoplasmLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
nucleolusLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
mitochondrionLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
mitochondrial outer membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
endoplasmic reticulumLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
endoplasmic reticulum membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
plasma membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
endoplasmic reticulumLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
membraneLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
mitochondrionLong-chain-fatty-acid--CoA ligase 5Homo sapiens (human)
plasma membraneALK tyrosine kinase receptorHomo sapiens (human)
plasma membraneALK tyrosine kinase receptorHomo sapiens (human)
extracellular exosomeALK tyrosine kinase receptorHomo sapiens (human)
protein-containing complexALK tyrosine kinase receptorHomo sapiens (human)
receptor complexALK tyrosine kinase receptorHomo sapiens (human)
cellular_componentSRSF protein kinase 3Homo sapiens (human)
nucleusSRSF protein kinase 3Homo sapiens (human)
cytoplasmSRSF protein kinase 3Homo sapiens (human)
fibrillar centerSerine/threonine-protein kinase ICKHomo sapiens (human)
nucleusSerine/threonine-protein kinase ICKHomo sapiens (human)
cytosolSerine/threonine-protein kinase ICKHomo sapiens (human)
ciliumSerine/threonine-protein kinase ICKHomo sapiens (human)
ciliary basal bodySerine/threonine-protein kinase ICKHomo sapiens (human)
ciliary tipSerine/threonine-protein kinase ICKHomo sapiens (human)
ciliary baseSerine/threonine-protein kinase ICKHomo sapiens (human)
nucleusSerine/threonine-protein kinase ICKHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase ICKHomo sapiens (human)
ciliumSerine/threonine-protein kinase ICKHomo sapiens (human)
nucleusCyclin-dependent kinase 11AHomo sapiens (human)
cytoplasmCyclin-dependent kinase 11AHomo sapiens (human)
nucleusCyclin-dependent kinase 11AHomo sapiens (human)
condensed chromosomeAurora kinase CHomo sapiens (human)
nucleusAurora kinase CHomo sapiens (human)
cytoplasmAurora kinase CHomo sapiens (human)
spindleAurora kinase CHomo sapiens (human)
midbodyAurora kinase CHomo sapiens (human)
spindle midzoneAurora kinase CHomo sapiens (human)
chromosome passenger complexAurora kinase CHomo sapiens (human)
kinetochoreAurora kinase CHomo sapiens (human)
spindle midzoneAurora kinase CHomo sapiens (human)
spindle pole centrosomeAurora kinase CHomo sapiens (human)
spindle microtubuleAurora kinase CHomo sapiens (human)
nucleusCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
nucleoplasmCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
mitochondrionCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
cytosolCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
postsynaptic densityCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
endocytic vesicle membraneCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
dendritic spineCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
calcium- and calmodulin-dependent protein kinase complexCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
neuron projectionCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
cytoplasmCalcium/calmodulin-dependent protein kinase type II subunit alphaHomo sapiens (human)
nucleusRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
membraneRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
nucleoplasmRAC-gamma serine/threonine-protein kinaseHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase 38-likeHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase 38-likeHomo sapiens (human)
cytosolSerine/threonine-protein kinase 38-likeHomo sapiens (human)
actin cytoskeletonSerine/threonine-protein kinase 38-likeHomo sapiens (human)
membraneSerine/threonine-protein kinase 38-likeHomo sapiens (human)
glutamatergic synapseSerine/threonine-protein kinase 38-likeHomo sapiens (human)
cytoplasmMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
cytoskeletonMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
plasma membraneMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
axonMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
dendriteMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
neuron projectionMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
neuronal cell bodyMicrotubule-associated serine/threonine-protein kinase 1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase SIK3Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 2Homo sapiens (human)
exon-exon junction complexThyroid hormone receptor-associated protein 3Homo sapiens (human)
nucleusThyroid hormone receptor-associated protein 3Homo sapiens (human)
nucleoplasmThyroid hormone receptor-associated protein 3Homo sapiens (human)
nuclear speckThyroid hormone receptor-associated protein 3Homo sapiens (human)
extracellular exosomeThyroid hormone receptor-associated protein 3Homo sapiens (human)
mediator complexThyroid hormone receptor-associated protein 3Homo sapiens (human)
nucleoplasmDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
chromosomeDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
nucleolusDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
nucleusDual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
cytosolMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
plasma membraneMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)
nucleusReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
nucleusReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
cytosolReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
protein-containing complexReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
cytoplasmReceptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)
cytosolSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
plasma membraneSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cell-cell junctionSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
lamellipodiumSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cell leading edgeSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
actomyosinSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cytoskeletonSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
cytoplasmSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
actomyosinSerine/threonine-protein kinase MRCK betaHomo sapiens (human)
nucleusInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
cytoplasmInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
nucleusInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
plasma membraneInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
cytoplasmInterleukin-1 receptor-associated kinase 3Homo sapiens (human)
Golgi membraneSerine/threonine-protein kinase 24Homo sapiens (human)
nucleusSerine/threonine-protein kinase 24Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase 24Homo sapiens (human)
nucleolusSerine/threonine-protein kinase 24Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 24Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 24Homo sapiens (human)
cytosolSerine/threonine-protein kinase 24Homo sapiens (human)
extracellular exosomeSerine/threonine-protein kinase 24Homo sapiens (human)
FAR/SIN/STRIPAK complexSerine/threonine-protein kinase 24Homo sapiens (human)
Golgi apparatusSerine/threonine-protein kinase 24Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase 24Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-3Homo sapiens (human)
plasma membraneCasein kinase I isoform gamma-3Homo sapiens (human)
cytoplasmCasein kinase I isoform gamma-3Homo sapiens (human)
nucleusCasein kinase I isoform gamma-3Homo sapiens (human)
cytoplasmMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
perinuclear region of cytoplasmMitogen-activated protein kinase kinase kinase 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1076)

Assay IDTitleYearJournalArticle
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345514Human fibroblast growth factor receptor 1 (Type V RTKs: FGF (fibroblast growth factor) receptor family)2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1345563Human platelet derived growth factor receptor alpha (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family)2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1345506Human kinase insert domain receptor (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family)2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1345520Human fms related tyrosine kinase 4 (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family)2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1345590Human platelet derived growth factor receptor beta (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family)2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1345535Human fibroblast growth factor receptor 3 (Type V RTKs: FGF (fibroblast growth factor) receptor family)2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1345517Human fibroblast growth factor receptor 2 (Type V RTKs: FGF (fibroblast growth factor) receptor family)2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1345568Human fibroblast growth factor receptor 4 (Type V RTKs: FGF (fibroblast growth factor) receptor family)2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1345548Human fms related tyrosine kinase 1 (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family)2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID507214Antiangiogenic activity in HUVEC assessed as inhibition of VEGF-induced apoptosis by [3H]thymidine incorporation assay2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625018Binding constant for YES kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624759Binding constant for PFCDPK1(P.falciparum) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624717Binding constant for JNK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624980Binding constant for ABL1(F317I)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1692004Cytotoxicity against rat NRK-49F cells assessed as cell survival rate at 10 uM incubated for 72 hrs by MTT assay2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID1425122Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624787Binding constant for KIT(A829P) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425150Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625035Binding constant for PHKG1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624708Binding constant for CDC2L1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625136Binding constant for YSK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425146Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424992Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507218Inhibition of VEGF-induced Akt phosphorylation in HUVEC at 100 nM treated 2 hrs before VEGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624840Binding constant for AXL kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424891Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624990Binding constant for ABL1(Y253F)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397066Antitumor activity against human FADU cells xenografted NMRI nu/nu mouse assessed as inhibition of mean tumor volume growth at 25 mg/kg, po qd after 21 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID507220Inhibition of VEGF-induced MAPK phosphorylation in HUASMC at 100 nM treated 2 hrs before VEGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1519459Inhibition of TGF-beta-induced collagen accumulation in rat NRK-49F cells incubated for 2 days by PSR staining based microscopic analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID507225Inhibition of bFGF-induced MAPK phosphorylation in BRP treated 2 hrs before bFGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1708225Inhibition of JAK2 pathway in human TF-1 cells assessed as decrease in IL3-induced STAT5 phosphorylation preincubated for 1 hr followed by IL-3 stimulation and measured after 20 mins by immunoassay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery and Biological Evaluation of
AID624895Binding constant for MEK6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425142Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424947Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625102Binding constant for PRKD2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424988Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425175Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425036Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624866Binding constant for MLK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425008Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1654027Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in alveolar septal swelling at 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomycin challenge by hematoxylin and eosin st2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID624841Binding constant for BLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425062Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1662302Inhibition of N-terminal GST-tagged human recombinant PDGFRalpha D842I mutant expressed in baculovirus-infected Sf9 cells using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobilit2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID624969Binding constant for ROCK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397069Antitumor activity against human Caki1 cells xenografted NMRI nu/nu mouse assessed as inhibition of mean tumor volume growth at 50 mg/kg, po qd after 21 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425069Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624834Binding constant for DAPK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624775Binding constant for STK16 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424985Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624835Binding constant for ERN1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425023Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625034Binding constant for PDGFRA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624747Binding constant for SgK110 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425007Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624996Binding constant for EGFR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1519472Oral bioavailability in Sprague-Dawley rat 10 mg/kg measured upto 24 hrs2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID1425009Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625033Binding constant for PCTK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425190Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624749Binding constant for CASK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624809Binding constant for MYLK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424908Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624736Binding constant for RPS6KA5(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624852Binding constant for FES kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624766Binding constant for p38-gamma kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624957Binding constant for EPHB6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624745Binding constant for PKN1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1441674Anti-inflammatory activity in BLM-induced C57BL/6 mouse model of acute lung neutrophilic inflammation assessed as reduction in number of neutrophils in BALF at 30 mg/kg, ip qd for 7 days post BLM challenge measured on day 72017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID624923Binding constant for MAPKAPK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625107Binding constant for DMPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624837Binding constant for IRAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624855Binding constant for FRK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424924Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624929Binding constant for BRSK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425135Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425162Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1427156Antiproliferative activity against human SKOV3 cells after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
AID624836Binding constant for IKK-beta kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507243Antitumor activity against human FADU cells xenografted in NMRI nu/nu mouse assessed as reduction of Meca 32-positive cells at 100 mg/kg, po qd for 5 days by double immunofluorescence staining2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625040Binding constant for PIK3CA(E545K) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624976Binding constant for PRKX kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624767Binding constant for MERTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624746Binding constant for WEE2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625048Binding constant for PRKCD kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425093Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1662306Inhibition of c-Kit (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID397067Antitumor activity against human FADU cells xenografted NMRI nu/nu mouse assessed as inhibition of mean tumor volume growth at 10 mg/kg, po qd after 21 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID507204Inhibition of human Lyn2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625128Binding constant for CSNK1G1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425131Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507208Antiangiogenic activity in HSMEC assessed as inhibition of VEGF-induced cell proliferation by [3H]thymidine incorporation assay2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425129Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1692030Anti-fibrotic activity in C57BL/6 mouse model of bleomycin-induced lung fibrosis assessed as protection of alveolar tissue structure at 50 mg/kg, po administered for 21 days starting from day 8 post bleomycin treatment by hematoxylin and eosin staining ba2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID397086Inhibition of human GSK3-beta at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1424909Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397077Inhibition of human Lck2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425141Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624778Binding constant for ACVRL1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625008Binding constant for EPHA1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424983Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397050Inhibition of human VEGFR32009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624710Binding constant for SRMS kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625014Binding constant for PRKCE kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507252Antitumor activity against human Caki1 cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 100 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425067Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425154Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625134Binding constant for PIP5K2C kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425116Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624738Binding constant for MLCK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425181Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624845Binding constant for CDK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425128Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507202Inhibition of human Flt32008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID507238Antitumor activity against human FADU cells xenografted in NMRI nu/nu mouse assessed as reduction of tumor perfusion at 100 mg/kg, po qd for 3 days by DCE-MRI analysis2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425189Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1662358Toxicity in nu/nu mouse xenografted with human HT-29 cells assessed as effect on body weight at 100 mg/kg, po qd for 18 days2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID625022Binding constant for MUSK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425001Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624921Binding constant for MAP4K3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424898Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624998Binding constant for EGFR(G719C) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID761353Inhibition of FGFR1 (unknown origin) using poly (Glu, Tyr)4:1 as substrate by ELISA2013European journal of medicinal chemistry, Jul, Volume: 65Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
AID624930Binding constant for TNK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625032Binding constant for TRKB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624723Binding constant for CSNK1A1L kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425064Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397078Inhibition of human Lyn2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624765Binding constant for TRKC kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625017Binding constant for TIE1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1519474Antifibrotic activity against C57BL/6 mouse pulmonary fibrosis model assessed as reduction in bleomycin-iduced hydroxyproline level at 50 mg/kg, po administered for 28 days and measured on day 14 and 28 by spectrophotometry2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID624935Binding constant for FLT3(D835H) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507187Inhibition of human GST-fused VEGFR2 expressed in Sf9 insect cells after 20 mins by scintillation counting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625061Binding constant for MAP4K5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397040Inhibition of human InsR2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID625027Binding constant for MAP3K4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397082Antiangiogenic activity BRP cells assessed as inhibition of cell proliferation by [3H]thymidine incorporation assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1662357Antitumor activity against human HT-29 cells xenografted in nu/nu mouse assessed as tumour growth inhibition at 100 mg/kg, po qd for 18 days and measured twice per week by vernier caliper method2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID1424960Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624946Binding constant for BRAF kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625074Binding constant for IKK-epsilon kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424963Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625043Binding constant for PIK3CA(I800L) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625076Binding constant for PLK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625119Binding constant for CAMK1G kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424961Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624982Binding constant for ABL1(F317L)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625097Binding constant for TNNI3K kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425100Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424975Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625055Binding constant for MST1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624918Binding constant for DYRK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425086Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507250Antitumor activity against human FADU cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 25 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID507224Inhibition of VEGF-induced MAPK phosphorylation in BRP treated 2 hrs before VEGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625114Binding constant for GSK3A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507253Antitumor activity against human Caki1 cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 50 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425037Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424938Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624909Binding constant for TGFBR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1510862Inhibition of VEGFR3 (unknown origin)2019European journal of medicinal chemistry, Oct-01, Volume: 179Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.
AID1876272Inhibition of FGFR2 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID1425019Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1504563Inhibition of recombinant PDGFRbeta (unknown origin) by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID624997Binding constant for EGFR(E746-A750del) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424981Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624719Binding constant for GRK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425070Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625103Binding constant for MST4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1692021Anti-fibrotic activity in C57BL/6 mouse model of bleomycin-induced lung fibrosis assessed as reduction in collagen deposition by measuring hydroxyproline content in lung at 50 mg/kg, po administered for 30 days starting from day 1 post bleomycin treatment2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID1519486Antifibrotic activity against BLM-induced C57BL/6 mouse pulmonary fibrosis model assessed as reduction in lymphocytes in BALF at 50 mg/kg, po administered for 28 days and measured on day 282020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID624812Binding constant for SBK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625005Binding constant for EGFR(L861Q) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425094Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1427152Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system at 1 uM preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
AID625106Binding constant for MARK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1510861Inhibition of VEGFR1 (unknown origin)2019European journal of medicinal chemistry, Oct-01, Volume: 179Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.
AID397048Inhibition of human PDGFRalpha2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID625126Binding constant for TAOK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507209Antiangiogenic activity in BRP assessed as inhibition of PDGF BB-induced cell proliferation by [3H]thymidine incorporation assay2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1587789Inhibition of Rho/MRTF/SRF pathway (unknown origin) expressed in human PC3 cells assessed as reduction in Galpha12 Q231L-stimulated MRTF-selective SRE.L promoter-driven luciferase activity after overnight incubation by luminescence assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.
AID1425049Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425153Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397065Antitumor activity against human FADU cells xenografted NMRI nu/nu mouse assessed as inhibition of mean tumor volume growth at 50 mg/kg, po bid after 21 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID625120Binding constant for EPHA8 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625090Binding constant for ICK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625071Binding constant for STK39 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425005Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625124Binding constant for RET(V804M) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624856Binding constant for GSK3B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397038Antiangiogenic activity in HUVEC assessed as inhibition of VEGF-induced cell proliferation by [3H]thymidine incorporation assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID625089Binding constant for AAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397061Antiangiogenic activity against human Calu6 cells assessed as inhibition of cell proliferation by [3H]thymidine incorporation assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624789Binding constant for KIT(D816V) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424965Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625068Binding constant for NEK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625100Binding constant for NLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425055Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424916Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624958Binding constant for PIK3C2G kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624750Binding constant for PRP4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625069Binding constant for TLK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424896Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424996Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624742Binding constant for NEK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507232Inhibition of bFGF-induced MAPK phosphorylation in BRP treated 2 hrs before bFGF challenge by Western blotting in presence of 5% fetal calf serum2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624879Binding constant for PIK3CG kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424931Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397052Half life in NMRI nu/nu mouse at 50 mg/kg, po administered as single dose2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1519477Antifibrotic activity against BLM-induced C57BL/6 mouse pulmonary fibrosis model assessed as decrease in bronchioles inflammatory cell infiltration at 50 mg/kg, po administered for 28 days and measured on day 14 and 28 by HE staining based fluorescence mi2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID1662300Inhibition of GST-tagged human recombinant VEGFR1 cytoplasmic domain (781 to 1338 residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID1474637Inhibition of His6-tagged MELK catalytic domain (1 to 340 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using Bcl-GL as substrate measured after 30 mins in presence of [gamma32P]ATP by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth.
AID624965Binding constant for LZK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624764Binding constant for CLK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507254Antitumor activity against human Caki1 cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 10 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624985Binding constant for ABL1(M351T)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425060Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507231Inhibition of PDGF-BB-induced MAPK phosphorylation in BRP at 100 nM treated 2 hrs before PDGF-BB challenge by Western blotting in presence of 5% fetal calf serum2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624825Binding constant for BMPR1B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624890Binding constant for p38-beta kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397076Inhibition of human Src2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID397088Inhibition of human DYRK1A at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1424899Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625129Binding constant for HIPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624910Binding constant for TTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625137Binding constant for MEK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625023Binding constant for HIPK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425157Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624878Binding constant for PIM1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424944Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425145Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425208Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1654033Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in collagen deposition by measuring hydroxyproline content in lungs at 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomyc2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID625009Binding constant for EPHA3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624915Binding constant for PIP5K2B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425004Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424895Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624971Binding constant for DAPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624955Binding constant for EPHB3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1504576Inhibition of recombinant PDGFRalpha (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID1504567Inhibition of recombinant ABL (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID624821Binding constant for YANK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625082Binding constant for RSK4(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425207Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507197Inhibition of human EGFR2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624779Binding constant for BTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425174Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624828Binding constant for CDK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624979Binding constant for ABL1(F317I)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624762Binding constant for DLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507192Inhibition of human FGFR42008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425057Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425127Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1662301Inhibition of GST-tagged human recombinant VEGFR3 cytoplasmic domain (800 to 1297 residues) Q890H/V1128L/H1146R mutant expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID397245Inhibition of human S6K1 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1424948Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507261Antitumor activity against human PAC120 cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 100 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624806Binding constant for RPS6KA4(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624860Binding constant for VEGFR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625053Binding constant for PRKG2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624986Binding constant for ABL1(Q252H)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425028Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425046Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624734Binding constant for YANK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625109Binding constant for BIKE kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1662323Inhibition of colony formation in human MKN74 cells at 1 uM measured after 14 days by crystal violet staining-based assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID625117Binding constant for PAK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624995Binding constant for CSF1R kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424923Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625135Binding constant for ADCK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624739Binding constant for GRK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424956Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507237Inhibition of bFGF-induced apoptosis in HUASMC assessed as increase of cleaved caspase 3 level at 100 nM treated 2 hrs before bFGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425078Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624711Binding constant for STK35 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424942Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425156Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425186Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425077Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624702Binding constant for BRSK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424990Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424897Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425102Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1504599Antifibrotic activity in BLM-induced chronic pulmonary fibrosis C57 mouse model assessed as increase in survival rate at 100 mg/kg, po administered qd measured up to 28 days2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID625123Binding constant for RET(V804L) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424991Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397090Inhibition of human MAPK2 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425073Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624853Binding constant for FLT1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625003Binding constant for EGFR(L858R) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624758Binding constant for RIPK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624943Binding constant for ACVR1B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625001Binding constant for EGFR(L747-S752del, P753S) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507242Antitumor activity against human FADU cells xenografted in NMRI nu/nu mouse assessed as reduction of PDGFR-beta-positive mural cells at 100 mg/kg, po qd for 5 days by DCE-MRI analysis relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1424979Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624776Binding constant for PCTK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624889Binding constant for JNK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507201Inhibition of human CDK42008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625046Binding constant for PIK3CB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507188Inhibition of human VEGFR32008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624793Binding constant for KIT(V559D,V654A) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397042Inhibition of human CDK42009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624813Binding constant for MINK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424970Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1478069Inhibition of human VEGFR22018Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.
AID625065Binding constant for CIT kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624810Binding constant for GCN2(Kin.Dom.2,S808G) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425194Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625092Binding constant for NDR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397039Inhibition of human IGFR12009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1504573Inhibition of recombinant c-KIT (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID625045Binding constant for PIK3CA(Q546K) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425161Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507193Inhibition of human PDGFRalpha2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624937Binding constant for FLT3(ITD) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1699266Antifibrotic activity in bleomycin-induced C57BL/6N mouse model of pulmonary fibrosis assessed as reduction in lung-fibrosis at 100 mg/kg, po qd administered from 7th day post-bleomycin challenge and measured post last dose
AID397043Inhibition of human EGFR2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624933Binding constant for PLK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625016Binding constant for SRC kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507259Antitumor activity against human SKOV3 cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 50 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625079Binding constant for NEK6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625141Binding constant for RIOK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397054Clearance in NMRI nu/nu mouse at 50 mg/kg, po or 10 mg/kg, iv administered as single dose2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624940Binding constant for FLT3(R834Q) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425188Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624703Binding constant for MAPKAPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1654037Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in oxidative stress by measuring reduction in MDA level in plasma at 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomycin2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID397075Inhibition of VEGF-stimulated human VEGFR2 phosphorylation expressed in mouse NIH3T3 cells pretreated for 1 hr measured 32 hrs after drug dose by immunoprecipitation based pulse-chase experiment2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID397053AUC in NMRI nu/nu mouse at 50 mg/kg, po administered as single dose2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID625044Binding constant for PIK3CA(M1043I) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624854Binding constant for FLT4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625130Binding constant for FGFR4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507244Antitumor activity against human FADU cells xenografted in NMRI nu/nu mouse assessed as reduction of PDGFR-beta-positive mural cells at 100 mg/kg, po qd for 5 days by double immunofluorescence staining2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1504582Inhibition of recombinant RET (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID1425173Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1876273Inhibition of FGFR3 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID1424984Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424929Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424919Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425124Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624873Binding constant for PAK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507185Inhibition of human VEGFR12008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425038Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425125Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1692028Anti-fibrotic activity in C57BL/6 mouse model of bleomycin-induced lung fibrosis assessed as protection of alveolar tissue structure at 50 mg/kg, po administered for 30 days starting from day 1 post bleomycin treatment by hematoxylin and eosin staining ba2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID624704Binding constant for NEK9 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625121Binding constant for RET kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425163Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425170Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425106Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625012Binding constant for GAK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625063Binding constant for PLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425147Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397247Inhibition of human CK1 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425084Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397091Inhibition of human ERK2 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624989Binding constant for ABL1(T315I)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397092Inhibition of human MSK1 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624748Binding constant for EPHA6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425117Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624869Binding constant for NEK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624934Binding constant for FLT3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425024Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425167Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1662299Inhibition of N-terminal GST-fused human PDGFRbeta cytoplasmic domain (557 to 1106 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured a2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID507186Inhibition of mouse GST-fused VEGFR2 expressed in Sf9 insect cells after 20 mins by scintillation counting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624887Binding constant for ERK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1504581Inhibition of recombinant HCK (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID1425042Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1501092Inhibition of N-terminal GST tagged human PDGFRalpha (550 to 1089 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr 2017European journal of medicinal chemistry, Oct-20, Volume: 139Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors.
AID1424905Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625020Binding constant for ITK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625122Binding constant for RET(M918T) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425072Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625132Binding constant for FGFR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425053Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425058Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425074Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624857Binding constant for HCK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424910Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1504578Inhibition of recombinant FGR (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID625075Binding constant for INSRR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425166Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1708217Antiproliferative activity human LX2 cells assessed as inhibition of TGF-beta induced hepatic stellate cell growth incubated for upto 72 hrs by CCK8 assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery and Biological Evaluation of
AID625105Binding constant for EPHB2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424950Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424930Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624760Binding constant for PFPK5(P.falciparum) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625030Binding constant for LOK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397059Plasma concentration in NMRI nu/nu mouse at 50 mg/kg, po administered as single dose after 2 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID507251Antitumor activity against human FADU cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 10 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID761356Inhibition of PDGFRalpha (unknown origin) using poly (Glu, Tyr)4:1 as substrate by ELISA2013European journal of medicinal chemistry, Jul, Volume: 65Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
AID1425165Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1504565Inhibition of PDGFR in mouse NIH/3T3 cells assessed as reduction in recombinant human PDGF-BB-induced cell proliferation after 42 hrs by cell titer 96 aqueous one solution based assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID624831Binding constant for CHEK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625084Binding constant for HUNK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425022Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1427162Inhibition of recombinant human GST-tagged FGFR1 cytoplasmic domain (398 to 822 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
AID624720Binding constant for HIPK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507191Inhibition of human FGFR32008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425202Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507205Inhibition of human Src2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425045Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397060Plasma concentration in NMRI nu/nu mouse at 50 mg/kg, po administered as single dose after 24 hrs2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID625138Binding constant for STK33 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625133Binding constant for CDC2L2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1845299Inhibition of GST-tagged FGFR4 (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
AID507190Inhibition of human FGFR22008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425133Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1662298Inhibition of N-terminal GST fused human VEGFR2 cytoplasmic domain (790 to 1356 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured afte2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID397252Inhibition of human JNK1A1 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624826Binding constant for BMPR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624728Binding constant for NIM1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624712Binding constant for DYRK1A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1708216Antiproliferative activity human LX2 cells assessed as inhibition of TGF-beta induced hepatic stellate cells activation by CCK8 assay2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery and Biological Evaluation of
AID624730Binding constant for CAMK2A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID775337Binding affinity to human MLK32013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
AID625101Binding constant for TAOK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507222Inhibition of VEGF-induced Akt phosphorylation in HUASMC at 100 nM treated 2 hrs before VEGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425031Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624815Binding constant for ERBB4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425144Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1708218Cytotoxicity against human LX2 cells assessed as cell viability incubated for 48 hrs by YOYO1 dye based fluorescence analysis2021Journal of medicinal chemistry, 01-28, Volume: 64, Issue:2
Discovery and Biological Evaluation of
AID397085Induction of apoptosis in BRP cells assessed as caspase-3 cleavage2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1424941Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424977Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425193Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1427157Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
AID1425126Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624974Binding constant for PIK3CD kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425199Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424925Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624975Binding constant for PLK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625054Binding constant for MST2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425054Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425191Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624777Binding constant for DDR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425085Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507219Inhibition of bFGF-induced Akt phosphorylation in HUVEC at 100 nM treated 2 hrs before bFGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625096Binding constant for STK36 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425033Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425065Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625098Binding constant for IRAK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507241Antitumor activity against human FADU cells xenografted in NMRI nu/nu mouse assessed as reduction of tumor vessel density at 100 mg/kg, po qd for 5 days by DCE-MRI analysis relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624706Binding constant for MLK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425087Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624882Binding constant for PKAC-beta kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1501094Inhibition of N-terminal GST tagged human FGFR1 (398 to 822 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by mob2017European journal of medicinal chemistry, Oct-20, Volume: 139Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors.
AID507239Inhibition of VEGFR2 transfected in mouse NIH3T3 cells at 50 nM incubated for 1 hr measured after 32 hrs washout followed by VEGF stimulation for 10 mins by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624960Binding constant for RSK2(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625112Binding constant for YANK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1845297Inhibition of GST-tagged FGFR2 (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
AID1425081Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624999Binding constant for EGFR(G719S) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425050Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624715Binding constant for ERK8 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424952Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID775336Binding affinity to human FLT32013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
AID624868Binding constant for MST1R kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624807Binding constant for TNK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425051Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1587792Cytotoxicity against human PC3 cells assessed as reduction in cell viability by CellTiter-Fluor assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.
AID507240Antitumor activity against human FADU cells xenografted in NMRI nu/nu mouse assessed as reduction of tumor vascular permeability at 100 mg/kg, po qd for 3 days by DCE-MRI analysis2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624823Binding constant for MKNK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624881Binding constant for PKAC-alpha kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507206Antiangiogenic activity in HUVEC assessed as inhibition of VEGF-induced cell proliferation by [3H]thymidine incorporation assay2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425111Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624983Binding constant for ABL1(H396P)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425209Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1519491Antifibrotic activity against BLM-induced C57BL/6 mouse pulmonary fibrosis model assessed as decrease in destruction alveolar structure at 50 mg/kg, po administered for 28 days and measured on day 14 and 28 by HE staining based fluorescence microscopy2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID1501068Inhibition of N-terminal GST tagged human PDGFRbeta (557 to 1106 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr b2017European journal of medicinal chemistry, Oct-20, Volume: 139Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors.
AID624808Binding constant for TRKA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425137Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425183Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397045Inhibition of human Plk12009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID625094Binding constant for CDK11 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507227Inhibition of bFGF-induced Akt phosphorylation in BRP treated 2 hrs before bFGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1510860Inhibition of VEGFR2 (unknown origin)2019European journal of medicinal chemistry, Oct-01, Volume: 179Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.
AID397051Cmax in NMRI nu/nu mouse at 50 mg/kg, po administered as single dose2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1424889Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397244Inhibition of human SAPK2A/P38 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624753Binding constant for PKNB(M.tuberculosis) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624725Binding constant for NEK11 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424995Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624788Binding constant for KIT(D816H) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1662310Inhibition of B-Raf (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID1845298Inhibition of GST-tagged FGFR3 (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
AID397041Inhibition of human CDK12009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID625088Binding constant for ARK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624902Binding constant for MEK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425013Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425048Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507212Antiangiogenic activity in human Calu6 assessed as inhibition of cell proliferation by [3H]thymidine incorporation assay in presence of fetal calf serum2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624847Binding constant for CSNK1E kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624876Binding constant for PDPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625031Binding constant for MRCKB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425148Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425104Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624897Binding constant for RAF1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1504566Inhibition of human ERG2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID1424894Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397250Inhibition of human SAPK2B/P38-beta-2 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1654030Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in lung coefficient at 30 to 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomycin challenge2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID1425158Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425063Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624838Binding constant for ACVR2A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625024Binding constant for PRKD3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1662304Inhibition of SRC (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID1424946Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624792Binding constant for KIT(V559D,T670I) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1501070Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors.
AID624973Binding constant for JAK2(JH1domain-catalytic) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425149Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624735Binding constant for ANKK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624799Binding constant for TIE2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624713Binding constant for ERK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424967Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624732Binding constant for PYK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424953Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397070Antitumor activity against human Caki1 cells xenografted NMRI nu/nu mouse assessed as inhibition of mean tumor volume growth at 10 mg/kg, po qd after 21 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624851Binding constant for ERBB3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1427159Inhibition of recombinant human GST-tagged VEGFR1 cytoplasmic domain (781 to 1338 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
AID624829Binding constant for CDK8 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624874Binding constant for PCTK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624791Binding constant for KIT(V559D) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624942Binding constant for DRAK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397073Antitumor activity against human Calu6 cells xenografted NMRI nu/nu mouse assessed as inhibition of mean tumor volume growth at 50 mg/kg, po qd after 21 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1692007Inhibition of TGF-beta-induced collagen-1 protein expression in rat NRK-49F cells at 20 to 40 uM incubated for 24 hrs by Western blotting analysis2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID1519490Antifibrotic activity against BLM-induced C57BL/6 mouse pulmonary fibrosis model assessed as increase in time for reduction of alveoli at 50 mg/kg, po administered for 28 days and measured on day 14 and 28 by HE staining based fluorescence microscopy2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID624931Binding constant for CLK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624798Binding constant for LKB1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424976Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624954Binding constant for EPHB1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425052Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424945Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424911Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507200Inhibition of human CDK22008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625026Binding constant for MAP3K1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424922Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424921Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624705Binding constant for MYLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425012Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1519478Antifibrotic activity against BLM-induced C57BL/6 mouse pulmonary fibrosis model assessed as decrease in perivascular inflammatory cell infiltration at 50 mg/kg, po administered for 28 days and measured on day 14 and 28 by HE staining based fluorescence m2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID624718Binding constant for PFTAIRE2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397074Antitumor activity against human PAC120 cells xenografted NMRI nu/nu mouse assessed as inhibition of mean tumor volume growth at 100 mg/kg, po qd after 21 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425059Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624818Binding constant for ULK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625037Binding constant for PIK3CA(C420R) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1692008Inhibition of TGF-beta-induced alpha-SMA protein expression in rat NRK-49F cells at 20 to 40 uM incubated for 24 hrs by Western blotting analysis2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID507203Inhibition of human Lck2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1662308Inhibition of CDK4 (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID397055Volume of distribution in NMRI nu/nu mouse at 50 mg/kg, po or 10 mg/kg, iv administered as single dose2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425176Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624977Binding constant for OSR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624761Binding constant for CDC2L5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625077Binding constant for DAPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624756Binding constant for MAP4K4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624783Binding constant for FGFR3(G697C) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1427160Inhibition of recombinant human GST-tagged VEGFR3 cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
AID1662303Inhibition of N-terminal GST fused human recombinant FGFR1 cytoplasmic domain (398 to 822 (end) residues) expressed in baculovirus expression system using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition mea2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID624938Binding constant for FLT3(K663Q) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425035Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397084Induction of apoptosis in HUASMC assessed as caspase-3 cleavage2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID507210Antiangiogenic activity in HUASMC assessed as inhibition of PDGF BB-induced cell proliferation by [3H]thymidine incorporation assay2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425160Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624962Binding constant for ASK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625011Binding constant for FGR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425076Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1427153Inhibition of human N-terminal GST-tagged VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
AID624903Binding constant for SRPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425068Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425025Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425113Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625047Binding constant for AMPK-alpha2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624804Binding constant for ERBB2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425134Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624754Binding constant for NEK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425044Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507236Inhibition of bFGF-induced apoptosis in BRP assessed as increase of cleaved caspase 3 level at 100 nM treated 2 hrs before bFGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425018Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624927Binding constant for RPS6KA4(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397249Inhibition of human PKA at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID625086Binding constant for SLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624782Binding constant for FGFR3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424955Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425138Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424904Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624961Binding constant for TGFBR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625131Binding constant for FGFR2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425003Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624905Binding constant for CDKL5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1504580Inhibition of recombinant FYN (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID1424987Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425169Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424962Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425040Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624993Binding constant for ABL2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397071Antitumor activity against human HT-29 cells xenografted NMRI nu/nu mouse assessed as inhibition of mean tumor volume growth at 100 mg/kg, po qd after 21 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID507234Inhibition of bFGF-induced Akt phosphorylation in BRP at 100 nM treated 2 hrs before bFGF challenge by Western blotting in presence of 5% fetal calf serum2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624901Binding constant for RSK1(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624907Binding constant for SYK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1587829Inhibition of Rho/MRTF/SRF pathway in human primary dermal fibroblasts assessed as reduction in LPA-stimulated CTGF mRNA expression by measuring CTGF mRNA level at 10'-6 M preincubated for 72 hrs followed by LPA stimulation and measured after 1 hr by qPCR2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.
AID1504585Inhibition of recombinant LYN-A (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID397056Oral bioavailability in NMRI nu/nu mouse at 50 mg/kg administered as single dose2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID397241Inhibition of human PDK1 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425172Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507262Plasma concentration in NMRI nu/nu mouse at 50 mg/kg, po after 1 hr2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1424907Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424937Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425105Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625140Binding constant for MARK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1662305Inhibition of LYN (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID1425115Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624952Binding constant for EPHA4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425000Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625007Binding constant for EGFR(T790M) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507246Antitumor activity against human FADU cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 100 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1504574Inhibition of recombinant YES (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID625049Binding constant for PRKCH kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1504570Inhibition of recombinant BTK (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID624795Binding constant for MET(M1250T) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624785Binding constant for JAK3(JH1domain-catalytic) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425210Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424935Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425130Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624994Binding constant for AKT1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625050Binding constant for PKN2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624752Binding constant for SNRK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507211Antiangiogenic activity in human FADU assessed as inhibition of cell proliferation by [3H]thymidine incorporation assay in presence of fetal calf serum2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624786Binding constant for KIT kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425071Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625127Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625073Binding constant for SGK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624757Binding constant for PKMYT1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624832Binding constant for IKK-alpha kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625057Binding constant for TYRO3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624919Binding constant for AURKA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425151Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425108Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424890Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624920Binding constant for MRCKA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625099Binding constant for TAOK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624781Binding constant for CDK4-cyclinD3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425039Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624709Binding constant for MYLK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397251Inhibition of human SAPK3/P38gamma at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425200Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1504572Inhibition of recombinant ITK (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID1424980Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625021Binding constant for LIMK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624722Binding constant for MKK7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624803Binding constant for CHEK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425119Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424958Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425205Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1654036Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in TNF-alpha expression in plasma at 30 to 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomycin challenge by FACSCalibur 2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID397047Inhibition of human FGFR12009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425177Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625013Binding constant for LCK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624833Binding constant for CSNK1G2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1504569Inhibition of recombinant BLK (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID1425056Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1662354Intrinsic clearance in human liver microsomes2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID1425029Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425061Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424951Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1519476Antifibrotic activity against BLM-induced C57BL/6 mouse pulmonary fibrosis model assessed as decrease in bronchiolar epithelial cell shedding at 50 mg/kg, po administered for 28 days and measured on day 14 and 28 by HE staining based fluorescence microsco2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID624914Binding constant for WEE1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624987Binding constant for ABL1(Q252H)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424971Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624947Binding constant for BRAF(V600E) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425101Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424940Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507198Inhibition of human HER22008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624924Binding constant for RIPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1654035Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in IL17A expression in plasma at 30 to 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomycin challenge by FACSCalibur flow2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID507189Inhibition of human FGFR12008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1519484Antifibrotic activity against BLM-induced C57BL/6 mouse pulmonary fibrosis model assessed as reduction in total white blood cells in BALF at 50 mg/kg, po administered for 28 days and measured on day 282020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID507249Antitumor activity against human FADU cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 50 mg/kg, po qd for 2 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624908Binding constant for TEC kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624950Binding constant for DMPK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424900Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507245Antitumor activity against human FADU cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 50 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID507226Inhibition of VEGF-induced Akt phosphorylation in BRP treated 2 hrs before VEGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625070Binding constant for PFTK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625058Binding constant for VRK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1692025Anti-fibrotic activity in C57BL/6 mouse model of bleomycin-induced lung fibrosis assessed as survival rate at 50 mg/kg, po administered for 30 days starting from day 1 post bleomycin treatment2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID625083Binding constant for LATS2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425047Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624867Binding constant for MLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625004Binding constant for EGFR(L858R,T790M) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624991Binding constant for ABL1-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424893Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1692019Oral bioavailability in Sprague-Dawley rat at 5 mg/kg2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID624721Binding constant for MEK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624733Binding constant for SIK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624707Binding constant for DCAMKL3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625139Binding constant for SNARK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624716Binding constant for CSNK1D kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1504579Inhibition of recombinant FLT3 (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID1424974Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425182Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625019Binding constant for AKT3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507248Toxicity in human FADU cells xenografted in NMRI nu/nu mouse assessed weight loss at 100 mg/kg, po qd for 5 days2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625006Binding constant for EGFR(S752-I759del) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425017Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397087Inhibition of human ROCK2 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID625010Binding constant for FER kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424928Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624743Binding constant for LTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625115Binding constant for PAK6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1519485Antifibrotic activity against BLM-induced C57BL/6 mouse pulmonary fibrosis model assessed as reduction in neutrophils in BALF at 50 mg/kg, po administered for 28 days and measured on day 282020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID1504577Inhibition of recombinant FER (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID625110Binding constant for TRPM6 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625080Binding constant for EIF2AK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425089Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624900Binding constant for RSK1(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424915Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424968Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624906Binding constant for S6K1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625002Binding constant for EGFR(L747-T751del,Sins) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624849Binding constant for CSNK2A2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624858Binding constant for JAK1(JH2domain-pseudokinase) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624740Binding constant for LRRK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507217Inhibition of bFGF-induced MAPK phosphorylation in HUVEC at 100 nM treated 2 hrs before bFGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID507263Trough plasma concentration in NMRI nu/nu mouse at 50 mg/kg, po after 24 hrs2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624805Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624948Binding constant for CSK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624966Binding constant for DCAMKL1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624769Binding constant for AURKC kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624724Binding constant for TAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425164Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624774Binding constant for QSK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1501071Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors.
AID1692023Anti-fibrotic activity in C57BL/6 mouse model of bleomycin-induced lung fibrosis assessed as reduction in collagen deposition by measuring hydroxyproline content in lung at 50 mg/kg, po administered for 21 days starting from day 8 post bleomycin treatment2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID624830Binding constant for CDK9 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425026Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624770Binding constant for CAMK2D kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424892Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624780Binding constant for CDK4-cyclinD1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624904Binding constant for NEK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624899Binding constant for ROS1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425021Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1519457Inhibition of TGF-beta-induced collagen accumulation in rat NRK-49F cells at 10 uM incubated for 2 days by PSR staining based microscopic analysis relative to control2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID624859Binding constant for JAK1(JH1domain-catalytic) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624959Binding constant for MAP4K2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397089Inhibition of human PKCalpha at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624984Binding constant for ABL1(H396P)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425136Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624822Binding constant for CDKL3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424998Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1823957Antifibrotic activity against Hypo fractionated palliative 17 Gy radiotherapy-induced C57BL/6J mouse lung fibrosis model assessed as reduction in collagen deposition at 60 mg/kg, po qd administered for 25 days starting from 16 weeks post irradiation by he
AID624884Binding constant for PRKD1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624755Binding constant for ZAK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507235Inhibition of PDGF-BB-induced apoptosis in BRP assessed as increase of cleaved caspase 3 level at 100 nM treated 2 hrs before PDGF-BB challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1501066Inhibition of N-terminal biotinylated DYKDDDDK tagged human VEGFR2 (790 to 1356 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measur2017European journal of medicinal chemistry, Oct-20, Volume: 139Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors.
AID624964Binding constant for DYRK1B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507216Inhibition of VEGF-induced MAPK phosphorylation in HUVEC at 100 nM treated 2 hrs before VEGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID397254Inhibition of human PHK at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624936Binding constant for FLT3(D835Y) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624896Binding constant for PRKR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507194Inhibition of human PDGFRbeta2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624842Binding constant for BMX kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507247Toxicity in human FADU cells xenografted in NMRI nu/nu mouse assessed mortality at 100 mg/kg, po qd for 5 days2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID397068Antitumor activity against human Caki1 cells xenografted NMRI nu/nu mouse assessed as inhibition of mean tumor volume growth at 100 mg/kg, po qd after 21 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID507256Antitumor activity against rat GL-9L cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 25 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624802Binding constant for PIM3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425043Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425197Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624926Binding constant for RIOK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624944Binding constant for ALK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624913Binding constant for TYK2(JH2domain-pseudokinase) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425140Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424966Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424939Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425083Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624772Binding constant for AURKB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625059Binding constant for YSK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425206Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397049Inhibition of human VEGFR12009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425120Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1504564Inhibition of recombinant VEGFR2 (unknown origin) by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID397079Inhibition of human Flt32009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID507199Inhibition of human CDK12008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1427161Inhibition of PDGFRalpha (unknown origin) preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assay2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
AID625072Binding constant for TBK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624726Binding constant for HIPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624846Binding constant for CSNK1A1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625095Binding constant for SIK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507213Antiangiogenic activity in human HeLa assessed as inhibition of cell proliferation by [3H]thymidine incorporation assay in presence of fetal calf serum2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1662307Inhibition of CDK2 (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID1425016Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624814Binding constant for DCAMKL2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624744Binding constant for ZAP70 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624953Binding constant for EPHA7 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624956Binding constant for EPHB4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425155Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425082Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397248Inhibition of human CK2 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425090Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425079Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625041Binding constant for PIK3CA(H1047L) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424913Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625039Binding constant for PIK3CA(E545A) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625078Binding constant for SRPK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625066Binding constant for IRAK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624925Binding constant for RIPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624888Binding constant for ERK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425097Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424912Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625113Binding constant for MARK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425159Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624893Binding constant for MEK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1519458Cytotoxicity against rat NRK-49F cells assessed as cell viability at 10 uM incubated for 72 hrs by MTT assay2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID507228Inhibition of VEGF-induced apoptosis in HUVEC assessed as increase of cleaved caspase 3 level treated 2 hrs before VEGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID507257Antitumor activity against rat GL-9L cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 10 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1425171Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425179Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624741Binding constant for LRRK2(G2019S) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425121Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624872Binding constant for PAK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624731Binding constant for CAMK2G kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1501093Inhibition of N-terminal GST tagged human VEGFR3 (798 to 1298 end residues) cytoplasmic domain expressed in baculovirus expression system preincubated for 10 mins followed by fluorescein amidite-labelled peptide substrate addition measured after 1 hr by m2017European journal of medicinal chemistry, Oct-20, Volume: 139Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors.
AID624819Binding constant for ACVR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624916Binding constant for ULK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625028Binding constant for ASK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID761355Inhibition of KDR (unknown origin) using poly (Glu, Tyr)4:1 as substrate by ELISA2013European journal of medicinal chemistry, Jul, Volume: 65Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
AID1424964Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1623456Inhibition of ABCB1 in human A2780/ADR cells assessed as potentiation of daunorubicin-induced cytotoxicity measured after 72 hrs by MTT assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2.
AID624844Binding constant for CDK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507196Inhibition of human IGF1R2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624922Binding constant for CAMK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425041Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625029Binding constant for BRK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625015Binding constant for ROCK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1501069Antiproliferative activity against human A549 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Novel methyl indolinone-6-carboxylates containing an indole moiety as angiokinase inhibitors.
AID624862Binding constant for LYN kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1654034Antifibrotic activity against bleomycin-induced pulmonary fibrosis C57BL/6J mouse model assessed as reduction in IL6 expression in plasma at 30 to 60 mg/kg, po administered via gavage qd for 14 days at 3 days post bleomycin challenge by FACSCalibur flow c2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
AID625064Binding constant for PIM2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624784Binding constant for INSR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507230Induction of apoptosis in HUVEC at 50 nM by TUNEL assay (Rvb = 2%)2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625081Binding constant for RSK4(Kin.Dom.1-N-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624951Binding constant for EPHA2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624912Binding constant for TYK2(JH1domain-catalytic) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507221Inhibition of bFGF-induced MAPK phosphorylation in HUASMC at >300 nM treated 2 hrs before bFGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625042Binding constant for PIK3CA(H1047Y) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624917Binding constant for MST3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625085Binding constant for ULK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1504562Inhibition of recombinant FGFR1 (unknown origin) by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID1424902Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424972Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625111Binding constant for RIOK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424917Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624790Binding constant for KIT(L576P) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1692032Anti-fibrotic activity in C57BL/6 mouse model of bleomycin-induced lung fibrosis assessed as reduction in inflammatory cell infiltration at 50 mg/kg, po administered for 30 days starting from day 1 post bleomycin treatment by hematoxylin and eosin stainin2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID625118Binding constant for CAMK1D kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624863Binding constant for MARK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624839Binding constant for AKT2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624992Binding constant for ABL1-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1504575Inhibition of recombinant JAK3 (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID624737Binding constant for EPHA5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1692006Antimigratory activity in mouse L929 cells assessed as inhibition of TGF-beta-induced cell migration at 10 uM incubated for 24 hrs by wound healing assay2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID507258Antitumor activity against human HT-29 cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 100 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID625116Binding constant for ADCK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397064Antitumor activity against human FADU cells xenografted NMRI nu/nu mouse assessed as inhibition of mean tumor volume growth at 50 mg/kg, po qd after 21 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425034Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425032Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424920Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1504568Inhibition of recombinant ALK (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID624875Binding constant for PDGFRB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624970Binding constant for CDK5 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624871Binding constant for PAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1504571Inhibition of recombinant INSR (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID625142Binding constant for TSSK1B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624848Binding constant for CSNK2A1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624978Binding constant for ABL1(E255K)-phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624773Binding constant for AMPK-alpha1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624843Binding constant for CAMK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425143Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425103Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424949Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625062Binding constant for MAP3K2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625025Binding constant for MAK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424934Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624928Binding constant for CDKL2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425213Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624939Binding constant for FLT3(N841I) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425112Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425110Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1662309Inhibition of CHK (unknown origin) using FAM-labeled peptide and ATP as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by mobility shift assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID1424957Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507223Inhibition of bFGF-induced Akt phosphorylation in HUASMC at 100 nM treated 2 hrs before bFGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624911Binding constant for TXK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624877Binding constant for PIK3C2B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624864Binding constant for CTK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397063Antitumor activity against human FADU cells xenografted NMRI nu/nu mouse assessed as inhibition of mean tumor volume growth at 100 mg/kg, po qd after 21 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624972Binding constant for MTOR kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1823954Antifibrotic activity against intranasal bleomycin-induced C57BL/6N mouse pulmonary fibrosis model assessed as reduction in Ashcroft score at 60 mg/kg, po qd administered for 15 days starting from 7 days post induction
AID625087Binding constant for MELK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397046Antiangiogenic activity against human HeLa cells assessed as inhibition of cell proliferation by [3H]thymidine incorporation assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425178Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625125Binding constant for CLK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624963Binding constant for LATS1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397243Inhibition of human MAPKAPK2 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624988Binding constant for ABL1(T315I)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425203Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625104Binding constant for MYO3A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397246Inhibition of human SGK at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID397242Inhibition of human CHK1 at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624892Binding constant for p38-delta kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625067Binding constant for NDR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624797Binding constant for PHKG2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624883Binding constant for PRKCI kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625036Binding constant for PIK3CA kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424989Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625051Binding constant for PRKCQ kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624811Binding constant for PAK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624861Binding constant for LIMK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID507215Antiangiogenic activity in HSMEC assessed as inhibition of VEGF-induced apoptosis by [3H]thymidine incorporation assay2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1692005Inhibition of TGF-beta-induced collagen accumulation in rat NRK-49F cells incubated for 2 days by PSR staining based microscopic analysis2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID507255Antitumor activity against rat GL-9L cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 50 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID1876271Inhibition of FGFR1 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
Kinase Inhibitors as Underexplored Antiviral Agents.
AID397080Antiangiogenic activity against HMSEC assessed as inhibition of cell proliferation by [3H]thymidine incorporation assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID397072Antitumor activity against human SKOV3 cells xenografted NMRI nu/nu mouse assessed as inhibition of mean tumor volume growth at 50 mg/kg, po qd after 21 days relative to control2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID625091Binding constant for MAST1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625056Binding constant for TESK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425168Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624981Binding constant for ABL1(F317L)-non phosphorylated kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624820Binding constant for ACVR2B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424933Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425014Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1504583Inhibition of recombinant C-SRC (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID624885Binding constant for ERK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624800Binding constant for IGF1R kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425196Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625060Binding constant for CAMKK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624796Binding constant for MET(Y1235D) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1504584Inhibition of recombinant LCK (unknown origin) at 1 uM by off-chip mobility shift assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.
AID507233Inhibition of PDGF-BB-induced Akt phosphorylation in BRP at 100 nM treated 2 hrs before PDGF-BB challenge by Western blotting in presence of 5% fetal calf serum2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624727Binding constant for FYN kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425010Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425027Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624801Binding constant for MAP3K15 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625052Binding constant for PRKG1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624880Binding constant for PIK4CB kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624763Binding constant for RIPK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425198Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624817Binding constant for MYO3B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424973Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID625108Binding constant for MKNK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625038Binding constant for PIK3CA(E542K) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425123Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1692003Inhibition of TGF-beta-induced collagen accumulation in rat NRK-49F cells at 10 uM incubated for 2 days by PSR staining based microscopic analysis relative to control2020European journal of medicinal chemistry, Jul-01, Volume: 197Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway.
AID624891Binding constant for JNK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625143Binding constant for CAMKK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1845296Inhibition of GST-tagged FGFR1 (unknown origin)2021European journal of medicinal chemistry, Jan-15, Volume: 210Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
AID1424901Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425201Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624794Binding constant for MET kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425098Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424969Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507260Antitumor activity against human Calu6 cells xenografted in NMRI nu/nu mouse assessed as inhibition of tumor growth at 50 mg/kg, po qd for 5 days relative to control2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID397081Antiangiogenic activity against HUASMC assessed as inhibition of cell proliferation by [3H]thymidine incorporation assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425095Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624967Binding constant for RPS6KA5(Kin.Dom.2-C-terminal) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424997Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624729Binding constant for FAK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624816Binding constant for HPK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397253Inhibition of human SAPK4/P38delta at 10 umol/L2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1425118Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1427155Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
AID624771Binding constant for TLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1662353Half life in human liver microsomes2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.
AID1427154Inhibition of human N-terminal GST-tagged PDGFRbeta cytoplasmic domain (557 to 1106 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labeled peptide substrate addition measured after 1 hr by mobility shift assa2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors.
AID624714Binding constant for p38-alpha kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424978Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425080Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624894Binding constant for MEK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID397044Inhibition of human HER22009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1519479Antifibrotic activity against BLM-induced C57BL/6 mouse pulmonary fibrosis model assessed as decrease in bronchial epithelial vacuolar degeneration at 50 mg/kg, po administered for 28 days and measured on day 14 and 28 by HE staining based fluorescence mi2020European journal of medicinal chemistry, Jan-01, Volume: 185Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis.
AID1425192Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507229Inhibition of bFGF-induced apoptosis in HUVEC assessed as increase of cleaved caspase 3 level treated 2 hrs before bFGF challenge by Western blotting2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID397062Antiangiogenic activity against human FADU cells assessed as inhibition of cell proliferation by [3H]thymidine incorporation assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID397083Induction of apoptosis in HMSEC assessed as caspase-3 cleavage2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID624941Binding constant for CDKL1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID761354Inhibition of PDGFRbeta (unknown origin) using poly (Glu, Tyr)4:1 as substrate by ELISA2013European journal of medicinal chemistry, Jul, Volume: 65Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
AID624968Binding constant for DRAK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624886Binding constant for ERK4 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424926Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID507207Antiangiogenic activity in HUVEC assessed as inhibition of bFGF-induced cell proliferation by [3H]thymidine incorporation assay2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID507195Inhibition of human insulin receptor2008Cancer research, Jun-15, Volume: 68, Issue:12
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
AID624870Binding constant for NEK3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425204Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425006Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624850Binding constant for DDR1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625093Binding constant for TNIK kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425212Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624945Binding constant for BMPR1A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624751Binding constant for PIP5K1C kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624827Binding constant for CAMK2B kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1424918Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424994Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID397037Inhibition of human VEGFR2 expressed in Sf9 cells2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).
AID1424954Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624865Binding constant for MAP3K3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624932Binding constant for CLK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID625000Binding constant for EGFR(L747-E749del, A750P) kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425030Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1424993Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425011Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624768Binding constant for SRPK2 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1699271In-vivo inhibition of CHIT1 in bleomycin-induced C57BL/6N mouse model of pulmonary fibrosis assessed as reduction in chitinolytic activity in plasma at 100 mg/kg, po qd administered from 7th day post-bleomycin challenge and measured 24 hrs post last dose
AID624824Binding constant for PIP5K1A kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1425002Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID1425185Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
The target landscape of clinical kinase drugs.
AID624898Binding constant for GRK1 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID624949Binding constant for CSNK1G3 kinase domain2011Nature biotechnology, Oct-30, Volume: 29, Issue:11
Comprehensive analysis of kinase inhibitor selectivity.
AID1801713Competition Binding Assays from Article 10.1021/acschembio.5b01063: \\Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors.\\2016ACS chemical biology, 05-20, Volume: 11, Issue:5
Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (815)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (0.61)29.6817
2010's481 (59.02)24.3611
2020's329 (40.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials133 (15.72%)5.53%
Reviews185 (21.87%)6.00%
Case Studies46 (5.44%)4.05%
Observational11 (1.30%)0.25%
Other471 (55.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (165)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Study of BIBF1120 in Recurrent and Platinum-Sensitive Small Cell Lung Cancer (SCLC)[NCT02152059]Phase 20 participants (Actual)Interventional2014-07-31Withdrawn(stopped due to contract issues)
An Open-label, Fixed-sequence Drug-drug Interaction Study in Healthy Subjects to Evaluate the Effect of GLPG4716 on the Pharmacokinetics of Nintedanib and Pirfenidone[NCT04971746]Phase 158 participants (Actual)Interventional2021-07-19Completed
A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil®) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149[NCT01485874]Phase 111 participants (Actual)Interventional2011-11-30Terminated(stopped due to Funding withdrawn due to drug unavailability)
BARIS - BIBF1120 and RAD001 in Solid Tumors. A Phase I Trial to Evaluate the Safety and Tolerability of Combined BIBF 1120 and RAD001 in Solid Tumors and to Determine the Maximum Tolerated Dose (MTD) of the Combination[NCT01349296]Phase 118 participants (Actual)Interventional2012-07-31Completed
Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan[NCT04559581]425 participants (Actual)Observational2020-09-28Active, not recruiting
Pragmatic Management of Progressive Disease in Idiopathic Pulmonary Fibrosis: a Randomized Trial[NCT03939520]Phase 4378 participants (Anticipated)Interventional2020-06-11Recruiting
Study of Pulmonary Rehabilitation In Nintedanib Treated Patients With IPF: Improvements in Activity, Exercise Endurance Time, and QoL[NCT03717012]Phase 419 participants (Actual)Interventional2018-11-15Terminated(stopped due to The trial was terminated prematurely due to difficulties with recruitment because of the COVID-19 pandemic.)
Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan[NCT03242759]101 participants (Actual)Observational2017-08-17Completed
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)[NCT02999178]Phase 3663 participants (Actual)Interventional2017-01-17Completed
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. A National, Randomized, Multicentre Phase II Study[NCT03954782]Phase 261 participants (Actual)Interventional2020-06-22Completed
"A Prospective, Observational Study on the Correlations Between Change in Lung Function and Change in Cough and Dyspnoea in Patients With Connective Tissue Disease-associated Progressive Fibrosing INTErstitial luNg diseaSE (CTD Associated PF-ILD) Treated [NCT05503030]120 participants (Anticipated)Observational2022-11-01Recruiting
TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)[NCT01362361]Phase 254 participants (Actual)Interventional2011-06-30Completed
Phase I Dose Escalation Trial to Determine the Maximum Tolerated Dose of BIBF 1120 in Combination With Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Patients With a First, Second or Third Platinum Sensitive Relapse of Advanced Epithelial Ovaria[NCT01314105]Phase 119 participants (Actual)Interventional2011-03-31Completed
Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis[NCT02171156]0 participants Expanded AccessApproved for marketing
Safety and Pharmacokinetics/Bioavailability of a Single Dose of 150 mg BIBF 1120 Administered as Soft Gelatine Capsules With and Without Food to Healthy Male Volunteers in an Open, Randomised, Intra-individual Crossover Comparison Design[NCT02182076]Phase 115 participants (Actual)Interventional2005-10-31Completed
Metabolism and Pharmacokinetics of [14C]-BIBF 1120 After Administration of Single Doses of 100 mg [14C]-BIBF 1120 Oral Solution in Healthy Male Volunteers[NCT02182154]Phase 18 participants (Actual)Interventional2005-10-31Completed
A Phase I Open Label Dose Escalation Study of Continuous Oral Treatment With BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer[NCT02182232]Phase 133 participants (Actual)Interventional2005-06-30Completed
Phase II Study of BIBF 1120 in Recurrent Glioblastoma Multiforme[NCT01251484]Phase 225 participants (Actual)Interventional2011-01-31Completed
A Phase I Open Label Dose Escalation Study of Oral Treatment With BIBF 1120 in Combination With Standard Treatment of Paclitaxel and Carboplatin in Patients With Advanced Gynaecological Malignancies[NCT02182245]Phase 122 participants (Actual)Interventional2005-10-31Completed
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer[NCT00706628]Phase 287 participants (Actual)Interventional2006-03-31Completed
An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)[NCT03820726]Phase 3435 participants (Actual)Interventional2019-04-16Completed
An Open-label, Dose Escalation Phase I Study of the Safety and Tolerability of BIBF 1120 in Combination With Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Japanese Patients With a First, Second or Third Platinum-sensitive Relapse of Advanced Ep[NCT01329549]Phase 12 participants (Actual)Interventional2011-04-30Terminated
Real-World Medication Adherence Trajectories to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients[NCT05022784]1,500 participants (Actual)Observational2021-08-23Completed
Relative Bioavailability of 100 mg Nintedanib (Ofev®) Given as Four Capsules of 25 mg Compared to One Capsule of 100 mg Following Oral Administration in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Stud[NCT04938453]Phase 120 participants (Actual)Interventional2021-07-14Completed
Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis[NCT02230982]0 participants Expanded AccessNo longer available
Safety of Nintedanib in Real World in China: a Non-interventional Study Based on Idiopathic Pulmonary (Interstitial) Fibrosis Registry China Study (PORTRAY) Data[NCT05676112]800 participants (Anticipated)Observational2023-12-29Not yet recruiting
Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease: a Pilot Study[NCT05335278]25 participants (Anticipated)Interventional2021-06-01Recruiting
A Single-centre, Open-label, Fixed-sequence Trial to Evaluate the Impact of C21 on the Exposure of CYP1A2, CYP2C9, CYP3A4 and P-gp Substrates in Healthy Volunteers[NCT05830799]Phase 118 participants (Actual)Interventional2023-03-29Completed
LUME-Colon 2: An Open-label Randomized Phase II Study to Assess the Efficacy and Safety of Nintedanib Alone or in Combination With Capecitabine for Patients With Refractory Metastatic Colorectal Cancer[NCT02780700]Phase 21 participants (Actual)Interventional2016-07-05Terminated(stopped due to Substance discontinued)
A Double-blind, Randomised Phase II Study to Determine Efficacy and Safety of Oral Treatment With BIBF 1120 ES 250 mg Twice Daily Versus 150 mg Twice Daily in Patients Suffering From Advanced Non-small-cell Lung Cancer[NCT02182050]Phase 273 participants (Actual)Interventional2005-08-31Completed
A Phase I Open-label Dose-escalation Study of Continuous Twice-daily Oral Treatment With BIBF 1120 in Japanese Patients With Advanced Solid Tumours[NCT02182128]Phase 124 participants (Actual)Interventional2006-06-30Completed
A Phase I Open Label Dose Escalation Study of Continuous Once-daily or Twice Daily Oral Treatment With BIBF 1120 in Patients With Advanced Solid Tumours[NCT02182206]Phase 150 participants (Actual)Interventional2003-06-30Completed
Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma[NCT01669798]Phase 232 participants (Actual)Interventional2013-02-28Completed
INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF[NCT02802345]Phase 3274 participants (Actual)Interventional2016-06-30Completed
A Phase I Open Label Study of Continuous Oral Treatment With BIBF 1120 Together With Pemetrexed in Previously Treated Patients With Non-small Cell Lung Cancer[NCT02182102]Phase 126 participants (Actual)Interventional2005-09-30Completed
Safety and Tolerability of Single Rising Doses of 1 mg, 3 mg, 10 mg and 20 mg of BIBF 1120 as Intravenous Infusion (Single-blind, Placebocontrolled at Each Dose Group) and Absolute Bioavailability of 100 mg BIBF 1120 as Soft Gelatine Capsule (Intra-indivi[NCT02182258]Phase 130 participants (Actual)Interventional2009-06-30Completed
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma[NCT01225887]Phase 237 participants (Actual)Interventional2011-10-31Completed
A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium[NCT02866370]Phase 2120 participants (Anticipated)Interventional2015-04-30Recruiting
A Multicenter, Open Label, Phase I /Randomised Phase II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Oral Sorafenib for Advanced Hepatocellular Carcinoma Patients.[NCT01004003]Phase 2125 participants (Actual)Interventional2009-10-22Completed
The Effect of Multiple Oral Doses of BI 1015550 on the Pharmacokinetics of Nintedanib and Pirfenidone Administered Single Dose to Healthy Male Subjects (Open-label, Two-period, Fixed-sequence Crossover Trial)[NCT06070610]Phase 114 participants (Actual)Interventional2023-11-08Completed
Safety and Relative Bioavailability of a Single Dose of 150 mg BIBF 1120 Administered as Soft Gelatine Capsules Charge 1 Compared to BIBF 1120 Soft Gelatine Capsules Charge 2 Compared to BIBF 1120 Administered as Drinking Solution Following Oral Administr[NCT02182193]Phase 154 participants (Actual)Interventional2006-09-30Completed
Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan[NCT04325217]550 participants (Anticipated)Observational2020-04-15Recruiting
A Phase 1, Single-Center, Fixed Sequence, Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects[NCT05817240]Phase 121 participants (Actual)Interventional2023-05-03Completed
Prospective Observational Investigation of Possible Correlations Between Change in FVC and Change in Cough or Dyspnea Scores Using the Living With Pulmonary Fibrosis Questionnaire (L-PF) Between Baseline and After Approximately 52 Weeks of Nintedanib Trea[NCT04702893]108 participants (Actual)Observational2021-05-28Active, not recruiting
Phase II Monocentric Randomized Study on Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients[NCT04976036]Phase 248 participants (Anticipated)Interventional2022-05-05Recruiting
An Open Label Randomized Phase II Study of Oral Treatment With BIBF 1120 250 mg Twice Daily Versus 150 mg Twice Daily in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen[NCT02182063]Phase 281 participants (Actual)Interventional2005-11-30Completed
An Open Label Dose Escalation Study of BIBF 1120 Administered Orally for Four Weeks in Patients With Relapsed or Refractory Multiple Myeloma With Repeated Administration in Patients With Clinical Benefit[NCT02182141]Phase 117 participants (Actual)Interventional2003-04-30Completed
A Phase I Open Label Dose Escalation Study of Continuous (Except on the Days of Chemotherapy Infusion) Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer[NCT02182219]Phase 121 participants (Actual)Interventional2005-11-30Completed
Nintedanib Plus Standard of Care Immunosuppression Versus Standard of Care Immunosuppression Alone in Patients With Progressive Fibrotic Myositis Associated - Interstitial Lung Disease: A Randomized, Double-Blind, Exploratory Trial[NCT05799755]Phase 4134 participants (Anticipated)Interventional2023-08-01Recruiting
Nintedanib as Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO): a Randomized Double Blinded Phase II Study of the EORTC Lung Cancer Group[NCT02863055]Phase 237 participants (Actual)Interventional2018-02-04Active, not recruiting
Multicenter Phase II Trial of Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With no Squamous Non Small Cell Lung Cancer Refractory to First Line Chemotherapy[NCT02531737]Phase 259 participants (Actual)Interventional2015-09-30Completed
A 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pu[NCT00514683]Phase 2432 participants (Actual)Interventional2007-08-31Completed
Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study[NCT02558387]Phase 220 participants (Actual)Interventional2014-11-30Active, not recruiting
Phase I Dose Escalation Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors[NCT02835833]Phase 121 participants (Actual)Interventional2016-06-09Completed
Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Per[NCT01583322]Phase 2188 participants (Actual)Interventional2012-06-30Completed
Phase Ib, Open Label, Combination Study of Nintedanib With 5-Azacitidine in Acute Myeloid Leukemia Characterized by HOX Gene Overexpression, That Are Not Candidates of Intensive Chemotherapy[NCT03513484]Phase 144 participants (Anticipated)Interventional2018-11-14Active, not recruiting
An Open Label, Randomised Study in Healthy Participants to Investigate the Effect of AZD5055 on the Pharmacokinetics of Nintedanib.[NCT05644600]Phase 118 participants (Actual)Interventional2023-05-26Terminated(stopped due to The study was terminated as no drug-drug interactions were observed in Part-A of the study and therefore Part-B of the study was not required as per protocol.)
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cel[NCT00806819]Phase 3718 participants (Actual)Interventional2008-12-31Completed
Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis[NCT02496585]Phase 233 participants (Anticipated)Interventional2015-07-31Active, not recruiting
Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell [NCT00805194]Phase 31,314 participants (Actual)Interventional2008-12-03Completed
A Combination Phase I Open Label Dose Escalation Study of Concomitant Administration of BIBW 2992 With BIBF 1120 in Patients With Advanced Solid Tumors[NCT00730821]Phase 128 participants (Actual)Interventional2007-01-31Completed
A Phase II Open Label, Roll Over Study of the Long Term Tolerability, Safety and Efficacy of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis[NCT01170065]Phase 2198 participants (Actual)Interventional2010-06-25Completed
Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN): A Randomized, Placebo-controlled, Triple-blind Phase II Study[NCT02856867]Phase 20 participants (Actual)Interventional2016-12-31Withdrawn
Prospective Observational Investigation of Possible Correlations Between Change in FVC and Change in Cough or Dyspnea Scores Using the Living With Pulmonary Fibrosis Questionnaire (L-PF) Between Baseline and After Approximately 52 Weeks of Nintedanib Trea[NCT05151640]123 participants (Anticipated)Observational2022-09-26Recruiting
The Special Drug Use-results Survey (All-Case Surveillance) of Ofev® Capsules in Patients With Idiopathic Pulmonary Fibrosis (IPF) in Japan[NCT02607722]10,117 participants (Actual)Observational2015-08-31Completed
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer[NCT00710762]Phase 289 participants (Actual)Interventional2006-03-31Completed
A Phase 1, Open-Label, Non-Randomized, Fixed Sequence Study to Evaluate the Steady-state Pharmacokinetics of BLD-0409, Nintedanib and Pirfenidone When Administered Concurrently in Healthy Volunteers[NCT04939467]Phase 186 participants (Actual)Interventional2021-10-15Completed
Economic Burden Associated With Nintedanib Non-adherence Among Medicare Beneficiaries With IPF[NCT05870956]1,798 participants (Actual)Observational2023-05-16Completed
Extension Study to Establish Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Patients With Previous Clinical Benefit From BIBF 1120[NCT00715403]Phase 141 participants (Actual)Interventional2004-10-31Completed
A Double-blind, Randomised, Placebo-controlled (Within a Dose Group) Study to Evaluate Safety and Pharmacokinetics of Multiple Rising Doses of BIBF 1120 at 50 mg Bid (14 Days), 100 mg Bid (14 Days), and 150 mg Bid (28 Days) p.o., on Top of Standard Medica[NCT01136174]Phase 250 participants (Actual)Interventional2010-05-31Completed
Nintedanib Plus Usual Transplant Care Compared to Usual Transplant Care Alone After Single Lung Transplantation in Patients With Idiopathic Pulmonary Fibrosis: a Pilot Randomized Controlled Trial[NCT03562416]Phase 21 participants (Actual)Interventional2019-07-05Terminated(stopped due to Low enrollment)
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer[NCT00801294]Phase 246 participants (Actual)Interventional2006-07-01Completed
Phase I Study of Induction Cisplatin, Docetaxel, and Nintedanib for Stage IB-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection[NCT02225405]Phase 126 participants (Actual)Interventional2015-04-03Active, not recruiting
Multicenter, Randomised, Double-blind Phase III Trial to Investigate the Efficacy and Safety of BIBF 1120 in Combination With Carboplatin and Paclitaxel Compared to Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer[NCT01015118]Phase 31,366 participants (Actual)Interventional2009-11-17Completed
Public-interest Multicenter Umbrella Trial Based on Genetic Analysis in Korean Head and Neck Cancer and Esophageal Cancer Patient - Part 1 (HNSCC)][NCT03292250]Phase 2180 participants (Actual)Interventional2017-09-10Completed
A Single Center, Open Label Study to Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers[NCT05383131]Phase 133 participants (Actual)Interventional2021-06-23Completed
The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial[NCT04161014]Phase 2100 participants (Anticipated)Interventional2020-10-09Recruiting
A Phase I/Phase II Study of Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients[NCT06071013]Phase 1/Phase 220 participants (Anticipated)Interventional2023-09-28Not yet recruiting
An Open Label Dose Escalation Study of BIBF 1120 Administered Orally for Four Weeks in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit[NCT01951846]Phase 161 participants (Actual)Interventional2002-11-30Completed
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.[NCT00998296]Phase 170 participants (Actual)Interventional2009-10-31Completed
Expanded Access Program of OFEV® (Nintedanib) in Children and Adolescents (6- to 17-year-old) With Clinically Significant Fibrosing Interstitial Lung Disease (ILD)[NCT05624281]0 participants Expanded AccessTemporarily not available
Investigating Trends in Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF) Under Treatment With Nintedanib[NCT03710824]180 participants (Actual)Observational2019-02-28Completed
An Open-label Trial of the Long-term Safety and Tolerability of Nintedanib Per os, on Top of Standard of Care, Over at Least 2 Years, in Children and Adolescents With Clinically Significant Fibrosing Interstitial Lung Disease (InPedILD®-ON)[NCT05285982]Phase 360 participants (Anticipated)Interventional2022-04-04Recruiting
Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug Effect[NCT05195918]Phase 150 participants (Anticipated)Interventional2023-08-24Recruiting
ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer[NCT02730416]Phase 2146 participants (Actual)Interventional2016-12-12Completed
Assessment of the Dose Reduction and Discontinuation Associated With Anti-Fibrotic Medications in Patients With Idiopathic Pulmonary Fibrosis[NCT05779007]2,778 participants (Actual)Observational2023-04-18Completed
A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)[NCT01335477]Phase 3551 participants (Actual)Interventional2011-05-31Completed
A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)[NCT01335464]Phase 3515 participants (Actual)Interventional2011-04-30Completed
LUME-Lung 3: A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology[NCT01346540]Phase 116 participants (Actual)Interventional2011-04-14Completed
Nintedanib Plus Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Phase 0/1 Safety and Pharmacodynamics[NCT02619162]Phase 125 participants (Actual)Interventional2015-07-31Completed
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 in Combination With Oral BIBF 1120 in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit[NCT01022853]Phase 130 participants (Actual)Interventional2009-12-31Completed
A Randomised, Open Label, Parallel Group Phase II Study Comparing the Efficacy and Tolerability of BIBF 1120 Versus Sunitinib in Previously Untreated Patients With Renal Cell Cancer[NCT01024920]Phase 299 participants (Actual)Interventional2009-12-16Completed
A Phase I/II Study of Continuous, Concomitant Oral Treatment With BIBF 1120 and Pemetrexed - a Phase I, Open-label, Dose-escalation Study & a Phase II, 2 Arm, Randomized, Double-blind, Placebo-controlled Study in Japanese Patients With Stage IIIB/IV or Re[NCT00979576]Phase 119 participants (Actual)Interventional2009-10-31Terminated
A Phase I Study of Continuous, Concomitant Oral Treatment With BIBF 1120 and Docetaxel - a Phase I, Open-label, Dose-escalation Study in Japanese Patients With Stage IIIB/IV or Recurrent Non-small-cell Lung Cancer After Failure of Chemotherapy[NCT00876460]Phase 143 participants (Actual)Interventional2009-03-31Completed
"A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxaz[NCT02808247]Phase 280 participants (Actual)Interventional2017-07-07Terminated(stopped due to Exceed of pre-specified number of failures in the experimental arm)
A Phase I Study for Formulation Selection and Subsequent Optimization of Two Different Oral Formulations of Nintedanib in Healthy Male Subjects (Open-label, Randomised, Single-dose Study in Three Parts)[NCT05262751]Phase 121 participants (Actual)Interventional2022-03-28Completed
"Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis"[NCT04541680]Phase 3250 participants (Anticipated)Interventional2020-10-29Recruiting
A Phase I-II Study of BIBF 1120 and FOLFOX Compared to Bevacizumab and FOLFOX in First Line Metastatic Colorectal Cancer Patients[NCT00904839]Phase 2128 participants (Actual)Interventional2009-05-31Completed
A 12-week, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial Followed by a Single Active Arm Phase of 40 Weeks Evaluating the Effect of Oral Nintedanib 150 mg Twice Daily on Change in Biomarkers of Extracellular Matrix (ECM) Turnover in P[NCT02788474]Phase 4347 participants (Actual)Interventional2016-06-09Completed
A Single-arm, Open Label, Multi-center Phase I/II Trial to Assess the Safety and Efficacy of BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With AML Unfit for an Intensive Induction Therapy[NCT01488344]Phase 1/Phase 2140 participants (Anticipated)Interventional2012-03-31Active, not recruiting
A Multicentre, Retrospective Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain.[NCT03281200]172 participants (Actual)Observational2017-10-24Completed
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Chinese Patients With Chronic Fibrosing ILDs With a Progressive Phenotype[NCT05065190]Phase 381 participants (Actual)Interventional2021-11-25Active, not recruiting
A Phase 1b and Pharmacodynamic Study of Nintedanib Monotherapy for Advanced Pancreatic Cancer[NCT02902484]Phase 1/Phase 214 participants (Actual)Interventional2017-09-07Active, not recruiting
A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia[NCT02665143]Phase 225 participants (Actual)Interventional2016-07-21Completed
An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF)[NCT01619085]Phase 3752 participants (Actual)Interventional2012-06-06Completed
Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors[NCT02399215]Phase 232 participants (Actual)Interventional2015-05-15Completed
An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet®) in Combination With Nintedanib (Ofev®) in Patients With Idiopathic Pulmonary Fibrosis[NCT02598193]Phase 489 participants (Actual)Interventional2016-01-14Completed
Phase Ib Trial Of Pembrolizumab And Nintedanib[NCT02856425]Phase 1221 participants (Anticipated)Interventional2016-11-10Recruiting
LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma[NCT03287947]Phase 25 participants (Actual)Interventional2017-11-10Terminated(stopped due to Low enrollment)
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120 in Recurrent High-Grade Gliomas[NCT01380782]Phase 237 participants (Actual)Interventional2012-05-31Completed
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (HSCT)- a Multicentre Phase II Trial[NCT03805477]Phase 220 participants (Anticipated)Interventional2019-03-20Recruiting
Bioequivalence of 1 Soft Gelatine Capsule Containing 200 mg Nintedanib Compared to 2 Soft Gelatine Capsules Containing 100 mg Nintedanib Following Oral Administration in Healthy Male Subjects[NCT02572752]Phase 170 participants (Actual)Interventional2015-08-31Completed
A Phase II Trial of BIBF1120 in Patients With Advanced FGFR3 Mutated, FGFR3 Overexpressed, or FGFR3 Wild Type Urothelial Carcinoma of Urinary Bladder, Urethra, Ureter, and Renal Pelvis and Who Have Failed Platinum-based Chemotherapy[NCT02278978]Phase 2129 participants (Anticipated)Interventional2014-10-31Active, not recruiting
An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV[NCT01683682]Phase 18 participants (Actual)Interventional2013-04-30Completed
An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV[NCT01684111]Phase 17 participants (Actual)Interventional2013-06-30Completed
A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a First or Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer[NCT01658462]Phase 251 participants (Actual)Interventional2013-05-31Completed
A Phase I/II, Randomized, Open-label, Multi-centre Study of BIBF1120 + Reirradiation (R-RT) Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma[NCT01666600]Phase 1/Phase 263 participants (Actual)Interventional2012-08-31Terminated(stopped due to Interim Analysis for Feasibility)
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer[NCT03377023]Phase 1/Phase 268 participants (Actual)Interventional2018-02-02Active, not recruiting
Relative Bioavailability of Nintedanib Given Alone and in Combination With Ketoconazole at Steady State in Healthy Male Volunteers (an Open-label, Randomised, Two-way Cross-over Clinical Phase I Study)[NCT01679613]Phase 134 participants (Actual)Interventional2012-09-30Completed
A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy.[NCT01788982]Phase 2100 participants (Actual)Interventional2014-05-31Completed
A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-Negative Inflammatory Breast Cancer (IBC)[NCT02389764]Phase 210 participants (Actual)Interventional2015-06-22Terminated(stopped due to Slow Accrual)
Characteristics of IPF Patients Initiating Nintedanib, Pirfenidone or no Antifibrotic Treatment in the US[NCT03958071]13,264 participants (Actual)Observational2019-02-01Completed
An Open Label Phase I Safety run-in Trial of Oral Nintedanib Plus Docetaxel Therapy in Japanese Patients With Locally Advanced or Metastatic Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of Platinum-based First Line Chemotherapy[NCT02300298]Phase 110 participants (Actual)Interventional2014-12-24Completed
A Phase II Study Of BIBF 1120 as Second-line Treatment for Patients With Small Cell Lung Cancer[NCT01441297]Phase 224 participants (Actual)Interventional2011-12-31Completed
A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Female Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)[NCT03675581]Phase 117 participants (Actual)Interventional2018-11-08Completed
"BGOG-cx1/ENGOT-cx1: Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma."[NCT02009579]Phase 2120 participants (Actual)Interventional2014-03-31Active, not recruiting
A Multicenter, Open Label, Phase I/Randomized II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Sorafenib for Advanced Hepatocellular Carcinoma Patients in Asia.[NCT00987935]Phase 2134 participants (Actual)Interventional2009-10-31Completed
Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology - An AIO Phase Ib Trial[NCT04046614]Phase 1/Phase 256 participants (Actual)Interventional2018-05-25Active, not recruiting
Efficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled Study[NCT04338802]Phase 296 participants (Anticipated)Interventional2020-04-02Not yet recruiting
A Twelve Week, Open-label, Randomised, Parallel-group Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Oral Nintedanib in Combination With Oral Pirfenidone, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmona[NCT02579603]Phase 4105 participants (Actual)Interventional2015-10-16Completed
Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer[NCT01610869]Phase 2117 participants (Actual)Interventional2014-08-31Completed
A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer[NCT02393755]Phase 1/Phase 242 participants (Actual)Interventional2015-05-08Completed
A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Mi[NCT01979952]Phase 3113 participants (Actual)Interventional2013-11-26Completed
A Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy[NCT02452463]Phase 28 participants (Actual)Interventional2015-06-29Terminated(stopped due to low accrual)
FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens[NCT01948141]Phase 26 participants (Actual)Interventional2014-01-30Completed
Influence of Bosentan on the Pharmacokinetics of Nintedanib in Healthy Male Subjects[NCT02667704]Phase 113 participants (Actual)Interventional2016-02-29Completed
A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer[NCT02751385]Phase 12 participants (Actual)Interventional2016-05-20Terminated(stopped due to Terminated- Study halted due to low recruitment.)
A Double Blind, Randomised, Placebo-controlled Trial to Evaluate the Dose-exposure and Safety of Nintedanib Per os on Top of Standard of Care for 24 Weeks, Followed by Open Label Treatment With Nintedanib of Variable Duration, in Children and Adolescents [NCT04093024]Phase 339 participants (Actual)Interventional2019-12-03Completed
Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions[NCT05635071]Phase 2/Phase 390 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Investigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study)[NCT02606877]Phase 437 participants (Actual)Interventional2016-04-19Completed
A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.[NCT02149108]Phase 3768 participants (Actual)Interventional2014-09-25Completed
An Open Label Phase I of Oral Nintedanib Plus Weekly Docetaxel Therapy in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of Platinum -Based First Line Chemotherapy[NCT02668393]Phase 114 participants (Actual)Interventional2016-03-07Completed
Pharmacokinetics, Safety and Tolerability of Nintedanib Single Oral Dose in Male and Female Patients With Different Degrees of Hepatic Impairment (Child-Pugh Classification A and B) as Compared With Nintedanib Administration to Male and Female Healthy Sub[NCT02191865]Phase 133 participants (Actual)Interventional2014-07-31Completed
A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)[NCT02597933]Phase 3580 participants (Actual)Interventional2015-11-12Completed
A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) Recipients With Bronchiolitis Obliterans Syndrome (BOS) Grade 0p-1-2[NCT03283007]Phase 380 participants (Anticipated)Interventional2019-10-30Recruiting
An Open Label, Dose Escalation Phase I Study to Evaluate the Safety and Tolerability of Continuous Twice-daily Oral Treatment of Nintedanib in Japanese Patients With Hepatocellular Carcinoma.[NCT01594125]Phase 130 participants (Actual)Interventional2012-05-31Completed
Relative Bioavailability of a Single Oral Dose of Nintedanib Given Alone and in Combination With Multiple Oral Doses of Rifampicin in Healthy Male Volunteers (an Open-label, Two-period, Fixed Sequence Phase I Trial)[NCT01770392]Phase 126 participants (Actual)Interventional2013-01-31Completed
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis[NCT01890265]Phase 2160 participants (Actual)Interventional2013-07-30Completed
"An Open Label, 2-part, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between DWN12088 and Pirfenidone or Nintedanib in Healthy Volunteers"[NCT04888715]Phase 148 participants (Actual)Interventional2021-07-23Completed
A Study of the Efficacy and Safety of Pirfenidone vs. Nintedanib in the Treatment of Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia[NCT04856111]Phase 448 participants (Anticipated)Interventional2021-03-17Active, not recruiting
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease (PF-CMD-ILD)[NCT05067517]Phase 3160 participants (Anticipated)Interventional2021-11-30Not yet recruiting
Early Nintedanib Deployment in COVID-19 Interstitial Lung Disease[NCT04619680]Phase 4103 participants (Actual)Interventional2020-11-18Active, not recruiting
LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Pl[NCT01907100]Phase 2/Phase 3545 participants (Actual)Interventional2013-09-19Terminated
A Phase II Open Label, Follow up Study to Investigate the Long Term Tolerability and Safety of Oral BIBF 1120 on Top of Pirfenidone in Japanese Patients With Idiopathic Pulmonary Fibrosis[NCT01417156]Phase 220 participants (Actual)Interventional2011-09-30Completed
A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)[NCT03062943]Phase 230 participants (Actual)Interventional2016-12-06Completed
Phase I/II,Multicenter,Randomized,Double-blind,Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients With BRAF Wildtype Metastatic Melanoma[NCT02308553]Phase 1/Phase 233 participants (Actual)Interventional2015-03-17Completed
An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD)[NCT03313180]Phase 3444 participants (Actual)Interventional2017-11-27Completed
Phase II Trial of Nintedanib in Patients With Advanced Esophagogastric Cancer[NCT02234596]Phase 234 participants (Actual)Interventional2014-09-04Completed
Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral Nintedanib Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent, Adenocarcinoma Subtype Non-smal[NCT02231164]Phase 312 participants (Actual)Interventional2014-10-31Terminated
A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma[NCT02568449]Phase 220 participants (Actual)Interventional2016-03-15Completed
Medical Need Program With Ofev® (Nintedanib) for the Treatment of Adult Patients With Non-IPF (Idiopathic Pulmonary Fibrosis) Chronic Fibrosing Interstitial Lung Diseases (ILDs) With a Progressive Phenotype (PF-ILD's)[NCT04739150]0 participants Expanded AccessNo longer available
A Phase 1, Four-part, Fixed-sequence, Open-label Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects[NCT03363815]Phase 156 participants (Actual)Interventional2017-12-04Completed
A Phase I Trial of Combination Nab-Paclitaxel and Nintedanib or Nab-paclitaxel and Placebo in Relapsed Non-Small Cell Lung Cancer Adenocarcinoma[NCT03361319]Phase 1/Phase 20 participants (Actual)Interventional2020-07-31Withdrawn(stopped due to Withdrawal of financial support from funder)
A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)[NCT02299141]Phase 220 participants (Actual)Interventional2015-05-07Active, not recruiting
A Regulatory Required Non-interventional Study to Monitor the Safety and Effectiveness of Ofev(Nintedanib 150mg/100mg BID) in Korean Patients[NCT04525547]70 participants (Actual)Observational2021-01-13Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00514683 (37) [back to overview]Change From Baseline in SGRQ Total Score
NCT00514683 (37) [back to overview]Number of Patients With at Least One IPF Exacerbation
NCT00514683 (37) [back to overview]Change From Baseline in VC
NCT00514683 (37) [back to overview]Change From Baseline in TLC
NCT00514683 (37) [back to overview]Change From Baseline in TGV
NCT00514683 (37) [back to overview]Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Domain Score Activities
NCT00514683 (37) [back to overview]Absolute Change From Baseline in SpO2 at Rest
NCT00514683 (37) [back to overview]Change From Baseline in SGRQ Domain Score Symptoms
NCT00514683 (37) [back to overview]Change From Baseline in SGRQ Domain Score Impacts
NCT00514683 (37) [back to overview]Change From Baseline in RV
NCT00514683 (37) [back to overview]Change From Baseline in IC
NCT00514683 (37) [back to overview]Change From Baseline in Dyspnoea Rating on Borg Scale After Exercise (6-MWT)
NCT00514683 (37) [back to overview]Absolute Change From Baseline in DLCO by Categories
NCT00514683 (37) [back to overview]Absolute Change From Baseline in PaO2
NCT00514683 (37) [back to overview]Absolute Change From Baseline in PaCO2
NCT00514683 (37) [back to overview]Absolute Change From Baseline in P(A-a)O2
NCT00514683 (37) [back to overview]Absolute Change From Baseline in FVC%Pred
NCT00514683 (37) [back to overview]Absolute Change From Baseline in FVC
NCT00514683 (37) [back to overview]St George's Respiratory Questionnaire (SGRQ) Responder
NCT00514683 (37) [back to overview]Relative Change From Baseline in FVC%Pred
NCT00514683 (37) [back to overview]Relative Change From Baseline in FVC
NCT00514683 (37) [back to overview]Number of Participants With Change From Baseline in FVC by Categories
NCT00514683 (37) [back to overview]Rate of Decline in FVC
NCT00514683 (37) [back to overview]Pre-dose Plasma Concentration of Nintedanib in Plasma at Steady State on Day 365 (Cpre,ss,365) and Day 729 (Cpre,ss,729).
NCT00514683 (37) [back to overview]Occurrences of IPF Exacerbations Per Patient Per Year
NCT00514683 (37) [back to overview]Time to Progression
NCT00514683 (37) [back to overview]Absolute Change From Baseline in FEV1/FVC
NCT00514683 (37) [back to overview]Absolute Change From Baseline in Dyspnoea Rating on Borg Scale Before Exercise (6-MWT)
NCT00514683 (37) [back to overview]Absolute Change From Baseline in DLCO
NCT00514683 (37) [back to overview]Absolute Change From Baseline in Distance Walk (6-MWT)
NCT00514683 (37) [back to overview]Time to First Occurrence of IPF Exacerbation
NCT00514683 (37) [back to overview]Survival (Death Due to Respiratory Cause, and Lung-transplant Free)
NCT00514683 (37) [back to overview]Survival (All Causes of Death and Lung-transplant Free)
NCT00514683 (37) [back to overview]Absolute Change From Baseline in SpO2 at Rest by Categories
NCT00514683 (37) [back to overview]Absolute Change From Baseline in PaO2 by Categories
NCT00514683 (37) [back to overview]Absolute Change From Baseline in P(A-a) O2 by Categories
NCT00514683 (37) [back to overview]Absolute Change From Baseline in MRC Dyspnea Scale by Categories
NCT00706628 (14) [back to overview]Progression Free Rate at 24 and 48 Weeks
NCT00706628 (14) [back to overview]Duration of PSA Response
NCT00706628 (14) [back to overview]Duration of RECIST Response
NCT00706628 (14) [back to overview]Overall Survival (Time to Death)
NCT00706628 (14) [back to overview]Progression Free Rate (PFR) at 12 Weeks
NCT00706628 (14) [back to overview]Time to Progression
NCT00706628 (14) [back to overview]Time to PSA Progression
NCT00706628 (14) [back to overview]Changes in Safety Laboratory Parameters
NCT00706628 (14) [back to overview]Trough Plasma Concentrations for BIBF 1120 and BIBW 2992 for the Monotherapy
NCT00706628 (14) [back to overview]Number of Patients Showing Prostate Serum Antigen (PSA) Response
NCT00706628 (14) [back to overview]Overall Objective Response by RECIST Criteria (Version 1.0) (Complete Response [CR] or Partial Response [PR]) for Patients With Measurable Disease at 12, 24, 36 and 48 Weeks
NCT00706628 (14) [back to overview]Incidence and Worst Intensity of Adverse Events With Grading According CTCAE
NCT00706628 (14) [back to overview]RECIST Tumour Progression Rate at 12, 24, 36, and 48 Weeks
NCT00706628 (14) [back to overview]Trough Plasma Concentrations for BIBF 1120 and BIBW 2992 for the Combination Therapy
NCT00710762 (5) [back to overview]PFS Rate at 12 Weeks (After 3 Months) and 24 Weeks ( After 6 Months)
NCT00710762 (5) [back to overview]Time to Tumour Progression
NCT00710762 (5) [back to overview]Incidence and Intensity of Adverse Events With Grading According CTCAE
NCT00710762 (5) [back to overview]PFS Rate at 36 Weeks (After 9 Months)
NCT00710762 (5) [back to overview]Clinical Relevant Abnormalities for Laboratory Parameters
NCT00715403 (18) [back to overview]Difference From Baseline for Liver Enzymes
NCT00715403 (18) [back to overview]Clinically Relevant Abnormalities for Vital Signs
NCT00715403 (18) [back to overview]Difference From Baseline for Haemoglobin
NCT00715403 (18) [back to overview]Incidence and Intensity of Adverse Events With Highest CTCAE Grade 4
NCT00715403 (18) [back to overview]Pre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss)
NCT00715403 (18) [back to overview]Clinical Benefit
NCT00715403 (18) [back to overview]Confirmed Objective Response
NCT00715403 (18) [back to overview]Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1
NCT00715403 (18) [back to overview]Difference From Baseline for Bilirubin, Creatinine and Glucose
NCT00715403 (18) [back to overview]Difference From Baseline for Coagulation Parameters
NCT00715403 (18) [back to overview]Difference From Baseline for Electrolytes
NCT00715403 (18) [back to overview]Difference From Baseline for Haematology and Differentials Parameters
NCT00715403 (18) [back to overview]Unconfirmed Best Overall Response
NCT00715403 (18) [back to overview]Unconfirmed Best Objective Response
NCT00715403 (18) [back to overview]Incidence and Intensity of Adverse Events With Highest CTCAE Grade 2
NCT00715403 (18) [back to overview]Progression Free Survival
NCT00715403 (18) [back to overview]Incidence and Intensity of Adverse Events With Highest CTCAE Grade 5
NCT00715403 (18) [back to overview]Incidence and Intensity of Adverse Events With Highest CTCAE Grade 3
NCT00805194 (14) [back to overview]Disease Control
NCT00805194 (14) [back to overview]Dose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide
NCT00805194 (14) [back to overview]Duration of Confirmed Objective Tumour Response
NCT00805194 (14) [back to overview]Duration of Disease Control
NCT00805194 (14) [back to overview]Incidence and Intensity of Adverse Events
NCT00805194 (14) [back to overview]Objective Tumour Response
NCT00805194 (14) [back to overview]Quality of Life (QoL)
NCT00805194 (14) [back to overview]Time to Confirmed Objective Tumour Response
NCT00805194 (14) [back to overview]Clinical Improvement
NCT00805194 (14) [back to overview]Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review
NCT00805194 (14) [back to overview]Change From Baseline in Tumour Size
NCT00805194 (14) [back to overview]Overall Survival (Key Secondary Endpoint)
NCT00805194 (14) [back to overview]Progression Free Survival (PFS) as Assessed by Central Independent Review
NCT00805194 (14) [back to overview]Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator
NCT00806819 (14) [back to overview]Time to Confirmed Objective Tumour Response
NCT00806819 (14) [back to overview]Progression Free Survival (PFS) as Assessed by Central Independent Review
NCT00806819 (14) [back to overview]Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator
NCT00806819 (14) [back to overview]Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review
NCT00806819 (14) [back to overview]Clinical Improvement.
NCT00806819 (14) [back to overview]Dose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide
NCT00806819 (14) [back to overview]Duration of Confirmed Objective Tumour Response
NCT00806819 (14) [back to overview]Duration of Disease Control
NCT00806819 (14) [back to overview]Incidence and Intensity of Adverse Events
NCT00806819 (14) [back to overview]Objective Tumor Response
NCT00806819 (14) [back to overview]Quality of Life (QoL)
NCT00806819 (14) [back to overview]Disease Control
NCT00806819 (14) [back to overview]Overall Survival (Key Secondary Endpoint)
NCT00806819 (14) [back to overview]Change From Baseline in Tumour Size
NCT00876460 (13) [back to overview]AUC0-inf of Docetaxel in Course 2
NCT00876460 (13) [back to overview]Objective Tumor Response
NCT00876460 (13) [back to overview]AUC0-inf of Docetaxel in Course 1
NCT00876460 (13) [back to overview]Disease Control
NCT00876460 (13) [back to overview]Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 for All Courses
NCT00876460 (13) [back to overview]Time to Treatment Failure (TTF)
NCT00876460 (13) [back to overview]Progression-Free Survival (PFS)
NCT00876460 (13) [back to overview]Number of Participants Who Experienced Dose Limited Toxicity in Combination Therapy of Nintedanib and Docetaxel
NCT00876460 (13) [back to overview]Clinical Relevant Abnormalities in Laboratory Parameters
NCT00876460 (13) [back to overview]Cmax of Docetaxel in Course 2
NCT00876460 (13) [back to overview]Cmax of Docetaxel in Course 1
NCT00876460 (13) [back to overview]AUC0-inf of Nintedanib in Course 1
NCT00876460 (13) [back to overview]Cmax of Nintedanib in Course 1
NCT00904839 (15) [back to overview]Confirmed Objective Response Rate
NCT00904839 (15) [back to overview]Maximum Plasma Concentration for Nintedanib at Steady State and Normalized by the Dosing Unit Administered (Cmax,ss,Norm) (Phase I)
NCT00904839 (15) [back to overview]Maximum Tolerable Dose (MTD)
NCT00904839 (15) [back to overview]Overall Survival
NCT00904839 (15) [back to overview]Progression-free Survival (PFS)
NCT00904839 (15) [back to overview]Progression-free Survival Rate at 9 Months (PFS-9)
NCT00904839 (15) [back to overview]Quality of Life Evaluation by a Standardised Questionnaires of EORTC: EORTC-QLQ-C30 for the Change From Baseline at 9 Months of Global Health Status Scores.
NCT00904839 (15) [back to overview]Resection Rate
NCT00904839 (15) [back to overview]Unconfirmed Objective Response Rate
NCT00904839 (15) [back to overview]Incidence and Intensity of Adverse Events With Grading According CTCAE
NCT00904839 (15) [back to overview]Number of Participants for Quality of Life Evaluation by a Standardised Questionnaires of EORTC: EORTC-QLQ-CR38 for the First Use of Stoma Bag.
NCT00904839 (15) [back to overview]Percentage of Patients With Dose Limit Toxicity (DLTs) Incidence During the First Two Treatment Cycles (Phase I).
NCT00904839 (15) [back to overview]Quality of Life Evaluation by a Standardised Questionnaires of EORTC: EORTC-QLQ-CR38 for the Change From Baseline at 9 Months.
NCT00904839 (15) [back to overview]Tumor Shrinkage
NCT00904839 (15) [back to overview]Area Under the Plasma Concentration Time-curve Over 12 Hours for Nintedanib in the Dosing Interval at Steady State and Normalized by the Dosing Unit Administered (AUCtau,ss,Norm) (Phase I)
NCT00979576 (10) [back to overview]Overall Response Rate
NCT00979576 (10) [back to overview]AUC0-inf of Nintedanib
NCT00979576 (10) [back to overview]Cmax of Nintedanib
NCT00979576 (10) [back to overview]Disease Control Rate
NCT00979576 (10) [back to overview]Dose Limiting Toxicities
NCT00979576 (10) [back to overview]Duration of Disease Control
NCT00979576 (10) [back to overview]Cmax of Pemetrexed
NCT00979576 (10) [back to overview]Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 for All Courses
NCT00979576 (10) [back to overview]AUC0-inf of Pemetrexed
NCT00979576 (10) [back to overview]Number of Participants With Clinically Relevant Abnormalities in Laboratory Parameters
NCT00987935 (15) [back to overview]Progression Free Survival (PFS)
NCT00987935 (15) [back to overview]fe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib
NCT00987935 (15) [back to overview]Time to Progression (TTP) in Phase II
NCT00987935 (15) [back to overview]Time to Progression (TTP) in Phase II (Follow-up Analyses)
NCT00987935 (15) [back to overview]Incidence and Intensity of Adverse Events (AEs) Reported as the Number of Patients With AEs According to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Throughout the Treatment Period.
NCT00987935 (15) [back to overview]AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 (Metabolite of Nintedanib)
NCT00987935 (15) [back to overview]AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 Glucuronide (Metabolite of Nintedanib)
NCT00987935 (15) [back to overview]AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of Nintedanib
NCT00987935 (15) [back to overview]Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 Glucuronide in Plasma at Steady State, Normalised Values)
NCT00987935 (15) [back to overview]Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 in Plasma at Steady State, Normalised Values)
NCT00987935 (15) [back to overview]Cmax,ss,Norm (Maximum Concentration of the Nintedanib in Plasma at Steady State, Normalised Values)
NCT00987935 (15) [back to overview]Incidence of Dose Limiting Toxicity in Phase I
NCT00987935 (15) [back to overview]Maximum Tolerated Dose in Phase I
NCT00987935 (15) [back to overview]Objective Tumour Response by RECIST
NCT00987935 (15) [back to overview]Overall Survival
NCT00998296 (10) [back to overview]Disease Control (DC) During the Expansion Phase
NCT00998296 (10) [back to overview]Cpre,ss,Norm (Dose Normalized Trough Plasma Concentration of Nintedanib at Steady State)
NCT00998296 (10) [back to overview]Changes in Safety Laboratory Parameters
NCT00998296 (10) [back to overview]Trough Plasma Concentration of Afatinib at Steady State
NCT00998296 (10) [back to overview]Stable Disease for at Least 12 Weeks During the Expansion Phase
NCT00998296 (10) [back to overview]Percentage Change in the Tumour Size From Baseline During the Expansion Phase
NCT00998296 (10) [back to overview]Overall Tumour Response Rate Assessed by the Investigator According to the Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1
NCT00998296 (10) [back to overview]Objective Response (OR) During the Expansion Phase
NCT00998296 (10) [back to overview]Maximum Tolerated Dose (MTD) of Nintedanib and Afatinib Based on the Percentage of Participants Experienced Dose Limiting Toxicities
NCT00998296 (10) [back to overview]Incidence and Intensity of Adverse Events According to CTCAE (Common Toxicity Criteria Adverse Event) Version 3.0
NCT01004003 (6) [back to overview]Incidence of Dose Limiting Toxicity in Phase I
NCT01004003 (6) [back to overview]Maximum Tolerated Dose in Phase I
NCT01004003 (6) [back to overview]Overall Survival
NCT01004003 (6) [back to overview]Progression Free Survival (PFS)
NCT01004003 (6) [back to overview]Time to Progression (TTP) in Phase II
NCT01004003 (6) [back to overview]Objective Tumour Response by RECIST
NCT01015118 (9) [back to overview]Objective Response Based on Investigator Assessment
NCT01015118 (9) [back to overview]Change in Abdominal/Gastro-intestinal Symptoms Over Time
NCT01015118 (9) [back to overview]Change in Global Health Status/ Quality of Life (QoL) Scale Over Time.
NCT01015118 (9) [back to overview]Overall Survival
NCT01015118 (9) [back to overview]PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).
NCT01015118 (9) [back to overview]PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria.
NCT01015118 (9) [back to overview]PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint - Follow up Analysis).
NCT01015118 (9) [back to overview]PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint).
NCT01015118 (9) [back to overview]Time to CA-125 Tumour Marker Progression
NCT01022853 (15) [back to overview]AUC(0-6h) of Nintedanib
NCT01022853 (15) [back to overview]Number of Patients With Best Overall Response
NCT01022853 (15) [back to overview]Number of Patients With Objective Response (OR)
NCT01022853 (15) [back to overview]Progression Free Survival (PFS)
NCT01022853 (15) [back to overview]CL of Volasertib
NCT01022853 (15) [back to overview]Cmax of Nintedanib
NCT01022853 (15) [back to overview]Cmax of Volasertib
NCT01022853 (15) [back to overview]Duration of Disease Control
NCT01022853 (15) [back to overview]Maximum Tolerated Dose (MTD) of Volasertib in Combination With Nintedanib
NCT01022853 (15) [back to overview]Number of Participants With Dose Limiting Toxicities
NCT01022853 (15) [back to overview]Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD).
NCT01022853 (15) [back to overview]Number of Participants With Drug Related Adverse Events
NCT01022853 (15) [back to overview]Number of Patients With Disease Control
NCT01022853 (15) [back to overview]Tmax of Nintedanib
NCT01022853 (15) [back to overview]Vss of Volasertib
NCT01024920 (43) [back to overview]Time to Progression
NCT01024920 (43) [back to overview]Absolute Values at Baseline (Day -1) and Day 1 and Changes From Baseline to Day 1 at Each Point in Time in QRS Interval
NCT01024920 (43) [back to overview]Time to Treatment Failure
NCT01024920 (43) [back to overview]Average Time-matched Changes From Baseline in QTcF Interval Over 1 h to 12 h After Dosing on Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Absolute Values at Baseline (Day -1) and Day 15 and Changes From Baseline to Day 15 at Each Point in Time in QRS Interval
NCT01024920 (43) [back to overview]Absolute Values at Baseline (Day -1) and Day 15 and Changes From Baseline to Day 15 at Each Point in Time in PR Interval
NCT01024920 (43) [back to overview]Time-matched Change From Baseline to Day 15 in QTcF (QT Interval Corrected by the Fridericia Formula) at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
NCT01024920 (43) [back to overview]Time-matched Changes From Baseline to Day 1 in QT Interval at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
NCT01024920 (43) [back to overview]Time-matched Changes From Baseline to Day 15 in QT Interval at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
NCT01024920 (43) [back to overview]Time-Matched Heart Rate (HR) Changes From Baseline to Day 1 at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
NCT01024920 (43) [back to overview]Frequency of Patients by Clinical Electrocardiogram (ECG) Measurement Interpretation, Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Frequency of Patients With Maximum Time-Matched QT Interval (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) Change From Baseline Categorized by Magnitude of Change, Days 1 and 15
NCT01024920 (43) [back to overview]Frequency of Patients With Maximum Time-Matched QTcF Interval Change From Baseline Categorized by Magnitude of Change, Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Absolute Values at Baseline (Day -1) and Day 1 and Changes From Baseline to Day 1 at Each Point in Time in PR Interval
NCT01024920 (43) [back to overview]Number of Participants With Adverse Events Leading to Dose Reduction
NCT01024920 (43) [back to overview]Time-matched Change From Baseline to Day 1 in QTcF (QT Interval Corrected by the Fridericia Formula) at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
NCT01024920 (43) [back to overview]Duration of Hospital Stays Due to Adverse Events Requiring or Prolonging Hospitalisation
NCT01024920 (43) [back to overview]Duration of Objective Response
NCT01024920 (43) [back to overview]Number of Participants With Adverse Events Leading to Discontinuation of Trial Drug
NCT01024920 (43) [back to overview]Number of Participants With Adverse Events Requiring or Prolonging Hospitalisation
NCT01024920 (43) [back to overview]Overall Survival
NCT01024920 (43) [back to overview]Time-Matched Heart Rate (HR) Changes From Baseline to Day 15 at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)
NCT01024920 (43) [back to overview]Probability Rates of Progression-free Survival at 9 Months
NCT01024920 (43) [back to overview]Progression Free Survival (PFS)
NCT01024920 (43) [back to overview]Averaged Time-matched Changes From Baseline in QT Interval (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) Over 1 h to 12 h After Dosing on Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Averaged Time-Matched Heart Rate (HR) Change From Baseline Over 1 to 12 Hours, Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Frequency of Adverse Events Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0
NCT01024920 (43) [back to overview]Frequency of Patients With Possible Clinically Significant Abnormal Lab Values
NCT01024920 (43) [back to overview]Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QT (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) > 500 ms (Notable Prolongation), Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF >450 to 470 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF ≤450 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF> 500 Milliseconds (ms) (Notable Prolongation), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Number of Participants With New Onset of QTcF> 470 to 500 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Objective Response According to RECIST Criteria
NCT01024920 (43) [back to overview]Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Nintedanib (BIBF 1120) Plasma Concentration, Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration of Nintedanib (BIBF 1120), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Time-matched Change From Baseline in QTcF Interval (QT Interval Corrected by the Fridericia Formula) at the Time of Each Participant's Maximum Plasma Concentration of Nintedanib (BIBF 1120), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Time-Matched Change From Baseline in QTcF Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01024920 (43) [back to overview]Time-Matched Change From Baseline in QTcF Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1
NCT01136174 (23) [back to overview]Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)
NCT01136174 (23) [back to overview]Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)
NCT01136174 (23) [back to overview]Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)
NCT01136174 (23) [back to overview]Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)
NCT01136174 (23) [back to overview]Lung Function Measurement: Diffusing Capacity for Carbon Monoxide (DLco)
NCT01136174 (23) [back to overview]Lung Function Measurement: Diffusing Capacity for Carbon Monoxide Percent of Predicted (%DLco)
NCT01136174 (23) [back to overview]Lung Function Measurement: Forced Expiratory Volume in 1 Second (FEV1)
NCT01136174 (23) [back to overview]Lung Function Measurement: Forced Vital Capacity (FVC)
NCT01136174 (23) [back to overview]Lung Function Measurement: Forced Vital Capacity Percent of Predicted (%FVC)
NCT01136174 (23) [back to overview]Clinical Relevant Abnormalities in Laboratory Parameters- No Pirfenidone Background
NCT01136174 (23) [back to overview]Clinical Relevant Abnormalities in Laboratory Parameters- With Pirfenidone Background
NCT01136174 (23) [back to overview]Drug-related Adverse Events
NCT01136174 (23) [back to overview]Withdrawal Due to Adverse Event
NCT01136174 (23) [back to overview]Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT01136174 (23) [back to overview]Cmax,ss After Multiple Doses of BIBF 1120 Without Pirfenidone
NCT01136174 (23) [back to overview]Change From Baseline in Pulse Rate
NCT01136174 (23) [back to overview]Cmax,ss After Multiple Doses of BIBF 1120 With Pirfenidone
NCT01136174 (23) [back to overview]AUCτ,ss After Multiple Doses of BIBF 1120 Without Pirfenidone
NCT01136174 (23) [back to overview]AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)
NCT01136174 (23) [back to overview]AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)
NCT01136174 (23) [back to overview]AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)
NCT01136174 (23) [back to overview]AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)
NCT01136174 (23) [back to overview]AUCτ,ss After Multiple Doses of BIBF 1120 With Pirfenidone
NCT01170065 (8) [back to overview]Annual Rate of Decline in Haemoglobin Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Decrease
NCT01170065 (8) [back to overview]Incidence of Patients With at Least One Acute IPF Exacerbation Over Time
NCT01170065 (8) [back to overview]Overall Survival
NCT01170065 (8) [back to overview]Percentage of Patients With at Least One Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
NCT01170065 (8) [back to overview]Progression-Free Survival
NCT01170065 (8) [back to overview]Time to First Acute IPF Exacerbation
NCT01170065 (8) [back to overview]Percentage of Patients With at Least One Adverse Events (AEs), With Investigator Defined Drug-Related AEs, AEs Leading to Discontinuation of Trial Drug, Serious AEs
NCT01170065 (8) [back to overview]Annual Rate of Decline in Forced Vital Capacity (FVC)
NCT01225887 (5) [back to overview]Objective Tumor Response
NCT01225887 (5) [back to overview]Overall Survival
NCT01225887 (5) [back to overview]Progression Free Survival
NCT01225887 (5) [back to overview]Progression-free Survival > 6 Months
NCT01225887 (5) [back to overview]Number of Participants With Adverse Events
NCT01314105 (16) [back to overview]Maximum Measured Plasma Concentration (Cmax) of Nintedanib
NCT01314105 (16) [back to overview]Maximum Measured Plasma Concentration (Cmax) of PLD (Determined as Total Plasma Doxorubicin) During Treatment Course 1 and Course 2
NCT01314105 (16) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Nintedanib
NCT01314105 (16) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Drug Concentration (AUC0-tz) of Carboplatin (Determined as Total Platinum)
NCT01314105 (16) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carboplatin (Determined as Total Platinum)
NCT01314105 (16) [back to overview]Maximum Tolerated Dose of Nintedanib Based on the Occurrence of DLTs During Treatment Course 1
NCT01314105 (16) [back to overview]Dose Limiting Toxicities During Treatment Course 1
NCT01314105 (16) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Drug Concentration (AUC0-tz) of Carboplatin (Determined as Ultrafilterable Platinum)
NCT01314105 (16) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Drug Concentration (AUC0-tz) of Nintedanib
NCT01314105 (16) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Drug Concentration (AUC0-tz) of PLD (Determined as Total Plasma Doxorubicin) During Treatment Course 1 and Course 2
NCT01314105 (16) [back to overview]Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero Extrapolated to Infinity (AUC 0-inf) of Carboplatin During Treatment Course 1 and Course 2 (Determined as Ultrafilterable Platinum)
NCT01314105 (16) [back to overview]Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero Extrapolated to Infinity (AUC 0-inf) of PLD (Determined as Total Plasma Doxorubicin) During Treatment Course 1 and Course 2
NCT01314105 (16) [back to overview]Change From Baseline in Safety Laboratory Parameters
NCT01314105 (16) [back to overview]Incidence and Intensity of Adverse Events
NCT01314105 (16) [back to overview]Maximum Measured Plasma Concentration (Cmax) of Carboplatin (Total Platinum)
NCT01314105 (16) [back to overview]Maximum Measured Plasma Concentration (Cmax) of Carboplatin During Course 1 and Course 2 (Determined as Ultrafilterable Platinum)
NCT01335464 (29) [back to overview]Time to On-treatment Death
NCT01335464 (29) [back to overview]Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
NCT01335464 (29) [back to overview]Time to Death Over 52 Weeks
NCT01335464 (29) [back to overview]Time to Death or Lung Transplant Over 52 Weeks
NCT01335464 (29) [back to overview]Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.
NCT01335464 (29) [back to overview]Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)
NCT01335464 (29) [back to overview]Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)
NCT01335464 (29) [back to overview]Absolute Categorical Change of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold
NCT01335464 (29) [back to overview]Absolute Categorical Change of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold
NCT01335464 (29) [back to overview]Risk of an Acute IPF Exacerbation Over 52 Weeks
NCT01335464 (29) [back to overview]Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
NCT01335464 (29) [back to overview]Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
NCT01335464 (29) [back to overview]Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)
NCT01335464 (29) [back to overview]Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)
NCT01335464 (29) [back to overview]Proportion of FVC Responders Using 5% Threshold at 52 Weeks
NCT01335464 (29) [back to overview]FVC Responders Using 10% Threshold at 52 Weeks
NCT01335464 (29) [back to overview]Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks
NCT01335464 (29) [back to overview]Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)
NCT01335464 (29) [back to overview]Change From Baseline in SGRQ Symptom Score at 52 Weeks: Patient Reported Outcomes (PROs)
NCT01335464 (29) [back to overview]Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
NCT01335464 (29) [back to overview]Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
NCT01335464 (29) [back to overview]Change From Baseline in Saint-George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks
NCT01335464 (29) [back to overview]Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
NCT01335464 (29) [back to overview]Change From Baseline in Cough Symptoms Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
NCT01335464 (29) [back to overview]Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks : Patient Reported Outcomes (PROs)
NCT01335464 (29) [back to overview]Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks
NCT01335464 (29) [back to overview]Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks
NCT01335464 (29) [back to overview]Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
NCT01335464 (29) [back to overview]Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
NCT01335477 (29) [back to overview]Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks
NCT01335477 (29) [back to overview]Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
NCT01335477 (29) [back to overview]Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
NCT01335477 (29) [back to overview]Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold
NCT01335477 (29) [back to overview]Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold
NCT01335477 (29) [back to overview]Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)
NCT01335477 (29) [back to overview]Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)
NCT01335477 (29) [back to overview]Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
NCT01335477 (29) [back to overview]Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
NCT01335477 (29) [back to overview]Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks
NCT01335477 (29) [back to overview]Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
NCT01335477 (29) [back to overview]Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.
NCT01335477 (29) [back to overview]FVC Responders Using 10% Threshold at 52 Weeks
NCT01335477 (29) [back to overview]Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
NCT01335477 (29) [back to overview]Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
NCT01335477 (29) [back to overview]Risk of an Acute IPF Exacerbation Over 52 Weeks
NCT01335477 (29) [back to overview]Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.
NCT01335477 (29) [back to overview]Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
NCT01335477 (29) [back to overview]Time to Death Over 52 Weeks
NCT01335477 (29) [back to overview]Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)
NCT01335477 (29) [back to overview]Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)
NCT01335477 (29) [back to overview]Proportion of FVC Responders Using 5% Threshold at 52 Weeks
NCT01335477 (29) [back to overview]Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks
NCT01335477 (29) [back to overview]Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
NCT01335477 (29) [back to overview]Time to On-treatment Death
NCT01335477 (29) [back to overview]Time to Death or Lung Transplant Over 52 Weeks
NCT01335477 (29) [back to overview]Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
NCT01335477 (29) [back to overview]Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
NCT01335477 (29) [back to overview]Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)
NCT01346540 (3) [back to overview]Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle for the Determination of the Maximum Tolerated Dose (MTD)
NCT01346540 (3) [back to overview]Maximum Tolerated Dose (MTD) of Nintedanib Added to Cisplatin/Gemcitabine Based on the Occurrence of DLTs During Treatment Cycle 1.
NCT01346540 (3) [back to overview]Incidence of Adverse Events (AEs) According to the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.00
NCT01380782 (7) [back to overview]Time-to-tumor Progression
NCT01380782 (7) [back to overview]Proportion of Participants Experiencing Stable Disease (SD) as Their Best Radiographic Response
NCT01380782 (7) [back to overview]Overall Survival
NCT01380782 (7) [back to overview]Exploratory Objective #1: Progression-free Survival at 3- and 6-months for Participants With Recurrent Anaplastic Gliomas (AG)
NCT01380782 (7) [back to overview]6-Month Progression Free Survival
NCT01380782 (7) [back to overview]3-Month Progression Free Survival
NCT01380782 (7) [back to overview]Safety Profile as Summarized With Descriptive Statistics (Using Toxicity Data Gathered on Trial)
NCT01417156 (5) [back to overview]Percentage of Patient With First Occurrence of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF) Until Week 234.
NCT01417156 (5) [back to overview]Incidence of Overall Adverse Events
NCT01417156 (5) [back to overview]Annual Rate of Decline in Haemoglobin (Hb) Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)
NCT01417156 (5) [back to overview]Annual Rate of Decline in Forced Vital Capacity (FVC).
NCT01417156 (5) [back to overview]Acute Exacerbations of IPF: Risk (Incidence Rate) of Acute Exacerbations of IPF.
NCT01594125 (5) [back to overview]Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib
NCT01594125 (5) [back to overview]Number of Participants With Objective Tumour Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0
NCT01594125 (5) [back to overview]Time to Progression (TTP)
NCT01594125 (5) [back to overview]Progression Free Survival (PFS)
NCT01594125 (5) [back to overview]Number of Participants With Response by Alpha Fetoprotein (AFP)
NCT01619085 (1) [back to overview]Incidence of Adverse Events (AEs)
NCT01669798 (9) [back to overview]Concentration of Select Growth Factors Reported Measured in Picograms Per Milliliter as a Function of Treatment Response
NCT01669798 (9) [back to overview]Duration of Progression-Free Survival
NCT01669798 (9) [back to overview]VEGF Levels Correlated With Treatment Outcome
NCT01669798 (9) [back to overview]Concentration of VCAM-1 Reported as a Function of Treatment Response
NCT01669798 (9) [back to overview]Objective Tumor Response Based on GCIG CA-125 Criteria
NCT01669798 (9) [back to overview]Objective Tumor Response Via RECIST (Response Evaluation Criteria in Solid Tumors) 1.1
NCT01669798 (9) [back to overview]Percentage of Patients Who Survive Progression-free
NCT01669798 (9) [back to overview]Adverse Event Frequency and Severity
NCT01669798 (9) [back to overview]Concentration of Select Growth Factors Measured in Nanograms Per Milliliter Reported as a Function of Treatment Response
NCT01679613 (3) [back to overview]Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)
NCT01679613 (3) [back to overview]Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)
NCT01679613 (3) [back to overview]Maximum Measured Concentration (Cmax)
NCT01770392 (3) [back to overview]Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)
NCT01770392 (3) [back to overview]Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)
NCT01770392 (3) [back to overview]Maximum Measured Concentration (Cmax)
NCT01890265 (7) [back to overview]Number of Participants With IPF Progression Events up to Week 48
NCT01890265 (7) [back to overview]Mean Change From Baseline in the HRCT Quantitative Lung Fibrosis (QLF) Score to Week 24 and Week 48
NCT01890265 (7) [back to overview]Mean Change From Baseline in the Health-Related Quality of Life (HRQoL) Saint George's Respiratory Questionnaire (SGRQ) Domain and Total Scores to Week 24 and Week 48
NCT01890265 (7) [back to overview]Change From Baseline in FVC (Percent of Predicted FVC Value [% Predicted]) to Week 48
NCT01890265 (7) [back to overview]Number of Participants With No Decline in FVC (% Predicted) at Week 48
NCT01890265 (7) [back to overview]Number of Participants With a Respiratory-Related Hospitalization
NCT01890265 (7) [back to overview]Number of Participants With a Respiratory-Related Death
NCT01907100 (4) [back to overview]Progression-Free Survival (PFS)
NCT01907100 (4) [back to overview]Disease Control According to Modified RECIST- Investigator Assessment
NCT01907100 (4) [back to overview]Overall Survival (OS)
NCT01907100 (4) [back to overview]Objective Response According to Modified RECIST- Investigator Assessment
NCT01948141 (7) [back to overview]Tumor Response Rate
NCT01948141 (7) [back to overview]Compare the 6-month PFS Rate for Each FGFR1 Amplified Group (Low, Intermediate, and High) Versus FGFR1 Non-amplified Patients.
NCT01948141 (7) [back to overview]Compare the 6-month PFS Rate for the Entire FGFR1 Amplified Group Versus the FGFR1 Non-amplified Patients.
NCT01948141 (7) [back to overview]Incidence of Adverse Events (AEs)
NCT01948141 (7) [back to overview]6-month Progression Free Survival (PFS) Rate Within the Entire FGFR1 Amplified Group
NCT01948141 (7) [back to overview]Overall Survival (OS)
NCT01948141 (7) [back to overview]Progression Free Survival
NCT01979952 (12) [back to overview]6MWT Total Distance Walked Change From Baseline at 6 Months
NCT01979952 (12) [back to overview]Relative Change in FVC From Baseline at 6 Months
NCT01979952 (12) [back to overview]Relative Change From Baseline in High Resolution Computerized Tomography (HRCT) Quantitative Lung Fibrosis (QLF) Score at 6 Months
NCT01979952 (12) [back to overview]Effect of Six Month Delayed Treatment Onset: Relative Change From Baseline in HRCT QLF Score at 12 Months
NCT01979952 (12) [back to overview]All-cause Mortality at 6 Months
NCT01979952 (12) [back to overview]Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbations at 6 Months
NCT01979952 (12) [back to overview]Absolute Change in Forced Vital Capacity (FVC) From Baseline at 6 Months
NCT01979952 (12) [back to overview]Respiratory Hospitalizations at 6 Months
NCT01979952 (12) [back to overview]Categorical Change in FVC From Baseline at 6 Months
NCT01979952 (12) [back to overview]University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) Change From Baseline at 6 Months
NCT01979952 (12) [back to overview]St. George's Respiratory Questionnaire (SGRQ) Total Score Change From Baseline at 6 Months
NCT01979952 (12) [back to overview]Respiratory Mortality at 6 Months
NCT02149108 (4) [back to overview]Objective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment
NCT02149108 (4) [back to overview]Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment
NCT02149108 (4) [back to overview]Overall Survival (OS)
NCT02149108 (4) [back to overview]Progression-Free Survival (PFS) by Central Review Assessment
NCT02191865 (4) [back to overview]Cmax of Nintedanib
NCT02191865 (4) [back to overview]AUC (0-tz) of Nintedanib
NCT02191865 (4) [back to overview]AUC (0-inf) of Nintedanib
NCT02191865 (4) [back to overview]Number (%) of Subjects With Drug-related Adverse Events (AEs)
NCT02231164 (1) [back to overview]Disease Control According to Response Evaluation Criteria in Solid Tumours (RECIST), Version 1.1
NCT02234596 (2) [back to overview]Participants Evaluated for Toxicities
NCT02234596 (2) [back to overview]6-month Progression-free Survival (PFS)
NCT02299141 (4) [back to overview]Response Rate (RR)
NCT02299141 (4) [back to overview]Response Rate by Mutation Type
NCT02299141 (4) [back to overview]Unique Genetic Variations Associated With Extreme Responders (Both Non-responders and Responders)
NCT02299141 (4) [back to overview]Median Progression-free Survival (PFS)
NCT02300298 (7) [back to overview]AUC0-tz of Docetaxel
NCT02300298 (7) [back to overview]AUC0-infinity of Docetaxel
NCT02300298 (7) [back to overview]Maximum Measured Concentration (Cmax) of Nintedanib
NCT02300298 (7) [back to overview]Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 to Time of the Last Quantifiable Concentration (AUC0-tz)
NCT02300298 (7) [back to overview]Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity)
NCT02300298 (7) [back to overview]Cmax of Docetaxel
NCT02300298 (7) [back to overview]Number of Patients Experiencing Dose Limiting Toxicity (DLT) in Cycle 1
NCT02389764 (1) [back to overview]Safety Measures of BIBF 1120 in Terms of Type, Frequency and Severity of Adverse Event According to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 in Patients With Metastatic IBC.
NCT02393755 (5) [back to overview]To Examine the DLT
NCT02393755 (5) [back to overview]Median OS (Phase II)
NCT02393755 (5) [back to overview]Median PFS (Phase II)
NCT02393755 (5) [back to overview]Objective Response Rate
NCT02393755 (5) [back to overview]Progression Free Survival (PFS) Rate, Defined as the Proportion of Patients Who Survive Without Disease Progression Via the RECIST Version 1.1 (Phase II)
NCT02399215 (5) [back to overview]Median OS
NCT02399215 (5) [back to overview]PFS
NCT02399215 (5) [back to overview]Plasma Concentrations at Steady State (Cpre,ss) of Nintedanib at Baseline and Week 8
NCT02399215 (5) [back to overview]Change in Quality of Life Score
NCT02399215 (5) [back to overview]Clinical Response (Complete Response + Partial Response) Measured Using Standard RECISTv1.1 Criteria
NCT02452463 (6) [back to overview]Portion of Common Terminology Criteria for Adverse Events Grade 2 or Higher Radiation Pneumonitis
NCT02452463 (6) [back to overview]Changes in Radiation Pneumonitis Scores
NCT02452463 (6) [back to overview]Overall Survival
NCT02452463 (6) [back to overview]Percent Change in Pulmonary Function Tests
NCT02452463 (6) [back to overview]Progression-free Survival
NCT02452463 (6) [back to overview]Percent Changes in Overall Quality of Life and Symptom Scores
NCT02568449 (4) [back to overview]Overall Survival
NCT02568449 (4) [back to overview]Incidence of Grade 3-4 Toxicity
NCT02568449 (4) [back to overview]Number of Participants Responded (Complete Response, Partial Response, Stable Disease, Progressive Disease, Not Evaluable)
NCT02568449 (4) [back to overview]Progression-free Survival (PFS)
NCT02572752 (3) [back to overview]AUC0-inf
NCT02572752 (3) [back to overview]AUC0-tz
NCT02572752 (3) [back to overview]Cmax
NCT02579603 (3) [back to overview]Predose Plasma Concentrations at Steady State (Cpre,ss) of Pirfenidone
NCT02579603 (3) [back to overview]Percentage of Patients With On-treatment Gastrointestinal (GI) AEs (SOC GI Disorders) From Baseline to Week 12
NCT02579603 (3) [back to overview]Predose Plasma Concentrations at Steady State (Cpre,ss) of Nintedanib at Baseline, Weeks 2 and 4
NCT02597933 (12) [back to overview]Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks
NCT02597933 (12) [back to overview]Absolute Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco) in % Predicted at Week 52
NCT02597933 (12) [back to overview]Absolute Change From Baseline in Digital Ulcer Net Burden at Week 52
NCT02597933 (12) [back to overview]Absolute Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnoea Score at Week 52
NCT02597933 (12) [back to overview]Absolute Change From Baseline in FVC in mL at Week 52
NCT02597933 (12) [back to overview]Absolute Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52
NCT02597933 (12) [back to overview]Absolute Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Week 52.
NCT02597933 (12) [back to overview]Absolute Change From Baseline in the Modified Rodnan Skin Score (mRSS) at Week 52
NCT02597933 (12) [back to overview]Annual Rate of Decline in FVC in Percentage (%) Predicted Over 52 Weeks
NCT02597933 (12) [back to overview]Relative Change From Baseline [%] of mRSS at Week 52
NCT02597933 (12) [back to overview]The Percentage (%) of Responder Based on Combined Response Index in Systemic Sclerosis (CRISS) at Week 52
NCT02597933 (12) [back to overview]Time to Death
NCT02598193 (5) [back to overview]Total Number of Days From the Initiation of Combination Treatment to Discontinuation of Pirfenidone, Nintedanib, or Both Study Treatments
NCT02598193 (5) [back to overview]Total Number of Participant Days of Combination Treatment With Pirfenidone and Nintedanib
NCT02598193 (5) [back to overview]Percentage of Participants With Adverse Events and Serious Adverse Events
NCT02598193 (5) [back to overview]Percentage of Participants Who Discontinue Pirfenidone, Nintedanib, or Both Study Treatments Because of Adverse Events Before the Week 24 Visit
NCT02598193 (5) [back to overview]Percentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day
NCT02606877 (5) [back to overview]Pirfenidone-treated, Area Under the Concentration-time Curve of Pirfenidone in Plasma Over a Dosing Interval at Steady State (AUCτ,ss)
NCT02606877 (5) [back to overview]Pirfenidone-treated, Maximum Measured Concentration of Pirfenidone in Plasma at Steady State (Cmax,ss)
NCT02606877 (5) [back to overview]Treatment naïve, Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT02606877 (5) [back to overview]Treatment naïve, Maximum Measured Concentration of Nintedanib in Plasma After Single Dose Administration (Cmax).
NCT02606877 (5) [back to overview]Treatment naïve, Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz).
NCT02665143 (2) [back to overview]Incidence of Hematological Improvement (Phase 2)
NCT02665143 (2) [back to overview]Count of Patients With Treatment-Emergent Adverse Events (Phase 1)
NCT02667704 (3) [back to overview]Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Concentration (AUC0-tz)
NCT02667704 (3) [back to overview]Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity)
NCT02667704 (3) [back to overview]Maximum Measured Concentration of Nintedanib in Plasma (Cmax)
NCT02668393 (2) [back to overview]Number of Participants With Dose-limiting Toxicity (DLT) During the First Treatment Cycle
NCT02668393 (2) [back to overview]Maximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With Docetaxel
NCT02751385 (3) [back to overview]Area Under the Concentration-time Curve of the the Ethinylestradiol and Levonorgestrel in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT02751385 (3) [back to overview]Maximum Measured Concentration (Cmax) of Ethinylestradiol and Levonorgestrel
NCT02751385 (3) [back to overview]Area Under the Concentration-time Curve of the Ethinylestradiol and Levonorgestrel in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity).
NCT02780700 (5) [back to overview]Objective Response Rate (ORR)
NCT02780700 (5) [back to overview]Overall Survival (OS)
NCT02780700 (5) [back to overview]Disease Control (DC)
NCT02780700 (5) [back to overview]Percentage of Patients With Grade 3 or Worse Adverse Events
NCT02780700 (5) [back to overview]Progression Free Survival (PFS)
NCT02788474 (4) [back to overview]The Rate of Change in Blood Collagen 3 Degraded by Matrix Metalloproteinase-9 (C3M) From Baseline to Week 12
NCT02788474 (4) [back to overview]The Rate of Change in Blood Collagen 1 Degraded by Matrix Metalloproteinase-2/9/13 (C1M) From Baseline to Week 12
NCT02788474 (4) [back to overview]Percentage of Patients With Disease Progression as Defined by Absolute Forced Vital Capacity (FVC) Decline >=10% or Death Until Week 52
NCT02788474 (4) [back to overview]The Rate of Change (Slope) in Blood C-reactive Protein Degraded by Matrix Metalloproteinase-1/8 (CRPM) From Baseline to Week 12.
NCT02802345 (5) [back to overview]Change From Baseline in SGRQ Total Score at Week 24
NCT02802345 (5) [back to overview]Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score at Week 12
NCT02802345 (5) [back to overview]Percentage of Patients With On-treatment Serious Adverse Events (SAE) From Baseline to Week 24
NCT02802345 (5) [back to overview]Change From Baseline in Dyspnoea Using the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) at Week 12
NCT02802345 (5) [back to overview]Change From Baseline in Dyspnoea Using UCSD SOBQ at Week 24
NCT02999178 (20) [back to overview]Absolute Change From Baseline in L-PF Symptoms Cough Domain Score at Week 52 - Overall Population
NCT02999178 (20) [back to overview]Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 5 Percent at Week 52 - Overall Population
NCT02999178 (20) [back to overview]Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 10 Percent at Week 52 - Overall Population
NCT02999178 (20) [back to overview]Annual Rate of Decline in Forced Vital Capacity - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
NCT02999178 (20) [back to overview]Absolute Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
NCT02999178 (20) [back to overview]Annual Rate of Decline in Forced Vital Capacity - Overall Population
NCT02999178 (20) [back to overview]Absolute Change From Baseline in L-PF Symptoms Dyspnea Domain Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
NCT02999178 (20) [back to overview]Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
NCT02999178 (20) [back to overview]Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 10 Percent at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
NCT02999178 (20) [back to overview]Absolute Change From Baseline in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) Total Score at Week 52 - Overall Population
NCT02999178 (20) [back to overview]Time to First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
NCT02999178 (20) [back to overview]Time to Progression or Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
NCT02999178 (20) [back to overview]Time to Death Due to Respiratory Cause Over 52 Weeks - Overall Population
NCT02999178 (20) [back to overview]Time to First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over 52 Weeks - Overall Population
NCT02999178 (20) [back to overview]Time to Death Due to Respiratory Cause Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
NCT02999178 (20) [back to overview]Time to Death Over 52 Weeks - Overall Population
NCT02999178 (20) [back to overview]Time to Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
NCT02999178 (20) [back to overview]Time to Progression or Death Over 52 Weeks - Overall Population
NCT02999178 (20) [back to overview]Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 52 - Overall Population
NCT02999178 (20) [back to overview]Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 5 Percent at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only
NCT03242759 (19) [back to overview]Overall Survival
NCT03242759 (19) [back to overview]Time to First Acute Exacerbation of Idiopathic Pulmonary Fibrosis
NCT03242759 (19) [back to overview]Number of Participants Per Death Reason Categories
NCT03242759 (19) [back to overview]Annual Change From Baseline in Percentage of Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLco) at Week 100
NCT03242759 (19) [back to overview]Annual Change in Total Score of St. Georges Respiratory Questionnaire (SGRQ) at Week 52
NCT03242759 (19) [back to overview]Annual Change From Baseline in Percentage of Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLco) at Week 52
NCT03242759 (19) [back to overview]Annual Change in Total Score of St. Georges Respiratory Questionnaire (SGRQ) at Week 100
NCT03242759 (19) [back to overview]Annual Change in Six-Minute Walk Test (6MWT) at Week 52
NCT03242759 (19) [back to overview]Annual Change in Six-Minute Walk Test (6MWT) at Week 100
NCT03242759 (19) [back to overview]Annual Change in Score of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) at Week 52
NCT03242759 (19) [back to overview]Annual Change in Score of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) at Week 100
NCT03242759 (19) [back to overview]Annual Change From Baseline in Percentage of Predicted Total Lung Capacity (TLC) at Week 52
NCT03242759 (19) [back to overview]Annual Change From Baseline in Percentage of Predicted Total Lung Capacity (TLC) at Week 100
NCT03242759 (19) [back to overview]Annual Change From Baseline in Percentage of Predicted Oxygen Saturation (SpO2) at Week 52
NCT03242759 (19) [back to overview]Annual Change From Baseline in Percentage of Predicted Oxygen Saturation (SpO2) at Week 100
NCT03242759 (19) [back to overview]Annual Change From Baseline in Percentage of Predicted Inspiratory Capacity (IC) at Week 52
NCT03242759 (19) [back to overview]Annual Change From Baseline in Percentage of Predicted Inspiratory Capacity (IC) at Week 100
NCT03242759 (19) [back to overview]Annual Change From Baseline in Percentage of Predicted Forced Vital Capacity (FVC) at Week 52
NCT03242759 (19) [back to overview]Annual Change From Baseline in Percentage of Predicted Forced Vital Capacity (FVC) at Week 100
NCT03281200 (19) [back to overview]The Demographic Baseline Characteristics - Height at the Start of Nintedanib Therapy
NCT03281200 (19) [back to overview]The Demographic Baseline Characteristics - Age at the Time of Treatment Initiation
NCT03281200 (19) [back to overview]The Demographic Baseline Characteristics - 6-minute Walk Test
NCT03281200 (19) [back to overview]The Clinical Baseline Characteristics - Duration of the Disease
NCT03281200 (19) [back to overview]Percentage of Patients With Other Concomitant Diseases at the Time of Treatment Initiation.
NCT03281200 (19) [back to overview]The Demographic Baseline Characteristics - Body Mass Index (BMI) at the Start of Nintedanib Therapy
NCT03281200 (19) [back to overview]The Demographic Baseline Characteristics - Percentage of Patients With Smoking Habit
NCT03281200 (19) [back to overview]The Clinical Baseline Characteristics - Percentage of Patients With Usual Interstitial Pneumonia (UIP) Histopathological Pattern
NCT03281200 (19) [back to overview]The Clinical Baseline Characteristics - Percentage of Patients With UIP Radiological Pattern
NCT03281200 (19) [back to overview]The Clinical Baseline Characteristics - Percentage of Patients With the Initial Dose of OFEV®
NCT03281200 (19) [back to overview]The Clinical Baseline Characteristics - Percentage of Patients With Exacerbations
NCT03281200 (19) [back to overview]The Clinical Baseline Characteristics - Percentage of Patients With Emphysema
NCT03281200 (19) [back to overview]The Clinical Baseline Characteristics - Percentage of Patients With Dyspnoea
NCT03281200 (19) [back to overview]The Clinical Baseline Characteristics - Percentage of Patients With Concomitant Treatments
NCT03281200 (19) [back to overview]Percentage of Patients With Prevalence of Comorbidity (Concomitant Diseases) at the Time of Treatment Initiation.
NCT03281200 (19) [back to overview]Percentage of Patients Distributed Across Different Lung Function Categories Based on the Reimbursement Threshold (%FVC)
NCT03281200 (19) [back to overview]Percentage of Patients Across Different Lung Function Categories (% FVC (Forced Vital Capacity))
NCT03281200 (19) [back to overview]Percentage of Patients Across Different Lung Function Categories (% DLCO (Diffusing Capacity of the Lungs for Carbon Monoxide))
NCT03281200 (19) [back to overview]The Demographic Baseline Characteristics - Weight at the Start of Nintedanib Therapy
NCT03287947 (4) [back to overview]Disease Control Rate
NCT03287947 (4) [back to overview]Overall Survival
NCT03287947 (4) [back to overview]Progression-free Survival
NCT03287947 (4) [back to overview]Treatment Administration of Nintedanib, as Measured by Average Daily Dose of Nintedanib.
NCT03675581 (6) [back to overview]Area Under the Concentration-time Curve of Ethinylestradiol in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT03675581 (6) [back to overview]Area Under the Concentration-time Curve of Ethinylestradiol in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT03675581 (6) [back to overview]Area Under the Concentration-time Curve of Levonorgestrel in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT03675581 (6) [back to overview]Area Under the Concentration-time Curve of Levonorgestrel in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT03675581 (6) [back to overview]Maximum Measured Concentration of Ethinylestradiol in Plasma (Cmax)
NCT03675581 (6) [back to overview]Maximum Measured Concentration of Levonorgestrel in Plasma (Cmax)
NCT03717012 (13) [back to overview]Change From Baseline in the 6 Minute Walk Test (6MWD) at 24 Weeks
NCT03717012 (13) [back to overview]Absolute Categorical Change of Forced Vital Capacity (FVC)% Predicted up to 12 and 24 Weeks (Decrease by >5%, Increase by >5%, and Change Within ≤5%)
NCT03717012 (13) [back to overview]Absolute Change From Baseline of Forced Vital Capacity (FVC) % Predicted at 12 and 24 Weeks
NCT03717012 (13) [back to overview]Change From Baseline in the 6 Minute Walk Test (6MWD) at 12 Weeks
NCT03717012 (13) [back to overview]Absolute Change From Baseline in The King's Brief Interstitial Lung Disease (KBILD) Questionnaire Total Score at 12 and 24 Weeks
NCT03717012 (13) [back to overview]Absolute Categorical Change of Forced Vital Capacity (FVC)% Predicted up to 12 and 24 Weeks (Decrease by >10%, Increase by >10%, and Change Within ≤10%)
NCT03717012 (13) [back to overview]Relative Change From Baseline of Forced Vital Capacity (FVC) at 12 and 24 Weeks
NCT03717012 (13) [back to overview]Relative Change From Baseline of Forced Vital Capacity (FVC) % Predicted at 12 and 24 Weeks
NCT03717012 (13) [back to overview]Change From Baseline in the University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) Total Score at 12 and 24 Weeks
NCT03717012 (13) [back to overview]Change From Baseline in the St George's Respiratory Questionnaire (SGRQ) Total Score at 12 and 24 Weeks
NCT03717012 (13) [back to overview]Change From Baseline in Daily Accelerometer Activity From Baseline at 12 and 24 Weeks: Score of Average Vector Magnitude Units (VMU)/Day
NCT03717012 (13) [back to overview]Change From Baseline in Daily Accelerometer Activity From Baseline at 12 and 24 Weeks: Score of Average Steps/Day
NCT03717012 (13) [back to overview]Absolute Change From Baseline of Forced Vital Capacity (FVC) at 12 and 24 Weeks
NCT03820726 (1) [back to overview]Number of Participants With Any Adverse Events
NCT03958071 (6) [back to overview]Odds Ratio of Receiving Treatment (Nintedanib or Pirfenidone) vs no Treatment
NCT03958071 (6) [back to overview]Baseline Patient Characteristics: Number of Participants Using Proton Pump Inhibitors at Baseline
NCT03958071 (6) [back to overview]Baseline Patient Characteristics: Number of Participants Using Inhaled Corticosteroids at Baseline
NCT03958071 (6) [back to overview]Baseline Patient Characteristics: Charlson Comorbidity Index (CCI)
NCT03958071 (6) [back to overview]Baseline Patient Characteristics: BMI
NCT03958071 (6) [back to overview]Baseline Patient Characteristics: Age
NCT04093024 (31) [back to overview]Absolute Change From Baseline in 6 Minutes (Min) Walk Distance at Week 52
NCT04093024 (31) [back to overview]Absolute Change From Baseline in 6 Minutes (Min) Walk Distance at Week 24
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Leg Length at Week 52 - Left
NCT04093024 (31) [back to overview]Number of Participants With at Least One Treatment-emergent Pathological Findings on Dental Examination or Imaging up to Week 52
NCT04093024 (31) [back to overview]Number of Participants With Treatment-emergent Pathological Findings on Dental Examination or Imaging up to Week 24
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Oxygen Saturation (SpO₂) on Room Air at Rest at Week 52
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Oxygen Saturation (SpO₂) on Room Air at Rest at Week 24
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Forced Vital Capacity (FVC) % Predicted at Week 52
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Leg Length at Week 76 - Right
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 24 - Participant Report
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Leg Length at Week 76 - Left
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Leg Length at Week 52 - Right
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Leg Length at Week 24 - Right
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Leg Length at Week 24 - Left
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Height at Week 52
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Height at Week 24
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Forced Vital Capacity (FVC) % Predicted at Week 24
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 52 - Parent Report
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 52 - Participant Report
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Sitting Height at Week 24
NCT04093024 (31) [back to overview]Area Under the Plasma Concentration-time Curve at Steady State (AUCτ,ss) Based on Sampling at Steady State (at Week 2 and Week 26)
NCT04093024 (31) [back to overview]Number of Participants With Occurrence of Death Over the Whole Trial
NCT04093024 (31) [back to overview]Number of Participants With Occurrence of First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over the Whole Trial
NCT04093024 (31) [back to overview]Number of Participants With Occurrence of First Respiratory-related Hospitalization Over the Whole Trial
NCT04093024 (31) [back to overview]Number of Participants With Treatment-emergent Adverse Events During the Double-blind Period
NCT04093024 (31) [back to overview]Number of Participants With Treatment-emergent Adverse Events Over the Whole Trial
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Height at Week 76
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Sitting Height at Week 52
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Sitting Height at Week 76
NCT04093024 (31) [back to overview]Number of Participants With at Least One Treatment-emergent Pathological Finding of Epiphyseal Growth Plate on Imaging up to Week 24, and Week 52
NCT04093024 (31) [back to overview]Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 24 - Parent Report
NCT04938453 (3) [back to overview]Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT04938453 (3) [back to overview]Maximum Measured Concentration of Nintedanib in Plasma (Cmax)
NCT04938453 (3) [back to overview]Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Change From Baseline in SGRQ Total Score

"Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) total score. Total score is defined as sum of the three domain scores symptoms, activities and impacts. Scores range from 0 to 100, with higher scores indicating worst possible health status.~Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region." (NCT00514683)
Timeframe: Baseline and 52 weeks

Interventionunits on a scale (Mean)
Placebo5.46
Nintedanib 50 qd4.67
Nintedanib 50 Bid2.18
Nintedanib 100 Bid1.48
Nintedanib 150 Bid-0.66

[back to top]

Number of Patients With at Least One IPF Exacerbation

Number of patients with at least one Idiopathic Pulmonary Fibrosis (IPF) exacerbation at 52 weeks (NCT00514683)
Timeframe: 52 weeks

Interventionparticipants (Number)
Placebo12
Nintedanib 50 qd10
Nintedanib 50 Bid10
Nintedanib 100 Bid6
Nintedanib 150 Bid2

[back to top]

Change From Baseline in VC

Change from baseline in Vital capacity (VC) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region. (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionLiters (Mean)
Placebo-0.191
Nintedanib 50 qd-0.095
Nintedanib 50 Bid-0.107
Nintedanib 100 Bid-0.082
Nintedanib 150 Bid0.010

[back to top]

Change From Baseline in TLC

Change from Baseline in Total Lung Capacity (TLC) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region. (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionLiters (Mean)
Placebo-0.240
Nintedanib 50 qd-0.218
Nintedanib 50 Bid-0.100
Nintedanib 100 Bid-0.082
Nintedanib 150 Bid0.118

[back to top]

Change From Baseline in TGV

Change from Baseline in Thoracic gas volume (TGV) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region. (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionLiters (Mean)
Placebo-0.137
Nintedanib 50 qd-0.075
Nintedanib 50 Bid-0.035
Nintedanib 100 Bid-0.016
Nintedanib 150 Bid0.200

[back to top]

Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Domain Score Activities

"Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) domain score activities. Scores range from 0 to 100, with higher scores indicating worst possible health status.~Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region." (NCT00514683)
Timeframe: Baseline and 52 weeks

Interventionunits on a scale (Mean)
Placebo7.48
Nintedanib 50 qd7.39
Nintedanib 50 Bid3.54
Nintedanib 100 Bid3.00
Nintedanib 150 Bid0.32

[back to top]

Absolute Change From Baseline in SpO2 at Rest

"Absolute change from baseline in oxygen saturation (SpO2) at rest.~Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region." (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionPercentage of SpO2 (Mean)
Placebo-1.29
Nintedanib 50 qd-0.86
Nintedanib 50 Bid-0.97
Nintedanib 100 Bid0.06
Nintedanib 150 Bid-0.18

[back to top]

Change From Baseline in SGRQ Domain Score Symptoms

"Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) domain score symptoms. Scores range from 0 to 100, with higher scores indicating more limitations.~Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region." (NCT00514683)
Timeframe: Baseline and 52 weeks

Interventionunits on a scale (Mean)
Placebo6.45
Nintedanib 50 qd3.39
Nintedanib 50 Bid2.11
Nintedanib 100 Bid2.33
Nintedanib 150 Bid-3.14

[back to top]

Change From Baseline in SGRQ Domain Score Impacts

"Change from baseline in Saint George's Respiratory Questionnaire (SGRQ) domain score impacts. Scores range from 0 to 100, with higher scores indicating worst possible health status.~Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region." (NCT00514683)
Timeframe: Baseline and 52 weeks

Interventionunits on a scale (Mean)
Placebo4.21
Nintedanib 50 qd3.71
Nintedanib 50 Bid1.73
Nintedanib 100 Bid0.79
Nintedanib 150 Bid-0.14

[back to top]

Change From Baseline in RV

Change from Baseline in Residual volume (RV) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region. (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionLiters (Mean)
Placebo-0.036
Nintedanib 50 qd-0.056
Nintedanib 50 Bid0.029
Nintedanib 100 Bid-0.012
Nintedanib 150 Bid0.086

[back to top]

Change From Baseline in IC

Change from Baseline in Inspiratory Capacity (IC) at 52 weeks. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region. (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionLiters (Mean)
Placebo-0.031
Nintedanib 50 qd-0.064
Nintedanib 50 Bid-0.053
Nintedanib 100 Bid-0.038
Nintedanib 150 Bid-0.012

[back to top]

Change From Baseline in Dyspnoea Rating on Borg Scale After Exercise (6-MWT)

"Change from baseline in Dyspnoea rating after exercise (6-MWT) at 52 weeks based on Borg scale as mentioned below :~0: Nothing at all, 0.5: Very, very slight (just noticable), 1: Very slight, 2: Slight (light), 3: Moderate, 4: Somewhat severe, 5: Severe (heavy), 6, 7:Very severe, 8, 9, 10: Very, very severe (Maximal).~The 6-Minutes Walk Test (6-MWT) was conducted according to the ATS Criteria. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region." (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionUnits on a scale (Mean)
Placebo0.527
Nintedanib 50 qd0.639
Nintedanib 50 Bid0.449
Nintedanib 100 Bid0.377
Nintedanib 150 Bid0.194

[back to top]

Absolute Change From Baseline in DLCO by Categories

"Absolute change from baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) by below mentioned categories:~Decrease > 15% or > 1~Change <= 15% or <= 1~Increase > 15% or > 1" (NCT00514683)
Timeframe: Baseline and 52 weeks

,,,,
Interventionpercentage of patients (Number)
Decrease > 15% or > 1Change <= 15% or <= 1Increase > 15% or > 1
Nintedanib 100 Bid35.856.87.4
Nintedanib 150 Bid50.744.94.3
Nintedanib 50 Bid43.851.35.0
Nintedanib 50 qd38.251.510.3
Placebo37.358.74.0

[back to top]

Absolute Change From Baseline in PaO2

Absolute change from baseline in Arterial oxygen partial pressure (PaO2) at week 52. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region. (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionmmHg (Mean)
Placebo-1.69
Nintedanib 50 qd-2.77
Nintedanib 50 Bid-3.00
Nintedanib 100 Bid-1.46
Nintedanib 150 Bid-0.76

[back to top]

Absolute Change From Baseline in PaCO2

Absolute change from baseline in Arterial carbon dioxyde partial pressure (PaCO2) at week 52. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region. (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionmmHg (Mean)
Placebo-0.63
Nintedanib 50 qd0.16
Nintedanib 50 Bid-0.44
Nintedanib 100 Bid-0.74
Nintedanib 150 Bid-0.77

[back to top]

Absolute Change From Baseline in P(A-a)O2

Absolute change from baseline in Alveolo-arterial oxygen gradient (P(A-a)O2) at week 52. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region. (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionmmHg (Mean)
Placebo1.21
Nintedanib 50 qd1.27
Nintedanib 50 Bid2.22
Nintedanib 100 Bid1.62
Nintedanib 150 Bid2.56

[back to top]

Absolute Change From Baseline in FVC%Pred

"Change from baseline in percentage of predicted Forced Vital Capacity (FVC%pred) at 52 weeks.~Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region." (NCT00514683)
Timeframe: Baseline and 52 weeks

Interventionpercentage of predicted FVC (Mean)
Placebo-6.00
Nintedanib 50 qd-4.58
Nintedanib 50 Bid-4.90
Nintedanib 100 Bid-3.15
Nintedanib 150 Bid-1.04

[back to top]

Absolute Change From Baseline in FVC

"Change from baseline in percentage of absolute Forced Vital Capacity (FVC) at 52 weeks.~Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region." (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionLiters (Mean)
Placebo-0.23
Nintedanib 50 qd-0.18
Nintedanib 50 Bid-0.19
Nintedanib 100 Bid-0.13
Nintedanib 150 Bid-0.06

[back to top]

St George's Respiratory Questionnaire (SGRQ) Responder

St George's Respiratory Questionnaire (SGRQ) responder (<= -4 points change) (%) at 52 weeks-worst case (NCT00514683)
Timeframe: 52 weeks

Interventionpercentage of participants (Number)
Placebo16.1
Nintedanib 50 qd23.0
Nintedanib 50 Bid26.7
Nintedanib 100 Bid32.6
Nintedanib 150 Bid29.1

[back to top]

Relative Change From Baseline in FVC%Pred

"Percent change from baseline in percentage of predicted Forced Vital Capacity (FVC%pred) at 52 weeks.~Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region." (NCT00514683)
Timeframe: Baseline and 52 weeks

Interventionpercentage of change (Mean)
Placebo-7.28
Nintedanib 50 qd-6.37
Nintedanib 50 Bid-6.42
Nintedanib 100 Bid-3.47
Nintedanib 150 Bid-1.81

[back to top]

Relative Change From Baseline in FVC

"Percent change from baseline in absolute Forced Vital Capacity (FVC) at 52 weeks.~Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline and region" (NCT00514683)
Timeframe: Baseline and 52 weeks

Interventionpercentage change (Mean)
Placebo-7.96
Nintedanib 50 qd-6.98
Nintedanib 50 Bid-7.16
Nintedanib 100 Bid-4.13
Nintedanib 150 Bid-2.52

[back to top]

Number of Participants With Change From Baseline in FVC by Categories

"Change from baseline in percentage of Forced Vital Capacity (FVC) at 52 weeks in below mentioned categories:~Decrease > 10% or 200mL~Change within <= 10% or <=200 mL~Increase > 10% or 200mL" (NCT00514683)
Timeframe: Baseline and 52 weeks

,,,,
Interventionparticipants (Number)
Decrease > 10% or 200mLChange within <= 10% or <=200mLIncrease > 10% or 200mL
Nintedanib 100 Bid30469
Nintedanib 150 Bid205212
Nintedanib 50 Bid41396
Nintedanib 50 qd35446
Placebo37416

[back to top]

Rate of Decline in FVC

"Rate of decline in Forced Vital Capacity (FVC) evaluated from baseline until 52 weeks of treatment.~The means presents actually the adjusted rate based on a MMRM with fixed terms for treatment*time, gender*height, gender*age and random terms for patient effect, patient*time." (NCT00514683)
Timeframe: Baseline until 52 weeks

InterventionLiters/year (Mean)
Placebo-0.190
Nintedanib 50 qd-0.174
Nintedanib 50 Bid-0.210
Nintedanib 100 Bid-0.162
Nintedanib 150 Bid-0.060

[back to top]

Pre-dose Plasma Concentration of Nintedanib in Plasma at Steady State on Day 365 (Cpre,ss,365) and Day 729 (Cpre,ss,729).

Cpre,ss,729 represents the pre-dose plasma concentration of nintedanib in plasma at steady state on Day 729 and Cpre,ss,365 represents the pre-dose plasma concentration of nintedanib in plasma at steady state on Day 365. At day 365, values only for Nintedanib 50 qd group are presented as no values reported for other groups and at day 729, values are presented for all group except for Nintedanib 50 qd group as no values reported for it. (NCT00514683)
Timeframe: day 365 and day 729

Interventionng/mL (Geometric Mean)
Nintedanib 50 qd1.07
Nintedanib 50 Bid2.12
Nintedanib 100 Bid4.20
Nintedanib 150 Bid6.66

[back to top]

Occurrences of IPF Exacerbations Per Patient Per Year

Occurrences of Idiopathic Pulmonary Fibrosis (IPF) exacerbations per patient per year at 52 weeks (NCT00514683)
Timeframe: 52 weeks

InterventionExacerbations Per Year (Mean)
Placebo0.243
Nintedanib 50 qd0.243
Nintedanib 50 Bid0.242
Nintedanib 100 Bid0.256
Nintedanib 150 Bid0.075

[back to top]

Time to Progression

"Time to progression. Progression was defined as at least one of the following: 5mmHg increase in the alveolo-arterial pressure difference in oxygen (P(A-a)O2), 10% decrease in FVC (FVC(baseline)-FVC(progression) >= 10%) or Death.~Failure means participants with event and Censored means participants with no event." (NCT00514683)
Timeframe: 52 weeks

InterventionDays (Median)
Placebo363
Nintedanib 50 qd365
Nintedanib 50 Bid365
Nintedanib 100 Bid365
Nintedanib 150 Bid365

[back to top]

Absolute Change From Baseline in FEV1/FVC

"Change from baseline of percentage of FVC expelled in the first second of a forced expiration (FEV1/FVC) at 52 weeks.~Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region." (NCT00514683)
Timeframe: Baseline and 52 weeks

Interventionpercentage of FVC (Mean)
Placebo1.25
Nintedanib 50 qd-0.10
Nintedanib 50 Bid0.00
Nintedanib 100 Bid-0.53
Nintedanib 150 Bid-0.42

[back to top]

Absolute Change From Baseline in Dyspnoea Rating on Borg Scale Before Exercise (6-MWT)

"Absolute change from baseline in Dyspnoea rating before exercise (6-MWT) at 52 weeks based on Borg scale as mentioned below :~0: Nothing at all, 0.5: Very, very slight (just noticable), 1: Very slight, 2: Slight (light), 3: Moderate, 4: Somewhat severe, 5: Severe (heavy), 6, 7:Very severe, 8, 9, 10: Very, very severe (Maximal).~The 6-Minutes Walk Test (6-MWT) was conducted according to the ATS Criteria. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region." (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionUnits on a scale (Mean)
Placebo0.227
Nintedanib 50 qd0.282
Nintedanib 50 Bid0.045
Nintedanib 100 Bid0.260
Nintedanib 150 Bid0.086

[back to top]

Absolute Change From Baseline in DLCO

"Absolute change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) at 52 weeks.~Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region." (NCT00514683)
Timeframe: Baseline and 52 weeks

Interventionmmol.min^-1.kPa^-1 (Mean)
Placebo-0.455
Nintedanib 50 qd-0.357
Nintedanib 50 Bid-0.610
Nintedanib 100 Bid-0.535
Nintedanib 150 Bid-0.576

[back to top]

Absolute Change From Baseline in Distance Walk (6-MWT)

Absolute change from baseline in distance walk (6-MWT) at 52 weeks. The 6-Minutes Walk Test (6-MWT) was conducted according to the American Thoracic Society (ATS) Criteria. Means were adjusted based on an ANCOVA with fixed terms for treatment, baseline, region. (NCT00514683)
Timeframe: Baseline and 52 weeks

InterventionMeter (Mean)
Placebo-35.67
Nintedanib 50 qd-46.91
Nintedanib 50 Bid-48.84
Nintedanib 100 Bid-36.80
Nintedanib 150 Bid-29.35

[back to top]

Time to First Occurrence of IPF Exacerbation

"This endpoint is called time to first occurrence of IPF exacerbation however it was actually analysed as the proportion of patients having occurrence of Idiopathic Pulmonary Fibrosis (IPF) exacerbation at 52 weeks.~Failure means participants with event and Censored means participants with no event." (NCT00514683)
Timeframe: 52 weeks

,,,,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 100 Bid7.093.0
Nintedanib 150 Bid2.397.7
Nintedanib 50 Bid11.688.4
Nintedanib 50 qd11.588.5
Placebo13.886.2

[back to top]

Survival (Death Due to Respiratory Cause, and Lung-transplant Free)

"Survival (death due to respiratory cause, and lung-transplant free) at 52 weeks.~Failure means participants with event and Censored means participants with no event." (NCT00514683)
Timeframe: 52 weeks

,,,,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 100 Bid2.397.7
Nintedanib 150 Bid2.397.7
Nintedanib 50 Bid3.596.5
Nintedanib 50 qd10.389.7
Placebo9.290.8

[back to top]

Survival (All Causes of Death and Lung-transplant Free)

"Survival (all causes of death and lung-transplant free) at 52 weeks, based on overall mortality and on-treatment survival.~Failure means participants with event and Censored means participants with no event." (NCT00514683)
Timeframe: 52 weeks

,,,,
Interventionparticipants (Number)
FailureCensored
Nintedanib 100 Bid482
Nintedanib 150 Bid779
Nintedanib 50 Bid383
Nintedanib 50 qd1176
Placebo978

[back to top]

Absolute Change From Baseline in SpO2 at Rest by Categories

"Absolute change from baseline in oxygen saturation (SpO2) at rest by below mentioned categories:~SpO2 (non-invasive) at 52 weeks:~Decrease > 4% SpO2~Change within +/- 4% SpO2~Increase > 4% SpO2" (NCT00514683)
Timeframe: Baseline and 52 weeks

,,,,
Interventionpercentage of participants (Number)
Decrease > 4%Change within +/- 4%Increase > 4%
Nintedanib 100 Bid6.089.34.8
Nintedanib 150 Bid3.692.83.6
Nintedanib 50 Bid8.189.52.3
Nintedanib 50 qd4.990.24.9
Placebo11.087.81.2

[back to top]

Absolute Change From Baseline in PaO2 by Categories

"Absolute change from baseline in Arterial oxygen partial pressure (PaO2) by below mentioned categories:~Decrease > 4 mmHg~Change within +/- 4 mmHg~Increase > 4 mmHg" (NCT00514683)
Timeframe: Baseline and 52 weeks

,,,,
Interventionpercentage of participants (Number)
Decrease > 4 mmHgChange within +/- 4 mmHgIncrease > 4 mmHg
Nintedanib 100 Bid39.730.929.4
Nintedanib 150 Bid29.443.127.5
Nintedanib 50 Bid42.232.825.0
Nintedanib 50 qd50.021.428.6
Placebo34.550.015.5

[back to top]

Absolute Change From Baseline in P(A-a) O2 by Categories

"Absolute change from baseline in Alveolo-arterial oxygen gradient (P(A-a) O2) by below mentioned categories:~Decrease > 4 mmHg~Change within +/- 4 mmHg~Increase > 4 mmHg" (NCT00514683)
Timeframe: Baseline and 52 weeks

,,,,
Interventionpercentage of participants (Number)
Decrease > 4 mmHgChange within +/- 4 mmHgIncrease > 4 mmHg
Nintedanib 100 Bid25.428.446.3
Nintedanib 150 Bid17.645.137.3
Nintedanib 50 Bid31.325.043.0
Nintedanib 50 qd37.014.848.1
Placebo25.033.941.1

[back to top]

Absolute Change From Baseline in MRC Dyspnea Scale by Categories

"Absolute change from baseline in Medical Research Council (MRC) dyspnea scale by below mentioned categories:~Decrease~No Change~Increase" (NCT00514683)
Timeframe: Baseline and 52 weeks

,,,,
Interventionpercentage of participants (Number)
DecreaseNo ChangeIncrease
Nintedanib 100 Bid14.645.140.2
Nintedanib 150 Bid11.853.934.2
Nintedanib 50 Bid8.653.138.3
Nintedanib 50 qd13.345.341.3
Placebo7.851.940.3

[back to top]

Progression Free Rate at 24 and 48 Weeks

"PFR is defined as a composite endpoint for disease progression.~If patients met one of the following criteria they were counted as having progressive disease (PD):~Prostate serum antigen (PSA) progression according to Prostate-Specific Antigen Working Group (PSAWG) criteria~Bone metastasis progression- development of new lesions on bone scan or development of disease-related skeletal related events (SREs)~Disease progression according to RECIST version 1.0" (NCT00706628)
Timeframe: 24 weeks and 48 weeks

,,
Interventionpercentage of participants (Number)
24 weeks48 weeks
BIBF 1120 Monotherapy22.218.5
BIBW 2992 Monotherapy0.00.0
ComBI 400.00.0

[back to top]

Duration of PSA Response

"Duration of PSA response was calculated from the time of first 50% decline in PSA (compared to baseline) until the time at which there was an increase of 50% from the PSA nadir, provided that the absolute increase was at least 5 ng/mL. The increase had to be confirmed by a second consecutive measurement that was at least 50% above the nadir. If the PSA never showed a 50% increase over the nadir value, then the patient was censored at the last PSA measurement.~Duration of PSA response expressed in median number of days." (NCT00706628)
Timeframe: End of trial visit, 29 ± 1 days after Day 1 of the last treatment cycle (Up to 48 weeks)

Interventiondays (Median)
BIBF 1120 MonotherapyNA
BIBW 2992 MonotherapyNA
ComBI 40NA

[back to top]

Duration of RECIST Response

"Time from first observation of response (PR, CR, confirmed or unconfirmed) until progression according to RECIST (version 1.0) or death.~Duration is expressed in Median number of days." (NCT00706628)
Timeframe: Up to 48 weeks

Interventiondays (Median)
BIBF 1120 Monotherapy116.0
BIBW 2992 MonotherapyNA
ComBI 40NA

[back to top]

Overall Survival (Time to Death)

Overall survival (time to death) was calculated in days from baseline to the date of reporting of death. Time is expressed in Median number of days. (NCT00706628)
Timeframe: start of treatment until 28 days after end of treatment (Up to 52 weeks)

Interventiondays (Median)
BIBF 1120 MonotherapyNA
BIBW 2992 MonotherapyNA
ComBI 40NA

[back to top]

Progression Free Rate (PFR) at 12 Weeks

"PFR is defined as a composite endpoint for disease progression.~If patients met one of the following criteria they were counted as having progressive disease (PD):~Prostate serum antigen (PSA) progression according to Prostate-Specific Antigen Working Group (PSAWG) criteria~Bone metastasis progression- development of new lesions on bone scan or development of disease-related skeletal related events (SREs)~Disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.0" (NCT00706628)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
BIBF 1120 Monotherapy25.9
BIBW 2992 Monotherapy0.0
ComBI 400.0
ComBI 70NA

[back to top]

Time to Progression

"Time from first administration of study drug until disease progression according to composite endpoint.~Time is expressed in Median number of days." (NCT00706628)
Timeframe: start of treatment until end of the treatment (Up to 48 weeks)

Interventiondays (Median)
BIBF 1120 Monotherapy31.0
BIBW 2992 Monotherapy29.0
ComBI 4057.0

[back to top]

Time to PSA Progression

"Time to PSA progression through 48 weeks was calculated as the number of days from first administration of study drug to the first time that there was an increase of 50% from the PSA nadir, provided the absolute increase was at least 5 ng/mL.~Time is expressed in median number of days." (NCT00706628)
Timeframe: Start of treatment until end of treatment (Up to 48 weeks)

Interventiondays (Median)
BIBF 1120 Monotherapy31.0
BIBW 2992 Monotherapy29.0
ComBI 4057.0

[back to top]

Changes in Safety Laboratory Parameters

Changes in safety laboratory Parameters reported as adverse events (NCT00706628)
Timeframe: from first intake of treatment until 29 days after last intake of treatment (Up to 52 weeks)

,,,
Interventionpercentage of participants (Number)
Alanine aminotransferase increasedGamma-glutamyltransferase increasedAspartate aminotransferase increasedBlood urea increasedBlood creatinine increasedBlood potassium decreasedTransaminases increasedBlood alkaline phosphatase increasedHepatic enzyme increased
BIBF 1120 Monotherapy17.44.310.92.22.20.04.32.22.2
BIBW 2992 Monotherapy5.00.00.010.05.05.00.00.00.0
ComBI 4018.812.518.80.00.00.00.00.00.0
ComBI 7033.333.30.00.00.00.00.00.00.0

[back to top]

Trough Plasma Concentrations for BIBF 1120 and BIBW 2992 for the Monotherapy

Trough plasma concentrations are defined either as pre-dose concentration of BIBF 1120 and BIBW 2992 in plasma at steady state immediately before administration of the next dose for the monotherapy treatment or as post dose concentrations taken after the dosing interval for the combination treatment (NCT00706628)
Timeframe: Day 15, Day 29 and Day 57

,
Interventionng/mL (Geometric Mean)
Cpre,ss,15 (N=28, 15)Cpre,ss,29 (N=35, 18)Cpre,ss,57 (N=27, 12)
BIBF 1120 Monotherapy10.211.811.8
BIBW 2992 Monotherapy18.019.118.2

[back to top]

Number of Patients Showing Prostate Serum Antigen (PSA) Response

"PSA response was evaluated according to the PSAWG guidelines. All patients achieving a fall in PSA of ≥50% from baseline (confirmed with a second value at least 4 weeks later) fulfilled the criteria for PSA response. The confirmatory value had to be at least 50% lower than the baseline value, but could be higher than the original drop in PSA (first PSA value).~However, the confirmatory value could not be 50% higher than the first PSA value. If it was ≥50% higher than the first PSA, another sample was taken to determine if response had been achieved." (NCT00706628)
Timeframe: End of trial visit, 29 ± 1 days after Day 1 of the last treatment cycle (Up to 48 weeks)

,,
Interventionpercentage of participants (Number)
ResponseNo Response
BIBF 1120 Monotherapy3.796.3
BIBW 2992 Monotherapy0.0100.0
ComBI 4010.090.0

[back to top]

Overall Objective Response by RECIST Criteria (Version 1.0) (Complete Response [CR] or Partial Response [PR]) for Patients With Measurable Disease at 12, 24, 36 and 48 Weeks

Objective response is defined as a Complete or Partial response Complete response [CR] for Target lesions: Disappearance of all target lesions. Complete response [CR] for Non- target lesions: Disappearance of all non-target lesions and normalization of tumour marker level Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. (NCT00706628)
Timeframe: 12, 24, 36 and 48 weeks

,,
Interventionpercentage of participants (Number)
12 weeks (N=12, 8, 7)24 weeks (N=6, 1, 1)36 weeks (N=3, 0, 0)48 weeks (N=2, 0, 0)
BIBF 1120 Monotherapy8.30.00.00.0
BIBW 2992 Monotherapy0.00.0NANA
ComBI 400.00.0NANA

[back to top]

Incidence and Worst Intensity of Adverse Events With Grading According CTCAE

Incidence and worst intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0). (NCT00706628)
Timeframe: from first intake of treatment until 29 days after last intake of treatment (Up to 52 weeks)

,,,
Interventionpercentage of participants (Number)
CTCAE Grade 1CTCAE Grade 2CTCAE Grade 3CTCAE Grade 4CTCAE Grade 5
BIBF 1120 Monotherapy26.130.437.06.50.0
BIBW 2992 Monotherapy0.055.040.00.05.0
ComBI 4037.518.837.50.06.3
ComBI 700.033.366.70.00.0

[back to top]

RECIST Tumour Progression Rate at 12, 24, 36, and 48 Weeks

RECIST (version 1.0) tumour progression rate at 12, 24, 36, and 48 weeks was calculated based on the occurrence of new lesions, or an increase in the sum of the longest lesion diameters of at least 20%. (NCT00706628)
Timeframe: 12, 24, 36, and 48 weeks

,,
Interventionpercentage of participants (Number)
12 weeks (N=12, 8, 7)24 weeks (N=6, 1, 1)36 weeks (N=3, 0, 0)48 weeks (N=2, 0, 0)
BIBF 1120 Monotherapy8.350.033.350.0
BIBW 2992 Monotherapy50.00.0NANA
ComBI 4042.90.0NANA

[back to top]

Trough Plasma Concentrations for BIBF 1120 and BIBW 2992 for the Combination Therapy

"Trough plasma concentrations are defined either as pre-dose concentration of BIBF 1120 and BIBW 2992 in plasma at steady state immediately before administration of the next dose for the monotherapy treatment or as post dose concentrations taken after the dosing interval for the combination treatment (C12,14 for BIBF1120 ; C24,7 and C24,14 for BIBW2992)~C12,14: plasma concentration at 12 hours Day 14" (NCT00706628)
Timeframe: Day7, Day 14

Interventionng/mL (Geometric Mean)
C 12,14 (N=14)C 24,7 (N=13)C 24,14 (N=12)
Combination Therapy of BIBF 1120 and BIBW 299213.711.416.4

[back to top]

PFS Rate at 12 Weeks (After 3 Months) and 24 Weeks ( After 6 Months)

The rate (probability) of being progression free at Week 12 and Week 24. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability. (NCT00710762)
Timeframe: 12 weeks (after 3 months) and 24 weeks ( after 6 months)

,
Interventionpercent probability of PFS (Number)
at 24 weeks ( after 6 months)at 12 weeks (after 3 months)
Nintedanib26.745.3
Placebo17.346.2

[back to top]

Time to Tumour Progression

"Time to Tumour Progression according to RECIST version 1.0 , CA-125 (ovarian tumour marker) levels and RECIST + CA-125 levels.~For CA-125, progressive disease was defined on the basis of progressive serial elevations of CA-125 according to the following criteria:~Patients with elevated CA-125 pre-treatment and normalisation of CA-125 had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart. or Patients with elevated CA-125 pre-treatment that never normalised had to show evidence of CA-125 levels ≥2 x the nadir value on 2 occasions at least 1 week apart. or Patients with CA-125 in the normal range pre-treatment had to show evidence of CA-125 levels ≥2 x ULN on 2 occasions at least 1 week apart.~Composite (RECIST+CA-125) endpoint is the RECIST progressive disease (PD) if it occurred or the CA-125 PD if it occurred in the absence of RECIST PD." (NCT00710762)
Timeframe: 9 months

,
Interventiondays (Median)
according to RECIST and CA-125according to CA-125according to RECIST
Nintedanib83.0085.00143.0
Placebo84.0086.0085.0

[back to top]

Incidence and Intensity of Adverse Events With Grading According CTCAE

Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0). (NCT00710762)
Timeframe: First drug administration until 28 days after last drug administration,up until 309 days

,
Interventionpercentage of participants (Number)
CTCAE grade 1CTCAE grade 2CTCAE grade 3CTCAE grade 4CTCAE grade 5
Nintedanib2.334.953.57.00.0
Placebo25.042.525.02.50.0

[back to top]

PFS Rate at 36 Weeks (After 9 Months)

The rate (probability) of being progression free at Week 36. Progression Free Survival (PFS) was defined according to RECIST version 1.0 from the time of first study drug administration to the first time of either objective tumour progression, the appearance of ≥1 new tumour lesion(s), occurrence or significant progression of malignant ascites, tumour related death, or the time when patients were censored at last known follow up. The rate is the Kaplan-Meier estimated percent probability. (NCT00710762)
Timeframe: 36 weeks (after 9 months)

Interventionpercent probability of PFS (Number)
Nintedanib15.6
Placebo2.9

[back to top]

Clinical Relevant Abnormalities for Laboratory Parameters

Clinical Relevant Abnormalities for laboratory parameters. Any new or clinically relevant worsening of baseline conditions was reported as Adverse Events. (NCT00710762)
Timeframe: First drug administration until 28 days after last drug administration, up until 309 days

,
InterventionPercentage of participants (Number)
Alanine aminotransferase increasedGamma-glutamyltransferase increasedAspartate aminotransferase increasedBlood alkaline phosphatase increasedBlood lactate dehydrogenase increasedBlood alkaline phosphataseBlood alkaline phosphatase abnormalLymphocyte count decreasedVitamin B12 decreasedAlanine aminotransferase abnormalBlood lactate dehydrogenase abnormalGamma-glutamyltransferase abnormalNeutrophil count decreasedWhite blood cells urine positiveBlood pressure increasedElectrocardiogram T wave amplitude decreasedLiver function test abnormal
Nintedanib37.230.225.67.04.70.02.30.00.02.32.32.32.32.30.00.02.3
Placebo7.52.52.55.00.02.52.52.52.50.00.00.00.00.02.52.50.0

[back to top]

Difference From Baseline for Liver Enzymes

Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25. (NCT00715403)
Timeframe: From signing the informed consent until end of treatment, up to 991 days

,,,,,,
InterventionU/L (Median)
Alkaline phosphataseAspartate aminotransferaseAlanine aminotransferase
100mg BID-39.09.60.6
150mg BID-21.26.8-1.6
200mg BID-11.74.39.1
200mg QD11.913.76.6
250mg BID16.015.917.0
300mg BID7.27.612.4
50mg QD127.014.310.6

[back to top]

Clinically Relevant Abnormalities for Vital Signs

Clinically relevant abnormalities for Vital Signs (systolic blood pressure, diastolic blood pressure, and pulse rate). New abnormal findings or worsening of baseline conditions were reported as Adverse Events. (NCT00715403)
Timeframe: From baseline until final follow-up, up to 991 days

Interventionpercentage of participants (Number)
50mg QD0.0
200mg QD0.0
100mg BID0.0
150mg BID0.0
200mg BID0.0
250mg BID0.0
300mg BID0.0

[back to top]

Difference From Baseline for Haemoglobin

Difference from baseline for Haemoglobin (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25. (NCT00715403)
Timeframe: From baseline until end of treatment, up to 991 days

Interventiong/dL (Median)
50mg QD-1.8
200mg QD1.4
100mg BID0.4
150mg BID1.0
200mg BID1.2
250mg BID-0.2
300mg BID1.1

[back to top]

Incidence and Intensity of Adverse Events With Highest CTCAE Grade 4

All patients who had grade 4 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE). (NCT00715403)
Timeframe: From signing the informed consent until final follow-up, up to 991 days

Interventionpercentage of participants (Number)
50mg QD0
200mg QD0
100mg BID0
150mg BID0
200mg BID0
250mg BID0
300mg BID0

[back to top]

Pre-dose Concentration of Nintedanib in Plasma at Steady-state (Cpre,ss)

Cpre,ss represents the pre-dose concentration of Nintedanib in Plasma at steady-state at day 29 (NCT00715403)
Timeframe: Just before drug administration every 28±7 days after day 29

Interventionng/mL (Geometric Mean)
150mg BID7.54
200mg BID11.8
250mg BID11.0

[back to top]

Clinical Benefit

Clinical benefit was defined as the absence of disease progression (no PD or nonevaluable clinically progressive disease) determined by RECIST (version 1.0). (NCT00715403)
Timeframe: Baseline until end of treatment, up to 991 days

,,,,,,
Interventionpercentage of participants (Number)
NoYes
100mg BID0100
150mg BID0100
200mg BID0100
200mg QD0100
250mg BID1189
300mg BID0100
50mg QD0100

[back to top]

Confirmed Objective Response

Confirmed objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0) (NCT00715403)
Timeframe: Baseline until end of treatment, up to 991 days

,,,,,,
Interventionpercentage of participants (Number)
NoYesUnknown
100mg BID10000
150mg BID56044
200mg BID10000
200mg QD01000
250mg BID58042
300mg BID10000
50mg QD10000

[back to top]

Incidence and Intensity of Adverse Events With Highest CTCAE Grade 1

All patients who had grade 1 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE). (NCT00715403)
Timeframe: From signing the informed consent until final follow-up, up to 991 days

,,,,,,
Interventionpercentage of participants (Number)
DyspepsiaFatigueNasopharyngitisAnorexiaHyperhidrosisDiarrhoeaBronchitisEye disorderEyelid oedemaHaemorrhoidsToothachePyrexiaMuscle spasmsNeck painPain in extremityVulvovaginal drynessArrhythmiaNauseaVomitingAbdominal painGastrooesophageal reflux diseaseTooth discolourationAstheniaXerosisGastrointestinal infectionBone painArthralgiaMusculoskeletal chest painMyalgiaDizzinessHeadacheAnxietyRalesNail disorderRashHot flushVertigoConstipationFlatulenceGastric disorderHypersensitivityViral infectionMusculoskeletal painBalance disorderCarpal tunnel syndromeSciaticaDysuriaDyspnoeaRash maculo-papularSinus tachycardiaEye painVisual impairmentAbdominal distensionGastrointestinal haemorrhageAdverse drug reactionChest painChillsHepatic painUrinary tract infectionWeight decreasedHyperglycaemiaMuscular weaknessBack painJoint swellingDysgeusiaPeripheral sensory neuropathyInsomniaHaematuriaIncontinenceCoughAlopeciaDry skinPruritusConjunctivitisHaemoptysis
100mg BID000000025252525252525252500000000000000000000000000000000000000000000000000000000000
150mg BID1133011114400000111101101133221111111111112211111122111111111111000000000000000000000000000000000000000
200mg BID017330050000001700170067333300330017500000000001717171717171717171717331700000000000000000000000000
200mg QD0000010010000000000000000000000000000000000000000000000000000000000000000000000
250mg BID0051653700050511050021511005000500550000001611000500000055555555551151155551155555500
300mg BID00000100000000000000000000000010000000000000000000000000000000000000000000000100100
50mg QD1001001001001000000000000000000000000000000000000000000000000000000000000000000000000

[back to top]

Difference From Baseline for Bilirubin, Creatinine and Glucose

Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25. (NCT00715403)
Timeframe: From signing the informed consent until end of treatment, up to 991 days

,,,,,,
Interventionmg/dL (Median)
Bilirubin (total)CreatinineGlucose (N=1,1,3,9,4,14,1)
100mg BID0.00.028.9
150mg BID0.0-0.1-11.3
200mg BID0.1-0.1-76.5
200mg QD0.0-0.3-2.2
250mg BID0.1-0.1-23.3
300mg BID0.00.0-40.0
50mg QD0.5-0.1-60.0

[back to top]

Difference From Baseline for Coagulation Parameters

Difference from baseline (normalized value) in coagulation parameters Prothrombin time, international normalised ratio (PT-INR) and partial thromboplastin time. Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25. (NCT00715403)
Timeframe: From signing the informed consent until end of treatment, up to 991 days

,,,,,,
Interventionsec (Median)
PT-INR (N=1,1,3,7,5,14,1)Partial thromboplastin time (N=1,1,3,9,4,14,1)
100mg BID0.3-3.6
150mg BID0.11.9
200mg BID0.21.9
200mg QD0.12.6
250mg BID-0.01.5
300mg BID0.1-2.9
50mg QD0.10.7

[back to top]

Difference From Baseline for Electrolytes

Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25. (NCT00715403)
Timeframe: From signing the informed consent until end of treatment, up to 991 days

,,,,,,
Interventionmmol/L (Median)
Potassium (N=1,1,4,9,6,18,1)Sodium (N=1,1,4,9,6,18,1)
100mg BID-0.33.3
150mg BID0.10.0
200mg BID-0.01.5
200mg QD-0.31.0
250mg BID0.1-1.3
300mg BID0.05.0
50mg QD0.22.0

[back to top]

Difference From Baseline for Haematology and Differentials Parameters

Difference from baseline (normalized value). Baseline was defined as the value at the time point closest to but prior to very first administration of trial medication. The standard error is actually the Interquartile Range calculated as P75 minus P25. (NCT00715403)
Timeframe: From signing the informed consent until end of treatment, up to 991 days

,,,,,,
Intervention10^9 /L (Median)
PlateletsWhite blood cell countLymphocytes (N=1,1,4,9,4,17,1)Neutrophils (N=1,1,4,9,6,17,1)
100mg BID1.00.2-0.10.9
150mg BID-2.5-0.81.0-1.0
200mg BID-38.1-0.10.0-2.4
200mg QD11.1-0.7-0.4-4.7
250mg BID11.20.70.6-0.5
300mg BID-27.10.01.1-1.2
50mg QD42.2-1.1-0.6-4.1

[back to top]

Unconfirmed Best Overall Response

"Unconfirmed best overall response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0).~PD = Progressive disease." (NCT00715403)
Timeframe: Baseline until end of treatment, up to 991 days

,,,,,,
Interventionpercentage of participants (Number)
Complete responsePartial responseStable diseaseNon-evaluable, clinically non-progressive diseasePD or non-evaluable , clinically PDUnknown
100mg BID00752500
150mg BID0033111144
200mg BID00083170
200mg QD10000000
250mg BID051653242
300mg BID00001000
50mg QD00100000

[back to top]

Unconfirmed Best Objective Response

Unconfirmed best objective response assessed by RECIST (Response Evaluation Criteria In Solid Tumours) criteria (version 1.0) (NCT00715403)
Timeframe: Baseline until end of treatment, up to 991 days

,,,,,,
Interventionpercentage of participants (Number)
NoYesUnknown
100mg BID10000
150mg BID56044
200mg BID10000
200mg QD01000
250mg BID53542
300mg BID10000
50mg QD10000

[back to top]

Incidence and Intensity of Adverse Events With Highest CTCAE Grade 2

All patients who had grade 2 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE). (NCT00715403)
Timeframe: From signing the informed consent until final follow-up, up to 991 days

,,,,,,
Interventionpercentage of participants (Number)
FatigueAnorexiaDiarrhoeaBronchitisNauseaVomitingAbdominal painAstheniaGastrointestinal infectionBone painArthralgiaMusculoskeletal chest painHeadacheConstipationFlatulenceMusculoskeletal painSciaticaDyspnoeaChest painUrinary tract infectionWeight decreasedBack painPeripheral sensory neuropathyCoughHaemoptysisOsteoarthritisParotitisOsteolysisAbdominal pain upperGastrointestinal disorderGroin painAnaemiaNeutropeniaOedema peripheralGamma-glutamyltransferase increasedDehydrationProductive coughDeep vein thrombosisPhlebitis superficial
100mg BID0000000250000250000002500000250000000000000
150mg BID220110001111000111101100111100110000111100000000000
200mg BID0033170000170000000000000170000017171700000000
200mg QD000000000000000000000000000000000000000
250mg BID111121011501101150050511110550011500000055555555
300mg BID000000000000000000000000000000000000000
50mg QD000000000000000000000000000000000000000

[back to top]

Progression Free Survival

"Percentage of participants that experienced progression free survival (PFS), assessed by RECIST (Response Evaluation Criteria In Solid Tumours) (version 1.0), by day 1230. Progression was defined as progressive disease (PD) or non-evaluable clinically progressive disease.~PFS was defined for patients without PD at screening as the time from first treatment with the trial drug in the previous trial until onset of PD or death, whatever comes earlier.~Patients with PD could enter the trial if they showed signs of clinical benefit. For patients with PD at screening, the RECIST assessment at screening was used as a new baseline value and PFS was the time from first treatment with the trial drug in this trial until the onset of progressive disease in this trial or death, whatever comes first." (NCT00715403)
Timeframe: First drug administration (in previous trial) until end of treatment, up to 1230 days

,,,,,,
Interventionpercentage of participants (Number)
Progression (RECIST)DeathNo progressive disease (RECIST) or deathUnknown
100mg BID250750
150mg BID1104445
200mg BID330670
200mg QD100000
250mg BID42321610
300mg BID100000
50mg QD001000

[back to top]

Incidence and Intensity of Adverse Events With Highest CTCAE Grade 5

All patients who had grade 5 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE). (NCT00715403)
Timeframe: From signing the informed consent until final follow-up, up to 991 days

,,,,,,
Interventionpercentage of participants (Number)
Subdural HaematomaMalignant neoplasm progression
100mg BID00
150mg BID00
200mg BID00
200mg QD00
250mg BID526
300mg BID00
50mg QD00

[back to top]

Incidence and Intensity of Adverse Events With Highest CTCAE Grade 3

All patients who had grade 3 adverse events (AEs) as the worst grade of the AE. Incidence and intensity of Adverse Events with grading of Adverse Events according to Common Terminology Criteria for Adverse Events (CTCAE). (NCT00715403)
Timeframe: From signing the informed consent until final follow-up, up to 991 days

,,,,,,
Interventionpercentage of participants (Number)
Gamma-glutamyltransferase increasedDiarrhoeaDiarrhoea infectiousDyspnoeaLymphopeniaConstipationHaemorrhoidsIleusSubileusVomitingPneumoniaConvulsionRenal failureUrinary tract obstructionPleural effusion
100mg BID02525000000000000
150mg BID01101100000000000
200mg BID000000000000000
200mg QD000000000000000
250mg BID0505555555551155
300mg BID000000000000000
50mg QD10000000000000000

[back to top]

Disease Control

"Disease control was defined as a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) and evaluated according to the modified RECIST criteria version 1.0.~As per RECIST v1.0 for target lesions : Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.~This endpoint was analysed based on the central independent reviewer as well as the investigator." (NCT00805194)
Timeframe: From randomisation until cut-off date 15 February 2013

,
Intervention% of participants (Number)
central independent reviewerinvestigator assessment
Nintedanib Plus Docetaxel54.063.4
Placebo Plus Docetaxel41.351.4

[back to top]

Dose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide

Geometric mean of dose normalised predose plasma concentration (Cpre,ss,norm) of nintedanib and of its metabolites BIBF 1202 and BIBF 1202 glucuronide evaluated at steady state based on course 2 and 3. If only one value was available and valid, then this value was used for calculation of Cpre,ss,norm. (NCT00805194)
Timeframe: Before the administration of nintedanib or placebo and between a window of 30 mins to an hour after administration of trial drug during Course 2 and between 1 and 3 hours after administration of trial drug during Course 3

,
Interventionng/mL/mg (Geometric Mean)
nintedanibmetabolite BIBF 1202metabolite BIBF 1202 glucuronide
Nintedanib 150 Bid mg Plus Docetaxel0.1060.1901.94
Nitedanib 200 mg Bid Plus Docetaxel0.07070.09071.04

[back to top]

Duration of Confirmed Objective Tumour Response

"The duration of objective response is the time from first documented (CR) or (PR) to the time of progression or death and evaluated according to the modified RECIST criteria version 1.0.~As per RECIST v1.0, Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.~This endpoint was analysed based on the central independent reviewer as well as the investigator." (NCT00805194)
Timeframe: From randomisation until cut-off date 15 February 2013

,
Interventionmonths (Median)
central independent reviewerinvestigator assessment
Nintedanib Plus Docetaxel4.35.7
Placebo Plus Docetaxel4.35.5

[back to top]

Duration of Disease Control

"The duration of disease control was defined as the time from randomisation to the date of disease progression or death (which ever occurs first) for patients with disease control.~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.~This endpoint was analysed based on the central independent reviewer as well as the investigator." (NCT00805194)
Timeframe: From randomisation until cut-off date 15 February 2013

,
Interventionmonths (Median)
central independent reviewerinvestigator assessment
Nintedanib Plus Docetaxel5.65.7
Placebo Plus Docetaxel5.65.6

[back to top]

Incidence and Intensity of Adverse Events

"Incidence and intensity of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The worst CTCAE grade per patient is reported and MedDRA version 15.1 used.~Serious signs and symptoms of progressive disease were reported as an adverse event in analysis of this endpoint." (NCT00805194)
Timeframe: From the first drug administration until 28 days after the last drug administration, up to 42 months

,
Intervention% of participants (Number)
Grade 1Grade 2Grade 3Grade 4Grade 5
Nitedanib Plus Docetaxel5.716.621.233.716.4
Placebo Plus Docetaxel8.220.521.231.311.8

[back to top]

Objective Tumour Response

"Confirmed objective response is defined as confirmed Complete Response (CR) and Partial Response (PR) and evaluated according to the modified RECIST criteria version 1.0.~As per RECIST v1.0, Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions.~This endpoint was analysed based on the central independent reviewer as well as the investigator." (NCT00805194)
Timeframe: From randomisation until cut-off date 15 February 2013

,
Intervention% of participants (Number)
central independent reviewerinvestigator assessment
Nintedanib Plus Docetaxel4.410.4
Placebo Plus Docetaxel3.37.6

[back to top]

Quality of Life (QoL)

"Quality of life (QoL) was measured by standardised questionnaires (Health Status Self-Assessment Questionnaire (EQ-5D), EORTC Quality of life questionnaire - Core 30 (EORTC QLQ-C30), Quality of life questionnaire - lung cancer module (EORTC QLQ-LC13). The EORTC QLQ-C30 comprises of 30 questions, using both multi-item scales and single-item measures. EORTC LC-13 comprises of 13 questions incorporating 1 multi-item scale and a series of single items.~The following were the main points of interest:~Time to deterioration of cough (EORTC QLQ-LC13 question 1), Time to deterioration of dyspnoea (QLQ-LC13, composite of questions 3 to 5), Time to deterioration of pain (QLQ- C30, composite of questions 9 and 19).~Time to deterioration of cough, dyspnoea and pain was defined as the time to a 10-point increase from the baseline score.~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve" (NCT00805194)
Timeframe: From randomisation until cut-off date 15 February 2013

,
Interventionmonths (Median)
Time to deterioration of coughTime to deterioration of dyspnoeaTime to deterioration of pain
Nitedanib Plus Docetaxel4.32.02.8
Placebo Plus Docetaxel3.52.12.6

[back to top]

Time to Confirmed Objective Tumour Response

"Time to confirmed objective response is defined as time from randomisation to the date of first documented (CR) or (PR) and evaluated according to the modified RECIST criteria version 1.0.~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.~This endpoint was analysed based on the central independent reviewer as well as the investigator." (NCT00805194)
Timeframe: From randomisation until cut-off date 15 February 2013

,
Interventionmonths (Median)
central independent reviewerinvestigator assessment
Nintedanib Plus Docetaxel1.52.6
Placebo Plus Docetaxel2.92.7

[back to top]

Clinical Improvement

"Clinical improvement was defined as the time from randomisation to deterioration in body weight and/or Eastern Cooperative Oncology group performance score (ECOG PS) whichever occurred first.~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve." (NCT00805194)
Timeframe: From randomisation until cut-off date 15 February 2013

Interventionmonths (Median)
Nitedanib Plus Docetaxel5.9
Placebo Plus Docetaxel5.2

[back to top]

Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review

"Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria.~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve." (NCT00805194)
Timeframe: From randomisation until cut-off date 15 February 2013

Interventionmonths (Median)
Nintedanib Plus Docetaxel3.5
Placebo Plus Docetaxel2.7

[back to top]

Change From Baseline in Tumour Size

"Percentage change from baseline in tumour size is defined as decrease in the sum of the longest diameter of the target lesion.~Presented means are in fact adjusted best means percentage changes generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (squamous vs non-squamous), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no)~This endpoint was analysed based on the central independent reviewer as well as the investigator." (NCT00805194)
Timeframe: From randomisation until cut-off date 15 February 2013

,
Interventionpercentage of change in tumor size in mm (Mean)
central independent reviewerinvestigator assessment
Nintedanib Plus Docetaxel-4.87-10.34
Placebo Plus Docetaxel0.58-2.14

[back to top]

Overall Survival (Key Secondary Endpoint)

"Overall Survival (OS) defined as the duration from randomisation to death (irrespective of the reason of death). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.~A fixed-sequence-testing was implemented for key secondary endpoint if both the primary and the follow-up analysis showed a treatment benefit (P<0.05) of nintedanib over placebo. In this case, the OS would be tested using hierarchical testing of statistical hypotheses in (1) patients with adenocarcinoma and <9 months since start of first-line therapy, (2) patients with adenocarcinoma, and (3) all patients. Each hypothesis could be only tested at the pre-specified alpha level if the previous null hypothesis in the testing sequence had been." (NCT00805194)
Timeframe: From randomisation until cut-off date 15 February 2013 (approximately 48 months or 1151 deaths among all patients )

,
Interventionmonths (Median)
Adenocarcinoma and <9 monthsAdenocarcinomaAll patients
Nintedanib Plus Docetaxel10.912.610.1
Placebo Plus Docetaxel7.910.39.1

[back to top]

Progression Free Survival (PFS) as Assessed by Central Independent Review

"Progression Free Survival (PFS) as assessed by central independent review according to the modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) . Progression free survival (PFS) is defined as the duration of time from date of randomisation to date of progression or death (whatever occurs earlier).~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve." (NCT00805194)
Timeframe: From randomisation until cut-off date 2 November 2010 (when 713 PFS events were observed)

Interventionmonths (Median)
Nintedanib Plus Docetaxel3.4
Placebo Plus Docetaxel2.7

[back to top]

Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator

"Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by investigator according to the modified RECIST (version 1.0) criteria.~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve." (NCT00805194)
Timeframe: From randomisation until cut-off date 15 February 2013

Interventionmonths (Median)
Nintedanib Plus Docetaxel4.2
Placebo Plus Docetaxel3.0

[back to top]

Time to Confirmed Objective Tumour Response

"Time to confirmed objective response is defined as time from randomisation to the date of first documented (CR) or (PR) and evaluated according to the modified RECIST criteria version 1.0. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.~This endpoint was analysed based on the central independent reviewer as well as the investigator." (NCT00806819)
Timeframe: From randomisation until data cut-off (15 February 2013), Up to 30 months

,
InterventionMonths (Median)
Central independent review (N=32, 30)Investigator assessment (N=53, 48)
Nintedanib Plus Pemetrexed2.62.6
Placebo Plus Pemetrexed2.72.8

[back to top]

Progression Free Survival (PFS) as Assessed by Central Independent Review

"Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria. Progression free survival (PFS) is defined as the duration of time from date of randomisation to date of progression or death (whatever occurs earlier).~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve." (NCT00806819)
Timeframe: From randomisation until cut-off date 9 July 2012

Interventionmonths (Median)
Nintedanib Plus Pemetrexed4.4
Placebo Plus Pemetrexed3.6

[back to top]

Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator

Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by investigator according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. (NCT00806819)
Timeframe: From randomisation until data cut-off (15 February 2013), Up to 30 months

InterventionMonths (Median)
Nintedanib Plus Pemetrexed5.3
Placebo Plus Pemetrexed4.3

[back to top]

Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review

Follow-up analysis was conducted at the time of overall survival analysis. Progression Free Survival (PFS) as assessed by central independent review according to the modified RECIST (version 1.0) criteria. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. (NCT00806819)
Timeframe: From randomisation until data cut-off (15 February 2013), Up to 30 months

InterventionMonths (Median)
Nintedanib Plus Pemetrexed4.4
Placebo Plus Pemetrexed3.4

[back to top]

Clinical Improvement.

"Clinical improvement was defined as the time from randomisation to deterioration in body weight and/or Eastern Cooperative Oncology group performance score (ECOG PS) whichever occurred first.~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve." (NCT00806819)
Timeframe: From randomisation until data cut-off (15 February 2013), Up to 30 months

InterventionMonths (Median)
Nintedanib Plus Pemetrexed7.2
Placebo Plus Pemetrexed7.5

[back to top]

Dose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide

Geometric mean of dose normalised predose plasma concentration (Cpre,ss,norm) of nintedanib and of its metabolites BIBF 1202 and BIBF 1202 glucuronide evaluated at steady state based on course 2 and 3. If only one value was available and valid, then this value was used for calculation of Cpre,ss,norm. (NCT00806819)
Timeframe: Before the administration of nintedanib or placebo and between a window of 30 mins to an hour after administration of trial drug during Course 2 and between 1 and 3 hours after administration of trial drug during Course 3

,
Interventionng/mL/mg (Geometric Mean)
Nintedanib BIBF 1120 (N=188, 39)Nintedanib BIBF 1202 (N=188, 40)Nintedanib BIBF 1202 glucuronide (N=184, 39)
Nintedanib 150 mg Bid Plus Pemetrexed0.1030.1511.72
Nintedanib Plus Pemetrexed0.08830.1311.40

[back to top]

Duration of Confirmed Objective Tumour Response

"The duration of objective response is the time from first documented (CR) or (PR) to the time of progression or death and evaluated according to the modified RECIST criteria version 1.0. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.~This endpoint was analysed based on the central independent reviewer as well as the investigator." (NCT00806819)
Timeframe: From randomisation until data cut-off (15 February 2013), Up to 30 months

,
InterventionMonths (Median)
central independent reviewer (N=32, 30)Investigator assessment (N=53, 48)
Nintedanib Plus Pemetrexed6.96.5
Placebo Plus Pemetrexed4.47.2

[back to top]

Duration of Disease Control

"The duration of disease control was defined as the time from randomisation to the date of disease progression or death (which ever occurs first) for patients with disease control. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve.~This endpoint was analysed based on the central independent reviewer as well as the investigator." (NCT00806819)
Timeframe: From randomisation until data cut-off (15 February 2013), Up to 30 months

,
InterventionMonths (Median)
Central independent review (N=215, 192)Investigator assessment (N=233, 217)
Nintedanib Plus Pemetrexed7.46.9
Placebo Plus Pemetrexed6.86.8

[back to top]

Incidence and Intensity of Adverse Events

"Incidence and intensity of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The worst CTCAE grade per patient is reported and MedDRA version 15.1 used.~Serious signs and symptoms of progressive disease were reported as an adverse event in analysis of this endpoint." (NCT00806819)
Timeframe: From the first drug administration until 28 days after the last drug administration, up to 36 months

,
Intervention% of participants (Number)
CTCAE grade 1CTCAE grade 2CTCAE grade 3CTCAE grade 4CTCAE grade 5
Nintedanib Plus Pemetrexed4.922.246.112.49.8
Placebo Plus Pemetrexed9.230.534.57.812.0

[back to top]

Objective Tumor Response

Confirmed objective response is defined as confirmed Complete Response (CR) and Partial Response (PR) and evaluated according to the modified RECIST criteria version 1.0. This endpoint was analysed based on the central independent reviewer as well as the investigator (NCT00806819)
Timeframe: From randomisation until data cut-off (15 February 2013), Up to 30 months

,
Intervention% of participants (Number)
Central independent reviewerInvestigator assessment
Nintedanib Plus Pemetrexed9.115.0
Placebo Plus Pemetrexed8.313.3

[back to top]

Quality of Life (QoL)

"QoL was measured by standardised questionnaires (EQ-5D, EORTC QLQ-C30, EORTC QLQ-LC13). The EORTC QLQ-C30 comprises of 30 questions, using both multi-item scales and single-item measures. EORTC LC-13 comprises of 13 questions incorporating 1 multi-item scale and a series of single items. The following were the main points of interest: Time to deterioration of cough (QLQ-LC13 question 1), Time to deterioration of dyspnoea (QLQ-LC13, composite of questions 3 to 5), Time to deterioration of pain (QLQ- C30, composite of questions 9 and 19). Time to deterioration of cough, dyspnoea and pain was defined as the time to a 10-point increase from the baseline score.~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve." (NCT00806819)
Timeframe: From randomisation until data cut-off (15 February 2013), Up to 30 months

,
InterventionMonths (Median)
Time to deterioration of coughTime to deterioration of dyspnoeaTime to deterioration of pain
Nintedanib Plus Pemetrexed6.02.42.8
Placebo Plus Pemetrexed4.32.02.7

[back to top]

Disease Control

"Disease control was defined as a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) and evaluated according to the modified RECIST criteria version 1.0.~This endpoint was analysed based on the central independent reviewer as well as the investigator." (NCT00806819)
Timeframe: From randomisation until data cut-off (15 February 2013), Up to 30 months

,
Intervention% of participants (Number)
Central independent review (N=215, 192)Investigator assessment (N=233, 217)
Nintedanib Plus Pemetrexed60.966.0
Placebo Plus Pemetrexed53.360.3

[back to top]

Overall Survival (Key Secondary Endpoint)

Overall Survival (OS) defined as the duration from randomisation to death (irrespective of the reason of death). Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve. (NCT00806819)
Timeframe: From randomisation until data cut-off (15 February 2013), Up to 30 months

Interventionmonths (Median)
Nintedanib Plus Pemetrexed12.0
Placebo Plus Pemetrexed12.7

[back to top]

Change From Baseline in Tumour Size

Percentage change from baseline in tumour size is defined as decrease in the sum of the longest diameter of the target lesion. Presented means are in fact adjusted best means percentage changes generated from ANOVA model adjusted for baseline ECOG PS (0 vs. 1), tumour histology (adenocarcinoma vs. non-adenocarcinoma), brain metastases at baseline (yes vs no) and prior treatment with bevacizumab (yes vs no) This endpoint was analysed based on the central independent reviewer as well as the investigator. (NCT00806819)
Timeframe: From randomisation until data cut-off (15 February 2013), Up to 30 months

,
Interventionpercentage of change in tumor size in mm (Mean)
Central independent review (N=298, 305)Investigator assessment (N=322, 325)
Nintedanib Plus Pemetrexed-10.10-15.60
Placebo Plus Pemetrexed-7.53-11.28

[back to top]

AUC0-inf of Docetaxel in Course 2

"AUC0-inf (area under the plasma concentration-time curve over the time interval from 0 extrapolated to infinity) after the first administration of docetaxel in course 2.~Docetaxel 50 mg/m2 patients were assigned to Docetaxel 60 mg/m2 in Cycle 1, but the dose was reduced to 50 mg/m2 in Cycle 2 as defined in the Clinical Trial Protocol." (NCT00876460)
Timeframe: -0:05h before drug administration and 1h, 1.5h, 2h, 3h, 4h, 7h, 23:55h and 47:55h after drug administration

Interventionng*h/mL (Geometric Mean)
Docetaxel 50 mg/m22320
Docetaxel 60 mg/m23750
Docetaxel 75 mg/m24270

[back to top]

Objective Tumor Response

Number of participants with objective response defined as complete response (CR) or partial response (PR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.0 (NCT00876460)
Timeframe: Pre-treatment, every 6 weeks from treatment course 3, end of treatment (up to 1367 days)

,,,,
InterventionParticipants (Number)
YesNo
Nintedanib 100 mg + Docetaxel 60 mg/m203
Nintedanib 150 mg + Docetaxel 60 mg/m227
Nintedanib 150 mg + Docetaxel 75 mg/m257
Nintedanib 200 mg + Docetaxel 60 mg/m226
Nintedanib 200 mg + Docetaxel 75 mg/m215

[back to top]

AUC0-inf of Docetaxel in Course 1

AUC0-inf (area under the plasma concentration-time curve over the time interval from 0 extrapolated to infinity) after the first administration of docetaxel in course 1 (NCT00876460)
Timeframe: -0:05h before drug administration and 1h, 1.5h, 2h, 3h, 4h, 7h, 23:55h and 47:55h after drug administration

Interventionng*h/mL (Geometric Mean)
Docetaxel 60 mg/m23270
Docetaxel 75 mg/m23810

[back to top]

Disease Control

Number of participants with disease control, defined as complete response (CR) or partial response (PR) or stable disease (SD) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 (NCT00876460)
Timeframe: Pre-treatment, every 6 weeks from treatment course 3, end of treatment (up to 1367 days)

,,,,
InterventionParticipants (Number)
YesNo
Nintedanib 100 mg + Docetaxel 60 mg/m221
Nintedanib 150 mg + Docetaxel 60 mg/m254
Nintedanib 150 mg + Docetaxel 75 mg/m2120
Nintedanib 200 mg + Docetaxel 60 mg/m253
Nintedanib 200 mg + Docetaxel 75 mg/m242

[back to top]

Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 for All Courses

"Number of participants with adverse events according to Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 for all courses.~The CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE), 5 (death related to AE)." (NCT00876460)
Timeframe: Between the first administration of docetaxel and 28 days after last administration of docetaxel and/or nintedanib, up to 1367 days

,,,,,,,
InterventionParticipants (Number)
Grade 1Grade 2Grade 3Grade 4Grade 5
Nintedanib 100 mg + Docetaxel 60 mg/m200030
Nintedanib 150 mg + Docetaxel 60 mg/m2 (BSA <1.5 m^2)00160
Nintedanib 150 mg + Docetaxel 60 mg/m2 (BSA >=1.5 m^2)00210
Nintedanib 150 mg + Docetaxel 75 mg/m2 (BSA <1.5 m^2)00051
Nintedanib 150 mg + Docetaxel 75 mg/m2 (BSA >=1.5 m^2)00070
Nintedanib 200 mg + Docetaxel 60 mg/m2 (BSA <1.5 m^2)00030
Nintedanib 200 mg + Docetaxel 60 mg/m2 (BSA >=1.5 m^2)00151
Nintedanib 200 mg + Docetaxel 75 mg/m2 (BSA >=1.5 m^2)00060

[back to top]

Time to Treatment Failure (TTF)

"For participants with known date of discontinuation of the study treatment (or progression [not necessarily confirmed by tumour imaging; can also be based on any clinical sign of tumour progression] or death): TTF [days] = earlier of date of discontinuation of the study treatment, progression, or death - date the study treatment started + 1.~For participants known to be alive without progression by the end of trial or follow-up visit: TTF (censored) [days] = date when the patient is known to be progression-free and alive - date the study treatment started + 1.~Progression is assessed according to RECIST version 1.0." (NCT00876460)
Timeframe: Pre-treatment, every 6 weeks from treatment course 3, end of treatment (up to 1367 days)

InterventionDays (Median)
Nintedanib 100 mg + Docetaxel 60 mg/m2200.0
Nintedanib 150 mg + Docetaxel 60 mg/m283.5
Nintedanib 150 mg + Docetaxel 75 mg/m2134.0
Nintedanib 200 mg + Docetaxel 60 mg/m287.0
Nintedanib 200 mg + Docetaxel 75 mg/m2176.0

[back to top]

Progression-Free Survival (PFS)

"For participants with known date of progression or death (of any cause): PFS [days] = earlier of date of progression or death - date the study treatment started + 1.~For participants known to be alive without progression by the end of trial or follow-up visit: PFS (censored) [days] = date of last imaging when the participant is known to be progression-free and alive - date the study treatment started + 1.~Progression is assessed according to RECIST version 1.0." (NCT00876460)
Timeframe: Pre-treatment, every 6 weeks from treatment course 3, end of treatment (up to 1367 days)

InterventionDays (Median)
Nintedanib 100 mg + Docetaxel 60 mg/m2229.5
Nintedanib 150 mg + Docetaxel 60 mg/m2117.0
Nintedanib 150 mg + Docetaxel 75 mg/m2139.0
Nintedanib 200 mg + Docetaxel 60 mg/m2351.0
Nintedanib 200 mg + Docetaxel 75 mg/m2184.0

[back to top]

Number of Participants Who Experienced Dose Limited Toxicity in Combination Therapy of Nintedanib and Docetaxel

"Number of participants experienced Dose Limited Toxicity (DLT) in combination therapy of nintedanib and docetaxel.~Maximum tolerated dose (MTD) of nintedanib combination with docetaxel were to be determined separately in the patient groups of body surface area (BSA) <1.5 m2 and BSA ≥1.5 m2. The MTD were to be determined as a combination of a dose equal to or less than 200 mg b.i.d. of nintedanib and 60 mg/m2 and 75 mg/m2 every 3 weeks of docetaxel at which either 0 out of 3, 1 out of 6, or 2 out of 6 patients experienced DLT." (NCT00876460)
Timeframe: During the first treatment course, up to 3 weeks

InterventionParticipants (Number)
Nintedanib 100 mg + Docetaxel 60 mg/m20
Nintedanib 150 mg + Docetaxel 60 mg/m2 (BSA <1.5 m^2)2
Nintedanib 150 mg + Docetaxel 60 mg/m2 (BSA >=1.5 m^2)0
Nintedanib 150 mg + Docetaxel 75 mg/m2 (BSA <1.5 m^2)1
Nintedanib 150 mg + Docetaxel 75 mg/m2 (BSA >=1.5 m^2)2
Nintedanib 200 mg + Docetaxel 60 mg/m2 (BSA <1.5 m^2)3
Nintedanib 200 mg + Docetaxel 60 mg/m2 (BSA >=1.5 m^2)2
Nintedanib 200 mg + Docetaxel 75 mg/m2 (BSA >=1.5 m^2)2

[back to top]

Clinical Relevant Abnormalities in Laboratory Parameters

Number of participants with clinically relevant abnormalities in laboratory parameters reported as adverse events (NCT00876460)
Timeframe: Between the first administration of docetaxel and 28 days after last administration of docetaxel and/or nintedanib, up to 1367 days

,,,,,,,
InterventionParticipants (Number)
Alanine aminotransferase increasedAspartate aminotransferase increasedBlood alkaline phosphatase increasedGamma-glutamyltransferase increasedBlood bilirubin increasedPlatelet count decreasedWhite blood cell count decreasedBlood calcium decreasedGamma-glutamyltransferaseBlood chloride decreasedBlood thyroid stimulating hormone increasedBlood urea increasedC-reactive protein increasedHaemoglobin decreasedLymphocyte count decreasedNeutrophil count decreasedProthrombin level decreasedTri-iodothyronine free decreasedBlood albumin decreasedBlood potassium decreasedBlood uric acid increasedBlood urineBlood urine presentElectrocardiogram QT prolonged
Nintedanib 100 mg + Docetaxel 60 mg/m2220100000000000000000000
Nintedanib 150 mg + Docetaxel 60 mg/m2 (BSA <1.5 m^2)443410100001101100000011
Nintedanib 150 mg + Docetaxel 60 mg/m2 (BSA >=1.5 m^2)000000010000000000000000
Nintedanib 150 mg + Docetaxel 75 mg/m2 (BSA <1.5 m^2)554403302111100011000000
Nintedanib 150 mg + Docetaxel 75 mg/m2 (BSA >=1.5 m^2)444410220010000100111100
Nintedanib 200 mg + Docetaxel 60 mg/m2 (BSA <1.5 m^2)333320000000000000000000
Nintedanib 200 mg + Docetaxel 60 mg/m2 (BSA >=1.5 m^2)442400000010100000000000
Nintedanib 200 mg + Docetaxel 75 mg/m2 (BSA >=1.5 m^2)553400202000111100000000

[back to top]

Cmax of Docetaxel in Course 2

"Cmax (maximum measured plasma concentration) after the first administration of docetaxel in course 2.~Docetaxel 50 mg/m2 patients were assigned to Docetaxel 60 mg/m2 in Cycle 1, but the dose was reduced to 50 mg/m2 in Cycle 2 as defined in the Clinical Trial Protocol." (NCT00876460)
Timeframe: -0:05h before drug administration and 1h, 1.5h, 2h, 3h, 4h, 7h, 23:55h and 47:55h after drug administration

Interventionng/mL (Geometric Mean)
Docetaxel 50 mg/m21870
Docetaxel 60 mg/m23740
Docetaxel 75 mg/m24070

[back to top]

Cmax of Docetaxel in Course 1

Cmax (maximum measured plasma concentration) after the first administration of docetaxel in course 1 (NCT00876460)
Timeframe: -0:05h before drug administration and 1h, 1.5h, 2h, 3h, 4h, 7h, 23:55h and 47:55h after drug administration

Interventionng/mL (Geometric Mean)
Docetaxel 60 mg/m23150
Docetaxel 75 mg/m23550

[back to top]

AUC0-inf of Nintedanib in Course 1

AUC0-inf (area under the plasma concentration-time curve over the time interval from 0 extrapolated to infinity) after the first administration of nintedanib in course 1 (NCT00876460)
Timeframe: -0:05 hours (h) before drug administration and 1h, 2h, 3h, 4h, 6h, 7h, 10h and 23:55h after drug administration in course 1

Interventionng*h/mL (Geometric Mean)
Nintedanib 100 mg169
Nintedanib 150 mg260
Nintedanib 200 mg349

[back to top]

Cmax of Nintedanib in Course 1

Cmax (maximum measured plasma concentration) after the first administration of nintedanib in course 1 (NCT00876460)
Timeframe: -0:05h before drug administration and 1h, 2h, 3h, 4h, 6h, 7h, 10h and 23:55h after drug administration in course 1

Interventionng/mL (Geometric Mean)
Nintedanib 100 mg29.3
Nintedanib 150 mg33.4
Nintedanib 200 mg59.9

[back to top]

Confirmed Objective Response Rate

Objective response rate is defined as a best response of either complete (CR) or partial response (PR) according to RECIST version 1.0. To be assigned a status of PR or CR, changes in tumour measurements had to be confirmed by repetition of the CT or MRI scan no less than 4 weeks after the criteria for response were first met. This confirmation was necessary to avoid overestimating the response rate observed. The 95% confidence interval represent the Clopper-Pearson exact confidence interval (NCT00904839)
Timeframe: First treatment administration until end of treatment, up to 892 days

Interventionpercentage of Participants (Number)
Nintedanib + mFolfox663.5
Bevacizumab + mFolfox656.1

[back to top]

Maximum Plasma Concentration for Nintedanib at Steady State and Normalized by the Dosing Unit Administered (Cmax,ss,Norm) (Phase I)

Maximum plasma concentration for Nintedanib at steady state and normalized by the dosing unit administered (Cmax,ss,norm) (Phase I) (NCT00904839)
Timeframe: -0:05h before drug administration and 1h, 2h, 2.5h, 3h, 4h, 6h, 8h, and 10h after drug administration.

Interventionng/mL/mg (Geometric Mean)
Nintedanib 150 mg + mFolfox6 (Phase I)0.294
Nintedanib 200 mg + mFolfox6 (Phase I)0.278

[back to top]

Maximum Tolerable Dose (MTD)

Determination of Maximum Tolerable Dose based on DLT incidence. (NCT00904839)
Timeframe: First two treatment cycles, up to 28 days

Interventionmg (Number)
Nintedanib 150 mg + mFolfox6 (Phase I)200
Nintedanib 200 mg + mFolfox6 (Phase I)200

[back to top]

Overall Survival

Overall survival is defined as the time from first treatment until death. Greenwood variance was used for the calculation of 95% confidence interval. (NCT00904839)
Timeframe: First treatment administration until end of treatment, up to 892 days

Interventionmonths (Median)
Nintedanib + mFolfox627.8
Bevacizumab + mFolfox633.4

[back to top]

Progression-free Survival (PFS)

PFS is defined as the time from first treatment with the trial drug until either the onset of progressive disease or death throughout the whole study. Progression is assessed according to RECIST criteria (version 1.0). In this endpoint, the Greenwood's variance estimate was used to calculate the Kaplan-Meier progression free survival median and its corresponding 95% confidence interval (NCT00904839)
Timeframe: First treatment administration until end of treatment, up to 892 days

Interventionmonths (Median)
Nintedanib + mFolfox610.5
Bevacizumab + mFolfox615.4

[back to top]

Progression-free Survival Rate at 9 Months (PFS-9)

"PFS-9 is defined as the time from first treatment with the trial drug until either the onset of progressive disease or death. A patient is defined as progression-free for 9 months if their PFS was at least 270 days. Progression is assessed according to following mentioned RECIST criteria (version 1.0).~20% increase in the sum of the longest diameter of target lesions.~The appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions." (NCT00904839)
Timeframe: First treatment administration to nine months

Interventionpercentage of Participants (Number)
Nintedanib + mFolfox662.1
Bevacizumab + mFolfox670.2

[back to top]

Quality of Life Evaluation by a Standardised Questionnaires of EORTC: EORTC-QLQ-C30 for the Change From Baseline at 9 Months of Global Health Status Scores.

"Quality of life evaluation by a standardised questionnaires of European Organisation for Research and Treatment of Cancer (EORTC): EORTC-QLQ-C30 for the change from baseline at 9 months for Global health status scores.~Raw scores are transformed to scales of 0-100. A higher score is associated with a better quality of life for Global health status scores" (NCT00904839)
Timeframe: Baseline and 9 months.

Interventionunits on scale (Mean)
Nintedanib + mFolfox6-1.7
Bevacizumab + mFolfox6-9.8

[back to top]

Resection Rate

"Surgical excision of the lesions is allowed if the previous assessment of tumoral response occurred after at least 6 cycles of treatment. Resection Rate includes resection rates R0, R1 and R2 before progressive disease.~Peto's variance estimate was used." (NCT00904839)
Timeframe: First treatment administration until end of treatment, up to 892 days

Interventionpercentage of Participants (Number)
Nintedanib + mFolfox619.5
Bevacizumab + mFolfox624.5

[back to top]

Unconfirmed Objective Response Rate

Objective response is defined as a best response of either complete (CR) or partial response (PR) according to RECIST version 1.0. To be assigned a status of PR or CR, changes in tumour measurements had to be confirmed by repetition of the CT or MRI scan no less than 4 weeks after the criteria for response were first met. This confirmation was necessary to avoid overestimating the response rate observed. The 95% Confidence interval represent the Clopper- Pearson exact confidence interval. (NCT00904839)
Timeframe: First treatment administration until end of treatment, up to 892 days

Interventionpercentage of Participants (Number)
Nintedanib + mFolfox669.4
Bevacizumab + mFolfox673.2

[back to top]

Incidence and Intensity of Adverse Events With Grading According CTCAE

Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0). (NCT00904839)
Timeframe: From the first dose of study medication up to 28 days after the day of the last intake of study medication, up to 920 days

,
Interventionparticipants (Number)
CTCAE Grade 1CTCAE Grade 2CTCAE Grade 3CTCAE Grade 4CTCAE Grade 5
Bevacizumab + mFolfox6022973
Nintedanib + mFolfox61962112

[back to top]

Number of Participants for Quality of Life Evaluation by a Standardised Questionnaires of EORTC: EORTC-QLQ-CR38 for the First Use of Stoma Bag.

Number of participants for Quality of life evaluation by a standardised questionnaires of European Organisation for Research and Treatment of Cancer (EORTC): EORTC-QLQ-CR38 for the first use of stoma bag. (NCT00904839)
Timeframe: from baseline until end of treatment, up to 892 days

,
Interventionparticipants (Number)
BaselineWeek 6Week 12Week 24Week 30Week 54No use of stoma bag
Bevacizumab + mFolfox640000037
Nintedanib + mFolfox6103111168

[back to top]

Percentage of Patients With Dose Limit Toxicity (DLTs) Incidence During the First Two Treatment Cycles (Phase I).

Percentage of patients with DLTs,AE were observed in Gastrointestinal,Hepatobiliary & skin and subcutaneous tissue disorder.Drug related DLT was defined:1)Gastrointestinal toxicity(vomiting, nausea and diarrhoea)or hypertension of CTCAEgrade(G)3 despite optimal supportive care/intervention.2)Non-haematological toxicity of G≥3 except AE:alopecia,nail modifications,& isolated elevation of gamma glutamyl transpeptidase.3)G4 neutropenia for>7days(not associated with fever≥38.5°C).4)Neutropenia of G≥3 of any duration associated with fever≥38.5ºC.5)Platelets <25,000/μLorG3 thrombocytopenia associated with bleeding requiring transfusion.6)Inability to resume nintedanib dosing within14days of stopping due to treatment related toxicity.7)ALT and/or AST elevation of G≥3orG≥2 in conjunction with bilirubin G>1. 8)Inability to recover from increase ALT/AST in conjunction with increase of bilirubin toALT/AST toG≤1 &bilirubin to normal or baseline within14days after nintedanib treatment interruption (NCT00904839)
Timeframe: First two treatment cycles, up to 28 days

,
Interventionpercentage of participants (Number)
DiarrhoeaHepatotoxicityRash maculo-papular
Nintedanib 150 mg + mFolfox6 (Phase I)0.00.033.3
Nintedanib 200 mg + mFolfox6 (Phase I)11.111.10.0

[back to top]

Quality of Life Evaluation by a Standardised Questionnaires of EORTC: EORTC-QLQ-CR38 for the Change From Baseline at 9 Months.

"Quality of life evaluation by a standardised questionnaires of European Organisation for Research and Treatment of Cancer (EORTC): EORTC-QLQ-CR38 for the change from baseline at 9 months for functional scales, Symptom scales Chemotherapy side effects .~The EORTC-QLQ-CR38 was composed of functioning scales (body image, future perspective, sexual enjoyment, sexual functioning) and symptom scales (chemotherapy side effects, defecation problems, symptoms of the gastrointestinal tract, micturition problems,female sexual problems, male sexual problems, stoma related problems, and weight loss).~Raw scores are transformed to scales of 0-100. A higher score is associated with a better quality of life for functional scales and a worse quality of life for symptom scales." (NCT00904839)
Timeframe: Baseline and 9 months.

,
Interventionunits on scale (Mean)
Body image (N=24, 11)Future perspective (N=25, 11)Sexual enjoyment (N=2, 3)Sexual functioning (N=15, 7)Chemotherapy side effects (N=25, 11)Defaecation problems (N=17, 8)Female sexual problems (N=0, 0)Male sexual problems (N=5, 4)Micturition problems (N=25,11)Stoma-related problems (N=4, 2)Symptoms area of gastro-intestinal tract (N=25,11)Weight loss (N=25,11)
Bevacizumab + mFolfox6-3.56.1-11.12.413.12.0NA4.2-7.12.43.4-12.1
Nintedanib + mFolfox6-3.222.7-33.3-11.120.0-5.4NA6.7-5.8-4.8-3.0-21.3

[back to top]

Tumor Shrinkage

"For each patient, the minimum percentage increase from baseline measurement (≤ 28 days before the beginning of the treatment) of the sum Longest diameter (LD) of target lesions was calculated based on the measurements of tumor size. The minimum percentage increase has been divided to four groups:~<= - 30%~> - 30% and < 0%~>= 0% and < 20%~>=20%" (NCT00904839)
Timeframe: Baseline and day 85

,
Interventionparticipants (Number)
<=-30%> - 30% and < 0%>= 0% and < 20%>=20%Non-evaluable
Bevacizumab + mFolfox6297401
Nintedanib + mFolfox65819422

[back to top]

Area Under the Plasma Concentration Time-curve Over 12 Hours for Nintedanib in the Dosing Interval at Steady State and Normalized by the Dosing Unit Administered (AUCtau,ss,Norm) (Phase I)

Area under the plasma concentration time-curve over 12 hours for Nintedanib in the dosing interval at steady state and normalized by the dosing unit administered (AUCtau,ss,norm) (Phase I) (NCT00904839)
Timeframe: -0:05h before drug administration and 1h, 2h, 2.5h, 3h, 4h, 6h, 8h and 10h after drug administration.

Interventionng*h/mL/mg (Geometric Mean)
Nintedanib 150 mg + mFolfox6 (Phase I)1.46
Nintedanib 200 mg + mFolfox6 (Phase I)1.53

[back to top]

Overall Response Rate

Number of participants with complete response (CR) or partial response (PR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 (NCT00979576)
Timeframe: Every 6 weeks after start of study treatment until end of treatment, up to 992 days

,,
InterventionParticipants (Number)
Complete responsePartial response
BIBF 1120 100 mg + Pemetrexed 500 mg/m^200
BIBF 1120 150 mg + Pemetrexed 500 mg/m^201
BIBF 1120 200 mg + Pemetrexed 500 mg/m^201

[back to top]

AUC0-inf of Nintedanib

Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) (NCT00979576)
Timeframe: 5 minutes (min) before nintedanib administration and 1h, 2h, 3h, 4h, 6h, 7h, 10h and 23h 55min after nintedanib administration in cycle 1

Interventionng*h/mL (Geometric Mean)
BIBF 1120 100 mg + Pemetrexed 500 mg/m^2105
BIBF 1120 150 mg + Pemetrexed 500 mg/m^2232
BIBF 1120 200 mg + Pemetrexed 500 mg/m^2323

[back to top]

Cmax of Nintedanib

Maximum measured concentration of nintedanib in plasma (Cmax) (NCT00979576)
Timeframe: 5 minutes (min) before nintedanib administration and 1h, 2h, 3h, 4h, 6h, 7h, 10h and 23h 55min after nintedanib administration in cycle 1

Interventionng/mL (Geometric Mean)
BIBF 1120 100 mg + Pemetrexed 500 mg/m^220.5
BIBF 1120 150 mg + Pemetrexed 500 mg/m^237.9
BIBF 1120 200 mg + Pemetrexed 500 mg/m^255.1

[back to top]

Disease Control Rate

Number of participants with complete response (CR), partial response (PR) or stable disease (SD) according to the Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 (NCT00979576)
Timeframe: Every 6 weeks after start of study treatment until end of treatment, up to 992 days

InterventionParticipants (Number)
BIBF 1120 100 mg + Pemetrexed 500 mg/m^22
BIBF 1120 150 mg + Pemetrexed 500 mg/m^24
BIBF 1120 200 mg + Pemetrexed 500 mg/m^26

[back to top]

Dose Limiting Toxicities

Number of participants with dose limiting toxicity (DLT) in combination therapy of BIBF 1120 and pemetrexed during the first course (NCT00979576)
Timeframe: During the first course, 21 days

InterventionParticipants (Number)
BIBF 1120 100 mg + Pemetrexed 500 mg/m^20
BIBF 1120 150 mg + Pemetrexed 500 mg/m^21
BIBF 1120 200 mg + Pemetrexed 500 mg/m^22

[back to top]

Duration of Disease Control

Duration of disease control was defined as the time period from the first study drug administration to the progressive disease (PD) or death of patients, whichever occurred earlier. (NCT00979576)
Timeframe: From first study drug administration until PD or death, up to 1003 days

InterventionDays (Median)
BIBF 1120 100 mg + Pemetrexed 500 mg/m^2248.5
BIBF 1120 150 mg + Pemetrexed 500 mg/m^2228.5
BIBF 1120 200 mg + Pemetrexed 500 mg/m^2149.0

[back to top]

Cmax of Pemetrexed

Maximum measured concentration of pemetrexed in plasma (Cmax) (NCT00979576)
Timeframe: 5 minutes (min) before pemetrexed administration and 10min, 40min, 1 hour (h), 2h, 4h, 6h, 23h 55min, 47h 55min after pemetrexed administration in cycles 1 and 2

Interventionng/mL (Geometric Mean)
Cycle 1Cycle 2 (N=11)
Pemetrexed 500 mg/m2139000149000

[back to top]

Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 for All Courses

"Number of patients with adverse events according to worst Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 for all courses.~CTCAE grades are: 1 (mild AE), 2 (moderate AE), 3 (severe AE), 4 (life-threatening or disabling AE) or 5 (death related to AE)." (NCT00979576)
Timeframe: Between first administration of pemetrexed and 28 days after last administration of pemetrexed and/or BIBF 1120, up to 1020 days

,,
Interventionparticipants (Number)
Grade 1Grade 2Grade 3Grade 4Grade 5
BIBF 1120 100 mg + Pemetrexed 500 mg/m^202100
BIBF 1120 150 mg + Pemetrexed 500 mg/m^201500
BIBF 1120 200 mg + Pemetrexed 500 mg/m^212510

[back to top]

AUC0-inf of Pemetrexed

Area under the concentration-time curve of pemetrexed in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) (NCT00979576)
Timeframe: 5 minutes (min) before pemetrexed administration and 10min, 40min, 1 hour (h), 2h, 4h, 6h, 23h 55min, 47h 55min after pemetrexed administration in cycles 1 and 2

Interventionng*h/mL (Geometric Mean)
Cycle 1Cycle 2 (N=11)
Pemetrexed 500 mg/m2194000200000

[back to top]

Number of Participants With Clinically Relevant Abnormalities in Laboratory Parameters

Number of participants with clinically relevant abnormalities in laboratory parameters reported as adverse events which occurred in >= 20% of patients (NCT00979576)
Timeframe: Between first administration of pemetrexed and 28 days after last administration of pemetrexed and/or BIBF 1120, up to 1020 days

,,
Interventionparticipants (Number)
Alanine aminotransferase increasedGamma-glutamyltransferase increasedAspartate aminotransferase increasedLymphocyte count decreasedNeutrophil count decreasedWhite blood cell count decreasedBlood alkaline phosphatase increasedBlood albumin decreasedHaemoglobin decreased
BIBF 1120 100 mg + Pemetrexed 500 mg/m^2222222001
BIBF 1120 150 mg + Pemetrexed 500 mg/m^2655132111
BIBF 1120 200 mg + Pemetrexed 500 mg/m^2887243433

[back to top]

Progression Free Survival (PFS)

PFS by RECIST 1.0 was defined as the duration from date of randomisation to date of progression or death, whichever occurred earlier, based on central independent review. (NCT00987935)
Timeframe: From randomization until data cut-off (16 July 2014); Up to 171 weeks

Interventionmonths (Median)
Phase II, 200 mg Nintedanib Bid2.66
Phase II, 400 mg Sorafenib Bid3.71

[back to top]

fe0-12,ss (Fraction Excreted in Urine Between 0 and 12 Hours at Steady State) for Nintedanib

"fe0-12,ss (fraction excreted in urine between 0 and 12 hours at steady state) for Nintedanib.~The reported value corresponds to the percentage of administered dose." (NCT00987935)
Timeframe: 0 to 4 hours (h), 4 to 12 h, and 12 to 24 h after nintedanib

Interventionpercentage (Geometric Mean)
Group 10.227
Group 20.286

[back to top]

Time to Progression (TTP) in Phase II

TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0. (NCT00987935)
Timeframe: From randomization until data cut-off (28 Sep 2012); Up to 77 weeks

Interventionmonths (Median)
Phase II, 200 mg Nintedanib Bid2.73
Phase II, 400 mg Sorafenib Bid3.71

[back to top]

Time to Progression (TTP) in Phase II (Follow-up Analyses)

TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0. (NCT00987935)
Timeframe: From randomization until disease progression or data cut-off (16 Jul 2014); Up to 171 weeks

Interventionmonths (Median)
Phase II, 200 mg Nintedanib Bid2.76
Phase II, 400 mg Sorafenib Bid3.71

[back to top]

Incidence and Intensity of Adverse Events (AEs) Reported as the Number of Patients With AEs According to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Throughout the Treatment Period.

Incidence and worst intensity (severity) of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0). (NCT00987935)
Timeframe: AEs with an onset during therapy with study treatment or within 28 days after discontinuation of study treatment (up to 1066 days)

,,,,,,,,
Interventionparticipants (Number)
Grade 1Grade 2Grade 3Grade 4Grade 5
Phase I Group 1, 150 mg Nintedanib Bid02100
Phase I Group 1, 200 mg Nintedanib Bid11100
Phase I Group 2, 100 mg Nintedanib Bid10312
Phase I Group 2, 150 mg Nintedanib Bid01200
Phase I Group 2, 200 mg Nintedanib Bid14515
Phase I Group 2, 50 mg Nintedanib Bid00120
Phase I Group I, 100 mg Nintedanib Bid02200
Phase II, 200 mg Nintedanib Bid121517810
Phase II, 400 mg Sorafenib Bid141854

[back to top]

AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 (Metabolite of Nintedanib)

"AUC0-12,ss,norm (area under the plasma concentration-time curve between 0 and 12 hours at steady state, normalised values) of BIBF 1202 (metabolite of Nintedanib).~Detailed time points of sampling are:~Phase I and selected phase II patients in the Nintedanib arm:~Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15." (NCT00987935)
Timeframe: Day1, Day15 and Day 16

Intervention(ng*h/mL)/mg (Geometric Mean)
Group 13.50
Group 28.95

[back to top]

AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of BIBF 1202 Glucuronide (Metabolite of Nintedanib)

"AUC0-12,ss,norm of BIBF 1202 glucuronide (Metabolite of Nintedanib):~Detailed time points of sampling are:~Phase I and selected phase II patients in the Nintedanib arm:~Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15." (NCT00987935)
Timeframe: Day1, Day15 and Day 16

Intervention(ng*h/mL)/mg (Geometric Mean)
Group 116.9
Group 245.0

[back to top]

AUC0-12,ss,Norm (Area Under the Plasma Concentration-time Curve Between 0 and 12 Hours at Steady State, Normalised Values) of Nintedanib

"AUC0-12,ss,norm (area under the plasma concentration-time curve between 0 and 12 hours at steady state, normalised values) of Nintedanib~Detailed time points of sampling are:~Phase I and selected phase II patients in the Nintedanib arm:~Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15." (NCT00987935)
Timeframe: Day1, Day15 and Day 16

Intervention(ng*h/mL)/mg (Geometric Mean)
Group 11.97
Group 23.82

[back to top]

Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 Glucuronide in Plasma at Steady State, Normalised Values)

"Cmax,ss,norm (maximum concentration of the BIBF 1202 glucuronide in plasma at steady state, normalised values).~Detailed time points of sampling are:~Phase I and selected phase II patients in the Nintedanib arm:~Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15." (NCT00987935)
Timeframe: Day1, Day15 and Day 16

Intervention(ng/mL)/mg (Geometric Mean)
Group 11.56
Group 23.48

[back to top]

Cmax,ss,Norm (Maximum Concentration of the BIBF 1202 in Plasma at Steady State, Normalised Values)

"Cmax,ss,norm (maximum concentration of the BIBF 1202 in plasma at steady state, normalised values).~Detailed time points of sampling are:~Phase I and selected phase II patients in the Nintedanib arm:~Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15." (NCT00987935)
Timeframe: Day1, Day15 and Day 16

Intervention(ng/mL)/mg (Geometric Mean)
Group 10.519
Group 21.01

[back to top]

Cmax,ss,Norm (Maximum Concentration of the Nintedanib in Plasma at Steady State, Normalised Values)

"Cmax,ss,norm (maximum concentration of the Nintedanib in plasma at steady state, normalised values).~Detailed time points of sampling are:~Phase I and selected phase II patients in the Nintedanib arm:~Cycle 1, Day 15 to 16: Immediately prior to swallowing the dose of nintedanib (predose) and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 7 h, 10 h, 12 h and 24 h after drug administration on Day 15; Cycle 2, Day 1: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 1; Cycle 2, Day 15: Immediately prior to swallowing the dose of nintedanib (predose) and 2 h after drug administration on Day 15." (NCT00987935)
Timeframe: Day1, Day15 and Day 16

Intervention(ng/mL)/mg (Geometric Mean)
Group 10.348
Group 20.630

[back to top]

Incidence of Dose Limiting Toxicity in Phase I

Number of patients with dose limiting toxicity are presented (NCT00987935)
Timeframe: 4 weeks

Interventionparticipants (Number)
Phase I Group 1, 100 mg Nintedanib Bid0
Phase I Group 1, 150 mg Nintedanib Bid0
Phase I Group 1, 200 mg Nintedanib Bid0
Phase I Group 2, 50 mg Nintedanib Bid0
Phase I Group 2, 100 mg Nintedanib Bid1
Phase I Group 2, 150 mg Nintedanib Bid0
Phase I Group 2, 200 mg Nintedanib Bid0

[back to top]

Maximum Tolerated Dose in Phase I

The MTD was defined as the highest dose studied for which the incidence of DLTs was 0/3 or less than 2/6 patients during the first treatment course. (NCT00987935)
Timeframe: 4 weeks

Interventionmg (Number)
Group 1200
Group 2200

[back to top]

Objective Tumour Response by RECIST

"Objective RECIST 1.0 tumour response was defined as Complete Response (CR) or Partial Response (PR) and was derived from the patient's best objective RECIST 1.0 response based on central independent review.~95% Confidence Interval presented below are computed by Clopper and Pearson method." (NCT00987935)
Timeframe: From randomization until data cut-off (16 July 2014); Up to 171 weeks

Interventionpercentage of participants (Number)
Phase II, 200 mg Nintedanib Bid6.3
Phase II, 400 mg Sorafenib Bid3.1

[back to top]

Overall Survival

Overall survival was defined as the duration from date of randomisation to the date of death. (NCT00987935)
Timeframe: From randomization until data cut-off (16 July 2014); Up to 171 weeks

Interventionmonths (Median)
Phase II, 200 mg Nintedanib Bid10.18
Phase II, 400 mg Sorafenib Bid10.71

[back to top]

Disease Control (DC) During the Expansion Phase

DC is defined as the best overall response of CR, PR, stable disease (SD) and non-CR/non-PD. CR for target lesions (TL): Disappearance of all target lesions. CR for non-target lesions (NTL): Disappearance of all non-target lesions . All lymph nodes must be non-pathological in size (<10mm short axis). PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. Other factors which add to the overall response of an imaging timepoint as PR are as below:- CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; SD for TL: change in the sum of diameters does not satisfy PR or PD. SD in TL, non-PD in NTL lead to overall response of SD, provided there is no appearance of new lesions. (NCT00998296)
Timeframe: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)

,
Interventionpercentage of participants (Number)
YesNoMissing
NSCLC83.311.15.6
Pancreatic Adenocarcinoma28.657.114.3

[back to top]

Cpre,ss,Norm (Dose Normalized Trough Plasma Concentration of Nintedanib at Steady State)

"Cpre,ss,norm (Dose normalized trough plasma concentration of nintedanib at steady state) are presented for the 2 MTD treatment groups (continuous administered nintedanib at 150 mg b.i.d. concomitantly with continuously administered afatinib 30 mg q.d. or with intermittently administered afatinib 40 mg q.d.)~As nintedanib is given twice daily, samples are taken at Day 8, Day 15, Day 22 and Day 28; the Pharmacokinetic (PK) parameter names will be Cpre,ss,15,norm (Day 8), Cpre,ss,29,norm (Day 15), Cpre,ss,43,norm (Day 22) and Cpre,ss,55,norm (Day 28)" (NCT00998296)
Timeframe: Day 8, Day 15, Day 22 and Day 28

,
Interventionnanogram/millilitre/milligram (ng/mL/mg) (Geometric Mean)
Cpre,ss,15,norm (N= 6, 7)Cpre,ss,29,norm (N= 6, 6)Cpre,ss,43,norm (N= 5, 6)Cpre,ss,55,norm (N= 8, NA)
Nintedanib 150 mg +Afatinib 30 mg- Continuously0.1220.09480.1120.0797
Nintedanib 150 mg +Afatinib 40 mg- Intermittently0.07310.07550.0762NA

[back to top]

Changes in Safety Laboratory Parameters

Changes in safety laboratory Parameters reported as adverse events (NCT00998296)
Timeframe: First treatment administration until cut-off date of 02 October 2014, up to 336 days

,,,,,,,,,,
Interventionparticipants (Number)
Alanine aminotransferase increasedAspartate aminotransferase increasedBlood creatinine increasedBlood alkaline phosphatase increasedBlood bilirubin increasedTroponin increasedGamma-glutamyltransferase increasedBlood creatinine phosphokinase increasedBlood fibrinogen increasedHepatic enzymes increased
Nintedanib 150 mg +Afatinib 30 mg - Continuously1110000000
Nintedanib 150 mg +Afatinib 40 mg - Continuously1101010000
Nintedanib 150 mg +Afatinib 40 mg - Intermittently1110004010
Nintedanib 200 mg +Afatinib 10 mg - Continuously1101100000
Nintedanib 200 mg +Afatinib 20 mg - Continuously1000000110
Nintedanib 200 mg +Afatinib 30 mg - Continuously3311000000
Nintedanib 200 mg +Afatinib 30 mg - Intermittently3211001000
Nintedanib 200 mg +Afatinib 40 mg - Continuously3310100000
Nintedanib 200 mg +Afatinib 40 mg - Intermittently3110000001
NSCLC1110000000
Pancreatic Adenocarcinoma1200200000

[back to top]

Trough Plasma Concentration of Afatinib at Steady State

"C(pre,ss) is defined as pre-dose (trough) concentration of afatinib in plasma at steady state immediately before administration of the next dose.~C24,7 corresponds to the plasma concentration at 24 hours on Day 7. C24,13 corresponds to the plasma concentration at 24 hours on Day 13. C24,27 corresponds to the plasma concentration at 24 hours on Day 27." (NCT00998296)
Timeframe: Day 7, Day 13, Day 15, Day 22, Day 27 and Day 28

,
Interventionnanogram/millilitre (ng/mL) (Geometric Mean)
Cpre,ss,15 (N= 6, NA)Cpre,ss,22 (N= 6, NA)Cpre,ss,28 (N= 8, NA)C24,7 (N= NA, 6)C24,13 (N= NA, 5)C24,27 (N= NA, 2)
Nintedanib 150 mg +Afatinib 30 mg - Continuously15.519.019.1NANANA
Nintedanib 150 mg +Afatinib 40 mg - IntermittentlyNANANA19.611.530.5

[back to top]

Stable Disease for at Least 12 Weeks During the Expansion Phase

"SD: Neither sufficient shrinkage to qualify for PR (Partial response) nor sufficient increase to qualify for PD(Progressive disease), taking as references the smallest sum of diameters SoD while on study.~PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters.~PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions." (NCT00998296)
Timeframe: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)

,
Interventionpercentage of participants (Number)
YesNoMissing
NSCLC44.450.05.6
Pancreatic Adenocarcinoma0.085.714.3

[back to top]

Percentage Change in the Tumour Size From Baseline During the Expansion Phase

Percentage change in the tumour size from baseline is expressed as Number of subjects with maximum decrease from baseline in the sum of longest diameters of target lesions. (NCT00998296)
Timeframe: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)

,
Interventionparticipants (Number)
>=20%>=0% and <20%>-30% and <0%<-30%
NSCLC1465
Pancreatic Adenocarcinoma3300

[back to top]

Overall Tumour Response Rate Assessed by the Investigator According to the Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1

"The investigator evaluated whether complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) occurred in a patient.~CR for target lesions: Disappearance of all target lesions. CR for non-target lesions: Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (<10mm short axis).~PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters.~SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as references the smallest SoD while on study.~PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions" (NCT00998296)
Timeframe: 6 weeks

,,,,,,,,,,
Interventionpercentage of participants (Number)
Complete responsePartial responseStable diseaseProgressive disease
Nintedanib 150 mg +Afatinib 30 mg - Continuously0.00.066.733.3
Nintedanib 150 mg +Afatinib 40 mg - Continuously0.00.066.733.3
Nintedanib 150 mg +Afatinib 40 mg - Intermittently0.00.066.733.3
Nintedanib 200 mg +Afatinib 10 mg - Continuously0.00.066.733.3
Nintedanib 200 mg +Afatinib 20 mg - Continuously0.00.033.366.7
Nintedanib 200 mg +Afatinib 30 mg - Continuously0.00.071.428.6
Nintedanib 200 mg +Afatinib 30 mg - Intermittently0.00.083.316.7
Nintedanib 200 mg +Afatinib 40 mg - Continuously0.00.01000.0
Nintedanib 200 mg +Afatinib 40 mg - Intermittently0.00.0100.00.0
NSCLC0.017.670.611.8
Pancreatic Adenocarcinoma0.00.033.366.6

[back to top]

Objective Response (OR) During the Expansion Phase

"OR is defined as a best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.1, CR for target lesions (TL): Disappearance of all target lesions.~CR for non-target lesions (NTL): Disappearance of all non-target lesions. All lymph nodes must be nonpathological in size (<10mm short axis). PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.~Other factors which add to the overall response of an imaging timepoint as PR are as below:~CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; All the above scenarios should also satisfy 'No occurrence of new lesions'." (NCT00998296)
Timeframe: Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)

,
Interventionpercentage of participants (Number)
YesNoMissing
NSCLC22.272.25.6
Pancreatic Adenocarcinoma0.085.714.3

[back to top]

Maximum Tolerated Dose (MTD) of Nintedanib and Afatinib Based on the Percentage of Participants Experienced Dose Limiting Toxicities

Maximum tolerated dose (MTD) of nintedanib and afatinib based on the Percentage of participants experienced dose limiting toxicities during the dose escalation phase. (NCT00998296)
Timeframe: first treatment cycle, up to 28 days

,,,,,,,,
Interventionpercentage of participants (Number)
Alanine aminotransferase increasedAspartate aminotransferase increasedBlood creatinine increasedDehydrationDiarrhoeaHepatocellular injuryRenal failure acuteHepatotoxicity
Nintedanib 150 mg +Afatinib 30 mg - Continuously0.00.00.00.00.00.00.00.0
Nintedanib 150 mg +Afatinib 40 mg - Continuously0.00.00.033.333.30.066.70.0
Nintedanib 150 mg +Afatinib 40 mg - Intermittently0.00.00.00.00.00.00.00.0
Nintedanib 200 mg +Afatinib 10 mg - Continuously0.00.00.00.00.00.00.00.0
Nintedanib 200 mg +Afatinib 20 mg - Continuously0.00.00.00.00.00.00.00.0
Nintedanib 200 mg +Afatinib 30 mg - Continuously12.512.50.00.025.00.00.00.0
Nintedanib 200 mg +Afatinib 30 mg - Intermittently0.00.016.70.016.716.70.00.0
Nintedanib 200 mg +Afatinib 40 mg - Continuously33.30.033.30.033.333.30.00.0
Nintedanib 200 mg +Afatinib 40 mg - Intermittently0.00.00.016.70.00.00.016.7

[back to top]

Incidence and Intensity of Adverse Events According to CTCAE (Common Toxicity Criteria Adverse Event) Version 3.0

Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0). (NCT00998296)
Timeframe: First treatment administration until cut-off date of 02Oct2014; up to 336 days

,,,,,,,,,,
Interventionparticipants (Number)
CTCAE Grade 1CTCAE Grade 2CTCAE Grade 3CTCAE Grade 4CTCAE Grade 5
Nintedanib 150 mg +Afatinib 30 mg - Continuously12120
Nintedanib 150 mg +Afatinib 40 mg - Continuously00201
Nintedanib 150 mg +Afatinib 40 mg - Intermittently12400
Nintedanib 200 mg +Afatinib 10 mg - Continuously01200
Nintedanib 200 mg +Afatinib 20 mg - Continuously02100
Nintedanib 200 mg +Afatinib 30 mg - Continuously01511
Nintedanib 200 mg +Afatinib 30 mg - Intermittently04200
Nintedanib 200 mg +Afatinib 40 mg - Continuously00210
Nintedanib 200 mg +Afatinib 40 mg - Intermittently00321
NSCLC07722
Pancreatic Adenocarcinoma12220

[back to top]

Incidence of Dose Limiting Toxicity in Phase I

Number of patients with dose limiting toxicity are presented (NCT01004003)
Timeframe: 4 weeks

Interventionparticipants (Number)
Phase I Group I, 100 mg Nintedanib Bid0
Phase I Group 1, 150 mg Nintedanib Bid0
Phase I Group 1, 200 mg Nintedanib Bid0
Phase I Group 2, 50 mg Nintedanib Bid0
Phase I Group 2, 100 mg Nintedanib Bid0
Phase I Group 2, 150 mg Nintedanib Bid0
Phase I Group 2, 200 mg Nintedanib Bid0

[back to top]

Maximum Tolerated Dose in Phase I

The MTD was defined as the highest dose studied for which the incidence of dose limiting toxicities (DLTs) was 0/3 or less than 2/6 patients during the first treatment course. (NCT01004003)
Timeframe: 4 weeks

Interventionmg bid (Number)
Group 1200
Group 2200

[back to top]

Overall Survival

Overall survival was defined as the duration from date of randomisation to the date of death. (NCT01004003)
Timeframe: From randomization until data cut-off (15 July 2014); Up to 1031 days

Interventionmonths (Median)
Phase II, 200 mg Nintedanib Bid11.86
Phase II, 400 mg Sorafenib Bid11.40

[back to top]

Progression Free Survival (PFS)

PFS by RECIST 1.0 was defined as the duration from date of randomisation to date of progression or death, whichever occurred earlier, based on central independent review. (NCT01004003)
Timeframe: From randomization until data cut-off (15 July 2014); Up to 1031 days

Interventionmonths (Median)
Phase II, 200 mg Nintedanib Bid5.32
Phase II, 400 mg Sorafenib Bid3.94

[back to top]

Time to Progression (TTP) in Phase II

TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0. (NCT01004003)
Timeframe: From randomization until data cut-off (15 July 2014); Up to 1031 days

Interventionmonths (Median)
Phase II, 200 mg Nintedanib Bid5.45
Phase II, 400 mg Sorafenib Bid4.63

[back to top]

Objective Tumour Response by RECIST

"Objective RECIST 1.0 tumour response was defined as Complete Response (CR) or Partial Response (PR) and was derived from the patient's best objective RECIST 1.0 response based on central independent review.~95% Confidence Interval presented below are computed by Clopper and Pearson method." (NCT01004003)
Timeframe: From randomization until data cut-off (15 July 2014); Up to 1031 days

Interventionpercentage of participants (Number)
Phase II, 200 mg Nintedanib Bid1.6
Phase II, 400 mg Sorafenib Bid6.5

[back to top]

Objective Response Based on Investigator Assessment

Objective tumour response defined as either complete response [CR] or partial response [PR] in patients with at least 1 target lesion reported at baseline (NCT01015118)
Timeframe: First drug administration until final DBL 26September16, upto 62 months

Interventionpercentage of participants (Number)
Nintedanib74.3
Placebo70.2

[back to top]

Change in Abdominal/Gastro-intestinal Symptoms Over Time

"Change in abdominal/gastro-intestinal over time was calculated on symptoms (scale composite of items 31 to 37 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Module for Ovarian Cancer 28 (EORTC QLQ OV-28).~As specified in the EORTC scoring manual, for each scale or item, a linear transformation was applied to standardize the raw score to a range from 0 to 100 (high scores represent a high/severe level of symptomatology).~Mean presented is Adjusted mean. Adjusted for the stratification factors macroscopic residual postoperative tumour at baseline (yes vs. no), FIGO stage (IIB-III vs IV), and Carboplatin level (AUC5 vs. AUC6)." (NCT01015118)
Timeframe: First drug administration until final DBL 26September16, upto 62 months

Interventionunits on a scale (Mean)
Nintedanib24.63
Placebo19.34

[back to top]

Change in Global Health Status/ Quality of Life (QoL) Scale Over Time.

"Change in Global Health Status/ Quality of life (QoL) over time was calculated on Global Health Status/QoL scale (composite of items 29 and 30 of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-C30) as a general measure.~As specified in the EORTC scoring manual, for each scale or item, a linear transformation was applied to standardize the raw score to a range from 0 to 100 (high scores represent a high/healthy level of functioning).~Mean presented is Adjusted mean. Adjusted for the stratification factors macroscopic residual postoperative tumour at baseline (yes vs. no), FIGO stage (IIB-III vs IV), and Carboplatin level (AUC5 vs. AUC6)." (NCT01015118)
Timeframe: First drug administration until final DBL 26September16, upto 62 months

Interventionunits on a scale (Mean)
Nintedanib68.79
Placebo70.67

[back to top]

Overall Survival

"Overall survival is defined as time from randomization to date of death (irrespective of reason).~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm." (NCT01015118)
Timeframe: First drug administration to date of death until final DBL 26September16, upto 62 months

InterventionMonths (Median)
Nintedanib62.0
Placebo62.8

[back to top]

PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).

"Follow-up analysis was conducted at the time of overall survival analysis. Progression free survival (PFS) is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first according to the Investigator assessment.~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm." (NCT01015118)
Timeframe: First drug administration to date of disease progression or death whichever occurs first until final Data Base Lock (DBL) 26September16, upto 62 months

InterventionMonths (Median)
Nintedanib17.6
Placebo16.6

[back to top]

PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria.

"Progression free survival (PFS) is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first according to the Investigator assessment.~The primary PFS analysis of this trial was performed when approximately 753 patients had experienced a PFS event~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm." (NCT01015118)
Timeframe: First drug administration to date of disease progression or death whichever occurs first , upto 29 months

InterventionMonths (Median)
Nintedanib17.2
Placebo16.6

[back to top]

PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint - Follow up Analysis).

Follow-up analysis was conducted at the time of overall survival analysis. Progression free survival is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first based on the Investigator assessment according to Modified Response Evaluation Criteria (mRECIST), version 1.1. Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm. (NCT01015118)
Timeframe: First drug administration to date of disease progression or death whichever occurs first until final Data Base Lock (DBL) 26September16, upto 62 months

InterventionMonths (Median)
Nintedanib18.4
Placebo16.6

[back to top]

PFS Based on Investigator Assessment According to mRECIST Version 1.1 (Key Secondary Endpoint).

"Progression free survival is calculated as the time from randomisation to the date of disease progression, or to the date of death, whichever occurs first based on the Investigator assessment according to Modified Response Evaluation Criteria (mRECIST), version 1.1.~The primary PFS analysis of this trial was performed when approximately 753 patients had experienced a PFS event.~Median, 25th and 75th percentiles are calculated from an unadjusted Kaplan-Meier curve for each treatment arm." (NCT01015118)
Timeframe: First drug administration to date of disease progression or death whichever occurs first , upto 29 months

InterventionMonths (Median)
Nintedanib18.3
Placebo16.6

[back to top]

Time to CA-125 Tumour Marker Progression

Time to tumour-marker progression was defined as the time from randomisation until the date when Carbohydrate (cancer) antigen (CA-125) values increased to higher than twice the nadir value. CA-125 >=2 x nadir in case nadir value > Upper limit of normal (ULN) or CA-125 >=2 x ULN in case nadir value <= ULN. (NCT01015118)
Timeframe: First drug administration until final DBL 26September16, upto 62 months

InterventionMonths (Median)
Nintedanib16.6
Placebo14.1

[back to top]

AUC(0-6h) of Nintedanib

"Area under the concentration-time curve (AUC) of Nintedanib over the time interval 0 to 6 hours in Cycle 1.~400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient." (NCT01022853)
Timeframe: 5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9

Interventionng*h/mL (Geometric Mean)
100 mg Volasertib + 200 mg Nintedanib69.5
200 mg Volasertib + 200 mg Nintedanib104.0
300 mg Volasertib + 200 mg Nintedanib135.0
350 mg Volasertib + 200 mg Nintedanib121.0

[back to top]

Number of Patients With Best Overall Response

Best overall response based on response evaluation criteria in solid tumors (RECIST) version 1.1. Best overall response is defined as the best overall response (complete response, partial response, stable disease, progressive disease or not evaluable) since the start of treatment. (NCT01022853)
Timeframe: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.

,,,,
Interventionparticipants (Number)
Complete ResponsePartial ResponseStable DiseaseProgressive DiseaseNot EvaluableMissing
100 mg Volasertib + 200 mg Nintedanib002100
200 mg Volasertib + 200 mg Nintedanib002200
300 mg Volasertib + 200 mg Nintedanib117301
350 mg Volasertib + 200 mg Nintedanib004301
400 mg Volasertib + 200 mg Nintedanib001001

[back to top]

Number of Patients With Objective Response (OR)

Objective tumor response based on response evaluation criteria in solid tumors (RECIST) version 1.1. OR is defined as complete response (CR) or partial response (PR) as best response throughout the study. (NCT01022853)
Timeframe: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.

,,,,
Interventionparticipants (Number)
Objective Response (OR)Missing
100 mg Volasertib + 200 mg Nintedanib00
200 mg Volasertib + 200 mg Nintedanib00
300 mg Volasertib + 200 mg Nintedanib21
350 mg Volasertib + 200 mg Nintedanib01
400 mg Volasertib + 200 mg Nintedanib01

[back to top]

Progression Free Survival (PFS)

PFS is defined as the time from start of treatment with study medication to tumour progression or death whichever occurs first. Tumour response was to be documented using appropriate techniques such as magnetic resonance imaging (MRI) or computer tomography (CT). (NCT01022853)
Timeframe: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.

Interventiondays (Median)
100 mg Volasertib + 200 mg Nintedanib114.0
200 mg Volasertib + 200 mg Nintedanib116.0
300 mg Volasertib + 200 mg Nintedanib99.0
350 mg Volasertib + 200 mg Nintedanib72.5
400 mg Volasertib + 200 mg Nintedanib83.0
Total Patients96.5

[back to top]

CL of Volasertib

Total plasma Clearance (CL) of Volasertib in Cycle 1. (NCT01022853)
Timeframe: 0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion

InterventionmL/min (Geometric Mean)
100 mg Volasertib + 200 mg Nintedanib720
200 mg Volasertib + 200 mg Nintedanib685
300 mg Volasertib + 200 mg Nintedanib792
350 mg Volasertib + 200 mg Nintedanib849
400 mg Volasertib + 200 mg Nintedanib589

[back to top]

Cmax of Nintedanib

"Maximum measured concentration (Cmax) of Nintedanib in Cycle 1.~400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient." (NCT01022853)
Timeframe: 5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9

Interventionng/mL (Geometric Mean)
100 mg Volasertib + 200 mg Nintedanib22.5
200 mg Volasertib + 200 mg Nintedanib30.2
300 mg Volasertib + 200 mg Nintedanib36.7
350 mg Volasertib + 200 mg Nintedanib34.2

[back to top]

Cmax of Volasertib

Maximum measured concentration (Cmax) in plasma of Volasertib in Cycle 1. (NCT01022853)
Timeframe: 0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion

Interventionng/mL (Geometric Mean)
100 mg Volasertib + 200 mg Nintedanib164
200 mg Volasertib + 200 mg Nintedanib409
300 mg Volasertib + 200 mg Nintedanib532
350 mg Volasertib + 200 mg Nintedanib534
400 mg Volasertib + 200 mg Nintedanib1210

[back to top]

Duration of Disease Control

Disease control based on response evaluation criteria in solid tumors (RECIST) version 1.1. Patients who had a best overall tumour response of complete response (CR), partial response (PR) or stable disease (SD) were assessed to show disease control. (NCT01022853)
Timeframe: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.

Interventiondays (Median)
100 mg Volasertib + 200 mg Nintedanib163.0
200 mg Volasertib + 200 mg Nintedanib348.0
300 mg Volasertib + 200 mg Nintedanib141.0
350 mg Volasertib + 200 mg Nintedanib215.0
400 mg Volasertib + 200 mg Nintedanib56.0
Total Patients161.5

[back to top]

Maximum Tolerated Dose (MTD) of Volasertib in Combination With Nintedanib

The MTD was determined using a 3+3 design with de-escalation. The MTD was defined as the highest dose level at which maximal 1 out of 6 patients experienced DLT in the first course of the escalation nd de-escalation phase. However, all DLT's occurring in the trial were considered for selection of the recommended dose for further development. (NCT01022853)
Timeframe: 28 days

Interventionmg (Number)
Volasertib in Combination With Nintedanib300

[back to top]

Number of Participants With Dose Limiting Toxicities

"Number of participants with dose limiting toxicities (DLTs).~DLT was defined as:~Drug-related CTCAE grade 3 or 4 non-haematological toxicity (except untreated vomiting, untreated nausea, or untreated diarrhoea) or~Drug-related CTCAE grade 4 neutropenia for 7 or more days and/or complicated by infection or~CTCAE grade 4 thrombocytopenia" (NCT01022853)
Timeframe: From first study drug administration until 28 days after the last administration of any study medication, up to 485 days

Interventionparticipants (Number)
100 mg Volasertib + 200 mg Nintedanib0
200 mg Volasertib + 200 mg Nintedanib1
300 mg Volasertib + 200 mg Nintedanib6
350 mg Volasertib + 200 mg Nintedanib2
400 mg Volasertib + 200 mg Nintedanib2

[back to top]

Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD).

"DLT was defined as:~Drug-related CTCAE (Common Terminology Criteria for Adverse Events) grade 3 or 4 non-haematological toxicity (except untreated vomiting, untreated nausea, or untreated diarrhoea) or~Drug-related CTCAE grade 4 neutropenia for 7 or more days and/or complicated by infection or~CTCAE grade 4 thrombocytopenia" (NCT01022853)
Timeframe: 28 days

Interventionparticipants (Number)
100 mg Volasertib + 200 mg Nintedanib0
200 mg Volasertib + 200 mg Nintedanib0
300 mg Volasertib + 200 mg Nintedanib3
350 mg Volasertib + 200 mg Nintedanib2
400 mg Volasertib + 200 mg Nintedanib2

[back to top] [back to top]

Number of Patients With Disease Control

Disease control based on response evaluation criteria in solid tumors (RECIST) version 1.1. Disease control is defined as complete response (CR), partial response (PR) or stable disease (SD) as best response throughout the study. (NCT01022853)
Timeframe: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.

Interventionparticipants (Number)
100 mg Volasertib + 200 mg Nintedanib2
200 mg Volasertib + 200 mg Nintedanib2
300 mg Volasertib + 200 mg Nintedanib9
350 mg Volasertib + 200 mg Nintedanib4
400 mg Volasertib + 200 mg Nintedanib1

[back to top]

Tmax of Nintedanib

"Time from dosing to the maximum measured concentration, Cmax, of Nintedanib (tmax) in Cycle 1.~400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient." (NCT01022853)
Timeframe: 5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9

Interventionh (Median)
100 mg Volasertib + 200 mg Nintedanib3.00
200 mg Volasertib + 200 mg Nintedanib1.88
300 mg Volasertib + 200 mg Nintedanib2.42
350 mg Volasertib + 200 mg Nintedanib2.00

[back to top]

Vss of Volasertib

Volume of distribution at steady state (Vss) of Volasertib in Cycle 1. (NCT01022853)
Timeframe: 0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion

InterventionL (Geometric Mean)
100 mg Volasertib + 200 mg Nintedanib5710
200 mg Volasertib + 200 mg Nintedanib5590
300 mg Volasertib + 200 mg Nintedanib5010
350 mg Volasertib + 200 mg Nintedanib6080
400 mg Volasertib + 200 mg Nintedanib2710

[back to top]

Time to Progression

"Time to progression is defined as the time period from randomisation to objective tumour progression. Patients with no progression (by RECIST Version 1.1) were censored at the date of the last evaluable imaging.~Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions.~Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates." (NCT01024920)
Timeframe: From randomisation up to objective tumour progression, up to 3 years.

InterventionMonths (Median)
Nintedanib (BIBF 1120)8.48
Sunitinib8.54

[back to top]

Absolute Values at Baseline (Day -1) and Day 1 and Changes From Baseline to Day 1 at Each Point in Time in QRS Interval

QRS interval is an electrocardiogram (ECG) interval and is the time interval from the onset to the end of the QRS complex (combination of the Q wave, R wave and S wave). The normal QRS duration is less than 120 milliseconds (ms). Absolute values and changes from baseline (Day-1 prior to the first dosing of nintedanib) to Day 1 (first drug dose of nintedanib (BIBF 1120)) at each point in time i.e., 10 time points from 0 to 12 in the QRS interval are reported. (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.

Interventionmilliseconds (ms) (Mean)
Absolute value in QRS interval on Day -1 at -5 minutes (min)Absolute value in QRS interval on Day -1 at 1 hAbsolute value in QRS interval on Day -1 at 2 hAbsolute value in QRS interval on Day -1 at 3 hAbsolute value in QRS interval on Day -1 at 4 hAbsolute value in QRS interval on Day -1 at 5 hAbsolute value in QRS interval on Day -1 at 6 hAbsolute value in QRS interval on Day -1 at 7 hAbsolute value in QRS interval on Day -1 at 10 hAbsolute value in QRS interval on Day -1, 12 hAbsolute value in QRS interval on Day 1 at -5 minAbsolute value in QRS interval on Day 1 at 1 hAbsolute value in QRS interval on Day 1 at 2 hAbsolute value in QRS interval on Day 1 at 3 hAbsolute value in QRS interval on Day 1 at 4 hAbsolute value in QRS interval on Day 1 at 5 hAbsolute value in QRS interval on Day 1 at 6 hAbsolute value in QRS interval on Day 1 at 7 hAbsolute value in QRS interval on Day 1 at 10 hAbsolute value in QRS interval on Day 1 at 12 hTime-matched change from Day -1 to Day 1 in QRS interval at -5 minTime-matched change from Day -1 to Day 1 in QRS interval at 1 hTime-matched change from Day -1 to Day 1 in QRS interval 2 hTime-matched change from Day -1 to Day 1 in QRS interval at 3hTime-matched change from Day -1 to day 1 in QRS interval at 4 hTime-matched change from Day -1 to Day 1 in QRS interval at 5 hTime-matched change from Day -1 to Day 1 in QRS interval at 6 hTime-matched change from Day -1 to Day 1 in QRS interval at 7 hTime-matched change from Day -1 to Day 1 in QRS interval at 10 hTime-matched change from Day -1 to Day 1 in QRS interval at 12 h
Nintedanib (BIBF 1120)92.493.793.293.692.792.692.593.092.892.592.693.293.093.393.593.493.493.292.392.80.7-0.5-0.2-0.30.20.20.3-0.2-0.50.3

[back to top]

Time to Treatment Failure

Time to treatment failure was defined as the time from randomisation to objective tumour progression (by RECIST Version 1.1), death, global deterioration of health status requiring treatment discontinuation, or start of new anticancer treatment, whichever came first. Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.The Kaplan-Meier method was used to calculate the estimates. (NCT01024920)
Timeframe: From randomisation up to objective tumour progression, up to 3 years.

InterventionMonth (Median)
Nintedanib (BIBF 1120)8.44
Sunitinib8.36

[back to top]

Average Time-matched Changes From Baseline in QTcF Interval Over 1 h to 12 h After Dosing on Days 1 and 15 of Treatment Cycle 1

"Average time-matched in QTcF interval (QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula) changes over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15." (NCT01024920)
Timeframe: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.

Interventionmilliseconds (ms) (Mean)
Averaged time-matched changes from baseline in QTcF interval over 1 h to 12 h after dosing on Day 1Averaged time-matched changes from baseline in QTcF interval over 1 h to 12 h after dosing on Day 15
Nintedanib (BIBF 1120)-2.20.5

[back to top]

Absolute Values at Baseline (Day -1) and Day 15 and Changes From Baseline to Day 15 at Each Point in Time in QRS Interval

QRS interval is an electrocardiogram (ECG) interval and is the time interval from the onset to the end of the QRS complex (combination of the Q wave, R wave and S wave). The normal QRS duration is less than 120 milliseconds (ms). Absolute values and changes from baseline (Day-1 prior to the first dosing of nintedanib) to Day 15 (steady state) at each point in time i.e., 10 time points from 0 to 12 in the QRS interval are reported. (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Interventionmilliseconds (ms) (Mean)
Absolute value in QRS interval on Day -1 at -5 minutes (min)Absolute value in QRS interval on Day -1 at 1 hour (h)Absolute value in QRS interval on Day -1 at 2 hAbsolute value in QRS interval on Day -1 at 3 hAbsolute value in QRS interval on Day -1 at 4 hAbsolute value in QRS interval on Day -1 at 5 hAbsolute value in QRS interval on Day -1 at 6 hAbsolute value in QRS interval on Day -1 at 7 hAbsolute value in QRS interval on Day -1 at 10 hAbsolute value in QRS interval on Day -1 at 12 hAbsolute value in QRS interval on Day 15 at -5 minAbsolute value Day 15, 1 hAbsolute value in QRS interval on Day 15 at 2 hAbsolute value in QRS interval on Day 15 at 3 hAbsolute value in QRS interval on Day 15 at 4 hAbsolute value in QRS interval on Day 15 at 5 hAbsolute value in QRS interval on Day 15 at 6 hAbsolute value in QRS interval on Day 15 at 7 hAbsolute value in QRS interval on Day 15 at 10 hAbsolute value in QRS interval on Day 15 at 12 hTime-matched change from Day -1 to Day 15 in QRS interval at -5 minTime-matched change from Day -1 to Day 15 in QRS interval at 1 hTime-matched change from Day -1 to Day 15 in QRS interval at 2 hTime-matched change from Day -1 to Day 15 in QRS interval at 3 hTime-matched change from Day -1 to Day 15 in QRS interval at 4 hTime-matched change from Day -1 to Day 15 in QRS interval at 5 hTime-matched change from Day -1 to Day 15 in QRS interval at 6 hTime-matched change from Day -1 to Day 15 in QRS interval at 7 hTime-matched change from Day -1 to Day 15 in QRS interval at 10 hTime-matched change from Day -1 to Day 15 in QRS interval at 12 h
Nintedanib (BIBF 1120)92.593.893.393.692.792.792.793.192.892.693.393.993.092.992.693.693.193.192.893.70.80.0-0.3-0.8-0.60.5-0.1-0.40.11.0

[back to top]

Absolute Values at Baseline (Day -1) and Day 15 and Changes From Baseline to Day 15 at Each Point in Time in PR Interval

The PR interval is an electrocardiogram (ECG) interval and is the time from the onset of the P wave to the start of the QRS complex (combination of the Q wave, R wave and S wave). It reflects conduction through the atrioventricular node (AV) node. The normal PR interval is between 120 - 200 milliseconds (ms) (0.12-0.20s) in duration. Absolute values at baseline (Day-1 prior to the first dosing of nintedanib (BIBF 1120) and at Day 15 (steady state) and changes from baseline to Day 15 at each point in time i.e., 10 time points from 0 to 12 in the PR interval are reported. (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Interventionmilliseconds (ms) (Mean)
Absolute value in PR interval on Day -1 at -5 minutes (min)Absolute value in PR interval on Day -1 at 1 hAbsolute value in PR interval on Day -1 at 2 hAbsolute value in PR interval on Day -1 at 3 hAbsolute value in PR interval on Day -1 at 4 hAbsolute value in PR interval on Day -1 at 5 hAbsolute value in PR interval on Day -1 at 6 hAbsolute value in PR interval on Day -1 at 7 hAbsolute value in PR interval on Day -1 at 10 hAbsolute value in PR interval on Day -1 at 12 hAbsolute value in PR interval on Day 15 at -5 minAbsolute value in PR interval on Day 15 at 1 hAbsolute value in PR interval on Day 15 at 2 hAbsolute value in PR interval on Day 15 at 3 hAbsolute value in PR interval on Day 15 at 4 hAbsolute value in PR interval on Day 15 at 5 hAbsolute value in PR interval on Day 15at 6 hAbsolute value in PR interval on Day 15 at 7 hAbsolute value in PR interval on Day 15 at 10 hAbsolute value in PR interval on Day 15 at 12:00 h:minTime-matched change from Day -1 to Day 15 in PR interval at -5 minTime-matched change from Day -1 to Day 15 in PR interval at 1 hTime-matched change from Day -1 to Day 15 in PR interval at 2 hTime-matched change from Day -1 to Day 15 in PR interval at 3 hTime matched - change from Day -1 to Day 15 in PR interval at 4 hTime-matched change from Day -1 to Day 15 in PR interval at 5 hTime-matched change from Day -1 to Day 15 in PR interval at 6 hTime-matched change from Day -1 to Day 15 in PR interval at 7 hTime-matched change from Day -1 to Day 15 in PR interval at 10 hTime-matched change from Day -1 to Day 15 in PR interval at 12 h
Nintedanib (BIBF 1120)164.7165.7166.8166.5168.0167.2168.3168.9168.1170.1164.5166.1166.8167.4168.7167.7169.3169.0169.1168.8-0.10.5-0.00.90.90.91.30.61.2-1.5

[back to top]

Time-matched Change From Baseline to Day 15 in QTcF (QT Interval Corrected by the Fridericia Formula) at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

"QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 15 in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 15 obtained at time t minus baseline QTcF measurement at time t. 0 h is 5 min prior to dosing on Day 15.~Time-matched change from baseline to Day 15 in QTcF was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h,1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 15 of are reported. (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Interventionmilliseconds (ms) (Least Squares Mean)
Time-matched change from baseline to Day 15 at -5 minutes (min)Time-matched change from baseline to Day 15 at 1 hour (h)Time-matched change from baseline to Day 15 at 2 hTime-matched change from baseline to Day 15 at 3 hTime-matched change from baseline to Day 15 at 4 hTime-matched change from baseline to Day 15 at 5 hTime-matched change from baseline to Day 15 at 6 hTime-matched change from baseline to Day 15 at 7 hTime-matched change from baseline to Day 15 at 10 hTime-matched change from baseline to Day 15 at 12 h
Nintedanib (BIBF 1120)2.60.4-1.7-0.5-0.50.32.23.10.11.6

[back to top]

Time-matched Changes From Baseline to Day 1 in QT Interval at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

"QT interval is the electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 obtained at time t minus baseline QT measurement at time t.~Time-matched change from baseline to Day 1 in QT was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 1 are reported." (NCT01024920)
Timeframe: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.

Interventionmillisecond (ms) (Least Squares Mean)
Time-matched QT interval change from baseline to Day 1 at 1 hour (h)Time-matched QT interval change from baseline to Day 1 at 2 hTime-matched QT interval change from baseline to Day 1 at 3 hTime-matched QT interval change from baseline to Day 1 at 4 hTime-matched QT interval change from baseline to Day 1 at 5 hTime-matched QT interval change from baseline to Day 1 at 6 hTime-matched QT interval change from baseline to Day 1 at 7 hTime-matched QT interval change from baseline to Day 1 at 10 hTime-matched QT interval change from baseline to Day 1 at 12 h
Nintedanib (BIBF 1120)-2.01.63.51.41.41.80.7-1.7-2.2

[back to top]

Time-matched Changes From Baseline to Day 15 in QT Interval at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

"QT interval is the electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 15 in QT at time t was defined as the QT measurement following administration of nintedanib on Day 15 obtained at time t minus baseline QT measurement at time t. 0 h is 5 min prior to dosing on Day 15.~Time-matched change from baseline to Day 15 in QT was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 15 of Cycle 1are reported." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Interventionmilliseconds (ms) (Least Squares Mean)
Time-matched QT interval change from baseline to Day 15 at -5 minutes (min)Time-matched QT interval change from baseline to Day 15 at 1 hour (h)Time-matched QT interval change from baseline to Day 15 at 2 hTime-matched QT interval change from baseline to Day 15 at 3 hTime-matched QT interval change from baseline to Day 15 at 4 hTime-matched QT interval change from baseline to Day 15 at 5 hTime-matched QT interval change from baseline to Day 15 at 6 hTime-matched QT interval change from baseline to Day 15 at 7 hTime-matched QT interval change from baseline to Day 15 at 10 hTime-matched QT interval change from baseline to Day 15 at 12 h
Nintedanib (BIBF 1120)1.00.51.64.44.75.17.77.13.44.2

[back to top]

Time-Matched Heart Rate (HR) Changes From Baseline to Day 1 at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

"Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib (BIBF 1120) at time t. Time-matched change from baseline to Day 1 in HR at time t was defined as the HR measurement following administration of nintedanib (BIBF 1120) on Day 1 obtained at time t minus baseline HR measurement at time t.~Time-matched change from baseline to Day 1 in HR was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib (BIBF 1120) on Day 1 are reported." (NCT01024920)
Timeframe: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.

Interventionbeats per minute (bpm) (Least Squares Mean)
Time-matched heart rate (HR) change from baseline to Day 1 at 1 hour (h)Time-matched heart rate (HR) change from baseline to Day 1 at 2 hTime-matched heart rate (HR) change from baseline to Day 1 at 3 hTime-matched heart rate (HR) change from baseline to Day 1 at 4 hTime-matched heart rate (HR) change from baseline to Day 1 at 5 hTime-matched heart rate (HR) change from baseline to Day 1 at 6 hTime-matched heart rate (HR) change from baseline to Day 1 at 7 hTime-matched heart rate (HR) change from baseline to Day 1 at 10 hTime-matched heart rate (HR) change from baseline to Day 1 at 12 h
Nintedanib (BIBF 1120)-0.0-2.9-3.8-2.5-1.8-2.2-1.4-1.30.0

[back to top]

Frequency of Patients by Clinical Electrocardiogram (ECG) Measurement Interpretation, Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"Based on the interpretation of the electrocardiogram (ECG) patients were classified in 3 categories:~Normal (a normal ECG reading would be a reading that includes the following normal findings: 1) normal general features; 2) no arrhythmia; 3) no conduction delays; 4) T-wave morphology of normal; and 5) normal U-wave morphology) on Day 1 or on Day 15)~Not normal and not normal at baseline (an abnormal ECG reading would be a reading that includes one or more of the following abnormal findings: 1) abnormal general features; 2) arrhythmia; 3) conduction delays; 4) T-wave morphology of flat, inverted or biphasic; and 5) abnormal U-wave morphology) on Day 1 or on Day 15)~Not normal and new onset of finding; Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.

InterventionParticipants (Count of Participants)
ECG interpretation on Day 172344306ECG interpretation on Day 1572344306
NormalNot normal and not normal at baselineNot normal and new onset of finding
Nintedanib (BIBF 1120)39
Nintedanib (BIBF 1120)24
Nintedanib (BIBF 1120)37
Nintedanib (BIBF 1120)25
Nintedanib (BIBF 1120)1

[back to top]

Frequency of Patients With Maximum Time-Matched QT Interval (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) Change From Baseline Categorized by Magnitude of Change, Days 1 and 15

"Number of patients with maximum time-matched change from baseline in the QT interval observed at each point in time, i.e., 9 time points on Day 1 and 10 timepoints on Day 15 is reported. 3 categories of individual QTcF increases from baseline to maximum value were defined:~<= 30 milliseconds (ms)~> 30 to 60 milliseconds (ms)~> 60 milliseconds (ms) Changes more than 60 ms in the QT interval represent notable changes. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

InterventionParticipants (Count of Participants)
Frequency of patients with maximum time-matched QTcF change from baseline on Day 1, 1-12 hour (h)72344306Frequency of patients with maximum time-matched QTcF change from baseline on Day 15, -0:05-12 h72344306
<= 60 milliseconds (ms)> 60 milliseconds (ms)
Nintedanib (BIBF 1120)64
Nintedanib (BIBF 1120)0
Nintedanib (BIBF 1120)62
Nintedanib (BIBF 1120)1

[back to top]

Frequency of Patients With Maximum Time-Matched QTcF Interval Change From Baseline Categorized by Magnitude of Change, Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula.~Number of patients with maximum time-matched change from baseline in the QTcF interval observed at each point in time, i.e., 9 time points on Day 1 and 10 timepoints on Day 15 is reported. 3 categories of individual QTcF increases from baseline to maximum value were defined:~<= 30 milliseconds (ms)~> 30 to 60 milliseconds (ms)~> 60 milliseconds (ms) Changes more than 60 ms in the QTcF interval represent notable changes. Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

InterventionParticipants (Count of Participants)
Frequency of patients with maximum time-matched QTcF change from baseline on Day 1, 1-12 hours (h)72344306Frequency of patients with maximum time-matched QTcF change from baseline on Day 15, -0:05-12 h72344306
> 60 milliseconds (ms)<= 30 milliseconds (ms)> 30 to 60 milliseconds (ms)
Nintedanib (BIBF 1120)64
Nintedanib (BIBF 1120)0
Nintedanib (BIBF 1120)57
Nintedanib (BIBF 1120)6

[back to top]

Absolute Values at Baseline (Day -1) and Day 1 and Changes From Baseline to Day 1 at Each Point in Time in PR Interval

The PR interval is an electrocardiogram (ECG) interval and is the time from the onset of the P wave to the start of the QRS complex (combination of the Q wave, R wave and S wave). It reflects conduction through the atrioventricular node (AV) node. The normal PR interval is between 120 - 200 milliseconds (ms) (0.12-0.20s) in duration. Absolute values at baseline (Day-1 prior to the first dosing of nintedanib) and at Day 1 (first drug dose of nintedanib (BIBF 1120)) and changes from baseline to Day 1 at each point in time i.e., 10 time points from 0 to 12 in the PR interval are reported. (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.

Interventionmilliseconds (ms) (Mean)
Absolute value in PR interval on Day -1 at -5 minutes (min)Absolute value in PR interval on Day -1 at 1 hour (h)Absolute value in PR interval on Day -1 at 2 hAbsolute value in PR interval on Day -1 at 3 hAbsolute value in PR interval on Day -1 at 4 hAbsolute value in PR interval on Day -1 at 5 hAbsolute value in PR interval on Day -1 at 6 hAbsolute value in PR interval on Day -1 at 7 hAbsolute value in PR interval on Day -1 at 10 hAbsolute value in PR interval on Day -1 at 12 hAbsolute value in PR interval on Day 1 at -5 minAbsolute value in PR interval on Day 1 at 1 hAbsolute value in PR interval on Day 1 at 2 hAbsolute value in PR interval on Day 1 at 3 hAbsolute value in PR interval on Day 1 at 4 hAbsolute value in PR interval on Day 1 at 5 hAbsolute value in PR interval on Day 1 at 6 hAbsolute value in PR interval on Day 1 at 7 hAbsolute value n PR interval on Day 1 at 10 hAbsolute value in PR interval on Day 1 at 12 hTime-matched change from Day -1 to Day 1 in PR interval at -5 minTime-matched change from Day -1 to Day 1 in PR interval at 1 hTime-matched change from Day -1 to Day 1 in PR interval at 2 hTime-matched change from Day -1 to Day 1 in PR interval at 3 hTime-matched change from Day -1 to Day 1 in PR interval at 4 hTime-matched change from Day -1 to Day 1 in PR interval at 5 hTime-matched change from Day -1 to Day 1 in PR interval at 6 hTime-matched change from Day -1 to Day 1 in PR interval at 7 hTime-matched change from Day -1 to Day 1 in PR interval at 10 hTime-matched change from Day -1 to Day 1 in PR interval at 12 h
Nintedanib (BIBF 1120)164.7165.7166.8166.6168.1167.2168.1168.9168.0170.0165.7167.4169.4170.0170.0169.4170.8169.9169.8171.30.71.72.63.42.22.83.31.61.80.7

[back to top]

Number of Participants With Adverse Events Leading to Dose Reduction

Number of participants who experienced Adverse Events which led to dose reduction of the trial medication is reported for each treatment arm. (NCT01024920)
Timeframe: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.

InterventionParticipants (Count of Participants)
Nintedanib (BIBF 1120)16
Sunitinib8

[back to top]

Time-matched Change From Baseline to Day 1 in QTcF (QT Interval Corrected by the Fridericia Formula) at 1 Hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

"QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 obtained at time t minus baseline QTcF measurement at time t.~Time-matched change from baseline to Day 1 in QTcF was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib on Day 1 are reported." (NCT01024920)
Timeframe: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 of treatment Cycle 1. Baseline (Day -1) values were taken at exactly the same time points as on Day 1.

Interventionmilliseconds (ms) (Least Squares Mean)
Time-matched change from baseline to Day 1 at 1 hour (h)Time-matched change from baseline to Day 1 at 2 hTime-matched change from baseline to Day 1 at 3 hTime-matched change from baseline to Day 1 at 4 hTime-matched change from baseline to Day 1 at 5 hTime-matched change from baseline to Day 1 at 6 hTime-matched change from baseline to Day 1 at 7 hTime-matched change from baseline to Day 1 at 10 hTime-matched change from baseline to Day 1 at 12 h
Nintedanib (BIBF 1120)-1.6-3.1-2.6-2.6-1.4-2.0-1.5-3.6-2.2

[back to top]

Duration of Hospital Stays Due to Adverse Events Requiring or Prolonging Hospitalisation

Duration of hospitalisation in days for each treatment arm is reported for those patients who experienced adverse events which required or prolonged hospitalisation (of the patients). (NCT01024920)
Timeframe: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.

Interventiondays (Mean)
Nintedanib (BIBF 1120)11.40
Sunitinib13.10

[back to top]

Duration of Objective Response

"Duration (months) of objective response was measured from the time of first objective response to the time of disease progression (by RECIST Version 1.1) or death, whichever occurred first.~Objective response was defined as complete response (CR, the disappearance of all target and non-target lesions and no new lesions) or partial response (PR, at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum of the longest diameters and no new lesions) as determined by RECIST Version 1.1.~Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication. The Kaplan-Meier method was used to calculate the estimates." (NCT01024920)
Timeframe: From the time of first objective response to the time of disease progression or death (whichever comes first), up to 3 years.

InterventionMonths (Median)
Nintedanib (BIBF 1120)19.42
Sunitinib11.66

[back to top]

Number of Participants With Adverse Events Leading to Discontinuation of Trial Drug

Number of participants with Adverse Events which lead to discontinuation of trial medication drug is reported for each treatment arm. (NCT01024920)
Timeframe: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.

InterventionParticipants (Count of Participants)
Nintedanib (BIBF 1120)11
Sunitinib5

[back to top]

Number of Participants With Adverse Events Requiring or Prolonging Hospitalisation

Number of participants who experienced Adverse Events which required or prolonged hospitalisation of patients is reported for each treatment arm. (NCT01024920)
Timeframe: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.

InterventionParticipants (Count of Participants)
Nintedanib (BIBF 1120)15
Sunitinib10

[back to top]

Overall Survival

"Overall survival was calculated as the time (months) from randomisation to death. Patients for whom there was no evidence of death at the time of analysis were censored on the date that they were last known to have been alive.~The Kaplan-Meier method was used to calculate the estimates." (NCT01024920)
Timeframe: From randomisation to death, up to 3 years.

InterventionMonths (Median)
Nintedanib (BIBF 1120)20.37
Sunitinib21.22

[back to top]

Time-Matched Heart Rate (HR) Changes From Baseline to Day 15 at 0 Hour (h), at 1 h, at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h After Dosing of Nintedanib (BIBF 1120)

"Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib (BIBF 1120) at time t. Time-matched change from baseline to Day 15 in HR at time t was defined as the HR measurement following administration of nintedanib (BIBF 1120) on Day 15 obtained at time t minus baseline HR measurement at time t. 0 h is 5 min prior to dosing on Day 15.~Time-matched change from baseline to Day 15 in HR was modelled using a linear mixed-effects model for repeated measures which included 'time' as repeated measures and the time-matched baseline value as a covariate. Adjusted means with corresponding 2-sided 90% confidence intervals at 0 h, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h and 12 h after dosing of nintedanib (BIBF 1120) on Day 15 of Cycle 1 are reported." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 15. Baseline (Day -1) values were taken at exactly the same time points as on Day 15.

Interventionbeats per minute (bpm) (Least Squares Mean)
Time-matched heart rate (HR) change from baseline to Day 15 at -5 minutes (min)Time-matched heart rate (HR) change from baseline to Day 15 at 1 hTime-matched heart rate (HR) change from baseline to Day 15 at 2 hTime-matched heart rate (HR) change from baseline to Day 15 at 3 hTime-matched heart rate (HR) change from baseline to Day 15 at 4 hTime-matched heart rate (HR) change from baseline to Day 15 at 5 hTime-matched heart rate (HR) change from baseline to Day 15 at 6 hTime-matched heart rate (HR) change from baseline to Day 15 at 7 hTime-matched heart rate (HR) change from baseline to Day 15 at 10 hTime-matched heart rate (HR) change from baseline to Day 15 at 12 h
Nintedanib (BIBF 1120)0.9-0.3-2.0-3.3-3.4-3.1-3.8-2.8-2.4-1.6

[back to top]

Probability Rates of Progression-free Survival at 9 Months

"Progression free survival rate at 9 months is the estimated probability of being alive and not having progressive disease at 9 months after randomisation.~Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria version 1.1 (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions.~Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication." (NCT01024920)
Timeframe: At 9 months after randomisation.

InterventionProbability (Number)
Nintedanib (BIBF 1120)0.431
Sunitinib0.452

[back to top]

Progression Free Survival (PFS)

"Progression free survival (PFS) from randomisation to the occurrence of disease progression (by RECIST Version 1.1) or death, whichever occurred first.~Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters recorded since the treatment started together with an absolute increase in the sum of the longest diameters of at least 5 mm, or the appearance of one or more new lesions.~Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication.~The Kaplan-Meier method was used to calculate the estimates." (NCT01024920)
Timeframe: From the start of study until the cut-off date for 3 year efficacy analysis, up to 3 years.

InterventionMonths (Median)
Nintedanib (BIBF 1120)8.44
Sunitinib8.38

[back to top]

Averaged Time-matched Changes From Baseline in QT Interval (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) Over 1 h to 12 h After Dosing on Days 1 and 15 of Treatment Cycle 1

"Averaged time-matched QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) changes from baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120) to Day 1 (first drug dose nintedanib (BIBF 1120)) and to Day 15 (steady state) over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15." (NCT01024920)
Timeframe: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle.

Interventionmillisecond (ms) (Mean)
Averaged time-matched changes from baseline in QT interval over 1 h to 12 h after dosing on Day 1Averaged time-matched changes from baseline in QT interval over 1 h to 12 h after dosing on Day 15
Nintedanib (BIBF 1120)0.94.2

[back to top]

Averaged Time-Matched Heart Rate (HR) Change From Baseline Over 1 to 12 Hours, Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"Averaged time-matched heart rate changes from baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) to Day 1 (first drug dose nintedanib (BIBF 1120)) and to Day 15 (steady state) over 1 to 12 hours was evaluated using a t-test for paired observation. The mean differences between post-treatment values (Days 1 and 15) and baseline (Day -1) along with two-sided 90% confidence limits are reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15." (NCT01024920)
Timeframe: At 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15.

Interventionbeats per minute (bpm) (Mean)
Averaged time-matched HR change from baseline over 1 to 12 hours on Day 1Averaged time-matched HR change from baseline over 1 to 12 hours on Day 15
Nintedanib (BIBF 1120)-1.9-2.5

[back to top]

Frequency of Adverse Events Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0

"The number of participants who experienced adverse events graded according to NCI CTCAE version 3.0, is reported below.The maximum grade of adverse event intensity for each type of treatment-related adverse event was recorded for each patient.~Grade 1 - Mild AE Grade 2 - Moderate AE Grade 3 - Severe AE Grade 4 - Life-threatening or disabling AE Grade 5 - Death related to AE" (NCT01024920)
Timeframe: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.

,
InterventionParticipants (Count of Participants)
Grade 1Grade 2Grade 3Grade 4Grade 5
Nintedanib (BIBF 1120)111614107
Sunitinib561621

[back to top]

Frequency of Patients With Possible Clinically Significant Abnormal Lab Values

Number of patients with possible clinically significant abnormal lab values for the lab parameters alkaline phosphatase, activated partial thromboplastin time (APTT), creatinine, haemoglobin, prothrombin time (PT)-international normalized ratio (INR), potassium, lymphocytes, sodium, neutrophils, platelets, aspartate amino transferase (AST), alanine aminotransferase (ALT), bilirubin and white blood cell count is reported. Only lab values with CTCAE rule for possible clinical significance are displayed. (NCT01024920)
Timeframe: From first dose of study drug administration up to 28 days after last dose of study drug, up to 121 months.

,
InterventionParticipants (Count of Participants)
Alkaline phosphataseAPTT (Activated partial thrombopl. time)CreatinineHaemoglobinProthrombin time (PT)-international normalized ratio (INR)PotassiumLymphocytesSodiumNeutrophilsPlateletsAspartate amino Transferase (AST)Alanine aminotransferase (ALT)Bilirubin, totalWhite blood cell count
Nintedanib (BIBF 1120)274651481432101440
Sunitinib305604113931337

[back to top]

Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QT (Electrocardiogram (ECG) Interval From the Beginning of the QRS Complex to the End of the T Wave) > 500 ms (Notable Prolongation), Days 1 and 15 of Treatment Cycle 1

"Number of participants with new onset of QT (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave)> 500 milliseconds (ms) (notable prolongation) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.

InterventionParticipants (Count of Participants)
Number of participants with new onset of QT> 500 (ms) on Day 1, 1-12 hour (h)Number of participants with new onset of QT> 500 (ms) on Day 15, -0:05-12 h
Nintedanib (BIBF 1120)00

[back to top]

Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF >450 to 470 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula.~Number of participants with new onset of QTcF >450 to 470 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

InterventionParticipants (Count of Participants)
Number of participants with new onset of QTcF >450 to 470 ms on Day 1Number of participants with new onset of QTcF >450 to 470 ms on Day 15
Nintedanib (BIBF 1120)11

[back to top]

Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF ≤450 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula.~Number of participants with new onset (not present at any time pre-dose) of QTcF ≤450 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

InterventionParticipants (Count of Participants)
Number of participants with new onset of QTcF ≤450 (ms) on Day 1Number of participants with new onset of QTcF ≤450 (ms) on Day 15
Nintedanib (BIBF 1120)32

[back to top]

Number of Participants With New (Not Present at Any Time Pre-dose) Onset of QTcF> 500 Milliseconds (ms) (Notable Prolongation), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula.~Number of participants with new onset of QTcF> 500 milliseconds (ms) (notable prolongation) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.

InterventionParticipants (Count of Participants)
Number of participants with new onset of QTcF> 500 (ms) on Day 1, 1-12 hour (h)Number of participants with new onset of QTcF> 500 (ms) (notable prolongation) on Day 15, -0:05-12 h
Nintedanib (BIBF 1120)00

[back to top]

Number of Participants With New Onset of QTcF> 470 to 500 Milliseconds (ms), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula.~Number of participants with new onset of QTcF> 470 to 500 milliseconds (ms) on Day 1 (first drug dose nintedanib (BIBF 1120)) and Day 15 (steady state) compared to the baseline (Day -1 prior to the first dosing of nintedanib (BIBF 1120)) is reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.

InterventionParticipants (Count of Participants)
Number of participants with new onset of QTcF> 470 to 500 ms on Day 1Number of participants with new onset of QTcF> 470 to 500 ms on Day 15
Nintedanib (BIBF 1120)01

[back to top]

Objective Response According to RECIST Criteria

"Objective response was defined as complete response (CR, the disappearance of all target and non-target lesions and no new lesions) or partial response (PR, at least a 30% decrease in the sum of the longest diameters of target lesions, taking as reference the baseline sum of the longest diameters and no new lesions) as determined by RECIST Version 1.1. Numbers of participants with objective response are reported.~Tumour imaging was made by investigators using Computed tomography (CT)/Magnetic Resonance imaging (MRI) every 12 weeks after the first administration of the trial medication." (NCT01024920)
Timeframe: From the start of study until the cut-off date for 3 year efficacy analysis, up to 3 years.

,
InterventionParticipants (Count of Participants)
Complete ResponsePartial response
Nintedanib (BIBF 1120)014
Sunitinib111

[back to top]

Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Nintedanib (BIBF 1120) Plasma Concentration, Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t.~For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

Interventionbeats per minute (bpm) (Mean)
Time-matched change from baseline in HR at maximum BIBF 1120 concentration on Day 1Time-matched change from baseline in HR at maximum BIBF 1120 concentration on Day 15
Nintedanib (BIBF 1120)-2.0-2.1

[back to top]

Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t.~For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

Interventionbeats per minute (bpm) (Mean)
Time-matched change from baseline in HR at maximum BIBF 1202 concentration on Day 1Time-matched change from baseline in HR at maximum BIBF 1202 concentration on Day 15
Nintedanib (BIBF 1120)-2.3-2.0

[back to top]

Time-Matched Change From Baseline in Heart Rate (HR) at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"Baseline heart rate (HR) measurement at time t was defined as the HR measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in HR at time t was defined as the HR measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline HR measurement at time t.~For each participant 'Time-matched change from baseline to Day 1 (Day 15) in HR' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of treatment cycle 1. Continues in the description.

Interventionbeats per minute (bpm) (Mean)
Time-matched change from baseline in HR at maximum BIBF 1202-glucuronide concentration on Day 1Time-matched change from baseline in HR at maximum BIBF 1202-glucuronide concentration on Day 15
Nintedanib (BIBF 1120)-1.2-1.6

[back to top]

Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t.~For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

Interventionmillisecond (ms) (Mean)
Time-matched change from baseline in QT at maximum BIBF 1202-glucuronide concentration on Day 1Time-matched change from baseline in QT at maximum BIBF 1202-glucuronide concentration on Day 15
Nintedanib (BIBF 1120)-0.41.3

[back to top]

Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t.~For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of first treatment cycle. Continues in the description.

Interventionmillisecond (ms) (Mean)
Time-matched change from baseline in QT interval at maximum BIBF 1202 concentration on Day 1Time-matched change from baseline in QT interval at maximum BIBF 1202 concentration on Day 15
Nintedanib (BIBF 1120)1.21.8

[back to top]

Time-Matched Change From Baseline in QT Interval at the Time of Each Patient's Maximum Plasma Concentration of Nintedanib (BIBF 1120), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"QT interval is the (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave. Baseline QT measurement at time t was defined as the QT measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QT at time t was defined as the QT measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QT measurement at time t.~For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QT' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 1 and on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

Interventionmillisecond (ms) (Mean)
Time-matched change from baseline in QT interval at maximum BIBF 1120 concentration on Day 1Time-matched change from baseline in QT interval at maximum BIBF 1120 concentration on Day 15
Nintedanib (BIBF 1120)0.9-0.4

[back to top]

Time-matched Change From Baseline in QTcF Interval (QT Interval Corrected by the Fridericia Formula) at the Time of Each Participant's Maximum Plasma Concentration of Nintedanib (BIBF 1120), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"QTcF interval is the QT interval (electrocardiogram (ECG) interval from the beginning of the QRS complex to the end of the T wave) corrected for the effects of heart rate (HR) by the Fridericia formula. Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t.~For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum nintedanib plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

Interventionmilliseconds (ms) (Mean)
Time-matched change from baseline in QTcF interval at maximum BIBF 1120 concentration on Day 1Time-matched change from baseline in QTcF interval at maximum BIBF 1120 concentration on Day 15
Nintedanib (BIBF 1120)-2.8-3.2

[back to top]

Time-Matched Change From Baseline in QTcF Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202 (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t.~For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum BIBF 1202 (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported.~Time frame: Baseline (Day -1) values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

Interventionmilliseconds (ms) (Mean)
Time-matched change from baseline in QTcF interval at maximum BIBF 1202 concentration on Day 1Time-matched change from baseline in QTcF interval at maximum BIBF 1202 concentration on Day 15
Nintedanib (BIBF 1120)-2.5-1.1

[back to top]

Time-Matched Change From Baseline in QTcF Interval at the Time of Each Patient's Maximum Plasma Concentration of BIBF 1202-glucuronide (a Nintedanib (BIBF 1120) Metabolite), Calculated Separately for Days 1 and 15 of Treatment Cycle 1

"Baseline QTcF measurement at time t was defined as the QTcF measurement collected 1 day prior to the day of the first administration of nintedanib at time t. Time-matched change from baseline to Day 1 (Day 15) in QTcF at time t was defined as the QTcF measurement following administration of nintedanib on Day 1 (Day 15) obtained at time t minus baseline QTcF measurement at time t.~For each participant 'Time-matched change from baseline to Day 1 (Day 15) in QTcF' at the time of the participant's maximum BIBF 1202-glucuronide (a nintedanib (BIBF 1120) metabolite) plasma concentration was obtained and the mean across all participants calculated. Corresponding two-sided 90% confidence intervals based on the t-distribution are reported.~Time frame: Baseline values were taken at exactly the same time points as on Day 15." (NCT01024920)
Timeframe: At 5 minutes (min) before the first dose on Day 15 and at 1 hour (h), at 2 h, at 3 h, at 4 h, at 5 h, at 6 h, at 7 h, at 10 h and at 12 h after the first dose of nintedanib on Day 1 and on Day 15 of the first treatment cycle. Continues in the description.

Interventionmilliseconds (ms) (Mean)
Time-matched change in QTcF from baseline at maximum BIBF 1202-glucuronide concentration on Day 1Time-matched change in QTcF from baseline at maximum BIBF 1202-glucuronide concentration on Day 15
Nintedanib (BIBF 1120)-2.4-1.5

[back to top]

Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)

Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast) (NCT01136174)
Timeframe: Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose

Interventionng/mL (Geometric Mean)
Placebo12000
BIBF 1120 50 mg12800
BIBF 1120 100 mg15300
BIBF 1120 150 mg12600

[back to top]

Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)

Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch) (NCT01136174)
Timeframe: Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose

Interventionng/mL (Geometric Mean)
Placebo10700
BIBF 1120 50 mg12000
BIBF 1120 100 mg12100
BIBF 1120 150 mg12500

[back to top]

Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)

Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast) (NCT01136174)
Timeframe: Day -1 at Visit 1: At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose

Interventionng/mL (Geometric Mean)
Placebo11300
BIBF 1120 50 mg11900
BIBF 1120 100 mg14600
BIBF 1120 150 mg11200

[back to top]

Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)

Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg Without BIBF 1120 (after lunch) (NCT01136174)
Timeframe: Day -1 at Visit 1: at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose

Interventionng/mL (Geometric Mean)
Placebo13500
BIBF 1120 50 mg14600
BIBF 1120 100 mg15100
BIBF 1120 150 mg12900

[back to top]

Lung Function Measurement: Diffusing Capacity for Carbon Monoxide (DLco)

Change in diffusing capacity for carbon monoxide (DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose. (NCT01136174)
Timeframe: baseline and day 35

InterventionmL/min/mmHg (Mean)
Placebo-1.131
BIBF 1120 150 mg-0.707

[back to top]

Lung Function Measurement: Diffusing Capacity for Carbon Monoxide Percent of Predicted (%DLco)

Change in Diffusing Capacity for Carbon Monoxide percent of predicted (%DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose. (NCT01136174)
Timeframe: baseline and day 35

Intervention% predicted (Mean)
Placebo-4.660
BIBF 1120 150 mg-1.193

[back to top]

Lung Function Measurement: Forced Expiratory Volume in 1 Second (FEV1)

Change in forced expiratory volume in 1 second (FEV1) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose. (NCT01136174)
Timeframe: baseline and day 35

InterventionLiter (Mean)
Placebo-0.021
BIBF 1120 150 mg0.036

[back to top]

Lung Function Measurement: Forced Vital Capacity (FVC)

Change in forced vital capacity (FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose. (NCT01136174)
Timeframe: baseline and day 35

InterventionLiter (Mean)
Placebo-0.081
BIBF 1120 150 mg0.050

[back to top]

Lung Function Measurement: Forced Vital Capacity Percent of Predicted (%FVC)

Change in Forced Vital Capacity percent of predicted (%FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose. (NCT01136174)
Timeframe: baseline and day 35

Intervention% predicted (Mean)
Placebo-2.311
BIBF 1120 150 mg1.432

[back to top]

Clinical Relevant Abnormalities in Laboratory Parameters- No Pirfenidone Background

Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - No pirfenidone background (NCT01136174)
Timeframe: after the first drug intake until 28 days from the last treatment administration, up to 60 days

,,,
Interventionparticipants (Number)
Alanine aminotransferase increasedAspartate aminotransferase increasedBlood creatine phosphokinase increasedGamma-glutamyltransferase increased
BIBF 1120 100 mg0000
BIBF 1120 150 mg2211
BIBF 1120 50 mg0000
Placebo0000

[back to top]

Clinical Relevant Abnormalities in Laboratory Parameters- With Pirfenidone Background

Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - With pirfenidone background (NCT01136174)
Timeframe: after the first drug intake until 28 days from the last treatment administration, up to 60 days

,,,
Interventionparticipants (Number)
HypothyroidismTransaminases increased
BIBF 1120 100 mg00
BIBF 1120 150 mg11
BIBF 1120 50 mg00
Placebo00

[back to top] [back to top]

Withdrawal Due to Adverse Event

Number of patients prematurely discontinued from trial medication due to adverse event. (NCT01136174)
Timeframe: after the first drug intake until 28 days from the last treatment administration, up to 60 days

,,,
Interventionparticipants (Number)
With Pirfenidone (N= 5, 4, 4, 13)Without Pirfenidone (N = 7, 2, 4, 11)
BIBF 1120 100 mg00
BIBF 1120 150 mg22
BIBF 1120 50 mg00
Placebo00

[back to top]

Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose. (NCT01136174)
Timeframe: baseline and day 35

,
InterventionmmHg (Mean)
DBPSBP
BIBF 1120 150 mg-0.82.5
Placebo0.51.3

[back to top]

Cmax,ss After Multiple Doses of BIBF 1120 Without Pirfenidone

"Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone.~Detailed outcome measure time frame:~In 50 mg and 100 mg dose group:~BIBF 1120:~days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose~In 150 mg dose group:~BIBF 1120:~days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose" (NCT01136174)
Timeframe: pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)

Interventionng/mL (Geometric Mean)
BIBF 1120 50 mg9.09
BIBF 1120 100 mg20.0
BIBF 1120 150 mg39.7

[back to top]

Change From Baseline in Pulse Rate

Change from baseline in pulse rate at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose. (NCT01136174)
Timeframe: baseline and day 35

Interventionbpm (Mean)
Placebo-2.5
BIBF 1120 150 mg1.9

[back to top]

Cmax,ss After Multiple Doses of BIBF 1120 With Pirfenidone

"Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone~Detailed outcome measure time frame:~In 50 mg and 100 mg dose group:~BIBF 1120:~days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose~In 150 mg dose group:~BIBF 1120:~days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose" (NCT01136174)
Timeframe: pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)

Interventionng/mL (Geometric Mean)
BIBF 1120 50 mg10.9
BIBF 1120 100 mg13.8
BIBF 1120 150 mg23.5

[back to top]

AUCτ,ss After Multiple Doses of BIBF 1120 Without Pirfenidone

"AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone in the time frame mentioned.~Detailed outcome measure time frame:~In 50 mg and 100 mg dose group:~BIBF 1120:~days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose~In 150 mg dose group:~BIBF 1120:~days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose" (NCT01136174)
Timeframe: pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)

Interventionng*h/mL (Geometric Mean)
BIBF 1120 50 mg33.7
BIBF 1120 100 mg115
BIBF 1120 150 mg218

[back to top]

AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)

AUC0-4,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast) in the time frame mentioned. (NCT01136174)
Timeframe: Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose

Interventionng*h/mL (Geometric Mean)
Placebo28800
BIBF 1120 50 mg34300
BIBF 1120 100 mg35000
BIBF 1120 150 mg35900

[back to top]

AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)

AUC0-4,ss was calculated as the area under the curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast) in the time frame mentioned. (NCT01136174)
Timeframe: Day -1 at Visit 1: At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose

Interventionng*h/mL (Geometric Mean)
Placebo28900
BIBF 1120 50 mg34400
BIBF 1120 100 mg45800
BIBF 1120 150 mg32500

[back to top]

AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)

AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch) in the time frame mentioned. (NCT01136174)
Timeframe: Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose

Interventionng*h/mL (Geometric Mean)
Placebo47000
BIBF 1120 50 mg71000
BIBF 1120 100 mg71500
BIBF 1120 150 mg63600

[back to top]

AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)

AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after lunch) in the time frame mentioned. (NCT01136174)
Timeframe: Day -1 at Visit 1: at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose

Interventionng*h/mL (Geometric Mean)
Placebo56600
BIBF 1120 50 mg72800
BIBF 1120 100 mg84100
BIBF 1120 150 mg60900

[back to top]

AUCτ,ss After Multiple Doses of BIBF 1120 With Pirfenidone

"AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone in the time frame mentioned.~Detailed outcome measure time frame:~In 50 mg and 100 mg dose group:~BIBF 1120:~days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose~In 150 mg dose group:~BIBF 1120:~days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose" (NCT01136174)
Timeframe: pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)

Interventionng*h/mL (Geometric Mean)
BIBF 1120 50 mg67.9
BIBF 1120 100 mg86.0
BIBF 1120 150 mg149

[back to top]

Annual Rate of Decline in Haemoglobin Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Decrease

"Haemoglobin corrected DLCO decrease was a secondary endpoint for the trial. It was considered important that all investigators used the same method of testing and recording data at each visit for each patient.~Haemoglobin corrected DLCO was calculated for each patient using the following formulae:~Males: Hb corrected DLCO = measured DLCO x (10.22 + Hb concentration) / (1.7 x Hb concentration) Females: Hb corrected DLCO = measured DLCO x (9.38 + Hb concentration) / (1.7 x Hb concentration). Annual rate of decline in haemoglobin corrected diffusing capacity of the lung for carbon monoxide (DLCO) decrease is presented." (NCT01170065)
Timeframe: From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months

Interventionmmol/min/kPa/yr (Mean)
Placebo-0.4
Nintedanib 50 mg- 100 mg-0.3
Nintedanib 150 mg-0.2

[back to top]

Incidence of Patients With at Least One Acute IPF Exacerbation Over Time

Incidence rate = (Patients with at least one acute IPF exacerbation / Total number of years at risk) x 100 (NCT01170065)
Timeframe: From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months

InterventionExacerbations Per Year (Number)
Placebo6.1
Nintedanib 50 mg- 100 mg7.6
Nintedanib 150 mg7.8

[back to top]

Overall Survival

"Overall survival is defined as the time from the first intake of nintedanib in trial 1199.35 to death.~For presentation of overall survival results, Kaplan-Meier estimates and confidence intervals (using Greenwood variance formula) for the overall on-treatment survival is calculated within each treatment arm." (NCT01170065)
Timeframe: From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months

Interventionpercentage of participants (Number)
Placebo37.4
Nintedanib 50 mg- 100 mg46.8
Nintedanib 150 mg66.2

[back to top]

Percentage of Patients With at Least One Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

"Percentage of patients with at least one acute idiopathic pulmonary fibrosis (IPF) exacerbation are presented.~An exacerbation was defined as otherwise unexplained clinical features occurring within~1 month including all of the following:~Progression of dyspnoea over several days to 4 weeks~New diffuse pulmonary infiltrates on chest X-ray and/or high-resolution computerised tomography (HRCT) Parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit~A decrease in arterial oxygen partial pressure (PaO2) of ≥10 mmHg or PaO2/fraction of inspired oxygen (FiO2) of <225 mmHg since the last visit~Exclusion of infection based on routine clinical practice and microbiological studies~Absence of other contributory causes such as congestive heart failure, pulmonary embolism, etc." (NCT01170065)
Timeframe: From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months

InterventionPercentage of participants (Number)
Placebo13.5
Nintedanib 50 mg- 100 mg19.8
Nintedanib 150 mg20.0

[back to top]

Progression-Free Survival

"Progression-free survival was defined as the time from the first nintedanib intake in trial 1199.35 to disease progression.~For presentation of progression-free survival results, Kaplan-Meier estimates and confidence intervals (using Greenwood variance formula) for the overall on-treatment progression-free survival is calculated within each treatment arm." (NCT01170065)
Timeframe: From first trial drug intake in 1199.35 to disease progression; up to 61.8 months

Interventionpercentage of participants (Number)
Placebo9.6
Nintedanib 50 mg- 100 mg3.5
Nintedanib 150 mg12.2

[back to top]

Time to First Acute IPF Exacerbation

Due to rare events, the median of time to event is not calculable, thus Kaplan-Meier estimates (providing the percentage of patients without acute IPF exacerbation for a certain amount of time after treatment) and confidence intervals (using Greenwood variance formula) are reported and presented within each treatment arm as secondary endpoint. (NCT01170065)
Timeframe: From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months

Interventionpercentage of participants (Number)
Placebo67.7
Nintedanib 50 mg- 100 mg68.6
Nintedanib 150 mg73.5

[back to top] [back to top]

Annual Rate of Decline in Forced Vital Capacity (FVC)

"Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.~For this endpoint reported means represent the adjusted rate." (NCT01170065)
Timeframe: From first drug administration in 1199.35 until database lock 15Oct2015, up to 61.8 Months

Interventionmilliliters per year (mL/ yr) (Mean)
Placebo-129.0
Nintedanib 50 mg- 100 mg-137.5
Nintedanib 150 mg-132.9

[back to top]

Objective Tumor Response

Complete and Partial Tumor Response by RECIST 1.1 (NCT01225887)
Timeframe: For disease that can be evaluated by physical exam,response was assessed prior to each cycle CT scan or MRI if used to follow lesion for measurable disease every other cycle up to 5 years.

Interventionpercentage of participants (Number)
Treatment (Nintedanib)9.4

[back to top]

Overall Survival

The observed length of life from entry into the study to death or the date of last contact. (NCT01225887)
Timeframe: From study entry to death or last contact, up to 5 years

Interventionmonths (Median)
Treatment (Nintedanib)10.1

[back to top]

Progression Free Survival

the period of progression free survival for patients with persistent or recurrent endometrial cancer treated with study drug. (NCT01225887)
Timeframe: The duration of time from study entry to time of progression or death, whichever occurs first, assessed up to 5 years

Interventionmonths (Median)
Treatment (Nintedanib)3.3

[back to top]

Progression-free Survival > 6 Months

Whether or not the patient survived progression-free for at least 6 months. (NCT01225887)
Timeframe: for disease that can be evaluated by physical exam, progression was assessed prior to each cycle. CT scan or MRI if used to follow lesion for measurable disease every other cycle up to 5 years.

Interventionpercentage of participants (Number)
Treatment (Nintedanib)21.9

[back to top]

Number of Participants With Adverse Events

The incidence of adverse events (grade 3 or higher) as assessed by the National Cancer Institute CTCAE version 4.0 (NCT01225887)
Timeframe: Up to 5 years

InterventionParticipants (Count of Participants)
LeukopeniaNeutropeniaAnemiaOther InvestigationsNauseaVomitingOther GastrointestinalGeneral & Administration siteInfections/infestationsMetabolism/nutritionMusculoskeletal/connective tissuePsychiatricRenal/UrinaryRespiratory/thoracic/mediastinalVascular Disorders
Treatment (Nintedanib)112422631122421

[back to top]

Maximum Measured Plasma Concentration (Cmax) of Nintedanib

Maximum measured plasma concentration (Cmax) of nintedanib during course 1 and course 2 (NCT01314105)
Timeframe: 5 minutes (min) before drug administration and 1 hour (h) 2h, 3h, 4h, 6h, 8h, 10h, 24h, 144h, 312h and 456h after drug administration

,
Interventionng/mL (Geometric Mean)
Treatment Course 1 (150mg: N=6; 200mg: N=11)Treatment Course 2 (150mg: N=8; 200mg: N=7)
Nintedanib 150mg38.865.8
Nintedanib 200mg69.082.2

[back to top]

Maximum Measured Plasma Concentration (Cmax) of PLD (Determined as Total Plasma Doxorubicin) During Treatment Course 1 and Course 2

"The maximum measured plasma concentration (Cmax) of pegylated liposomal doxorubicin (PLD) (determined as total plasma doxorubicin) during treatment course 1 and course 2.~Geometric mean (gMean) and Geometric coefficient of Variation (gCV) were not calculable for treatment course 1 as for only 2 patients evaluable concentrations were available." (NCT01314105)
Timeframe: 5 minutes (min) before drug administration and 30 min,59 min, 1 hour (h) 15 min, 1h 29min, 1h 45min, 2h 15min, 2h 45min, 4h, 6h, 7h 30min, 9h, 25h, 27h, 30h, 34h, 48h, 168h, 336h and 480h after drug administration

,
Interventionµg/mL (Geometric Mean)
Treatment Course 1 (200mg:N=NA; All Patients:N=8)Treatment Course 2 (200mg:N=3; All Patients:N=8)
All Patients18.919.0
Nintedanib 200mgNA19.0

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Nintedanib

Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-inf) of nintedanib during course 1 and course 2 (NCT01314105)
Timeframe: 5 minutes (min) before drug administration and 1 hour (h) 2h, 3h, 4h, 6h, 8h, 10h, 24h, 144h, 312h and 456h after drug administration

,
Interventionnanogram*hour/millilitre (ng*h/mL) (Geometric Mean)
Treatment Course 1 (150mg: N=5; 200mg: N=10)Treatment Course 2 (150mg: N=7)
Nintedanib 150mg335482
Nintedanib 200mg482NA

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Drug Concentration (AUC0-tz) of Carboplatin (Determined as Total Platinum)

Area under the plasma concentration-time curve from time zero to the time of the last quantifiable drug concentration (AUC0-tz) of carboplatin during course 1 and course 2 (determined as total platinum). (NCT01314105)
Timeframe: 5 minutes (min) before drug administration and 30 min,59 min, 1 hour (h) 15 min, 1h 29min, 1h 45min, 2h 15min, 2h 45min, 4h, 6h, 7h 30min, 9h, 23h 55min, 26h, 28h, 32h, 48h, 168h, 336h and 480h after drug administration

,
Interventionng*h/mL (Geometric Mean)
Treatment Course 1 (200mg:N=10; All Patients:N=16)Treatment Course 2 (200mg:N=7; All Patients:N=16)
All Patients220000260000
Nintedanib 200mg223000258000

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Carboplatin (Determined as Total Platinum)

Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-inf) of carboplatin (determined as total platinum) during treatment course 1 and course 2. (NCT01314105)
Timeframe: 5 minutes (min) before drug administration and 30 min,59 min, 1 hour (h) 15 min, 1h 29min, 1h 45min, 2h 15min, 2h 45min, 4h, 6h, 7h 30min, 9h, 23h 55min, 26h, 28h, 32h, 48h, 168h, 336h and 480h after drug administration

,
Interventionng/mL (Geometric Mean)
Treatment Course 1 (200mg:N=10; All Patients:N=16)Treatment Course 2 (200mg:N=7; All Patients:N=16)
All Patients267000324000
Nintedanib 200mg271000325000

[back to top]

Maximum Tolerated Dose of Nintedanib Based on the Occurrence of DLTs During Treatment Course 1

Maximum Tolerated Dose (MTD) of nintedanib in combination with carboplatin and pegylated liposomal doxorubicin based on the occurrence of dose limiting toxicities (DLTs) during treatment course 1. MTD will be determined among the first 6 evaluable patients in each dose level. MTD is the highest dose at which the incidence of DLT is less than 2/6. (NCT01314105)
Timeframe: First 28-day treatment cycle

Interventionmg (Number)
Nintedanib 150mgNA
Nintedanib 200mg200

[back to top]

Dose Limiting Toxicities During Treatment Course 1

"Number of patients with dose limiting toxicity (DLT) occurring during treatment course 1~The following AEs were to be reported as DLT events if their occurrence was considered to be drug-related:~Haematological toxicity:~Any CTCAE grade 4 haematological toxicity~CTCAE grade 4 neutropenia that was not associated with fever ≥38.5°C, if persisting for >7 days despite adequate supportive treatment~CTCAE grade ≥3 neutropenia of any duration if associated with fever ≥38.5°C~Any CTCAE grade 4 thrombocytopenia~CTCAE grade ≥3 thrombocytopenia if associated with bleeding of CTCAE grade ≥2~Non-haematological toxicity:~CTCAE grade ≥3 diarrhoea despite optimal medical management~CTCAE grade 2 diarrhoea persisting for more than 7 days despite optimal medical management~CTCAE grade ≥2 vomiting despite optimal medical management~ALT and/or AST elevation of CTCAE grade ≥3~ALT and/or AST elevation of >3x ULN in conjunction with bilirubin increase >2x ULN" (NCT01314105)
Timeframe: First 28-day treatment cycle

Interventionparticipants (Number)
Nintedanib 150mg1
Nintedanib 200mg1

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Drug Concentration (AUC0-tz) of Carboplatin (Determined as Ultrafilterable Platinum)

Area under the plasma concentration-time curve from time zero to the time of the last quantifiable drug concentration (AUC0-tz) of carboplatin during course 1 and course 2 (determined as ultrafilterable platinum). (NCT01314105)
Timeframe: 5 minutes (min) before drug administration and 30 min,59 min, 1 hour (h) 15 min, 1h 29min, 1h 45min, 2h 15min, 2h 45min, 4h, 6h, 7h 30min, 9h, 23h 55min, 25h, 26h, 27h, 28h, 30h, 32h, and 34h after drug administration

,
Interventionng*h/mL (Geometric Mean)
Treatment Course 1 (200mg:N=9; All Patients:N=16)Treatment Course 2 (200mg:N=6; All Patients:N=15)
All Patients5380055700
Nintedanib 200mg5850056200

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Drug Concentration (AUC0-tz) of Nintedanib

Area under the plasma concentration-time curve from time zero to the time of the last quantifiable drug concentration (AUC0-tz) of nintedanib during course 1 and course 2. (NCT01314105)
Timeframe: 5 minutes (min) before drug administration and 1 hour (h) 2h, 3h, 4h, 6h, 8h, 10h, 24h, 144h, 312h and 456h after drug administration

,
Interventionng*h/mL (Geometric Mean)
Treatment Course 1 (150mg: N=6; 200mg: N=11)Treatment Course 2 (150mg: N=8; 200mg: N=7)
Nintedanib 150mg283406
Nintedanib 200mg422476

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Drug Concentration (AUC0-tz) of PLD (Determined as Total Plasma Doxorubicin) During Treatment Course 1 and Course 2

"Area under the plasma concentration-time curve from time zero to the time of the last quantifiable drug concentration (AUC0-tz) of pegylated liposomal doxorubicin (PLD) (determined as total plasma doxorubicin) during treatment course 1 and course 2.~Geometric mean (gMean) and Geometric coefficient of Variation (gCV) were not calculable for treatment course 1 as for only 2 patients evaluable concentrations were available." (NCT01314105)
Timeframe: 5 minutes (min) before drug administration and 30 min,59 min, 1 hour (h) 15 min, 1h 29min, 1h 45min, 2h 15min, 2h 45min, 4h, 6h, 7h 30min, 9h, 25h, 27h, 30h, 34h, 48h, 168h, 336h and 480h after drug administration

,
Interventionµg*h/mL (Geometric Mean)
Treatment Course 1 (200mg:N=NA; All Patients:N=8)Treatment Course 2 (200mg:N=3; All Patients:N=10)
All Patients22302210
Nintedanib 200mgNA2060

[back to top]

Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero Extrapolated to Infinity (AUC 0-inf) of Carboplatin During Treatment Course 1 and Course 2 (Determined as Ultrafilterable Platinum)

"Area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC 0-inf) of carboplatin during treatment course 1 and course 2 (determined as ultrafilterable platinum).~Geometric mean (gMean) and Geometric coefficient of Variation (gCV) were not calculable for treatment course 2 as 2/3 of patients had quantifiable values." (NCT01314105)
Timeframe: 5 minutes (min) before drug administration and 30 min,59 min, 1 hour (h) 15 min, 1h 29min, 1h 45min, 2h 15min, 2h 45min, 4h, 6h, 7h 30min, 9h, 23h 55min, 25h, 26h, 27h, 28h, 30h, 32h, and 34h after drug administration

,
Interventionng*h/mL (Geometric Mean)
Treatment Course 1 (200mg:N=9; All Patients:N=16)Treatment Course 2 (200mg:N=NA; All Patients:N=NA)
All Patients70700NA
Nintedanib 200mg71000NA

[back to top]

Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero Extrapolated to Infinity (AUC 0-inf) of PLD (Determined as Total Plasma Doxorubicin) During Treatment Course 1 and Course 2

"Area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC 0-inf) of pegylated liposomal doxorubicin (PLD) (determined as total plasma doxorubicin) during treatment course 1 and course 2.~Geometric mean (gMean) and Geometric coefficient of Variation (gCV) were not calculable for treatment course 1 as for only 2 patients evaluable concentrations were available." (NCT01314105)
Timeframe: 5 minutes (min) before drug administration and 30 min,59 min, 1 hour (h) 15 min, 1h 29min, 1h 45min, 2h 15min, 2h 45min, 4h, 6h, 7h 30min, 9h, 25h, 27h, 30h, 34h, 48h, 168h, 336h and 480h after drug administration

,
Interventionµg*h/mL (Geometric Mean)
Treatment Course 1 (200mg:N=NA; All Patients:N=8)Treatment Course 2 (200mg:N=3; All Patients:N=10)
All Patients22802300
Nintedanib 200mgNA2120

[back to top]

Change From Baseline in Safety Laboratory Parameters

Change from baseline in safety laboratory parameters. (NCT01314105)
Timeframe: From the first drug administration until 28 days after the last drug administration, up to 31 months

,
Interventionpercentage of participants (Number)
Alanine aminotransferase increasedAspartate aminotransferase increasedGamma-glutamyltransferase increasedPlatelet count decreasedBlood alkaline phosphataseBlood lactate dehydrogenase increasedBlood alkaline phosphatase increasedHaemoglobin decreasedNeutrophil count decreasedBlood bilirubin increasedBlood creatinine decreasedGamma-glutamyltransferaseHaemoglobinNeutrophil countWhite blood cell count decreasedAmylase increasedBlood creatinine increasedPlatelet count increased
Nintedanib 150mg57.171.442.928.628.628.614.30014.314.314.314.314.314.3000
Nintedanib 200mg91.791.766.758.3016.725.016.716.78.3000008.38.38.3

[back to top]

Incidence and Intensity of Adverse Events

"Safety of nintedanib as indicated by intensity and incidence of adverse events, graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.~The CTCAE grades are the worst grade per patient. The CTCAE grades are Grade 1 as mild AE, Grade 2 as moderate AE, Grade 3 as severe AE, Grade 4 as lifethreatening or disabling AE, and Grade 5 as death related to AE." (NCT01314105)
Timeframe: From the first drug administration until 28 days after the last drug administration, up to 31 months

,
Interventionparticipants (Number)
Grade 1Grade 2Grade 3Grade 4Grade 5
Nintedanib 150mg02320
Nintedanib 200mg00930

[back to top]

Maximum Measured Plasma Concentration (Cmax) of Carboplatin (Total Platinum)

Maximum measured plasma concentration (Cmax) of carboplatin during course 1 and course 2 (determined as total platinum). (NCT01314105)
Timeframe: 5 minutes (min) before drug administration and 30 min,59 min, 1 hour (h) 15 min, 1h 29min, 1h 45min, 2h 15min, 2h 45min, 4h, 6h, 7h 30min, 9h, 23h 55min, 26h, 28h, 32h, 48h, 168h, 336h and 480h after drug administration

,
Interventionng/mL (Geometric Mean)
Treatment Course 1 (200mg:N=10; All Patients:N=16)Treatment Course 2 (200mg:N=7; All Patients:N=16)
All Patients2400023900
Nintedanib 200mg2460027100

[back to top]

Maximum Measured Plasma Concentration (Cmax) of Carboplatin During Course 1 and Course 2 (Determined as Ultrafilterable Platinum)

Maximum measured plasma concentration (Cmax) of carboplatin during course 1 and course 2 (determined as ultrafilterable platinum). (NCT01314105)
Timeframe: 5 minutes (min) before drug administration and 30 min,59 min, 1 hour (h) 15 min, 1h 29min, 1h 45min, 2h 15min, 2h 45min, 4h, 6h, 7h 30min, 9h, 23h 55min, 25h, 26h, 27h, 28h, 30h, 32h, and 34h after drug administration

,
Interventionng/mL (Geometric Mean)
Treatment Course 1 (200mg:N=9; All Patients:N=16)Treatment Course 2 (200mg:N=6; All Patients:N=15)
All Patients2460024400
Nintedanib 200mg2600027000

[back to top]

Time to On-treatment Death

"Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported.~Failure is the the proportion of patients who died on-treatment." (NCT01335464)
Timeframe: 52 weeks

,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 150mg Bid2.697.4
Placebo4.495.6

[back to top]

Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

"Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows:~Otherwise unexplained clinical features including all of the following:~Unexplained worsening or development of dyspnoea within 30 days~New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit~Exclusion of infection as per routine clinical practice and microbiological studies~Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury.~Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs ." (NCT01335464)
Timeframe: 52 weeks

,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 150mg Bid6.193.9
Placebo5.494.6

[back to top]

Time to Death Over 52 Weeks

"Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.~Failure is the proportion of patients who died over 52 weeks (373 days time-period) ." (NCT01335464)
Timeframe: 52 weeks

,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 150mg Bid4.295.8
Placebo6.493.6

[back to top]

Time to Death or Lung Transplant Over 52 Weeks

"Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.~Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period)." (NCT01335464)
Timeframe: 52 weeks

,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 150mg Bid5.294.8
Placebo6.993.1

[back to top]

Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.

"Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria:~FVC <45% predicted or Carbon monoxide diffusion capacity (DL(CO)) <30% pred or Oxygen saturation on pulse oximetry (SpO2) <88% at rest, at sea level (to be adapted for other heights).~These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period)." (NCT01335464)
Timeframe: 52 weeks

,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 150mg Bid14.985.1
Placebo18.181.9

[back to top]

Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)

"Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.~Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period)." (NCT01335464)
Timeframe: 52 weeks

,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 150mg Bid3.296.8
Placebo4.995.1

[back to top]

Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)

The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale. (NCT01335464)
Timeframe: baseline, 12 weeks, 24 weeks and 52 weeks

,
Interventionpoints on a scale (Mean)
12 weeks (N= 194, 287)24 weeks (N= 190, 279)52 weeks (N=160, 247)
Nintedanib 150mg Bid-1.75-0.74-2.46
Placebo0.04-0.84-5.88

[back to top]

Absolute Categorical Change of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold

Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by >5%, increase by >5%, and change within ≤5%). (NCT01335464)
Timeframe: Baseline and 52 weeks

,
Interventionpercentage of participants (Number)
Decrease > 5%Change within ≤ 5%Increase > 5%
Nintedanib 150mg Bid34.854.011.2
Placebo52.741.26.1

[back to top]

Absolute Categorical Change of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold

Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by >10%, and change within ≤10%) (NCT01335464)
Timeframe: Baseline and 52 weeks

,
Interventionpercentage of participants (Number)
Decrease > 10%Change within ≤10%Increase > 10%
Nintedanib 150mg Bid12.884.42.8
Placebo29.769.11.2

[back to top]

Risk of an Acute IPF Exacerbation Over 52 Weeks

The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years*100) (NCT01335464)
Timeframe: 52 weeks

InterventionParticipants/Year *100 (Number)
Placebo5.6
Nintedanib 150mg Bid6.6

[back to top]

Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks

Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52). (NCT01335464)
Timeframe: Baseline and 52 weeks

Interventionpercent change (Mean)
Placebo-7.38
Nintedanib 150mg Bid-3.36

[back to top]

Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks

Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52). (NCT01335464)
Timeframe: Baseline and 52 weeks

Interventionpercent change (Mean)
Placebo-7.32
Nintedanib 150mg Bid-3.32

[back to top]

Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)

"Proportion of SGRQ responders at 52 weeks~Responders defined as <= -4 points change in change from baseline in SGRQ total score at 52 weeks." (NCT01335464)
Timeframe: Baseline and 52 weeks

Interventionpercentage of participants (Number)
Placebo24.02
Nintedanib 150mg Bid20.39

[back to top]

Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)

Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'. (NCT01335464)
Timeframe: 52 weeks

Interventionpercentage of participants (Number)
Placebo54.90
Nintedanib 150mg Bid60.84

[back to top]

Proportion of FVC Responders Using 5% Threshold at 52 Weeks

Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks. (NCT01335464)
Timeframe: 52 weeks

Interventionpercentage of participants (Number)
Placebo38.24
Nintedanib 150mg Bid52.75

[back to top]

FVC Responders Using 10% Threshold at 52 Weeks

FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks. (NCT01335464)
Timeframe: 52 weeks

Interventionpercentage of participants (Number)
Placebo56.86
Nintedanib 150mg Bid70.55

[back to top]

Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks

Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52) (NCT01335464)
Timeframe: Baseline and 52 weeks

Interventionpercent of oxygen saturation (Mean)
Placebo-0.53
Nintedanib 150mg Bid-0.24

[back to top]

Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)

"Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335464)
Timeframe: baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo7.61
Nintedanib 150mg Bid6.73

[back to top]

Change From Baseline in SGRQ Symptom Score at 52 Weeks: Patient Reported Outcomes (PROs)

"SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life.~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335464)
Timeframe: Baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo3.89
Nintedanib 150mg Bid1.56

[back to top]

Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

"SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life.~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335464)
Timeframe: Baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo4.01
Nintedanib 150mg Bid4.87

[back to top]

Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

"SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life.~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335464)
Timeframe: baseline and 52 weeks

Interventionpoints on scale (Mean)
Placebo5.81
Nintedanib 150mg Bid4.62

[back to top]

Change From Baseline in Saint-George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks

"This is a key secondary endpoint.~SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact.~The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status.~Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335464)
Timeframe: baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo4.39
Nintedanib 150mg Bid4.34

[back to top]

Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

"SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score.~The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale." (NCT01335464)
Timeframe: Baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo5.08
Nintedanib 150mg Bid4.30

[back to top]

Change From Baseline in Cough Symptoms Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

"The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335464)
Timeframe: Baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo-0.52
Nintedanib 150mg Bid-0.76

[back to top]

Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks : Patient Reported Outcomes (PROs)

"The cough domains of the Cough and Sputum Assessment Questionnaire (CASA-Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335464)
Timeframe: Baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo-4.00
Nintedanib 150mg Bid-2.36

[back to top]

Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks

Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52). (NCT01335464)
Timeframe: Baseline and 52 weeks

Interventionmmol/min/kPa (Mean)
Placebo-0.365
Nintedanib 150mg Bid-0.380

[back to top]

Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks

"Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.~For this endpoint reported means represent the adjusted rate" (NCT01335464)
Timeframe: 52 weeks

InterventionmL/year (Mean)
Placebo-239.91
Nintedanib 150mg Bid-114.65

[back to top]

Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks

Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52). (NCT01335464)
Timeframe: Baseline and 52 weeks

InterventionmL (Mean)
Placebo-205.00
Nintedanib 150mg Bid-95.07

[back to top]

Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks

Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52). (NCT01335464)
Timeframe: Baseline and 52 weeks

Intervention% predicted (Mean)
Placebo-5.98
Nintedanib 150mg Bid-2.76

[back to top]

Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks

Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52). (NCT01335477)
Timeframe: baseline and 52 weeks

Interventionmmol/min/kPa (Mean)
Placebo-0.400
Nintedanib 150 mg Bid-0.286

[back to top]

Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

"The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335477)
Timeframe: baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo-2.38
Nintedanib 150 mg Bid-0.33

[back to top]

Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

"SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life.~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335477)
Timeframe: baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo3.43
Nintedanib 150 mg Bid2.03

[back to top]

Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold

Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by >10%, and change within ≤10%) (NCT01335477)
Timeframe: Baseline and 52 weeks

,
Interventionpercentage of participants (Number)
Decrease > 10%Change within ≤ 10%Increase > 10%
Nintedanib 150 mg Bid14.980.74.5
Placebo22.277.20.6

[back to top]

Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold

Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by >5%, increase by >5%, and change within ≤5%). (NCT01335477)
Timeframe: Baseline and 52 weeks

,
Interventionpercentage of participants (Number)
Decrease > 5%Change within ≤ 5%Increase > 5%
Nintedanib 150 mg Bid34.950.214.9
Placebo52.245.02.8

[back to top]

Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)

The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale. (NCT01335477)
Timeframe: baseline, 12 weeks, 24 weeks and 52 weeks

,
Interventionpoints on a scale (Mean)
12 weeks (N=207, 306)24 weeks (N=204, 297)52 weeks (N=178, 265)
Nintedanib 150 mg Bid-0.57-1.10-2.52
Placebo-1.48-4.86-5.60

[back to top]

Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)

"Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.~Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period)." (NCT01335477)
Timeframe: 52 weeks

,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 150 mg Bid4.395.7
Placebo5.095.0

[back to top]

Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

"SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life.~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335477)
Timeframe: baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo5.93
Nintedanib 150 mg Bid2.85

[back to top]

Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks

Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52). (NCT01335477)
Timeframe: Baseline and 52 weeks

Interventionpercent change (Mean)
Placebo-8.14
Nintedanib 150 mg Bid-3.90

[back to top]

Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks

"This is a key secondary endpoint. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact.~The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status.~Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335477)
Timeframe: Baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo5.48
Nintedanib 150 mg Bid2.80

[back to top]

Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

"The cough domains of the Cough and Sputum Assessment Questionnaire (CASA- Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335477)
Timeframe: baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo-4.39
Nintedanib 150 mg Bid-2.58

[back to top]

Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.

"Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.~For this endpoint reported means represent the adjusted rate." (NCT01335477)
Timeframe: 52 weeks

InterventionmL/year (Mean)
Placebo-207.32
Nintedanib 150 mg Bid-113.59

[back to top]

FVC Responders Using 10% Threshold at 52 Weeks

FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks. (NCT01335477)
Timeframe: 52 weeks

Interventionpercentage of participants (Number)
Placebo63.93
Nintedanib 150 mg Bid69.60

[back to top]

Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks

Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52). (NCT01335477)
Timeframe: Baseline and 52 weeks

InterventionmL (Mean)
Placebo-205.03
Nintedanib 150 mg Bid-95.26

[back to top]

Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks

Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52). (NCT01335477)
Timeframe: Baseline and 52 weeks

Intervention%predicted (Mean)
Placebo-6.15
Nintedanib 150 mg Bid-3.09

[back to top]

Risk of an Acute IPF Exacerbation Over 52 Weeks

The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years*100) (NCT01335477)
Timeframe: 52 weeks

InterventionParticipants/Year *100 (Number)
Placebo10.2
Nintedanib 150 mg Bid3.9

[back to top]

Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.

"Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria:~FVC <45% predicted or Carbon monoxide diffusion capacity (DL(CO)) <30% pred or Oxygen saturation on pulse oximetry (SpO2) <88% at rest, at sea level (to be adapted for other heights).~These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period)." (NCT01335477)
Timeframe: 52 weeks

,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 150 mg Bid19.580.5
Placebo23.776.3

[back to top]

Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks

Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52). (NCT01335477)
Timeframe: Baseline and 52 weeks

Interventionpercent change (Mean)
Placebo-8.13
Nintedanib 150 mg Bid-3.92

[back to top]

Time to Death Over 52 Weeks

"Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.~Failure is the proportion of patients who died over 52 weeks (373 days time-period)." (NCT01335477)
Timeframe: 52 weeks

,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 150 mg Bid6.793.3
Placebo9.190.9

[back to top]

Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)

"Proportion of SGRQ responders at 52 weeks.~Responders defined as <= -4 points change in change from baseline in SGRQ total score at 52 weeks." (NCT01335477)
Timeframe: baseline and 52 weeks

Interventionpercentage of participants (Number)
Placebo16.89
Nintedanib 150 mg Bid25.23

[back to top]

Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)

Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'. (NCT01335477)
Timeframe: 52 weeks

Interventionpercentage of participants (Number)
Placebo53.88
Nintedanib 150 mg Bid61.70

[back to top]

Proportion of FVC Responders Using 5% Threshold at 52 Weeks

Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks. (NCT01335477)
Timeframe: 52 weeks

Interventionpercentage of participants (Number)
Placebo39.27
Nintedanib 150 mg Bid53.19

[back to top]

Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks

Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52) (NCT01335477)
Timeframe: baseline and 52 weeks

Interventionpercent of oxygen saturation (Mean)
Placebo-0.66
Nintedanib 150 mg Bid-0.39

[back to top]

Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

"Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows:~Otherwise unexplained clinical features including all of the following:~Unexplained worsening or development of dyspnoea within 30 days New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit Exclusion of infection as per routine clinical practice and microbiological studies Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury.~Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs ." (NCT01335477)
Timeframe: 52 weeks

,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 150 mg Bid3.696.4
Placebo9.690.4

[back to top]

Time to On-treatment Death

"Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported.~Failure is the the proportion of patients who died on-treatment." (NCT01335477)
Timeframe: 52 weeks

,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 150 mg Bid4.995.1
Placebo7.892.2

[back to top]

Time to Death or Lung Transplant Over 52 Weeks

Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period). (NCT01335477)
Timeframe: 52 weeks

,
Interventionpercentage of participants (Number)
FailureCensored
Nintedanib 150 mg Bid6.793.3
Placebo10.090.0

[back to top]

Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

"SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life.~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335477)
Timeframe: baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo7.20
Nintedanib 150 mg Bid3.89

[back to top]

Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

"SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score.~The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale." (NCT01335477)
Timeframe: baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo5.84
Nintedanib 150 mg Bid2.72

[back to top]

Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)

"Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT01335477)
Timeframe: baseline and 52 weeks

Interventionpoints on a scale (Mean)
Placebo9.07
Nintedanib 150 mg Bid6.69

[back to top]

Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle for the Determination of the Maximum Tolerated Dose (MTD)

The following drug-related adverse events (AEs) qualified as a DLT: Non-hematological toxicity - Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥3 events excluding transient electrolyte abnormality, hyperuricemia and isolated elevation of gamma-glutamyl trans-peptidase. Gastrointestinal AEs (nausea, vomiting, diarrhoea, abdominal pain) or hypertension of CTCAE Grade ≥3 despite optimal supportive care/intervention. Alanine aminotransferase and or Aspartate aminotransferase elevation of CTCAE Grade ≥3. Haematological toxicity - Uncomplicated CTCAE Grade 4 neutropenia (that was not associated with fever of ≥38.5° Celsius) for >7 days (except during Cycle 1). CTCAE Grade 4 febrile neutropenia associated with fever ≥38.5º Celsius. A decrease in platelet levels to CTCAE Grade 4 or CTCAE Grade 3 associated with bleeding or requiring transfusion. The inability to resume nintedanib dosing within 14 days of stopping due to a drug-related AE was also considered a DLT. (NCT01346540)
Timeframe: Up to 21 days from first drug administration

InterventionParticipants (Number)
Nintedanib 150 Milligram0
Nintedanib 200 Milligram0

[back to top]

Maximum Tolerated Dose (MTD) of Nintedanib Added to Cisplatin/Gemcitabine Based on the Occurrence of DLTs During Treatment Cycle 1.

The MTD was defined as the dose of nintedanib administered with gemcitabine/cisplatin at which no more than 1 of 6 patients experienced DLT (or one dose tier below that dose at which 2 or more of 6 patients experienced DLT) during the first 21-day treatment cycle. Any DLTs experienced after the start of the second treatment period were considered separately. (NCT01346540)
Timeframe: Up to 21 days from first drug administration

InterventionMilligram (Number)
Nintedanib 150/200 Milligram200

[back to top]

Incidence of Adverse Events (AEs) According to the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.00

Incidence of adverse events (AEs) according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.00 with grade 1-5. (NCT01346540)
Timeframe: From the first drug administration until 28 days after last study drug administration, up to 804 days

,
InterventionParticipants (Number)
Grade 1Grade 2Grade 3Grade 4Grade 5
Nintedanib 150 Milligram00130
Nintedanib 200 Milligram00822

[back to top]

Time-to-tumor Progression

Time-to-tumor progression in both populations. (NCT01380782)
Timeframe: 2 years

Interventiondays (Median)
Arm A (Bevacizumab-naive) - GBM28
Arm A (Bevacizumab-naive) - AG28
Arm B (Bevacizumab Treated) - GBM28
Arm B (Bevacizumab Treated) - AG36

[back to top]

Proportion of Participants Experiencing Stable Disease (SD) as Their Best Radiographic Response

Best radiographic response in both populations. There were no participants with partial or complete responses, so the results are being reported in the proportion of participants who experienced stable disease (SD) as their best response (as opposed to progressive disease). (NCT01380782)
Timeframe: 2 years

Intervention% of patients with best response SD (Number)
Arm A (Bevacizumab-naive) - GBM33
Arm A (Bevacizumab-naive) - AG40
Arm B (Bevacizumab Treated) - GBM10
Arm B (Bevacizumab Treated) - AG25

[back to top]

Overall Survival

Overall survival in both populations (NCT01380782)
Timeframe: 2 years

Interventionmonths (Median)
Arm A (Bevacizumab-naive) - GBM6.9
Arm A (Bevacizumab-naive) - AG11.3
Arm B (Bevacizumab Treated) - GBM2.6
Arm B (Bevacizumab Treated) - AG7.3

[back to top]

Exploratory Objective #1: Progression-free Survival at 3- and 6-months for Participants With Recurrent Anaplastic Gliomas (AG)

To explore the efficacy of BIBF 1120 in bevacizumab-naïve and bevacizumab-treated participants with recurrent anaplastic gliomas (AG) survival was assessed at 6 months for Arm A and 3 months for Arm B. (NCT01380782)
Timeframe: Arm A - 6 months; Arm B - 3 months

Interventionpercentage of participants (Number)
Arm A (Bevacizumab-naive) - AG0
Arm B (Bevacizumab Treated) - AG0

[back to top]

6-Month Progression Free Survival

To determine the efficacy of BIBF 1120 in bevacizumab-naive participants with recurrent glioblastoma (GBM) as measured by 6-month progression-free survival (PFS6). (NCT01380782)
Timeframe: Six months

Interventionpercentage of participants (Number)
Arm A (Bevacizumab-naive) - GBM0

[back to top]

3-Month Progression Free Survival

To determine the efficacy of BIBF 1120 in bevacizumab-treated participants with recurrent GBM as measured by 3-month progression free survival (PFS3). (NCT01380782)
Timeframe: 3 months

Interventionpercentage of participants (Number)
Arm B (Bevacizumab Treated) - GBM0

[back to top]

Safety Profile as Summarized With Descriptive Statistics (Using Toxicity Data Gathered on Trial)

Safety profile in both populations - as adverse events are posted separately in detail, these results will demonstrate serious adverse events (defined as grades 3-5) that were judged at least possibly related to Nintedanib (BIBF 1120). (NCT01380782)
Timeframe: 2 years

Interventionnumber of incidents (Number)
Abdominal painReversible transaminase elevationHypertensionHypophosphatemiaIntracranial hemorrhageColonic perforationPulmonary embolism
All Participants (Arm A and B)1813121

[back to top]

Percentage of Patient With First Occurrence of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (IPF) Until Week 234.

The percentage of patient having first acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF) based on investigator reported adverse events until week 234. (NCT01417156)
Timeframe: Week 234

Interventionpercentage of participants (Number)
Failure (Week 234)Censored (Week 234)
Nintedanib40.060.0

[back to top]

Incidence of Overall Adverse Events

Incidence (Number of patients) of Adverse events (AEs) over the course of treatment period including serious adverse events (SAEs), AEs leading to discontinuation of study medication, and fatal AEs. (NCT01417156)
Timeframe: First drug administration until end of treatment, up to 5 years

Interventionparticipants (Number)
AEs leading to discontinuation of trial drugFatalSevere AEs
Nintedanib12811

[back to top]

Annual Rate of Decline in Haemoglobin (Hb) Corrected Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)

"Adjusted annual rate of decline in Hb corrected DLCO. The means presents actually adjusted rate based on random coefficient regression with fixed effects for gender, age, height & random effect of patient specific intercept & time. Within-patient errors are modelled by Unstructured variance-covariance matrix.Inter-individual variability is modelled by a variance-Components variance-covariance matrix.~mmHg: millimeters of mercury" (NCT01417156)
Timeframe: Baseline & every 8 weeks after drug administration until end of treatment, up to 5 years

InterventionmL/Minute(min)/mmHg per year (Mean)
Nintedanib-1.3

[back to top]

Annual Rate of Decline in Forced Vital Capacity (FVC).

"The adjusted annual rate of decline in Forced Vital Capacity (FVC). The means presents actually the adjusted rate based on a random coefficient regression with fixed effects for gender, age, height and random effect of patient specific intercept and time. Within-patient errors are modelled by an Unstructured variance-covariance matrix. Inter-individual variability is modelled by a Variance-Components variance-covariance matrix.~The result for Annual rate of decline (ROD) in FVC should be interpreted with caution and along with descriptive statistics, because inferences used for this analysis might not be valid as suggested by skewed distribution of the data." (NCT01417156)
Timeframe: Baseline and every 8 weeks after drug administration until end of treatment, up to 5 years

Intervention(mililitre (mL)/year) (Least Squares Mean)
Nintedanib-233.3

[back to top]

Acute Exacerbations of IPF: Risk (Incidence Rate) of Acute Exacerbations of IPF.

The risk (incidence rate calculated as number of patients with at least 1 exacerbation, divided by the total time at risk ×100) of acute exacerbation of IPF. (NCT01417156)
Timeframe: First drug administration until end of treatment, up to 5 years

Interventionpatients per 100 patient-year (Number)
Nintedanib19.2

[back to top]

Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib

The MTD is based on the incidence of Dose Limiting Toxicities (DLTs). A drug-related AE was considered as a DLT if one of the following met: CTCAE grade 4 thrombocytopenia of any duration, CTCAE grade 4 neutropenia lasting for ≥8 days, CTCAE grade 4 febrile neutropenia of any duration, CTCAE grade 3 or 4 non-haematologic toxicity (with the following exception: Alopecia, Vomiting, nausea, or diarrhoea with no adequate supportive care, Transient electrolyte abnormality, which resolves spontaneously or can be corrected with appropriate treatment within 3 days, Liver toxicity), Liver enzyme toxicity of AST, ALT, alkaline phosphatase [ALP] elevation >5x ULN, or total bilirubin >3x ULN if baseline liver enzymes are within the normal range, or AST, ALT or ALP > baseline value + 4x ULN if the baseline value is elevated. The MTD was determined to be 200mg bid. (NCT01594125)
Timeframe: up to 28 days

Interventionparticipants (Number)
Group I: Nintedanib 150mg Bid0
Group I: Nintedanib 200mg Bid0
Group II: Nintedanib 100mg Bid0
Group II: Nintedanib 150mg Bid0
Group II: Nintedanib 200mg Bid0

[back to top]

Number of Participants With Objective Tumour Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0

"Objective response (Complete response (CR) + Partial response (PR), regardless of confirmation) is derived from a patient's best objective response by RECIST. Best objective response is calculated based on the overall visit response from each assessment. Best objective response represents the best response a patient has had during their time in the study up until progression, last evaluable assessment in the absence of progression or the start of subsequent anti-cancer therapy. For patients whose progression event is death, best objective response will be calculated based on data up until the last evaluable RECIST assessment prior to death." (NCT01594125)
Timeframe: up to 28 months

Interventionparticipants (Number)
Group I: Nintedanib 150mg Bid0
Group I: Nintedanib 200mg Bid0
Group II: Nintedanib 100mg Bid0
Group II: Nintedanib 150mg Bid0
Group II: Nintedanib 200mg Bid0

[back to top]

Time to Progression (TTP)

TTP is defined as the duration from the start date of the study treatment to PD according to RECIST 1.0. (NCT01594125)
Timeframe: up to 28 months

Interventionmonths (Median)
Group I: Nintedanib 150mg Bid6.05
Group I: Nintedanib 200mg Bid2.76
Group II: Nintedanib 100mg Bid7.26
Group II: Nintedanib 150mg Bid2.40
Group II: Nintedanib 200mg Bid2.76

[back to top]

Progression Free Survival (PFS)

PFS is defined as the duration from start date of the study treatment to PD according to RECIST 1.0, or any death whichever occurs earlier. (NCT01594125)
Timeframe: up to 28 months

Interventionmonths (Median)
Group I: Nintedanib 150mg Bid6.05
Group I: Nintedanib 200mg Bid2.76
Group II: Nintedanib 100mg Bid7.26
Group II: Nintedanib 150mg Bid2.40
Group II: Nintedanib 200mg Bid2.76

[back to top]

Number of Participants With Response by Alpha Fetoprotein (AFP)

Response by AFP is defined as 20% or more decline in AFP between the baseline value and the AFP value after three courses (12 weeks) of therapy. If patients only receive two courses of therapy the AFP value after two courses (8 weeks) will be used for the analysis. (NCT01594125)
Timeframe: up to 28 months

Interventionparticipants (Number)
Group I: Nintedanib 150mg Bid2
Group I: Nintedanib 200mg Bid1
Group II: Nintedanib 100mg Bid1
Group II: Nintedanib 150mg Bid1
Group II: Nintedanib 200mg Bid1

[back to top]

Incidence of Adverse Events (AEs)

This is the measure for percentage of patients with adverse events (AEs) observed during the trial. The incidence of adverse events (% of patients) over the course of the trial, including the incidence of serious AEs, AEs leading to discontinuation, and fatal AEs are presented. (NCT01619085)
Timeframe: From first drug administration until end of treatment period + 28 days, in total up to 56.3 months plus 28 days.

InterventionPercentage of patients (%) (Number)
Any AEsAEs leading to discontinuation of trial drugSerious AEsFatal AEs
Total (1199.32/.34)98.542.668.923.8

[back to top]

Concentration of Select Growth Factors Reported Measured in Picograms Per Milliliter as a Function of Treatment Response

Correlating baseline and on treatment levels of additional growth factors measured in picograms per milliliter that may be co- or counter- regulated with VEGF with response to treatment (NCT01669798)
Timeframe: 1 year

Interventionpicograms per milliliter (Median)
CD73: Partial Response or Stable DiseaseCD73: Progressive DiseaseHGF: Partial Response or Stable DiseaseHGF: Progressive DiseaseIL-6: Partial Response or Stable DiseaseIL-6: Progressive DiseasePDGF-AA: Partial Response or Stable DiseasePDGF-AA: Progressive DiseasePDGF-BB: Partial Response or Stable DiseasePDGF-BB (pg/ml): PDPIGF: Partial Response or Stable DiseasePIGF: Progressive DiseaseSDF-1: Partial Response or Stable DiseaseSDF-1: Progressive DiseaseTGFBeta-R3: Partial Respone or Stable DiseaseTGFBeta-R3: Progressive DiseaseAng2: Partial Response or Stable DiseaseAng2: Progressive DiseaseBMP-9: Partial Response or Stable DiseaseBMP-9: Progressive Disease
BIBF 11203.03.8130.1191.018.232.689.5233.9184.7396.423.424.31968.62121.950.652.5261.1189.547.045.9

[back to top]

Duration of Progression-Free Survival

The duration of progression-free survival and overall survival measured in months; Progression-Free Survival (PFS) is defined as the duration of time from study entry to time of progression or death, whichever occurs first. (NCT01669798)
Timeframe: Through study completion, on average 2 years

InterventionMonths (Median)
Progression Free Survival (PFS)Overall Survival (OS)
BIBF 11201.816

[back to top]

VEGF Levels Correlated With Treatment Outcome

"Baseline levels of VEGF were correlated with treatment outcome. Results are stratified in groups: Partial Response (PR) or Stable Disease (SD) and Progressive Disease (PD)" (NCT01669798)
Timeframe: 1 year

Interventionpicograms per milliliter (Median)
Partial Response or Stable DiseaseProgressive Disease
BIBF 112014051033

[back to top]

Concentration of VCAM-1 Reported as a Function of Treatment Response

Correlating baseline and on treatment levels of VCAM-1 measured in micrograms per milliliter that may be co- or counter- regulated with VEGF with response to treatment (NCT01669798)
Timeframe: 1 year

Interventionmicrograms per milliliter (Median)
VCAM-1: Partial Response or Stable DiseaseVCAM-1: Progressive Disease
BIBF 11202.22.3

[back to top]

Objective Tumor Response Based on GCIG CA-125 Criteria

"The proportion of patients who have objective tumor response (complete or partial) based on Gynaecologic Cancer InterGroup(GCIG) CA-125 criteria which is: A response according to CA 125 has occurred if there is at least a 50% reduction in CA 125 levels from a pretreatment sample. The response must be confirmed and maintained for at least 28 days.." (NCT01669798)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
BIBF 11200

[back to top]

Objective Tumor Response Via RECIST (Response Evaluation Criteria in Solid Tumors) 1.1

Evaluating the percentage of patients who have objective tumor response (complete or partial) based on RECIST 1.1 criteria. (NCT01669798)
Timeframe: 1 year

Interventionpercentage of participants (Number)
BIBF 11207.4

[back to top]

Percentage of Patients Who Survive Progression-free

Measure of Progression Free Survival (PFS) by the percentage of patients who survive progression-free for at least 6 months after initiating study therapy in patients with bevacizumab-resistant, persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. (NCT01669798)
Timeframe: 6 months

Interventionpercentage of participants (Number)
BIBF 112011.5

[back to top]

Adverse Event Frequency and Severity

To determine frequency and severity of adverse events as assessed using NCI Common Toxicity Criteria version 4. (NCT01669798)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
AnemiaSinus tachycardiaTinnitusAbdominal painBloatingDiarrheaDry mouthConstipationDyspepsiaGastroesophageal reflux diseaseNauseaVomitingChillsEdema limbsFatigueNon-cardiac chest painAlanine aminotransferase increasedAlkaline phosphatase increasedAspartate aminotransferase increasedCreatinine increasedNeutrophil count decreasedPlatelet count decreasedWeight lossAnorexiaHypoalbuminemiaHypocalcemiaHypomagnesemiaHyponatremiaArthralgiaArthritisBack PainBone painPain in extremityDysgeusiaHeadacheHematuriaProteinuriaUrinary incontinenceVaginal drynessVaginal painAtelectasisDyspneaPleural effusionWheezingRash maculo-papularHypertensionIntermittent leg crampsBilateral neuropathy, hands and feet
BIBF 1120211731714111713131411081211234214441211281411112111411

[back to top]

Concentration of Select Growth Factors Measured in Nanograms Per Milliliter Reported as a Function of Treatment Response

Correlating baseline and on treatment levels of additional growth factors measured in nanograms per milliliter that may be co- or counter- regulated with VEGF with response to treatment (NCT01669798)
Timeframe: 1 year

Interventionnanograms per milliliter (Median)
ICAM-1: Partial Response or Stable DiseaseICAM-1: Progressive DiseaseOPN: Partial Response or Stable DiseaseOPN: Progressive DiseaseTGF-Beta1: Partial Response or Stable DiseaseTGF-Beta1: Progressive DiseaseTGF-Beta2: Partial Response or Stable DiseaseTGF-Beta2: Progressive DiseaseTIMP-1: Partial Response or Stable DiseaseTIMP-1: Progressive DiseaseTSP-2: Partial Response or Stable DiseaseTSP-2: Progressive Disease
BIBF 1120635.1686.8643.0923.0122.590.322.033.493.5116.495.1104.9

[back to top]

Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)

"AUC0-tz represents the area under the plasma concentration-time curve of nintedanib from time 0 to the last quantifiable nintedanib plasma concentration.~For this endpoint, the measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities" (NCT01679613)
Timeframe: 1 hour (h) before drug administration and 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 15h, 24h, 36h, 48h and 72h after the drug administration

Interventionng*h/mL (Geometric Mean)
Nintedanib35.7
Nintedanib + Ketoconazole59.4

[back to top]

Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)

"AUC0-∞ represents the Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity~For this endpoint, the measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities" (NCT01679613)
Timeframe: 1 hour (h) before drug administration and 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 15h, 24h, 36h, 48h and 72h after the drug administration

Interventionng*h/mL (Geometric Mean)
Nintedanib38.6
Nintedanib + Ketoconazole61.3

[back to top]

Maximum Measured Concentration (Cmax)

"Cmax represents the maximum concentration of nintedanib in plasma~For this endpoint, the measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities" (NCT01679613)
Timeframe: 1 hour (h) before drug administration and 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 15h, 24h, 36h, 48h and 72h after the drug administration

Interventionng/mL (Geometric Mean)
Nintedanib4.19
Nintedanib + Ketoconazole7.13

[back to top]

Area Under the Curve From 0 Extrapolated to Infinity (AUC0-∞)

"AUC0-∞ represents the Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity.~For this endpoint, the measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities." (NCT01770392)
Timeframe: 1.5 hour (h) before the first drug administration and 0.5h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after administration of nintedanib

Interventionng*h/mL (Geometric Mean)
Nintedanib183
Nintedanib + Rifampicin89.4

[back to top]

Area Under the Curve From 0 to the Last Quantifiable Concentration (AUC0-tz)

"AUC0-tz represents the area under the plasma concentration-time curve of nintedanib from 0 to the last quantifiable analyte plasma concentration.~For this endpoint, the measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities." (NCT01770392)
Timeframe: 1.5 hour (h) before the first drug administration and 0.5h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after administration of nintedanib

Interventionng*h/mL (Geometric Mean)
Nintedanib173
Nintedanib + Rifampicin84.1

[back to top]

Maximum Measured Concentration (Cmax)

"Cmax represents the maximum concentration of nintedanib in plasma. For this endpoint, the measured values show inter-individual variabilities, whereas the statistical analyses show intra-individual variabilities." (NCT01770392)
Timeframe: 1.5 hour (h) before the first drug administration and 0.5h, 1h, 2h, 2.5h, 3h, 3.5h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h and 72h after administration of nintedanib

Interventionng/mL (Geometric Mean)
Nintedanib22.1
Nintedanib + Rifampicin12.8

[back to top]

Number of Participants With IPF Progression Events up to Week 48

IPF progression events included death from any cause or absolute decline in FVC (% predicted) value of ≥10%, confirmed by repeat spirometry. Classification of FVC (% predicted) declined ≥10% was based on observed and imputed data. Missing data in FVC (% predicted) were imputed using the predicted values from the random coefficient module with treatment, visit, visit-by-treatment interaction, and Baseline FVC (% predicted) as fixed effects and linear slope as random effect. (NCT01890265)
Timeframe: Baseline (Screening and Day 1) up to Week 48

InterventionParticipants (Count of Participants)
Pamrevlumab5
Placebo16

[back to top]

Mean Change From Baseline in the HRCT Quantitative Lung Fibrosis (QLF) Score to Week 24 and Week 48

The extent of pulmonary fibrosis was measured by HRCT scans of the chest at screening and at Weeks 24 and 48, to determine the HRCT QLF score. Each lung was divided into 5 lobes (right upper, right middle, right lower, left upper, left lower). For the quantitative HRCT analyses, a computer read the images and quantified the percent (%) and volume (mL) of fibrosis for the whole lung by averaging the scores from each of 5 lung lobes. Baseline was defined as the Screening evaluation. Missing data were imputed using the multiple imputation (MI) method to handle missing values. (NCT01890265)
Timeframe: Baseline (Screening), Week 24 and Week 48

,
InterventionPercent of fibrosis (Mean)
BaselineChange from Baseline at Week 24Change from Baseline at Week 48
Pamrevlumab13.90.82.7
Placebo14.72.66.0

[back to top] [back to top]

Change From Baseline in FVC (Percent of Predicted FVC Value [% Predicted]) to Week 48

FVC in liters was measured during the spirometry assessments at screening and during the randomized treatment period at Day 1 and every 12 weeks. The FVC (% predicted) was calculated for the corresponding gender-race-age group. The least squares (LS) mean change from Baseline to Week 48 (end of the randomized treatment period) in FVC (% predicted) is presented. Baseline was defined as the mean of the last screening visit and the Day 1 visit values. Other statistical analysis data is reported in the statistical analysis section. Observed data from all visits were included in the model. (NCT01890265)
Timeframe: Baseline (Screening and Day 1), Week 48

,
Intervention% predicted FVC (Mean)
BaselineChange from Baseline at Week 48
Pamrevlumab74.51-2.71
Placebo72.82-7.20

[back to top]

Number of Participants With No Decline in FVC (% Predicted) at Week 48

FVC in liters was measured during the spirometry assessments. The FVC (% predicted) was calculated for the corresponding gender-race-age group. Baseline was defined as the mean of the last screening visit and the Day 1 visit values. Classification of 'No decline' is based on observed and imputed data. Missing data in FVC (% predicted) are imputed using the predicted values from the random coefficient model with treatment, visit, visit-by-treatment interaction, and Baseline FVC (% predicted) as fixed effects and linear slope of visit as random effect. (NCT01890265)
Timeframe: Baseline (Day 1) to Week 48.

InterventionParticipants (Count of Participants)
Pamrevlumab11
Placebo13

[back to top] [back to top] [back to top]

Progression-Free Survival (PFS)

This outcome measure presents progression-free survival. Disease progression was defined according to the modified Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Progression-free survival time was calculated as the duration from the date of randomization to the date of disease progression or death, whichever occurred first. For patients with known date of progression (or death): PFS (days) = min (date of progression, date of death) - date of randomization + 1 day. For patients without progression or death, PFS was censored at the last imaging date that showed no disease progression: PFS (days, censored) = date of last imaging showing no progression - date randomization + 1 day. (NCT01907100)
Timeframe: From randomization until the earliest of disease progression, death or (Phase II: cut-off date of 4-March-2016; up to 889 days) (Phase III: cut-off date of 16-March-2018; up to 31 months)

,
InterventionMonths (Median)
Phase IIPhase III
Nintedanib9.366.77
Placebo5.726.97

[back to top]

Disease Control According to Modified RECIST- Investigator Assessment

"Disease control (best overall response of confirmed CR or PR, or Stable Disease (SD) that lasted ≥36 days) according to modified RECIST.~Percentage of Patients with Disease control is presented. This endpoint was only evaluated for Phase III part." (NCT01907100)
Timeframe: Tumour imaging was to be performed every 6 weeks until disease progression, death or start of subsequent anti-cancer therapy, whichever occurred earlier; up to 54 months

InterventionPercentage of participants (Number)
Placebo92.6
Nintedanib90.8

[back to top]

Overall Survival (OS)

"Overall survival was defined as the duration of time from randomization to time of death.~This is the key secondary endpoint of the trial." (NCT01907100)
Timeframe: From randomization until the earliest of disease progression, death or (Phase II: cut-off date of 4-March-2016; up to 889 days) (Phase III: cut-off date of 16-March-2018; up to 31 months)

,
InterventionMonths (Median)
Phase IIPhase III
Nintedanib18.3014.36
Placebo14.4616.07

[back to top]

Objective Response According to Modified RECIST- Investigator Assessment

"Objective response (best overall tumour response of confirmed complete response [CR] or confirmed partial response [PR]).~Complete Response: disappearance of all target lesions Partial Response: at least a 30 % decrease in the total tumour measurement of target lesions, taking as reference the baseline total tumour measurement.~Percentage of Patients with confirmed objective response is presented. This endpoint was only evaluated for Phase III part." (NCT01907100)
Timeframe: Tumour imaging was to be performed every 6 weeks until disease progression, death or start of subsequent anti-cancer therapy, whichever occurred earlier; up to 54 months

InterventionPercentage of participants (Number)
Placebo42.8
Nintedanib45.0

[back to top]

Tumor Response Rate

Tumor Response rate was defined as the proportion of patients who had Complete Response (CR) or Partial Response (PR) by RECIST 1.1 Criteria. Complete Response (CR): Disappearance of all target lesions. Any lymph nodes must have a reduction in short axis to < 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT01948141)
Timeframe: Up to 3 years

Interventionpercentage of participants (Number)
AmplifiedNon-amplifiedTotal
Treatment (Nintedanib)000

[back to top]

Compare the 6-month PFS Rate for Each FGFR1 Amplified Group (Low, Intermediate, and High) Versus FGFR1 Non-amplified Patients.

The 6-month PFS rate was defined as the proportion of patients who were alive and progression-free at 6 months after start of study treatment. (NCT01948141)
Timeframe: Time from study entry to the first of either disease progression or death, assessed at 6 months

Interventionpercentage of participants (Number)
Non-amplifiedIntermediate amplificationHigh amplificiationTotal
Treatment (Nintedanib)0000

[back to top]

Compare the 6-month PFS Rate for the Entire FGFR1 Amplified Group Versus the FGFR1 Non-amplified Patients.

The 6-month PFS rate was defined as the proportion of patients who were alive and progression-free at 6 months after start of study treatment. (NCT01948141)
Timeframe: Time from study entry to the first of either disease progression or death, assessed at 6 months

Interventionpercentage of participants (Number)
AmplifiedNon-amplifiedTotal
Treatment (Nintedanib)000

[back to top]

Incidence of Adverse Events (AEs)

Percentage of participants with adverse events. Incidence of Adverse Events (AEs) was Accessed by the National Cancer Institute (NCI) CTCAE Version 4.0. (NCT01948141)
Timeframe: Up to 30 days post-treatment

Interventionpercentage of participants (Number)
TotalAmplifiedNon-amplified
Treatment (Nintedanib)100100100

[back to top]

6-month Progression Free Survival (PFS) Rate Within the Entire FGFR1 Amplified Group

The 6-month PFS rate was defined as the proportion of patients who were alive and progression-free at 6 months after start of study treatment. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. (NCT01948141)
Timeframe: At 6 months

Interventionpercentage of participants (Number)
Treatment (Nintedanib)0

[back to top]

Overall Survival (OS)

Overall survival (OS) was defined as the time from study entry to death from any cause. (NCT01948141)
Timeframe: From study entry to death from any cause, assessed up to 3 years

Interventionmonths (Median)
AmplifiedNon-amplifiedOverall
Treatment (Nintedanib)10.25.810.6

[back to top]

Progression Free Survival

Progression-free survival (PFS) was defined as the time from study entry to the first of either disease progression or death. (NCT01948141)
Timeframe: Time from study entry to the first of either disease progression or death, assessed up to 3 years

Interventionmonths (Median)
OverallAmplifiedNon-amplified
Treatment (Nintedanib)2.71.83.4

[back to top]

6MWT Total Distance Walked Change From Baseline at 6 Months

"Change in total distance covered in 6-minute walk test (6MWT) from baseline at 6 month is presented.~The 6-Minutes Walk Test (6-MWT) was conducted according to the American Thoracic Society (ATS) Criteria." (NCT01979952)
Timeframe: Baseline and 6 Months

Interventionmeters (Least Squares Mean)
Nintedanib4.93
Placebo-13.00

[back to top]

Relative Change in FVC From Baseline at 6 Months

Relative change in FVC from baseline at 6 months is presented. (NCT01979952)
Timeframe: Baseline and 6 Months

Interventionpercentage of change (Least Squares Mean)
Nintedanib-0.67
Placebo-3.02

[back to top]

Relative Change From Baseline in High Resolution Computerized Tomography (HRCT) Quantitative Lung Fibrosis (QLF) Score at 6 Months

Relative change from baseline in HRCT QLF score at 6 months was calculated as the difference of the QLF score at month 6 minus the QLF score at baseline divided by the baseline QLF score. The QLF score itself ranges from 0 to 100%, where greater values represent a greater amount of lung fibrosis and are considered a worse health status. Hence smaller relative changes from baseline (i.e., ratios) were considered favorable. HCRT assessment obtained during screening visit was considered as baseline. (NCT01979952)
Timeframe: Baseline and 6 Months

Interventionpercent change (Least Squares Mean)
Nintedanib11.407
Placebo14.583

[back to top]

Effect of Six Month Delayed Treatment Onset: Relative Change From Baseline in HRCT QLF Score at 12 Months

"Relative change from baseline in HRCT QLF score at 12 months was calculated as the ratio of the QLF score at 12 months to baseline. Greater values of the QLF score represented a worse health status and hence smaller relative changes from baseline (i.e., ratios) were considered favorable.~HCRT assessment obtained during screening visit was considered as baseline. Note that due to the change in study design, patients randomized to the placebo group were treated with nintedanib after completion of the first 6-month treatment period. Therefore, this new endpoint was defined to address the effect of a 6-month delayed onset of nintedanib treatment." (NCT01979952)
Timeframe: Baseline and 12 Months

Interventionpercent change (Least Squares Mean)
Nintedanib13.103
Placebo15.622

[back to top]

All-cause Mortality at 6 Months

Percentage of subjects died from all causes between 0 to 6 months are presented. (NCT01979952)
Timeframe: 6 Months

InterventionPercentage of participants (Number)
Nintedanib0.0
Placebo5.3

[back to top]

Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbations at 6 Months

Percentage of subjects experienced first acute IPF exacerbations (based on Investigator reported adverse events) between 0 to 6 months are presented. (NCT01979952)
Timeframe: 6 Months

InterventionPercentage of participants (Number)
Nintedanib1.8
Placebo1.8

[back to top]

Absolute Change in Forced Vital Capacity (FVC) From Baseline at 6 Months

Absolute change in Forced Vital Capacity (FVC) from baseline at 6 months is presented. (NCT01979952)
Timeframe: Baseline and 6 Months

Interventionmilliliter (mL) (Least Squares Mean)
Nintedanib-14.18
Placebo-83.18

[back to top]

Respiratory Hospitalizations at 6 Months

Percentage of subjects hospitalized due to respiratory problems between 0 to 6 months are presented. (NCT01979952)
Timeframe: 6 Months

InterventionPercentage of participants (Number)
Nintedanib0.0
Placebo7.0

[back to top]

Categorical Change in FVC From Baseline at 6 Months

Percentage of participants reporting categorical change in FVC from baseline at 6 months are presented. (NCT01979952)
Timeframe: Baseline and 6 Months

,
InterventionPercentage of participants (Number)
Decrease >10% or 200 mLChange within ≤10% AND ≤200 mLIncrease >10% or 200 mL
Nintedanib6.576.117.4
Placebo23.971.74.3

[back to top]

University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) Change From Baseline at 6 Months

"University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) change from baseline at 6 months is presented. Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).~Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at month 6)." (NCT01979952)
Timeframe: Baseline and 6 Months

InterventionUnits on a scale (Least Squares Mean)
Nintedanib3.42
Placebo-1.46

[back to top]

St. George's Respiratory Questionnaire (SGRQ) Total Score Change From Baseline at 6 Months

"SGRQ total score change from baseline at 6 months is presented. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact.~The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status.~Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at month 6)." (NCT01979952)
Timeframe: Baseline and 6 Months

InterventionUnits on a scale (Least Squares Mean)
Nintedanib-2.24
Placebo-2.19

[back to top]

Respiratory Mortality at 6 Months

Percentage of subjects who died due to respiratory cause between 0 to 6 months are presented. (NCT01979952)
Timeframe: 6 Months

InterventionPercentage of participants (Number)
Nintedanib0.0
Placebo3.5

[back to top]

Objective Tumour Response (Complete Response (CR)) + Partial Response (PR) by Central Review Assessment

Objective tumour response was defined as best overall response of CR or PR determined by central review assessment. (NCT02149108)
Timeframe: From randomisation until cut-off date 14JUN2016.

InterventionPercentage of participants (Number)
Placebo0
Nintedanib0

[back to top]

Disease Control (Complete Response + Partial Response + Stable Disease) by Central Review Assessment

Disease control was defined as best overall response of CR, PR, or Stable Disease (SD). (NCT02149108)
Timeframe: From randomisation until cut-off date 14JUN2016.

InterventionPercentage of participants (Number)
Placebo10.5
Nintedanib25.6

[back to top]

Overall Survival (OS)

"OS was defined as the time from randomisation to the time of death from any cause.~Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm." (NCT02149108)
Timeframe: From randomisation until cut-off date 14JUN2016.

InterventionMonths (Median)
Placebo6.05
Nintedanib6.44

[back to top]

Progression-Free Survival (PFS) by Central Review Assessment

"PFS by central review assessment was defined as the time from the date of randomisation to the date of disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 or death from any cause, whichever occurred first.~Median, 95% Confidence Interval were calculated from an unadjusted Kaplan-Meier curve for each treatment arm." (NCT02149108)
Timeframe: From randomisation until cut-off date 14JUN2016.

InterventionMonths (Median)
Placebo1.38
Nintedanib1.51

[back to top]

Cmax of Nintedanib

Cmax (Maximum measured concentration of the Nintedanib in plasma) (NCT02191865)
Timeframe: Pre-dose and 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h after drug administration

Interventionng/mL (Geometric Mean)
Child-Pugh A20.5
Child-Pugh B59.4
Healthy Matched Child-Pugh A9.25
Healthy Matched Child-Pugh B7.81

[back to top]

AUC (0-tz) of Nintedanib

AUC (0-tz) (Area under the concentration-time curve of the Nintedanib in plasma over the time interval from 0 to the last quantifiable drug plasma concentration) (NCT02191865)
Timeframe: Pre-dose and 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h after drug administration

Interventionng*h/mL (Geometric Mean)
Child-Pugh A193
Child-Pugh B652
Healthy Matched Child-Pugh A89.2
Healthy Matched Child-Pugh B74.8

[back to top]

AUC (0-inf) of Nintedanib

AUC (0-inf) (Area under the concentration-time curve of the Nintedanib in plasma over the time interval from 0 extrapolated to infinity) (NCT02191865)
Timeframe: Pre-dose and 1 hour (h), 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h and 168h after drug administration

Interventionng*h/mL (Geometric Mean)
Child-Pugh A200
Child-Pugh B674
Healthy Matched Child-Pugh A92.7
Healthy Matched Child-Pugh B77.8

[back to top] [back to top]

Disease Control According to Response Evaluation Criteria in Solid Tumours (RECIST), Version 1.1

This outcome measure presents the number of patients with disease control according to RECIST, version 1.1, defined as number of patients with Complete response, partial response or stable disease. (NCT02231164)
Timeframe: Up to 6 months.

,
InterventionPercentage of participants (Number)
YesNo
Nintedanib50.050.0
Placebo66.733.3

[back to top]

Participants Evaluated for Toxicities

The severity of adverse event should be classified and recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. (NCT02234596)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Nintedanib32

[back to top]

6-month Progression-free Survival (PFS)

(NCT02234596)
Timeframe: 6 months

Interventionmonths (Median)
Nintedanib1.9

[back to top]

Response Rate (RR)

"RR = Partial response plus complete response using RECIST 1.1~Complete response (CR) = disappearance of all target lesions, non-target lesions, and normalization of tumor marker level~Partial response (PR) = at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline of sum diameters" (NCT02299141)
Timeframe: After 2 cycles of therapy (approximately Day 56)

InterventionParticipants (Count of Participants)
Nintedanib3

[back to top]

Response Rate by Mutation Type

(NCT02299141)
Timeframe: At the time of response (approximately day 56)

InterventionParticipants (Count of Participants)
TP53 mutationPDGFR-A mutationPDGFR-B mutationFGFR1-3 mutationVEGFR1-3 mutationRET alteration
Nintedanib300100

[back to top]

Unique Genetic Variations Associated With Extreme Responders (Both Non-responders and Responders)

Correlate baseline genetic mutations with treatment response and progression of disease (NCT02299141)
Timeframe: Baseline and at the time of response (approximately Day 56)

,,,,,,
Interventionmutations (Number)
TP53 C242FTP53 A159VTP53 A27VTP53 P72RTP53 M160_A161delTP53 D281ETP53 R342PTP53 D207fsTP53 Tyr234*FGFR3 S249CFGFR1 amplificationPDGFRA G166E
Progressive Disease A000001000001
Progressive Disease B000000110000
Progressive Disease C000000001000
Progressive Disease D000000000010
Responder A100000000100
Responder B011100000000
Responder C000010000000

[back to top]

Median Progression-free Survival (PFS)

"PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.~Progressive disease (PD) = at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, appearance of one or more non-target lesion(s) and/or unequivocal progression of existing non-target lesions" (NCT02299141)
Timeframe: 12 months follow-up minimum

Interventionweeks (Median)
Nintedanib18

[back to top]

AUC0-tz of Docetaxel

This outcome measure presents AUC0-tz of docetaxel in plasma in cycles 1 and 2. (NCT02300298)
Timeframe: just before administration of docetaxel administration -0:05 hours (h), at the end of infusion (1:00), and at timepoints after the first dose of docetaxel 1:30 h, 2, 3, 4, 7, 23:55, 47:55 h in cycle 1 and 2 (if administered)

Interventionng*h/mL (Geometric Mean)
Cycle 1Cycle 2
Nintedanib Plus Docetaxel30803320

[back to top]

AUC0-infinity of Docetaxel

This outcome measure presents the AUC0-infinity of docetaxel in plasma in cycles 1 and 2. (NCT02300298)
Timeframe: just before administration of docetaxel administration -0:05 hours (h), at the end of infusion (1:00), and at timepoints after the first dose of docetaxel 1:30 h, 2, 3, 4, 7, 23:55, 47:55 h in cycle 1 and 2 (if administered)

Interventionng*h/mL (Geometric Mean)
Cycle 1Cycle 2
Nintedanib Plus Docetaxel33203590

[back to top]

Maximum Measured Concentration (Cmax) of Nintedanib

This outcome measure presents the maximum measured concentration (Cmax) of nintedanib in plasma in cycle 1. (NCT02300298)
Timeframe: At 23:55 hours (h) after the first dose of docetaxel (which is 5 minutes prior to first dose of nintedanib) and at 25, 26, 27, 28, 30, 31, 34 and 47:55 h after first drug administration of docetaxel in cycle 1.

Interventionnanogram (ng)/ millilitre (mL) (Geometric Mean)
Nintedanib Plus Docetaxel65.1

[back to top]

Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 to Time of the Last Quantifiable Concentration (AUC0-tz)

This outcome measure presents the area under the concentration-time curve of nintedanib over the time interval from 0 to time of the last quantifiable concentration in plasma (AUC0-tz) in cycle 1. (NCT02300298)
Timeframe: At 23:55 hours (h) after the first dose of docetaxel (which is 5 minutes prior to first dose of nintedanib) and at 25, 26, 27, 28, 30, 31, 34 and 47:55 after first drug administration of docetaxel in cycle 1.

Interventionng*h/mL (Geometric Mean)
Nintedanib Plus Docetaxel342

[back to top]

Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity)

This outcome measure presents the Area under the concentration-time curve of nintedanib over the time interval from 0 extrapolated to infinity in plasma (AUC0-infinity) in cycle 1. (NCT02300298)
Timeframe: at 23:55 hours (h) after the first dose of docetaxel (which is 5 minutes prior to first dose of nintedanib) and at 25, 26, 27, 28, 30, 31, 34 and 47:55 h after first drug administration of docetaxel in cycle 1.

Interventionng*h/mL (Geometric Mean)
Nintedanib Plus Docetaxel381

[back to top]

Cmax of Docetaxel

This outcome measure presents the Cmax of docetaxel in plasma in cycles 1 and 2. (NCT02300298)
Timeframe: just before administration of docetaxel administration -0:05 hours (h), at the end of infusion (1:00), and at timepoints after the first dose of docetaxel 1:30 h, 2, 3, 4, 7, 23:55, 47:55 h in cycle 1 and 2 (if administered)

Interventionnanogram (ng)/ millilitre (mL) (Geometric Mean)
Cycle 1Cycle 2
Nintedanib Plus Docetaxel27102680

[back to top]

Number of Patients Experiencing Dose Limiting Toxicity (DLT) in Cycle 1

"DLT was defined as any of the following study drug related adverse events (AEs):~Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 non-haematological toxicity except transient electrolyte abnormality and isolated increase of gamma-glutamyltransferase (GGT); gastrointestinal toxicity, despite adequate supportive care~CTCAE grade 4 haematological toxicity; Neutrophil count decreased or white blood cell count (not associated with fever) for >7 days despite adequate supportive treatment~CTCAE grade 4 febrile neutropenia with fever ≥38.5 degrees~CTCAE grade ≥2 alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) increase in conjunction with CTCAE grade ≥2 total bilirubin increase~Inability to resume nintedanib dosing within 14 days after stopping Investigators judged clinically as DLT after dose reduction and severity medically notable (CTCAE, version 3). Sponsor with safety review committee was allowed to confirm the adequacy of this judgment." (NCT02300298)
Timeframe: Cycle 1, from first administration of study medication up to 21 days thereafter.

InterventionParticipants (Number)
Total with DLTs - all gradesTotal with DLTs - grade 1/2Total with DLTs - grade 3/4/5Hepatobiliary disorders (hep. dis.) - all gradesHep. dis. - grade 1/2Hep. dis. - grade 3/4/5Hep. dis. - hyperbilirubinaemia - all gradesHep. dis. - hyperbilirubinaemia - grade 1/2Hep. dis. - hyperbilirubinaemia - grades 3/4/5Investigations (inv.) - all gradesInv. - grade 1/2Inv. - grade 3/4/5Inv. - ALT increased - all gradesInv. - ALT increased - grades 1/2Inv. - ALT increased - grades 3/4/5Inv. - AST increased - all gradesInv. - AST increased - grades 1/2Inv. - AST increased - grades 3/4/5
Nintedanib Plus Docetaxel202110110202202202

[back to top]

Safety Measures of BIBF 1120 in Terms of Type, Frequency and Severity of Adverse Event According to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 in Patients With Metastatic IBC.

An adverse event (AE) is defined as any untoward medical occurrence, including an exacerbation of a pre-existing condition, in a patient in a clinical investigation who received a pharmaceutical product. The event does not necessarily have to have a causal relationship with this treatment. All adverse events (grade 3 or higher for hematological toxicity, grade 2 or higher for non-hematological toxicity) (NCT02389764)
Timeframe: 2 years

Interventionparticipants (Number)
Grade 3-hematological toxicityGrade 4-hematological toxicityGrade 2-non-hematological toxicityGrade 3-non-hematological toxicityGrade 4-non-hematological toxicity
BIBF 112000940

[back to top]

To Examine the DLT

"The recommended Phase II dose is of the Nintedanib and Capecitabine combination is defined as the dose level that causes dose limiting toxicities (DLTs) in ≤ 1 out of 6 patients at highest dose level below the maximally administered dose.~Capecitabine is fixed dose at 2000 mg/m2; while Nintedanib is evaluated at 150mg (dose level 1) and 200 mg (dose level 2)." (NCT02393755)
Timeframe: At least 21 days.

Interventionmg (Number)
Treatment (Capecitabine, Nintedanib)200

[back to top]

Median OS (Phase II)

Overall survival is defined as time from date of subject enrollment to the date of death due to any cause. Estimates of median OS will be obtained with corresponding 90% confidence intervals. (NCT02393755)
Timeframe: From the date of enrollment to the time of death, assessed up to 2 years

Interventionmonths (Median)
Treatment (Capecitabine, Nintedanib)8.9

[back to top]

Median PFS (Phase II)

Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions (the sum must also demonstrate an absolute increase of at least 5 mm) or the appearance of new lesions. Estimates of median PFS will be obtained with corresponding 90% confidence intervals. (NCT02393755)
Timeframe: Up to 2 years

Interventionmonths (Median)
Treatment (Capecitabine, Nintedanib)3.4

[back to top]

Objective Response Rate

Overall Response is defined as Complete Response: Disappearance of all target lesions and any lymph nodes must have a reduction in short axis to < 10 mm; or Partial Response: At least a 30% decrease in the sum of diameters of target lesions; or Stable Disease: Neither sufficient shrinkage to qualify for partial response, nor sufficient increase to qualify for progressive disease. (NCT02393755)
Timeframe: After every 3 cycles (9 weeks) of therapy.

Interventionpercentage of participants (Number)
Treatment (Capecitabine, Nintedanib)58.3

[back to top]

Progression Free Survival (PFS) Rate, Defined as the Proportion of Patients Who Survive Without Disease Progression Via the RECIST Version 1.1 (Phase II)

"Progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions (the sum must also demonstrate an absolute increase of at least 5 mm) or the appearance of new lesions.~Will be summarized using standard Kaplan-Meier methods." (NCT02393755)
Timeframe: At 18 weeks

Interventionpercentage of participants (Number)
Treatment (Capecitabine, Nintedanib)41.7

[back to top]

Median OS

Will be reported using standard Kaplan-Meier methods. Ninety-five percent confidence intervals for the median OS will be calculated using Greenwood's formula. The association between survival and quantified variables will be investigated using the Cox-proportional hazard model. (NCT02399215)
Timeframe: Up to 3 years (telephone contact is acceptable).

Interventionmonths (Median)
Treatment (Nintedanib)32.7

[back to top]

PFS

Will be reported using standard Kaplan-Meier methods. Ninety percent confidence intervals for the median PFS will be calculated using Greenwood's formula. Additionally, a confidence interval for the 16-week PFS rate will be obtained using Jeffrey's prior method. The association between survival and quantified variables will be investigated using the Cox-proportional hazard model. (NCT02399215)
Timeframe: Time interval from initiation of therapy, to its cessation for documentation of PD or death, assessed up to 2 years

Interventionmonths (Median)
Treatment (Nintedanib)11

[back to top]

Plasma Concentrations at Steady State (Cpre,ss) of Nintedanib at Baseline and Week 8

Sample collection will be obtained at baseline and week 8 (NCT02399215)
Timeframe: Baseline to week 8

Interventionng/mL (Median)
Treatment (Nintedanib)11.2

[back to top]

Change in Quality of Life Score

"Quality of life will be investigated calculated by Subjects filing out EORTC Gastrointestinal Neuroendocrine Tumour 21 Questionnaire (QLQ-GI.NET21) A 21 question questionnaire that use a 4-point scale (1 = Not at all, 2 = A little, 3 = Quite a bit, 4 = Very much). The scores for different scales (i.e. endocrine, gastrointestinal, treatment, social function, disease Related, and global) are calculated by summing related questions from the questionnaire. The range of the subscale scores are from 0 to 100, with higher scores being worse.~After the subscale scores being calculated, the Change in quality of life is calculated by subtracting baseline score from end of treatment" (NCT02399215)
Timeframe: Baseline to 30 days post-treatment

Interventionscore on a scale (Median)
Change in endocrine scaleChange in gastrointestinal scaleChange in treatment scaleChange in social function scaleChange in Disease Related Worry ScaleChange in Global scale
Treatment (Nintedanib)0000-61

[back to top]

Clinical Response (Complete Response + Partial Response) Measured Using Standard RECISTv1.1 Criteria

Exact 90% confidence interval estimates using the Clopper-Pearson method will be given for the response rates. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI, response rates are categorized as Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT02399215)
Timeframe: Up to 2 years

InterventionParticipants (Count of Participants)
SDPDPR
Treatment (Nintedanib)2611

[back to top]

Portion of Common Terminology Criteria for Adverse Events Grade 2 or Higher Radiation Pneumonitis

"Will compare the rate of symptomatic radiation pneumonitis in patients who received nintedanib versus placebo. Assessed using the intent-to-treat principle and a one-sided exact test about the Cochran-Mantel-Haenszel correlation and regression test.~The grade 2 or higher radiation penumonitis is identified by the Common Terminology Criteria for Adverse Events." (NCT02452463)
Timeframe: At 6 months after completion of chemoradiation

Interventionproportion of participants (Number)
Arm I (Nintedanib)0.00
Arm II (Placebo)0.67

[back to top]

Changes in Radiation Pneumonitis Scores

"Changes in radiation pneumonitis scores, relative to baseline, will be evaluated within each study arm using the Wilcoxon signed rank or paired t-tests, as appropriate. Changes in radiation pneumonitis scores may be compared between study arms using the Wilcoxon rank sum or independent sample t-tests, as appropriate.~The radiation pneumonitis scores were obtained using semi quantitative analysis will be performed for the presence of ground-glass opacity, consolidation, reticulation, mosaic perfusion, traction bronchiectasis and honeycombing for each lung zone and scored on a four point scale (0 = no involvement, 1 ≤ 25%; 2 = 26 50%; 3 = 51 75% and 4 ≥ 76%). The scores are averaged across two radiologists." (NCT02452463)
Timeframe: Baseline up to 2.5 years post-treatment

Interventionscore on a scale (Mean)
Arm I (Nintedanib)0.50
Arm II (Placebo)0.75

[back to top]

Overall Survival

Overall survival will be reported using standard Kaplan-Meier methods. Comparisons of overall survival between study arms may utilize the two-sided stratified log-rank test. (NCT02452463)
Timeframe: 1 year survival, with follow-up assessed up to 2.5 years post-treatment

InterventionPercent survival at 1 year (Number)
Arm I (Nintedanib)53.0
Arm II (Placebo)100.0

[back to top]

Percent Change in Pulmonary Function Tests

Percent change in pulmonary function test, relative to baseline, will be evaluated within each study arm using the Wilcoxon signed rank or paired t-tests, as appropriate. Changes in pulmonary function tests may be compared between study arms using the Wilcoxon rank sum or independent sample t-tests, as appropriate. (NCT02452463)
Timeframe: Baseline up to 2.5 years post-treatment

Interventionpercent of change (Mean)
Arm I (Nintedanib)-28.29
Arm II (Placebo)11.02

[back to top]

Progression-free Survival

Progression-free survival will be reported using standard Kaplan-Meier methods. Comparisons of progression-free survival between study arms may utilize the two-sided stratified log-rank test. (NCT02452463)
Timeframe: 1 year progression-free survival, with follow-up assessed up to 2.5 years post-treatment

InterventionPercent survival at 1 year (Number)
Arm I (Nintedanib)25.0
Arm II (Placebo)100.0

[back to top]

Percent Changes in Overall Quality of Life and Symptom Scores

"Percent changes in the quality of life and symptom scores may be compared between study arms using the Wilcoxon rank sum or independent sample t-tests, as appropriate.~The quality of life scores are obtained using the Lung Cancer Symptom Scale (LCSS) The scores range from 0 to 68, where 0 indicates poor quality of life and 68 indicates good quality of life. The percent change from baseline was calculated as 100*(post treatment - baseline) / baseline." (NCT02452463)
Timeframe: Baseline up to 2.5 years post-treatment

Interventionpercent change (Mean)
Arm I (Nintedanib)110.00
Arm II (Placebo)-16.35

[back to top]

Overall Survival

Overall survival will be estimated using standard Kaplan-Meier methods for censored data, from which the median and other statistics of interest will be calculated (e.g., rates at 3 months, 6 months, 12 months). (NCT02568449)
Timeframe: Up to 1 year

Interventionmonths (Median)
Treatment (Nintedanib)4.1

[back to top]

Incidence of Grade 3-4 Toxicity

Number of participants with grade 3 or grade 4 for each type of toxicity encountered, using all toxicity evaluable patients. (NCT02568449)
Timeframe: Up to 1 year

InterventionParticipants (Count of Participants)
Dyspnea (shortness of breath)LymphopeniaHypoxiaSyncope (fainting)pulmonary/upper respiratory- other, acute respiratory eventThrombosis/thrombus/embolismEncephalopathyPericardial effusionPain - Chest wallAscites (non-malignant)Edema: trunk/genitalSupraventricular and nodal arrhythmia - Atrial fibrillation
Treatment (Nintedanib)542111111111

[back to top]

Number of Participants Responded (Complete Response, Partial Response, Stable Disease, Progressive Disease, Not Evaluable)

number of participants responded (complete response, partial response, stable disease, progressive disease, not evaluable) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) (NCT02568449)
Timeframe: Up to 1 year

InterventionParticipants (Count of Participants)
complete responsepartial responsestable diseaseprogressive diseasenot evaluable
Treatment (Nintedanib)000182

[back to top]

Progression-free Survival (PFS)

PFS will be estimated using standard Kaplan-Meier methods for censored data, from which the median and other statistics of interest will be calculated (e.g., rates at 3 months, 6 months, 12 months). (NCT02568449)
Timeframe: From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause; assessed up to 4 months

Interventionmonths (Median)
Treatment (Nintedanib)1.8

[back to top]

AUC0-inf

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference 1 treatment (R1) and Reference 2 treatment (R2) separately. (NCT02572752)
Timeframe: -1:00 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 4:30h, 5:00h, 5:30h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration.

Interventionng*h/mL (Geometric Mean)
Nintedanib, Test Treatment (T)311
Nintedanib, Reference Treatment (R1)322
Nintedanib, Reference Treatment (R2)319

[back to top]

AUC0-tz

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference treatment 1 (R1) and Reference treatment 2 (R2) separately. (NCT02572752)
Timeframe: -1:00 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 4:30h, 5:00h, 5:30h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration.

Interventionng*h/mL (Geometric Mean)
Nintedanib, Test Treatment (T)300
Nintedanib, Reference Treatment (R1)310
Nintedanib, Reference Treatment (R2)306

[back to top]

Cmax

Maximum measured concentration of the analyte in plasma (Cmax). The unadjusted geometric mean (gMean) and geometric coefficient variation (gCV) was calculated for Test treatment (T), Reference 1 treatment (R1) and Reference 2 treatment (R2) separately. (NCT02572752)
Timeframe: -1:00 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 4:30h, 5:00h, 5:30h, 6:00h, 7:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h and 72:00h after drug administration.

Interventionng/mL (Geometric Mean)
Nintedanib, Test Treatment (T)39.3
Nintedanib, Reference Treatment (R1)41.1
Nintedanib, Reference Treatment (R2)39.8

[back to top]

Predose Plasma Concentrations at Steady State (Cpre,ss) of Pirfenidone

Predose plasma concentrations at steady state (Cpre,ss) of pirfenidone at Week 2 (Visit 4) and Week 4 (Visit 5) (NCT02579603)
Timeframe: Prior to intake of study medication on week 2 and week 4

Interventionng/mL (Geometric Mean)
Week 2Week 4
Nintedanib + Pirfenidone11201220

[back to top]

Percentage of Patients With On-treatment Gastrointestinal (GI) AEs (SOC GI Disorders) From Baseline to Week 12

"Percentage of patients with on-treatment gastrointestinal (GI) Adverse events (AEs) (SOC GI disorders) from baseline to week 12.~On-treatment AEs were defined as AEs with an onset from the first dose of randomised treatment up to the last dose of randomised treatment (inclusive)." (NCT02579603)
Timeframe: Baseline to week 12

Interventionpercentage of participants (Number)
Nintedanib52.9
Nintedanib + Pirfenidone69.8

[back to top]

Predose Plasma Concentrations at Steady State (Cpre,ss) of Nintedanib at Baseline, Weeks 2 and 4

Predose plasma concentrations at steady state (Cpre,ss) of nintedanib at baseline (Visit 3), Week 2 (Visit 4) and Week 4 (Visit 5) (NCT02579603)
Timeframe: baseline, prior to intake of study medication on week 2 and week 4

,
Interventionng/mL (Geometric Mean)
baselineWeek 2Week 4
Nintedanib7.087.255.92
Nintedanib + Pirfenidone7.658.177.13

[back to top]

Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks

"Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.~For this endpoint reported means represent the adjusted rate." (NCT02597933)
Timeframe: up to week (wk) 52 after the start of administration

Interventionmillilitre (mL)/year (yr) (Mean)
Placebo-93.3
Nintedanib-52.4

[back to top]

Absolute Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco) in % Predicted at Week 52

"Absolute change from baseline in Carbon Monoxide Diffusion Capacity (DLco) in % predicted at Week 52.~Least square mean is actually the adjusted mean. Adjusted mean is based on all analysed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT02597933)
Timeframe: Baseline and up to 52 weeks after the start of administration

Intervention% predicted DLco (Least Squares Mean)
Placebo-2.77
Nintedanib-3.21

[back to top]

Absolute Change From Baseline in Digital Ulcer Net Burden at Week 52

"Absolute change from baseline in digital ulcer net burden (defined as the number of new digital ulcers (DUs) plus the number of DUs that have been verified at any earlier assessment during the trial) at Week 52.~It is calculated at a visit by counting the total number of fingertips with ulcers (i.e. number of fingers with presence of digital ulcer ticked Yes) at the corresponding visit~Least square mean is actually the adjusted mean. Adjusted mean is based on all analysed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT02597933)
Timeframe: Baseline and up to 52 weeks after the start of administration

Interventionfingers (Least Squares Mean)
Placebo0.06
Nintedanib0.03

[back to top]

Absolute Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Dyspnoea Score at Week 52

"Absolute change from baseline in Functional Assessment of Chronic Illness Therapy (FACIT) dyspnoea score at Week 52.~FACIT-Dyspnoea (Dyspnoea) 10 Item Short Form include a 4-point rating scale (no shortness of breath=0; mildly short of breath=1; moderately short of breath = 2; severely short of breath =3; or I did not do this in the past 7 days =4).~A raw score is calculated as: Sum individual item scores * 10 / number of items answered. Raw scores are then converted to scale scores using the table included in the FACIT Dyspnoea Scale Short Form Scoring Guideline. FACIT dyspnea scale score ranges between 0 and 75.9.~The FACIT-Dyspnea short forms are scored such that a high score represents high levels of dyspnea.~Least square mean is actually the adjusted mean. Adjusted mean is based on all analysed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT02597933)
Timeframe: Baseline and up to 52 weeks after the start of administration

InterventionUnit on a scale (Least Squares Mean)
Placebo0.34
Nintedanib0.99

[back to top]

Absolute Change From Baseline in FVC in mL at Week 52

Absolute change from baseline in FVC in mL at Week 52. Least square mean is actually the adjusted mean. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at Week 52). (NCT02597933)
Timeframe: Baseline and up to 52 weeks after the start of administration

InterventionmL (Least Squares Mean)
Placebo-101.03
Nintedanib-54.63

[back to top]

Absolute Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52

"Absolute change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) score at Week 52.~The HAQ-DI score is calculated as follows:~Each question is scored 0-3 (where 0= without difficulty & 3= unable to do). There are 8 categories (Dressing & Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, Activities), each including 2 or 3 questions. The score for each category corresponds to maximum question score within each category.~Finally, HAQ-DI score corresponds to sum of the sub-scores of all 8 categories divided by number of categories completed. Please note that if there are fewer than 6 categories with responses, then a score cannot be calculated.~The HAQ-DI score scale has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 … 3). A high score corresponds to worse impairment.~Least square mean is actually the adjusted mean. Adjusted mean is based on all analysed patients in the model (not only patients with a baseline and measurement at week 52)." (NCT02597933)
Timeframe: Baseline and up to 52 weeks after the start of administration

Interventionunit on a scale (Least Squares Mean)
Placebo0.022
Nintedanib0.054

[back to top]

Absolute Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Week 52.

"This is the second key secondary endpoint.~The Saint George's Respiratory Questionnaire measures the health status in patients with chronic airflow limitation. It consists of 2 parts that cover 3 domains: symptoms, activities, and impacts. The symptom domain relates to the effect, frequency and severity of respiratory symptoms. The activity domain relates to activities that cause or are limited by breathlessness. The impact domain evaluates a range of aspects concerned with social functioning and psychological disturbances resulting from airways disease. The scores of these domains range from 0 (no impairment) to 100 (worst possible). The calculated total score summarises the impact of the disease on overall health status. A high score corresponds to worse health.~Least square mean is actually the adjusted mean. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at Week 52)." (NCT02597933)
Timeframe: Baseline and up to 52 weeks after the start of administration

Interventionunit on scale (Least Squares Mean)
Placebo-0.88
Nintedanib0.81

[back to top]

Absolute Change From Baseline in the Modified Rodnan Skin Score (mRSS) at Week 52

"This is the first key secondary endpoint.~The modified Rodnan Skin Score (mRSS) is an evaluation of the patient's skin thickness rated by clinical palpation using a 0 to 3 scale. The scale differentiates between 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness with inability to pinch the skin into a fold.~The palpation is done for each of the 17 surface anatomic areas of the body: face, anterior chest, abdomen, fingers (right and left separately), forearms, upper arms, thighs, lower legs, dorsum of hands and feet. The sum of these individual values is defined as the total skin score. The mRSS has a range from 0 (no thickening) to 51 (severe thickening in all 17 areas). A high score corresponds to worse skin thickness.~Least square mean is actually the adjusted mean. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at Week 52)." (NCT02597933)
Timeframe: Baseline and up to 52 weeks after the start of administration

Interventionunit on scale (Least Squares Mean)
Placebo-1.96
Nintedanib-2.17

[back to top]

Annual Rate of Decline in FVC in Percentage (%) Predicted Over 52 Weeks

"Annual rate of decline in FVC in percentage (%) predicted over 52 weeks.~For this endpoint reported means represent the adjusted rate." (NCT02597933)
Timeframe: up to 52 weeks after the start of administration

Intervention% predicted/yr (Mean)
Placebo-2.6
Nintedanib-1.4

[back to top]

Relative Change From Baseline [%] of mRSS at Week 52

"Relative change from baseline [%] of mRSS at Week 52.~The modified Rodnan Skin Score (mRSS) is an evaluation of the patient's skin thickness rated by clinical palpation using a 0 to 3 scale. The scale differentiates between 0 = normal skin, 1 = mild thickness, 2 = moderate thickness, and 3 = severe thickness with inability to pinch the skin into a fold.~The palpation is done for each of the 17 surface anatomic areas of the body: face, anterior chest, abdomen, fingers (right and left separately), forearms, upper arms, thighs, lower legs, dorsum of hands and feet. The sum of these individual values is defined as the total skin score. The mRSS has a range from 0 (no thickening) to 51 (severe thickening in all 17 areas). A high score corresponds to worse skin thickness.~Least square mean is actually the adjusted mean. Adjusted mean was based on all analysed patients in the model (not only patients with a baseline and measurement at Week 52)." (NCT02597933)
Timeframe: Baseline and up to 52 weeks after the start of administration

Interventionpercent change (Least Squares Mean)
Placebo-3.92
Nintedanib-10.20

[back to top]

The Percentage (%) of Responder Based on Combined Response Index in Systemic Sclerosis (CRISS) at Week 52

"The percentage (%) of responder based on Combined Response Index in Systemic Sclerosis (CRISS) at Week 52.~This is a composite endpoint, based on the mRSS, FVC percent predicted, HAQ-DI, patient's global impression of overall health Visual Analogue Scale (VAS) and physician's global impression of patient's overall health VAS, as well as the absence of significant worsening of interstitial lung disease, a new scleroderma renal crisis, left ventricular failure or pulmonary arterial hypertension.~The CRISS index score represents a probability of improvement and ranges between 0 and 1.~This is a 2 stage process to predict probability of improvement:~Step 1 - absence of major organ progression (SRC etc.) - score 0 Step 2 - predicted probability of improvement - (score 0 - 1)" (NCT02597933)
Timeframe: Week 52

Intervention(%) of responder based on CRISS (Number)
Placebo11.8
Nintedanib12.2

[back to top]

Time to Death

Time to event analysis of patients with death. The number of observed patients with death are reported. (NCT02597933)
Timeframe: From date of first trial drug intake up to date of death or last contact date (ie., up to 100 weeks)

InterventionParticipants (Count of Participants)
Placebo9
Nintedanib10

[back to top]

Total Number of Days From the Initiation of Combination Treatment to Discontinuation of Pirfenidone, Nintedanib, or Both Study Treatments

(NCT02598193)
Timeframe: Baseline up to Week 24

InterventionNumber of Days (Mean)
Pirfenidone+Nintedanib149.8

[back to top]

Total Number of Participant Days of Combination Treatment With Pirfenidone and Nintedanib

(NCT02598193)
Timeframe: Baseline up to Week 24

InterventionParticipant Days (Number)
Pirfenidone+Nintedanib13330

[back to top]

Percentage of Participants With Adverse Events and Serious Adverse Events

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT02598193)
Timeframe: Baseline up to Week 28

InterventionPercentage of Participants (Number)
Adverse EventSerious Adverse Event
Pirfenidone+Nintedanib98.918.0

[back to top]

Percentage of Participants Who Discontinue Pirfenidone, Nintedanib, or Both Study Treatments Because of Adverse Events Before the Week 24 Visit

(NCT02598193)
Timeframe: Baseline up to Week 24

InterventionPercentage of Praticipants (Number)
Pirfenidone+Nintedanib14.6

[back to top]

Percentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day

(NCT02598193)
Timeframe: Week 24

InterventionPercentage of Participants (Number)
Pirfenidone+Nintedanib77.5

[back to top]

Pirfenidone-treated, Area Under the Concentration-time Curve of Pirfenidone in Plasma Over a Dosing Interval at Steady State (AUCτ,ss)

AUCτ,ss, area under the concentration-time curve of pirfenidone in plasma over a dosing interval at steady state. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error. (NCT02606877)
Timeframe: Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.

Interventionnanogram*hour/mililitre [ng*h/mL] (Geometric Mean)
Pirfenidone+Nintedanib (T2)39040.84
Pirfenidone (R2)40178.46

[back to top]

Pirfenidone-treated, Maximum Measured Concentration of Pirfenidone in Plasma at Steady State (Cmax,ss)

Cmax,ss, maximum measured concentration of pirfenidone in plasma at steady state. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error. (NCT02606877)
Timeframe: Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.

Interventionnanogram/mililitre [ng/mL] (Geometric Mean)
Pirfenidone+Nintedanib (T2)10537.26
Pirfenidone (R2)10591.08

[back to top]

Treatment naïve, Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

AUC0-∞, area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error. (NCT02606877)
Timeframe: Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.

Interventionnanogram*hour/mililitre [ng*h/mL] (Geometric Mean)
Nintedanib + Pirfenidone (T1)175.04
Nintedanib (R1)195.59

[back to top]

Treatment naïve, Maximum Measured Concentration of Nintedanib in Plasma After Single Dose Administration (Cmax).

Cmax, maximum measured concentration of nintedanib in plasma. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error. (NCT02606877)
Timeframe: Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.

Interventionnanogram/mililitre [ng/mL] (Geometric Mean)
Nintedanib + Pirfenidone (T1)23.04
Nintedanib (R1)28.58

[back to top]

Treatment naïve, Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval 0 to the Last Quantifiable Data Point (AUC0-tz).

AUC0-tz , area under the concentration-time curve of nintedanib in plasma over the time interval from 0 to the last quantifiable concentration. Standard error mentioned in the Method of Dispersion is actually a Geometric Standard Error. (NCT02606877)
Timeframe: Blood samples were collected at pre-dose and at 0:30, 1:00, 2:00, 3:00, 4:00, 6:00, 8:00 and 10:00 hours post dose.

Interventionnanogram*hour/mililitre [ng*h/mL] (Geometric Mean)
Nintedanib + Pirfenidone (T1)150.31
Nintedanib (R1)169.69

[back to top]

Incidence of Hematological Improvement (Phase 2)

"Evaluation of hematological improvement will be assessed based on IWG MDS 2006 criteria. Due to differing pretreatment conditions of participants, response to treatment in this construct will be assessed in the following manner:~Erythroid response (pretreatment <11 g/dL) : Hgb increase at least by 1.5 g/dL. Relevant reduction of units of RBC transfusions by an absolute number of at least 4 RBC transfusions/8 wk compared with the pretreatment transfusion number in the previous 8 wk. Only RBC transfusions given for a Hgb of below or equal to 9.0 g/dL pretreatment will count in the RBC transfusion response evaluation.~Platelet response (pretreatment 100x109/L): Absolute increase of at least 30x109/L for patients starting with more than 20x109/L platelets. Increase from less than 20x109/L to more than 20x109/L and by at least 100%.~Neutrophil response (pretreatment, <1.0x109/L) At least 100% increase and an absolute increase of at least 0.5x109/L." (NCT02665143)
Timeframe: Up to 2 years

InterventionParticipants (Count of Participants)
Hematological Improvement Erythroid72294708Hematological Improvement Neutrophils72294708Hematological Improvement Platelet72294708
MissingYesNo
Nintedanib and AML Induction13
Nintedanib and AML Induction3
Nintedanib and AML Induction6
Nintedanib and AML Induction10

[back to top]

Count of Patients With Treatment-Emergent Adverse Events (Phase 1)

In the Phase 1 portion of the study, safety will be assessed after the inclusion of the first 6 patients, to analyze tolerance and adverse events occurring during this trial and will decide on any action to be taken. Safety will be evaluated according to NCI CTCAE V4 criteria. TEAE's were considered adverse events that occurred within 60 days of treatment initiation. The title of this outcome measure was adjusted when results were entered. (NCT02665143)
Timeframe: 60 days

InterventionParticipants (Count of Participants)
Nintedanib and AML Induction6

[back to top]

Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Concentration (AUC0-tz)

Area under the concentration-time curve of Nintedanib in plasma over the time interval from 0 to the last quantifiable concentration (AUC0-tz). PK plasma samples were taken at: 1 hour (h) before drug administration (approximate time for predose sample) and 30 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 144.5h, 145h, 145.5h, 146h, 146.5h, 147h, 148h, 149h, 150h, 152h, 154h, 156h, 168h, 180h, 192h, 216h after drug administration. Two different visits; Visit 2 (R): -1 to 72 h, Visit 3 (T) 144 to 216 h. AUC0-tz was calculated for each visit separately. (NCT02667704)
Timeframe: Up to 216 hours. The details are mentioned in description.

Interventionnanogram (ng)*hour (h) /millilitre (mL) (Geometric Mean)
Nintedanib (R)195
Bosentan+Nintedanib (T)193

[back to top]

Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity)

Area under the concentration-time curve of Nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity). PK plasma samples were taken at: 1 hour (h) before drug administration and 30 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 144.5h, 145h, 145.5h, 146h, 146.5h, 147h, 148h, 149h, 150h, 152h, 154h, 156h, 168h, 180h, 192h, 216h after drug administration. Two different visits; Visit 2 (R): -1 to 72 h, Visit 3 (T) 144 to 216 h. AUC0-infinity was calculated for each visit separately. (NCT02667704)
Timeframe: Up to 216 hours. The details are mentioned in description.

Interventionng*h / mL (Geometric Mean)
Nintedanib (R)204
Bosentan+Nintedanib (T)208

[back to top]

Maximum Measured Concentration of Nintedanib in Plasma (Cmax)

Maximum measured concentration of Nintedanib in plasma (Cmax). PK plasma samples were taken at: 1 hour (h) before drug administration and 30 minutes, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h, 144h, 144.5h, 145h, 145.5h, 146h, 146.5h, 147h, 148h, 149h, 150h, 152h, 154h, 156h, 168h, 180h, 192h, 216h after drug administration. Two different visits; Visit 2 (R): -1 to 72 h, Visit 3 (T) 144 to 216 h. Cmax was determined for each visit separately. (NCT02667704)
Timeframe: Up to 216 hours. The details are mentioned in description.

Interventionng/mL (Geometric Mean)
Nintedanib (R)21.9
Bosentan+Nintedanib (T)22.7

[back to top]

Number of Participants With Dose-limiting Toxicity (DLT) During the First Treatment Cycle

"Number of participants with DLT occurring during the first treatment cycle. DLT was defined as any of the following adverse events related to nintedanib:~Non-haematological drug-related Common Terminology Criteria for AEs (CTCAE) grade 3 or greater~diarrhoea CTCAE grade 2 for >7 days despite supportive care~nausea CTCAE grade 3 or greater despite supportive care~vomiting CTCAE grade 2 or greater despite supportive care~increase in Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) to CTCAE grade 3 or greater~A increase in ALT and/or AST to CTCAE grade 2 or greater in conjunction with~total bilirubin increase of CTCAE grade 1 or greater~Platelets <50 000/mm3 with bleeding (CTCAE ≥3)~neutropenia of any grade or duration accompanied by fever >38.5°C~neutropenia grade 4 without fever of >7 days duration~Inability to resume nintedanib dosing within 21 days after stopping due to toxicity." (NCT02668393)
Timeframe: First treatment cycle, the first 28 days following the start of trial medication.

InterventionParticipants (Count of Participants)
150 mg Nintedanib + Docetaxel1
200 mg Nintedanib + Docetaxel1

[back to top]

Maximum Tolerated Dose (MTD) of Nintedanib Administered in Combination With Docetaxel

Maximum tolerated dose (MTD) of nintedanib administered in combination with docetaxel. The MTD was defined as the highest dose combination studied for which the incidence of DLTs was no more than 1 out of 6 subjects experiencing a DLT during the first treatment cycle i.e. the incidence of DLTs was no more than 17%. In case dose escalation reached dose level 3 (200 mg bid nintedanib administered without interruption on days of docetaxel infusion) and no more than 1 out of 6 subjects experienced a DLT during the first 28-day cycle at this dose level, dose level 3 was considered the MTD. (NCT02668393)
Timeframe: First treatment cycle, the first 28 days following the start of trial medication.

Interventionmilligram (Number)
Nintedanib + DocetaxelNA

[back to top]

Area Under the Concentration-time Curve of the the Ethinylestradiol and Levonorgestrel in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

"Area under the concentration-time curve in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC 0-tz) for ethinylestradiol and levonorgestrel after a single dose of the combination of ethinylestradiol and levonorgestrel. In Period 1, blood samples were collected at pre-dose at 0.35 hour (h) and at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h and 72h after drug administration of Microgynon®. Nintedanib in Period 2 was started at least 7 days before Microgynon® administration.~In Period 2, blood samples were collected at pre-dose at 0.35 hour (h) and at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 11.55h, 23.55h, 47.55h and 71.55h after drug administration of Microgynon®." (NCT02751385)
Timeframe: Please refer to description section for the details about the actual sampling time points

,
Interventionpicogram*hour/mililiter (Geometric Mean)
EthinylestradiolLevonorgestrel
Microgynon®41041500
Microgynon® With Nintedanib34843600

[back to top]

Maximum Measured Concentration (Cmax) of Ethinylestradiol and Levonorgestrel

"Maximum blood concentrations (Cmax) for ethinylestradiol and levonorgestrel after a single dose of the combination of ethinylestradiol and levonorgestrel. In Period 1, blood samples were collected at pre-dose at 0.35 hour (h) and at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h and 72h after drug administration of Microgynon®. Nintedanib in Period 2 was started at least 7 days before Microgynon® administration.~In Period 2, blood samples were collected at pre-dose at 0.35 hour (h) and at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 11.55h, 23.55h, 47.55h and 71.55h after drug administration of Microgynon®." (NCT02751385)
Timeframe: Please refer to description section for the details about the actual sampling time points

,
Interventionpicogram/milliliter[pg/mL] (Geometric Mean)
EthinylestradiolLevonorgestrel
Microgynon®32.62680
Microgynon® With Nintedanib36.91630

[back to top]

Area Under the Concentration-time Curve of the Ethinylestradiol and Levonorgestrel in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity).

"Area under curve from zero to infinity (AUC0-∞) for ethinylestradiol and for levonorgestrel after intake of a single dose of the combination of ethinylestradiol and levonorgestrel. In Period 1, blood samples were collected at pre-dose at 0.35 hour (h) and at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 48h and 72h after drug administration of Microgynon®. Nintedanib in Period 2 was started at least 7 days before Microgynon® administration.~In Period 2, blood samples were collected at pre-dose at 0.35 hour (h) and at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 11.55h, 23.55h, 47.55h and 71.55h after drug administration of Microgynon®." (NCT02751385)
Timeframe: Please refer to description section for the details about the actual sampling time points

,
Interventionpg*h/mL (Geometric Mean)
EthinylestradiolLevonorgestrel
Microgynon®50354500
Microgynon® With Nintedanib58057600

[back to top]

Objective Response Rate (ORR)

"ORR is defined as complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.~Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out." (NCT02780700)
Timeframe: tumor response was to be assessed by imaging according to RECIST (version 1.1) every 6 weeks.

InterventionPercentage of participants (Number)
Nintedanib Plus CapecitabineNA

[back to top]

Overall Survival (OS)

"Overall survival is defined as the time from randomization until death from any cause.~Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out." (NCT02780700)
Timeframe: Data collected up to cut-off date 09 Sep 2016, Up to 02 months

Interventionmonths (Median)
Nintedanib Plus CapecitabineNA

[back to top]

Disease Control (DC)

"Disease control is defined as CR or PR or Stable disease (SD) per RECIST version 1.1.~Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out." (NCT02780700)
Timeframe: Data collected up to cut-off date 09 Sep 2016, Up to 02 months

InterventionPercentage of participants (Number)
Nintedanib Plus CapecitabineNA

[back to top]

Percentage of Patients With Grade 3 or Worse Adverse Events

Percentage of patients with grade 3 or worse adverse events. (NCT02780700)
Timeframe: Data collected up to cut-off date 09 Sep 2016, Up to 02 months

InterventionPercentage of participants (Number)
Nintedanib Plus Capecitabine0

[back to top]

Progression Free Survival (PFS)

"PFS is defined as the time from randomization until objective tumor progression or death.~Since only one patient was enrolled prior to termination of the trial, no data summarization or analysis was carried out." (NCT02780700)
Timeframe: Data collected up to cut-off date 09 Sep 2016, Up to 02 months

Interventionmonths (Median)
Nintedanib Plus CapecitabineNA

[back to top]

The Rate of Change in Blood Collagen 3 Degraded by Matrix Metalloproteinase-9 (C3M) From Baseline to Week 12

"The rate of change in blood Collagen 3 degraded by matrix metalloproteinase-9 (C3M) from baseline to week 12 is presented.~The mean presented is the adjusted rate based on a random coefficient regression (C3M- log 10 transformation) with fixed effects for gender, age, height and random effect of patient specific intercept and time." (NCT02788474)
Timeframe: baseline and 12 weeks

Interventionng/ml/mth (Mean)
Placebo/ Nintedanib-0.00091
Nintedanib/ Nintedanib-0.00398

[back to top]

The Rate of Change in Blood Collagen 1 Degraded by Matrix Metalloproteinase-2/9/13 (C1M) From Baseline to Week 12

"The rate of change in blood Collagen 1 degraded by matrix metalloproteinase-2/9/13 (C1M) from baseline to week 12 is presented.~The mean presented is the adjusted rate based on a random coefficient regression (C1M (negative reciprocal root transformation)) with fixed effects for gender, age, height and random effect of patient specific intercept and time." (NCT02788474)
Timeframe: baseline and 12 weeks

Interventionng/ml/mth (Mean)
Placebo/ Nintedanib0.00041
Nintedanib/ Nintedanib0.00162

[back to top]

Percentage of Patients With Disease Progression as Defined by Absolute Forced Vital Capacity (FVC) Decline >=10% or Death Until Week 52

"For this endpoint, disease progression was defined by absolute FVC (percentage of predicted) decline ≥10% or death up to Week 52 based on in-clinic supervised spirometry.~This is a key secondary endpoint of the trial. This outcome measure is percentage of patients with disease progression and CRPM is included in the various models as a factor/covariate, and that this outcome measure, the percentage of progressors are displayed under Measured values" (NCT02788474)
Timeframe: 52 weeks

InterventionPercentage of participants (Number)
Placebo/ Nintedanib30.43
Nintedanib/ Nintedanib25.00

[back to top]

The Rate of Change (Slope) in Blood C-reactive Protein Degraded by Matrix Metalloproteinase-1/8 (CRPM) From Baseline to Week 12.

The rate of change (slope) in blood C-reactive protein degraded by matrix metalloproteinase-1/8 (CRPM) from baseline to week 12 is presented. The mean presented is the adjusted rate based on a random coefficient regression (CRPM log 10 transformed) with fixed effects for gender, age, height and random effect of patient specific intercept and time. (NCT02788474)
Timeframe: baseline and 12 weeks

Interventionnanogram/ millitre/ month (ng/ mL/ mth) (Mean)
Placebo/ Nintedanib-0.00190
Nintedanib/ Nintedanib-0.00257

[back to top]

Change From Baseline in SGRQ Total Score at Week 24

The SGRQ is a 50-item questionnaire developed to measure health status (quality of life). Scores are calculated for three domains: Symptoms, Activity and Impacts (Psycho-social) as well as a total score. A minimum change in score of 4 units was established as clinically relevant after patient and clinician testing. The mean and standard error presented for descriptive statistics are actually adjusted mean for change from baseline and its standard error. (NCT02802345)
Timeframe: Baseline and week 24

InterventionUnit on scale (Mean)
Nintedanib+Placebo2.42
Nintedanib+Sildenafil0.23

[back to top]

Change From Baseline in St George's Respiratory Questionnaire (SGRQ) Total Score at Week 12

The SGRQ is a 50-item questionnaire developed to measure health status (quality of life). Scores are calculated for three domains: Symptoms, Activity and Impacts (Psycho-social) as well as a total score. A minimum change in score of 4 units was established as clinically relevant after patient and clinician testing. Scores range from 0 to 100, with higher scores indicating more limitations. The mean and standard error presented are actually adjusted mean for change from baseline and its standard error. (NCT02802345)
Timeframe: Baseline and week 12

InterventionUnit on scale (Mean)
Nintedanib+Placebo-0.77
Nintedanib+Sildenafil-1.28

[back to top]

Percentage of Patients With On-treatment Serious Adverse Events (SAE) From Baseline to Week 24

Percentage of patients with on-treatment serious adverse events (SAE) from baseline to Week 24 is presented. (NCT02802345)
Timeframe: Baseline and week 24

InterventionPercentage of participants (%) (Number)
Nintedanib+Placebo32.4
Nintedanib+Sildenafil27.0

[back to top]

Change From Baseline in Dyspnoea Using the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) at Week 12

The UCSD SOBQ is a 24-item questionnaire developed to measure breathlessness on a scale between zero and five where 0 is not at all breathless and 5 is maximally breathless or too breathless to do the activity. The mean and standard error presented for descriptive statistics are actually adjusted mean for change from baseline and its standard error. (NCT02802345)
Timeframe: Baseline and week 12

InterventionUnit on scale (Mean)
Nintedanib+Placebo4.40
Nintedanib+Sildenafil1.46

[back to top]

Change From Baseline in Dyspnoea Using UCSD SOBQ at Week 24

The UCSD SOBQ is a 24-item questionnaire developed to to measure breathlessness on a scale between zero and five where 0 is not at all breathless and 5 is maximally breathless or too breathless to do the activity. The mean and standard error presented for descriptive statistics are actually adjusted mean for change from baseline and its standard error. (NCT02802345)
Timeframe: Baseline and week 24

InterventionUnit on scale (Mean)
Nintedanib+Placebo6.85
Nintedanib+Sildenafil4.44

[back to top]

Absolute Change From Baseline in L-PF Symptoms Cough Domain Score at Week 52 - Overall Population

Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules Symptoms (23 items) and Impacts (21 items) where the symptoms module yields three domain scores dyspnea, cough and fatigue as well as a total symptoms score (impacts module yields a single impacts score). L-PF Symptoms cough domain score (cough score) ranges from 0-100, the higher the score the greater the impairment. If missing items were ≥50 % within a score, then the corresponding score was set to missing. Absolute change from baseline in cough score at week 52 is based on a Mixed Model Repeated Measures, with fixed effects for baseline cough score, HRCT fibrotic pattern, visit, treatment-by-visit interaction, baseline cough score-by-visit interaction and random effect for participant, visit as repeated measure. The Adjusted mean is based on all analysed participants in the model (not only participants with a baseline and measurement at week 52). (NCT02999178)
Timeframe: Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

InterventionUnit on scale (Least Squares Mean)
150 mg Nintedanib-1.84
Placebo4.25

[back to top]

Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 5 Percent at Week 52 - Overall Population

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. Participants with relative decline from baseline in FVC % pred greater than 5% at week 52 were those participants with a negative relative change from baseline in FVC % pred at week 52 the absolute value of which being greater than 5% and those participants with missing data (worst case analysis). (NCT02999178)
Timeframe: Baseline and up to 52 weeks after first drug intake

InterventionPercentage of participants (Number)
150 mg Nintedanib52.4
Placebo68.6

[back to top]

Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 10 Percent at Week 52 - Overall Population

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. Participants with relative decline from baseline in FVC % pred greater than 10% at week 52 were those participants with a negative relative change from baseline in FVC % pred at week 52 the absolute value of which being greater than 10% and those participants with missing data (worst case analysis). (NCT02999178)
Timeframe: Baseline and up to 52 weeks after first drug intake

InterventionPercentage of participants (Number)
150 mg Nintedanib40.7
Placebo48.9

[back to top]

Annual Rate of Decline in Forced Vital Capacity - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Annual rate of decline in Forced Vital Capacity in milliliter (mL) per year in participants with HRCT fibrotic pattern=UIP-like fibrotic pattern only is based on a random coefficient regression with fixed effects for treatment, baseline FVC [mL], and including treatment-by-time and baseline-by-time interactions. Within-participant errors are modelled by an unstructured variance-covariance matrix. (NCT02999178)
Timeframe: Baseline, 2, 4, 6, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

InterventionMilliliter per year (Least Squares Mean)
150 mg Nintedanib-82.87
Placebo-211.07

[back to top]

Absolute Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) Questionnaire Total Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

King's Brief Interstitial Lung Disease questionnaire (K-BILD) consists of 15 items and 3 domains: breathlessness and activities, psychological, and chest symptoms. Possible score ranges from 0-100, score of 100 representing the best health status. If missing items were >50% per domain, the domain score was set to missing. If any of the domain scores were missing, the total score was set to missing. Absolute change from baseline in K-BILD Total score at week 52 in participants with HRCT fibrotic pattern=UIP-like fibrotic pattern only was based on a Mixed Model Repeated Measures (MMRM), with fixed effects for baseline K-BILD Total score, HRCT fibrotic pattern, visit, treatment-by-visit interaction, baseline-by-visit interactions and random effect for participant. Visit was the repeated measure. Within-participant errors were modelled by unstructured variance-covariance matrix. (NCT02999178)
Timeframe: Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

InterventionUnit on scale (Least Squares Mean)
150 mg Nintedanib0.75
Placebo-0.78

[back to top]

Annual Rate of Decline in Forced Vital Capacity - Overall Population

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Overall population consists of all randomized participants with HRCT fibrotic pattern=UIP-like fibrotic pattern only or HRCT fibrotic pattern= Other fibrotic patterns. Annual rate of decline in Forced Vital Capacity in milliliter (mL) per year in the overall population is based on a random coefficient regression with fixed effects for treatment, HRCT fibrotic pattern, and baseline FVC [mL], and including treatment-by-time and baseline-by-time interactions. Within-participant errors are modelled by an unstructured variance-covariance matrix. (NCT02999178)
Timeframe: Baseline, 2, 4, 6, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

InterventionMilliliter per year (Least Squares Mean)
150 mg Nintedanib-80.82
Placebo-187.78

[back to top]

Absolute Change From Baseline in L-PF Symptoms Dyspnea Domain Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules Symptoms (23 items) and Impacts (21 items) where the symptoms module yields three domain scores dyspnea, cough and fatigue as well as a total symptoms score (impacts module yields a single impacts score). L-PF Symptoms dyspnea domain score (dyspnea score) ranges from 0-100, the higher the score the greater the impairment. If missing items were ≥50 % within a score, then the corresponding score was set to missing. Absolute change from baseline in dyspnea score at week 52 is based on a Mixed Model Repeated Measures, with fixed effects for baseline dyspnea score, visit, treatment-by-visit interaction, baseline dyspnea score-by-visit interaction and random effect for participant, visit as repeated measure. The Adjusted mean is based on all analysed participants in the model (not only participants with a baseline and measurement at week 52). (NCT02999178)
Timeframe: Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

InterventionUnit on scale (Least Squares Mean)
150 mg Nintedanib4.14
Placebo8.32

[back to top]

Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Cough Domain Score at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules Symptoms (23 items) and Impacts (21 items) where the symptoms module yields three domain scores dyspnea, cough and fatigue as well as a total symptoms score (impacts module yields a single impacts score). L-PF Symptoms cough domain score (cough score) ranges from 0-100, the higher the score the greater the impairment. If missing items were ≥50 % within a score, then the corresponding score was set to missing. Absolute change from baseline in cough score at week 52 is based on a Mixed Model Repeated Measures, with fixed effects for baseline cough score, visit, treatment-by-visit interaction, baseline cough score-by-visit interaction and random effect for participant, visit as repeated measure. The Adjusted mean is based on all analysed participants in the model (not only participants with a baseline and measurement at week 52). (NCT02999178)
Timeframe: Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

InterventionUnit on scale (Least Squares Mean)
150 mg Nintedanib-3.20
Placebo4.09

[back to top]

Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 10 Percent at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. Participants with relative decline from baseline in FVC % pred greater than 10% at week 52 were those participants with a negative relative change from baseline in FVC % pred at week 52 the absolute value of which being greater than 10% and those participants with missing data (worst case analysis). (NCT02999178)
Timeframe: Baseline and up to 52 weeks after first drug intake

InterventionPercentage of participants (Number)
150 mg Nintedanib41.3
Placebo52.4

[back to top]

Absolute Change From Baseline in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) Total Score at Week 52 - Overall Population

King's Brief Interstitial Lung Disease questionnaire (K-BILD) consists of 15 items and 3 domains: breathlessness and activities, psychological, and chest symptoms. Possible score ranges from 0-100, score of 100 representing the best health status. If missing items were >50% per domain, the domain score was set to missing. If any of the domain scores were missing, the total score was set to missing. Absolute change from baseline in K-BILD Total score at week 52 in the overall population was based on a Mixed Model Repeated Measures (MMRM), with fixed effects for baseline K-BILD Total score, HRCT fibrotic pattern, visit, treatment-by-visit interaction, baseline-by-visit interactions and random effect for participant. Visit was the repeated measure. Within-participant errors were modelled by unstructured variance-covariance matrix. (NCT02999178)
Timeframe: Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

InterventionUnit on scale (Least Squares Mean)
150 mg Nintedanib0.55
Placebo-0.79

[back to top]

Time to First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Time to first acute ILD exacerbation or death over 52 weeks was defined as time to first acute ILD exacerbation or death due to any cause within the first 52 weeks and was computed as earliest of date of first documented acute ILD exacerbation or death - date of first drug intake + 1. Participants alive who did not experience any ILD exacerbation event or with unknown status within the first 52 weeks were censored. (NCT02999178)
Timeframe: From first drug intake until date of first acute ILD exacerbation or date of death or last contact date, up to 372 days

InterventionDays (Median)
150 mg NintedanibNA
PlaceboNA

[back to top]

Time to Progression or Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Time to progression or death over 52 weeks is defined as the time from date of first drug intake to date of progression, or date of death (from any cause) if a participant died earlier. Participants with no event (progression or death from any cause) or unknown status were censored. Date of progression is defined as the date when ≥ 10% of absolute decline in FVC percent predicted compared to baseline occured for the first time. Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. (NCT02999178)
Timeframe: From first drug intake until date of progression or date of death or last contact date, up to 372 days

InterventionDays (Median)
150 mg NintedanibNA
PlaceboNA

[back to top]

Time to Death Due to Respiratory Cause Over 52 Weeks - Overall Population

Time to death due to respiratory cause over 52 weeks is defined as the time from date of first drug intake until date of death attributed to respiratory causes (determined by an independent Adjudication Committee) for participants with known date of death (from respiratory causes) within the first 52 weeks. Participants with no event (death from respiratory causes) or unknown status within the first 52 weeks were censored. As less than 4.95% of the total of participants in the analysis population experienced an event, only descriptive statistics were performed, as pre-specified. (NCT02999178)
Timeframe: From date of first trial drug intake up to date of death from respiratory causes or last contact date, up to 372 days

InterventionDays (Median)
150 mg NintedanibNA
PlaceboNA

[back to top]

Time to First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over 52 Weeks - Overall Population

Time to first acute ILD exacerbation or death over 52 weeks was defined as time to first acute ILD exacerbation or death due to any cause within the first 52 weeks and was computed as earliest of date of first documented acute ILD exacerbation or death - date of first drug intake + 1. Participants alive who did not experience any ILD exacerbation event or with unknown status within the first 52 weeks were censored. (NCT02999178)
Timeframe: From first drug intake until date of first acute ILD exacerbation or date of death or last contact date, up to 372 days

InterventionDays (Median)
150 mg NintedanibNA
PlaceboNA

[back to top]

Time to Death Due to Respiratory Cause Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Time to death due to respiratory cause over 52 weeks is defined as the time from date of first drug intake until date of death attributed to respiratory causes (determined by an independent Adjudication Committee) for participants with known date of death (from respiratory causes) within the first 52 weeks. Participants with no event (death from respiratory causes) or unknown status within the first 52 weeks were censored. As less than 4.95% of the total of participants in the analysis population experienced an event, only descriptive statistics were performed, as pre-specified. (NCT02999178)
Timeframe: From date of first trial drug intake up to date of death from respiratory causes or last contact date, up to 372 days

InterventionDays (Median)
150 mg NintedanibNA
PlaceboNA

[back to top]

Time to Death Over 52 Weeks - Overall Population

Time to death over 52 weeks defined as the time from date of first drug intake until date of death from any cause for participants with known date of death (from any cause) within the first 52 weeks. Participants with no event (death from any cause) or unknown status within the first 52 weeks were censored. (NCT02999178)
Timeframe: From first drug intake until date of death or last contact date, up to 372 days

InterventionDays (Median)
150 mg NintedanibNA
PlaceboNA

[back to top]

Time to Death Over 52 Weeks - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Time to death over 52 weeks defined as the time from date of first drug intake until date of death from any cause for participants with known date of death (from any cause) within the first 52 weeks. Participants with no event (death from any cause) or unknown status within the first 52 weeks were censored. (NCT02999178)
Timeframe: From first drug intake until date of death or last contact date, up to 372 days

InterventionDays (Median)
150 mg NintedanibNA
PlaceboNA

[back to top]

Time to Progression or Death Over 52 Weeks - Overall Population

Time to progression or death over 52 weeks is defined as the time from date of first drug intake to date of progression, or date of death (from any cause) if a participant died earlier. Participants with no event (progression or death from any cause) or unknown status were censored. Date of progression is defined as the date when ≥ 10% of absolute decline in FVC percent predicted compared to baseline occured for the first time. Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. (NCT02999178)
Timeframe: From first drug intake until date of progression or date of death or last contact date, up to 372 days

InterventionDays (Median)
150 mg NintedanibNA
PlaceboNA

[back to top]

Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptoms Dyspnea Domain Score at Week 52 - Overall Population

Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules Symptoms (23 items) and Impacts (21 items) where the symptoms module yields three domain scores dyspnea, cough and fatigue as well as a total symptoms score (impacts module yields a single impacts score). L-PF Symptoms dyspnea domain score (dyspnea score) ranges from 0-100, the higher the score the greater the impairment. If missing items were ≥50 % within a score, then the corresponding score was set to missing. Absolute change from baseline in dyspnea score at week 52 is based on a Mixed Model Repeated Measures, with fixed effects for baseline dyspnea score, HRCT fibrotic pattern, visit, treatment-by-visit interaction, baseline dyspnea score-by-visit interaction and random effect for participant, visit as repeated measure. The Adjusted mean is based on all analysed participants in the model (not only participants with a baseline and measurement at week 52). (NCT02999178)
Timeframe: Baseline, 12, 24, 36, 52 weeks after first drug intake (planned post-baseline visits)

InterventionUnit on scale (Least Squares Mean)
150 mg Nintedanib4.28
Placebo7.81

[back to top]

Percentage of Participants With a Relative Decline From Baseline in FVC Percent Predicted of More Than 5 Percent at Week 52 - Participants With HRCT Fibrotic Pattern=UIP-like Fibrotic Pattern Only

Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. Predicted normal values of FVC were calculated according to the Global Lung Initiative. FVC percent predicted (FVC % pred) is the FVC divided by its predicted value in percent. Participants with relative decline from baseline in FVC % pred greater than 5% at week 52 were those participants with a negative relative change from baseline in FVC % pred at week 52 the absolute value of which being greater than 5% and those participants with missing data (worst case analysis). (NCT02999178)
Timeframe: Baseline and up to 52 weeks after first drug intake

InterventionPercentage of participants (Number)
150 mg Nintedanib52.4
Placebo70.4

[back to top]

Overall Survival

Overall survival was reported. Overall survival was defined as the time from randomization to death due to any cause. (NCT03242759)
Timeframe: From baseline until end of follow-up, up to 899 days.

InterventionDays (Median)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug686.0
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug641.0

[back to top]

Time to First Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Time to first acute exacerbation of idiopathic pulmonary fibrosis was reported. (NCT03242759)
Timeframe: From baseline until end of follow-up, up to 899 days.

InterventionDays (Median)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug497.0
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug521.5

[back to top]

Number of Participants Per Death Reason Categories

Number of participants per death reason categories was reported. (NCT03242759)
Timeframe: From baseline until end of follow-up, up to 899 days.

,
InterventionParticipants (Count of Participants)
Related to idiopathic pulmonary fibrosisRelated to comorbidityOtherUnknown
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug11746
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug0100

[back to top]

Annual Change From Baseline in Percentage of Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLco) at Week 100

Annual Change from Baseline in percentage of predicted Diffusing capacity of the Lungs for Carbon monoxide (DLco) at Week 100 was reported. (NCT03242759)
Timeframe: At baseline and Week 100.

InterventionPercentage of predicted DLco (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug0.5
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug-2.6

[back to top]

Annual Change in Total Score of St. Georges Respiratory Questionnaire (SGRQ) at Week 52

The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in patients with diseases of airways obstruction. The questionnaire included 3 subscales measures: symptoms, activity limitation, and social, and emotional impact of disease (each subscale score ranges from 0 to 100 with higher score indicating poorer quality of life). The SGRQ total score was calculated by summing weights from all positive items, divided by sum of weights for all items in SGRQ questionnaire and multiplying by 100. The total score of SGRQ ranged from 0 (no effect on quality of life) to 100 (maximum perceived distress). Thus, a higher score indicated a poorer quality of life. Annual change in score of St. Georges Respiratory Questionnaire (SGRQ) at Week 52 was reported. (NCT03242759)
Timeframe: At baseline and Week 52.

InterventionScore on a scale (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug8.4
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug0.2

[back to top]

Annual Change From Baseline in Percentage of Predicted Diffusing Capacity of the Lungs for Carbon Monoxide (DLco) at Week 52

Annual Change from Baseline in percentage of predicted Diffusing capacity of the Lungs for Carbon monoxide (DLco) at Week 52 was reported (NCT03242759)
Timeframe: At baseline and Week 52.

InterventionPercentage of predicted DLco (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug-7.3
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug-2.8

[back to top]

Annual Change in Total Score of St. Georges Respiratory Questionnaire (SGRQ) at Week 100

The SGRQ is a 50-item questionnaire developed to measure health status (quality of life) in patients with diseases of airways obstruction. The questionnaire included 3 subscales measures: symptoms, activity limitation, and social, and emotional impact of disease (each subscale score ranges from 0 to 100 with higher score indicating poorer quality of life). The SGRQ total score was calculated by summing weights from all positive items, divided by sum of weights for all items in SGRQ questionnaire and multiplying by 100. The total score of SGRQ ranged from 0 (no effect on quality of life) to 100 (maximum perceived distress). Thus, a higher score indicated a poorer quality of life. Annual change in score of St. Georges Respiratory Questionnaire (SGRQ) at Week 100 was reported. (NCT03242759)
Timeframe: At baseline and Week 100.

InterventionScore on a scale (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug2.6
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug1.6

[back to top]

Annual Change in Six-Minute Walk Test (6MWT) at Week 52

Annual change in Six-Minute Walk Test (6MWT) at Week 52 was reported. The 6MWT measured the distance that a person can walk in 6 minutes, providing information regarding functional capacity, response to therapy and prognosis. (NCT03242759)
Timeframe: At baseline and Week 52.

InterventionMeter (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug-7.6
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug7.1

[back to top]

Annual Change in Six-Minute Walk Test (6MWT) at Week 100

Annual change in Six-Minute Walk Test (6MWT) at Week 100 was reported. The 6MWT measured the distance that a person can walk in 6 minutes, providing information regarding functional capacity, response to therapy and prognosis. (NCT03242759)
Timeframe: At baseline and Week 100.

InterventionMeter (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug-20.7
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug-2.3

[back to top]

Annual Change in Score of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) at Week 52

The Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) is an 8-item, health status instrument which provides a method for assessing the impact of COPD on the patient's health and quality of life. The CAT score (ranging from 0 to 40) was calculated for each individual by summing the points for each item. A decrease in CAT score represents an improvement in health status, whereas an increase in CAT score represents a worsening in health status. (NCT03242759)
Timeframe: At baseline and Week 52

InterventionScore on a scale (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug1.4
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug0.2

[back to top]

Annual Change in Score of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) at Week 100

The Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) is an 8-item, health status instrument which provides a method for assessing the impact of COPD on the patient's health and quality of life. The CAT score (ranging from 0 to 40) was calculated for each individual by summing the points for each item. A decrease in CAT score represents an improvement in health status, whereas an increase in CAT score represents a worsening in health status. (NCT03242759)
Timeframe: At baseline and Week 100

InterventionScore on a scale (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug0.7
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug0.7

[back to top]

Annual Change From Baseline in Percentage of Predicted Total Lung Capacity (TLC) at Week 52

Annual Change from Baseline in percentage of predicted Total Lung Capacity (TLC) at Week 52was reported. (NCT03242759)
Timeframe: At baseline and Week 52.

InterventionPercentage of predicted TLC (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug-0.4
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug-1.4

[back to top]

Annual Change From Baseline in Percentage of Predicted Total Lung Capacity (TLC) at Week 100

Annual Change from Baseline in percentage of predicted Total Lung Capacity (TLC) at Week 100 was reported. (NCT03242759)
Timeframe: At baseline and Week 100.

InterventionPercentage of predicted TLC (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug-2.3
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug-3.4

[back to top]

Annual Change From Baseline in Percentage of Predicted Oxygen Saturation (SpO2) at Week 52

Annual Change from Baseline in percentage of predicted oxygen saturation (SpO2) at Week 52 was reported. (NCT03242759)
Timeframe: At baseline and Week 52.

InterventionPercentage of predicted SpO2 (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug-0.8
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug-0.8

[back to top]

Annual Change From Baseline in Percentage of Predicted Oxygen Saturation (SpO2) at Week 100

Annual Change from Baseline in percentage of predicted oxygen saturation (SpO2) at Week 100 was reported. (NCT03242759)
Timeframe: At baseline and Week 100.

InterventionPercentage of predicted SpO2 (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug-0.2
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug-0.6

[back to top]

Annual Change From Baseline in Percentage of Predicted Inspiratory Capacity (IC) at Week 52

Annual Change from Baseline in percentage of predicted Inspiratory Capacity (IC) at Week 52 was reported. (NCT03242759)
Timeframe: At baseline and Week 52.

InterventionPercentage of predicted IC (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug-6.8
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug-6.1

[back to top]

Annual Change From Baseline in Percentage of Predicted Inspiratory Capacity (IC) at Week 100

Annual Change from Baseline in percentage of predicted Inspiratory Capacity (IC) at Week 100 was reported. (NCT03242759)
Timeframe: At baseline and Week 100.

InterventionPercentage of predicted IC (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug-4.5
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug-6.0

[back to top]

Annual Change From Baseline in Percentage of Predicted Forced Vital Capacity (FVC) at Week 52

Annual Change from Baseline in percentage of predicted Forced Vital Capacity (FVC) at Week 52 was reported. (NCT03242759)
Timeframe: At baseline and Week 52.

InterventionPercentage of predicted FVC (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug-0.5
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug4.1

[back to top]

Annual Change From Baseline in Percentage of Predicted Forced Vital Capacity (FVC) at Week 100

Annual Change from Baseline in percentage of predicted Forced Vital Capacity (FVC) at Week 100 was reported. (NCT03242759)
Timeframe: At baseline and Week 100.

InterventionPercentage of predicted FVC (Mean)
Idiopathic Pulmonary Fibrosis With Anti-fibrotic Drug-0.2
Idiopathic Pulmonary Fibrosis Without Anti-fibrotic Drug-2.5

[back to top]

The Demographic Baseline Characteristics - Height at the Start of Nintedanib Therapy

The height of IPF patients at the start of treatment with nintedanib (OFEV®) is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionCentimeters (cm) (Mean)
Total Patients With IPF164.5

[back to top]

The Demographic Baseline Characteristics - Age at the Time of Treatment Initiation

The age of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionYears (Mean)
Total Patients With IPF70.1

[back to top]

The Demographic Baseline Characteristics - 6-minute Walk Test

The 6-minute walk test of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionMeter (m) (Mean)
Total Patients With IPF421.7

[back to top]

The Clinical Baseline Characteristics - Duration of the Disease

Duration of the disease of IPF patients, calculated as the time elapsed from the date of diagnosis until the start date of treatment with OFEV® (years). (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionYears (Mean)
Total Patients With IPF1.5

[back to top]

Percentage of Patients With Other Concomitant Diseases at the Time of Treatment Initiation.

The percentage of patients with other concomitant diseases at the start of treatment with nintedanib (OFEV®) is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentages of Patients (Number)
Total Patients With IPF41.9

[back to top]

The Demographic Baseline Characteristics - Body Mass Index (BMI) at the Start of Nintedanib Therapy

The body mass index (BMI) of IPF patients at the start of treatment with nintedanib (OFEV®) is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionKilogram/ meter^2 (kg/m^2) (Mean)
Total Patients With IPF28.4

[back to top]

The Demographic Baseline Characteristics - Percentage of Patients With Smoking Habit

The percentage of patients with smoking habit at the start of treatment with nintedanib (OFEV®) is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentage of Participants (Number)
Never smokerFormer smokerActive smoker
Total Patients With IPF33.164.02.9

[back to top]

The Clinical Baseline Characteristics - Percentage of Patients With Usual Interstitial Pneumonia (UIP) Histopathological Pattern

The usual interstitial pneumonia (UIP) histopathological pattern of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentages of Patients (Number)
NoYesNo data
Total Patients With IPF13.430.855.8

[back to top]

The Clinical Baseline Characteristics - Percentage of Patients With UIP Radiological Pattern

The UIP radiological pattern of IPF patients at the time of treatment initiation with nintedanib (OFEV®) is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentages of Patients (Number)
NoYesNo data
Total Patients With IPF9.989.01.2

[back to top]

The Clinical Baseline Characteristics - Percentage of Patients With the Initial Dose of OFEV®

The percentage of patients initiated OFEV® dose of 150 milligram (mg)/ 12 hours (h) and 100 mg/12 h is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentages of Patients (Number)
150 mg/12 h100 mg/12 hNo data
Total Patients With IPF88.411.00.6

[back to top]

The Clinical Baseline Characteristics - Percentage of Patients With Exacerbations

The percentage of patients with exacerbations of IPF in the year prior to initiating treatment is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentages of patients (Number)
NoYesNo data
Total Patients With IPF84.911.63.5

[back to top]

The Clinical Baseline Characteristics - Percentage of Patients With Emphysema

The percentage of patients with emphysema at the start of treatment with nintedanib (OFEV®) is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentages of Patients (Number)
NoYes
Total Patients With IPF84.315.7

[back to top]

The Clinical Baseline Characteristics - Percentage of Patients With Dyspnoea

The percentage of patients with dyspnoea at the start of treatment with nintedanib (OFEV®) is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentages of Partients (Number)
NoYesNo data
Total Patients With IPF5.293.01.7

[back to top]

The Clinical Baseline Characteristics - Percentage of Patients With Concomitant Treatments

The percentage of patients taking any concomitant medication at the start of nintedanib therapy is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentages of Patients (Number)
NoYes
Total Patients With IPF20.379.7

[back to top]

Percentage of Patients With Prevalence of Comorbidity (Concomitant Diseases) at the Time of Treatment Initiation.

The percentage of patients with comorbidity (concomitant diseases) at the start of treatment with nintedanib (OFEV®) is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentages of Patients (Number)
HypertensionDyslipidaemiaGastroesophageal refluxDiabetes mellitusEmphysemaCardiovascular diseaseObstructive sleep apnoeaPulmonary hypertensionLung cancerPulmonary infection
Total Patients With IPF45.942.425.619.815.715.711.65.81.71.2

[back to top]

Percentage of Patients Distributed Across Different Lung Function Categories Based on the Reimbursement Threshold (%FVC)

The distribution of patients across different lung function categories based on the reimbursement threshold (FVC >80%, 50-80%, and <50%). (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentages of Patients (Number)
Mild IPF: FVC > 80%Moderate IPF: FVC between 50% and 80%Severe IPF: FVC < 50%
Total Patients With IPF33.162.24.7

[back to top]

Percentage of Patients Across Different Lung Function Categories (% FVC (Forced Vital Capacity))

The distribution of patients across different lung function categories (% FVC serving as surrogate markers for IPF severity) of IPF patients treated with nintedanib (OFEV®) in routine clinical practice, at the time of treatment initiation. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentage of Patients (%) (Number)
Mild IPF: FVC ≥ 70%Moderate IPF: FVC between 50% and 69%Severe IPF: FVC < 50%
Total Patients With IPF57.038.44.7

[back to top]

Percentage of Patients Across Different Lung Function Categories (% DLCO (Diffusing Capacity of the Lungs for Carbon Monoxide))

The distribution of patients across different lung function categories (% DLCO serving as surrogate markers for IPF severity) of IPF patients treated with nintedanib (OFEV®) in routine clinical practice, at the time of treatment initiation. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionPercentage of Patients (%) (Number)
Mild IPF: DLCO ≥ 50%Moderate IPF: DLCO between 35% and 49%Severe IPF: DLCO < 35%
Total Patients With IPF42.535.322.2

[back to top]

The Demographic Baseline Characteristics - Weight at the Start of Nintedanib Therapy

The weight of IPF patients at the start of treatment with nintedanib (OFEV®) is presented. (NCT03281200)
Timeframe: From start of drug administration (01Jan16) until data collected in the database cut off date (31Jan18), i.e. Up to 765 days.

InterventionKilogram (Kg) (Mean)
Total Patients With IPF77.1

[back to top]

Disease Control Rate

The disease control rate is the proportion of those subjects with complete response, partial response, or stable disease, as defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1). Per RECIST 1.1 criteria for target lesions assessed by radiologic evaluation of CT and tumor measurements: Complete Response (CR), Disappearance of all target and non-target lesions, any pathological lymph nodes reduced in short axis to <10 mm; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor PD; Disease Control Rate (DCR) = CR + PR + SD. (NCT03287947)
Timeframe: From first dose of study drug to date of progression as determined by RECIST 1.1, assessed up to 7.5 months.

InterventionProportion of participants (Number)
Nintedanib.25

[back to top]

Overall Survival

Overall survival was defined as the duration from the start of nintedanib treatment to the date of death from any cause; subjects who are alive or lost to follow-up at the time of the analysis were censored at the last known date they were alive. Median overall survival was estimated using Kaplan-Meier methods. No formal comparative statistical analysis of overall survival was performed due to low accrual. (NCT03287947)
Timeframe: From date of first dose of study treatment to the date of death from any cause, assessed up to 14.5 months.

Interventionmonths (Median)
Nintedanib2.62

[back to top]

Progression-free Survival

Progression-free survival was defined as the duration from the start of nintedanib treatment to the first occurrence of either progressive disease or death; disease progression was objectively determined per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1) or subjectively determined by the investigator. Per RECIST 1.1 criteria for target lesions assessed by radiologic evaluation of CT and tumor measurements: Progressive Disease (PD), >= 20% increase in the sum of the longest diameter of target lesions (at least 5 mm), or a measurable increase or progression in a non-target lesion, or the appearance of new lesions. Median progression-free survival was estimated using Kaplan-Meier methods. No formal comparative statistical analysis of progression-free survival was performed due to low accrual. (NCT03287947)
Timeframe: From date of first dose of study treatment to the date of progressive disease or death from any cause, whichever occurred first, assessed up to 7.5 months.

Interventionmonths (Median)
Nintedanib1.34

[back to top]

Treatment Administration of Nintedanib, as Measured by Average Daily Dose of Nintedanib.

The average daily dose of nintedanib is calculated as the total cumulative dose (in mg) of nintedanib administered divided by the number of 28-day cycles on nintedanib treatment. Prescribed daily dose of nintedanib is 400 mg. (NCT03287947)
Timeframe: From the first dose of study drug to the last dose, assessed up to 7.5 months.

Interventionmg per cycle day (Mean)
Nintedanib350.4

[back to top]

Area Under the Concentration-time Curve of Ethinylestradiol in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

"Area under the concentration-time curve of ethinylestradiol in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).~For Microgynon (ethinylestradiol + levonorgestrel) alone (Reference treatment, R) and Microgynon (ethinylestradiol + levonorgestrel) + nintedanib (Test treatment, T) plasma concentrations of ethinylestradiol were measured 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after Microgynon administration alone or in combination with nintedanib." (NCT03675581)
Timeframe: 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after microgynon administration alone or in combination with nintedanib.

Interventionpicograms * hours per milliliters (Geometric Mean)
Microgynon Alone (Reference Treatment, R)749.65
Microgynon + Nintedanib (Test Treatment, T)758.95

[back to top]

Area Under the Concentration-time Curve of Ethinylestradiol in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

"Area under the concentration-time curve of ethinylestradiol in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).~For Microgynon (ethinylestradiol + levonorgestrel) alone (Reference treatment, R) and Microgynon (ethinylestradiol + levonorgestrel) + nintedanib (Test treatment, T) plasma concentrations of ethinylestradiol were measured 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after Microgynon administration alone or in combination with nintedanib." (NCT03675581)
Timeframe: 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after microgynon administration alone or in combination with nintedanib.

Interventionpicograms * hours per milliliters (Geometric Mean)
Microgynon Alone (Reference Treatment, R)610.00
Microgynon + Nintedanib (Test Treatment, T)618.28

[back to top]

Area Under the Concentration-time Curve of Levonorgestrel in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

"Area under the concentration-time curve of levonorgestrel in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞).~For Microgynon (ethinylestradiol + levonorgestrel) alone (Reference treatment, R) and Microgynon (ethinylestradiol + levonorgestrel) + nintedanib (Test treatment, T) plasma concentrations of levonorgestrel were measured 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after Microgynon administration alone or in combination with nintedanib." (NCT03675581)
Timeframe: 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after microgynon administration alone or in combination with nintedanib.

Interventionpicograms * hours per milliliters (Geometric Mean)
Microgynon Alone (Reference Treatment, R)56311.68
Microgynon + Nintedanib (Test Treatment, T)49605.41

[back to top]

Area Under the Concentration-time Curve of Levonorgestrel in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

"Area under the concentration-time curve of levonorgestrel in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz).~For Microgynon (ethinylestradiol + levonorgestrel) alone (Reference treatment, R) and Microgynon (ethinylestradiol + levonorgestrel) + nintedanib (Test treatment, T) plasma concentrations of levonorgestrel were measured 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after Microgynon administration alone or in combination with nintedanib." (NCT03675581)
Timeframe: 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after microgynon administration alone or in combination with nintedanib.

Interventionpicograms * hours per milliliters (Geometric Mean)
Microgynon Alone (Reference Treatment, R)33062.73
Microgynon + Nintedanib (Test Treatment, T)31872.47

[back to top]

Maximum Measured Concentration of Ethinylestradiol in Plasma (Cmax)

Maximum measured concentration of ethinylestradiol in plasma (Cmax). For Microgynon (ethinylestradiol + levonorgestrel) alone (Reference treatment, R) and Microgynon (ethinylestradiol + levonorgestrel) + nintedanib (Test treatment, T) plasma concentrations of ethinylestradiol were measured 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after Microgynon administration alone or in combination with nintedanib. (NCT03675581)
Timeframe: 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after microgynon administration alone or in combination with nintedanib.

Interventionpicograms per milliliters (Geometric Mean)
Microgynon Alone (Reference Treatment, R)54.75
Microgynon + Nintedanib (Test Treatment, T)63.89

[back to top]

Maximum Measured Concentration of Levonorgestrel in Plasma (Cmax)

Maximum measured concentration of levonorgestrel in plasma (Cmax). For Microgynon (ethinylestradiol + levonorgestrel) alone (Reference treatment, R) and Microgynon (ethinylestradiol + levonorgestrel) + nintedanib (Test treatment, T) plasma concentrations of levonorgestrel were measured 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after Microgynon administration alone or in combination with nintedanib. (NCT03675581)
Timeframe: 35 minutes (min) before and at 30 min, 1 hour (h), 1h 30 min, 2h, 3h, 4h, 6h, 8h, 11h 55 min, 23h 55 min, 47h 55 min after microgynon administration alone or in combination with nintedanib.

Interventionpicograms per milliliters (Geometric Mean)
Microgynon Alone (Reference Treatment, R)3124.48
Microgynon + Nintedanib (Test Treatment, T)3152.35

[back to top]

Change From Baseline in the 6 Minute Walk Test (6MWD) at 24 Weeks

Absolute change from baseline in the 6 minute walk distance (6MWD) test at 24 weeks. The last assessment before treatment period start (included) will be used as baseline. If the baseline value is missing and the screening value is available, then the baseline value will be defined as the screening value taken closest to baseline date. (NCT03717012)
Timeframe: Baseline (day 1) and week 24 (day 169).

Interventionmeter (Mean)
Nintedanib 150 mg-38.34
Nintedanib 150 mg + Pulmonary Rehabilitation9.04

[back to top]

Absolute Categorical Change of Forced Vital Capacity (FVC)% Predicted up to 12 and 24 Weeks (Decrease by >5%, Increase by >5%, and Change Within ≤5%)

Absolute categorical change of forced vital capacity (FVC)% predicted up to 12 and 24 weeks, the following three categories were defined: decrease by >5%, increase by >5%, and change within ≤5%. Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. For predicted normal values, different sites may use different prediction formulas, based on the method used to measure diffusing capacity of the lung for carbon monoxide (DLco). In any case, the method used must be in compliance with the European Respiratory Society (ERS)/American Thoracic Society(ATS) guideline on DLco measurements, and the prediction formula appropriate for that method. (NCT03717012)
Timeframe: Baseline (day 1), week 12 (day 85) and week 24 (day 169).

InterventionParticipants (Count of Participants)
Change from baseline at week 1272488811Change from baseline at week 1272488810Change from baseline at week 2472488810Change from baseline at week 2472488811
Within 5% changeDecrease by >5%Increase by >5%
Nintedanib 150 mg4
Nintedanib 150 mg2
Nintedanib 150 mg + Pulmonary Rehabilitation5
Nintedanib 150 mg + Pulmonary Rehabilitation1
Nintedanib 150 mg1
Nintedanib 150 mg + Pulmonary Rehabilitation2
Nintedanib 150 mg + Pulmonary Rehabilitation0

[back to top]

Absolute Change From Baseline of Forced Vital Capacity (FVC) % Predicted at 12 and 24 Weeks

Absolute change from baseline of forced vital capacity (FVC) % predicted at 12 and 24 weeks. Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. For predicted normal values, different sites may use different prediction formulas, based on the method used to measure diffusing capacity of the lung for carbon monoxide (DLco). In any case, the method used must be in compliance with the European Respiratory Society (ERS)/American Thoracic Society (ATS) guideline on DLco measurements, and the prediction formula appropriate for that method. (NCT03717012)
Timeframe: Baseline (day 1), week 12 (day 85) and week 24 (day 169).

,
InterventionPercent predicted (Mean)
Change from baseline at week 12Change from baseline at week 24
Nintedanib 150 mg-3.843.63
Nintedanib 150 mg + Pulmonary Rehabilitation-1.50-1.93

[back to top]

Change From Baseline in the 6 Minute Walk Test (6MWD) at 12 Weeks

Absolute change from baseline in the 6 minute walk distance (6MWD) test at 12 weeks. The last assessment before treatment period start (included) will be used as baseline. If the baseline value is missing and the screening value is available, then the baseline value will be defined as the screening value taken closest to baseline date. (NCT03717012)
Timeframe: Baseline (day 1) and week 12 (day 85).

Interventionmeter (Mean)
Nintedanib 150 mg-20.60
Nintedanib 150 mg + Pulmonary Rehabilitation-14.10

[back to top]

Absolute Change From Baseline in The King's Brief Interstitial Lung Disease (KBILD) Questionnaire Total Score at 12 and 24 Weeks

Absolute change from baseline in The King's Brief Interstitial Lung Disease (KBILD) questionnaire total score at 12 and 24 weeks. The KBILD questionnaire is a disease specific questionnaire evaluating health related quality of life. The questionnaire consists of 15 items. Raw total scores were weighted with a Likert response scale to create the total score, total scores were transformed to a range of 0-100 ((actual score-lowest possible score/range)*100), with a score of 100 representing the best health status. (NCT03717012)
Timeframe: Baseline (day 1), week 12 (day 85) and week 24 (day 169).

,
InterventionScore on a scale. (Mean)
Change from baseline at week 12Change from baseline at week 24
Nintedanib 150 mg-3.20-4.42
Nintedanib 150 mg + Pulmonary Rehabilitation1.28-0.63

[back to top]

Absolute Categorical Change of Forced Vital Capacity (FVC)% Predicted up to 12 and 24 Weeks (Decrease by >10%, Increase by >10%, and Change Within ≤10%)

Absolute categorical change of forced vital capacity (FVC)% predicted up to 12 and 24 weeks, the following three categories were defined: decrease by >10%, increase by >10%, and change within ≤10%. Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. For predicted normal values, different sites may use different prediction formulas, based on the method used to measure diffusing capacity of the lung for carbon monoxide (DLco). In any case, the method used must be in compliance with the European Respiratory Society (ERS)/American Thoracic Society(ATS) guideline on DLco measurements, and the prediction formula appropriate for that method. (NCT03717012)
Timeframe: Baseline (day 1), week 12 (day 85) and week 24 (day 169).

InterventionParticipants (Count of Participants)
Change from baseline at week 1272488810Change from baseline at week 1272488811Change from baseline at week 2472488811Change from baseline at week 2472488810
Decrease by >10%Within 10% changeIncrease by >10%
Nintedanib 150 mg2
Nintedanib 150 mg + Pulmonary Rehabilitation1
Nintedanib 150 mg5
Nintedanib 150 mg + Pulmonary Rehabilitation7
Nintedanib 150 mg0
Nintedanib 150 mg + Pulmonary Rehabilitation0
Nintedanib 150 mg4
Nintedanib 150 mg + Pulmonary Rehabilitation3
Nintedanib 150 mg1

[back to top]

Relative Change From Baseline of Forced Vital Capacity (FVC) at 12 and 24 Weeks

Relative change (unitless) from baseline of forced vital capacity (FVC) at 12 and 24 weeks. Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC is measured in milliliter (mL). Its relative change from baseline at 12 (24) weeks is calculated as: (FVC measured at 12 (24) weeks - FVC measured at baseline)/ FVC measured at baseline *100%. (NCT03717012)
Timeframe: Baseline (day 1), week 12 (day 85) and week 24 (day 169).

,
InterventionPercent change (Mean)
Change from baseline at week 12Change from baseline at week 24
Nintedanib 150 mg-3.682.80
Nintedanib 150 mg + Pulmonary Rehabilitation-2.60-2.16

[back to top]

Relative Change From Baseline of Forced Vital Capacity (FVC) % Predicted at 12 and 24 Weeks

Relative change (unitless) from baseline of forced vital capacity (FVC) % predicted at 12 and 24 weeks. Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. For predicted normal values, different sites may use different prediction formulas, based on the method used to measure diffusing capacity of the lung for carbon monoxide (DLco). In any case, the method used must be in compliance with the European Respiratory Society (ERS)/American Thoracic Society (ATS) guideline on DLco measurements, and the prediction formula appropriate for that method. The relative change from baseline of FVC % predicted at 12 (24) weeks is calculated as: (FVC % Predicted measured at 12 (24) weeks - FVC % Predicted measured at baseline)/ FVC % Predicted measured at baseline *100%. (NCT03717012)
Timeframe: Baseline (day 1), week 12 (day 85) and week 24 (day 169).

,
InterventionPercent change (Mean)
Change from baseline at week 12Change from baseline at week 24
Nintedanib 150 mg-3.682.80
Nintedanib 150 mg + Pulmonary Rehabilitation-2.60-2.16

[back to top]

Change From Baseline in the University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) Total Score at 12 and 24 Weeks

Change from baseline in the University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) total score at 12 and 24 weeks. The UCSD-SOBQ is a 24-item questionnaire that assesses self-reported shortness of breath while performing a variety of activities of daily living, scores for each item range from 0 to 5, with higher scores indicating more limitations. Total score is calculated as the sum of all individual scores. Scores range from 0 to 120, with higher scores indicating more limitations. (NCT03717012)
Timeframe: Baseline (day 1), week 12 (day 85) and week 24 (day 169).

,
InterventionScore on a scale. (Mean)
Change from baseline at week 12Change from baseline at week 24
Nintedanib 150 mg13.2917.50
Nintedanib 150 mg + Pulmonary Rehabilitation6.130.00

[back to top]

Change From Baseline in the St George's Respiratory Questionnaire (SGRQ) Total Score at 12 and 24 Weeks

Absolute change from baseline in the St George's Respiratory Questionnaire (SGRQ) total score at 12 and 24 weeks. The SGRQ is a widely used disease specific questionnaire evaluating health related quality of life. The SGRQ Total Score is measured using patient self-reported question on disease impact on symptoms, patient activity, and daily life. SGRQ scores are calculated using weights attached to each item of the questionnaire which provides an estimate of the distress associated with the symptoms or state described in each item. The total score for SGRQ ranges from 0 to 100, with higher scores indicating more limitations. (NCT03717012)
Timeframe: Baseline (day 1), week 12 (day 85) and week 24 (day 169).

,
InterventionScore on a scale. (Mean)
Change from baseline at week 12Change from baseline at week 24
Nintedanib 150 mg5.606.06
Nintedanib 150 mg + Pulmonary Rehabilitation-1.48-6.54

[back to top]

Change From Baseline in Daily Accelerometer Activity From Baseline at 12 and 24 Weeks: Score of Average Vector Magnitude Units (VMU)/Day

"Change from baseline in daily accelerometer activity from baseline at 12 and 24 weeks: Score of average vector magnitude units (VMU)/day. Categories were defined as follows:~VMU (daily VMU/min) 0 = 0 to 50 VMU/min~= 51 to 110 VMU/min~= 111 to 190 VMU/min~= 191 to 270 VMU/min~= 271 to 440 VMU/min~= >441 VMU/min" (NCT03717012)
Timeframe: Baseline (day 1), week 12 (day 85) and week 24 (day 169).

,
InterventionScore on a scale (Mean)
Change from baseline at week 12Change from baseline at week 24
Nintedanib 150 mg0.4-0.5
Nintedanib 150 mg + Pulmonary Rehabilitation0.3-0.5

[back to top]

Change From Baseline in Daily Accelerometer Activity From Baseline at 12 and 24 Weeks: Score of Average Steps/Day

"Change from baseline in daily accelerometer activity from baseline at 12 and 24 weeks: Score of average Steps/day. Categories were defined as follows:~Steps (total daily value) 0 = 0 to 1900 steps/day~= 1901 to 3700 steps/day~= 3701 to 5500 steps/day~= 5501 to 7300 steps/day~= >7301 steps/day" (NCT03717012)
Timeframe: Baseline (day 1), week 12 (day 85) and week 24 (day 169).

,
InterventionScore on a scale (Mean)
Change from baseline at week 12Change from baseline at week 24
Nintedanib 150 mg0.4-0.8
Nintedanib 150 mg + Pulmonary Rehabilitation0.50.0

[back to top]

Absolute Change From Baseline of Forced Vital Capacity (FVC) at 12 and 24 Weeks

Absolute change from baseline of forced vital capacity (FVC) at 12 and 24 weeks. Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. (NCT03717012)
Timeframe: Baseline (day 1), week 12 (day 85) and week 24 (day 169).

,
InterventionMilliliter (mL) (Mean)
Change from baseline at week 12Change from baseline at week 24
Nintedanib 150 mg-152.8676.00
Nintedanib 150 mg + Pulmonary Rehabilitation-87.50-86.67

[back to top]

Number of Participants With Any Adverse Events

Number of participants with adverse events over the course of the extension trial, AEs defined as any untoward medical occurrence in a patient administered with the investigational product and which does not necessarily have to have a causal relationship with this treatment. (NCT03820726)
Timeframe: From first nintedanib intake until last nintedanib intake + 28 days of Residual effect period (REP), up to 1195 days.

InterventionParticipants (Count of Participants)
Nintedanib417

[back to top]

Odds Ratio of Receiving Treatment (Nintedanib or Pirfenidone) vs no Treatment

"Odds ratio of receiving nintedanib or pirfenidone vs. no antifibrotic treatment, adjusting for patient characteristics; to identify baseline characteristics that drive initiation of a treatment while minimizing prescription bias.~Logistic regression models were developed to assess the odds. Baseline patient characteristics that were sufficiently populated, had ASD >10% or p-value <0.05, and were agreed upon as important variables to include, were included as covariates for a full model. Linearity of age was confirmed before including it as a continuous variable in one version of the model. Backward selection was applied to develop a reduced model, only retaining covariates with p<0.1 after forcing age at index, gender, geographic region, BMI, CCI, and Chronic obstructive pulmonary disease (COPD) into the model.~Odds presented for key patient characteristics. Odd ratio of >1 indicates increased odds of receiving treatment." (NCT03958071)
Timeframe: Baseline characteristics were recorded 12 months pre-index event (pre-treatment).

InterventionOdds ratio (Number)
AgeGenderBMI category: OverweightBMI category: ObeseBMI category: Very obeseComorbidities: COPDComorbidities: Heart failureComorbidities: StrokeComorbidities: HypertensionComorbidities: Peripheral arterial diseasesComorbidities: Severe diseasesGastroesophageal reflux disease
Overall Population1.0220.4901.3591.8331.6380.5810.4490.4490.6630.3830.4631.621

[back to top]

Baseline Patient Characteristics: Number of Participants Using Proton Pump Inhibitors at Baseline

"IQVIA's GE Centricity Electronic medical records database was used for this study. This is an anonymized Health Insurance Portability and Accountability Act of 1996 (HIPPA) compliant database populated with patient data from ambulatory care records.~Treatment with Proton pump inhibitors for Idiopathic Pulmonary Fibrosis (IPF) patients at 12-month pre-treatment (baseline) was compared between each of the cohorts (nintedanib vs. pirfenidone, nintedanib vs. untreated, pirfenidone vs. untreated), differences are presented in absolute standardized differences (ASD), differences were tested using t-test for means of continuous variables, Wilcoxon signed tank test for medians of continuous variables, and Chi-square test for categorical variables." (NCT03958071)
Timeframe: Baseline characteristics were recorded 12 months pre-index event (pre-treatment).

InterventionParticipants (Count of Participants)
Nintedanib113
Pirfenidone133
Untreated3141

[back to top]

Baseline Patient Characteristics: Number of Participants Using Inhaled Corticosteroids at Baseline

"IQVIA's GE Centricity Electronic medical records database was used for this study. This is an anonymized Health Insurance Portability and Accountability Act of 1996 (HIPPA) compliant database populated with patient data from ambulatory care records.~Treatment with inhaled corticosteroids for Idiopathic Pulmonary Fibrosis (IPF) patients at 12-month pre-treatment (baseline) was compared between each of the cohorts (nintedanib vs. pirfenidone, nintedanib vs. untreated, pirfenidone vs. untreated), differences are presented in absolute standardized differences (ASD), differences were tested using t-test for means of continuous variables, Wilcoxon signed tank test for medians of continuous variables, and Chi-square test for categorical variables." (NCT03958071)
Timeframe: Baseline characteristics were recorded 12 months pre-index event (pre-treatment).

InterventionParticipants (Count of Participants)
Nintedanib125
Pirfenidone134
Untreated3311

[back to top]

Baseline Patient Characteristics: Charlson Comorbidity Index (CCI)

"IQVIA's GE Centricity Electronic medical records database was used for this study. This is an anonymized HIPPA compliant database populated with patient data from ambulatory care records. Charlson Comorbidity Index (CCI) for Idiopathic Pulmonary Fibrosis (IPF) patients at 12-month pre-treatment (baseline) was compared between each of the cohorts.~The Charlson Comorbidity Index is a method of categorizing comorbidities of patients based on the International Classification of Diseases (ICD) diagnosis. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a patient. A score of zero indicates that no comorbidities were found. The higher the score, the more likely the predicted outcome will result in mortality or higher resource use. Up to 12 comorbidities with various weightings can result in a maximum score of 24. The minimum score is zero." (NCT03958071)
Timeframe: Baseline characteristics were recorded 12 months pre-index event (pre-treatment).

InterventionScore on a scale (Mean)
Nintedanib0.71
Pirfenidone0.79
Untreated1.09

[back to top]

Baseline Patient Characteristics: BMI

The patient characteristic Body mass index (BMI) for Idiopathic Pulmonary Fibrosis (IPF) patients at 12-month pre-treatment (baseline) was compared between each of the cohorts (nintedanib vs. pirfenidone, nintedanib vs. untreated, pirfenidone vs. untreated), differences are presented in absolute standardized differences (ASD), differences were tested using t-test for means of continuous variables, Wilcoxon signed tank test for medians of continuous variables, and Chi-square test for categorical variables. (NCT03958071)
Timeframe: Baseline characteristics were recorded 12 months pre-index event (pre-treatment).

Interventionkilogram/height in meters squared(kg/m²) (Mean)
Nintedanib29.5
Pirfenidone30.1
Untreated28.6

[back to top]

Baseline Patient Characteristics: Age

"IQVIA's GE Centricity Electronic medical records database was used for this study. This is an anonymized Health Insurance Portability and Accountability Act of 1996 (HIPPA) compliant database populated with patient data from ambulatory care records.~The patient characteristic age for Idiopathic Pulmonary Fibrosis (IPF) patients at 12-month pre-treatment (baseline) was compared between each of the cohorts (nintedanib vs. pirfenidone, nintedanib vs. untreated, pirfenidone vs. untreated), differences are presented in absolute standardized differences (ASD), differences were tested using t-test for means of continuous variables, Wilcoxon signed tank test for medians of continuous variables, and Chi-square test for categorical variables." (NCT03958071)
Timeframe: Baseline characteristics were recorded 12 months pre-index event (pre-treatment).

Interventionyears (Mean)
Nintedanib71.6
Pirfenidone72.1
Untreated70.9

[back to top]

Absolute Change From Baseline in 6 Minutes (Min) Walk Distance at Week 52

Absolute change from baseline in 6 minutes (min) walk distance at Week 52 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements. (NCT04093024)
Timeframe: MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

InterventionMeter (m) (Least Squares Mean)
DBP+OLNP: Randomised to Placebo28.1
DBP+OLNP: Randomised Nintedanib-4.9

[back to top]

Absolute Change From Baseline in 6 Minutes (Min) Walk Distance at Week 24

Absolute change from baseline in 6 minutes (min) walk distance at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements. (NCT04093024)
Timeframe: MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

InterventionMeter (Least Squares Mean)
DBP: Randomised to Placebo10.5
DBP: Randomised to Nintedanib17.6

[back to top]

Absolute Change From Baseline in Leg Length at Week 52 - Left

"Absolute change from baseline in left leg length at Week 52 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point.~Absolute change from baseline in left leg length at Week 52 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

InterventionCentimeter (Least Squares Mean)
DBP+OLNP: Randomised to Placebo2.8
DBP+OLNP: Randomised to Nintedanib2.9

[back to top]

Number of Participants With at Least One Treatment-emergent Pathological Findings on Dental Examination or Imaging up to Week 52

Number of participants with treatment-emergent pathological findings on dental examination (clinical examination) based on dentist assessment or imaging (panoramic x-ray) based on central review were analyzed. Number of participants with treatment-emergent pathological findings on dental imaging were analyzed cumulatively. (NCT04093024)
Timeframe: Dental examination: at Week 12, 24, 34, and Week 52; Dental imaging: at Week 24 and at Week 52.

,
InterventionParticipants (Count of Participants)
Dental examination: Pathological findings up to week 52Dental imaging: Stunted growth of dental rootDental imaging: Accelerated growth of dental rootDental imaging: extra / supernumerary teethDental imaging: Impacted permanent teethDental imaging: Additional findingsDental imaging: Other findings
DBP+OLNP: Randomised to Nintedanib7600562
DBP+OLNP: Randomised to Placebo3000213

[back to top]

Number of Participants With Treatment-emergent Pathological Findings on Dental Examination or Imaging up to Week 24

Number of participants with treatment-emergent pathological findings on dental examination (clinical examination) based on dentist assessment or imaging (panoramic x-ray) based on central review were analyzed. Number of participants with treatment-emergent pathological findings on dental imaging were analyzed cumulatively. (NCT04093024)
Timeframe: Dental examination: at Week 12 and Week 24; Dental imaging: at Week 24

,
InterventionParticipants (Count of Participants)
Dental examination: Pathological findings up to week 24Dental imaging: Stunted growth of dental rootDental imaging: Accelerated growth of dental rootDental imaging: extra / supernumerary teethDental imaging: Impacted permanent teethDental imaging: Additional findingsDental imaging: Other findings
DBP: Randomised to Nintedanib5600451
DBP: Randomised to Placebo1000212

[back to top]

Absolute Change From Baseline in Oxygen Saturation (SpO₂) on Room Air at Rest at Week 52

"Oxygen saturation (SpO₂) was measured after minimum 5 minutes on room air by standard pulse oximetry at rest.~Absolute change from baseline in SpO₂ at Week 52 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements pre-administration at -4 weeks and at 0, 2, 6, 12, 24, 26, 36, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

InterventionPercentage of SpO₂ (Least Squares Mean)
DBP+OLNP: Randomised to Placebo-2.60
DBP+OLNP: Randomised to Nintedanib-0.32

[back to top]

Absolute Change From Baseline in Oxygen Saturation (SpO₂) on Room Air at Rest at Week 24

"Oxygen saturation (SpO₂) was measured after minimum 5 minutes on room air by standard pulse oximetry at rest.~Absolute change from baseline in SpO₂ at Week 24 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements pre-administration at -4 weeks and at 0, 2, 6, 12, 24, 26, 36, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

InterventionPercentage of SpO₂ (Least Squares Mean)
DBP: Randomised to Placebo-2.25
DBP: Randomised to Nintedanib0.07

[back to top]

Absolute Change From Baseline in Forced Vital Capacity (FVC) % Predicted at Week 52

"Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. The predicted values were calculated according to the Global Lungs Initiative (GLI) 2012 equations.~Absolute change from baseline in Forced Vital Capacity (FVC) % predicted at Week 52 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements pre-administration at -4 weeks and at 0, 2, 6, 12, 24, 26, 36, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

InterventionPercentage of predicted FVC (Least Squares Mean)
DBP+OLNP: Randomised to Placebo-0.9827
DBP + OLNP: Randomised to Nintedanib0.7906

[back to top]

Absolute Change From Baseline in Leg Length at Week 76 - Right

"Absolute change from baseline in right leg length at Week 76 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point.~Absolute change from baseline in right leg length at Week 76 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 76 are reported in the table below

InterventionCentimeter (Least Squares Mean)
DBP+OLNP: Randomised to Placebo3.9
DBP+OLNP: Randomised to Nintedanib4.3

[back to top]

Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 24 - Participant Report

"The PedsQL™ questionnaires consists of 23 items (i) and 4 dimensions: physical (8i), emotional (5i), social (5i) and school (5i) functioning. A 5-point Likert response scale (0 = never (worst outcome) to 4=almost always (best outcome)) was used except for the Young Child Report, where a 3-point scale (0=not at all (worst outcome) to 4=a lot (best outcome)) was used. Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100 to 4 = 0). Higher scores indicated better health-related quality of life. To create total scores, the mean was computed.~Absolute change from baseline in PedsQL™ was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

InterventionUnit on scale (Least Squares Mean)
DBP: Randomised to Placebo5.484
DBP: Randomised to Nintedanib6.514

[back to top]

Absolute Change From Baseline in Leg Length at Week 76 - Left

"Absolute change from baseline in left leg length at Week 76 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point.~Absolute change from baseline in left leg length at Week 76 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 76 are reported in the table below

InterventionCentimeter (Least Squares Mean)
DBP+OLNP: Randomised to Placebo5.2
DBP+OLNP: Randomised to Nintedanib2.6

[back to top]

Absolute Change From Baseline in Leg Length at Week 52 - Right

"Absolute change from baseline in right leg length at Week 52 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point.~Absolute change from baseline in right leg length at Week 52 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

InterventionCentimeter (Least Squares Mean)
DBP+OLNP: Randomised to Placebo2.8
DBP+OLNP: Randomised to Nintedanib3.4

[back to top]

Absolute Change From Baseline in Leg Length at Week 24 - Right

"Absolute change from baseline in right leg length at Week 24 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point.~Absolute change from baseline in right leg length at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

InterventionCentimeters (Least Squares Mean)
DBP: Randomised to Placebo1.6
DBP: Randomised to Nintedanib1.6

[back to top]

Absolute Change From Baseline in Leg Length at Week 24 - Left

"Absolute change from baseline in left leg length at Week 24 was assessed by measuring the distance between the anterior iliac spine and the medial malleolus 3 times at each leg and each time point. The average of these 3 measurements was taken per time point.~Absolute change from baseline in left leg length at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements at 0, 12, 24, 36, 52, 64, and 76 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

InterventionCentimeters (Least Squares Mean)
DBP: Randomised to Placebo1.6
DBP: Randomised to Nintedanib1.7

[back to top]

Absolute Change From Baseline in Height at Week 52

"Absolute change from baseline in height at Week 52 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point.~Absolute change from baseline in height at Week 52 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements pre-administration at -4 weeks and at 0, 12, 24, 36, 52, 64, 76, and 88 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

InterventionCentimeter (Least Squares Mean)
DBP+OLNP: Randomised to Placebo2.8
DBP+OLNP: Randomised to Nintedanib2.8

[back to top]

Absolute Change From Baseline in Height at Week 24

"Absolute change from baseline in height at Week 24 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point.~Absolute change from baseline in height at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements pre-administration at -4 weeks and at 0, 12, 24, 36, 52, 64, 76, and 88 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

InterventionCentimeter (Least Squares Mean)
DBP: Randomised to Placebo1.3
DBP: Randomised to Nintedanib1.3

[back to top]

Absolute Change From Baseline in Forced Vital Capacity (FVC) % Predicted at Week 24

"Forced Vital Capacity (FVC) is the volume of air (measured in milliliter) which can be forcibly exhaled from the lungs after taking the deepest breath possible. The predicted values were calculated according to the Global Lungs Initiative (GLI) 2012 equations.~Absolute change from baseline in Forced Vital Capacity (FVC) % predicted at Week 24 in the treated set(TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements pre-administration at -4 weeks and at 0, 2, 6, 12, 24, 26, 36, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

InterventionPercentage of predicted FVC (Least Squares Mean)
DBP: Randomised to Placebo-0.8939
DBP: Randomised to Nintedanib0.3112

[back to top]

Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 52 - Parent Report

"The PedsQL™ questionnaires consists of 23 items (i) and 4 dimensions: physical (8i), emotional (5i), social (5i) and school (5i) functioning. A 5-point Likert response scale (0 = never (worst outcome) to 4=almost always (best outcome)) was used except for the Young Child Report, where a 3-point scale (0=not at all (worst outcome) to 4=a lot (best outcome)) was used. Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100 to 4 = 0). Higher scores indicated better health-related quality of life. To create total scores, the mean was computed.~Absolute change from baseline in PedsQL™ reported by parents was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

InterventionUnit on scale (Least Squares Mean)
DBP+OLNP: Randomised to Placebo4.377
DBP+OLNP: Randomised to Nintedanib7.830

[back to top]

Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 52 - Participant Report

"The PedsQL™ questionnaires consists of 23 items (i) and 4 dimensions: physical (8i), emotional (5i), social (5i) and school (5i) functioning. A 5-point Likert response scale (0 = never (worst outcome) to 4=almost always (best outcome)) was used except for the Young Child Report, where a 3-point scale (0=not at all (worst outcome) to 4=a lot (best outcome)) was used. Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100 to 4 = 0). Higher scores indicated better health-related quality of life. To create total scores, the mean was computed.~Absolute change from baseline in PedsQL™ was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 52 are reported in the table below

InterventionUnit on scale (Least Squares Mean)
DBP+OLNP: Randomised to Placebo0.902
DBP+OLNP: Randomised to Nintedanib1.243

[back to top]

Absolute Change From Baseline in Sitting Height at Week 24

"Absolute change from baseline in sitting height at Week 24 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point.~Absolute change from baseline in sitting height at Week 24 in the treated set (TS) was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements pre-administration at -4 weeks and at 0, 12, 24, 36, 52, 64, 76, and 88 weeks after first drug administration. MMRM values at Week 24 are reported in the table below.

InterventionCentimeters (Least Squares Mean)
DBP: Randomised to Placebo1.0
DBP: Randomised to Nintedanib2.1

[back to top]

Area Under the Plasma Concentration-time Curve at Steady State (AUCτ,ss) Based on Sampling at Steady State (at Week 2 and Week 26)

"Area under the plasma concentration-time curve at steady state (AUCt,ss) based on sampling at steady state (at Week 2 and Week 26) after multiple oral administration of Nintedanib by age group over all treatments.~Values of samples taken at Week 2 (for randomised Nintedanib participants) and at Week 26 (for randomised placebo participants) were used. Missing values at Week 2 of randomised Nintedanib participants were replaced with values taken at Week 26." (NCT04093024)
Timeframe: At Week 2 and at Week 26: at 5 minutes before and at 0, 1, 2, 3, 4, 6, and 8 hours post administration of the morning dose

InterventionHours times nanogram per mililiter (Geometric Mean)
DBP+OLNP: 6 to < 12 Years - Exposed to Nintedanib175
DBP+OLNP: 12 to <18 Years - Exposed to Nintedanib167

[back to top]

Number of Participants With Occurrence of Death Over the Whole Trial

Number of participants with occurrence of death over the whole trial over the whole trial was computed. The number of participants with occurrence of death is reported instead of a metric summarizing the time-to-event data with unit of time, as the numbers resulting from the Kaplan-Meier-analysis were even below the first quartile. (NCT04093024)
Timeframe: From first drug administration until the last drug intake + 28 days REP, up to 92.6 weeks

InterventionParticipants (Count of Participants)
DBP+OLNP: Randomised to Placebo0
DBP+OLNP: Randomised to Nintedanib0

[back to top]

Number of Participants With Occurrence of First Acute Interstitial Lung Disease (ILD) Exacerbation or Death Over the Whole Trial

Number of participants with occurrence of first acute Interstitial Lung Disease (ILD) exacerbation or death over the whole trial. The number of participants with first acute ILD exacerbation is reported instead of a metric summarizing the time-to-event data with unit of time, as the numbers resulting from the Kaplan-Meier-analysis were even below the first quartile. (NCT04093024)
Timeframe: From first drug administration until the last drug intake + 28 days REP, up to 92.6 weeks

InterventionParticipants (Count of Participants)
DBP+OLNP: Randomised to Placebo0
DBP+OLNP: Randomised to Nintedanib2

[back to top] [back to top]

Number of Participants With Treatment-emergent Adverse Events During the Double-blind Period

Treatment-emergent was defined as: Adverse events with onset or worsening on or after date of treatment start until end of double-blind period (defined as the day before first intake of open-label nintedanib or last double-blind drug intake + residual effect period, whichever is earlier) were considered as treatment-emergent and were included in the analysis. Adverse events were counted under the treatment as randomized for the double-blind period. (NCT04093024)
Timeframe: From first drug administration until the earlier of (i) first intake of open-label nintedanib (exclusive) and (ii) last drug intake, up to 28 weeks

InterventionParticipants (Count of Participants)
DBP: Randomised to Placebo11
DBP: Randomised to Nintedanib22

[back to top]

Number of Participants With Treatment-emergent Adverse Events Over the Whole Trial

Treatment-emergent was defined as: Adverse events with onset or worsening on or after date of treatment start until last drug intake + residual effect period was considered as treatment-emergent and was included in the analysis. Adverse events were counted under the treatment as randomized for the double-blind period. (NCT04093024)
Timeframe: From first drug administration until the last drug intake, up to 92 weeks

InterventionParticipants (Count of Participants)
DBP: Randomised to Placebo11
OLNP: Randomised to Placebo and Switched to Nintedanib11
DBP+OLNP: Randomised to Nintedanib26

[back to top]

Absolute Change From Baseline in Height at Week 76

"Absolute change from baseline in height at Week 76 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point.~MMRM has been calculated but did not provide estimates for this time point due to low sample size. Thus, change in height from baseline to Week 76 was analyzed descriptively only." (NCT04093024)
Timeframe: Measurements were assessed at Week 0 and at Week 76

,
InterventionCentimeter (Mean)
At BaselineAt Week 76
DBP+OLNP: Randomised to Nintedanib162.5165.5
DBP+OLNP: Randomised to Placebo143.7150.0

[back to top]

Absolute Change From Baseline in Sitting Height at Week 52

"Absolute change from baseline in sitting height at Week 52 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was taken per time point.~MMRM has been calculated but did not provide estimates for this time point due to low sample size. Thus, change in sitting height from baseline to Week 52 was analyzed descriptively only." (NCT04093024)
Timeframe: Measurements were assessed at Week 0 and at Week 52

,
InterventionCentimeters (Mean)
At BaselineAt Week 52
DBP + OLNP: Randomised to Nintedanib77.679.3
DBP + OLNP: Randomised to Placebo78.779.0

[back to top]

Absolute Change From Baseline in Sitting Height at Week 76

"Absolute change from baseline in sitting height at Week 76 was measured with a stadiometer 3 times at each time point. The average of these 3 measurements was take per time point.~MMRM has been calculated but did not provide estimates for this time point due to low sample size. Thus, change in sitting height from baseline to Week 76 was analyzed descriptively only." (NCT04093024)
Timeframe: Measurements were assessed at Week 0 and at Week 76

,
InterventionCentimeters (Mean)
At BaselineAt Week 76
DBP + OLNP: Randomised to Placebo65.065.0
DBP+OLNP: Randomised to Nintedanib83.084.5

[back to top]

Number of Participants With at Least One Treatment-emergent Pathological Finding of Epiphyseal Growth Plate on Imaging up to Week 24, and Week 52

Number of participants with at least one treatment-emergent pathological finding of the epiphyseal growth plate imaging (Magnetic Resonance Imaging (MRI)s/x-rays) were analyzed cumulatively and based on central review. (NCT04093024)
Timeframe: Up to Week 24 (included values at Week 12 and Week 24); Up to Week 52 (included values at Week 12, 24, 36 and 52)

,
InterventionParticipants (Count of Participants)
At Week 24At Week 52
DBP+OLNP: Randomised to Nintedanib23
DBP+OLNP: Randomised to Placebo12

[back to top]

Absolute Change From Baseline in Pediatric Quality of Life Questionnaire™(PedsQL™) at Week 24 - Parent Report

"The PedsQL™ questionnaires consists of 23 items (i) and 4 dimensions: physical (8i), emotional (5i), social (5i) and school (5i) functioning. A 5-point Likert response scale (0 = never (worst outcome) to 4=almost always (best outcome)) was used except for the Young Child Report, where a 3-point scale (0=not at all (worst outcome) to 4=a lot (best outcome)) was used. Items were reverse-scored and linearly transformed to a 0-100 scale (0 = 100 to 4 = 0). Higher scores indicated better health-related quality of life. To create total scores, the mean was computed.~Absolute change from baseline in PedsQL™ reported by parents was based on a Mixed Model Repeated Measures (MMRM), with fixed categorical effects of (randomised) treatment at each visit, age-group and the fixed continuous effects of baseline at each visit, and random effect for participant. Visit was treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements." (NCT04093024)
Timeframe: MMRM included measurements at 0, 24, and 52 weeks after first drug administration. MMRM values at Week 24 are reported in the table below

InterventionUnit on scale (Least Squares Mean)
DBP: Randomised to Placebo5.615
DBP: Randomised to Nintedanib5.481

[back to top]

Area Under the Concentration-time Curve of the Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of the nintedanib in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. (NCT04938453)
Timeframe: For both arms: Within 3 hours (h) before and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 34 h, 48 h and 72h after nintedanib administration.

Interventionhours (h) *nanogram(ng)/milliliter (mL) (Geometric Least Squares Mean)
Nintedanib 1 X 100 mg (R)150.65
Nintedanib 4 X 25 mg (T)148.34

[back to top]

Maximum Measured Concentration of Nintedanib in Plasma (Cmax)

Maximum measured concentration of nintedanib in plasma (Cmax) is reported. (NCT04938453)
Timeframe: For both arms: Within 3 hours (h) before and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 34 h, 48 h and 72h after nintedanib administration.

Interventionnanogram (ng)/milliliter (mL) (Geometric Least Squares Mean)
Nintedanib 1 X 100 mg (R)15.23
Nintedanib 4 X 25 mg (T)15.27

[back to top]

Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of nintedanib in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. (NCT04938453)
Timeframe: For both arms: Within 3 hours (h) before and 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 34 h, 48 h and 72h after nintedanib administration.

Interventionhours * nanogram/milliliter (Geometric Least Squares Mean)
Nintedanib 1 X 100 mg (R)157.55
Nintedanib 4 X 25 mg (T)155.85

[back to top]